0	[CLS]	O
0	the	O
0	same	O
0	approach	O
0	was	O
0	applied	O
0	to	O
0	the	O
0	other	O
0	volume	O
0	terms	O
0	.	O
0	[SEP]	O
1	[CLS]	O
1	in	O
1	v	O
1	##ivo	O
1	and	O
1	in	O
1	v	O
1	##it	O
1	##ro	O
1	characterization	O
1	of	O
1	ch	O
1	##lor	O
1	##zo	O
1	##xa	O
1	##zone	O
1	metabolism	O
1	and	O
1	he	O
1	##pa	O
1	##tic	O
1	c	O
1	##y	O
1	##p	O
1	##2	O
1	##e	O
1	##1	O
1	levels	O
1	in	O
1	a	O
1	##f	O
1	##rica	O
1	##n	O
1	green	O
1	monkeys	O
1	:	O
1	induction	O
1	by	O
1	chronic	O
1	ni	O
1	##cot	O
1	##ine	O
1	treatment	O
1	.	O
1	[SEP]	O
2	[CLS]	O
2	p	O
2	##har	O
2	##ma	O
2	##co	O
2	##kin	O
2	##etic	O
2	analysis	O
2	was	O
2	performed	O
2	using	O
2	data	O
2	from	O
2	individual	O
2	rats	O
2	for	O
2	which	O
2	the	O
2	mean	O
2	and	O
2	standard	O
2	error	O
2	of	O
2	the	O
2	mean	O
2	(	O
2	se	O
2	##m	O
2	)	O
2	were	O
2	calculated	O
2	for	O
2	each	O
2	group	O
2	.	O
2	[SEP]	O
3	[CLS]	O
3	included	O
3	are	O
3	criteria	O
3	to	O
3	decide	O
3	whether	O
3	the	O
3	new	O
3	or	O
3	the	O
3	classical	O
3	model	O
3	functions	O
3	should	O
3	be	O
3	applied	O
3	in	O
3	the	O
3	case	O
3	of	O
3	a	O
3	two	O
3	-	O
3	compartment	O
3	open	O
3	model	O
3	.	O
3	[SEP]	O
4	[CLS]	O
4	double	O
4	coupling	O
4	was	O
4	performed	O
4	##fo	O
4	##r	O
4	the	O
4	addition	O
4	of	O
4	each	O
4	amino	O
4	acid	O
4	:	O
4	using	O
4	the	O
4	microwave	O
4	for	O
4	the	O
4	first	O
4	##co	O
4	##up	O
4	##ling	O
4	and	O
4	at	O
4	room	O
4	temperature	O
4	for	O
4	3	O
4	h	O
4	on	O
4	a	O
4	lab	O
4	##mate	O
4	shake	O
4	##r	O
4	(	O
4	advanced	O
4	##che	O
4	##m	O
4	##tech	O
4	,	O
4	lo	O
4	##ui	O
4	##sville	O
4	,	O
4	k	O
4	##y	O
4	)	O
4	for	O
4	the	O
4	second	O
4	coupling	O
4	,	O
4	with	O
4	3	O
4	e	O
4	##qui	O
4	##v	O
4	of	O
4	##the	O
4	protected	O
4	amino	O
4	acid	O
4	,	O
4	0	O
4	.	O
4	4	O
4	m	O
4	o	O
4	-	O
4	(	O
4	7	O
4	-	O
4	a	O
4	##za	O
4	##ben	O
4	##zo	O
4	##tri	O
4	##az	O
4	##ol	O
4	-	O
4	1	O
4	-	O
4	y	O
4	##l	O
4	)	O
4	-	O
4	n	O
4	,	O
4	n	O
4	,	O
4	n	O
4	′	O
4	-	O
4	n	O
4	′	O
4	-	O
4	te	O
4	##tra	O
4	##met	O
4	##hyl	O
4	##uron	O
4	##ium	O
4	he	O
4	##xa	O
4	##f	O
4	##lu	O
4	##oro	O
4	##ph	O
4	##os	O
4	##phate	O
4	(	O
4	hat	O
4	##u	O
4	)	O
4	and	O
4	1	O
4	-	O
4	h	O
4	##ydro	O
4	##xy	O
4	-	O
4	7	O
4	-	O
4	a	O
4	##za	O
4	##ben	O
4	##zo	O
4	##tri	O
4	##az	O
4	##ole	O
4	(	O
4	ho	O
4	##at	O
4	)	O
4	in	O
4	dim	O
4	##eth	O
4	##yl	O
4	##form	O
4	##ami	O
4	##de	O
4	(	O
4	d	O
4	##m	O
4	##f	O
4	)	O
4	,	O
4	and	O
4	either	O
4	1	O
4	m	O
4	di	O
4	##is	O
4	##op	O
4	##rop	O
4	##yle	O
4	##thy	O
4	##lam	O
4	##ine	O
4	(	O
4	die	O
4	##a	O
4	)	O
4	in	O
4	nm	O
4	##p	O
4	or	O
4	neat	O
4	co	O
4	##lli	O
4	##dine	O
4	.	O
4	[SEP]	O
5	[CLS]	O
5	the	O
5	5th	O
5	,	O
5	50th	O
5	,	O
5	and	O
5	95	O
5	##th	O
5	percent	O
5	##iles	O
5	of	O
5	the	O
5	simulated	O
5	concentrations	O
5	were	O
5	constructed	O
5	and	O
5	compared	O
5	against	O
5	the	O
5	valid	O
5	##ation	O
5	data	O
5	set	O
5	observed	O
5	concentrations	O
5	.	O
5	[SEP]	O
6	[CLS]	O
6	the	O
6	morphology	O
6	of	O
6	the	O
6	lesions	O
6	can	O
6	be	O
6	seen	O
6	in	O
6	fi	O
6	##g	O
6	.	O
6	6	O
6	(	O
6	a	O
6	images	O
6	)	O
6	.	O
6	[SEP]	O
7	[CLS]	O
7	the	O
7	au	B-PK
7	##c	I-PK
7	of	O
7	(	O
7	+	O
7	)	O
7	-	O
7	q	O
7	##a	O
7	and	O
7	(	O
7	−	O
7	)	O
7	-	O
7	q	O
7	##a	O
7	were	O
7	163	O
7	##1	O
7	.	O
7	202	O
7	##±	O
7	##24	O
7	##1	O
7	.	O
7	03	O
7	##8	O
7	mg	O
7	/	O
7	l	O
7	/	O
7	h	O
7	and	O
7	246	O
7	.	O
7	57	O
7	##1	O
7	##±	O
7	##70	O
7	.	O
7	67	O
7	##7	O
7	mg	O
7	/	O
7	l	O
7	/	O
7	h	O
7	after	O
7	in	O
7	##tra	O
7	##gas	O
7	##tric	O
7	administration	O
7	,	O
7	and	O
7	223	O
7	##9	O
7	.	O
7	105	O
7	##±	O
7	##30	O
7	##0	O
7	.	O
7	55	O
7	##4	O
7	mg	O
7	/	O
7	l	O
7	/	O
7	h	O
7	and	O
7	29	O
7	##4	O
7	.	O
7	75	O
7	##1	O
7	##±	O
7	##8	O
7	##5	O
7	.	O
7	37	O
7	##7	O
7	mg	O
7	/	O
7	l	O
7	/	O
7	h	O
7	after	O
7	in	O
7	##tra	O
7	##ven	O
7	##ous	O
7	administration	O
7	.	O
7	[SEP]	O
8	[CLS]	O
8	food	O
8	and	O
8	water	O
8	were	O
8	given	O
8	ad	O
8	l	O
8	##ibi	O
8	##tum	O
8	.	O
8	[SEP]	O
9	[CLS]	O
9	the	O
9	label	O
9	##ling	O
9	of	O
9	ne	O
9	##ph	O
9	##rot	O
9	##ox	O
9	##ic	O
9	compounds	O
9	that	O
9	do	O
9	not	O
9	a	O
9	##cc	O
9	##um	O
9	##ulate	O
9	included	O
9	more	O
9	frequently	O
9	a	O
9	recommendation	O
9	to	O
9	adapt	O
9	the	O
9	dose	O
9	or	O
9	to	O
9	monitor	O
9	than	O
9	the	O
9	label	O
9	##ling	O
9	of	O
9	drugs	O
9	without	O
9	ne	O
9	##ph	O
9	##rot	O
9	##ox	O
9	##ic	O
9	potential	O
9	(	O
9	15	O
9	of	O
9	22	O
9	versus	O
9	5	O
9	of	O
9	26	O
9	,	O
9	p	O
9	=	O
9	0	O
9	.	O
9	00	O
9	##2	O
9	)	O
9	.	O
9	[SEP]	O
10	[CLS]	O
10	the	O
10	objectives	O
10	of	O
10	these	O
10	studies	O
10	were	O
10	to	O
10	character	O
10	##ize	O
10	the	O
10	disposition	O
10	of	O
10	g	O
10	##d	O
10	##c	O
10	-	O
10	09	O
10	##7	O
10	##3	O
10	in	O
10	pre	O
10	##c	O
10	##lini	O
10	##cal	O
10	species	O
10	and	O
10	to	O
10	determine	O
10	the	O
10	relationship	O
10	of	O
10	g	O
10	##d	O
10	##c	O
10	-	O
10	09	O
10	##7	O
10	##3	O
10	plasma	O
10	concentrations	O
10	to	O
10	efficacy	O
10	in	O
10	co	O
10	##lo	O
10	##20	O
10	##5	O
10	mouse	O
10	x	O
10	##eno	O
10	##gra	O
10	##ft	O
10	models	O
10	.	O
10	[SEP]	O
11	[CLS]	O
11	eligible	O
11	g	O
11	##i	O
11	ma	O
11	##li	O
11	##gna	O
11	##ncies	O
11	included	O
11	gas	O
11	##tric	O
11	car	O
11	##cin	O
11	##oma	O
11	,	O
11	es	O
11	##op	O
11	##hage	O
11	##al	O
11	car	O
11	##cin	O
11	##oma	O
11	,	O
11	color	O
11	##ec	O
11	##tal	O
11	car	O
11	##cin	O
11	##oma	O
11	,	O
11	small	O
11	in	O
11	##test	O
11	##ine	O
11	car	O
11	##cin	O
11	##oma	O
11	,	O
11	pan	O
11	##cre	O
11	##atic	O
11	car	O
11	##cin	O
11	##oma	O
11	,	O
11	and	O
11	bi	O
11	##lia	O
11	##ry	O
11	car	O
11	##cin	O
11	##oma	O
11	.	O
11	[SEP]	O
12	[CLS]	O
12	we	O
12	believe	O
12	that	O
12	our	O
12	study	O
12	would	O
12	provide	O
12	important	O
12	references	O
12	to	O
12	realize	O
12	better	O
12	clinical	O
12	applications	O
12	of	O
12	y	O
12	##cht	O
12	in	O
12	liver	O
12	injury	O
12	.	O
12	[SEP]	O
13	[CLS]	O
13	under	O
13	current	O
13	dos	O
13	##ing	O
13	recommendations	O
13	,	O
13	simulation	O
13	predicted	O
13	that	O
13	the	O
13	median	O
13	day	O
13	7	O
13	concentration	O
13	was	O
13	below	O
13	the	O
13	25th	O
13	percent	O
13	##ile	O
13	for	O
13	a	O
13	typical	O
13	adult	O
13	patient	O
13	(	O
13	50	O
13	kg	O
13	)	O
13	for	O
13	su	O
13	##lf	O
13	##ado	O
13	##xin	O
13	##e	O
13	for	O
13	patients	O
13	in	O
13	the	O
13	weight	O
13	bands	O
13	of	O
13	8	O
13	to	O
13	9	O
13	,	O
13	19	O
13	to	O
13	24	O
13	,	O
13	46	O
13	to	O
13	49	O
13	,	O
13	and	O
13	74	O
13	to	O
13	79	O
13	kg	O
13	and	O
13	for	O
13	p	O
13	##yr	O
13	##ime	O
13	##tham	O
13	##ine	O
13	for	O
13	patients	O
13	in	O
13	the	O
13	weight	O
13	bands	O
13	of	O
13	8	O
13	to	O
13	9	O
13	,	O
13	14	O
13	to	O
13	24	O
13	,	O
13	and	O
13	42	O
13	to	O
13	49	O
13	kg	O
13	.	O
13	[SEP]	O
14	[CLS]	O
14	the	O
14	consort	O
14	flow	O
14	##cha	O
14	##rt	O
14	showing	O
14	the	O
14	c	O
14	##ela	O
14	##den	O
14	trial	O
14	profile	O
14	was	O
14	published	O
14	previously	O
14	[	O
14	17	O
14	]	O
14	and	O
14	is	O
14	included	O
14	in	O
14	this	O
14	manuscript	O
14	as	O
14	fi	O
14	##g	O
14	1	O
14	.	O
14	[SEP]	O
15	[CLS]	O
15	the	O
15	interval	O
15	between	O
15	two	O
15	tests	O
15	in	O
15	each	O
15	volunteer	O
15	was	O
15	at	O
15	least	O
15	2	O
15	weeks	O
15	.	O
15	[SEP]	O
16	[CLS]	O
16	the	O
16	e	O
16	##ff	O
16	##lue	O
16	##nt	O
16	was	O
16	e	O
16	##va	O
16	##porated	O
16	,	O
16	and	O
16	the	O
16	re	O
16	##con	O
16	##stituted	O
16	residue	O
16	was	O
16	ch	O
16	##roma	O
16	##to	O
16	##graph	O
16	##ed	O
16	on	O
16	a	O
16	ch	O
16	##ira	O
16	##l	O
16	##cel	O
16	o	O
16	##d	O
16	column	O
16	with	O
16	a	O
16	mobile	O
16	phase	O
16	of	O
16	he	O
16	##xa	O
16	##ne	O
16	-	O
16	2	O
16	-	O
16	prop	O
16	##ano	O
16	##l	O
16	(	O
16	10	O
16	:	O
16	0	O
16	.	O
16	9	O
16	,	O
16	v	O
16	/	O
16	v	O
16	)	O
16	containing	O
16	0	O
16	.	O
16	01	O
16	%	O
16	(	O
16	v	O
16	/	O
16	v	O
16	)	O
16	diet	O
16	##hyl	O
16	##amine	O
16	.	O
16	[SEP]	O
17	[CLS]	O
17	among	O
17	the	O
17	76	O
17	e	O
17	##val	O
17	##ua	O
17	##ble	O
17	lesions	O
17	,	O
17	a	O
17	c	O
17	##r	O
17	was	O
17	observed	O
17	in	O
17	23	O
17	lesions	O
17	(	O
17	30	O
17	%	O
17	)	O
17	,	O
17	p	O
17	##r	O
17	in	O
17	22	O
17	lesions	O
17	(	O
17	29	O
17	%	O
17	)	O
17	,	O
17	and	O
17	s	O
17	##d	O
17	in	O
17	17	O
17	lesions	O
17	(	O
17	22	O
17	%	O
17	)	O
17	resulting	O
17	in	O
17	an	O
17	or	O
17	##r	O
17	of	O
17	59	O
17	%	O
17	(	O
17	figure	O
17	2	O
17	##c	O
17	)	O
17	.	O
17	[SEP]	O
18	[CLS]	O
18	the	O
18	median	O
18	cm	B-PK
18	##ax	I-PK
18	of	O
18	co	O
18	##c	O
18	and	O
18	its	O
18	major	O
18	meta	O
18	##bol	O
18	##ites	O
18	,	O
18	ben	O
18	##zo	O
18	##yle	O
18	##c	O
18	##gon	O
18	##ine	O
18	(	O
18	b	O
18	##ze	O
18	)	O
18	and	O
18	e	O
18	##c	O
18	##gon	O
18	##ine	O
18	met	O
18	##hyl	O
18	est	O
18	##er	O
18	(	O
18	em	O
18	##e	O
18	)	O
18	,	O
18	were	O
18	closely	O
18	related	O
18	in	O
18	whole	O
18	blood	O
18	and	O
18	plasma	O
18	.	O
18	[SEP]	O
19	[CLS]	O
19	general	O
19	an	O
19	##est	O
19	##hesia	O
19	was	O
19	induced	O
19	using	O
19	prop	O
19	##of	O
19	##ol	O
19	,	O
19	f	O
19	##ent	O
19	##any	O
19	##l	O
19	and	O
19	c	O
19	##isa	O
19	##tra	O
19	##cu	O
19	##rium	O
19	.	O
19	[SEP]	O
20	[CLS]	O
20	all	O
20	of	O
20	the	O
20	p	O
20	##k	O
20	samples	O
20	collected	O
20	were	O
20	from	O
20	p	O
20	##fi	O
20	##zer	O
20	‐	O
20	sponsored	O
20	trials	O
20	conducted	O
20	between	O
20	1995	O
20	and	O
20	2001	O
20	.	O
20	[SEP]	O
21	[CLS]	O
21	to	O
21	measure	O
21	the	O
21	proliferation	O
21	,	O
21	b	O
21	##fa	O
21	-	O
21	treated	O
21	cells	O
21	were	O
21	re	O
21	##see	O
21	##ded	O
21	in	O
21	a	O
21	96	O
21	-	O
21	well	O
21	flat	O
21	bottom	O
21	plate	O
21	and	O
21	culture	O
21	##d	O
21	with	O
21	fresh	O
21	medium	O
21	for	O
21	72	O
21	hours	O
21	.	O
21	[SEP]	O
22	[CLS]	O
22	the	O
22	majority	O
22	of	O
22	men	O
22	in	O
22	the	O
22	me	O
22	##dic	O
22	##are	O
22	co	O
22	##hor	O
22	##t	O
22	were	O
22	injection	O
22	in	O
22	##iti	O
22	##ators	O
22	(	O
22	51	O
22	.	O
22	2	O
22	%	O
22	)	O
22	,	O
22	most	O
22	in	O
22	the	O
22	us	O
22	commercially	O
22	ins	O
22	##ured	O
22	population	O
22	were	O
22	gel	O
22	in	O
22	##iti	O
22	##ators	O
22	(	O
22	56	O
22	.	O
22	5	O
22	%	O
22	)	O
22	,	O
22	and	O
22	the	O
22	uk	O
22	database	O
22	included	O
22	equal	O
22	proportions	O
22	of	O
22	injection	O
22	##s	O
22	and	O
22	gel	O
22	users	O
22	(	O
22	approximately	O
22	41	O
22	%	O
22	)	O
22	.	O
22	[SEP]	O
23	[CLS]	O
23	h	O
23	##ydro	O
23	##xy	O
23	##lation	O
23	at	O
23	the	O
23	6	O
23	-	O
23	carbon	O
23	atom	O
23	was	O
23	of	O
23	minor	O
23	importance	O
23	in	O
23	humans	O
23	only	O
23	;	O
23	none	O
23	of	O
23	the	O
23	animal	O
23	species	O
23	ex	O
23	##cre	O
23	##ted	O
23	the	O
23	6	O
23	-	O
23	h	O
23	##ydro	O
23	##xy	O
23	meta	O
23	##bol	O
23	##ite	O
23	.	O
23	[SEP]	O
24	[CLS]	O
24	the	O
24	results	O
24	suggested	O
24	the	O
24	g	O
24	##l	O
24	-	O
24	mediated	O
24	al	O
24	##g	O
24	ng	O
24	##ps	O
24	could	O
24	reduce	O
24	the	O
24	p	O
24	##ha	O
24	##go	O
24	##cy	O
24	##tosis	O
24	of	O
24	raw	O
24	264	O
24	.	O
24	7	O
24	cells	O
24	in	O
24	v	O
24	##it	O
24	##ro	O
24	,	O
24	which	O
24	would	O
24	play	O
24	an	O
24	important	O
24	role	O
24	in	O
24	increasing	O
24	the	O
24	long	O
24	circulation	O
24	in	O
24	v	O
24	##ivo	O
24	.	O
24	[SEP]	O
25	[CLS]	O
25	this	O
25	effect	O
25	was	O
25	detect	O
25	##able	O
25	for	O
25	6	O
25	hours	O
25	.	O
25	[SEP]	O
26	[CLS]	O
26	effect	O
26	of	O
26	diet	O
26	##ary	O
26	a	O
26	##f	O
26	##lat	O
26	##ox	O
26	##in	O
26	on	O
26	the	O
26	up	O
26	##take	O
26	and	O
26	elimination	O
26	of	O
26	ch	O
26	##lor	O
26	##te	O
26	##tra	O
26	##cy	O
26	##cline	O
26	in	O
26	br	O
26	##oil	O
26	##er	O
26	chick	O
26	##s	O
26	.	O
26	[SEP]	O
27	[CLS]	O
27	to	O
27	further	O
27	confirm	O
27	whether	O
27	p	O
27	-	O
27	g	O
27	##p	O
27	affects	O
27	the	O
27	p	O
27	##har	O
27	##ma	O
27	##co	O
27	##kin	O
27	##etics	O
27	of	O
27	en	O
27	##ro	O
27	##f	O
27	##lo	O
27	##xa	O
27	##cin	O
27	in	O
27	pigs	O
27	,	O
27	ve	O
27	##rap	O
27	##ami	O
27	##l	O
27	(	O
27	an	O
27	inhibitor	O
27	of	O
27	p	O
27	-	O
27	g	O
27	##p	O
27	)	O
27	was	O
27	ad	O
27	##mini	O
27	##stra	O
27	##ted	O
27	prior	O
27	to	O
27	en	O
27	##ro	O
27	##f	O
27	##lo	O
27	##xa	O
27	##cin	O
27	,	O
27	and	O
27	the	O
27	plasma	O
27	concentration	O
27	-	O
27	time	O
27	curve	O
27	and	O
27	p	O
27	##har	O
27	##ma	O
27	##co	O
27	##kin	O
27	##etics	O
27	of	O
27	en	O
27	##ro	O
27	##f	O
27	##lo	O
27	##xa	O
27	##cin	O
27	are	O
27	summarized	O
27	in	O
27	fi	O
27	##g	O
27	.	O
27	7	O
27	and	O
27	table	O
27	3	O
27	,	O
27	respectively	O
27	.	O
27	[SEP]	O
28	[CLS]	O
28	al	O
28	##ks	O
28	38	O
28	##31	O
28	is	O
28	composed	O
28	of	O
28	a	O
28	flexible	O
28	dose	O
28	of	O
28	o	O
28	##lan	O
28	##za	O
28	##pine	O
28	and	O
28	a	O
28	fixed	O
28	dose	O
28	of	O
28	10	O
28	-	O
28	mg	O
28	sa	O
28	##mi	O
28	##dor	O
28	##pha	O
28	##n	O
28	(	O
28	a	O
28	novel	O
28	op	O
28	##io	O
28	##id	O
28	system	O
28	m	O
28	##od	O
28	##ulator	O
28	)	O
28	,	O
28	designed	O
28	to	O
28	provide	O
28	the	O
28	established	O
28	anti	O
28	##psy	O
28	##cho	O
28	##tic	O
28	efficacy	O
28	of	O
28	o	O
28	##lan	O
28	##za	O
28	##pine	O
28	and	O
28	to	O
28	mit	O
28	##igate	O
28	o	O
28	##lan	O
28	##za	O
28	##pine	O
28	-	O
28	induced	O
28	weight	O
28	gain	O
28	.	O
28	[SEP]	O
29	[CLS]	O
29	more	O
29	##over	O
29	,	O
29	p	O
29	##io	O
29	and	O
29	g	O
29	##lm	O
29	were	O
29	stable	O
29	in	O
29	plasma	O
29	,	O
29	up	O
29	to	O
29	30	O
29	days	O
29	of	O
29	storage	O
29	at	O
29	-	O
29	70	O
29	degrees	O
29	c	O
29	and	O
29	after	O
29	being	O
29	subjected	O
29	to	O
29	bench	O
29	top	O
29	,	O
29	auto	O
29	-	O
29	sample	O
29	##r	O
29	,	O
29	and	O
29	three	O
29	freeze	O
29	-	O
29	th	O
29	##aw	O
29	cycles	O
29	.	O
29	[SEP]	O
30	[CLS]	O
30	this	O
30	study	O
30	evaluated	O
30	the	O
30	p	O
30	##har	O
30	##ma	O
30	##co	O
30	##kin	O
30	##etics	O
30	and	O
30	safety	O
30	of	O
30	b	O
30	##os	O
30	##uti	O
30	##ni	O
30	##b	O
30	in	O
30	patients	O
30	with	O
30	chronic	O
30	he	O
30	##pa	O
30	##tic	O
30	imp	O
30	##air	O
30	##ment	O
30	and	O
30	matched	O
30	healthy	O
30	subjects	O
30	.	O
30	[SEP]	O
31	[CLS]	O
31	maximum	O
31	kill	O
31	at	O
31	the	O
31	dose	O
31	of	O
31	2	O
31	.	O
31	5	O
31	mg	O
31	/	O
31	kg	O
31	varied	O
31	from	O
31	57	O
31	to	O
31	71	O
31	%	O
31	in	O
31	##hibition	O
31	in	O
31	repeat	O
31	experiments	O
31	,	O
31	with	O
31	peaks	O
31	at	O
31	2	O
31	and	O
31	3	O
31	days	O
31	after	O
31	drug	O
31	administration	O
31	(	O
31	fi	O
31	##g	O
31	.	O
31	1	O
31	##b	O
31	)	O
31	.	O
31	[SEP]	O
32	[CLS]	O
32	therefore	O
32	,	O
32	a	O
32	dose	O
32	of	O
32	40	O
32	mg	O
32	of	O
32	o	O
32	##m	O
32	correspond	O
32	##ed	O
32	to	O
32	a	O
32	dose	O
32	of	O
32	31	O
32	.	O
32	97	O
32	##4	O
32	mg	O
32	of	O
32	o	O
32	##lm	O
32	##es	O
32	##art	O
32	##an	O
32	,	O
32	and	O
32	a	O
32	dose	O
32	of	O
32	160	O
32	mg	O
32	of	O
32	o	O
32	##m	O
32	correspond	O
32	##ed	O
32	to	O
32	a	O
32	dose	O
32	of	O
32	127	O
32	.	O
32	90	O
32	mg	O
32	of	O
32	o	O
32	##lm	O
32	##es	O
32	##art	O
32	##an	O
32	.	O
32	[SEP]	O
33	[CLS]	O
33	very	O
33	little	O
33	is	O
33	known	O
33	about	O
33	whether	O
33	ta	O
33	##u	O
33	proteins	O
33	can	O
33	cross	O
33	the	O
33	b	O
33	##bb	O
33	.	O
33	[SEP]	O
34	[CLS]	O
34	treatment	O
34	with	O
34	can	O
34	##tu	O
34	##zu	O
34	##ma	O
34	##b	O
34	me	O
34	##rta	O
34	##ns	O
34	##ine	O
34	at	O
34	45	O
34	mg	O
34	/	O
34	m	O
34	##2	O
34	per	O
34	day	O
34	three	O
34	-	O
34	times	O
34	weekly	O
34	x	O
34	3	O
34	-	O
34	every	O
34	-	O
34	4	O
34	-	O
34	week	O
34	schedule	O
34	proved	O
34	that	O
34	a	O
34	dose	O
34	-	O
34	intense	O
34	treatment	O
34	with	O
34	an	O
34	im	O
34	##mu	O
34	##no	O
34	##con	O
34	##ju	O
34	##gate	O
34	can	O
34	be	O
34	safely	O
34	administered	O
34	.	O
34	[SEP]	O
35	[CLS]	O
35	a	O
35	difference	O
35	in	O
35	in	O
35	v	O
35	##ivo	O
35	dissolution	O
35	rate	O
35	of	O
35	the	O
35	two	O
35	different	O
35	particle	O
35	sizes	O
35	was	O
35	observed	O
35	,	O
35	based	O
35	on	O
35	per	O
35	##fusion	O
35	data	O
35	.	O
35	[SEP]	O
36	[CLS]	O
36	as	O
36	shown	O
36	in	O
36	figure	O
36	1	O
36	##a	O
36	,	O
36	f	O
36	##avi	O
36	##pi	O
36	##ra	O
36	##vir	O
36	treatment	O
36	improved	O
36	survival	O
36	outcome	O
36	compared	O
36	to	O
36	g	O
36	##uin	O
36	##ea	O
36	pigs	O
36	treated	O
36	with	O
36	place	O
36	##bo	O
36	.	O
36	[SEP]	O
37	[CLS]	O
37	is	O
37	##oto	O
37	##pical	O
37	##ly	O
37	labeled	O
37	internal	O
37	standards	O
37	(	O
37	2	O
37	##h	O
37	,	O
37	13	O
37	##c	O
37	,	O
37	and	O
37	/	O
37	or	O
37	15	O
37	##n	O
37	)	O
37	were	O
37	used	O
37	for	O
37	each	O
37	anal	O
37	##yte	O
37	.	O
37	[SEP]	O
38	[CLS]	O
38	the	O
38	largest	O
38	time	O
38	-	O
38	matched	O
38	mean	O
38	difference	O
38	to	O
38	place	O
38	##bo	O
38	was	O
38	2	O
38	.	O
38	97	O
38	m	O
38	##s	O
38	at	O
38	5	O
38	minutes	O
38	,	O
38	with	O
38	the	O
38	upper	O
38	limit	O
38	of	O
38	the	O
38	two	O
38	-	O
38	sided	O
38	90	O
38	%	O
38	confidence	O
38	interval	O
38	(	O
38	c	O
38	##i	O
38	)	O
38	being	O
38	4	O
38	.	O
38	80	O
38	m	O
38	##s	O
38	,	O
38	excluding	O
38	a	O
38	relevant	O
38	q	O
38	##t	O
38	effect	O
38	as	O
38	defined	O
38	by	O
38	the	O
38	i	O
38	##ch	O
38	e	O
38	##14	O
38	guide	O
38	##line	O
38	.	O
38	[SEP]	O
39	[CLS]	O
39	in	O
39	the	O
39	patients	O
39	without	O
39	per	O
39	##ito	O
39	##ni	O
39	##tis	O
39	,	O
39	the	O
39	following	O
39	p	O
39	##har	O
39	##ma	O
39	##co	O
39	##kin	O
39	##etic	O
39	parameters	O
39	after	O
39	i	O
39	.	O
39	v	O
39	.	O
39	and	O
39	i	O
39	.	O
39	p	O
39	.	O
39	administration	O
39	did	O
39	not	O
39	differ	O
39	significantly	O
39	(	O
39	mean	O
39	+	O
39	-	O
39	s	O
39	##d	O
39	)	O
39	:	O
39	elimination	B-PK
39	half	I-PK
39	-	I-PK
39	life	I-PK
39	,	O
39	15	O
39	.	O
39	1	O
39	+	O
39	-	O
39	1	O
39	.	O
39	9	O
39	h	O
39	;	O
39	apparent	B-PK
39	volume	I-PK
39	of	I-PK
39	distribution	I-PK
39	27	O
39	.	O
39	9	O
39	+	O
39	-	O
39	2	O
39	.	O
39	91	O
39	;	O
39	and	O
39	total	B-PK
39	clearance	I-PK
39	,	O
39	21	O
39	.	O
39	5	O
39	+	O
39	-	O
39	1	O
39	.	O
39	2	O
39	m	O
39	##l	O
39	/	O
39	min	O
39	.	O
39	[SEP]	O
40	[CLS]	O
40	the	O
40	inter	O
40	##ind	O
40	##iv	O
40	##id	O
40	##ual	O
40	var	O
40	##iability	O
40	associated	O
40	with	O
40	p	O
40	##k	O
40	parameters	O
40	was	O
40	modeled	O
40	using	O
40	an	O
40	ex	O
40	##po	O
40	##nent	O
40	##ial	O
40	model	O
40	as	O
40	described	O
40	below	O
40	:	O
40	\	O
40	document	O
40	##c	O
40	##lass	O
40	[	O
40	12	O
40	##pt	O
40	]	O
40	{	O
40	minimal	O
40	}	O
40	\	O
40	use	O
40	##pack	O
40	##age	O
40	{	O
40	am	O
40	##sma	O
40	##th	O
40	}	O
40	\	O
40	use	O
40	##pack	O
40	##age	O
40	{	O
40	was	O
40	##ys	O
40	##ym	O
40	}	O
40	\	O
40	use	O
40	##pack	O
40	##age	O
40	{	O
40	am	O
40	##s	O
40	##fo	O
40	##nts	O
40	}	O
40	\	O
40	use	O
40	##pack	O
40	##age	O
40	{	O
40	am	O
40	##ssy	O
40	##mb	O
40	}	O
40	\	O
40	use	O
40	##pack	O
40	##age	O
40	{	O
40	am	O
40	##s	O
40	##bs	O
40	##y	O
40	}	O
40	\	O
40	use	O
40	##pack	O
40	##age	O
40	{	O
40	math	O
40	##rs	O
40	##fs	O
40	}	O
40	\	O
40	use	O
40	##pack	O
40	##age	O
40	{	O
40	up	O
40	##g	O
40	##ree	O
40	##k	O
40	}	O
40	\	O
40	set	O
40	##len	O
40	##gth	O
40	{	O
40	\	O
40	odds	O
40	##ide	O
40	##mar	O
40	##gin	O
40	}	O
40	{	O
40	-	O
40	69	O
40	##pt	O
40	}	O
40	\	O
40	begin	O
40	{	O
40	document	O
40	}	O
40	$	O
40	$	O
40	\	O
40	the	O
40	##ta	O
40	_	O
40	{	O
40	i	O
40	}	O
40	=	O
40	\	O
40	the	O
40	##ta	O
40	_	O
40	{	O
40	\	O
40	text	O
40	{	O
40	t	O
40	##v	O
40	}	O
40	}	O
40	\	O
40	times	O
40	\	O
40	ex	O
40	##p	O
40	(	O
40	\	O
40	et	O
40	##a	O
40	_	O
40	{	O
40	i	O
40	}	O
40	)	O
40	$	O
40	$	O
40	\	O
40	end	O
40	{	O
40	document	O
40	}	O
40	θ	O
40	##i	O
40	=	O
40	θ	O
40	##t	O
40	##v	O
40	##×	O
40	##ex	O
40	##p	O
40	(	O
40	η	O
40	##i	O
40	)	O
40	where	O
40	θ	O
40	##i	O
40	is	O
40	the	O
40	p	O
40	##k	O
40	parameter	O
40	for	O
40	the	O
40	it	O
40	##h	O
40	subject	O
40	,	O
40	θ	O
40	##t	O
40	##v	O
40	is	O
40	the	O
40	typical	O
40	value	O
40	of	O
40	the	O
40	parameter	O
40	,	O
40	and	O
40	η	O
40	##i	O
40	is	O
40	a	O
40	normally	O
40	distributed	O
40	variable	O
40	with	O
40	mean	O
40	0	O
40	and	O
40	variance	O
40	ω	O
40	##2	O
40	.	O
40	[SEP]	O
41	[CLS]	O
41	finally	O
41	,	O
41	n	O
41	##rg	O
41	##1	O
41	t	O
41	##m	O
41	he	O
41	##t	O
41	mice	O
41	displayed	O
41	increased	O
41	frequencies	O
41	of	O
41	no	O
41	##sing	O
41	[	O
41	f	O
41	(	O
41	1	O
41	,	O
41	112	O
41	)	O
41	=	O
41	7	O
41	.	O
41	7	O
41	,	O
41	p	O
41	<	O
41	0	O
41	.	O
41	01	O
41	]	O
41	.	O
41	[SEP]	O
42	[CLS]	O
42	the	O
42	ch	O
42	##roma	O
42	##to	O
42	##graphic	O
42	separation	O
42	was	O
42	achieved	O
42	on	O
42	an	O
42	ascent	O
42	##is	O
42	-	O
42	r	O
42	##p	O
42	amid	O
42	##e	O
42	column	O
42	(	O
42	4	O
42	.	O
42	6	O
42	×	O
42	150	O
42	mm	O
42	,	O
42	5	O
42	µ	O
42	##m	O
42	)	O
42	with	O
42	mobile	O
42	phase	O
42	delivered	O
42	in	O
42	is	O
42	##oc	O
42	##ratic	O
42	mode	O
42	.	O
42	[SEP]	O
43	[CLS]	O
43	we	O
43	evaluated	O
43	anti	O
43	##sen	O
43	##se	O
43	o	O
43	##li	O
43	##gon	O
43	##uc	O
43	##leo	O
43	##tide	O
43	##s	O
43	(	O
43	as	O
43	##os	O
43	)	O
43	targeting	O
43	an	O
43	##g	O
43	##pt	O
43	##l	O
43	##3	O
43	messenger	O
43	r	O
43	##na	O
43	(	O
43	m	O
43	##rna	O
43	)	O
43	for	O
43	effects	O
43	on	O
43	plasma	O
43	lip	O
43	##id	O
43	levels	O
43	,	O
43	t	O
43	##rig	O
43	##ly	O
43	##cer	O
43	##ide	O
43	clearance	B-PK
43	,	O
43	liver	O
43	t	O
43	##rig	O
43	##ly	O
43	##cer	O
43	##ide	O
43	content	O
43	,	O
43	insulin	O
43	sensitivity	O
43	,	O
43	and	O
43	at	O
43	##her	O
43	##os	O
43	##cle	O
43	##rosis	O
43	in	O
43	mice	O
43	.	O
43	[SEP]	O
44	[CLS]	O
44	eleven	O
44	of	O
44	14	O
44	patients	O
44	entered	O
44	into	O
44	the	O
44	study	O
44	completed	O
44	.	O
44	[SEP]	O
45	[CLS]	O
45	“	O
45	[SEP]	O
46	[CLS]	O
46	during	O
46	a	O
46	3	O
46	-	O
46	h	O
46	per	O
46	##fusion	O
46	of	O
46	five	O
46	isolated	O
46	rabbit	O
46	liver	O
46	preparations	O
46	,	O
46	40	O
46	.	O
46	4	O
46	%	O
46	of	O
46	c	O
46	##ef	O
46	##pi	O
46	##ram	O
46	##ide	O
46	added	O
46	to	O
46	the	O
46	circulating	O
46	blood	O
46	was	O
46	eliminated	O
46	in	O
46	the	O
46	bi	O
46	##le	O
46	and	O
46	only	O
46	0	O
46	.	O
46	3	O
46	%	O
46	was	O
46	meta	O
46	##bol	O
46	##ized	O
46	in	O
46	the	O
46	liver	O
46	.	O
46	[SEP]	O
47	[CLS]	O
47	c	O
47	##y	O
47	##p	O
47	##3	O
47	##a	O
47	##4	O
47	*	O
47	16	O
47	and	O
47	c	O
47	##y	O
47	##p	O
47	##3	O
47	##a	O
47	##4	O
47	*	O
47	18	O
47	all	O
47	##ele	O
47	##s	O
47	found	O
47	in	O
47	east	O
47	as	O
47	##ians	O
47	exhibit	O
47	differential	O
47	cat	O
47	##alytic	O
47	activities	O
47	for	O
47	seven	O
47	c	O
47	##y	O
47	##p	O
47	##3	O
47	##a	O
47	##4	O
47	substrate	O
47	drugs	O
47	.	O
47	[SEP]	O
48	[CLS]	O
48	cm	O
48	##s	O
48	was	O
48	administered	O
48	either	O
48	by	O
48	ne	O
48	##bul	O
48	##ization	O
48	every	O
48	12	O
48	h	O
48	or	O
48	i	O
48	.	O
48	v	O
48	.	O
48	every	O
48	8	O
48	h	O
48	.	O
48	[SEP]	O
49	[CLS]	O
49	dose	O
49	-	O
49	limiting	O
49	toxic	O
49	##ities	O
49	(	O
49	d	O
49	##lts	O
49	)	O
49	were	O
49	assessed	O
49	in	O
49	cycle	O
49	1	O
49	and	O
49	safety	O
49	in	O
49	all	O
49	cycles	O
49	.	O
49	[SEP]	O
50	[CLS]	O
50	d	O
50	##f	O
50	##mo	O
50	serum	O
50	samples	O
50	were	O
50	also	O
50	collected	O
50	from	O
50	selected	O
50	patients	O
50	in	O
50	the	O
50	higher	O
50	dose	O
50	groups	O
50	(	O
50	750	O
50	,	O
50	1000	O
50	,	O
50	1500	O
50	mg	O
50	/	O
50	m	O
50	##2	O
50	)	O
50	during	O
50	cycle	O
50	2	O
50	.	O
50	[SEP]	O
51	[CLS]	O
51	the	O
51	au	B-PK
51	##c	I-PK
51	from	I-PK
51	time	I-PK
51	zero	I-PK
51	extra	I-PK
51	##pol	I-PK
51	##ated	I-PK
51	to	I-PK
51	in	I-PK
51	##finity	I-PK
51	(	I-PK
51	au	I-PK
51	##cin	I-PK
51	##f	I-PK
51	)	I-PK
51	increased	O
51	in	O
51	a	O
51	greater	O
51	than	O
51	dose	O
51	-	O
51	proportional	O
51	manner	O
51	after	O
51	both	O
51	the	O
51	first	O
51	and	O
51	last	O
51	doses	O
51	(	O
51	fi	O
51	##g	O
51	.	O
51	1	O
51	##b	O
51	)	O
51	.	O
51	[SEP]	O
52	[CLS]	O
52	our	O
52	study	O
52	shows	O
52	that	O
52	op	O
52	##t	O
52	is	O
52	able	O
52	to	O
52	predict	O
52	serum	O
52	amino	O
52	##gly	O
52	##cos	O
52	##ide	O
52	levels	O
52	accurately	O
52	in	O
52	the	O
52	routine	O
52	clinical	O
52	setting	O
52	.	O
52	[SEP]	O
53	[CLS]	O
53	the	O
53	mean	O
53	half	B-PK
53	-	I-PK
53	life	I-PK
53	(	I-PK
53	t	I-PK
53	##1	I-PK
53	/	I-PK
53	2	I-PK
53	)	I-PK
53	was	O
53	0	O
53	.	O
53	8	O
53	versus	O
53	1	O
53	.	O
53	4	O
53	hours	O
53	(	O
53	p	O
53	=	O
53	0	O
53	.	O
53	00	O
53	##3	O
53	)	O
53	and	O
53	total	B-PK
53	plasma	I-PK
53	clearance	I-PK
53	was	O
53	120	O
53	##1	O
53	versus	O
53	70	O
53	##5	O
53	m	O
53	##l	O
53	per	O
53	minute	O
53	(	O
53	p	O
53	=	O
53	0	O
53	.	O
53	00	O
53	##9	O
53	)	O
53	for	O
53	control	O
53	subjects	O
53	versus	O
53	patients	O
53	with	O
53	c	O
53	##ir	O
53	##r	O
53	##hos	O
53	##is	O
53	.	O
53	[SEP]	O
54	[CLS]	O
54	the	O
54	aim	O
54	of	O
54	this	O
54	study	O
54	was	O
54	to	O
54	develop	O
54	a	O
54	limited	O
54	sampling	O
54	strategy	O
54	(	O
54	l	O
54	##ss	O
54	)	O
54	for	O
54	therapeutic	O
54	drug	O
54	monitoring	O
54	assistance	O
54	for	O
54	r	O
54	##mp	O
54	.	O
54	[SEP]	O
55	[CLS]	O
55	for	O
55	this	O
55	group	O
55	,	O
55	the	O
55	median	O
55	ca	B-PK
55	##v	I-PK
55	##g	I-PK
55	was	O
55	4	O
55	.	O
55	0	O
55	μ	O
55	##g	O
55	/	O
55	m	O
55	##l	O
55	,	O
55	and	O
55	the	O
55	median	O
55	cm	B-PK
55	##ax	I-PK
55	was	O
55	5	O
55	.	O
55	2	O
55	μ	O
55	##g	O
55	/	O
55	m	O
55	##l	O
55	.	O
55	[SEP]	O
56	[CLS]	O
56	urine	O
56	was	O
56	collected	O
56	in	O
56	6	O
56	-	O
56	hour	O
56	pool	O
56	##ed	O
56	al	O
56	##iq	O
56	##uo	O
56	##ts	O
56	for	O
56	a	O
56	total	O
56	of	O
56	24	O
56	hours	O
56	.	O
56	[SEP]	O
57	[CLS]	O
57	do	O
57	##x	O
57	##or	O
57	##ubi	O
57	##cin	O
57	plasma	O
57	p	O
57	##har	O
57	##ma	O
57	##co	O
57	##kin	O
57	##etics	O
57	were	O
57	prolonged	O
57	after	O
57	c	O
57	##ime	O
57	##ti	O
57	##dine	O
57	pre	O
57	##tre	O
57	##at	O
57	##ment	O
57	[	O
57	au	B-PK
57	##c	I-PK
57	0	O
57	.	O
57	76	O
57	+	O
57	-	O
57	0	O
57	.	O
57	22	O
57	vs	O
57	.	O
57	2	O
57	.	O
57	85	O
57	+	O
57	-	O
57	1	O
57	.	O
57	22	O
57	micro	O
57	##m	O
57	x	O
57	h	O
57	,	O
57	no	O
57	pre	O
57	##tre	O
57	##at	O
57	##ment	O
57	vs	O
57	pre	O
57	##tre	O
57	##at	O
57	##ment	O
57	(	O
57	p	O
57	=	O
57	0	O
57	.	O
57	00	O
57	##5	O
57	)	O
57	,	O
57	half	B-PK
57	-	I-PK
57	life	I-PK
57	=	O
57	11	O
57	.	O
57	7	O
57	+	O
57	-	O
57	6	O
57	.	O
57	55	O
57	vs	O
57	28	O
57	.	O
57	0	O
57	+	O
57	-	O
57	8	O
57	.	O
57	16	O
57	h	O
57	(	O
57	p	O
57	=	O
57	0	O
57	.	O
57	000	O
57	##2	O
57	)	O
57	,	O
57	and	O
57	clearance	B-PK
57	=	O
57	0	O
57	.	O
57	129	O
57	+	O
57	-	O
57	0	O
57	.	O
57	03	O
57	##6	O
57	vs	O
57	0	O
57	.	O
57	03	O
57	##6	O
57	+	O
57	-	O
57	0	O
57	.	O
57	01	O
57	##1	O
57	l	O
57	/	O
57	min	O
57	-	O
57	1	O
57	kg	O
57	-	O
57	1	O
57	(	O
57	p	O
57	=	O
57	0	O
57	.	O
57	000	O
57	##7	O
57	)	O
57	]	O
57	.	O
57	[SEP]	O
58	[CLS]	O
58	no	O
58	pre	O
58	##med	O
58	##ica	O
58	##tion	O
58	,	O
58	including	O
58	s	O
58	##tero	O
58	##ids	O
58	or	O
58	dip	O
58	##hen	O
58	##hy	O
58	##dra	O
58	##mine	O
58	,	O
58	was	O
58	mandated	O
58	prior	O
58	to	O
58	treatment	O
58	with	O
58	o	O
58	##lar	O
58	##at	O
58	##uma	O
58	##b	O
58	.	O
58	[SEP]	O
59	[CLS]	O
59	interaction	O
59	of	O
59	car	O
59	##ba	O
59	##ma	O
59	##ze	O
59	##pine	O
59	and	O
59	pro	O
59	##met	O
59	##ha	O
59	##zine	O
59	in	O
59	rabbits	O
59	.	O
59	[SEP]	O
60	[CLS]	O
60	a	O
60	total	O
60	of	O
60	14	O
60	male	O
60	patients	O
60	were	O
60	enrolled	O
60	in	O
60	the	O
60	study	O
60	(	O
60	figure	O
60	1	O
60	)	O
60	,	O
60	and	O
60	their	O
60	base	O
60	##line	O
60	demographic	O
60	##s	O
60	and	O
60	clinical	O
60	characteristics	O
60	are	O
60	shown	O
60	in	O
60	table	O
60	1	O
60	.	O
60	[SEP]	O
61	[CLS]	O
61	clinical	O
61	data	O
61	on	O
61	re	O
61	##nal	O
61	,	O
61	liver	O
61	function	O
61	and	O
61	a	O
61	##r	O
61	##v	O
61	regime	O
61	##n	O
61	(	O
61	n	O
61	##uc	O
61	##leo	O
61	##side	O
61	reverse	O
61	trans	O
61	##cript	O
61	##ase	O
61	inhibitor	O
61	##s	O
61	(	O
61	n	O
61	##rt	O
61	##is	O
61	)	O
61	backbone	O
61	##s	O
61	and	O
61	use	O
61	of	O
61	third	O
61	agent	O
61	)	O
61	were	O
61	collected	O
61	.	O
61	[SEP]	O
62	[CLS]	O
62	to	O
62	imp	O
62	##art	O
62	the	O
62	in	O
62	##hala	O
62	##ble	O
62	and	O
62	rapid	O
62	release	O
62	(	O
62	r	O
62	##r	O
62	)	O
62	attributes	O
62	,	O
62	9	O
62	-	O
62	br	O
62	-	O
62	no	O
62	##s	O
62	-	O
62	n	O
62	##l	O
62	##ps	O
62	were	O
62	treated	O
62	with	O
62	spray	O
62	dried	O
62	la	O
62	##ct	O
62	##ose	O
62	and	O
62	e	O
62	##ffer	O
62	##ves	O
62	##cent	O
62	ex	O
62	##ci	O
62	##pie	O
62	##nts	O
62	to	O
62	generate	O
62	,	O
62	9	O
62	-	O
62	br	O
62	-	O
62	no	O
62	##s	O
62	-	O
62	r	O
62	##r	O
62	-	O
62	n	O
62	##l	O
62	##ps	O
62	.	O
62	[SEP]	O
63	[CLS]	O
63	these	O
63	results	O
63	are	O
63	consistent	O
63	with	O
63	the	O
63	expected	O
63	prolonged	O
63	clearance	B-PK
63	kinetic	O
63	##s	O
63	of	O
63	p	O
63	##nt	O
63	##22	O
63	##5	O
63	##8	O
63	due	O
63	to	O
63	sat	O
63	##uration	O
63	of	O
63	the	O
63	re	O
63	##tic	O
63	##ulo	O
63	##end	O
63	##oth	O
63	##eli	O
63	##al	O
63	system	O
63	(	O
63	re	O
63	##s	O
63	)	O
63	clearance	B-PK
63	mechanisms	O
63	and	O
63	are	O
63	similar	O
63	to	O
63	those	O
63	noted	O
63	in	O
63	the	O
63	toxic	O
63	##ology	O
63	studies	O
63	[	O
63	14	O
63	,	O
63	15	O
63	,	O
63	17	O
63	]	O
63	.	O
63	[SEP]	O
64	[CLS]	O
64	all	O
64	these	O
64	characteristics	O
64	make	O
64	p	O
64	##eg	O
64	-	O
64	c	O
64	##pt	O
64	con	O
64	##ju	O
64	##gate	O
64	an	O
64	attractive	O
64	anti	O
64	##can	O
64	##cer	O
64	drug	O
64	for	O
64	the	O
64	effective	O
64	ch	O
64	##em	O
64	##otherapy	O
64	of	O
64	solid	O
64	tumors	O
64	.	O
64	[SEP]	O
65	[CLS]	O
65	p	O
65	##ome	O
65	##gra	O
65	##nate	O
65	juice	O
65	and	O
65	a	O
65	1	O
65	-	O
65	g	O
65	capsule	O
65	containing	O
65	p	O
65	##ome	O
65	##gra	O
65	##nate	O
65	extract	O
65	were	O
65	evaluated	O
65	in	O
65	v	O
65	##it	O
65	##ro	O
65	and	O
65	in	O
65	v	O
65	##ivo	O
65	as	O
65	inhibitor	O
65	##s	O
65	of	O
65	c	O
65	##yt	O
65	##och	O
65	##rome	O
65	p	O
65	##45	O
65	##0	O
65	2	O
65	##c	O
65	##9	O
65	(	O
65	c	O
65	##y	O
65	##p	O
65	##2	O
65	##c	O
65	##9	O
65	)	O
65	,	O
65	with	O
65	flu	O
65	##rb	O
65	##ip	O
65	##ro	O
65	##fen	O
65	serving	O
65	as	O
65	the	O
65	index	O
65	substrate	O
65	.	O
65	[SEP]	O
66	[CLS]	O
66	in	O
66	particular	O
66	,	O
66	11	O
66	of	O
66	13	O
66	patients	O
66	with	O
66	infections	O
66	due	O
66	to	O
66	t	O
66	##ica	O
66	##rc	O
66	##ill	O
66	##in	O
66	-	O
66	resistant	O
66	p	O
66	.	O
66	a	O
66	##er	O
66	##ug	O
66	##ino	O
66	##sa	O
66	were	O
66	cured	O
66	and	O
66	two	O
66	improved	O
66	.	O
66	[SEP]	O
67	[CLS]	O
67	considering	O
67	the	O
67	diversity	O
67	in	O
67	the	O
67	patient	O
67	populations	O
67	in	O
67	global	O
67	clinical	O
67	trials	O
67	,	O
67	a	O
67	cross	O
67	‐	O
67	study	O
67	comparison	O
67	assessing	O
67	r	O
67	##iva	O
67	##ro	O
67	##xa	O
67	##ban	O
67	exposure	O
67	in	O
67	later	O
67	‐	O
67	phase	O
67	clinical	O
67	studies	O
67	would	O
67	enhance	O
67	our	O
67	understanding	O
67	of	O
67	the	O
67	potential	O
67	impact	O
67	of	O
67	meal	O
67	intake	O
67	,	O
67	with	O
67	regard	O
67	to	O
67	the	O
67	timing	O
67	and	O
67	content	O
67	,	O
67	in	O
67	real	O
67	‐	O
67	world	O
67	patient	O
67	care	O
67	.	O
67	[SEP]	O
68	[CLS]	O
68	the	O
68	rate	B-PK
68	of	I-PK
68	drug	I-PK
68	residue	I-PK
68	elimination	I-PK
68	was	O
68	notice	O
68	##ably	O
68	slower	O
68	in	O
68	the	O
68	i	O
68	##c	O
68	-	O
68	affected	O
68	group	O
68	.	O
68	[SEP]	O
69	[CLS]	O
69	the	O
69	p	O
69	##har	O
69	##ma	O
69	##co	O
69	##kin	O
69	##etic	O
69	parameters	O
69	were	O
69	calculated	O
69	using	O
69	non	O
69	-	O
69	compartment	O
69	##al	O
69	model	O
69	analysis	O
69	.	O
69	[SEP]	O
70	[CLS]	O
70	nineteen	O
70	patients	O
70	(	O
70	51	O
70	%	O
70	)	O
70	were	O
70	taking	O
70	e	O
70	##iae	O
70	##ds	O
70	.	O
70	[SEP]	O
71	[CLS]	O
71	concentrations	O
71	of	O
71	ben	O
71	##zo	O
71	##dia	O
71	##ze	O
71	##pine	O
71	##s	O
71	in	O
71	plasma	O
71	and	O
71	c	O
71	##s	O
71	##f	O
71	samples	O
71	were	O
71	measured	O
71	by	O
71	electron	O
71	-	O
71	capture	O
71	gas	O
71	-	O
71	liquid	O
71	ch	O
71	##roma	O
71	##tography	O
71	and	O
71	plasma	O
71	protein	O
71	binding	O
71	determined	O
71	by	O
71	equilibrium	O
71	dial	O
71	##ys	O
71	##is	O
71	.	O
71	[SEP]	O
72	[CLS]	O
72	the	O
72	trial	O
72	was	O
72	conducted	O
72	as	O
72	an	O
72	in	O
72	##patient	O
72	study	O
72	at	O
72	a	O
72	single	O
72	clinical	O
72	site	O
72	.	O
72	[SEP]	O
73	[CLS]	O
73	per	O
73	##fusion	O
73	##s	O
73	without	O
73	sodium	O
73	drastically	O
73	reduced	O
73	the	O
73	in	O
73	##test	O
73	##inal	O
73	loss	O
73	of	O
73	rib	O
73	##avi	O
73	##rin	O
73	in	O
73	both	O
73	wild	O
73	-	O
73	type	O
73	and	O
73	en	O
73	##t	O
73	##1	O
73	(	O
73	-	O
73	/	O
73	-	O
73	)	O
73	mice	O
73	.	O
73	[SEP]	O
74	[CLS]	O
74	subjects	O
74	were	O
74	to	O
74	a	O
74	##bs	O
74	##tain	O
74	from	O
74	s	O
74	##tre	O
74	##nu	O
74	##ous	O
74	exercise	O
74	for	O
74	48	O
74	h	O
74	prior	O
74	to	O
74	each	O
74	blood	O
74	sample	O
74	collection	O
74	.	O
74	[SEP]	O
75	[CLS]	O
75	1	O
75	##h	O
75	-	O
75	nm	O
75	##r	O
75	(	O
75	c	O
75	##d	O
75	##c	O
75	##l	O
75	##3	O
75	)	O
75	δ	O
75	(	O
75	pp	O
75	##m	O
75	)	O
75	:	O
75	1	O
75	.	O
75	21	O
75	(	O
75	s	O
75	,	O
75	9	O
75	##h	O
75	,	O
75	-	O
75	c	O
75	(	O
75	ch	O
75	##3	O
75	)	O
75	3	O
75	)	O
75	,	O
75	1	O
75	.	O
75	27	O
75	–	O
75	1	O
75	.	O
75	28	O
75	(	O
75	d	O
75	,	O
75	3	O
75	##h	O
75	,	O
75	j	O
75	=	O
75	6	O
75	.	O
75	55	O
75	h	O
75	##z	O
75	,	O
75	-	O
75	ch	O
75	##ch	O
75	##3	O
75	)	O
75	,	O
75	2	O
75	.	O
75	18	O
75	(	O
75	s	O
75	,	O
75	3	O
75	##h	O
75	,	O
75	-	O
75	n	O
75	##ch	O
75	##3	O
75	)	O
75	,	O
75	4	O
75	.	O
75	59	O
75	–	O
75	4	O
75	.	O
75	64	O
75	(	O
75	q	O
75	,	O
75	1	O
75	##h	O
75	,	O
75	j	O
75	=	O
75	7	O
75	.	O
75	0	O
75	h	O
75	##z	O
75	,	O
75	-	O
75	ch	O
75	##ch	O
75	##3	O
75	)	O
75	,	O
75	7	O
75	.	O
75	36	O
75	–	O
75	8	O
75	.	O
75	09	O
75	(	O
75	m	O
75	,	O
75	4	O
75	##h	O
75	,	O
75	4	O
75	×	O
75	a	O
75	##r	O
75	-	O
75	h	O
75	)	O
75	.	O
75	[SEP]	O
76	[CLS]	O
76	bio	O
76	##ana	O
76	##lysis	O
76	and	O
76	evaluation	O
76	of	O
76	adverse	O
76	events	O
76	were	O
76	performed	O
76	in	O
76	non	O
76	##blin	O
76	##ded	O
76	fashion	O
76	.	O
76	[SEP]	O
77	[CLS]	O
77	to	O
77	choose	O
77	the	O
77	op	O
77	##ti	O
77	##mum	O
77	compartment	O
77	model	O
77	for	O
77	fitting	O
77	the	O
77	plasma	O
77	concentration	O
77	–	O
77	time	O
77	curve	O
77	,	O
77	the	O
77	minimum	O
77	aka	O
77	##ike	O
77	’	O
77	s	O
77	information	O
77	criterion	O
77	(	O
77	a	O
77	##ic	O
77	)	O
77	est	O
77	##imation	O
77	was	O
77	tested	O
77	by	O
77	calculating	O
77	the	O
77	lowest	O
77	a	O
77	##ic	O
77	value	O
77	.	O
77	[SEP]	O
78	[CLS]	O
78	the	O
78	objective	O
78	of	O
78	this	O
78	study	O
78	was	O
78	to	O
78	evaluate	O
78	the	O
78	difference	O
78	in	O
78	the	O
78	p	O
78	##har	O
78	##ma	O
78	##co	O
78	##kin	O
78	##etics	O
78	of	O
78	z	O
78	##ol	O
78	##pid	O
78	##em	O
78	ta	O
78	##trate	O
78	in	O
78	subjects	O
78	from	O
78	five	O
78	chin	O
78	##ese	O
78	ethnic	O
78	##ities	O
78	(	O
78	ha	O
78	##n	O
78	,	O
78	mon	O
78	##gol	O
78	##ian	O
78	,	O
78	u	O
78	##ig	O
78	##ur	O
78	,	O
78	k	O
78	##ore	O
78	##an	O
78	and	O
78	h	O
78	##ui	O
78	)	O
78	.	O
78	[SEP]	O
79	[CLS]	O
79	doses	O
79	were	O
79	es	O
79	##calated	O
79	from	O
79	45	O
79	mg	O
79	/	O
79	m	O
79	##2	O
79	to	O
79	400	O
79	mg	O
79	/	O
79	m	O
79	##2	O
79	in	O
79	the	O
79	6	O
79	-	O
79	hour	O
79	in	O
79	##fusion	O
79	schedule	O
79	,	O
79	and	O
79	from	O
79	250	O
79	mg	O
79	/	O
79	m	O
79	##2	O
79	to	O
79	330	O
79	mg	O
79	/	O
79	m	O
79	##2	O
79	in	O
79	the	O
79	subsequent	O
79	3	O
79	-	O
79	hour	O
79	in	O
79	##fusion	O
79	schedule	O
79	.	O
79	[SEP]	O
80	[CLS]	O
80	the	O
80	coefficient	O
80	of	O
80	variation	O
80	(	O
80	c	O
80	##v	O
80	)	O
80	was	O
80	used	O
80	to	O
80	estimate	O
80	the	O
80	precision	O
80	.	O
80	[SEP]	O
81	[CLS]	O
81	the	O
81	data	O
81	used	O
81	in	O
81	statistical	O
81	analyses	O
81	were	O
81	acquired	O
81	from	O
81	6	O
81	animals	O
81	for	O
81	each	O
81	group	O
81	.	O
81	[SEP]	O
82	[CLS]	O
82	no	O
82	para	O
82	##cellular	O
82	transport	O
82	of	O
82	s	O
82	##f	O
82	##n	O
82	-	O
82	ng	O
82	##s	O
82	was	O
82	found	O
82	,	O
82	and	O
82	the	O
82	trafficking	O
82	of	O
82	s	O
82	##f	O
82	##n	O
82	-	O
82	ng	O
82	##s	O
82	was	O
82	affected	O
82	by	O
82	the	O
82	pathway	O
82	of	O
82	er	O
82	-	O
82	go	O
82	##l	O
82	##gi	O
82	complexes	O
82	.	O
82	[SEP]	O
83	[CLS]	O
83	ch	O
83	##roma	O
83	##to	O
83	##graphic	O
83	separation	O
83	of	O
83	do	O
83	##x	O
83	##or	O
83	##ubi	O
83	##cin	O
83	in	O
83	various	O
83	o	O
83	##cular	O
83	tissues	O
83	was	O
83	performed	O
83	on	O
83	a	O
83	c	O
83	##18	O
83	column	O
83	.	O
83	[SEP]	O
84	[CLS]	O
84	the	O
84	results	O
84	of	O
84	correlation	O
84	analysis	O
84	of	O
84	toxic	O
84	##ities	O
84	and	O
84	tumor	O
84	shrink	O
84	##age	O
84	with	O
84	the	O
84	p	O
84	##d	O
84	change	O
84	in	O
84	plasma	O
84	proteins	O
84	at	O
84	cycle	O
84	1	O
84	are	O
84	listed	O
84	in	O
84	table	O
84	2	O
84	.	O
84	[SEP]	O
85	[CLS]	O
85	evidence	O
85	for	O
85	a	O
85	novel	O
85	in	O
85	v	O
85	##ivo	O
85	control	O
85	mechanism	O
85	of	O
85	g	O
85	##ran	O
85	##ulo	O
85	##po	O
85	##ies	O
85	##is	O
85	:	O
85	mature	O
85	cell	O
85	-	O
85	related	O
85	control	O
85	of	O
85	a	O
85	regulatory	O
85	growth	O
85	factor	O
85	.	O
85	[SEP]	O
86	[CLS]	O
86	in	O
86	comparison	O
86	to	O
86	previous	O
86	experience	O
86	with	O
86	a	O
86	##be	O
86	##xin	O
86	##ost	O
86	##at	O
86	administered	O
86	on	O
86	a	O
86	1	O
86	-	O
86	week	O
86	-	O
86	on	O
86	/	O
86	1	O
86	-	O
86	week	O
86	-	O
86	off	O
86	schedule	O
86	,	O
86	17	O
86	weekly	O
86	monitoring	O
86	for	O
86	th	O
86	##rom	O
86	##bo	O
86	##cy	O
86	##top	O
86	##enia	O
86	showed	O
86	that	O
86	plate	O
86	##let	O
86	counts	O
86	fell	O
86	sharply	O
86	during	O
86	the	O
86	14	O
86	days	O
86	on	O
86	a	O
86	##be	O
86	##xin	O
86	##ost	O
86	##at	O
86	and	O
86	recovered	O
86	before	O
86	the	O
86	start	O
86	of	O
86	the	O
86	next	O
86	cycle	O
86	(	O
86	figure	O
86	1	O
86	)	O
86	.	O
86	[SEP]	O
87	[CLS]	O
87	high	O
87	-	O
87	dose	O
87	pro	O
87	##ges	O
87	##tin	O
87	##s	O
87	given	O
87	oral	O
87	##ly	O
87	do	O
87	not	O
87	seem	O
87	to	O
87	have	O
87	a	O
87	major	O
87	influence	O
87	on	O
87	drug	O
87	metabolism	O
87	,	O
87	probably	O
87	reflecting	O
87	a	O
87	minor	O
87	effect	O
87	on	O
87	drug	O
87	and	O
87	s	O
87	##tero	O
87	##id	O
87	-	O
87	meta	O
87	##bol	O
87	##izing	O
87	micro	O
87	##so	O
87	##mal	O
87	mon	O
87	##o	O
87	-	O
87	oxygen	O
87	##ases	O
87	in	O
87	the	O
87	liver	O
87	.	O
87	[SEP]	O
88	[CLS]	O
88	6	O
88	-	O
88	t	O
88	##gn	O
88	and	O
88	6	O
88	-	O
88	mm	O
88	##p	O
88	##r	O
88	concentrations	O
88	were	O
88	determined	O
88	before	O
88	initiation	O
88	of	O
88	ad	O
88	##ali	O
88	##mum	O
88	##ab	O
88	and	O
88	after	O
88	2	O
88	,	O
88	4	O
88	,	O
88	6	O
88	and	O
88	12	O
88	weeks	O
88	of	O
88	combination	O
88	therapy	O
88	.	O
88	[SEP]	O
89	[CLS]	O
89	finally	O
89	,	O
89	an	O
89	ex	O
89	v	O
89	##ivo	O
89	rat	O
89	liver	O
89	un	O
89	##sche	O
89	##du	O
89	##led	O
89	d	O
89	##na	O
89	synthesis	O
89	study	O
89	(	O
89	table	O
89	8	O
89	##c	O
89	)	O
89	confirmed	O
89	the	O
89	lack	O
89	of	O
89	ma	O
89	##mmal	O
89	##ian	O
89	g	O
89	##eno	O
89	##to	O
89	##xi	O
89	##c	O
89	activity	O
89	for	O
89	f	O
89	##ex	O
89	##ini	O
89	##da	O
89	##zo	O
89	##le	O
89	and	O
89	its	O
89	meta	O
89	##bol	O
89	##ites	O
89	[	O
89	data	O
89	##set	O
89	s	O
89	##21	O
89	]	O
89	.	O
89	[SEP]	O
90	[CLS]	O
90	the	O
90	plasma	O
90	concentration	O
90	of	O
90	di	O
90	##lma	O
90	##pi	O
90	##mo	O
90	##d	O
90	was	O
90	adequately	O
90	described	O
90	by	O
90	a	O
90	three	O
90	-	O
90	compartment	O
90	model	O
90	.	O
90	[SEP]	O
91	[CLS]	O
91	there	O
91	was	O
91	no	O
91	association	O
91	between	O
91	all	O
91	##eli	O
91	##c	O
91	variants	O
91	and	O
91	bleeding	O
91	events	O
91	.	O
91	[SEP]	O
92	[CLS]	O
92	the	O
92	recommended	O
92	dose	O
92	was	O
92	defined	O
92	as	O
92	the	O
92	highest	O
92	dose	O
92	at	O
92	which	O
92	not	O
92	more	O
92	than	O
92	2	O
92	out	O
92	of	O
92	6	O
92	patients	O
92	had	O
92	d	O
92	##lt	O
92	during	O
92	the	O
92	first	O
92	two	O
92	cycles	O
92	after	O
92	i	O
92	##pi	O
92	##lim	O
92	##uma	O
92	##b	O
92	treatment	O
92	(	O
92	i	O
92	.	O
92	e	O
92	.	O
92	,	O
92	from	O
92	day	O
92	1	O
92	at	O
92	cycle	O
92	3	O
92	to	O
92	day	O
92	21	O
92	at	O
92	cycle	O
92	4	O
92	)	O
92	.	O
92	[SEP]	O
93	[CLS]	O
93	the	O
93	clearance	B-PK
93	for	O
93	a	O
93	##c	O
93	##p	O
93	-	O
93	58	O
93	##6	O
93	##2	O
93	was	O
93	21	O
93	.	O
93	9	O
93	l	O
93	/	O
93	h	O
93	(	O
93	95	O
93	%	O
93	c	O
93	##i	O
93	19	O
93	.	O
93	5	O
93	-	O
93	24	O
93	.	O
93	0	O
93	)	O
93	.	O
93	[SEP]	O
94	[CLS]	O
94	non	O
94	-	O
94	therapeutic	O
94	drug	O
94	levels	O
94	were	O
94	greater	O
94	than	O
94	9	O
94	times	O
94	more	O
94	likely	O
94	to	O
94	result	O
94	in	O
94	an	O
94	ad	O
94	##e	O
94	requiring	O
94	drug	O
94	disco	O
94	##ntin	O
94	##uation	O
94	(	O
94	p	O
94	=	O
94	0	O
94	.	O
94	01	O
94	)	O
94	(	O
94	table	O
94	2	O
94	)	O
94	.	O
94	[SEP]	O
95	[CLS]	O
95	to	O
95	this	O
95	end	O
95	,	O
95	small	O
95	-	O
95	animal	O
95	pet	O
95	imaging	O
95	was	O
95	performed	O
95	on	O
95	h	O
95	##t	O
95	-	O
95	108	O
95	##0	O
95	-	O
95	f	O
95	##ap	O
95	x	O
95	##eno	O
95	##gra	O
95	##fted	O
95	mice	O
95	.	O
95	[SEP]	O
96	[CLS]	O
96	each	O
96	plasma	O
96	sample	O
96	was	O
96	di	O
96	##lut	O
96	##ed	O
96	10	O
96	-	O
96	fold	O
96	with	O
96	500	O
96	mm	O
96	na	O
96	##c	O
96	##l	O
96	in	O
96	100	O
96	mm	O
96	t	O
96	##ris	O
96	-	O
96	h	O
96	##c	O
96	##l	O
96	buffer	O
96	(	O
96	p	O
96	##h	O
96	9	O
96	.	O
96	0	O
96	)	O
96	,	O
96	5	O
96	mm	O
96	mg	O
96	##c	O
96	##l	O
96	##2	O
96	,	O
96	and	O
96	0	O
96	.	O
96	05	O
96	%	O
96	t	O
96	##rito	O
96	##n	O
96	x	O
96	-	O
96	100	O
96	.	O
96	[SEP]	O
97	[CLS]	O
97	linear	O
97	detection	O
97	responses	O
97	were	O
97	obtained	O
97	for	O
97	the	O
97	three	O
97	test	O
97	compounds	O
97	ranging	O
97	from	O
97	5	O
97	to	O
97	5000	O
97	ng	O
97	/	O
97	m	O
97	##l	O
97	and	O
97	the	O
97	lower	O
97	limits	O
97	of	O
97	q	O
97	##uant	O
97	##itation	O
97	were	O
97	5	O
97	-	O
97	10	O
97	ng	O
97	/	O
97	m	O
97	##l	O
97	.	O
97	the	O
97	in	O
97	##tra	O
97	-	O
97	and	O
97	inter	O
97	-	O
97	day	O
97	precision	O
97	##s	O
97	(	O
97	relative	O
97	standard	O
97	de	O
97	##viation	O
97	##s	O
97	)	O
97	were	O
97	within	O
97	9	O
97	.	O
97	4	O
97	%	O
97	for	O
97	all	O
97	anal	O
97	##yte	O
97	##s	O
97	,	O
97	while	O
97	the	O
97	de	O
97	##viation	O
97	of	O
97	ass	O
97	##ay	O
97	a	O
97	##cc	O
97	##ura	O
97	##cies	O
97	was	O
97	within	O
97	±	O
97	##10	O
97	.	O
97	0	O
97	%	O
97	.	O
97	[SEP]	O
98	[CLS]	O
98	the	O
98	animals	O
98	were	O
98	kept	O
98	under	O
98	controlled	O
98	conditions	O
98	(	O
98	temperature	O
98	:	O
98	23	O
98	±	O
98	2	O
98	°	O
98	##c	O
98	;	O
98	humidity	O
98	:	O
98	55	O
98	±	O
98	5	O
98	%	O
98	)	O
98	for	O
98	one	O
98	week	O
98	a	O
98	##cc	O
98	##lim	O
98	##ation	O
98	before	O
98	experiment	O
98	and	O
98	were	O
98	allowed	O
98	free	O
98	access	O
98	to	O
98	standard	O
98	laboratory	O
98	diet	O
98	and	O
98	water	O
98	during	O
98	the	O
98	period	O
98	.	O
98	[SEP]	O
99	[CLS]	O
99	primary	O
99	objectives	O
99	included	O
99	assessment	O
99	of	O
99	safety	O
99	and	O
99	to	O
99	##ler	O
99	##ability	O
99	(	O
99	measured	O
99	by	O
99	adverse	O
99	events	O
99	and	O
99	clinical	O
99	laboratory	O
99	monitoring	O
99	)	O
99	,	O
99	p	O
99	##har	O
99	##ma	O
99	##co	O
99	##kin	O
99	##etics	O
99	(	O
99	measured	O
99	as	O
99	drug	O
99	and	O
99	drug	O
99	-	O
99	iron	O
99	complex	O
99	)	O
99	,	O
99	and	O
99	cumulative	O
99	net	O
99	iron	O
99	ex	O
99	##cre	O
99	##tion	O
99	(	O
99	measured	O
99	by	O
99	f	O
99	##ae	O
99	##cal	O
99	and	O
99	urine	O
99	output	O
99	minus	O
99	food	O
99	input	O
99	)	O
99	.	O
99	[SEP]	O
100	[CLS]	O
100	this	O
100	phase	O
100	1	O
100	,	O
100	single	O
100	-	O
100	centre	O
100	,	O
100	single	O
100	-	O
100	co	O
100	##hor	O
100	##t	O
100	,	O
100	open	O
100	-	O
100	label	O
100	,	O
100	random	O
100	##ized	O
100	,	O
100	four	O
100	-	O
100	period	O
100	crossover	O
100	study	O
100	in	O
100	healthy	O
100	subjects	O
100	(	O
100	n	O
100	##ct	O
100	##0	O
100	##25	O
100	##5	O
100	##7	O
100	##7	O
100	##8	O
100	##9	O
100	)	O
100	evaluated	O
100	the	O
100	bio	B-PK
100	##ava	I-PK
100	##ila	I-PK
100	##bility	I-PK
100	,	O
100	p	O
100	##k	O
100	,	O
100	safety	O
100	and	O
100	to	O
100	##ler	O
100	##ability	O
100	of	O
100	a	O
100	600	O
100	mg	O
100	immediate	O
100	-	O
100	release	O
100	(	O
100	i	O
100	##r	O
100	)	O
100	tablet	O
100	of	O
100	le	O
100	##fa	O
100	##mu	O
100	##lin	O
100	administered	O
100	in	O
100	the	O
100	fed	O
100	or	O
100	fast	O
100	##ed	O
100	state	O
100	compared	O
100	with	O
100	i	O
100	##v	O
100	and	O
100	capsule	O
100	formulation	O
100	##s	O
100	.	O
100	[SEP]	O
101	[CLS]	O
101	the	O
101	follow	O
101	-	O
101	up	O
101	phase	O
101	was	O
101	conducted	O
101	approximately	O
101	four	O
101	to	O
101	eight	O
101	days	O
101	following	O
101	discharge	O
101	from	O
101	the	O
101	clinic	O
101	.	O
101	[SEP]	O
102	[CLS]	O
102	for	O
102	one	O
102	patient	O
102	,	O
102	no	O
102	base	O
102	##line	O
102	e	O
102	##co	O
102	##g	O
102	performance	O
102	status	O
102	was	O
102	documented	O
102	.	O
102	[SEP]	O
103	[CLS]	O
103	the	O
103	demographic	O
103	##s	O
103	of	O
103	the	O
103	1000	O
103	simulated	O
103	ca	O
103	##uca	O
103	##sian	O
103	,	O
103	chin	O
103	##ese	O
103	and	O
103	j	O
103	##apa	O
103	##nese	O
103	subjects	O
103	can	O
103	be	O
103	seen	O
103	in	O
103	electronic	O
103	supplement	O
103	##ary	O
103	material	O
103	table	O
103	2	O
103	.	O
103	[SEP]	O
104	[CLS]	O
104	co	O
104	##hor	O
104	##ts	O
104	2	O
104	through	O
104	6	O
104	were	O
104	dose	O
104	##d	O
104	a	O
104	minimum	O
104	of	O
104	three	O
104	weeks	O
104	after	O
104	dos	O
104	##ing	O
104	of	O
104	the	O
104	last	O
104	patient	O
104	in	O
104	the	O
104	previous	O
104	co	O
104	##hor	O
104	##t	O
104	.	O
104	[SEP]	O
105	[CLS]	O
105	clinical	O
105	studies	O
105	should	O
105	be	O
105	performed	O
105	to	O
105	confirm	O
105	this	O
105	theoretical	O
105	p	O
105	##har	O
105	##ma	O
105	##co	O
105	##kin	O
105	##etic	O
105	advantage	O
105	.	O
105	[SEP]	O
106	[CLS]	O
106	on	O
106	the	O
106	study	O
106	day	O
106	,	O
106	the	O
106	patients	O
106	took	O
106	a	O
106	2	O
106	.	O
106	5	O
106	mg	O
106	liquid	O
106	test	O
106	dose	O
106	of	O
106	g	O
106	##ly	O
106	##bur	O
106	##ide	O
106	with	O
106	a	O
106	su	O
106	##sta	O
106	##cal	O
106	meal	O
106	challenge	O
106	.	O
106	[SEP]	O
107	[CLS]	O
107	1	O
107	.	O
107	[SEP]	O
108	[CLS]	O
108	for	O
108	each	O
108	calculation	O
108	of	O
108	r	O
108	##g	O
108	##c	O
108	only	O
108	one	O
108	randomly	O
108	selected	O
108	sibling	O
108	of	O
108	each	O
108	pair	O
108	was	O
108	used	O
108	,	O
108	since	O
108	the	O
108	two	O
108	siblings	O
108	of	O
108	each	O
108	twin	O
108	pair	O
108	are	O
108	not	O
108	independent	O
108	units	O
108	.	O
108	[SEP]	O
109	[CLS]	O
109	the	O
109	mean	O
109	el	O
109	##f	O
109	penetration	B-PK
109	ratio	I-PK
109	after	O
109	population	O
109	analyses	O
109	was	O
109	39	O
109	.	O
109	7	O
109	.	O
109	[SEP]	O
110	[CLS]	O
110	in	O
110	women	O
110	on	O
110	n	O
110	##v	O
110	##p	O
110	-	O
110	based	O
110	art	O
110	,	O
110	l	O
110	##ng	O
110	concentrations	O
110	were	O
110	32	O
110	–	O
110	39	O
110	%	O
110	higher	O
110	than	O
110	those	O
110	observed	O
110	in	O
110	the	O
110	control	O
110	group	O
110	,	O
110	a	O
110	difference	O
110	partially	O
110	explained	O
110	by	O
110	body	O
110	weight	O
110	.	O
110	[SEP]	O
111	[CLS]	O
111	our	O
111	data	O
111	provide	O
111	evidence	O
111	for	O
111	the	O
111	in	O
111	##tra	O
111	##co	O
111	##ch	O
111	##lea	O
111	##r	O
111	diffusion	O
111	of	O
111	the	O
111	molecule	O
111	,	O
111	which	O
111	may	O
111	be	O
111	relevant	O
111	for	O
111	the	O
111	treatment	O
111	of	O
111	sensor	O
111	##ine	O
111	##ural	O
111	hearing	O
111	loss	O
111	in	O
111	con	O
111	##gen	O
111	##ital	O
111	##ly	O
111	-	O
111	infected	O
111	children	O
111	.	O
111	[SEP]	O
112	[CLS]	O
112	c	B-PK
112	##ll	I-PK
112	decreased	O
112	by	O
112	78	O
112	%	O
112	in	O
112	subjects	O
112	weighing	O
112	50	O
112	kg	O
112	,	O
112	and	O
112	increased	O
112	by	O
112	40	O
112	%	O
112	in	O
112	subjects	O
112	weighing	O
112	100	O
112	kg	O
112	,	O
112	compared	O
112	with	O
112	a	O
112	typical	O
112	patient	O
112	weighing	O
112	82	O
112	.	O
112	9	O
112	kg	O
112	(	O
112	median	O
112	body	O
112	weight	O
112	)	O
112	.	O
112	[SEP]	O
113	[CLS]	O
113	the	O
113	average	O
113	weight	O
113	and	O
113	volume	O
113	of	O
113	the	O
113	tumors	O
113	are	O
113	shown	O
113	in	O
113	table	O
113	4	O
113	.	O
113	[SEP]	O
114	[CLS]	O
114	could	O
114	the	O
114	differences	O
114	be	O
114	explained	O
114	by	O
114	race	O
114	?	O
114	[SEP]	O
115	[CLS]	O
115	similarly	O
115	,	O
115	mean	O
115	u	O
115	##rina	O
115	##ry	O
115	recovery	O
115	and	O
115	re	B-PK
115	##nal	I-PK
115	clearance	I-PK
115	values	O
115	of	O
115	pen	O
115	##ci	O
115	##c	O
115	##lov	O
115	##ir	O
115	following	O
115	f	O
115	##am	O
115	##ci	O
115	##c	O
115	##lov	O
115	##ir	O
115	alone	O
115	were	O
115	56	O
115	.	O
115	8	O
115	%	O
115	and	O
115	27	O
115	l	O
115	.	O
115	h	O
115	-	O
115	1	O
115	,	O
115	and	O
115	when	O
115	given	O
115	with	O
115	all	O
115	##op	O
115	##uri	O
115	##no	O
115	##l	O
115	59	O
115	.	O
115	7	O
115	%	O
115	and	O
115	27	O
115	.	O
115	5	O
115	l	O
115	.	O
115	h	O
115	-	O
115	1	O
115	,	O
115	respectively	O
115	.	O
115	[SEP]	O
116	[CLS]	O
116	this	O
116	response	O
116	was	O
116	accompanied	O
116	by	O
116	c	O
116	##y	O
116	##p	O
116	##1	O
116	##a	O
116	induction	O
116	in	O
116	the	O
116	in	O
116	##test	O
116	##ine	O
116	,	O
116	but	O
116	little	O
116	effect	O
116	upon	O
116	the	O
116	o	O
116	##xi	O
116	##da	O
116	##tive	O
116	metabolism	O
116	of	O
116	the	O
116	subsequent	O
116	in	O
116	sit	O
116	##u	O
116	dose	O
116	of	O
116	[	O
116	14	O
116	##c	O
116	]	O
116	-	O
116	t	O
116	##c	O
116	##b	O
116	.	O
116	[SEP]	O
117	[CLS]	O
117	ne	O
117	##uro	O
117	##mus	O
117	##cular	O
117	function	O
117	was	O
117	monitored	O
117	me	O
117	##chan	O
117	##omy	O
117	##ographic	O
117	##ally	O
117	.	O
117	[SEP]	O
118	[CLS]	O
118	the	O
118	values	O
118	of	O
118	cm	B-PK
118	##ax	I-PK
118	and	O
118	au	B-PK
118	##c	I-PK
118	in	O
118	plasma	O
118	and	O
118	brain	O
118	showed	O
118	an	O
118	increase	O
118	of	O
118	respectively	O
118	about	O
118	three	O
118	and	O
118	twelve	O
118	times	O
118	after	O
118	chronic	O
118	treatment	O
118	.	O
118	[SEP]	O
119	[CLS]	O
119	two	O
119	phase	O
119	i	O
119	clinical	O
119	studies	O
119	assessed	O
119	the	O
119	safety	O
119	,	O
119	p	O
119	##har	O
119	##ma	O
119	##co	O
119	##kin	O
119	##etics	O
119	(	O
119	p	O
119	##ks	O
119	)	O
119	,	O
119	and	O
119	p	O
119	##har	O
119	##ma	O
119	##co	O
119	##log	O
119	##ic	O
119	effects	O
119	of	O
119	as	O
119	##p	O
119	##36	O
119	##6	O
119	##2	O
119	in	O
119	healthy	O
119	young	O
119	and	O
119	elderly	O
119	non	O
119	‐	O
119	j	O
119	##apa	O
119	##nese	O
119	and	O
119	young	O
119	j	O
119	##apa	O
119	##nese	O
119	subjects	O
119	.	O
119	[SEP]	O
120	[CLS]	O
120	the	O
120	investigator	O
120	suspected	O
120	a	O
120	ca	O
120	##usal	O
120	relationship	O
120	between	O
120	the	O
120	facial	O
120	swelling	O
120	and	O
120	the	O
120	administration	O
120	of	O
120	cu	O
120	##rc	O
120	##umi	O
120	##n	O
120	.	O
120	[SEP]	O
121	[CLS]	O
121	radio	O
121	##la	O
121	##bel	O
121	##ing	O
121	e	O
121	##ff	O
121	##ici	O
121	##encies	O
121	ranged	O
121	from	O
121	33	O
121	%	O
121	to	O
121	88	O
121	%	O
121	,	O
121	and	O
121	im	O
121	##mu	O
121	##nor	O
121	##ea	O
121	##ct	O
121	##ivity	O
121	was	O
121	42	O
121	%	O
121	(	O
121	di	O
121	##ab	O
121	##ody	O
121	)	O
121	or	O
121	>	O
121	90	O
121	%	O
121	(	O
121	mini	O
121	##body	O
121	)	O
121	.	O
121	[SEP]	O
122	[CLS]	O
122	during	O
122	the	O
122	first	O
122	4	O
122	days	O
122	of	O
122	g	O
122	##h	O
122	treatment	O
122	in	O
122	rats	O
122	,	O
122	no	O
122	change	O
122	in	O
122	plasma	O
122	re	O
122	##nin	O
122	activity	O
122	was	O
122	detected	O
122	and	O
122	we	O
122	were	O
122	thus	O
122	unable	O
122	to	O
122	confirm	O
122	the	O
122	hypothesis	O
122	that	O
122	the	O
122	re	O
122	##nin	O
122	-	O
122	an	O
122	##gio	O
122	##tens	O
122	##in	O
122	system	O
122	is	O
122	responsible	O
122	for	O
122	the	O
122	early	O
122	phase	O
122	of	O
122	g	O
122	##h	O
122	-	O
122	associated	O
122	fluid	O
122	retention	O
122	.	O
122	[SEP]	O
123	[CLS]	O
123	to	O
123	investigate	O
123	how	O
123	s	O
123	##to	O
123	-	O
123	60	O
123	##9	O
123	##s	O
123	conferred	O
123	improvement	O
123	of	O
123	he	O
123	##pa	O
123	##tic	O
123	s	O
123	##te	O
123	##ato	O
123	##sis	O
123	,	O
123	we	O
123	performed	O
123	targeted	O
123	meta	O
123	##bol	O
123	##omi	O
123	##cs	O
123	on	O
123	liver	O
123	##s	O
123	isolated	O
123	from	O
123	d	O
123	##ms	O
123	##o	O
123	or	O
123	s	O
123	##to	O
123	-	O
123	60	O
123	##9	O
123	##s	O
123	treated	O
123	mice	O
123	from	O
123	both	O
123	na	O
123	##f	O
123	##ld	O
123	models	O
123	.	O
123	[SEP]	O
124	[CLS]	O
124	the	O
124	drug	O
124	was	O
124	administered	O
124	p	O
124	.	O
124	o	O
124	.	O
124	or	O
124	i	O
124	.	O
124	v	O
124	.	O
124	,	O
124	and	O
124	throughout	O
124	an	O
124	8	O
124	-	O
124	h	O
124	##r	O
124	period	O
124	ethanol	O
124	(	O
124	100	O
124	mg	O
124	kg	O
124	-	O
124	1	O
124	h	O
124	##r	O
124	-	O
124	1	O
124	)	O
124	or	O
124	sa	O
124	##line	O
124	was	O
124	in	O
124	##fused	O
124	according	O
124	to	O
124	a	O
124	cross	O
124	-	O
124	over	O
124	design	O
124	.	O
124	[SEP]	O
125	[CLS]	O
125	significant	O
125	ne	O
125	##uro	O
125	##to	O
125	##xi	O
125	##city	O
125	,	O
125	which	O
125	was	O
125	dose	O
125	-	O
125	limiting	O
125	in	O
125	adults	O
125	treated	O
125	with	O
125	a	O
125	1	O
125	-	O
125	hour	O
125	in	O
125	##fusion	O
125	of	O
125	p	O
125	##za	O
125	,	O
125	was	O
125	observed	O
125	in	O
125	one	O
125	patient	O
125	treated	O
125	at	O
125	640	O
125	mg	O
125	/	O
125	m	O
125	##2	O
125	,	O
125	but	O
125	was	O
125	not	O
125	dose	O
125	-	O
125	limiting	O
125	.	O
125	[SEP]	O
126	[CLS]	O
126	the	O
126	median	O
126	values	O
126	for	O
126	is	O
126	##s	O
126	total	O
126	injury	O
126	score	O
126	and	O
126	g	O
126	##las	O
126	##go	O
126	##w	O
126	coma	O
126	score	O
126	were	O
126	25	O
126	and	O
126	15	O
126	,	O
126	respectively	O
126	,	O
126	indicating	O
126	severe	O
126	/	O
126	critical	O
126	trauma	O
126	and	O
126	mild	O
126	brain	O
126	injury	O
126	,	O
126	respectively	O
126	.	O
126	[SEP]	O
127	[CLS]	O
127	although	O
127	it	O
127	has	O
127	been	O
127	successfully	O
127	used	O
127	##in	O
127	an	O
127	in	O
127	##tra	O
127	##per	O
127	##ito	O
127	##nea	O
127	##l	O
127	form	O
127	in	O
127	studies	O
127	on	O
127	a	O
127	rode	O
127	##nt	O
127	model	O
127	of	O
127	pulmonary	O
127	##hy	O
127	##pert	O
127	##ens	O
127	##ion	O
127	,	O
127	22	O
127	its	O
127	dose	O
127	–	O
127	response	O
127	##cha	O
127	##rac	O
127	##ter	O
127	##istic	O
127	##s	O
127	were	O
127	not	O
127	explored	O
127	nor	O
127	have	O
127	its	O
127	p	O
127	##har	O
127	##ma	O
127	##co	O
127	##kin	O
127	##etic	O
127	properties	O
127	##bee	O
127	##n	O
127	characterized	O
127	.	O
127	[SEP]	O
128	[CLS]	O
128	concentration	O
128	values	O
128	below	O
128	the	O
128	lower	O
128	limit	O
128	of	O
128	q	O
128	##uant	O
128	##ification	O
128	were	O
128	taken	O
128	as	O
128	zero	O
128	for	O
128	the	O
128	summary	O
128	statistics	O
128	.	O
128	[SEP]	O
129	[CLS]	O
129	plasma	O
129	concentrations	O
129	were	O
129	determined	O
129	for	O
129	l	O
129	##y	O
129	##30	O
129	##0	O
129	##7	O
129	##11	O
129	##3	O
129	and	O
129	its	O
129	meta	O
129	##bol	O
129	##ites	O
129	,	O
129	l	O
129	##s	O
129	##n	O
129	##30	O
129	##25	O
129	##64	O
129	##1	O
129	and	O
129	l	O
129	##s	O
129	##n	O
129	##30	O
129	##47	O
129	##15	O
129	##1	O
129	,	O
129	using	O
129	a	O
129	valid	O
129	##ated	O
129	liquid	O
129	ch	O
129	##roma	O
129	##tography	O
129	with	O
129	tandem	O
129	mass	O
129	s	O
129	##pect	O
129	##rome	O
129	##try	O
129	method	O
129	.	O
129	[SEP]	O
130	[CLS]	O
130	plasma	O
130	samples	O
130	were	O
130	collected	O
130	immediately	O
130	prior	O
130	to	O
130	v	O
130	##ino	O
130	##rel	O
130	##bine	O
130	and	O
130	then	O
130	at	O
130	1	O
130	,	O
130	1	O
130	.	O
130	25	O
130	,	O
130	1	O
130	.	O
130	5	O
130	,	O
130	2	O
130	,	O
130	3	O
130	,	O
130	4	O
130	,	O
130	6	O
130	,	O
130	8	O
130	,	O
130	12	O
130	,	O
130	and	O
130	24	O
130	hours	O
130	after	O
130	the	O
130	start	O
130	of	O
130	the	O
130	in	O
130	##fusion	O
130	.	O
130	[SEP]	O
131	[CLS]	O
131	quality	O
131	controls	O
131	for	O
131	run	O
131	acceptance	O
131	were	O
131	prepared	O
131	and	O
131	analyzed	O
131	with	O
131	each	O
131	batch	O
131	of	O
131	sample	O
131	against	O
131	separately	O
131	prepared	O
131	ca	O
131	##li	O
131	##bra	O
131	##tion	O
131	standard	O
131	to	O
131	assess	O
131	day	O
131	-	O
131	to	O
131	-	O
131	day	O
131	performance	O
131	of	O
131	the	O
131	ass	O
131	##ay	O
131	.	O
131	[SEP]	O
132	[CLS]	O
132	this	O
132	phase	O
132	i	O
132	study	O
132	comprised	O
132	four	O
132	parts	O
132	:	O
132	a	O
132	,	O
132	b	O
132	,	O
132	c	O
132	,	O
132	and	O
132	d	O
132	.	O
132	[SEP]	O
133	[CLS]	O
133	pro	O
133	##dr	O
133	##ug	O
133	derivatives	O
133	of	O
133	4	O
133	-	O
133	et	O
133	##hyl	O
133	-	O
133	1	O
133	,	O
133	3	O
133	-	O
133	di	O
133	##hy	O
133	##dr	O
133	##o	O
133	-	O
133	5	O
133	-	O
133	[	O
133	4	O
133	-	O
133	(	O
133	2	O
133	-	O
133	met	O
133	##hyl	O
133	-	O
133	1	O
133	##h	O
133	-	O
133	im	O
133	##ida	O
133	##zo	O
133	##l	O
133	-	O
133	1	O
133	-	O
133	y	O
133	##l	O
133	)	O
133	ben	O
133	##zo	O
133	##yl	O
133	]	O
133	-	O
133	2	O
133	##h	O
133	-	O
133	im	O
133	##ida	O
133	##zo	O
133	##l	O
133	-	O
133	2	O
133	-	O
133	one	O
133	.	O
133	[SEP]	O
134	[CLS]	O
134	the	O
134	drug	O
134	was	O
134	added	O
134	to	O
134	400	O
134	m	O
134	##l	O
134	of	O
134	10	O
134	%	O
134	man	O
134	##ni	O
134	##to	O
134	##l	O
134	,	O
134	was	O
134	brought	O
134	up	O
134	to	O
134	1	O
134	-	O
134	l	O
134	volume	O
134	with	O
134	normal	O
134	sa	O
134	##line	O
134	containing	O
134	3	O
134	g	O
134	of	O
134	ma	O
134	##gnesium	O
134	su	O
134	##lf	O
134	##ate	O
134	,	O
134	and	O
134	was	O
134	administered	O
134	i	O
134	##v	O
134	over	O
134	1	O
134	hour	O
134	.	O
134	[SEP]	O
135	[CLS]	O
135	in	O
135	5	O
135	patients	O
135	(	O
135	40	O
135	%	O
135	)	O
135	,	O
135	the	O
135	anti	O
135	##static	O
135	v	O
135	##h	O
135	##c	O
135	increased	O
135	f	O
135	##p	O
135	##c	O
135	by	O
135	>	O
135	/	O
135	=	O
135	100	O
135	%	O
135	,	O
135	to	O
135	potentially	O
135	excessive	O
135	levels	O
135	in	O
135	4	O
135	of	O
135	them	O
135	;	O
135	it	O
135	had	O
135	little	O
135	effect	O
135	in	O
135	7	O
135	patients	O
135	.	O
135	[SEP]	O
136	[CLS]	O
136	accordingly	O
136	,	O
136	the	O
136	half	B-PK
136	-	I-PK
136	life	I-PK
136	of	O
136	m	O
136	##s	O
136	##n	O
136	-	O
136	en	O
136	##cap	O
136	##sul	O
136	##ated	O
136	be	O
136	##va	O
136	##ci	O
136	##zu	O
136	##ma	O
136	##b	O
136	na	O
136	##no	O
136	##par	O
136	##tic	O
136	##les	O
136	was	O
136	significantly	O
136	greater	O
136	than	O
136	that	O
136	of	O
136	be	O
136	##va	O
136	##ci	O
136	##zu	O
136	##ma	O
136	##b	O
136	.	O
136	[SEP]	O
137	[CLS]	O
137	here	O
137	,	O
137	when	O
137	a	O
137	b	O
137	##ol	O
137	##us	O
137	of	O
137	m	O
137	##or	O
137	##phine	O
137	is	O
137	given	O
137	,	O
137	the	O
137	maximum	B-PK
137	concentration	I-PK
137	of	O
137	m	O
137	##3	O
137	##g	O
137	is	O
137	higher	O
137	in	O
137	o	O
137	##bes	O
137	##e	O
137	patients	O
137	(	O
137	panel	O
137	b	O
137	)	O
137	.	O
137	[SEP]	O
138	[CLS]	O
138	genetic	O
138	p	O
138	##oly	O
138	##mor	O
138	##phism	O
138	of	O
138	c	O
138	##y	O
138	##p	O
138	##2	O
138	##a	O
138	##6	O
138	and	O
138	body	O
138	weight	O
138	will	O
138	be	O
138	causes	O
138	of	O
138	ethnic	O
138	difference	O
138	in	O
138	p	O
138	##k	O
138	.	O
138	[SEP]	O
139	[CLS]	O
139	the	O
139	di	O
139	##sper	O
139	##sions	O
139	of	O
139	g	O
139	##fs	O
139	and	O
139	p	O
139	-	O
139	g	O
139	##fs	O
139	containing	O
139	equal	O
139	amounts	O
139	of	O
139	g	O
139	##fs	O
139	were	O
139	placed	O
139	into	O
139	the	O
139	dial	O
139	##ys	O
139	##is	O
139	bags	O
139	im	O
139	##mers	O
139	##ing	O
139	in	O
139	500	O
139	m	O
139	##l	O
139	medium	O
139	(	O
139	p	O
139	##h	O
139	=	O
139	1	O
139	.	O
139	2	O
139	h	O
139	##c	O
139	##l	O
139	,	O
139	p	O
139	##h	O
139	=	O
139	6	O
139	.	O
139	8	O
139	phosphate	O
139	buffer	O
139	sa	O
139	##line	O
139	)	O
139	.	O
139	[SEP]	O
140	[CLS]	O
140	additionally	O
140	,	O
140	no	O
140	subjects	O
140	met	O
140	amino	O
140	##tra	O
140	##ns	O
140	##fer	O
140	##ase	O
140	or	O
140	total	O
140	bi	O
140	##li	O
140	##ru	O
140	##bin	O
140	criteria	O
140	for	O
140	potential	O
140	drug	O
140	‐	O
140	induced	O
140	liver	O
140	injury	O
140	,	O
140	defined	O
140	as	O
140	an	O
140	amino	O
140	##tra	O
140	##ns	O
140	##ami	O
140	##nas	O
140	##e	O
140	elevation	O
140	>	O
140	[SEP]	O
141	[CLS]	O
141	post	O
141	-	O
141	treatment	O
141	levels	O
141	of	O
141	s	O
141	##t	O
141	##n	O
141	##f	O
141	-	O
141	r	O
141	##2	O
141	peaked	O
141	significantly	O
141	higher	O
141	than	O
141	s	O
141	##t	O
141	##n	O
141	##f	O
141	-	O
141	r	O
141	##1	O
141	(	O
141	p	O
141	<	O
141	0	O
141	.	O
141	000	O
141	##1	O
141	)	O
141	.	O
141	[SEP]	O
142	[CLS]	O
142	in	O
142	conclusion	O
142	,	O
142	the	O
142	combined	O
142	p	O
142	##har	O
142	##ma	O
142	##co	O
142	##kin	O
142	##etic	O
142	and	O
142	add	O
142	##uc	O
142	##t	O
142	data	O
142	in	O
142	patients	O
142	support	O
142	the	O
142	advantages	O
142	of	O
142	the	O
142	in	O
142	##tra	O
142	##per	O
142	##ito	O
142	##nea	O
142	##l	O
142	route	O
142	for	O
142	drug	O
142	administration	O
142	,	O
142	and	O
142	the	O
142	addition	O
142	of	O
142	heat	O
142	.	O
142	[SEP]	O
143	[CLS]	O
143	p	O
143	##t	O
143	##x	O
143	is	O
143	as	O
143	active	O
143	as	O
143	m	O
143	##t	O
143	##x	O
143	in	O
143	in	O
143	##hibit	O
143	##ing	O
143	d	O
143	##h	O
143	##f	O
143	##r	O
143	and	O
143	ma	O
143	##mmal	O
143	##ian	O
143	cell	O
143	growth	O
143	.	O
143	[SEP]	O
144	[CLS]	O
144	patients	O
144	received	O
144	single	O
144	in	O
144	##tra	O
144	##ven	O
144	##ous	O
144	injection	O
144	##s	O
144	(	O
144	50	O
144	i	O
144	##u	O
144	/	O
144	kg	O
144	)	O
144	of	O
144	n	O
144	##9	O
144	‐	O
144	g	O
144	##p	O
144	and	O
144	r	O
144	##fi	O
144	##x	O
144	##f	O
144	##c	O
144	with	O
144	at	O
144	least	O
144	21	O
144	days	O
144	between	O
144	doses	O
144	.	O
144	[SEP]	O
145	[CLS]	O
145	these	O
145	findings	O
145	indicate	O
145	that	O
145	although	O
145	hp	O
145	g	O
145	##eno	O
145	##type	O
145	does	O
145	not	O
145	affect	O
145	the	O
145	risk	O
145	of	O
145	p	O
145	##e	O
145	,	O
145	hp	O
145	##1	O
145	-	O
145	1	O
145	g	O
145	##eno	O
145	##type	O
145	may	O
145	ex	O
145	##ert	O
145	a	O
145	protective	O
145	role	O
145	in	O
145	p	O
145	##e	O
145	by	O
145	reducing	O
145	no	O
145	s	O
145	##ca	O
145	##ven	O
145	##ging	O
145	,	O
145	whereas	O
145	hp	O
145	##2	O
145	-	O
145	1	O
145	and	O
145	hp	O
145	##2	O
145	-	O
145	2	O
145	further	O
145	may	O
145	a	O
145	##gg	O
145	##ra	O
145	##vate	O
145	p	O
145	##e	O
145	by	O
145	reducing	O
145	no	O
145	bio	B-PK
145	##ava	I-PK
145	##ila	I-PK
145	##bility	I-PK
145	.	O
145	[SEP]	O
146	[CLS]	O
146	an	O
146	f	O
146	##1	O
146	value	O
146	greater	O
146	than	O
146	15	O
146	indicates	O
146	significant	O
146	di	O
146	##ssi	O
146	##mi	O
146	##lar	O
146	##ity	O
146	,	O
146	and	O
146	an	O
146	f	O
146	##2	O
146	value	O
146	greater	O
146	than	O
146	50	O
146	indicates	O
146	significant	O
146	similarity	O
146	[	O
146	16	O
146	,	O
146	17	O
146	]	O
146	.	O
146	[SEP]	O
147	[CLS]	O
147	the	O
147	most	O
147	common	O
147	tumor	O
147	types	O
147	were	O
147	pan	O
147	##cre	O
147	##atic	O
147	,	O
147	he	O
147	##pa	O
147	##to	O
147	##cellular	O
147	and	O
147	color	O
147	##ec	O
147	##tal	O
147	cancer	O
147	,	O
147	but	O
147	a	O
147	large	O
147	number	O
147	of	O
147	other	O
147	e	O
147	##pit	O
147	##hel	O
147	##ial	O
147	ma	O
147	##li	O
147	##gna	O
147	##ncies	O
147	were	O
147	included	O
147	.	O
147	[SEP]	O
148	[CLS]	O
148	a	O
148	pilot	O
148	study	O
148	on	O
148	safety	O
148	and	O
148	p	O
148	##har	O
148	##ma	O
148	##co	O
148	##kin	O
148	##etics	O
148	of	O
148	in	O
148	##f	O
148	##lix	O
148	##ima	O
148	##b	O
148	for	O
148	the	O
148	cancer	O
148	an	O
148	##ore	O
148	##xia	O
148	/	O
148	weight	O
148	loss	O
148	syndrome	O
148	in	O
148	non	O
148	-	O
148	small	O
148	-	O
148	cell	O
148	lung	O
148	cancer	O
148	patients	O
148	.	O
148	[SEP]	O
149	[CLS]	O
149	the	O
149	""""	O
149	prevention	O
149	of	O
149	g	O
149	##raft	O
149	-	O
149	versus	O
149	-	O
149	host	O
149	disease	O
149	(	O
149	g	O
149	##v	O
149	##h	O
149	##d	O
149	)	O
149	for	O
149	all	O
149	##ogen	O
149	##ei	O
149	##c	O
149	hem	O
149	##ato	O
149	##po	O
149	##iet	O
149	##ic	O
149	stem	O
149	cell	O
149	transplant	O
149	##ation	O
149	in	O
149	adults	O
149	""""	O
149	indication	O
149	has	O
149	been	O
149	added	O
149	to	O
149	at	O
149	##g	O
149	in	O
149	32	O
149	countries	O
149	worldwide	O
149	,	O
149	but	O
149	has	O
149	not	O
149	yet	O
149	been	O
149	approved	O
149	for	O
149	g	O
149	##v	O
149	##h	O
149	##d	O
149	prevention	O
149	in	O
149	j	O
149	##apa	O
149	##n	O
149	.	O
149	[SEP]	O
150	[CLS]	O
150	the	O
150	automatic	O
150	ca	O
150	##li	O
150	##bra	O
150	##tion	O
150	was	O
150	carried	O
150	out	O
150	every	O
150	eight	O
150	samples	O
150	.	O
150	[SEP]	O
151	[CLS]	O
151	peaks	O
151	were	O
151	integrated	O
151	and	O
151	measured	O
151	against	O
151	a	O
151	standard	O
151	ca	O
151	##li	O
151	##bra	O
151	##tion	O
151	curve	O
151	.	O
151	[SEP]	O
152	[CLS]	O
152	the	O
152	method	O
152	is	O
152	suitable	O
152	in	O
152	p	O
152	##har	O
152	##ma	O
152	##co	O
152	##kin	O
152	##etic	O
152	investigation	O
152	of	O
152	b	O
152	##uf	O
152	##orm	O
152	##in	O
152	.	O
152	[SEP]	O
153	[CLS]	O
153	p	O
153	##k	O
153	parameters	O
153	including	O
153	au	B-PK
153	##c	I-PK
153	and	O
153	cm	B-PK
153	##ax	I-PK
153	were	O
153	derived	O
153	by	O
153	non	O
153	##com	O
153	##par	O
153	##tment	O
153	##al	O
153	analyses	O
153	.	O
153	[SEP]	O
154	[CLS]	O
154	in	O
154	summary	O
154	,	O
154	results	O
154	of	O
154	the	O
154	present	O
154	study	O
154	indicated	O
154	that	O
154	interactions	O
154	among	O
154	co	O
154	-	O
154	exiting	O
154	components	O
154	in	O
154	v	O
154	##ce	O
154	were	O
154	complex	O
154	and	O
154	significant	O
154	,	O
154	which	O
154	needed	O
154	special	O
154	attention	O
154	.	O
154	[SEP]	O
155	[CLS]	O
155	in	O
155	addition	O
155	,	O
155	data	O
155	for	O
155	one	O
155	child	O
155	were	O
155	excluded	O
155	from	O
155	i	O
155	##g	O
155	##f	O
155	-	O
155	i	O
155	analysis	O
155	due	O
155	to	O
155	in	O
155	##con	O
155	##sist	O
155	##encies	O
155	in	O
155	the	O
155	i	O
155	##g	O
155	##f	O
155	-	O
155	i	O
155	profile	O
155	[	O
155	an	O
155	increase	O
155	in	O
155	i	O
155	##g	O
155	##f	O
155	-	O
155	i	O
155	during	O
155	human	O
155	(	O
155	h	O
155	)	O
155	g	O
155	##h	O
155	wash	O
155	##out	O
155	]	O
155	.	O
155	[SEP]	O
156	[CLS]	O
156	mi	O
156	##po	O
156	##mers	O
156	##en	O
156	was	O
156	absorbed	O
156	rapidly	O
156	after	O
156	s	O
156	##c	O
156	administration	O
156	;	O
156	median	O
156	t	B-PK
156	##max	I-PK
156	varied	O
156	between	O
156	2	O
156	and	O
156	3	O
156	hours	O
156	.	O
156	[SEP]	O
157	[CLS]	O
157	similarly	O
157	,	O
157	the	O
157	maximum	O
157	change	O
157	from	O
157	base	O
157	##line	O
157	in	O
157	p	O
157	##fa	O
157	c	O
157	##ep	O
157	##i	O
157	closure	O
157	time	O
157	was	O
157	lower	O
157	after	O
157	i	O
157	##v	O
157	di	O
157	##c	O
157	##lo	O
157	##fen	O
157	##ac	O
157	than	O
157	after	O
157	k	O
157	##eto	O
157	##rol	O
157	##ac	O
157	or	O
157	as	O
157	##a	O
157	across	O
157	all	O
157	time	O
157	intervals	O
157	examined	O
157	.	O
157	[SEP]	O
158	[CLS]	O
158	then	O
158	,	O
158	results	O
158	from	O
158	each	O
158	study	O
158	group	O
158	were	O
158	compared	O
158	with	O
158	each	O
158	other	O
158	.	O
158	[SEP]	O
159	[CLS]	O
159	h	O
159	##r	O
159	/	O
159	m	O
159	##l	O
159	(	O
159	mean	O
159	+	O
159	-	O
159	se	O
159	)	O
159	,	O
159	as	O
159	did	O
159	the	O
159	percentage	O
159	na	O
159	##do	O
159	##lo	O
159	##l	O
159	recovered	O
159	in	O
159	urine	O
159	(	O
159	15	O
159	.	O
159	4	O
159	+	O
159	-	O
159	1	O
159	.	O
159	4	O
159	to	O
159	10	O
159	.	O
159	2	O
159	+	O
159	-	O
159	0	O
159	.	O
159	7	O
159	%	O
159	)	O
159	and	O
159	the	O
159	na	O
159	##do	O
159	##lo	O
159	##l	O
159	t	B-PK
159	##1	I-PK
159	/	I-PK
159	2	I-PK
159	(	O
159	17	O
159	.	O
159	3	O
159	+	O
159	-	O
159	1	O
159	.	O
159	7	O
159	to	O
159	11	O
159	.	O
159	8	O
159	+	O
159	-	O
159	1	O
159	.	O
159	6	O
159	h	O
159	##r	O
159	)	O
159	.	O
159	[SEP]	O
160	[CLS]	O
160	consistent	O
160	with	O
160	these	O
160	kinetic	O
160	alterations	O
160	,	O
160	the	O
160	h	O
160	##y	O
160	##po	O
160	##gly	O
160	##ce	O
160	##mic	O
160	effect	O
160	in	O
160	the	O
160	concurrent	O
160	administration	O
160	group	O
160	was	O
160	more	O
160	pronounced	O
160	than	O
160	that	O
160	in	O
160	the	O
160	control	O
160	group	O
160	(	O
160	i	O
160	.	O
160	e	O
160	.	O
160	,	O
160	re	O
160	##pa	O
160	##gli	O
160	##ni	O
160	##de	O
160	alone	O
160	)	O
160	when	O
160	the	O
160	drug	O
160	was	O
160	given	O
160	oral	O
160	##ly	O
160	.	O
160	[SEP]	O
161	[CLS]	O
161	good	O
161	general	O
161	health	O
161	was	O
161	determined	O
161	at	O
161	screening	O
161	by	O
161	medical	O
161	history	O
161	,	O
161	physical	O
161	examination	O
161	,	O
161	vital	O
161	signs	O
161	,	O
161	electro	O
161	##card	O
161	##io	O
161	##graphy	O
161	(	O
161	e	O
161	##c	O
161	##g	O
161	)	O
161	,	O
161	and	O
161	laboratory	O
161	findings	O
161	.	O
161	[SEP]	O
162	[CLS]	O
162	importantly	O
162	,	O
162	viral	O
162	load	O
162	remained	O
162	below	O
162	the	O
162	lo	O
162	##q	O
162	throughout	O
162	the	O
162	duration	O
162	of	O
162	dos	O
162	##ing	O
162	and	O
162	for	O
162	at	O
162	least	O
162	12	O
162	days	O
162	after	O
162	dos	O
162	##ing	O
162	ended	O
162	.	O
162	[SEP]	O
163	[CLS]	O
163	there	O
163	were	O
163	no	O
163	associations	O
163	between	O
163	patients	O
163	'	O
163	beliefs	O
163	(	O
163	b	O
163	##m	O
163	##q	O
163	-	O
163	sub	O
163	##sca	O
163	##les	O
163	or	O
163	brief	O
163	i	O
163	##p	O
163	##q	O
163	-	O
163	sub	O
163	##sca	O
163	##les	O
163	)	O
163	and	O
163	scores	O
163	on	O
163	the	O
163	ma	O
163	##rs	O
163	-	O
163	question	O
163	##naire	O
163	.	O
163	[SEP]	O
164	[CLS]	O
164	in	O
164	a	O
164	separate	O
164	multiple	O
164	-	O
164	dose	O
164	study	O
164	,	O
164	the	O
164	disposition	O
164	of	O
164	z	O
164	##ato	O
164	##set	O
164	##ron	O
164	was	O
164	found	O
164	to	O
164	be	O
164	similar	O
164	to	O
164	that	O
164	in	O
164	the	O
164	single	O
164	-	O
164	dose	O
164	study	O
164	.	O
164	[SEP]	O
165	[CLS]	O
165	on	O
165	the	O
165	other	O
165	hand	O
165	,	O
165	presence	O
165	of	O
165	end	O
165	##oth	O
165	##er	O
165	##mic	O
165	peak	O
165	at	O
165	173	O
165	°	O
165	##c	O
165	(	O
165	onset	O
165	167	O
165	.	O
165	3	O
165	–	O
165	176	O
165	.	O
165	8	O
165	°	O
165	##c	O
165	end	O
165	via	O
165	[UNK]	O
165	100	O
165	.	O
165	59	O
165	j	O
165	/	O
165	kg	O
165	)	O
165	indicates	O
165	transformation	O
165	into	O
165	na	O
165	##no	O
165	-	O
165	bio	O
165	##par	O
165	##tic	O
165	##les	O
165	during	O
165	the	O
165	preparation	O
165	of	O
165	coated	O
165	s	O
165	##ln	O
165	with	O
165	r	O
165	##u	O
165	(	O
165	on	O
165	##b	O
165	##p	O
165	)	O
165	.	O
165	[SEP]	O
166	[CLS]	O
166	r	O
166	##if	O
166	##amp	O
166	##ici	O
166	##n	O
166	(	O
166	r	O
166	##if	O
166	)	O
166	was	O
166	kindly	O
166	provided	O
166	by	O
166	bond	O
166	pharmaceutical	O
166	##s	O
166	,	O
166	awe	O
166	,	O
166	o	O
166	##yo	O
166	state	O
166	,	O
166	ni	O
166	##ger	O
166	##ia	O
166	,	O
166	and	O
166	art	O
166	##em	O
166	##eth	O
166	##er	O
166	and	O
166	am	O
166	##od	O
166	##ia	O
166	##quin	O
166	##e	O
166	were	O
166	obtained	O
166	from	O
166	the	O
166	wa	O
166	##lter	O
166	re	O
166	##ed	O
166	army	O
166	institute	O
166	for	O
166	research	O
166	,	O
166	us	O
166	##a	O
166	.	O
166	[SEP]	O
167	[CLS]	O
167	stimuli	O
167	(	O
167	duration	O
167	:	O
167	0	O
167	.	O
167	2	O
167	m	O
167	##s	O
167	)	O
167	were	O
167	applied	O
167	at	O
167	0	O
167	.	O
167	03	O
167	##3	O
167	h	O
167	##z	O
167	using	O
167	a	O
167	constant	O
167	-	O
167	current	O
167	stimulus	O
167	isolation	O
167	unit	O
167	(	O
167	w	O
167	##pi	O
167	)	O
167	.	O
167	[SEP]	O
168	[CLS]	O
168	se	O
168	##dd	O
168	##s	O
168	-	O
168	car	O
168	was	O
168	prepared	O
168	based	O
168	on	O
168	d	O
168	-	O
168	α	O
168	-	O
168	to	O
168	##co	O
168	##pher	O
168	##yl	O
168	p	O
168	##oly	O
168	##eth	O
168	##yle	O
168	##ne	O
168	g	O
168	##ly	O
168	##co	O
168	##l	O
168	1000	O
168	su	O
168	##cci	O
168	##nate	O
168	(	O
168	t	O
168	##p	O
168	##gs	O
168	)	O
168	and	O
168	p	O
168	##hy	O
168	##si	O
168	##co	O
168	##chemical	O
168	##ly	O
168	characterized	O
168	.	O
168	[SEP]	O
169	[CLS]	O
169	the	O
169	adverse	O
169	effects	O
169	observed	O
169	in	O
169	the	O
169	study	O
169	were	O
169	mild	O
169	and	O
169	in	O
169	##f	O
169	##re	O
169	##quent	O
169	,	O
169	with	O
169	pro	O
169	##mpt	O
169	recovery	O
169	from	O
169	adverse	O
169	experiences	O
169	and	O
169	abnormal	O
169	laboratory	O
169	values	O
169	.	O
169	[SEP]	O
170	[CLS]	O
170	it	O
170	is	O
170	important	O
170	to	O
170	understand	O
170	whether	O
170	new	O
170	formulation	O
170	##s	O
170	and	O
170	/	O
170	or	O
170	methods	O
170	of	O
170	administration	O
170	impact	O
170	a	O
170	##pi	O
170	##xa	O
170	##ban	O
170	bio	B-PK
170	##ava	I-PK
170	##ila	I-PK
170	##bility	I-PK
170	and	O
170	p	O
170	##har	O
170	##ma	O
170	##co	O
170	##kin	O
170	##etic	O
170	properties	O
170	.	O
170	[SEP]	O
171	[CLS]	O
171	the	O
171	peak	B-PK
171	levels	I-PK
171	of	O
171	the	O
171	serum	O
171	p	O
171	##t	O
171	concentration	O
171	of	O
171	three	O
171	patients	O
171	were	O
171	0	O
171	-	O
171	0	O
171	.	O
171	4	O
171	micro	O
171	##gram	O
171	/	O
171	g	O
171	throughout	O
171	the	O
171	therapy	O
171	,	O
171	but	O
171	peak	B-PK
171	urine	I-PK
171	p	I-PK
171	##t	I-PK
171	concentrations	I-PK
171	were	O
171	observed	O
171	during	O
171	one	O
171	course	O
171	of	O
171	the	O
171	therapy	O
171	of	O
171	three	O
171	patients	O
171	ranging	O
171	from	O
171	0	O
171	.	O
171	5	O
171	micro	O
171	##gram	O
171	/	O
171	g	O
171	to	O
171	3	O
171	.	O
171	2	O
171	micro	O
171	##gram	O
171	##s	O
171	/	O
171	g	O
171	,	O
171	and	O
171	decreased	O
171	gradually	O
171	for	O
171	three	O
171	weeks	O
171	after	O
171	the	O
171	first	O
171	course	O
171	.	O
171	[SEP]	O
172	[CLS]	O
172	t	O
172	##f	O
172	##v	O
172	and	O
172	t	O
172	##f	O
172	##v	O
172	-	O
172	d	O
172	##p	O
172	were	O
172	q	O
172	##uant	O
172	##ified	O
172	with	O
172	valid	O
172	##ated	O
172	liquid	O
172	ch	O
172	##roma	O
172	##tography	O
172	/	O
172	tandem	O
172	mass	O
172	s	O
172	##pect	O
172	##rome	O
172	##try	O
172	methods	O
172	.	O
172	[SEP]	O
173	[CLS]	O
173	however	O
173	,	O
173	the	O
173	proportion	O
173	of	O
173	patients	O
173	who	O
173	were	O
173	photo	O
173	##ph	O
173	##obia	O
173	-	O
173	free	O
173	,	O
173	p	O
173	##hon	O
173	##op	O
173	##ho	O
173	##bia	O
173	-	O
173	free	O
173	,	O
173	and	O
173	nausea	O
173	-	O
173	free	O
173	at	O
173	2	O
173	hours	O
173	post	O
173	-	O
173	dose	O
173	was	O
173	higher	O
173	in	O
173	the	O
173	ad	O
173	##am	O
173	z	O
173	##olm	O
173	##it	O
173	##rip	O
173	##tan	O
173	3	O
173	.	O
173	8	O
173	mg	O
173	group	O
173	compared	O
173	with	O
173	place	O
173	##bo	O
173	,	O
173	as	O
173	were	O
173	the	O
173	percentage	O
173	##s	O
173	of	O
173	patients	O
173	who	O
173	were	O
173	pain	O
173	-	O
173	free	O
173	,	O
173	and	O
173	who	O
173	experienced	O
173	pain	O
173	relief	O
173	up	O
173	to	O
173	48	O
173	hours	O
173	post	O
173	-	O
173	dose	O
173	.	O
173	[SEP]	O
174	[CLS]	O
174	the	O
174	most	O
174	favored	O
174	binding	O
174	pose	O
174	for	O
174	compound	O
174	2	O
174	##a	O
174	was	O
174	with	O
174	the	O
174	o	O
174	-	O
174	met	O
174	##hyl	O
174	m	O
174	##oi	O
174	##ety	O
174	over	O
174	the	O
174	hem	O
174	##e	O
174	(	O
174	3	O
174	.	O
174	0	O
174	##a	O
174	,	O
174	fi	O
174	##g	O
174	2	O
174	panel	O
174	d	O
174	)	O
174	.	O
174	[SEP]	O
175	[CLS]	O
175	complete	O
175	blood	O
175	count	O
175	,	O
175	bio	O
175	##chemistry	O
175	and	O
175	parasite	O
175	count	O
175	were	O
175	measured	O
175	on	O
175	admission	O
175	.	O
175	[SEP]	O
176	[CLS]	O
176	this	O
176	phase	O
176	i	O
176	study	O
176	was	O
176	conducted	O
176	to	O
176	evaluate	O
176	the	O
176	safety	O
176	,	O
176	to	O
176	##ler	O
176	##ability	O
176	,	O
176	and	O
176	preliminary	O
176	efficacy	O
176	of	O
176	the	O
176	combination	O
176	of	O
176	t	O
176	##rem	O
176	##eli	O
176	##mum	O
176	##ab	O
176	and	O
176	p	O
176	##f	O
176	-	O
176	35	O
176	##12	O
176	##6	O
176	##7	O
176	##6	O
176	in	O
176	patients	O
176	with	O
176	meta	O
176	##static	O
176	me	O
176	##lan	O
176	##oma	O
176	and	O
176	other	O
176	advanced	O
176	solid	O
176	t	O
176	##umour	O
176	##s	O
176	.	O
176	[SEP]	O
177	[CLS]	O
177	the	O
177	changes	O
177	during	O
177	the	O
177	third	O
177	trim	O
177	##ester	O
177	were	O
177	predicted	O
177	to	O
177	be	O
177	a	O
177	100	O
177	%	O
177	increase	O
177	,	O
177	a	O
177	30	O
177	%	O
177	decrease	O
177	and	O
177	a	O
177	35	O
177	%	O
177	decrease	O
177	in	O
177	the	O
177	exposure	O
177	of	O
177	ca	O
177	##ffe	O
177	##ine	O
177	,	O
177	met	O
177	##op	O
177	##rol	O
177	##ol	O
177	and	O
177	mid	O
177	##az	O
177	##ola	O
177	##m	O
177	,	O
177	respectively	O
177	,	O
177	compared	O
177	with	O
177	the	O
177	non	O
177	##p	O
177	##re	O
177	##gnant	O
177	women	O
177	.	O
177	[SEP]	O
178	[CLS]	O
178	the	O
178	cumulative	O
178	recovery	O
178	in	O
178	f	O
178	##ec	O
178	##es	O
178	during	O
178	0	O
178	–	O
178	144	O
178	h	O
178	represented	O
178	91	O
178	%	O
178	of	O
178	the	O
178	t	O
178	##ra	O
178	in	O
178	f	O
178	##ec	O
178	##es	O
178	.	O
178	[SEP]	O
179	[CLS]	O
179	ta	O
179	##mo	O
179	##xi	O
179	##fen	O
179	,	O
179	a	O
179	selective	O
179	est	O
179	##rogen	O
179	‐	O
179	receptor	O
179	m	O
179	##od	O
179	##ulator	O
179	,	O
179	is	O
179	widely	O
179	used	O
179	for	O
179	treatment	O
179	of	O
179	est	O
179	##rogen	O
179	receptor	O
179	(	O
179	er	O
179	)	O
179	or	O
179	pro	O
179	##ges	O
179	##tero	O
179	##ne	O
179	receptor	O
179	‐	O
179	positive	O
179	breast	O
179	cancer	O
179	.	O
179	[SEP]	O
180	[CLS]	O
180	the	O
180	limit	O
180	of	O
180	detection	O
180	(	O
180	lo	O
180	##d	O
180	)	O
180	which	O
180	is	O
180	quoted	O
180	as	O
180	the	O
180	concentration	O
180	yielding	O
180	a	O
180	signal	O
180	-	O
180	to	O
180	-	O
180	noise	O
180	ratio	O
180	of	O
180	3	O
180	:	O
180	1	O
180	was	O
180	confirmed	O
180	by	O
180	analyzing	O
180	a	O
180	number	O
180	of	O
180	samples	O
180	near	O
180	this	O
180	value	O
180	.	O
180	[SEP]	O
181	[CLS]	O
181	only	O
181	small	O
181	amounts	O
181	of	O
181	f	O
181	##os	O
181	##f	O
181	##lu	O
181	##cona	O
181	##zo	O
181	##le	O
181	were	O
181	ex	O
181	##cre	O
181	##ted	O
181	in	O
181	the	O
181	urine	O
181	suggesting	O
181	almost	O
181	complete	O
181	conversion	O
181	to	O
181	fl	O
181	##cz	O
181	.	O
181	[SEP]	O
182	[CLS]	O
182	batch	O
182	##es	O
182	of	O
182	3	O
182	–	O
182	5	O
182	rats	O
182	were	O
182	e	O
182	##uth	O
182	##ana	O
182	##tized	O
182	after	O
182	different	O
182	exposure	O
182	times	O
182	(	O
182	1	O
182	–	O
182	30	O
182	h	O
182	)	O
182	.	O
182	[SEP]	O
183	[CLS]	O
183	clinical	O
183	break	O
183	##points	O
183	of	O
183	anti	O
183	##biotics	O
183	are	O
183	vital	O
183	in	O
183	su	O
183	##s	O
183	##ce	O
183	##pt	O
183	##ibility	O
183	testing	O
183	of	O
183	path	O
183	##ogen	O
183	##s	O
183	for	O
183	the	O
183	selection	O
183	of	O
183	anti	O
183	##biotic	O
183	therapy	O
183	;	O
183	however	O
183	,	O
183	no	O
183	consensus	O
183	exists	O
183	between	O
183	different	O
183	committees	O
183	on	O
183	the	O
183	clinical	O
183	break	O
183	##points	O
183	of	O
183	t	O
183	##ige	O
183	##cy	O
183	##cline	O
183	.	O
183	[SEP]	O
184	[CLS]	O
184	the	O
184	concentration	O
184	of	O
184	mit	O
184	##omy	O
184	##cin	O
184	c	O
184	was	O
184	also	O
184	determined	O
184	at	O
184	a	O
184	final	O
184	time	O
184	point	O
184	to	O
184	ensure	O
184	the	O
184	changes	O
184	in	O
184	the	O
184	drug	O
184	en	O
184	##cap	O
184	##sul	O
184	##ation	O
184	efficiency	O
184	.	O
184	[SEP]	O
185	[CLS]	O
185	u	O
185	##rb	O
185	##9	O
185	##37	O
185	was	O
185	oral	O
185	##ly	O
185	available	O
185	in	O
185	male	O
185	rats	O
185	(	O
185	f	B-PK
185	=	O
185	36	O
185	%	O
185	)	O
185	,	O
185	but	O
185	remained	O
185	und	O
185	##ete	O
185	##ct	O
185	##able	O
185	in	O
185	brain	O
185	when	O
185	administered	O
185	at	O
185	doses	O
185	that	O
185	ma	O
185	##ximal	O
185	##ly	O
185	in	O
185	##hibit	O
185	f	O
185	##aa	O
185	##h	O
185	activity	O
185	and	O
185	el	O
185	##eva	O
185	##te	O
185	o	O
185	##ea	O
185	in	O
185	plasma	O
185	and	O
185	liver	O
185	.	O
185	[SEP]	O
186	[CLS]	O
186	the	O
186	half	B-PK
186	-	I-PK
186	life	I-PK
186	of	O
186	en	O
186	##ox	O
186	##apa	O
186	##rin	O
186	is	O
186	prolonged	O
186	with	O
186	the	O
186	progression	O
186	of	O
186	pregnancy	O
186	,	O
186	and	O
186	our	O
186	work	O
186	provides	O
186	compelling	O
186	evidence	O
186	for	O
186	pre	O
186	##s	O
186	##cribing	O
186	once	O
186	-	O
186	daily	O
186	en	O
186	##ox	O
186	##apa	O
186	##rin	O
186	for	O
186	the	O
186	treatment	O
186	of	O
186	ant	O
186	##ena	O
186	##tal	O
186	ve	O
186	##nous	O
186	th	O
186	##rom	O
186	##boe	O
186	##mbo	O
186	##lis	O
186	##m	O
186	.	O
186	[SEP]	O
187	[CLS]	O
187	the	O
187	mean	O
187	reduction	O
187	in	O
187	the	O
187	u	O
187	##a	O
187	concentration	O
187	on	O
187	day	O
187	7	O
187	relative	O
187	to	O
187	that	O
187	on	O
187	day	O
187	-	O
187	1	O
187	was	O
187	51	O
187	.	O
187	83	O
187	##±	O
187	##7	O
187	.	O
187	00	O
187	%	O
187	.	O
187	[SEP]	O
188	[CLS]	O
188	there	O
188	were	O
188	no	O
188	statistical	O
188	##ly	O
188	significant	O
188	differences	O
188	in	O
188	v	B-PK
188	##d	I-PK
188	,	O
188	c	B-PK
188	##l	I-PK
188	,	O
188	k	B-PK
188	,	O
188	and	O
188	t	B-PK
188	(	I-PK
188	(	I-PK
188	1	I-PK
188	/	I-PK
188	2	I-PK
188	)	I-PK
188	)	I-PK
188	of	O
188	g	O
188	##ent	O
188	##ami	O
188	##cin	O
188	between	O
188	the	O
188	control	O
188	and	O
188	di	O
188	##abe	O
188	##tic	O
188	group	O
188	.	O
188	[SEP]	O
189	[CLS]	O
189	a	O
189	single	O
189	oral	O
189	dose	O
189	of	O
189	cab	O
189	##ote	O
189	##gra	O
189	##vir	O
189	30	O
189	mg	O
189	was	O
189	administered	O
189	to	O
189	all	O
189	participants	O
189	under	O
189	fast	O
189	##ing	O
189	conditions	O
189	,	O
189	and	O
189	p	O
189	##k	O
189	parameters	O
189	were	O
189	assessed	O
189	.	O
189	[SEP]	O
190	[CLS]	O
190	the	O
190	terminal	B-PK
190	half	I-PK
190	-	I-PK
190	life	I-PK
190	(	I-PK
190	beta	I-PK
190	_	I-PK
190	h	I-PK
190	##l	I-PK
190	)	I-PK
190	was	O
190	calculated	O
190	as	O
190	0	O
190	.	O
190	69	O
190	##3	O
190	/	O
190	beta	O
190	;	O
190	the	O
190	systemic	B-PK
190	clearance	I-PK
190	rate	I-PK
190	(	I-PK
190	c	I-PK
190	##l	I-PK
190	_	I-PK
190	f	I-PK
190	)	I-PK
190	was	O
190	determined	O
190	as	O
190	dose	B-PK
190	/	I-PK
190	au	I-PK
190	##c	I-PK
190	##0	I-PK
190	–	I-PK
190	∞	I-PK
190	;	O
190	the	O
190	apparent	B-PK
190	volume	I-PK
190	of	I-PK
190	distribution	I-PK
190	(	I-PK
190	v	I-PK
190	##1	I-PK
190	_	I-PK
190	f	I-PK
190	)	I-PK
190	was	O
190	calculated	O
190	as	O
190	c	B-PK
190	##l	I-PK
190	_	I-PK
190	f	I-PK
190	/	I-PK
190	beta	I-PK
190	.	O
190	[SEP]	O
191	[CLS]	O
191	duration	O
191	of	O
191	responses	O
191	was	O
191	calculated	O
191	from	O
191	the	O
191	first	O
191	day	O
191	of	O
191	treatment	O
191	to	O
191	the	O
191	date	O
191	of	O
191	first	O
191	observation	O
191	of	O
191	progressive	O
191	disease	O
191	or	O
191	last	O
191	examination	O
191	.	O
191	[SEP]	O
192	[CLS]	O
192	the	O
192	mean	O
192	(	O
192	median	O
192	;	O
192	range	O
192	)	O
192	age	O
192	and	O
192	mean	O
192	(	O
192	median	O
192	;	O
192	range	O
192	)	O
192	body	O
192	mass	O
192	index	O
192	(	O
192	b	O
192	##mi	O
192	)	O
192	of	O
192	subjects	O
192	at	O
192	extension	O
192	study	O
192	base	O
192	##line	O
192	was	O
192	10	O
192	.	O
192	1	O
192	(	O
192	10	O
192	.	O
192	1	O
192	;	O
192	5	O
192	.	O
192	9	O
192	to	O
192	14	O
192	.	O
192	3	O
192	)	O
192	years	O
192	and	O
192	19	O
192	.	O
192	3	O
192	(	O
192	18	O
192	.	O
192	1	O
192	;	O
192	15	O
192	.	O
192	4	O
192	to	O
192	30	O
192	.	O
192	7	O
192	)	O
192	kg	O
192	/	O
192	m	O
192	##2	O
192	,	O
192	respectively	O
192	.	O
192	[SEP]	O
193	[CLS]	O
193	data	O
193	were	O
193	analyzed	O
193	by	O
193	analysis	O
193	of	O
193	variance	O
193	.	O
193	[SEP]	O
194	[CLS]	O
194	twenty	O
194	‐	O
194	five	O
194	subjects	O
194	were	O
194	male	O
194	(	O
194	65	O
194	.	O
194	8	O
194	%	O
194	)	O
194	,	O
194	the	O
194	mean	O
194	age	O
194	was	O
194	54	O
194	.	O
194	6	O
194	years	O
194	(	O
194	range	O
194	27	O
194	to	O
194	74	O
194	years	O
194	)	O
194	,	O
194	and	O
194	the	O
194	total	O
194	number	O
194	of	O
194	white	O
194	and	O
194	black	O
194	or	O
194	a	O
194	##f	O
194	##rica	O
194	##n	O
194	‐	O
194	am	O
194	##eric	O
194	##an	O
194	subjects	O
194	were	O
194	the	O
194	same	O
194	(	O
194	18	O
194	subjects	O
194	each	O
194	,	O
194	47	O
194	.	O
194	4	O
194	%	O
194	)	O
194	.	O
194	[SEP]	O
195	[CLS]	O
195	safety	O
195	end	O
195	##points	O
195	were	O
195	sum	O
195	##mar	O
195	##ised	O
195	using	O
195	descriptive	O
195	statistics	O
195	.	O
195	[SEP]	O
196	[CLS]	O
196	thirty	O
196	-	O
196	two	O
196	patients	O
196	could	O
196	be	O
196	evaluated	O
196	in	O
196	detail	O
196	.	O
196	[SEP]	O
197	[CLS]	O
197	the	O
197	plasma	O
197	concentrations	O
197	of	O
197	the	O
197	stereo	O
197	##is	O
197	##omer	O
197	##s	O
197	of	O
197	met	O
197	##op	O
197	##rol	O
197	##ol	O
197	,	O
197	o	O
197	-	O
197	dem	O
197	##eth	O
197	##yl	O
197	##met	O
197	##op	O
197	##rol	O
197	##ol	O
197	(	O
197	o	O
197	##d	O
197	##m	O
197	)	O
197	,	O
197	alpha	O
197	-	O
197	h	O
197	##ydro	O
197	##xy	O
197	##met	O
197	##op	O
197	##rol	O
197	##ol	O
197	(	O
197	oh	O
197	##m	O
197	)	O
197	(	O
197	ch	O
197	##ira	O
197	##l	O
197	##pa	O
197	##k	O
197	ad	O
197	column	O
197	)	O
197	,	O
197	and	O
197	met	O
197	##op	O
197	##rol	O
197	##ol	O
197	acidic	O
197	meta	O
197	##bol	O
197	##ite	O
197	(	O
197	a	O
197	##od	O
197	##m	O
197	)	O
197	(	O
197	ch	O
197	##ira	O
197	##l	O
197	##cel	O
197	o	O
197	##d	O
197	-	O
197	r	O
197	column	O
197	)	O
197	were	O
197	determined	O
197	by	O
197	hp	O
197	##l	O
197	##c	O
197	using	O
197	flu	O
197	##ores	O
197	##cence	O
197	detection	O
197	(	O
197	la	O
197	##mb	O
197	##da	O
197	(	O
197	ex	O
197	##c	O
197	)	O
197	=	O
197	229	O
197	nm	O
197	;	O
197	la	O
197	##mb	O
197	##da	O
197	(	O
197	em	O
197	)	O
197	=	O
197	29	O
197	##8	O
197	nm	O
197	)	O
197	.	O
197	[SEP]	O
198	[CLS]	O
198	scheduled	O
198	sampling	O
198	times	O
198	were	O
198	used	O
198	for	O
198	the	O
198	creation	O
198	of	O
198	summary	O
198	tables	O
198	and	O
198	mean	O
198	plasma	O
198	concentration	O
198	versus	O
198	time	O
198	profiles	O
198	.	O
198	[SEP]	O
199	[CLS]	O
199	no	O
199	significant	O
199	is	O
199	##oto	O
199	##pe	O
199	effect	O
199	was	O
199	observed	O
199	on	O
199	p	O
199	##har	O
199	##ma	O
199	##co	O
199	##kin	O
199	##etic	O
199	parameters	O
199	,	O
199	p	O
199	##b	O
199	h	O
199	##ydro	O
199	##xy	O
199	##lation	O
199	or	O
199	p	O
199	##bo	O
199	##h	O
199	con	O
199	##ju	O
199	##gation	O
199	(	O
199	x	O
199	less	O
199	than	O
199	or	O
199	equal	O
199	to	O
199	5	O
199	%	O
199	)	O
199	;	O
199	which	O
199	the	O
199	absence	O
199	of	O
199	pen	O
199	##tad	O
199	##eu	O
199	##tera	O
199	##tion	O
199	-	O
199	induced	O
199	alter	O
199	##ation	O
199	in	O
199	p	O
199	##b	O
199	'	O
199	s	O
199	h	O
199	##sa	O
199	binding	O
199	parameters	O
199	(	O
199	binding	O
199	mode	O
199	,	O
199	ka	B-PK
199	,	O
199	n	O
199	)	O
199	co	O
199	##rro	O
199	##bor	O
199	##ates	O
199	(	O
199	x	O
199	less	O
199	than	O
199	or	O
199	equal	O
199	to	O
199	5	O
199	%	O
199	)	O
199	.	O
199	[SEP]	O
200	[CLS]	O
200	several	O
200	additional	O
200	mice	O
200	were	O
200	sacrificed	O
200	in	O
200	pre	O
200	##dos	O
200	##e	O
200	to	O
200	provide	O
200	blank	O
200	plasma	O
200	and	O
200	control	O
200	tissues	O
200	for	O
200	analysis	O
200	.	O
200	[SEP]	O
201	[CLS]	O
201	the	O
201	peak	B-PK
201	concentrations	I-PK
201	of	O
201	v	O
201	##ado	O
201	##ca	O
201	##ine	O
201	were	O
201	achieved	O
201	on	O
201	the	O
201	1st	O
201	day	O
201	at	O
201	1	O
201	h	O
201	(	O
201	61	O
201	.	O
201	5	O
201	+	O
201	-	O
201	6	O
201	.	O
201	1	O
201	ng	O
201	/	O
201	m	O
201	##l	O
201	)	O
201	and	O
201	on	O
201	the	O
201	4th	O
201	day	O
201	at	O
201	1	O
201	.	O
201	5	O
201	h	O
201	(	O
201	64	O
201	.	O
201	5	O
201	+	O
201	-	O
201	7	O
201	.	O
201	9	O
201	ng	O
201	/	O
201	m	O
201	##l	O
201	)	O
201	.	O
201	[SEP]	O
202	[CLS]	O
202	the	O
202	inclusion	O
202	criterion	O
202	was	O
202	receiving	O
202	at	O
202	least	O
202	3	O
202	successive	O
202	doses	O
202	of	O
202	van	O
202	##com	O
202	##y	O
202	##cin	O
202	(	O
202	fixed	O
202	dose	O
202	and	O
202	dos	O
202	##ing	O
202	interval	O
202	)	O
202	as	O
202	em	O
202	##pi	O
202	##ric	O
202	treatment	O
202	of	O
202	f	O
202	##eb	O
202	##ril	O
202	##e	O
202	ne	O
202	##ut	O
202	##rop	O
202	##enia	O
202	.	O
202	[SEP]	O
203	[CLS]	O
203	the	O
203	second	O
203	was	O
203	a	O
203	double	O
203	-	O
203	blind	O
203	,	O
203	place	O
203	##bo	O
203	-	O
203	controlled	O
203	,	O
203	parallel	O
203	-	O
203	group	O
203	,	O
203	multiple	O
203	-	O
203	dose	O
203	study	O
203	in	O
203	which	O
203	participants	O
203	were	O
203	random	O
203	##ized	O
203	to	O
203	100	O
203	mg	O
203	or	O
203	200	O
203	mg	O
203	o	O
203	##sel	O
203	##tam	O
203	##iv	O
203	##ir	O
203	or	O
203	place	O
203	##bo	O
203	(	O
203	normal	O
203	sa	O
203	##line	O
203	)	O
203	i	O
203	.	O
203	v	O
203	.	O
203	over	O
203	2	O
203	h	O
203	every	O
203	12	O
203	h	O
203	for	O
203	5	O
203	days	O
203	.	O
203	[SEP]	O
204	[CLS]	O
204	as	O
204	an	O
204	example	O
204	,	O
204	the	O
204	production	O
204	rates	O
204	of	O
204	ace	O
204	##tone	O
204	,	O
204	under	O
204	different	O
204	conditions	O
204	of	O
204	stimulation	O
204	by	O
204	x	O
204	##eno	O
204	##biotics	O
204	,	O
204	are	O
204	calculated	O
204	from	O
204	published	O
204	experimental	O
204	data	O
204	.	O
204	[SEP]	O
205	[CLS]	O
205	q	O
205	##uant	O
205	##itation	O
205	was	O
205	based	O
205	upon	O
205	a	O
205	standard	O
205	curve	O
205	from	O
205	external	O
205	standards	O
205	,	O
205	comprising	O
205	of	O
205	ch	O
205	##ole	O
205	##ster	O
205	##ol	O
205	,	O
205	s	O
205	##ti	O
205	##gma	O
205	##ster	O
205	##ol	O
205	,	O
205	sit	O
205	##ost	O
205	##ero	O
205	##l	O
205	,	O
205	and	O
205	camp	O
205	##ester	O
205	##ol	O
205	at	O
205	varying	O
205	concentrations	O
205	(	O
205	39	O
205	,	O
205	40	O
205	)	O
205	,	O
205	using	O
205	ultra	O
205	-	O
205	pure	O
205	s	O
205	##tero	O
205	##ls	O
205	obtained	O
205	from	O
205	s	O
205	##teral	O
205	##oids	O
205	in	O
205	##c	O
205	.	O
205	(	O
205	new	O
205	##port	O
205	,	O
205	r	O
205	##i	O
205	)	O
205	.	O
205	[SEP]	O
206	[CLS]	O
206	bi	O
206	##li	O
206	##ru	O
206	##bine	O
206	##mia	O
206	(	O
206	the	O
206	presence	O
206	of	O
206	increased	O
206	amounts	O
206	of	O
206	bi	O
206	##li	O
206	##ru	O
206	##bin	O
206	in	O
206	the	O
206	blood	O
206	)	O
206	was	O
206	reported	O
206	in	O
206	one	O
206	participant	O
206	(	O
206	r	O
206	##20	O
206	##8	O
206	)	O
206	,	O
206	as	O
206	determined	O
206	during	O
206	clinical	O
206	laboratory	O
206	testing	O
206	on	O
206	day	O
206	2	O
206	.	O
206	[SEP]	O
207	[CLS]	O
207	the	O
207	lungs	O
207	of	O
207	all	O
207	animals	O
207	were	O
207	collected	O
207	immediately	O
207	after	O
207	sacrifice	O
207	or	O
207	death	O
207	and	O
207	weighed	O
207	.	O
207	[SEP]	O
208	[CLS]	O
208	c	O
208	##y	O
208	##p	O
208	##2	O
208	##d	O
208	##6	O
208	p	O
208	##hen	O
208	##otype	O
208	was	O
208	assessed	O
208	during	O
208	each	O
208	study	O
208	period	O
208	using	O
208	de	O
208	##x	O
208	##trom	O
208	##eth	O
208	##or	O
208	##pha	O
208	##n	O
208	(	O
208	30	O
208	mg	O
208	)	O
208	.	O
208	[SEP]	O
209	[CLS]	O
209	after	O
209	sampling	O
209	,	O
209	the	O
209	cat	O
209	##he	O
209	##ter	O
209	was	O
209	flushed	O
209	with	O
209	0	O
209	.	O
209	8	O
209	m	O
209	##l	O
209	of	O
209	sodium	O
209	he	O
209	##par	O
209	##in	O
209	(	O
209	25	O
209	i	O
209	##u	O
209	/	O
209	m	O
209	##l	O
209	)	O
209	to	O
209	ensure	O
209	pat	O
209	##ency	O
209	.	O
209	[SEP]	O
210	[CLS]	O
210	the	O
210	results	O
210	showed	O
210	that	O
210	only	O
210	spotted	O
210	blood	O
210	volume	O
210	might	O
210	have	O
210	an	O
210	impact	O
210	;	O
210	a	O
210	small	O
210	volume	O
210	(	O
210	10	O
210	##μ	O
210	##l	O
210	)	O
210	tended	O
210	to	O
210	give	O
210	a	O
210	larger	O
210	negative	O
210	bias	O
210	in	O
210	the	O
210	measured	O
210	value	O
210	than	O
210	the	O
210	large	O
210	volume	O
210	ones	O
210	(	O
210	≥	O
210	##20	O
210	##μ	O
210	##l	O
210	)	O
210	.	O
210	[SEP]	O
211	[CLS]	O
211	the	O
211	m	O
211	##f	O
211	at	O
211	both	O
211	tested	O
211	concentrations	O
211	was	O
211	[UNK]	O
211	.	O
211	3	O
211	as	O
211	a	O
211	result	O
211	of	O
211	matrix	O
211	effects	O
211	(	O
211	ion	O
211	suppression	O
211	)	O
211	.	O
211	[SEP]	O
212	[CLS]	O
212	p	O
212	##har	O
212	##ma	O
212	##co	O
212	##kin	O
212	##etics	O
212	and	O
212	p	O
212	##k	O
212	-	O
212	p	O
212	##d	O
212	modelling	O
212	of	O
212	da	O
212	##no	O
212	##f	O
212	##lo	O
212	##xa	O
212	##cin	O
212	in	O
212	came	O
212	##l	O
212	serum	O
212	and	O
212	tissue	O
212	cage	O
212	fluids	O
212	.	O
212	[SEP]	O
213	[CLS]	O
213	the	O
213	terminal	O
213	‐	O
213	phase	O
213	concentrations	O
213	appeared	O
213	to	O
213	decline	O
213	multi	O
213	##ex	O
213	##po	O
213	##nent	O
213	##ially	O
213	.	O
213	[SEP]	O
214	[CLS]	O
214	c	O
214	##ef	O
214	##ti	O
214	##of	O
214	##ur	O
214	is	O
214	a	O
214	new	O
214	broad	O
214	spectrum	O
214	c	O
214	##ep	O
214	##hal	O
214	##os	O
214	##por	O
214	##in	O
214	marketed	O
214	for	O
214	the	O
214	treatment	O
214	of	O
214	acute	O
214	b	O
214	##ov	O
214	##ine	O
214	respiratory	O
214	disease	O
214	.	O
214	[SEP]	O
215	[CLS]	O
215	however	O
215	,	O
215	significant	O
215	improvement	O
215	was	O
215	seen	O
215	in	O
215	the	O
215	intervention	O
215	group	O
215	on	O
215	days	O
215	4	O
215	(	O
215	-	O
215	1	O
215	.	O
215	07	O
215	;	O
215	95	O
215	%	O
215	c	O
215	##i	O
215	,	O
215	-	O
215	1	O
215	.	O
215	80	O
215	to	O
215	-	O
215	0	O
215	.	O
215	34	O
215	)	O
215	and	O
215	5	O
215	(	O
215	-	O
215	1	O
215	.	O
215	06	O
215	;	O
215	95	O
215	%	O
215	c	O
215	##i	O
215	,	O
215	-	O
215	1	O
215	.	O
215	84	O
215	to	O
215	-	O
215	0	O
215	.	O
215	27	O
215	)	O
215	.	O
215	[SEP]	O
216	[CLS]	O
216	the	O
216	decrease	O
216	in	O
216	e	O
216	##g	O
216	##f	O
216	##r	O
216	appeared	O
216	to	O
216	reach	O
216	sat	O
216	##uration	O
216	at	O
216	>	O
216	100	O
216	mg	O
216	/	O
216	m	O
216	##2	O
216	with	O
216	n	O
216	##c	O
216	-	O
216	600	O
216	##4	O
216	.	O
216	[SEP]	O
217	[CLS]	O
217	the	O
217	effect	O
217	of	O
217	weight	O
217	‐	O
217	based	O
217	and	O
217	flat	O
217	‐	O
217	dos	O
217	##ing	O
217	regime	O
217	##ns	O
217	were	O
217	evaluated	O
217	using	O
217	simulation	O
217	##s	O
217	based	O
217	on	O
217	the	O
217	final	O
217	population	O
217	p	O
217	##k	O
217	model	O
217	(	O
217	semi	O
217	##me	O
217	##chan	O
217	##istic	O
217	time	O
217	‐	O
217	varying	O
217	c	B-PK
217	##l	I-PK
217	)	O
217	.	O
217	[SEP]	O
218	[CLS]	O
218	we	O
218	suggest	O
218	that	O
218	these	O
218	dose	O
218	-	O
218	independent	O
218	p	O
218	##har	O
218	##ma	O
218	##co	O
218	##kin	O
218	##etic	O
218	characteristics	O
218	of	O
218	α	O
218	-	O
218	man	O
218	##gos	O
218	##tin	O
218	in	O
218	mice	O
218	provide	O
218	an	O
218	important	O
218	basis	O
218	for	O
218	pre	O
218	##c	O
218	##lini	O
218	##cal	O
218	applications	O
218	of	O
218	α	O
218	-	O
218	man	O
218	##gos	O
218	##tin	O
218	as	O
218	well	O
218	as	O
218	man	O
218	##gos	O
218	##teen	O
218	.	O
218	[SEP]	O
219	[CLS]	O
219	the	O
219	p	O
219	##har	O
219	##ma	O
219	##co	O
219	##kin	O
219	##etic	O
219	study	O
219	combined	O
219	with	O
219	the	O
219	p	O
219	##har	O
219	##ma	O
219	##cology	O
219	research	O
219	of	O
219	si	O
219	##m	O
219	##vas	O
219	##tat	O
219	##in	O
219	with	O
219	be	O
219	##rber	O
219	##ine	O
219	improvement	O
219	of	O
219	the	O
219	lip	O
219	##id	O
219	-	O
219	lowering	O
219	efficacy	O
219	,	O
219	suggest	O
219	this	O
219	may	O
219	be	O
219	a	O
219	promising	O
219	drug	O
219	-	O
219	drug	O
219	combination	O
219	to	O
219	overcome	O
219	its	O
219	adverse	O
219	effects	O
219	and	O
219	to	O
219	improve	O
219	its	O
219	lip	O
219	##id	O
219	-	O
219	lowering	O
219	efficacy	O
219	in	O
219	##c	O
219	##lini	O
219	##cal	O
219	use	O
219	.	O
219	[SEP]	O
220	[CLS]	O
220	the	O
220	urine	O
220	samples	O
220	for	O
220	the	O
220	possible	O
220	analysis	O
220	of	O
220	km	O
220	-	O
220	81	O
220	##9	O
220	and	O
220	q	O
220	##ual	O
220	##itative	O
220	analysis	O
220	of	O
220	any	O
220	meta	O
220	##bol	O
220	##ites	O
220	were	O
220	collected	O
220	at	O
220	day	O
220	1	O
220	pre	O
220	##dos	O
220	##e	O
220	and	O
220	from	O
220	0	O
220	to	O
220	24	O
220	hours	O
220	post	O
220	##dos	O
220	##e	O
220	.	O
220	[SEP]	O
221	[CLS]	O
221	point	O
221	estimates	O
221	for	O
221	the	O
221	p	O
221	##k	O
221	parameters	O
221	and	O
221	the	O
221	associated	O
221	90	O
221	%	O
221	c	O
221	##is	O
221	for	O
221	the	O
221	co	O
221	##hor	O
221	##t	O
221	difference	O
221	(	O
221	re	O
221	##nal	O
221	imp	O
221	##air	O
221	##ment	O
221	vs	O
221	healthy	O
221	controls	O
221	)	O
221	were	O
221	calculated	O
221	.	O
221	[SEP]	O
222	[CLS]	O
222	h	O
222	/	O
222	l	O
222	,	O
222	range	O
222	10	O
222	.	O
222	4	O
222	-	O
222	24	O
222	.	O
222	4	O
222	mg	O
222	.	O
222	[SEP]	O
223	[CLS]	O
223	dissolution	O
223	versus	O
223	per	B-PK
223	##me	I-PK
223	##ability	I-PK
223	.	O
223	[SEP]	O
224	[CLS]	O
224	[	O
224	bio	B-PK
224	##ava	I-PK
224	##ila	I-PK
224	##bility	I-PK
224	of	O
224	am	O
224	##pic	O
224	##ill	O
224	##in	O
224	preparations	O
224	for	O
224	internal	O
224	use	O
224	]	O
224	.	O
224	[SEP]	O
225	[CLS]	O
225	the	O
225	her	O
225	##2	O
225	+	O
225	b	O
225	##t	O
225	##47	O
225	##4	O
225	human	O
225	breast	O
225	cancer	O
225	cell	O
225	line	O
225	/	O
225	x	O
225	##eno	O
225	##gra	O
225	##ft	O
225	is	O
225	a	O
225	well	O
225	-	O
225	established	O
225	model	O
225	of	O
225	human	O
225	her	O
225	##2	O
225	+	O
225	breast	O
225	cancer	O
225	,	O
225	the	O
225	population	O
225	for	O
225	which	O
225	the	O
225	drug	O
225	is	O
225	approved	O
225	.	O
225	[SEP]	O
226	[CLS]	O
226	the	O
226	probability	O
226	of	O
226	being	O
226	a	O
226	s	O
226	##ri	O
226	respond	O
226	##er	O
226	was	O
226	obtained	O
226	by	O
226	the	O
226	equation	O
226	:	O
226	\	O
226	document	O
226	##c	O
226	##lass	O
226	[	O
226	12	O
226	##pt	O
226	]	O
226	{	O
226	minimal	O
226	}	O
226	\	O
226	use	O
226	##pack	O
226	##age	O
226	{	O
226	am	O
226	##sma	O
226	##th	O
226	}	O
226	\	O
226	use	O
226	##pack	O
226	##age	O
226	{	O
226	was	O
226	##ys	O
226	##ym	O
226	}	O
226	\	O
226	use	O
226	##pack	O
226	##age	O
226	{	O
226	am	O
226	##s	O
226	##fo	O
226	##nts	O
226	}	O
226	\	O
226	use	O
226	##pack	O
226	##age	O
226	{	O
226	am	O
226	##ssy	O
226	##mb	O
226	}	O
226	\	O
226	use	O
226	##pack	O
226	##age	O
226	{	O
226	am	O
226	##s	O
226	##bs	O
226	##y	O
226	}	O
226	\	O
226	use	O
226	##pack	O
226	##age	O
226	{	O
226	math	O
226	##rs	O
226	##fs	O
226	}	O
226	[SEP]	O
227	[CLS]	O
227	this	O
227	study	O
227	did	O
227	not	O
227	investigate	O
227	the	O
227	efficacy	O
227	of	O
227	the	O
227	21	O
227	-	O
227	day	O
227	fixed	O
227	et	O
227	##hin	O
227	##yl	O
227	est	O
227	##rad	O
227	##iol	O
227	-	O
227	nor	O
227	##eth	O
227	##ind	O
227	##rone	O
227	regime	O
227	##n	O
227	,	O
227	but	O
227	the	O
227	results	O
227	suggest	O
227	that	O
227	th	O
227	##ali	O
227	##dom	O
227	##ide	O
227	is	O
227	unlikely	O
227	to	O
227	affect	O
227	the	O
227	p	O
227	##har	O
227	##ma	O
227	##co	O
227	##kin	O
227	##etics	O
227	of	O
227	oral	O
227	##ly	O
227	administered	O
227	ho	O
227	##rmon	O
227	##al	O
227	con	O
227	##tra	O
227	##ceptive	O
227	##s	O
227	.	O
227	[SEP]	O
228	[CLS]	O
228	the	O
228	(	O
228	mean	O
228	+	O
228	-	O
228	standard	O
228	de	O
228	##viation	O
228	)	O
228	elimination	B-PK
228	t	I-PK
228	(	I-PK
228	1	I-PK
228	/	I-PK
228	2	I-PK
228	)	I-PK
228	was	O
228	102	O
228	+	O
228	-	O
228	20	O
228	hours	O
228	in	O
228	plasma	O
228	,	O
228	180	O
228	+	O
228	-	O
228	68	O
228	hours	O
228	in	O
228	blood	O
228	,	O
228	and	O
228	28	O
228	##9	O
228	+	O
228	-	O
228	166	O
228	hours	O
228	in	O
228	pm	O
228	##nn	O
228	##s	O
228	.	O
228	[SEP]	O
229	[CLS]	O
229	modelling	O
229	the	O
229	anti	O
229	-	O
229	mi	O
229	##gra	O
229	##ine	O
229	effects	O
229	of	O
229	bi	O
229	##b	O
229	##n	O
229	40	O
229	##9	O
229	##6	O
229	b	O
229	##s	O
229	:	O
229	a	O
229	new	O
229	ca	O
229	##l	O
229	##ci	O
229	##ton	O
229	##in	O
229	gene	O
229	-	O
229	related	O
229	p	O
229	##eptide	O
229	receptor	O
229	antagonist	O
229	.	O
229	[SEP]	O
230	[CLS]	O
230	a	O
230	physiological	O
230	##ly	O
230	based	O
230	p	O
230	##har	O
230	##ma	O
230	##co	O
230	##kin	O
230	##etic	O
230	model	O
230	was	O
230	used	O
230	to	O
230	quantitative	O
230	##ly	O
230	predict	O
230	the	O
230	impact	O
230	of	O
230	inter	O
230	##le	O
230	##uki	O
230	##n	O
230	-	O
230	6	O
230	(	O
230	il	O
230	-	O
230	6	O
230	)	O
230	on	O
230	sensitive	O
230	c	O
230	##y	O
230	##p	O
230	##3	O
230	##a	O
230	##4	O
230	substrates	O
230	.	O
230	[SEP]	O
231	[CLS]	O
231	in	O
231	contrast	O
231	,	O
231	with	O
231	one	O
231	blood	O
231	level	O
231	,	O
231	median	O
231	c	B-PK
231	##l	I-PK
231	became	O
231	similar	O
231	to	O
231	groups	O
231	having	O
231	2	O
231	,	O
231	3	O
231	,	O
231	and	O
231	4	O
231	blood	O
231	levels	O
231	only	O
231	after	O
231	about	O
231	35	O
231	patients	O
231	had	O
231	been	O
231	studied	O
231	,	O
231	versus	O
231	about	O
231	10	O
231	.	O
231	[SEP]	O
232	[CLS]	O
232	this	O
232	result	O
232	is	O
232	not	O
232	in	O
232	accordance	O
232	with	O
232	go	O
232	##yar	O
232	##ts	O
232	and	O
232	da	O
232	##nick	O
232	##e	O
232	(	O
232	2006	O
232	)	O
232	[	O
232	14	O
232	]	O
232	,	O
232	but	O
232	could	O
232	be	O
232	explained	O
232	by	O
232	the	O
232	difference	O
232	in	O
232	don	O
232	administration	O
232	route	O
232	(	O
232	diet	O
232	vs	O
232	.	O
232	oral	O
232	g	O
232	##ava	O
232	##ge	O
232	)	O
232	.	O
232	[SEP]	O
233	[CLS]	O
233	when	O
233	results	O
233	from	O
233	both	O
233	studies	O
233	were	O
233	compared	O
233	,	O
233	60	O
233	%	O
233	of	O
233	the	O
233	drug	O
233	administered	O
233	to	O
233	the	O
233	re	O
233	##ct	O
233	##um	O
233	was	O
233	absorbed	O
233	from	O
233	the	O
233	superior	O
233	hem	O
233	##or	O
233	##r	O
233	##ho	O
233	##idal	O
233	vein	O
233	and	O
233	the	O
233	remaining	O
233	40	O
233	%	O
233	was	O
233	absorbed	O
233	from	O
233	the	O
233	inferior	O
233	hem	O
233	##or	O
233	##r	O
233	##ho	O
233	##idal	O
233	vein	O
233	.	O
233	[SEP]	O
234	[CLS]	O
234	the	O
234	higher	O
234	the	O
234	dose	O
234	of	O
234	ha	O
234	##l	O
234	or	O
234	r	O
234	##hal	O
234	injected	O
234	,	O
234	or	O
234	after	O
234	repeated	O
234	injection	O
234	##s	O
234	,	O
234	the	O
234	greater	O
234	the	O
234	r	O
234	##hal	O
234	to	O
234	ha	O
234	##l	O
234	ratio	O
234	produced	O
234	.	O
234	[SEP]	O
235	[CLS]	O
235	figure	O
235	1	O
235	##a	O
235	provides	O
235	a	O
235	simulation	O
235	using	O
235	the	O
235	final	O
235	parameter	O
235	estimates	O
235	from	O
235	the	O
235	p	O
235	##k	O
235	model	O
235	for	O
235	each	O
235	dose	O
235	level	O
235	after	O
235	a	O
235	single	O
235	dose	O
235	administration	O
235	,	O
235	which	O
235	is	O
235	in	O
235	alignment	O
235	with	O
235	the	O
235	data	O
235	that	O
235	were	O
235	collected	O
235	from	O
235	the	O
235	study	O
235	and	O
235	modeled	O
235	.	O
235	[SEP]	O
236	[CLS]	O
236	the	O
236	present	O
236	study	O
236	demonstrated	O
236	that	O
236	modeling	O
236	and	O
236	simulation	O
236	permits	O
236	a	O
236	reasonable	O
236	r	O
236	##o	O
236	est	O
236	##imation	O
236	in	O
236	the	O
236	human	O
236	c	O
236	##ns	O
236	.	O
236	[SEP]	O
237	[CLS]	O
237	na	O
237	##vo	O
237	##xi	O
237	##mo	O
237	##d	O
237	was	O
237	prepared	O
237	by	O
237	w	O
237	##ux	O
237	##i	O
237	app	O
237	##tec	O
237	co	O
237	.	O
237	,	O
237	l	O
237	##t	O
237	##d	O
237	(	O
237	s	O
237	##hang	O
237	##hai	O
237	,	O
237	chin	O
237	##a	O
237	)	O
237	and	O
237	the	O
237	film	O
237	‐	O
237	coated	O
237	200	O
237	mg	O
237	na	O
237	##vo	O
237	##xi	O
237	##mo	O
237	##d	O
237	tablet	O
237	was	O
237	prepared	O
237	by	O
237	ho	O
237	##ff	O
237	##man	O
237	‐	O
237	la	O
237	##ro	O
237	##che	O
237	(	O
237	base	O
237	##l	O
237	,	O
237	s	O
237	##witz	O
237	##erland	O
237	)	O
237	.	O
237	[SEP]	O
238	[CLS]	O
238	however	O
238	,	O
238	cm	B-PK
238	##ax	I-PK
238	of	O
238	the	O
238	commercial	O
238	product	O
238	reached	O
238	79	O
238	%	O
238	of	O
238	simulation	O
238	,	O
238	and	O
238	magnitude	O
238	of	O
238	decrease	O
238	in	O
238	cm	B-PK
238	##ax	I-PK
238	value	O
238	of	O
238	commercial	O
238	product	O
238	was	O
238	smaller	O
238	than	O
238	other	O
238	parameters	O
238	.	O
238	[SEP]	O
239	[CLS]	O
239	our	O
239	institution	O
239	developed	O
239	dos	O
239	##ing	O
239	guidelines	O
239	for	O
239	patients	O
239	with	O
239	re	O
239	##nal	O
239	imp	O
239	##air	O
239	##ment	O
239	based	O
239	on	O
239	p	O
239	##har	O
239	##ma	O
239	##co	O
239	##kin	O
239	##etic	O
239	data	O
239	and	O
239	class	O
239	-	O
239	specific	O
239	p	O
239	##har	O
239	##ma	O
239	##co	O
239	##dynamic	O
239	##s	O
239	.	O
239	[SEP]	O
240	[CLS]	O
240	effect	O
240	of	O
240	food	O
240	on	O
240	bio	B-PK
240	##ava	I-PK
240	##ila	I-PK
240	##bility	I-PK
240	of	O
240	na	O
240	##lid	O
240	##ix	O
240	##ic	O
240	acid	O
240	from	O
240	un	O
240	##coat	O
240	##ed	O
240	tablets	O
240	having	O
240	different	O
240	dissolution	O
240	rates	O
240	.	O
240	[SEP]	O
241	[CLS]	O
241	cm	B-PK
241	##ax	I-PK
241	values	O
241	of	O
241	co	O
241	##hor	O
241	##ts	O
241	1	O
241	and	O
241	2	O
241	were	O
241	similar	O
241	,	O
241	but	O
241	cm	B-PK
241	##ax	I-PK
241	of	O
241	co	O
241	##hor	O
241	##t	O
241	3	O
241	was	O
241	higher	O
241	than	O
241	that	O
241	of	O
241	the	O
241	other	O
241	co	O
241	##hor	O
241	##ts	O
241	.	O
241	[SEP]	O
242	[CLS]	O
242	ale	O
242	##m	O
242	##tu	O
242	##zu	O
242	##ma	O
242	##b	O
242	is	O
242	registered	O
242	for	O
242	the	O
242	treatment	O
242	of	O
242	multiple	O
242	s	O
242	##cle	O
242	##rosis	O
242	(	O
242	m	O
242	##s	O
242	)	O
242	and	O
242	is	O
242	also	O
242	used	O
242	in	O
242	chronic	O
242	l	O
242	##ymph	O
242	##oc	O
242	##ytic	O
242	le	O
242	##uke	O
242	##mia	O
242	(	O
242	c	O
242	##ll	O
242	)	O
242	.	O
242	[SEP]	O
243	[CLS]	O
243	compared	O
243	with	O
243	control	O
243	,	O
243	ta	O
243	##o	O
243	treatment	O
243	significantly	O
243	decreased	O
243	the	O
243	mean	O
243	time	O
243	-	O
243	averaged	O
243	er	O
243	##mb	O
243	##t	O
243	result	O
243	by	O
243	77	O
243	%	O
243	(	O
243	95	O
243	%	O
243	c	O
243	##i	O
243	,	O
243	68	O
243	,	O
243	85	O
243	%	O
243	)	O
243	,	O
243	the	O
243	mean	O
243	apparent	B-PK
243	oral	I-PK
243	clearance	I-PK
243	of	O
243	q	O
243	##uin	O
243	##ine	O
243	(	O
243	c	B-PK
243	##l	I-PK
243	/	I-PK
243	f	I-PK
243	)	O
243	by	O
243	45	O
243	%	O
243	(	O
243	95	O
243	%	O
243	c	O
243	##i	O
243	,	O
243	39	O
243	,	O
243	52	O
243	%	O
243	)	O
243	,	O
243	and	O
243	the	O
243	mean	O
243	apparent	B-PK
243	formation	I-PK
243	clearance	I-PK
243	of	O
243	3	O
243	-	O
243	h	O
243	##ydro	O
243	##xy	O
243	##quin	O
243	##ine	O
243	(	O
243	c	B-PK
243	##l	I-PK
243	##3	I-PK
243	-	I-PK
243	oh	I-PK
243	)	O
243	by	O
243	81	O
243	%	O
243	(	O
243	95	O
243	%	O
243	c	O
243	##i	O
243	,	O
243	76	O
243	,	O
243	87	O
243	%	O
243	)	O
243	.	O
243	[SEP]	O
244	[CLS]	O
244	about	O
244	65	O
244	%	O
244	of	O
244	the	O
244	dose	O
244	was	O
244	absorbed	O
244	in	O
244	rats	O
244	,	O
244	and	O
244	at	O
244	least	O
244	88	O
244	%	O
244	in	O
244	dogs	O
244	.	O
244	[SEP]	O
245	[CLS]	O
245	the	O
245	p	O
245	##ear	O
245	##son	O
245	correlation	O
245	coefficient	O
245	(	O
245	r	O
245	)	O
245	for	O
245	the	O
245	relationship	O
245	between	O
245	percentage	O
245	change	O
245	in	O
245	selected	O
245	safety	O
245	laboratory	O
245	values	O
245	and	O
245	total	B-PK
245	drug	I-PK
245	c	I-PK
245	##tro	I-PK
245	##ugh	I-PK
245	on	O
245	day	O
245	28	O
245	of	O
245	cycles	O
245	2	O
245	and	O
245	3	O
245	,	O
245	respectively	O
245	,	O
245	was	O
245	−	O
245	0	O
245	.	O
245	59	O
245	and	O
245	−	O
245	0	O
245	.	O
245	55	O
245	for	O
245	absolute	O
245	ne	O
245	##ut	O
245	##rop	O
245	##hil	O
245	count	O
245	,	O
245	and	O
245	−	O
245	0	O
245	.	O
245	64	O
245	and	O
245	−	O
245	0	O
245	.	O
245	66	O
245	for	O
245	plate	O
245	##let	O
245	count	O
245	,	O
245	indicating	O
245	an	O
245	overall	O
245	moderate	O
245	negative	O
245	correlation	O
245	(	O
245	−	O
245	0	O
245	.	O
245	7	O
245	<	O
245	r	O
245	≤	O
245	−	O
245	0	O
245	.	O
245	5	O
245	)	O
245	.	O
245	[SEP]	O
246	[CLS]	O
246	these	O
246	data	O
246	provided	O
246	dose	O
246	selection	O
246	support	O
246	for	O
246	so	O
246	##lit	O
246	##hr	O
246	##omy	O
246	##cin	O
246	for	O
246	clinical	O
246	trials	O
246	in	O
246	patients	O
246	with	O
246	community	O
246	-	O
246	acquired	O
246	bacterial	O
246	pneumonia	O
246	.	O
246	[SEP]	O
247	[CLS]	O
247	in	O
247	the	O
247	expansion	O
247	phase	O
247	of	O
247	step	O
247	1	O
247	,	O
247	ta	O
247	##s	O
247	-	O
247	116	O
247	was	O
247	administered	O
247	5	O
247	days	O
247	on	O
247	/	O
247	2	O
247	days	O
247	off	O
247	per	O
247	week	O
247	(	O
247	q	O
247	##d	O
247	×	O
247	5	O
247	)	O
247	.	O
247	[SEP]	O
248	[CLS]	O
248	diverse	O
248	car	O
248	##ote	O
248	##no	O
248	##ids	O
248	with	O
248	different	O
248	chemical	O
248	structures	O
248	exist	O
248	in	O
248	edible	O
248	plants	O
248	in	O
248	significant	O
248	amounts	O
248	.	O
248	[SEP]	O
249	[CLS]	O
249	l	O
249	-	O
249	a	O
249	##rg	O
249	##ini	O
249	##ne	O
249	in	O
249	##fusion	O
249	was	O
249	well	O
249	tolerate	O
249	##d	O
249	.	O
249	[SEP]	O
250	[CLS]	O
250	more	O
250	##over	O
250	,	O
250	further	O
250	studies	O
250	with	O
250	highly	O
250	protein	O
250	-	O
250	bound	O
250	drugs	O
250	are	O
250	recommended	O
250	to	O
250	check	O
250	the	O
250	classical	O
250	'	O
250	hem	O
250	##od	O
250	##ial	O
250	##ys	O
250	##is	O
250	'	O
250	equation	O
250	as	O
250	the	O
250	standard	O
250	equation	O
250	in	O
250	calculating	O
250	the	O
250	c	O
250	##v	O
250	##v	O
250	##h	O
250	clearance	B-PK
250	of	O
250	highly	O
250	protein	O
250	-	O
250	bound	O
250	drugs	O
250	.	O
250	[SEP]	O
251	[CLS]	O
251	the	O
251	pattern	O
251	of	O
251	heart	O
251	rate	O
251	observed	O
251	in	O
251	all	O
251	subjects	O
251	,	O
251	including	O
251	those	O
251	who	O
251	received	O
251	place	O
251	##bo	O
251	,	O
251	was	O
251	consistent	O
251	with	O
251	the	O
251	circa	O
251	##dian	O
251	rhythm	O
251	,	O
251	and	O
251	heart	O
251	rate	O
251	reduction	O
251	in	O
251	the	O
251	second	O
251	12	O
251	hours	O
251	was	O
251	also	O
251	consistent	O
251	with	O
251	normal	O
251	di	O
251	##urn	O
251	##al	O
251	variation	O
251	.	O
251	[SEP]	O
252	[CLS]	O
252	the	O
252	actual	O
252	maximum	B-PK
252	concentration	I-PK
252	(	I-PK
252	cm	I-PK
252	##ax	I-PK
252	)	I-PK
252	occurring	O
252	at	O
252	time	B-PK
252	to	I-PK
252	maximum	I-PK
252	concentration	I-PK
252	(	I-PK
252	t	I-PK
252	##max	I-PK
252	)	I-PK
252	were	O
252	recorded	O
252	.	O
252	[SEP]	O
253	[CLS]	O
253	plasma	O
253	concentrations	O
253	were	O
253	computer	O
253	fitted	O
253	to	O
253	a	O
253	three	O
253	-	O
253	compartment	O
253	open	O
253	model	O
253	using	O
253	a	O
253	zero	O
253	-	O
253	order	O
253	input	O
253	function	O
253	for	O
253	the	O
253	injection	O
253	period	O
253	.	O
253	[SEP]	O
254	[CLS]	O
254	the	O
254	limit	O
254	of	O
254	q	O
254	##uant	O
254	##ification	O
254	was	O
254	0	O
254	.	O
254	4	O
254	ng	O
254	.	O
254	m	O
254	##l	O
254	-	O
254	1	O
254	.	O
254	[SEP]	O
255	[CLS]	O
255	serial	O
255	blood	O
255	samples	O
255	were	O
255	collected	O
255	to	O
255	character	O
255	##ize	O
255	the	O
255	plasma	O
255	concentration	O
255	curve	O
255	.	O
255	[SEP]	O
256	[CLS]	O
256	cumulative	O
256	incidence	O
256	##s	O
256	of	O
256	grades	O
256	ii	O
256	-	O
256	i	O
256	##v	O
256	and	O
256	ii	O
256	##i	O
256	-	O
256	i	O
256	##v	O
256	acute	O
256	g	O
256	##v	O
256	##h	O
256	##d	O
256	at	O
256	day	O
256	100	O
256	were	O
256	50	O
256	%	O
256	and	O
256	17	O
256	%	O
256	,	O
256	respectively	O
256	.	O
256	[SEP]	O
257	[CLS]	O
257	the	O
257	first	O
257	group	O
257	was	O
257	subjected	O
257	to	O
257	me	O
257	##so	O
257	##ca	O
257	##val	O
257	s	O
257	##hun	O
257	##t	O
257	(	O
257	m	O
257	##cs	O
257	)	O
257	and	O
257	the	O
257	other	O
257	employed	O
257	as	O
257	a	O
257	control	O
257	.	O
257	[SEP]	O
258	[CLS]	O
258	si	O
258	##lica	O
258	coating	O
258	marked	O
258	##ly	O
258	improved	O
258	the	O
258	stability	O
258	of	O
258	flexible	O
258	lip	O
258	##oso	O
258	##mes	O
258	,	O
258	and	O
258	cu	O
258	##r	O
258	-	O
258	s	O
258	##ls	O
258	exhibited	O
258	a	O
258	3	O
258	.	O
258	31	O
258	-	O
258	fold	O
258	increase	O
258	in	O
258	bio	B-PK
258	##ava	I-PK
258	##ila	I-PK
258	##bility	I-PK
258	compared	O
258	with	O
258	cu	O
258	##r	O
258	-	O
258	fl	O
258	##s	O
258	,	O
258	indicating	O
258	that	O
258	si	O
258	##lica	O
258	-	O
258	coated	O
258	flexible	O
258	lip	O
258	##oso	O
258	##mes	O
258	may	O
258	be	O
258	employed	O
258	as	O
258	a	O
258	potential	O
258	carrier	O
258	to	O
258	deliver	O
258	drugs	O
258	with	O
258	poor	O
258	water	O
258	so	O
258	##lub	O
258	##ility	O
258	via	O
258	the	O
258	oral	O
258	route	O
258	with	O
258	improved	O
258	bio	B-PK
258	##ava	I-PK
258	##ila	I-PK
258	##bility	I-PK
258	.	O
258	[SEP]	O
259	[CLS]	O
259	lab	O
259	##ras	O
259	##ol	O
259	was	O
259	determined	O
259	to	O
259	be	O
259	the	O
259	most	O
259	likely	O
259	cu	O
259	##l	O
259	##p	O
259	##rit	O
259	for	O
259	this	O
259	double	O
259	peaking	O
259	phenomenon	O
259	.	O
259	[SEP]	O
260	[CLS]	O
260	blood	O
260	samples	O
260	at	O
260	the	O
260	first	O
260	dose	O
260	of	O
260	na	O
260	##b	O
260	-	O
260	p	O
260	##ac	O
260	##lit	O
260	##ax	O
260	##el	O
260	were	O
260	collected	O
260	for	O
260	p	O
260	##har	O
260	##ma	O
260	##co	O
260	##kin	O
260	##etic	O
260	analysis	O
260	.	O
260	[SEP]	O
261	[CLS]	O
261	demographic	O
261	##s	O
261	,	O
261	clinical	O
261	characteristics	O
261	,	O
261	and	O
261	genetic	O
261	p	O
261	##oly	O
261	##mor	O
261	##phism	O
261	##s	O
261	were	O
261	screened	O
261	as	O
261	co	O
261	##var	O
261	##iate	O
261	##s	O
261	.	O
261	[SEP]	O
262	[CLS]	O
262	[	O
262	p	O
262	##har	O
262	##ma	O
262	##co	O
262	##kin	O
262	##etics	O
262	of	O
262	3	O
262	'	O
262	-	O
262	a	O
262	##zi	O
262	##do	O
262	-	O
262	3	O
262	de	O
262	##ox	O
262	##y	O
262	-	O
262	thy	O
262	##mi	O
262	##dine	O
262	(	O
262	a	O
262	##z	O
262	##t	O
262	)	O
262	in	O
262	a	O
262	patient	O
262	undergoing	O
262	hem	O
262	##od	O
262	##ial	O
262	##ys	O
262	##is	O
262	]	O
262	.	O
262	[SEP]	O
263	[CLS]	O
263	a	O
263	significant	O
263	difference	O
263	was	O
263	observed	O
263	between	O
263	but	O
263	not	O
263	within	O
263	the	O
263	tested	O
263	products	O
263	.	O
263	[SEP]	O
264	[CLS]	O
264	p	O
264	##har	O
264	##ma	O
264	##co	O
264	##kin	O
264	##etics	O
264	and	O
264	p	O
264	##har	O
264	##ma	O
264	##co	O
264	##dynamic	O
264	##s	O
264	of	O
264	p	O
264	##ones	O
264	##imo	O
264	##d	O
264	,	O
264	a	O
264	selective	O
264	s	O
264	##1	O
264	##p	O
264	##1	O
264	receptor	O
264	m	O
264	##od	O
264	##ulator	O
264	,	O
264	in	O
264	the	O
264	first	O
264	-	O
264	in	O
264	-	O
264	human	O
264	study	O
264	.	O
264	[SEP]	O
265	[CLS]	O
265	in	O
265	contrast	O
265	,	O
265	co	O
265	##ad	O
265	##mini	O
265	##stra	O
265	##tion	O
265	of	O
265	m	O
265	##k	O
265	##5	O
265	##7	O
265	##1	O
265	or	O
265	mid	O
265	##az	O
265	##ola	O
265	##m	O
265	increased	O
265	sq	O
265	##v	O
265	absorption	O
265	only	O
265	2	O
265	-	O
265	to	O
265	3	O
265	-	O
265	fold	O
265	without	O
265	improving	O
265	the	O
265	variation	O
265	in	O
265	au	B-PK
265	##cs	I-PK
265	.	O
265	[SEP]	O
266	[CLS]	O
266	the	O
266	au	B-PK
266	##cs	I-PK
266	for	O
266	tablets	O
266	alone	O
266	,	O
266	with	O
266	ch	O
266	##ole	O
266	##sty	O
266	##ram	O
266	##ine	O
266	,	O
266	and	O
266	with	O
266	prop	O
266	##ant	O
266	##hel	O
266	##ine	O
266	were	O
266	32	O
266	.	O
266	8	O
266	+	O
266	-	O
266	13	O
266	.	O
266	3	O
266	(	O
266	+	O
266	-	O
266	s	O
266	##d	O
266	)	O
266	,	O
266	22	O
266	.	O
266	4	O
266	+	O
266	-	O
266	12	O
266	.	O
266	1	O
266	,	O
266	and	O
266	40	O
266	.	O
266	6	O
266	+	O
266	-	O
266	13	O
266	.	O
266	9	O
266	,	O
266	respectively	O
266	,	O
266	while	O
266	corresponding	O
266	values	O
266	for	O
266	capsule	O
266	##s	O
266	were	O
266	31	O
266	.	O
266	7	O
266	+	O
266	-	O
266	9	O
266	.	O
266	3	O
266	,	O
266	24	O
266	.	O
266	7	O
266	+	O
266	-	O
266	7	O
266	.	O
266	9	O
266	,	O
266	and	O
266	35	O
266	.	O
266	9	O
266	+	O
266	-	O
266	12	O
266	.	O
266	8	O
266	.	O
266	[SEP]	O
267	[CLS]	O
267	it	O
267	was	O
267	recommended	O
267	to	O
267	perform	O
267	the	O
267	treatment	O
267	with	O
267	monitoring	O
267	the	O
267	anti	O
267	##biotic	O
267	plasma	O
267	concentrations	O
267	to	O
267	prevent	O
267	the	O
267	drug	O
267	failure	O
267	because	O
267	of	O
267	the	O
267	changes	O
267	in	O
267	the	O
267	distribution	O
267	and	O
267	ex	O
267	##cre	O
267	##tion	O
267	patterns	O
267	.	O
267	[SEP]	O
268	[CLS]	O
268	the	O
268	analytical	O
268	method	O
268	was	O
268	applied	O
268	in	O
268	a	O
268	random	O
268	##ized	O
268	,	O
268	crossover	O
268	bio	O
268	##e	O
268	##qui	O
268	##valence	O
268	study	O
268	of	O
268	v	O
268	##als	O
268	##art	O
268	##an	O
268	tablets	O
268	;	O
268	the	O
268	study	O
268	enrolled	O
268	18	O
268	chin	O
268	##ese	O
268	volunteers	O
268	(	O
268	12	O
268	were	O
268	men	O
268	and	O
268	6	O
268	were	O
268	women	O
268	)	O
268	.	O
268	[SEP]	O
269	[CLS]	O
269	published	O
269	and	O
269	unpublished	O
269	p	O
269	##k	O
269	/	O
269	p	O
269	##d	O
269	data	O
269	from	O
269	2	O
269	,	O
269	187	O
269	b	O
269	##al	O
269	##b	O
269	/	O
269	c	O
269	and	O
269	nude	O
269	mice	O
269	were	O
269	used	O
269	.	O
269	2	O
269	,	O
269	9	O
269	,	O
269	14	O
269	,	O
269	15	O
269	,	O
269	16	O
269	mice	O
269	in	O
269	each	O
269	experiment	O
269	were	O
269	block	O
269	‐	O
269	random	O
269	##ized	O
269	to	O
269	treatment	O
269	assignment	O
269	after	O
269	a	O
269	##ero	O
269	##sol	O
269	infection	O
269	with	O
269	m	O
269	.	O
269	tuberculosis	O
269	h	O
269	##37	O
269	##r	O
269	##v	O
269	.	O
269	[SEP]	O
270	[CLS]	O
270	at	O
270	present	O
270	,	O
270	prediction	O
270	of	O
270	flu	O
270	##cona	O
270	##zo	O
270	##le	O
270	doses	O
270	according	O
270	to	O
270	developmental	O
270	changes	O
270	in	O
270	flu	O
270	##cona	O
270	##zo	O
270	##le	O
270	clearance	B-PK
270	is	O
270	not	O
270	being	O
270	done	O
270	in	O
270	these	O
270	patients	O
270	.	O
270	[SEP]	O
271	[CLS]	O
271	all	O
271	adverse	O
271	events	O
271	were	O
271	re	O
271	##versible	O
271	.	O
271	[SEP]	O
272	[CLS]	O
272	the	O
272	h	O
272	##y	O
272	##poli	O
272	##pid	O
272	##em	O
272	##ic	O
272	agent	O
272	f	O
272	##eno	O
272	##fi	O
272	##bra	O
272	##te	O
272	is	O
272	an	O
272	ideal	O
272	model	O
272	drug	O
272	for	O
272	testing	O
272	the	O
272	performance	O
272	of	O
272	drug	O
272	delivery	O
272	systems	O
272	designed	O
272	for	O
272	poorly	O
272	soluble	O
272	compounds	O
272	.	O
272	[SEP]	O
273	[CLS]	O
273	the	O
273	most	O
273	common	O
273	a	O
273	##es	O
273	were	O
273	viral	O
273	infection	O
273	(	O
273	16	O
273	.	O
273	7	O
273	%	O
273	)	O
273	,	O
273	na	O
273	##so	O
273	##pha	O
273	##ryn	O
273	##git	O
273	##is	O
273	(	O
273	11	O
273	.	O
273	1	O
273	%	O
273	)	O
273	,	O
273	and	O
273	h	O
273	##yper	O
273	##cal	O
273	##ce	O
273	##mia	O
273	(	O
273	11	O
273	.	O
273	1	O
273	%	O
273	)	O
273	in	O
273	the	O
273	place	O
273	##bo	O
273	group	O
273	,	O
273	and	O
273	r	O
273	##hin	O
273	##itis	O
273	(	O
273	16	O
273	.	O
273	7	O
273	%	O
273	)	O
273	in	O
273	the	O
273	par	O
273	##ical	O
273	##ci	O
273	##to	O
273	##l	O
273	group	O
273	.	O
273	[SEP]	O
274	[CLS]	O
274	among	O
274	tested	O
274	formulation	O
274	##s	O
274	,	O
274	f	O
274	##b	O
274	-	O
274	am	O
274	##p	O
274	(	O
274	3	O
274	)	O
274	,	O
274	dramatically	O
274	increased	O
274	the	O
274	dissolution	O
274	of	O
274	f	O
274	##b	O
274	and	O
274	achieved	O
274	rapid	O
274	and	O
274	complete	O
274	drug	O
274	release	O
274	within	O
274	2	O
274	hours	O
274	.	O
274	[SEP]	O
275	[CLS]	O
275	written	O
275	consent	O
275	was	O
275	obtained	O
275	from	O
275	the	O
275	patients	O
275	prior	O
275	to	O
275	the	O
275	trial	O
275	.	O
275	[SEP]	O
276	[CLS]	O
276	in	O
276	the	O
276	event	O
276	that	O
276	it	O
276	is	O
276	difficult	O
276	to	O
276	determine	O
276	which	O
276	structure	O
276	best	O
276	character	O
276	##izes	O
276	the	O
276	data	O
276	,	O
276	it	O
276	may	O
276	be	O
276	helpful	O
276	to	O
276	fit	O
276	each	O
276	subject	O
276	individually	O
276	to	O
276	explore	O
276	the	O
276	reasons	O
276	for	O
276	une	O
276	##x	O
276	##plain	O
276	##ed	O
276	var	O
276	##iability	O
276	.	O
276	[SEP]	O
277	[CLS]	O
277	the	O
277	following	O
277	for	O
277	all	O
277	anal	O
277	##yte	O
277	##s	O
277	after	O
277	administration	O
277	were	O
277	also	O
277	calculated	O
277	:	O
277	t	B-PK
277	##max	I-PK
277	and	O
277	the	O
277	elimination	B-PK
277	half	I-PK
277	-	I-PK
277	life	I-PK
277	(	I-PK
277	t	I-PK
277	##1	I-PK
277	/	I-PK
277	2	I-PK
277	)	I-PK
277	.	O
277	[SEP]	O
278	[CLS]	O
278	consistent	O
278	with	O
278	overall	O
278	survival	O
278	and	O
278	event	O
278	free	O
278	survival	O
278	,	O
278	the	O
278	complete	O
278	re	O
278	##mission	O
278	rates	O
278	7	O
278	+	O
278	3	O
278	treatment	O
278	,	O
278	first	O
278	,	O
278	second	O
278	,	O
278	third	O
278	,	O
278	and	O
278	fourth	O
278	q	O
278	##ua	O
278	##rt	O
278	##iles	O
278	were	O
278	26	O
278	.	O
278	5	O
278	%	O
278	,	O
278	30	O
278	.	O
278	3	O
278	%	O
278	,	O
278	37	O
278	.	O
278	5	O
278	%	O
278	,	O
278	30	O
278	.	O
278	3	O
278	%	O
278	,	O
278	and	O
278	59	O
278	.	O
278	4	O
278	%	O
278	,	O
278	respectively	O
278	(	O
278	table	O
278	s	O
278	##8	O
278	)	O
278	.	O
278	[SEP]	O
279	[CLS]	O
279	initial	O
279	absorption	B-PK
279	rate	I-PK
279	constant	I-PK
279	##s	I-PK
279	were	O
279	determined	O
279	by	O
279	the	O
279	plot	O
279	of	O
279	log	O
279	%	O
279	remaining	O
279	amount	O
279	of	O
279	drug	O
279	in	O
279	per	O
279	##fu	O
279	##sat	O
279	##e	O
279	vs	O
279	time	O
279	.	O
279	[SEP]	O
280	[CLS]	O
280	in	O
280	radio	O
280	##im	O
280	##mu	O
280	##not	O
280	##her	O
280	##ap	O
280	##y	O
280	trials	O
280	,	O
280	12	O
280	patients	O
280	with	O
280	breast	O
280	or	O
280	pro	O
280	##state	O
280	cancer	O
280	were	O
280	given	O
280	two	O
280	imaging	O
280	doses	O
280	(	O
280	5	O
280	m	O
280	##ci	O
280	each	O
280	)	O
280	of	O
280	(	O
280	111	O
280	)	O
280	in	O
280	-	O
280	dot	O
280	##a	O
280	-	O
280	g	O
280	##ly	O
280	##3	O
280	##phe	O
280	-	O
280	m	O
280	##17	O
280	##0	O
280	1	O
280	week	O
280	apart	O
280	.	O
280	[SEP]	O
281	[CLS]	O
281	detect	O
281	##able	O
281	serum	O
281	concentrations	O
281	of	O
281	c	O
281	##lar	O
281	##ith	O
281	##rom	O
281	##y	O
281	##cin	O
281	were	O
281	found	O
281	in	O
281	3	O
281	of	O
281	6	O
281	f	O
281	##oa	O
281	##ls	O
281	at	O
281	10	O
281	minutes	O
281	and	O
281	in	O
281	all	O
281	f	O
281	##oa	O
281	##ls	O
281	by	O
281	20	O
281	minutes	O
281	post	O
281	-	O
281	administration	O
281	.	O
281	[SEP]	O
282	[CLS]	O
282	to	O
282	sum	O
282	##mar	O
282	##ize	O
282	,	O
282	43	O
282	analog	O
282	##s	O
282	were	O
282	synthesized	O
282	out	O
282	of	O
282	which	O
282	15	O
282	compounds	O
282	showed	O
282	very	O
282	potent	O
282	sub	O
282	-	O
282	na	O
282	##no	O
282	##mo	O
282	##lar	O
282	efficacy	O
282	in	O
282	in	O
282	v	O
282	##it	O
282	##ro	O
282	systems	O
282	but	O
282	the	O
282	liability	O
282	of	O
282	metabolic	O
282	instability	O
282	seemed	O
282	to	O
282	be	O
282	the	O
282	major	O
282	challenge	O
282	for	O
282	this	O
282	chemical	O
282	class	O
282	and	O
282	remains	O
282	to	O
282	be	O
282	addressed	O
282	.	O
282	[SEP]	O
283	[CLS]	O
283	the	O
283	automatic	O
283	p	O
283	##ca	O
283	-	O
283	based	O
283	approach	O
283	minimize	O
283	##s	O
283	the	O
283	var	O
283	##iability	O
283	associated	O
283	to	O
283	obtaining	O
283	individual	O
283	volume	O
283	-	O
283	based	O
283	a	O
283	##if	O
283	##s	O
283	in	O
283	d	O
283	##ce	O
283	-	O
283	m	O
283	##r	O
283	studies	O
283	of	O
283	the	O
283	pro	O
283	##state	O
283	.	O
283	[SEP]	O
284	[CLS]	O
284	the	O
284	mean	O
284	sa	O
284	##liva	O
284	/	O
284	plasma	O
284	concentration	O
284	of	O
284	test	O
284	and	O
284	reference	O
284	were	O
284	2	O
284	.	O
284	29	O
284	and	O
284	2	O
284	.	O
284	33	O
284	,	O
284	respectively	O
284	.	O
284	[SEP]	O
285	[CLS]	O
285	the	O
285	c	O
285	##dd	O
285	##p	O
285	and	O
285	p	O
285	##t	O
285	##x	O
285	in	O
285	co	O
285	-	O
285	n	O
285	##ps	O
285	are	O
285	mainly	O
285	dispersed	O
285	to	O
285	the	O
285	blood	O
285	,	O
285	liver	O
285	,	O
285	and	O
285	s	O
285	##ple	O
285	##en	O
285	,	O
285	and	O
285	bone	O
285	ma	O
285	##rrow	O
285	,	O
285	followed	O
285	by	O
285	secondary	O
285	distribution	O
285	in	O
285	the	O
285	kidney	O
285	and	O
285	tumor	O
285	.	O
285	[SEP]	O
286	[CLS]	O
286	to	O
286	investigate	O
286	sequence	O
286	effects	O
286	on	O
286	toxicity	O
286	,	O
286	tumor	O
286	response	O
286	and	O
286	p	O
286	##har	O
286	##ma	O
286	##co	O
286	##kin	O
286	##etics	O
286	of	O
286	do	O
286	##ce	O
286	##ta	O
286	##xe	O
286	##l	O
286	and	O
286	car	O
286	##bo	O
286	##p	O
286	##lat	O
286	##in	O
286	,	O
286	together	O
286	with	O
286	a	O
286	determination	O
286	of	O
286	the	O
286	maximum	O
286	-	O
286	tolerate	O
286	##d	O
286	dose	O
286	(	O
286	m	O
286	##t	O
286	##d	O
286	)	O
286	and	O
286	recommended	O
286	dose	O
286	for	O
286	each	O
286	schedule	O
286	.	O
286	[SEP]	O
287	[CLS]	O
287	the	O
287	peak	O
287	area	O
287	of	O
287	r	O
287	##s	O
287	-	O
287	1	O
287	was	O
287	enhanced	O
287	after	O
287	en	O
287	##zy	O
287	##mo	O
287	##lysis	O
287	of	O
287	the	O
287	samples	O
287	with	O
287	β	O
287	-	O
287	g	O
287	##lu	O
287	##cu	O
287	##ron	O
287	##idas	O
287	##e	O
287	or	O
287	su	O
287	##lf	O
287	##ata	O
287	##se	O
287	,	O
287	which	O
287	indicated	O
287	that	O
287	it	O
287	contains	O
287	r	O
287	##s	O
287	-	O
287	1	O
287	g	O
287	##lu	O
287	##cu	O
287	##ron	O
287	##ide	O
287	and	O
287	su	O
287	##lf	O
287	##ate	O
287	con	O
287	##ju	O
287	##gate	O
287	##s	O
287	.	O
287	[SEP]	O
288	[CLS]	O
288	m	O
288	##s	O
288	(	O
288	es	O
288	##i	O
288	)	O
288	(	O
288	m	O
288	/	O
288	z	O
288	)	O
288	:	O
288	[	O
288	m	O
288	]	O
288	+	O
288	302	O
288	.	O
288	00	O
288	,	O
288	[	O
288	m	O
288	+	O
288	h	O
288	]	O
288	+	O
288	303	O
288	.	O
288	00	O
288	.	O
288	[SEP]	O
289	[CLS]	O
289	h	O
289	##r	O
289	)	O
289	than	O
289	in	O
289	men	O
289	(	O
289	3	O
289	.	O
289	19	O
289	+	O
289	-	O
289	0	O
289	.	O
289	48	O
289	mm	O
289	##ol	O
289	/	O
289	l	O
289	.	O
289	[SEP]	O
290	[CLS]	O
290	liquid	O
290	mi	O
290	##cs	O
290	were	O
290	performed	O
290	as	O
290	described	O
290	above	O
290	with	O
290	the	O
290	additional	O
290	step	O
290	of	O
290	determining	O
290	the	O
290	number	O
290	of	O
290	bacteria	O
290	added	O
290	to	O
290	each	O
290	well	O
290	.	O
290	[SEP]	O
291	[CLS]	O
291	reaction	O
291	was	O
291	halted	O
291	by	O
291	the	O
291	addition	O
291	of	O
291	5	O
291	μ	O
291	##l	O
291	of	O
291	1	O
291	m	O
291	su	O
291	##l	O
291	##ph	O
291	##uri	O
291	##c	O
291	acid	O
291	.	O
291	[SEP]	O
292	[CLS]	O
292	a	O
292	good	O
292	p	O
292	##har	O
292	##ma	O
292	##co	O
292	##kin	O
292	##etic	O
292	profile	O
292	(	O
292	serum	O
292	and	O
292	brain	O
292	concentrations	O
292	and	O
292	u	O
292	##rina	O
292	##ry	O
292	recovery	O
292	)	O
292	was	O
292	obtained	O
292	for	O
292	the	O
292	two	O
292	c	O
292	##yclic	O
292	compounds	O
292	(	O
292	3	O
292	##e	O
292	and	O
292	3	O
292	##g	O
292	)	O
292	,	O
292	but	O
292	that	O
292	of	O
292	the	O
292	vinyl	O
292	##ic	O
292	compounds	O
292	(	O
292	3	O
292	##m	O
292	and	O
292	3	O
292	##o	O
292	)	O
292	was	O
292	less	O
292	favorable	O
292	.	O
292	[SEP]	O
293	[CLS]	O
293	all	O
293	patients	O
293	had	O
293	received	O
293	prior	O
293	systemic	O
293	therapy	O
293	.	O
293	[SEP]	O
294	[CLS]	O
294	j	O
294	##ej	O
294	##un	O
294	##um	O
294	portions	O
294	of	O
294	1	O
294	cm	O
294	were	O
294	stored	O
294	in	O
294	the	O
294	tissue	O
294	proceeding	O
294	medium	O
294	o	O
294	##ct	O
294	and	O
294	frozen	O
294	at	O
294	−	O
294	##80	O
294	°	O
294	##c	O
294	.	O
294	[SEP]	O
295	[CLS]	O
295	re	O
295	##sm	O
295	##ino	O
295	##sta	O
295	##t	O
295	was	O
295	safely	O
295	administered	O
295	with	O
295	a	O
295	dose	O
295	-	O
295	proportional	O
295	p	O
295	##har	O
295	##ma	O
295	##co	O
295	##kin	O
295	##etic	O
295	profile	O
295	,	O
295	optimal	O
295	on	O
295	-	O
295	target	O
295	p	O
295	##har	O
295	##ma	O
295	##co	O
295	##dynamic	O
295	activity	O
295	at	O
295	dose	O
295	levels	O
295	≥	O
295	##40	O
295	##0	O
295	mg	O
295	and	O
295	signs	O
295	of	O
295	anti	O
295	##tum	O
295	##or	O
295	efficacy	O
295	.	O
295	[SEP]	O
296	[CLS]	O
296	all	O
296	4	O
296	antagonist	O
296	##s	O
296	bound	O
296	to	O
296	their	O
296	respective	O
296	receptors	O
296	with	O
296	high	O
296	affinity	O
296	and	O
296	select	O
296	##ivity	O
296	in	O
296	v	O
296	##it	O
296	##ro	O
296	.	O
296	[SEP]	O
297	[CLS]	O
297	based	O
297	on	O
297	pre	O
297	-	O
297	dose	O
297	p	O
297	##k	O
297	samples	O
297	obtained	O
297	,	O
297	er	O
297	##yt	O
297	##hr	O
297	##omy	O
297	##cin	O
297	plasma	B-PK
297	concentrations	I-PK
297	at	I-PK
297	t	I-PK
297	##rough	I-PK
297	were	O
297	determined	O
297	and	O
297	attain	O
297	##ment	O
297	of	O
297	steady	O
297	-	O
297	state	O
297	conditions	O
297	was	O
297	assessed	O
297	visually	O
297	.	O
297	[SEP]	O
298	[CLS]	O
298	the	O
298	dose	O
298	of	O
298	co	O
298	##u	O
298	that	O
298	promoted	O
298	the	O
298	br	O
298	##on	O
298	##cho	O
298	##di	O
298	##lator	O
298	effect	O
298	in	O
298	g	O
298	##uin	O
298	##ea	O
298	pigs	O
298	(	O
298	ad	O
298	##50	O
298	:	O
298	75	O
298	mg	O
298	/	O
298	kg	O
298	)	O
298	[	O
298	15	O
298	]	O
298	was	O
298	used	O
298	as	O
298	a	O
298	reference	O
298	to	O
298	conduct	O
298	the	O
298	study	O
298	.	O
298	[SEP]	O
299	[CLS]	O
299	data	O
299	acquisition	O
299	and	O
299	processing	O
299	were	O
299	operated	O
299	through	O
299	mass	O
299	##lyn	O
299	##x	O
299	v	O
299	##4	O
299	.	O
299	1	O
299	works	O
299	##tation	O
299	.	O
299	[SEP]	O
300	[CLS]	O
300	the	O
300	p	O
300	##har	O
300	##ma	O
300	##co	O
300	##kin	O
300	##etic	O
300	data	O
300	recorded	O
300	after	O
300	a	O
300	##ero	O
300	##sol	O
300	administration	O
300	,	O
300	v	O
300	##iz	O
300	.	O
300	[SEP]	O
301	[CLS]	O
301	the	O
301	workers	O
301	had	O
301	previously	O
301	been	O
301	found	O
301	to	O
301	have	O
301	elevated	O
301	levels	O
301	of	O
301	high	O
301	-	O
301	and	O
301	medium	O
301	-	O
301	br	O
301	##omi	O
301	##nated	O
301	dip	O
301	##hen	O
301	##yl	O
301	et	O
301	##hers	O
301	compared	O
301	with	O
301	the	O
301	refer	O
301	##ent	O
301	populations	O
301	.	O
301	[SEP]	O
302	[CLS]	O
302	a	O
302	selective	O
302	and	O
302	sensitive	O
302	liquid	O
302	ch	O
302	##roma	O
302	##tography	O
302	tandem	O
302	mass	O
302	s	O
302	##pect	O
302	##rome	O
302	##try	O
302	method	O
302	was	O
302	developed	O
302	for	O
302	the	O
302	first	O
302	time	O
302	for	O
302	the	O
302	identification	O
302	and	O
302	q	O
302	##uant	O
302	##ification	O
302	of	O
302	cu	O
302	##rdi	O
302	##one	O
302	in	O
302	rabbit	O
302	plasma	O
302	after	O
302	v	O
302	##agi	O
302	##nal	O
302	drug	O
302	administration	O
302	and	O
302	in	O
302	##tra	O
302	##ven	O
302	##ous	O
302	administration	O
302	of	O
302	z	O
302	##ed	O
302	##oar	O
302	##y	O
302	t	O
302	##ur	O
302	##mer	O
302	##ic	O
302	oil	O
302	(	O
302	z	O
302	##to	O
302	)	O
302	solution	O
302	(	O
302	10	O
302	mg	O
302	/	O
302	kg	O
302	)	O
302	.	O
302	[SEP]	O
303	[CLS]	O
303	benefits	O
303	must	O
303	be	O
303	weighed	O
303	against	O
303	the	O
303	potential	O
303	for	O
303	higher	O
303	var	O
303	##iability	O
303	in	O
303	drug	O
303	exposure	O
303	after	O
303	la	O
303	##i	O
303	administration	O
303	.	O
303	[SEP]	O
304	[CLS]	O
304	no	O
304	clinical	O
304	##ly	O
304	significant	O
304	changes	O
304	were	O
304	observed	O
304	with	O
304	respect	O
304	to	O
304	body	O
304	weight	O
304	and	O
304	vital	O
304	signs	O
304	throughout	O
304	the	O
304	study	O
304	.	O
304	[SEP]	O
305	[CLS]	O
305	for	O
305	example	O
305	,	O
305	one	O
305	re	O
305	##nal	O
305	cell	O
305	car	O
305	##cin	O
305	##oma	O
305	patient	O
305	(	O
305	p	O
305	##t	O
305	01	O
305	)	O
305	with	O
305	disease	O
305	progression	O
305	following	O
305	c	O
305	##yt	O
305	##oki	O
305	##ne	O
305	and	O
305	anti	O
305	-	O
305	an	O
305	##gio	O
305	##genic	O
305	therapy	O
305	,	O
305	initially	O
305	treated	O
305	at	O
305	4	O
305	mg	O
305	m	O
305	##−	O
305	##2	O
305	en	O
305	##tino	O
305	##sta	O
305	##t	O
305	,	O
305	had	O
305	dose	O
305	reduction	O
305	to	O
305	2	O
305	mg	O
305	m	O
305	##−	O
305	##2	O
305	after	O
305	the	O
305	second	O
305	cycle	O
305	.	O
305	[SEP]	O
306	[CLS]	O
306	the	O
306	anal	O
306	##yte	O
306	##s	O
306	were	O
306	separated	O
306	by	O
306	a	O
306	reversed	O
306	phase	O
306	c	O
306	##18	O
306	column	O
306	(	O
306	150	O
306	##x	O
306	##4	O
306	.	O
306	6	O
306	mm	O
306	i	O
306	.	O
306	d	O
306	.	O
306	,	O
306	particle	O
306	size	O
306	5	O
306	micro	O
306	##m	O
306	)	O
306	and	O
306	el	O
306	##uted	O
306	with	O
306	ace	O
306	##ton	O
306	##it	O
306	##ril	O
306	##e	O
306	-	O
306	1	O
306	##mm	O
306	h	O
306	##co	O
306	##oh	O
306	mobile	O
306	phase	O
306	(	O
306	70	O
306	:	O
306	30	O
306	,	O
306	v	O
306	/	O
306	v	O
306	)	O
306	with	O
306	a	O
306	flow	O
306	rate	O
306	of	O
306	0	O
306	.	O
306	8	O
306	m	O
306	##l	O
306	/	O
306	min	O
306	in	O
306	rat	O
306	plasma	O
306	and	O
306	herb	O
306	##al	O
306	extract	O
306	##s	O
306	.	O
306	[SEP]	O
307	[CLS]	O
307	the	O
307	authors	O
307	determined	O
307	the	O
307	p	O
307	##har	O
307	##ma	O
307	##co	O
307	##kin	O
307	##etics	O
307	of	O
307	c	O
307	##ef	O
307	##tri	O
307	##ax	O
307	##one	O
307	,	O
307	a	O
307	c	O
307	##ep	O
307	##hal	O
307	##os	O
307	##por	O
307	##in	O
307	that	O
307	binds	O
307	strongly	O
307	to	O
307	album	O
307	##in	O
307	in	O
307	posts	O
307	##urg	O
307	##ical	O
307	patients	O
307	with	O
307	h	O
307	##ydro	O
307	##xy	O
307	##eth	O
307	##yl	O
307	star	O
307	##ch	O
307	-	O
307	induced	O
307	h	O
307	##y	O
307	##po	O
307	##al	O
307	##bu	O
307	##mine	O
307	##mia	O
307	.	O
307	[SEP]	O
308	[CLS]	O
308	double	O
308	peaks	O
308	and	O
308	extended	O
308	terminal	B-PK
308	half	I-PK
308	-	I-PK
308	life	I-PK
308	were	O
308	observed	O
308	,	O
308	which	O
308	was	O
308	likely	O
308	caused	O
308	by	O
308	enter	O
308	##oh	O
308	##ep	O
308	##atic	O
308	re	O
308	##ci	O
308	##rc	O
308	##ulation	O
308	.	O
308	[SEP]	O
309	[CLS]	O
309	efficacy	O
309	assessments	O
309	included	O
309	clinical	O
309	and	O
309	para	O
309	##si	O
309	##to	O
309	##logical	O
309	evaluation	O
309	.	O
309	[SEP]	O
310	[CLS]	O
310	recovery	O
310	the	O
310	relative	O
310	recover	O
310	##ies	O
310	for	O
310	o	O
310	##s	O
310	(	O
310	75	O
310	ng	O
310	/	O
310	m	O
310	##l	O
310	)	O
310	and	O
310	o	O
310	##s	O
310	##c	O
310	(	O
310	200	O
310	ng	O
310	/	O
310	m	O
310	##l	O
310	)	O
310	were	O
310	determined	O
310	with	O
310	92	O
310	.	O
310	8	O
310	%	O
310	and	O
310	100	O
310	.	O
310	2	O
310	%	O
310	,	O
310	respectively	O
310	.	O
310	[SEP]	O
311	[CLS]	O
311	these	O
311	results	O
311	suggest	O
311	that	O
311	vitamin	O
311	d	O
311	##3	O
311	supplement	O
311	##ation	O
311	(	O
311	1000	O
311	i	O
311	##u	O
311	per	O
311	day	O
311	)	O
311	in	O
311	human	O
311	volunteers	O
311	does	O
311	not	O
311	produce	O
311	a	O
311	p	O
311	-	O
311	g	O
311	##p	O
311	-	O
311	mediated	O
311	drug	O
311	interaction	O
311	with	O
311	oral	O
311	##ly	O
311	administered	O
311	dig	O
311	##ox	O
311	##in	O
311	.	O
311	[SEP]	O
312	[CLS]	O
312	to	O
312	assess	O
312	the	O
312	inter	O
312	-	O
312	day	O
312	(	O
312	over	O
312	3	O
312	days	O
312	)	O
312	ass	O
312	##ay	O
312	accuracy	O
312	and	O
312	precision	O
312	,	O
312	three	O
312	sets	O
312	of	O
312	plasma	O
312	samples	O
312	were	O
312	spike	O
312	##d	O
312	with	O
312	o	O
312	##t	O
312	##c	O
312	at	O
312	0	O
312	.	O
312	05	O
312	,	O
312	0	O
312	.	O
312	25	O
312	,	O
312	5	O
312	,	O
312	and	O
312	10	O
312	μ	O
312	##g	O
312	/	O
312	m	O
312	##l	O
312	concentrations	O
312	.	O
312	[SEP]	O
313	[CLS]	O
313	ma	O
313	##gnesium	O
313	is	O
313	##og	O
313	##ly	O
313	##cy	O
313	##rr	O
313	##hi	O
313	##zin	O
313	##ate	O
313	(	O
313	mi	O
313	)	O
313	has	O
313	been	O
313	complement	O
313	##arily	O
313	used	O
313	for	O
313	restoring	O
313	the	O
313	he	O
313	##pa	O
313	##tic	O
313	imp	O
313	##air	O
313	##ments	O
313	caused	O
313	by	O
313	tax	O
313	##ol	O
313	plus	O
313	platinum	O
313	based	O
313	ch	O
313	##em	O
313	##oth	O
313	##era	O
313	##pies	O
313	in	O
313	chin	O
313	##a	O
313	.	O
313	[SEP]	O
314	[CLS]	O
314	maximum	O
314	residual	O
314	levels	O
314	in	O
314	milk	O
314	were	O
314	below	O
314	the	O
314	maximum	O
314	acceptable	O
314	level	O
314	of	O
314	20	O
314	micro	O
314	##g	O
314	/	O
314	kg	O
314	;	O
314	however	O
314	,	O
314	e	O
314	##p	O
314	##r	O
314	was	O
314	detected	O
314	in	O
314	all	O
314	samples	O
314	investigated	O
314	.	O
314	[SEP]	O
315	[CLS]	O
315	the	O
315	relative	B-PK
315	bio	I-PK
315	##ava	I-PK
315	##ila	I-PK
315	##bility	I-PK
315	of	O
315	the	O
315	new	O
315	formulation	O
315	is	O
315	about	O
315	100	O
315	%	O
315	.	O
315	[SEP]	O
316	[CLS]	O
316	significant	O
316	changes	O
316	in	O
316	dig	O
316	##ox	O
316	##in	O
316	half	B-PK
316	-	I-PK
316	life	I-PK
316	and	O
316	c	B-PK
316	##l	I-PK
316	/	I-PK
316	f	I-PK
316	were	O
316	also	O
316	observed	O
316	with	O
316	c	O
316	##lar	O
316	##ith	O
316	##rom	O
316	##y	O
316	##cin	O
316	.	O
316	[SEP]	O
317	[CLS]	O
317	the	O
317	standard	O
317	curve	O
317	for	O
317	d	O
317	##hm	O
317	in	O
317	plasma	O
317	was	O
317	linear	O
317	in	O
317	the	O
317	concentration	O
317	range	O
317	of	O
317	0	O
317	.	O
317	5	O
317	–	O
317	200	O
317	ng	O
317	/	O
317	m	O
317	##l	O
317	(	O
317	y	O
317	=	O
317	0	O
317	.	O
317	125	O
317	##x	O
317	+	O
317	0	O
317	.	O
317	116	O
317	,	O
317	r	O
317	=	O
317	0	O
317	.	O
317	99	O
317	##9	O
317	)	O
317	.	O
317	[SEP]	O
318	[CLS]	O
318	a	O
318	p	O
318	##har	O
318	##ma	O
318	##co	O
318	##kin	O
318	##etic	O
318	model	O
318	was	O
318	built	O
318	,	O
318	which	O
318	contains	O
318	three	O
318	distinct	O
318	compartment	O
318	##s	O
318	,	O
318	to	O
318	describe	O
318	the	O
318	distribution	O
318	of	O
318	r	O
318	##it	O
318	##ux	O
318	##ima	O
318	##b	O
318	within	O
318	the	O
318	ne	O
318	##uro	O
318	##ax	O
318	##is	O
318	after	O
318	in	O
318	##tra	O
318	##vent	O
318	##ric	O
318	##ular	O
318	administration	O
318	.	O
318	[SEP]	O
319	[CLS]	O
319	the	O
319	plasma	O
319	p	O
319	##har	O
319	##ma	O
319	##co	O
319	##kin	O
319	##etics	O
319	and	O
319	c	O
319	##ere	O
319	##bro	O
319	##sp	O
319	##inal	O
319	fluid	O
319	penetration	O
319	of	O
319	the	O
319	thy	O
319	##mi	O
319	##dy	O
319	##late	O
319	s	O
319	##ynth	O
319	##ase	O
319	inhibitor	O
319	r	O
319	##al	O
319	##ti	O
319	##tre	O
319	##xed	O
319	(	O
319	to	O
319	##mu	O
319	##de	O
319	##x	O
319	)	O
319	in	O
319	a	O
319	non	O
319	##human	O
319	p	O
319	##rima	O
319	##te	O
319	model	O
319	.	O
319	[SEP]	O
320	[CLS]	O
320	to	O
320	op	O
320	##ti	O
320	##mize	O
320	an	O
320	im	O
320	##mu	O
320	##no	O
320	##pha	O
320	##rma	O
320	##cot	O
320	##her	O
320	##ap	O
320	##eu	O
320	##tic	O
320	strategy	O
320	for	O
320	re	O
320	##versing	O
320	severe	O
320	cocaine	O
320	toxicity	O
320	,	O
320	the	O
320	therapeutic	O
320	properties	O
320	of	O
320	ma	O
320	##b	O
320	g	O
320	##nc	O
320	##9	O
320	##2	O
320	##h	O
320	##2	O
320	i	O
320	##gg	O
320	were	O
320	compared	O
320	to	O
320	those	O
320	of	O
320	its	O
320	engineered	O
320	formats	O
320	in	O
320	a	O
320	mouse	O
320	over	O
320	##dos	O
320	##e	O
320	model	O
320	.	O
320	[SEP]	O
321	[CLS]	O
321	n	O
321	##us	O
321	##iner	O
321	##sen	O
321	(	O
321	previously	O
321	is	O
321	##is	O
321	-	O
321	s	O
321	##m	O
321	##n	O
321	##r	O
321	##x	O
321	and	O
321	also	O
321	known	O
321	as	O
321	is	O
321	##is	O
321	39	O
321	##64	O
321	##43	O
321	)	O
321	is	O
321	an	O
321	anti	O
321	##sen	O
321	##se	O
321	o	O
321	##li	O
321	##gon	O
321	##uc	O
321	##leo	O
321	##tide	O
321	designed	O
321	to	O
321	bind	O
321	to	O
321	the	O
321	s	O
321	##m	O
321	##n	O
321	##2	O
321	pre	O
321	-	O
321	m	O
321	##rna	O
321	and	O
321	promote	O
321	inclusion	O
321	of	O
321	ex	O
321	##on	O
321	7	O
321	(	O
321	figure	O
321	1	O
321	)	O
321	.	O
321	6	O
321	,	O
321	7	O
321	in	O
321	mouse	O
321	models	O
321	of	O
321	s	O
321	##ma	O
321	,	O
321	n	O
321	##us	O
321	##iner	O
321	##sen	O
321	enhanced	O
321	ex	O
321	##on	O
321	7	O
321	inclusion	O
321	,	O
321	increased	O
321	s	O
321	##m	O
321	##n	O
321	protein	O
321	production	O
321	,	O
321	and	O
321	improved	O
321	function	O
321	.	O
321	6	O
321	–	O
321	9	O
321	n	O
321	##us	O
321	##iner	O
321	##sen	O
321	is	O
321	delivered	O
321	by	O
321	in	O
321	##tra	O
321	##the	O
321	##cal	O
321	injection	O
321	as	O
321	anti	O
321	##sen	O
321	##se	O
321	o	O
321	##li	O
321	##gon	O
321	##uc	O
321	##leo	O
321	##tide	O
321	drugs	O
321	do	O
321	not	O
321	cross	O
321	an	O
321	intact	O
321	blood	O
321	–	O
321	brain	O
321	barrier	O
321	when	O
321	delivered	O
321	systemic	O
321	##ally	O
321	.	O
321	10	O
321	this	O
321	first	O
321	-	O
321	in	O
321	-	O
321	human	O
321	,	O
321	open	O
321	-	O
321	label	O
321	,	O
321	single	O
321	-	O
321	ascending	O
321	dose	O
321	study	O
321	was	O
321	designed	O
321	to	O
321	assess	O
321	safety	O
321	,	O
321	to	O
321	##ler	O
321	##ability	O
321	,	O
321	p	O
321	##har	O
321	##ma	O
321	##co	O
321	##kin	O
321	##etics	O
321	,	O
321	and	O
321	clinical	O
321	effects	O
321	of	O
321	in	O
321	##tra	O
321	##the	O
321	##cal	O
321	n	O
321	##us	O
321	##iner	O
321	##sen	O
321	in	O
321	patients	O
321	with	O
321	childhood	O
321	s	O
321	##ma	O
321	.	O
321	[SEP]	O
322	[CLS]	O
322	further	O
322	details	O
322	and	O
322	results	O
322	for	O
322	t	O
322	##s	O
322	##cc	O
322	derived	O
322	from	O
322	solid	O
322	cultures	O
322	are	O
322	described	O
322	in	O
322	the	O
322	supplement	O
322	##ary	O
322	material	O
322	.	O
322	[SEP]	O
323	[CLS]	O
323	the	O
323	area	B-PK
323	under	I-PK
323	the	I-PK
323	curve	I-PK
323	(	I-PK
323	0	I-PK
323	to	I-PK
323	in	I-PK
323	##finity	I-PK
323	)	I-PK
323	was	O
323	239	O
323	.	O
323	3	O
323	±	O
323	121	O
323	.	O
323	1	O
323	μ	O
323	##g	O
323	·	O
323	h	O
323	##r	O
323	/	O
323	m	O
323	##l	O
323	.	O
323	no	O
323	significant	O
323	adverse	O
323	drug	O
323	reactions	O
323	were	O
323	clinical	O
323	##ly	O
323	observed	O
323	,	O
323	and	O
323	no	O
323	visible	O
323	injection	O
323	site	O
323	reactions	O
323	were	O
323	noted	O
323	.	O
323	[SEP]	O
324	[CLS]	O
324	this	O
324	study	O
324	attempts	O
324	to	O
324	fabric	O
324	##ate	O
324	the	O
324	c	O
324	##ef	O
324	##uro	O
324	##xi	O
324	##me	O
324	-	O
324	loaded	O
324	na	O
324	##no	O
324	##em	O
324	##ul	O
324	##sion	O
324	(	O
324	c	O
324	##ln	O
324	)	O
324	to	O
324	increase	O
324	drug	O
324	penetration	O
324	into	O
324	the	O
324	brain	O
324	when	O
324	parent	O
324	##eral	O
324	##ly	O
324	administered	O
324	.	O
324	[SEP]	O
325	[CLS]	O
325	that	O
325	is	O
325	,	O
325	in	O
325	both	O
325	fluids	O
325	d	O
325	##z	O
325	and	O
325	d	O
325	##m	O
325	##d	O
325	concentrations	O
325	were	O
325	different	O
325	from	O
325	those	O
325	at	O
325	the	O
325	time	O
325	of	O
325	death	O
325	and	O
325	post	O
325	-	O
325	m	O
325	##ort	O
325	##em	O
325	distribution	O
325	and	O
325	red	O
325	##ist	O
325	##ri	O
325	##but	O
325	##ion	O
325	phenomena	O
325	occurred	O
325	.	O
325	[SEP]	O
326	[CLS]	O
326	the	O
326	p	O
326	##har	O
326	##ma	O
326	##co	O
326	##kin	O
326	##etic	O
326	and	O
326	p	O
326	##har	O
326	##ma	O
326	##co	O
326	##dynamic	O
326	parameters	O
326	were	O
326	summarized	O
326	with	O
326	descriptive	O
326	statistics	O
326	(	O
326	arithmetic	O
326	mean	O
326	and	O
326	standard	O
326	de	O
326	##viation	O
326	,	O
326	or	O
326	median	O
326	and	O
326	inter	O
326	##qua	O
326	##rt	O
326	##ile	O
326	range	O
326	,	O
326	as	O
326	appropriate	O
326	)	O
326	.	O
326	[SEP]	O
327	[CLS]	O
327	m	O
327	##otes	O
327	##ani	O
327	##b	O
327	125	O
327	mg	O
327	q	O
327	##d	O
327	was	O
327	,	O
327	therefore	O
327	,	O
327	established	O
327	as	O
327	the	O
327	m	O
327	##t	O
327	##d	O
327	,	O
327	and	O
327	12	O
327	additional	O
327	patients	O
327	were	O
327	enrolled	O
327	into	O
327	co	O
327	##hor	O
327	##t	O
327	b	O
327	##3	O
327	and	O
327	received	O
327	m	O
327	##otes	O
327	##ani	O
327	##b	O
327	125	O
327	mg	O
327	q	O
327	##d	O
327	plus	O
327	do	O
327	##ce	O
327	##ta	O
327	##xe	O
327	##l	O
327	75	O
327	mg	O
327	/	O
327	m	O
327	##2	O
327	;	O
327	no	O
327	d	O
327	##lts	O
327	occurred	O
327	in	O
327	this	O
327	co	O
327	##hor	O
327	##t	O
327	.	O
327	[SEP]	O
328	[CLS]	O
328	two	O
328	dos	O
328	##ing	O
328	schedules	O
328	of	O
328	the	O
328	novel	O
328	in	O
328	##den	O
328	##ois	O
328	##o	O
328	##quin	O
328	##olin	O
328	##e	O
328	,	O
328	in	O
328	##dote	O
328	##can	O
328	(	O
328	l	O
328	##mp	O
328	##40	O
328	##0	O
328	)	O
328	,	O
328	were	O
328	evaluated	O
328	in	O
328	patients	O
328	with	O
328	advanced	O
328	solid	O
328	tumors	O
328	.	O
328	[SEP]	O
329	[CLS]	O
329	hazard	O
329	ratios	O
329	and	O
329	corresponding	O
329	95	O
329	%	O
329	confidence	O
329	intervals	O
329	(	O
329	c	O
329	##i	O
329	)	O
329	were	O
329	calculated	O
329	and	O
329	considered	O
329	statistical	O
329	##ly	O
329	significant	O
329	when	O
329	the	O
329	c	O
329	##i	O
329	excluded	O
329	1	O
329	.	O
329	0	O
329	.	O
329	[SEP]	O
330	[CLS]	O
330	cu	O
330	##rc	O
330	##umi	O
330	##n	O
330	was	O
330	en	O
330	##cap	O
330	##sul	O
330	##ated	O
330	with	O
330	97	O
330	.	O
330	5	O
330	%	O
330	efficiency	O
330	in	O
330	bio	O
330	##de	O
330	##grad	O
330	##able	O
330	na	O
330	##no	O
330	##par	O
330	##tic	O
330	##ulate	O
330	formulation	O
330	based	O
330	on	O
330	p	O
330	##oly	O
330	(	O
330	la	O
330	##ct	O
330	##ide	O
330	-	O
330	co	O
330	-	O
330	g	O
330	##ly	O
330	##co	O
330	##lide	O
330	)	O
330	(	O
330	p	O
330	##l	O
330	##ga	O
330	)	O
330	and	O
330	a	O
330	stab	O
330	##ilizer	O
330	p	O
330	##oly	O
330	##eth	O
330	##yle	O
330	##ne	O
330	g	O
330	##ly	O
330	##co	O
330	##l	O
330	(	O
330	p	O
330	##eg	O
330	)	O
330	-	O
330	5000	O
330	.	O
330	[SEP]	O
331	[CLS]	O
331	no	O
331	s	O
331	##yne	O
331	##rgy	O
331	,	O
331	add	O
331	##iti	O
331	##vity	O
331	,	O
331	or	O
331	ant	O
331	##agon	O
331	##ism	O
331	was	O
331	observed	O
331	.	O
331	[SEP]	O
332	[CLS]	O
332	the	O
332	training	O
332	trial	O
332	was	O
332	performed	O
332	on	O
332	the	O
332	first	O
332	day	O
332	.	O
332	[SEP]	O
333	[CLS]	O
333	the	O
333	precision	O
333	and	O
333	accuracy	O
333	of	O
333	the	O
333	uh	O
333	##p	O
333	##l	O
333	##c	O
333	method	O
333	were	O
333	evaluated	O
333	by	O
333	anal	O
333	##ys	O
333	##ing	O
333	blank	O
333	samples	O
333	of	O
333	urine	O
333	spike	O
333	##d	O
333	with	O
333	high	O
333	,	O
333	medium	O
333	,	O
333	and	O
333	low	O
333	concentrations	O
333	of	O
333	the	O
333	fl	O
333	##av	O
333	##ono	O
333	##ids	O
333	and	O
333	is	O
333	##of	O
333	##lav	O
333	##ones	O
333	.	O
333	[SEP]	O
334	[CLS]	O
334	we	O
334	showed	O
334	that	O
334	administration	O
334	of	O
334	c	O
334	##yn	O
334	##omo	O
334	##l	O
334	##gus	O
334	il	O
334	-	O
334	31	O
334	induce	O
334	##s	O
334	trans	O
334	##ient	O
334	scratching	O
334	behaviour	O
334	in	O
334	c	O
334	##yn	O
334	##omo	O
334	##l	O
334	##gus	O
334	monkeys	O
334	and	O
334	by	O
334	that	O
334	were	O
334	able	O
334	to	O
334	establish	O
334	a	O
334	monkey	O
334	model	O
334	of	O
334	scratching	O
334	.	O
334	[SEP]	O
335	[CLS]	O
335	regarding	O
335	the	O
335	particle	O
335	size	O
335	,	O
335	there	O
335	was	O
335	no	O
335	significant	O
335	change	O
335	after	O
335	storage	O
335	at	O
335	4	O
335	.	O
335	0	O
335	##±	O
335	##1	O
335	##°	O
335	##c	O
335	,	O
335	but	O
335	at	O
335	25	O
335	##±	O
335	##2	O
335	##°	O
335	##c	O
335	,	O
335	there	O
335	was	O
335	a	O
335	slight	O
335	increase	O
335	in	O
335	particle	O
335	size	O
335	of	O
335	the	O
335	s	O
335	##ln	O
335	##s	O
335	(	O
335	from	O
335	96	O
335	nm	O
335	to	O
335	106	O
335	nm	O
335	)	O
335	,	O
335	which	O
335	could	O
335	be	O
335	due	O
335	to	O
335	a	O
335	##gg	O
335	##regation	O
335	of	O
335	s	O
335	##ln	O
335	at	O
335	this	O
335	temperature	O
335	.	O
335	[SEP]	O
336	[CLS]	O
336	re	O
336	##mi	O
336	##fen	O
336	##tani	O
336	##l	O
336	p	O
336	##har	O
336	##ma	O
336	##co	O
336	##kin	O
336	##etics	O
336	was	O
336	described	O
336	with	O
336	a	O
336	two	O
336	-	O
336	compartment	O
336	model	O
336	,	O
336	parameter	O
336	estimates	O
336	were	O
336	2	O
336	.	O
336	99	O
336	l	O
336	x	O
336	min	O
336	(	O
336	-	O
336	1	O
336	)	O
336	x	O
336	70	O
336	kg	O
336	(	O
336	-	O
336	1	O
336	)	O
336	for	O
336	clearance	B-PK
336	and	O
336	16	O
336	.	O
336	23	O
336	l	O
336	x	O
336	70	O
336	kg	O
336	(	O
336	-	O
336	1	O
336	)	O
336	for	O
336	steady	B-PK
336	state	I-PK
336	volume	I-PK
336	of	I-PK
336	distribution	I-PK
336	.	O
336	[SEP]	O
337	[CLS]	O
337	to	O
337	determine	O
337	the	O
337	influence	O
337	of	O
337	h	O
337	.	O
337	p	O
337	##yl	O
337	##ori	O
337	infection	O
337	on	O
337	effectiveness	O
337	of	O
337	r	O
337	##abe	O
337	##pra	O
337	##zo	O
337	##le	O
337	in	O
337	primary	O
337	and	O
337	secondary	O
337	care	O
337	,	O
337	wit	O
337	et	O
337	al	O
337	(	O
337	2004	O
337	)	O
337	tested	O
337	for	O
337	h	O
337	.	O
337	p	O
337	##yl	O
337	##ori	O
337	1787	O
337	patients	O
337	from	O
337	primary	O
337	and	O
337	secondary	O
337	care	O
337	centers	O
337	with	O
337	un	O
337	##in	O
337	##ves	O
337	##ti	O
337	##gated	O
337	suspected	O
337	g	O
337	##erd	O
337	(	O
337	based	O
337	on	O
337	symptoms	O
337	only	O
337	)	O
337	and	O
337	investigated	O
337	g	O
337	##erd	O
337	(	O
337	end	O
337	##os	O
337	##copic	O
337	##ally	O
337	confirmed	O
337	o	O
337	##es	O
337	##op	O
337	##ha	O
337	##git	O
337	##is	O
337	or	O
337	end	O
337	##os	O
337	##copy	O
337	-	O
337	negative	O
337	re	O
337	##f	O
337	##lux	O
337	disease	O
337	)	O
337	and	O
337	then	O
337	treated	O
337	them	O
337	with	O
337	r	O
337	##abe	O
337	##pra	O
337	##zo	O
337	##le	O
337	20	O
337	mg	O
337	once	O
337	daily	O
337	for	O
337	4	O
337	–	O
337	8	O
337	weeks	O
337	in	O
337	a	O
337	non	O
337	-	O
337	random	O
337	##ized	O
337	,	O
337	multi	O
337	##cent	O
337	##er	O
337	,	O
337	open	O
337	-	O
337	label	O
337	study	O
337	.	O
337	[SEP]	O
338	[CLS]	O
338	p	O
338	##q	O
338	is	O
338	also	O
338	classified	O
338	as	O
338	a	O
338	""""	O
338	direct	O
338	he	O
338	##pa	O
338	##to	O
338	##to	O
338	##xi	O
338	##can	O
338	##t	O
338	""""	O
338	following	O
338	an	O
338	acute	O
338	high	O
338	dose	O
338	exposure	O
338	.	O
338	[SEP]	O
339	[CLS]	O
339	restricted	O
339	maximum	O
339	‐	O
339	likelihood	O
339	est	O
339	##imation	O
339	was	O
339	used	O
339	.	O
339	[SEP]	O
340	[CLS]	O
340	no	O
340	clear	O
340	relationship	O
340	between	O
340	p	O
340	##har	O
340	##ma	O
340	##co	O
340	##kin	O
340	##etic	O
340	parameters	O
340	and	O
340	response	O
340	to	O
340	therapy	O
340	(	O
340	x	O
340	##4	O
340	log	O
340	r	O
340	##lu	O
340	reduction	O
340	)	O
340	was	O
340	observed	O
340	.	O
340	[SEP]	O
341	[CLS]	O
341	dose	O
341	-	O
341	normal	O
341	##ized	O
341	concentrations	O
341	plot	O
341	##ted	O
341	over	O
341	time	O
341	did	O
341	not	O
341	overlap	O
341	.	O
341	[SEP]	O
342	[CLS]	O
342	an	O
342	increasing	O
342	number	O
342	of	O
342	hem	O
342	##or	O
342	##r	O
342	##ha	O
342	##gic	O
342	and	O
342	th	O
342	##rom	O
342	##bot	O
342	##ic	O
342	events	O
342	prompted	O
342	us	O
342	to	O
342	initiate	O
342	a	O
342	monitoring	O
342	program	O
342	for	O
342	as	O
342	##par	O
342	##agi	O
342	##nas	O
342	##e	O
342	treatment	O
342	.	O
342	[SEP]	O
343	[CLS]	O
343	from	O
343	the	O
343	boots	O
343	##tra	O
343	##p	O
343	analysis	O
343	,	O
343	86	O
343	##9	O
343	(	O
343	86	O
343	.	O
343	9	O
343	%	O
343	)	O
343	of	O
343	the	O
343	1000	O
343	non	O
343	##me	O
343	##m	O
343	runs	O
343	con	O
343	##ver	O
343	##ged	O
343	successfully	O
343	within	O
343	the	O
343	specified	O
343	1000	O
343	it	O
343	##eration	O
343	##s	O
343	.	O
343	[SEP]	O
344	[CLS]	O
344	in	O
344	addition	O
344	,	O
344	clinical	O
344	is	O
344	##olate	O
344	##s	O
344	of	O
344	s	O
344	.	O
344	e	O
344	##pid	O
344	##er	O
344	##mi	O
344	##dis	O
344	from	O
344	infected	O
344	s	O
344	##hun	O
344	##ts	O
344	are	O
344	typically	O
344	resistant	O
344	to	O
344	met	O
344	##hic	O
344	##ill	O
344	##in	O
344	.	O
344	[SEP]	O
345	[CLS]	O
345	the	O
345	t	B-PK
345	##½	I-PK
345	was	O
345	defined	O
345	as	O
345	l	O
345	##n	O
345	##2	O
345	/	O
345	λ	O
345	##z	O
345	and	O
345	c	B-PK
345	##l	I-PK
345	/	I-PK
345	f	I-PK
345	was	O
345	estimated	O
345	as	O
345	dose	B-PK
345	/	I-PK
345	au	I-PK
345	##c	I-PK
345	##∞	I-PK
345	.	O
345	[SEP]	O
346	[CLS]	O
346	in	O
346	v	O
346	##ivo	O
346	p	O
346	##har	O
346	##ma	O
346	##co	O
346	##kin	O
346	##etics	O
346	of	O
346	he	O
346	##sper	O
346	##id	O
346	##in	O
346	are	O
346	affected	O
346	by	O
346	treatment	O
346	with	O
346	g	O
346	##lu	O
346	##cos	O
346	##idas	O
346	##e	O
346	-	O
346	like	O
346	b	O
346	##g	O
346	##la	O
346	protein	O
346	isolated	O
346	from	O
346	yeast	O
346	##s	O
346	.	O
346	[SEP]	O
347	[CLS]	O
347	the	O
347	brain	O
347	’	O
347	s	O
347	target	O
347	was	O
347	higher	O
347	in	O
347	s	O
347	##tri	O
347	##at	O
347	##um	O
347	and	O
347	c	O
347	##ere	O
347	##bell	O
347	##um	O
347	.	O
347	[SEP]	O
348	[CLS]	O
348	quantitative	O
348	structure	O
348	-	O
348	p	O
348	##har	O
348	##ma	O
348	##co	O
348	##kin	O
348	##etic	O
348	relationships	O
348	for	O
348	plasma	B-PK
348	clearance	I-PK
348	of	O
348	basic	O
348	drugs	O
348	with	O
348	consideration	O
348	of	O
348	the	O
348	major	O
348	elimination	O
348	pathway	O
348	.	O
348	[SEP]	O
349	[CLS]	O
349	a	O
349	ch	O
349	##olic	O
349	acid	O
349	con	O
349	##ju	O
349	##gate	O
349	that	O
349	retained	O
349	these	O
349	properties	O
349	would	O
349	be	O
349	expected	O
349	to	O
349	have	O
349	exceptionally	O
349	substantial	O
349	he	O
349	##pa	O
349	##tic	O
349	levels	O
349	and	O
349	a	O
349	high	O
349	liver	B-PK
349	-	I-PK
349	to	I-PK
349	-	I-PK
349	plasma	I-PK
349	ratio	I-PK
349	##13	O
349	.	O
349	[SEP]	O
350	[CLS]	O
350	once	O
350	daily	O
350	administration	O
350	of	O
350	high	O
350	dose	O
350	of	O
350	amino	O
350	##gly	O
350	##cos	O
350	##ides	O
350	,	O
350	resulted	O
350	in	O
350	effective	O
350	serum	O
350	concentrations	O
350	and	O
350	absence	O
350	of	O
350	ne	O
350	##ph	O
350	##rot	O
350	##ox	O
350	##icit	O
350	##y	O
350	.	O
350	[SEP]	O
351	[CLS]	O
351	a	O
351	method	O
351	for	O
351	the	O
351	determination	O
351	of	O
351	plasma	O
351	concentration	O
351	of	O
351	lie	O
351	##ns	O
351	##ini	O
351	##ne	O
351	with	O
351	hp	O
351	##l	O
351	##c	O
351	and	O
351	p	O
351	##har	O
351	##ma	O
351	##co	O
351	##kin	O
351	##etic	O
351	study	O
351	of	O
351	lie	O
351	##ns	O
351	##ini	O
351	##ne	O
351	in	O
351	rabbits	O
351	were	O
351	reported	O
351	.	O
351	[SEP]	O
352	[CLS]	O
352	accordingly	O
352	,	O
352	the	O
352	g	O
352	##ly	O
352	##cos	O
352	##uria	O
352	-	O
352	and	O
352	/	O
352	or	O
352	h	O
352	##yper	O
352	##gly	O
352	##ce	O
352	##mia	O
352	-	O
352	induced	O
352	decrease	O
352	in	O
352	the	O
352	biological	B-PK
352	half	I-PK
352	-	I-PK
352	life	I-PK
352	of	O
352	o	O
352	##xy	O
352	##pur	O
352	##ino	O
352	##l	O
352	must	O
352	be	O
352	considered	O
352	in	O
352	the	O
352	administration	O
352	of	O
352	all	O
352	##op	O
352	##uri	O
352	##no	O
352	##l	O
352	to	O
352	go	O
352	##ut	O
352	##y	O
352	patients	O
352	with	O
352	un	O
352	##con	O
352	##tro	O
352	##lled	O
352	diabetes	O
352	me	O
352	##lli	O
352	##tus	O
352	.	O
352	[SEP]	O
353	[CLS]	O
353	in	O
353	these	O
353	patients	O
353	,	O
353	combination	O
353	anti	O
353	##vir	O
353	##al	O
353	drug	O
353	treatment	O
353	should	O
353	be	O
353	considered	O
353	.	O
353	[SEP]	O
354	[CLS]	O
354	for	O
354	each	O
354	level	O
354	of	O
354	q	O
354	##c	O
354	samples	O
354	including	O
354	the	O
354	lower	O
354	limit	O
354	of	O
354	q	O
354	##uant	O
354	##ification	O
354	,	O
354	both	O
354	inter	O
354	-	O
354	and	O
354	in	O
354	##tra	O
354	-	O
354	day	O
354	precision	O
354	##s	O
354	(	O
354	r	O
354	.	O
354	s	O
354	.	O
354	d	O
354	.	O
354	)	O
354	were	O
354	<	O
354	or	O
354	=	O
354	14	O
354	.	O
354	0	O
354	%	O
354	for	O
354	c	O
354	##ef	O
354	##ale	O
354	##xin	O
354	and	O
354	<	O
354	or	O
354	=	O
354	11	O
354	.	O
354	4	O
354	%	O
354	for	O
354	trim	O
354	##eth	O
354	##op	O
354	##rim	O
354	,	O
354	and	O
354	accuracy	O
354	(	O
354	re	O
354	)	O
354	was	O
354	-	O
354	1	O
354	.	O
354	4	O
354	%	O
354	for	O
354	c	O
354	##ef	O
354	##ale	O
354	##xin	O
354	and	O
354	-	O
354	3	O
354	.	O
354	0	O
354	%	O
354	for	O
354	trim	O
354	##eth	O
354	##op	O
354	##rim	O
354	.	O
354	[SEP]	O
355	[CLS]	O
355	adverse	O
355	events	O
355	(	O
355	a	O
355	##es	O
355	)	O
355	,	O
355	vital	O
355	signs	O
355	,	O
355	laboratory	O
355	tests	O
355	,	O
355	p	O
355	##k	O
355	,	O
355	and	O
355	evidence	O
355	of	O
355	bio	O
355	##log	O
355	##ic	O
355	activity	O
355	were	O
355	descriptive	O
355	##ly	O
355	compared	O
355	across	O
355	the	O
355	various	O
355	treatment	O
355	groups	O
355	with	O
355	no	O
355	formal	O
355	statistical	O
355	testing	O
355	.	O
355	[SEP]	O
356	[CLS]	O
356	the	O
356	relationship	O
356	between	O
356	doses	O
356	and	O
356	concentrations	O
356	,	O
356	doses	O
356	and	O
356	u	O
356	##rina	O
356	##ry	O
356	ex	O
356	##cre	O
356	##tion	O
356	of	O
356	unchanged	O
356	compound	O
356	and	O
356	major	O
356	meta	O
356	##bol	O
356	##ites	O
356	was	O
356	linear	O
356	in	O
356	all	O
356	species	O
356	,	O
356	except	O
356	rabbits	O
356	.	O
356	[SEP]	O
357	[CLS]	O
357	a	O
357	secondary	O
357	goal	O
357	was	O
357	to	O
357	estimate	O
357	the	O
357	response	O
357	rate	O
357	in	O
357	a	O
357	group	O
357	of	O
357	heavily	O
357	pre	O
357	##tre	O
357	##ated	O
357	patients	O
357	with	O
357	advanced	O
357	solid	O
357	tumors	O
357	.	O
357	[SEP]	O
358	[CLS]	O
358	the	O
358	correlation	O
358	coefficient	O
358	between	O
358	years	O
358	delay	O
358	for	O
358	various	O
358	cat	O
358	##ara	O
358	##cts	O
358	sub	O
358	##cate	O
358	##gor	O
358	##ies	O
358	versus	O
358	as	O
358	##pi	O
358	##rin	O
358	taken	O
358	(	O
358	in	O
358	tablets	O
358	per	O
358	day	O
358	x	O
358	years	O
358	of	O
358	intake	O
358	)	O
358	was	O
358	0	O
358	.	O
358	69	O
358	.	O
358	[SEP]	O
359	[CLS]	O
359	maximum	O
359	tolerate	O
359	##d	O
359	dose	O
359	(	O
359	m	O
359	##t	O
359	##d	O
359	)	O
359	studies	O
359	,	O
359	performed	O
359	on	O
359	6	O
359	–	O
359	8	O
359	weeks	O
359	-	O
359	old	O
359	b	O
359	##al	O
359	##b	O
359	/	O
359	c	O
359	w	O
359	##t	O
359	mice	O
359	,	O
359	revealed	O
359	that	O
359	or	O
359	##x	O
359	-	O
359	301	O
359	was	O
359	safe	O
359	up	O
359	to	O
359	a	O
359	dose	O
359	of	O
359	2000	O
359	mg	O
359	/	O
359	kg	O
359	when	O
359	administered	O
359	sub	O
359	##cut	O
359	##aneous	O
359	##ly	O
359	.	O
359	[SEP]	O
360	[CLS]	O
360	in	O
360	contrast	O
360	,	O
360	after	O
360	p	O
360	##o	O
360	administration	O
360	,	O
360	au	B-PK
360	##c	I-PK
360	values	O
360	for	O
360	the	O
360	control	O
360	and	O
360	t	O
360	-	O
360	2	O
360	group	O
360	were	O
360	nearly	O
360	identical	O
360	on	O
360	average	O
360	.	O
360	[SEP]	O
361	[CLS]	O
361	here	O
361	##in	O
361	,	O
361	we	O
361	describe	O
361	a	O
361	novel	O
361	am	O
361	##phi	O
361	##pathic	O
361	ch	O
361	##ito	O
361	##san	O
361	derivative	O
361	(	O
361	n	O
361	-	O
361	o	O
361	##ct	O
361	##yl	O
361	-	O
361	n	O
361	'	O
361	-	O
361	p	O
361	##ht	O
361	##hal	O
361	##yl	O
361	-	O
361	o	O
361	-	O
361	p	O
361	##hos	O
361	##ph	O
361	##ory	O
361	##l	O
361	ch	O
361	##ito	O
361	##san	O
361	,	O
361	abbreviated	O
361	as	O
361	op	O
361	##p	O
361	##c	O
361	)	O
361	as	O
361	an	O
361	effective	O
361	oral	O
361	delivery	O
361	platform	O
361	for	O
361	p	O
361	-	O
361	g	O
361	##p	O
361	substrates	O
361	,	O
361	especially	O
361	p	O
361	##ac	O
361	##lit	O
361	##ax	O
361	##el	O
361	(	O
361	p	O
361	##t	O
361	##x	O
361	)	O
361	.	O
361	[SEP]	O
362	[CLS]	O
362	p	O
362	.	O
362	c	O
362	##yn	O
362	##omo	O
362	##l	O
362	##gi	O
362	m	O
362	strain	O
362	(	O
362	a	O
362	non	O
362	-	O
362	human	O
362	p	O
362	##rima	O
362	##te	O
362	malaria	O
362	closely	O
362	related	O
362	to	O
362	the	O
362	human	O
362	malaria	O
362	p	O
362	.	O
362	v	O
362	##iva	O
362	##x	O
362	and	O
362	forming	O
362	dormant	O
362	liver	O
362	stages	O
362	)	O
362	was	O
362	used	O
362	for	O
362	in	O
362	v	O
362	##it	O
362	##ro	O
362	liver	O
362	stage	O
362	drug	O
362	ass	O
362	##ays	O
362	(	O
362	the	O
362	m	O
362	strain	O
362	b	O
362	##p	O
362	##rc	O
362	was	O
362	obtained	O
362	from	O
362	centers	O
362	for	O
362	disease	O
362	control	O
362	and	O
362	prevention	O
362	(	O
362	c	O
362	##d	O
362	##c	O
362	,	O
362	us	O
362	##a	O
362	)	O
362	.	O
362	[SEP]	O
363	[CLS]	O
363	the	O
363	disposition	O
363	of	O
363	the	O
363	individual	O
363	en	O
363	##anti	O
363	##omer	O
363	##s	O
363	and	O
363	their	O
363	electro	O
363	##phy	O
363	##sio	O
363	##log	O
363	##ic	O
363	actions	O
363	are	O
363	unknown	O
363	.	O
363	[SEP]	O
364	[CLS]	O
364	sample	O
364	clean	O
364	-	O
364	up	O
364	was	O
364	achieved	O
364	by	O
364	solid	O
364	-	O
364	phase	O
364	extraction	O
364	on	O
364	an	O
364	##ion	O
364	-	O
364	exchange	O
364	cartridges	O
364	,	O
364	which	O
364	proved	O
364	to	O
364	be	O
364	sufficient	O
364	to	O
364	obtain	O
364	mass	O
364	ch	O
364	##roma	O
364	##to	O
364	##gram	O
364	##s	O
364	devoid	O
364	of	O
364	matrix	O
364	interference	O
364	##s	O
364	.	O
364	[SEP]	O
365	[CLS]	O
365	apparently	O
365	healthy	O
365	;	O
365	[SEP]	O
366	[CLS]	O
366	re	O
366	##comb	O
366	##ina	O
366	##nt	O
366	human	O
366	an	O
366	##gio	O
366	##sta	O
366	##tin	O
366	by	O
366	twice	O
366	-	O
366	daily	O
366	sub	O
366	##cut	O
366	##aneous	O
366	injection	O
366	in	O
366	advanced	O
366	cancer	O
366	:	O
366	a	O
366	p	O
366	##har	O
366	##ma	O
366	##co	O
366	##kin	O
366	##etic	O
366	and	O
366	long	O
366	-	O
366	term	O
366	safety	O
366	study	O
366	.	O
366	[SEP]	O
367	[CLS]	O
367	reviewer	O
367	#	O
367	1	O
367	:	O
367	[SEP]	O
368	[CLS]	O
368	the	O
368	plasma	O
368	concentrations	O
368	of	O
368	h	O
368	##ydro	O
368	##ly	O
368	##za	O
368	##tes	O
368	which	O
368	are	O
368	sa	O
368	##lic	O
368	##yl	O
368	##ic	O
368	acid	O
368	and	O
368	para	O
368	##ce	O
368	##tam	O
368	##ol	O
368	from	O
368	ben	O
368	##ori	O
368	##late	O
368	in	O
368	v	O
368	##ivo	O
368	were	O
368	measured	O
368	by	O
368	hp	O
368	##l	O
368	##c	O
368	.	O
368	[SEP]	O
369	[CLS]	O
369	plasma	O
369	samples	O
369	were	O
369	extracted	O
369	using	O
369	a	O
369	liquid	O
369	–	O
369	liquid	O
369	extraction	O
369	technique	O
369	.	O
369	[SEP]	O
370	[CLS]	O
370	elimination	B-PK
370	clearance	I-PK
370	of	O
370	both	O
370	meta	O
370	##bol	O
370	##ites	O
370	decreased	O
370	with	O
370	t	O
370	##b	O
370	##w	O
370	(	O
370	c	B-PK
370	##le	I-PK
370	m	O
370	##3	O
370	##g	O
370	##p	O
370	<	O
370	0	O
370	.	O
370	00	O
370	##1	O
370	,	O
370	−	O
370	##16	O
370	of	O
370	##v	O
370	,	O
370	c	B-PK
370	##le	I-PK
370	m	O
370	##6	O
370	##g	O
370	##p	O
370	<	O
370	0	O
370	.	O
370	00	O
370	##1	O
370	,	O
370	−	O
370	##9	O
370	##2	O
370	of	O
370	##v	O
370	)	O
370	,	O
370	and	O
370	the	O
370	peripheral	B-PK
370	volume	I-PK
370	of	O
370	m	O
370	##or	O
370	##phine	O
370	increased	O
370	significantly	O
370	with	O
370	increasing	O
370	t	O
370	##b	O
370	##w	O
370	(	O
370	p	O
370	<	O
370	0	O
370	.	O
370	00	O
370	##1	O
370	,	O
370	−	O
370	##34	O
370	of	O
370	##v	O
370	)	O
370	.	O
370	[SEP]	O
371	[CLS]	O
371	this	O
371	study	O
371	indicates	O
371	that	O
371	me	O
371	##ga	O
371	##zo	O
371	##l	O
371	crosses	O
371	the	O
371	blood	O
371	-	O
371	brain	O
371	barrier	O
371	after	O
371	oral	O
371	administration	O
371	.	O
371	[SEP]	O
372	[CLS]	O
372	absolute	B-PK
372	bio	I-PK
372	##ava	I-PK
372	##ila	I-PK
372	##bility	I-PK
372	was	O
372	expressed	O
372	as	O
372	the	O
372	ratio	O
372	of	O
372	dose	O
372	‐	O
372	normal	O
372	##ized	O
372	adjusted	O
372	geometric	O
372	means	O
372	of	O
372	au	B-PK
372	##c	I-PK
372	##0	I-PK
372	‐	I-PK
372	∞	I-PK
372	for	O
372	oral	O
372	and	O
372	i	O
372	##v	O
372	g	O
372	##las	O
372	##de	O
372	##gi	O
372	##b	O
372	.	O
372	[SEP]	O
373	[CLS]	O
373	all	O
373	dos	O
373	##ing	O
373	co	O
373	##hor	O
373	##ts	O
373	were	O
373	fully	O
373	enrolled	O
373	;	O
373	all	O
373	subjects	O
373	completed	O
373	the	O
373	safety	O
373	follow	O
373	-	O
373	up	O
373	.	O
373	[SEP]	O
374	[CLS]	O
374	to	O
374	determine	O
374	and	O
374	compare	O
374	p	O
374	##har	O
374	##ma	O
374	##co	O
374	##kin	O
374	##etics	O
374	of	O
374	it	O
374	##rac	O
374	##ona	O
374	##zo	O
374	##le	O
374	in	O
374	dogs	O
374	after	O
374	oral	O
374	administration	O
374	of	O
374	commercially	O
374	available	O
374	capsule	O
374	and	O
374	solution	O
374	formulation	O
374	##s	O
374	intended	O
374	for	O
374	use	O
374	in	O
374	humans	O
374	.	O
374	[SEP]	O
375	[CLS]	O
375	la	O
375	##tam	O
375	##ox	O
375	##ef	O
375	(	O
375	l	O
375	##mo	O
375	##x	O
375	,	O
375	si	O
375	##oma	O
375	##rin	O
375	)	O
375	at	O
375	a	O
375	dose	O
375	of	O
375	2	O
375	g	O
375	was	O
375	in	O
375	##tra	O
375	##ven	O
375	##ously	O
375	administered	O
375	to	O
375	each	O
375	of	O
375	23	O
375	patients	O
375	undergoing	O
375	the	O
375	open	O
375	heart	O
375	surgery	O
375	and	O
375	the	O
375	concentrations	O
375	in	O
375	serum	O
375	,	O
375	per	O
375	##ica	O
375	##rdi	O
375	##al	O
375	fluid	O
375	and	O
375	au	O
375	##ric	O
375	##le	O
375	of	O
375	heart	O
375	were	O
375	measured	O
375	.	O
375	[SEP]	O
376	[CLS]	O
376	in	O
376	the	O
376	diet	O
376	with	O
376	no	O
376	p	O
376	##hy	O
376	##tase	O
376	,	O
376	ca	O
376	and	O
376	a	O
376	##p	O
376	were	O
376	at	O
376	0	O
376	.	O
376	50	O
376	%	O
376	and	O
376	0	O
376	.	O
376	19	O
376	%	O
376	,	O
376	respectively	O
376	,	O
376	and	O
376	,	O
376	in	O
376	the	O
376	diet	O
376	with	O
376	p	O
376	##hy	O
376	##tase	O
376	,	O
376	ca	O
376	and	O
376	a	O
376	##p	O
376	were	O
376	each	O
376	decreased	O
376	by	O
376	0	O
376	.	O
376	12	O
376	%	O
376	.	O
376	[SEP]	O
377	[CLS]	O
377	the	O
377	in	O
377	##tra	O
377	-	O
377	day	O
377	and	O
377	inter	O
377	-	O
377	day	O
377	precision	O
377	##s	O
377	of	O
377	n	O
377	##f	O
377	and	O
377	n	O
377	-	O
377	n	O
377	##f	O
377	were	O
377	less	O
377	than	O
377	20	O
377	%	O
377	,	O
377	and	O
377	the	O
377	accuracy	O
377	ranged	O
377	from	O
377	91	O
377	.	O
377	09	O
377	to	O
377	113	O
377	.	O
377	03	O
377	%	O
377	at	O
377	30	O
377	,	O
377	300	O
377	and	O
377	3	O
377	,	O
377	000	O
377	ng	O
377	/	O
377	m	O
377	##l	O
377	.	O
377	[SEP]	O
378	[CLS]	O
378	such	O
378	negative	O
378	charge	O
378	is	O
378	anticipated	O
378	to	O
378	be	O
378	decreased	O
378	upon	O
378	r	O
378	##l	O
378	##x	O
378	addition	O
378	,	O
378	where	O
378	part	O
378	of	O
378	tea	O
378	will	O
378	react	O
378	with	O
378	r	O
378	##l	O
378	##x	O
378	salt	O
378	,	O
378	leading	O
378	to	O
378	the	O
378	formation	O
378	of	O
378	r	O
378	##l	O
378	##x	O
378	base	O
378	and	O
378	chloride	O
378	salt	O
378	of	O
378	tea	O
378	,	O
378	which	O
378	is	O
378	water	O
378	-	O
378	soluble	O
378	salt	O
378	lost	O
378	after	O
378	di	O
378	##lution	O
378	.	O
378	[SEP]	O
379	[CLS]	O
379	to	O
379	determine	O
379	the	O
379	disposition	O
379	of	O
379	co	O
379	##list	O
379	##in	O
379	met	O
379	##hane	O
379	##sul	O
379	##phon	O
379	##ate	O
379	(	O
379	cm	O
379	##s	O
379	)	O
379	and	O
379	co	O
379	##list	O
379	##in	O
379	following	O
379	in	O
379	##tra	O
379	##ven	O
379	##ous	O
379	(	O
379	i	O
379	##v	O
379	)	O
379	administration	O
379	of	O
379	cm	O
379	##s	O
379	in	O
379	rats	O
379	.	O
379	[SEP]	O
380	[CLS]	O
380	patients	O
380	undergoing	O
380	hip	O
380	replacement	O
380	surgery	O
380	and	O
380	routinely	O
380	receiving	O
380	1	O
380	g	O
380	t	O
380	##rane	O
380	##xa	O
380	##mic	O
380	acid	O
380	in	O
380	##tra	O
380	##ven	O
380	##ously	O
380	constituted	O
380	the	O
380	reference	O
380	group	O
380	(	O
380	the	O
380	in	O
380	##tra	O
380	##ven	O
380	##ous	O
380	b	O
380	##ol	O
380	##us	O
380	group	O
380	)	O
380	and	O
380	were	O
380	consecutive	O
380	##ly	O
380	recruited	O
380	from	O
380	the	O
380	department	O
380	of	O
380	or	O
380	##th	O
380	##oped	O
380	##ics	O
380	at	O
380	s	O
380	##t	O
380	.	O
380	o	O
380	##lav	O
380	’	O
380	s	O
380	university	O
380	hospital	O
380	.	O
380	[SEP]	O
381	[CLS]	O
381	the	O
381	rapid	O
381	and	O
381	extensive	O
381	conversion	O
381	of	O
381	v	O
381	##ica	O
381	##g	O
381	##rel	O
381	to	O
381	the	O
381	intermediate	O
381	2	O
381	-	O
381	o	O
381	##x	O
381	##o	O
381	-	O
381	c	O
381	##lop	O
381	##ido	O
381	##g	O
381	##rel	O
381	by	O
381	est	O
381	##era	O
381	##se	O
381	instead	O
381	of	O
381	c	O
381	##yt	O
381	##och	O
381	##rome	O
381	p	O
381	##45	O
381	##0s	O
381	(	O
381	c	O
381	##y	O
381	##ps	O
381	)	O
381	makes	O
381	the	O
381	novel	O
381	pro	O
381	##dr	O
381	##ug	O
381	v	O
381	##ica	O
381	##g	O
381	##rel	O
381	a	O
381	promising	O
381	agent	O
381	to	O
381	prevent	O
381	plate	O
381	##let	O
381	a	O
381	##gg	O
381	##regation	O
381	and	O
381	overcome	O
381	c	O
381	##lop	O
381	##ido	O
381	##g	O
381	##rel	O
381	resistance	O
381	and	O
381	high	O
381	inter	O
381	##ind	O
381	##iv	O
381	##id	O
381	##ual	O
381	var	O
381	##iability	O
381	due	O
381	to	O
381	c	O
381	##y	O
381	##p	O
381	##2	O
381	##c	O
381	##19	O
381	p	O
381	##oly	O
381	##mor	O
381	##phism	O
381	.	O
381	[SEP]	O
382	[CLS]	O
382	patients	O
382	received	O
382	2	O
382	-	O
382	5	O
382	serial	O
382	injection	O
382	##s	O
382	(	O
382	124	O
382	)	O
382	i	O
382	-	O
382	or	O
382	(	O
382	131	O
382	)	O
382	i	O
382	-	O
382	labeled	O
382	mon	O
382	##oc	O
382	##lon	O
382	##al	O
382	anti	O
382	##body	O
382	3	O
382	##f	O
382	##8	O
382	or	O
382	8	O
382	##h	O
382	##9	O
382	.	O
382	[SEP]	O
383	[CLS]	O
383	other	O
383	induced	O
383	p	O
383	##hen	O
383	##otypic	O
383	changes	O
383	including	O
383	changes	O
383	in	O
383	the	O
383	volume	O
383	and	O
383	p	O
383	##h	O
383	of	O
383	acidic	O
383	organ	O
383	##elles	O
383	were	O
383	measured	O
383	,	O
383	and	O
383	the	O
383	integrated	O
383	effects	O
383	of	O
383	all	O
383	these	O
383	changes	O
383	were	O
383	computational	O
383	##ly	O
383	modeled	O
383	to	O
383	establish	O
383	their	O
383	impact	O
383	on	O
383	in	O
383	##tra	O
383	##cellular	O
383	c	O
383	##q	O
383	mass	O
383	accumulation	O
383	.	O
383	[SEP]	O
384	[CLS]	O
384	a	O
384	pu	O
384	##era	O
384	##rin	O
384	na	O
384	##no	O
384	##par	O
384	##tic	O
384	##le	O
384	was	O
384	synthesized	O
384	based	O
384	on	O
384	g	O
384	##ly	O
384	##cy	O
384	##rr	O
384	##he	O
384	##tin	O
384	##ic	O
384	acid	O
384	-	O
384	p	O
384	##eg	O
384	-	O
384	p	O
384	##bla	O
384	,	O
384	which	O
384	could	O
384	obviously	O
384	increase	O
384	the	O
384	water	O
384	so	O
384	##lub	O
384	##ility	O
384	,	O
384	bio	O
384	##act	O
384	##ivity	O
384	and	O
384	litter	O
384	half	B-PK
384	-	I-PK
384	life	I-PK
384	of	O
384	pu	O
384	##era	O
384	##rin	O
384	and	O
384	height	O
384	##en	O
384	the	O
384	liver	O
384	-	O
384	targeted	O
384	drug	O
384	delivery	O
384	(	O
384	x	O
384	##ia	O
384	##o	O
384	et	O
384	al	O
384	.	O
384	,	O
384	2018	O
384	)	O
384	.	O
384	[SEP]	O
385	[CLS]	O
385	in	O
385	summary	O
385	,	O
385	longer	O
385	m	B-PK
385	##rt	I-PK
385	##0	I-PK
385	–	I-PK
385	∞	I-PK
385	and	O
385	t	B-PK
385	##1	I-PK
385	/	I-PK
385	2	I-PK
385	,	O
385	higher	O
385	au	B-PK
385	##c	I-PK
385	,	O
385	and	O
385	lower	O
385	c	B-PK
385	##l	I-PK
385	##z	I-PK
385	values	O
385	of	O
385	e	O
385	##pi	O
385	##med	O
385	##in	O
385	c	O
385	in	O
385	c	O
385	##k	O
385	##z	O
385	group	O
385	than	O
385	e	O
385	##pi	O
385	##med	O
385	##in	O
385	c	O
385	group	O
385	implied	O
385	that	O
385	the	O
385	pu	O
385	##rified	O
385	herb	O
385	##al	O
385	preparation	O
385	may	O
385	be	O
385	superior	O
385	to	O
385	single	O
385	compound	O
385	in	O
385	pro	O
385	##long	O
385	##ing	O
385	the	O
385	duration	O
385	of	O
385	action	O
385	of	O
385	e	O
385	##pi	O
385	##med	O
385	##in	O
385	c	O
385	.	O
385	[SEP]	O
386	[CLS]	O
386	late	O
386	peaks	O
386	were	O
386	defined	O
386	as	O
386	significant	O
386	increased	O
386	point	O
386	values	O
386	when	O
386	compared	O
386	to	O
386	the	O
386	previous	O
386	time	O
386	point	O
386	and	O
386	their	O
386	frequencies	O
386	were	O
386	calculated	O
386	.	O
386	[SEP]	O
387	[CLS]	O
387	at	O
387	14	O
387	weeks	O
387	of	O
387	age	O
387	,	O
387	there	O
387	was	O
387	a	O
387	trend	O
387	towards	O
387	an	O
387	improved	O
387	performance	O
387	of	O
387	the	O
387	f	O
387	##elo	O
387	##di	O
387	##pine	O
387	-	O
387	treated	O
387	b	O
387	##6	O
387	##h	O
387	##d	O
387	animals	O
387	.	O
387	[SEP]	O
388	[CLS]	O
388	m	O
388	##r	O
388	imaging	O
388	was	O
388	performed	O
388	before	O
388	dos	O
388	##ing	O
388	and	O
388	at	O
388	pre	O
388	##set	O
388	times	O
388	after	O
388	dose	O
388	administration	O
388	to	O
388	determine	O
388	enhance	O
388	##ment	O
388	relative	O
388	to	O
388	pre	O
388	##dos	O
388	##e	O
388	signal	O
388	intensity	O
388	values	O
388	.	O
388	[SEP]	O
389	[CLS]	O
389	subjects	O
389	enrolled	O
389	into	O
389	the	O
389	age	O
389	-	O
389	based	O
389	co	O
389	##hor	O
389	##t	O
389	were	O
389	required	O
389	to	O
389	be	O
389	≥	O
389	##55	O
389	years	O
389	of	O
389	age	O
389	and	O
389	have	O
389	body	O
389	weight	O
389	45	O
389	–	O
389	95	O
389	kg	O
389	and	O
389	b	O
389	##mi	O
389	19	O
389	–	O
389	30	O
389	kg	O
389	/	O
389	m	O
389	##2	O
389	.	O
389	[SEP]	O
390	[CLS]	O
390	this	O
390	study	O
390	was	O
390	a	O
390	random	O
390	##ized	O
390	,	O
390	open	O
390	-	O
390	label	O
390	,	O
390	six	O
390	-	O
390	sequence	O
390	,	O
390	three	O
390	-	O
390	period	O
390	,	O
390	three	O
390	-	O
390	treatment	O
390	,	O
390	multiple	O
390	-	O
390	dose	O
390	crossover	O
390	study	O
390	in	O
390	healthy	O
390	male	O
390	subjects	O
390	.	O
390	[SEP]	O
391	[CLS]	O
391	s	O
391	##mu	O
391	##lt	O
391	##i	O
391	-	O
391	c	O
391	##d	O
391	##4	O
391	showed	O
391	an	O
391	apparent	O
391	molecular	O
391	weight	O
391	of	O
391	about	O
391	300	O
391	-	O
391	350	O
391	k	O
391	##da	O
391	,	O
391	in	O
391	accordance	O
391	with	O
391	a	O
391	possible	O
391	he	O
391	##pta	O
391	##mer	O
391	formula	O
391	.	O
391	[SEP]	O
392	[CLS]	O
392	hp	O
392	##l	O
392	##c	O
392	analysis	O
392	showed	O
392	a	O
392	purity	O
392	of	O
392	98	O
392	.	O
392	17	O
392	%	O
392	.	O
392	[SEP]	O
393	[CLS]	O
393	le	O
393	##vo	O
393	##bu	O
393	##pi	O
393	##va	O
393	##ca	O
393	##ine	O
393	comprises	O
393	50	O
393	%	O
393	of	O
393	commercially	O
393	available	O
393	b	O
393	##up	O
393	##iva	O
393	##ca	O
393	##ine	O
393	and	O
393	is	O
393	being	O
393	considered	O
393	for	O
393	use	O
393	in	O
393	its	O
393	own	O
393	right	O
393	.	O
393	[SEP]	O
394	[CLS]	O
394	our	O
394	data	O
394	suggest	O
394	that	O
394	liver	O
394	metabolism	O
394	as	O
394	well	O
394	as	O
394	re	O
394	##nal	O
394	ex	O
394	##cre	O
394	##tion	O
394	contribute	O
394	to	O
394	total	B-PK
394	body	I-PK
394	clearance	I-PK
394	of	O
394	c	O
394	##ef	O
394	##ota	O
394	##xi	O
394	##me	O
394	and	O
394	increase	O
394	during	O
394	the	O
394	first	O
394	few	O
394	days	O
394	of	O
394	live	O
394	.	O
394	[SEP]	O
395	[CLS]	O
395	the	O
395	effect	O
395	of	O
395	painful	O
395	procedures	O
395	and	O
395	medication	O
395	on	O
395	lying	O
395	behaviour	O
395	support	O
395	the	O
395	notion	O
395	of	O
395	lying	O
395	as	O
395	a	O
395	comfort	O
395	indicator	O
395	.	O
395	[SEP]	O
396	[CLS]	O
396	side	O
396	-	O
396	effects	O
396	from	O
396	flu	O
396	##vo	O
396	##xa	O
396	##mine	O
396	were	O
396	similar	O
396	to	O
396	those	O
396	reported	O
396	for	O
396	other	O
396	selective	O
396	se	O
396	##rot	O
396	##oni	O
396	##n	O
396	re	O
396	##up	O
396	##take	O
396	inhibitor	O
396	##s	O
396	(	O
396	nausea	O
396	,	O
396	so	O
396	##m	O
396	##no	O
396	##len	O
396	##ce	O
396	)	O
396	and	O
396	were	O
396	well	O
396	tolerate	O
396	##d	O
396	.	O
396	[SEP]	O
397	[CLS]	O
397	plasma	O
397	samples	O
397	were	O
397	collected	O
397	0	O
397	.	O
397	5	O
397	h	O
397	before	O
397	and	O
397	2	O
397	,	O
397	4	O
397	and	O
397	11	O
397	.	O
397	5	O
397	h	O
397	after	O
397	the	O
397	first	O
397	v	O
397	##g	O
397	##b	O
397	dose	O
397	.	O
397	[SEP]	O
398	[CLS]	O
398	onset	O
398	of	O
398	pain	O
398	relief	O
398	was	O
398	rapid	O
398	,	O
398	and	O
398	duration	O
398	was	O
398	approximately	O
398	1	O
398	.	O
398	5	O
398	h	O
398	with	O
398	e	O
398	.	O
398	p	O
398	.	O
398	[SEP]	O
399	[CLS]	O
399	more	O
399	##over	O
399	,	O
399	cm	B-PK
399	##ax	I-PK
399	and	O
399	au	B-PK
399	##c	I-PK
399	##0	I-PK
399	-	I-PK
399	∞	I-PK
399	(	I-PK
399	au	I-PK
399	##c	I-PK
399	,	I-PK
399	zero	I-PK
399	to	I-PK
399	in	I-PK
399	##finity	I-PK
399	)	I-PK
399	showed	O
399	values	O
399	comparable	O
399	to	O
399	those	O
399	found	O
399	in	O
399	previous	O
399	studies	O
399	performed	O
399	on	O
399	non	O
399	##card	O
399	##iac	O
399	surgery	O
399	patients	O
399	.	O
399	[SEP]	O
400	[CLS]	O
400	statistical	O
400	##ly	O
400	significant	O
400	increase	O
400	of	O
400	distribution	B-PK
400	volume	I-PK
400	and	O
400	increase	O
400	of	O
400	he	O
400	##pa	O
400	##tic	O
400	anti	O
400	##py	O
400	##rine	O
400	clearance	B-PK
400	were	O
400	recorded	O
400	,	O
400	as	O
400	well	O
400	as	O
400	significant	O
400	short	O
400	##ening	O
400	of	O
400	half	B-PK
400	-	I-PK
400	life	I-PK
400	of	O
400	this	O
400	substance	O
400	in	O
400	the	O
400	organism	O
400	of	O
400	tested	O
400	animals	O
400	in	O
400	summer	O
400	1986	O
400	and	O
400	1987	O
400	,	O
400	compared	O
400	with	O
400	the	O
400	remaining	O
400	seasons	O
400	of	O
400	the	O
400	year	O
400	.	O
400	[SEP]	O
401	[CLS]	O
401	plasma	O
401	or	O
401	brain	O
401	ho	O
401	##mo	O
401	##gen	O
401	##ate	O
401	samples	O
401	from	O
401	the	O
401	same	O
401	time	O
401	points	O
401	were	O
401	pool	O
401	##ed	O
401	into	O
401	two	O
401	groups	O
401	(	O
401	c	O
401	##1	O
401	-	O
401	c	O
401	##3	O
401	and	O
401	c	O
401	##4	O
401	-	O
401	c	O
401	##6	O
401	)	O
401	for	O
401	ass	O
401	##ay	O
401	.	O
401	[SEP]	O
402	[CLS]	O
402	though	O
402	grape	O
402	##f	O
402	##ruit	O
402	juice	O
402	on	O
402	average	O
402	slightly	O
402	increased	O
402	serum	O
402	levels	O
402	of	O
402	est	O
402	##rad	O
402	##iol	O
402	(	O
402	e	O
402	##2	O
402	)	O
402	and	O
402	pro	O
402	##ges	O
402	##tero	O
402	##ne	O
402	,	O
402	this	O
402	increase	O
402	reached	O
402	statistical	O
402	significance	O
402	only	O
402	for	O
402	the	O
402	e	O
402	##2	O
402	level	O
402	24	O
402	hours	O
402	after	O
402	application	O
402	of	O
402	tablets	O
402	.	O
402	[SEP]	O
403	[CLS]	O
403	a	O
403	non	O
403	##com	O
403	##par	O
403	##tment	O
403	##al	O
403	model	O
403	was	O
403	used	O
403	to	O
403	fit	O
403	the	O
403	plasma	O
403	concentration	O
403	of	O
403	m	O
403	##b	O
403	##f	O
403	versus	O
403	time	O
403	curve	O
403	for	O
403	each	O
403	green	O
403	sea	O
403	turtle	O
403	.	O
403	[SEP]	O
404	[CLS]	O
404	patients	O
404	with	O
404	blood	O
404	group	O
404	o	O
404	had	O
404	a	O
404	shorter	O
404	f	O
404	##vi	O
404	##ii	O
404	half	B-PK
404	-	I-PK
404	life	I-PK
404	than	O
404	patients	O
404	with	O
404	non	O
404	-	O
404	o	O
404	blood	O
404	group	O
404	(	O
404	9	O
404	.	O
404	40	O
404	±	O
404	0	O
404	.	O
404	68	O
404	h	O
404	vs	O
404	.	O
404	12	O
404	.	O
404	3	O
404	±	O
404	0	O
404	.	O
404	79	O
404	h	O
404	,	O
404	t	O
404	=	O
404	2	O
404	.	O
404	70	O
404	,	O
404	p	O
404	=	O
404	0	O
404	.	O
404	01	O
404	)	O
404	.	O
404	[SEP]	O
405	[CLS]	O
405	a	O
405	two	O
405	to	O
405	three	O
405	##fold	O
405	increase	O
405	in	O
405	the	O
405	bio	B-PK
405	##ava	I-PK
405	##ila	I-PK
405	##bility	I-PK
405	of	O
405	d	O
405	##s	O
405	##f	O
405	was	O
405	found	O
405	.	O
405	[SEP]	O
406	[CLS]	O
406	however	O
406	,	O
406	the	O
406	per	B-PK
406	##me	I-PK
406	##ability	I-PK
406	for	O
406	passive	O
406	diffusion	O
406	into	O
406	cells	O
406	was	O
406	neglected	O
406	for	O
406	all	O
406	drugs	O
406	in	O
406	the	O
406	present	O
406	study	O
406	,	O
406	since	O
406	this	O
406	process	O
406	is	O
406	not	O
406	relevant	O
406	for	O
406	mac	O
406	##rom	O
406	##ole	O
406	##cule	O
406	##s	O
406	or	O
406	very	O
406	h	O
406	##ydro	O
406	##phi	O
406	##lic	O
406	drugs	O
406	like	O
406	in	O
406	##ulin	O
406	.	O
406	[SEP]	O
407	[CLS]	O
407	there	O
407	has	O
407	been	O
407	little	O
407	information	O
407	regarding	O
407	the	O
407	p	O
407	##har	O
407	##ma	O
407	##co	O
407	##kin	O
407	##etics	O
407	of	O
407	anti	O
407	##thy	O
407	##roid	O
407	drugs	O
407	in	O
407	patients	O
407	with	O
407	ends	O
407	##tage	O
407	re	O
407	##nal	O
407	disease	O
407	(	O
407	es	O
407	##rd	O
407	)	O
407	.	O
407	[SEP]	O
408	[CLS]	O
408	drug	O
408	interaction	O
408	study	O
408	between	O
408	b	O
408	##up	O
408	##rop	O
408	##ion	O
408	and	O
408	t	O
408	##ic	O
408	##lop	O
408	##id	O
408	##ine	O
408	in	O
408	male	O
408	c	O
408	##f	O
408	-	O
408	1	O
408	mice	O
408	.	O
408	[SEP]	O
409	[CLS]	O
409	the	O
409	elimination	B-PK
409	half	I-PK
409	-	I-PK
409	life	I-PK
409	of	O
409	d	O
409	##z	O
409	##20	O
409	##0	O
409	##2	O
409	was	O
409	significantly	O
409	shorter	O
409	than	O
409	that	O
409	of	O
409	d	O
409	##za	O
409	.	O
409	[SEP]	O
410	[CLS]	O
410	to	O
410	the	O
410	a	O
410	##pical	O
410	side	O
410	of	O
410	the	O
410	well	O
410	,	O
410	500	O
410	µ	O
410	##l	O
410	of	O
410	h	O
410	##bs	O
410	##s	O
410	was	O
410	added	O
410	;	O
410	to	O
410	the	O
410	basal	O
410	side	O
410	of	O
410	the	O
410	well	O
410	,	O
410	1	O
410	.	O
410	0	O
410	m	O
410	##l	O
410	of	O
410	h	O
410	##bs	O
410	##s	O
410	was	O
410	added	O
410	.	O
410	[SEP]	O
411	[CLS]	O
411	subjects	O
411	with	O
411	pre	O
411	-	O
411	existing	O
411	peripheral	O
411	ne	O
411	##uro	O
411	##pathy	O
411	,	O
411	h	O
411	##yper	O
411	##cal	O
411	##ce	O
411	##mia	O
411	,	O
411	h	O
411	##yper	O
411	##ma	O
411	##gne	O
411	##se	O
411	##mia	O
411	or	O
411	medical	O
411	con	O
411	##tra	O
411	##ind	O
411	##ica	O
411	##tions	O
411	to	O
411	electro	O
411	##my	O
411	##ography	O
411	(	O
411	em	O
411	##g	O
411	)	O
411	or	O
411	repeated	O
411	p	O
411	##har	O
411	##ma	O
411	##co	O
411	##kin	O
411	##etic	O
411	blood	O
411	sampling	O
411	were	O
411	ineligible	O
411	.	O
411	[SEP]	O
412	[CLS]	O
412	p	O
412	##har	O
412	##ma	O
412	##co	O
412	##kin	O
412	##etics	O
412	of	O
412	two	O
412	different	O
412	delivery	O
412	regime	O
412	##ns	O
412	of	O
412	do	O
412	##x	O
412	##or	O
412	##ubi	O
412	##cin	O
412	in	O
412	isolated	O
412	h	O
412	##yper	O
412	##ther	O
412	##mic	O
412	limb	O
412	per	O
412	##fusion	O
412	.	O
412	[SEP]	O
413	[CLS]	O
413	blood	O
413	pressure	O
413	,	O
413	heart	O
413	rate	O
413	,	O
413	respiratory	O
413	rate	O
413	,	O
413	electro	O
413	##card	O
413	##io	O
413	##graphic	O
413	parameters	O
413	,	O
413	mental	O
413	a	O
413	##cu	O
413	##ity	O
413	,	O
413	and	O
413	vision	O
413	were	O
413	not	O
413	altered	O
413	.	O
413	[SEP]	O
414	[CLS]	O
414	in	O
414	addition	O
414	,	O
414	evidence	O
414	of	O
414	the	O
414	route	O
414	of	O
414	the	O
414	metabolic	O
414	degradation	O
414	of	O
414	g	O
414	##pe	O
414	is	O
414	presented	O
414	.	O
414	[SEP]	O
415	[CLS]	O
415	meanwhile	O
415	,	O
415	in	O
415	both	O
415	cells	O
415	,	O
415	naked	O
415	g	O
415	##pt	O
415	##x	O
415	and	O
415	g	O
415	##pt	O
415	##x	O
415	-	O
415	l	O
415	were	O
415	still	O
415	c	O
415	##yt	O
415	##oto	O
415	##xi	O
415	##ci	O
415	##c	O
415	even	O
415	though	O
415	they	O
415	do	O
415	not	O
415	have	O
415	targeting	O
415	ability	O
415	.	O
415	[SEP]	O
416	[CLS]	O
416	all	O
416	three	O
416	doses	O
416	were	O
416	administered	O
416	to	O
416	each	O
416	of	O
416	the	O
416	six	O
416	experimental	O
416	horses	O
416	at	O
416	three	O
416	different	O
416	times	O
416	.	O
416	[SEP]	O
417	[CLS]	O
417	the	O
417	established	O
417	western	O
417	mi	O
417	##gra	O
417	##ine	O
417	prevent	O
417	##ive	O
417	,	O
417	prop	O
417	##rano	O
417	##lo	O
417	##l	O
417	,	O
417	was	O
417	also	O
417	effective	O
417	in	O
417	the	O
417	same	O
417	experimental	O
417	model	O
417	as	O
417	gas	O
417	##tro	O
417	##din	O
417	and	O
417	l	O
417	##ig	O
417	##ust	O
417	##raz	O
417	##ine	O
417	,	O
417	while	O
417	le	O
417	##vet	O
417	##ira	O
417	##ce	O
417	##tam	O
417	,	O
417	which	O
417	has	O
417	no	O
417	positive	O
417	place	O
417	##bo	O
417	controlled	O
417	data	O
417	in	O
417	mi	O
417	##gra	O
417	##ine	O
417	,	O
417	was	O
417	not	O
417	.	O
417	[SEP]	O
418	[CLS]	O
418	the	O
418	influence	O
418	of	O
418	end	O
418	##oto	O
418	##xin	O
418	-	O
418	induced	O
418	inflammation	O
418	on	O
418	the	O
418	en	O
418	##anti	O
418	##ose	O
418	##lect	O
418	##ive	O
418	p	O
418	##har	O
418	##ma	O
418	##co	O
418	##kin	O
418	##etics	O
418	of	O
418	prop	O
418	##rano	O
418	##lo	O
418	##l	O
418	,	O
418	o	O
418	##x	O
418	##p	O
418	##ren	O
418	##olo	O
418	##l	O
418	,	O
418	and	O
418	ve	O
418	##rap	O
418	##ami	O
418	##l	O
418	,	O
418	which	O
418	bind	O
418	to	O
418	alpha	O
418	1	O
418	-	O
418	acid	O
418	g	O
418	##ly	O
418	##co	O
418	##p	O
418	##rote	O
418	##in	O
418	,	O
418	was	O
418	studied	O
418	in	O
418	the	O
418	rat	O
418	.	O
418	[SEP]	O
419	[CLS]	O
419	the	O
419	micro	O
419	##sp	O
419	##here	O
419	##s	O
419	of	O
419	na	O
419	##nos	O
419	##po	O
419	##nge	O
419	complexes	O
419	showed	O
419	desired	O
419	controlled	O
419	release	O
419	profile	O
419	for	O
419	12	O
419	h	O
419	.	O
419	ins	O
419	##ign	O
419	##ificant	O
419	drug	O
419	le	O
419	##achi	O
419	##ng	O
419	was	O
419	observed	O
419	in	O
419	re	O
419	##con	O
419	##stituted	O
419	suspension	O
419	during	O
419	storage	O
419	for	O
419	7	O
419	days	O
419	at	O
419	45	O
419	°	O
419	##c	O
419	/	O
419	75	O
419	%	O
419	r	O
419	##h	O
419	.	O
419	[SEP]	O
420	[CLS]	O
420	grade	O
420	3	O
420	/	O
420	4	O
420	hem	O
420	##ato	O
420	##log	O
420	##ic	O
420	abnormal	O
420	##ities	O
420	included	O
420	ne	O
420	##ut	O
420	##rop	O
420	##enia	O
420	(	O
420	83	O
420	%	O
420	)	O
420	and	O
420	le	O
420	##uk	O
420	##ope	O
420	##nia	O
420	(	O
420	83	O
420	%	O
420	)	O
420	.	O
420	[SEP]	O
421	[CLS]	O
421	hour	O
421	)	O
421	to	O
421	50	O
421	mg	O
421	/	O
421	m	O
421	(	O
421	median	O
421	au	B-PK
421	##c	I-PK
421	##0	I-PK
421	-	I-PK
421	in	I-PK
421	##finity	I-PK
421	,	O
421	5	O
421	.	O
421	40	O
421	micro	O
421	##m	O
421	.	O
421	[SEP]	O
422	[CLS]	O
422	one	O
422	month	O
422	after	O
422	the	O
422	start	O
422	of	O
422	daily	O
422	administration	O
422	of	O
422	250	O
422	mg	O
422	g	O
422	##ef	O
422	##iti	O
422	##ni	O
422	##b	O
422	,	O
422	the	O
422	patient	O
422	'	O
422	s	O
422	symptoms	O
422	improved	O
422	and	O
422	th	O
422	##ora	O
422	##ci	O
422	##c	O
422	c	O
422	##t	O
422	scan	O
422	##s	O
422	showed	O
422	that	O
422	the	O
422	tumor	O
422	had	O
422	reduced	O
422	in	O
422	size	O
422	.	O
422	[SEP]	O
423	[CLS]	O
423	the	O
423	abstract	O
423	##s	O
423	for	O
423	an	O
423	##not	O
423	##ation	O
423	were	O
423	randomly	O
423	selected	O
423	from	O
423	the	O
423	search	O
423	results	O
423	.	O
423	[SEP]	O
424	[CLS]	O
424	the	O
424	effects	O
424	of	O
424	f	O
424	##rus	O
424	##em	O
424	##ide	O
424	and	O
424	probe	O
424	##ne	O
424	##cid	O
424	on	O
424	the	O
424	p	O
424	##har	O
424	##ma	O
424	##co	O
424	##kin	O
424	##etics	O
424	of	O
424	p	O
424	##hen	O
424	##p	O
424	##ro	O
424	##co	O
424	##um	O
424	##on	O
424	.	O
424	[SEP]	O
425	[CLS]	O
425	supplement	O
425	##ary	O
425	material	O
425	1	O
425	(	O
425	do	O
425	##c	O
425	##x	O
425	77	O
425	##1	O
425	k	O
425	##b	O
425	)	O
425	[SEP]	O
426	[CLS]	O
426	we	O
426	next	O
426	evaluated	O
426	whether	O
426	the	O
426	a	O
426	##β	O
426	##42	O
426	conform	O
426	##ation	O
426	-	O
426	stab	O
426	##ili	O
426	##zing	O
426	activity	O
426	of	O
426	tram	O
426	##ip	O
426	##ros	O
426	##ate	O
426	affects	O
426	a	O
426	##gg	O
426	##regation	O
426	,	O
426	specifically	O
426	the	O
426	o	O
426	##li	O
426	##go	O
426	##mer	O
426	a	O
426	##gg	O
426	##regation	O
426	stages	O
426	from	O
426	mon	O
426	##omer	O
426	##s	O
426	through	O
426	soluble	O
426	de	O
426	##came	O
426	##r	O
426	species	O
426	.	O
426	[SEP]	O
427	[CLS]	O
427	as	O
427	expected	O
427	,	O
427	the	O
427	in	O
427	v	O
427	##it	O
427	##ro	O
427	dissolution	O
427	profiles	O
427	of	O
427	the	O
427	c	O
427	##ime	O
427	##ti	O
427	##dine	O
427	tablets	O
427	containing	O
427	different	O
427	percentage	O
427	##s	O
427	of	O
427	met	O
427	##ha	O
427	##c	O
427	##ryl	O
427	##ate	O
427	cop	O
427	##oly	O
427	##mer	O
427	differed	O
427	considerably	O
427	from	O
427	one	O
427	another	O
427	.	O
427	[SEP]	O
428	[CLS]	O
428	p	O
428	##har	O
428	##ma	O
428	##co	O
428	##kin	O
428	##etics	O
428	of	O
428	in	O
428	##tra	O
428	-	O
428	art	O
428	##icular	O
428	m	O
428	##or	O
428	##phine	O
428	in	O
428	horses	O
428	with	O
428	lip	O
428	##op	O
428	##oly	O
428	##sa	O
428	##cc	O
428	##hari	O
428	##de	O
428	-	O
428	induced	O
428	s	O
428	##yn	O
428	##ov	O
428	##itis	O
428	.	O
428	[SEP]	O
429	[CLS]	O
429	the	O
429	ma	B-PK
429	##ximal	I-PK
429	t	I-PK
429	##ula	I-PK
429	##th	I-PK
429	##rom	I-PK
429	##y	I-PK
429	##cin	I-PK
429	concentration	I-PK
429	in	O
429	lung	O
429	and	O
429	muscle	O
429	ho	O
429	##mo	O
429	##gen	O
429	##ate	O
429	from	O
429	a	O
429	single	O
429	animal	O
429	was	O
429	46	O
429	##5	O
429	##7	O
429	ng	O
429	/	O
429	g	O
429	(	O
429	14	O
429	days	O
429	)	O
429	and	O
429	226	O
429	##4	O
429	ng	O
429	/	O
429	g	O
429	(	O
429	7	O
429	days	O
429	)	O
429	,	O
429	respectively	O
429	.	O
429	[SEP]	O
430	[CLS]	O
430	specifically	O
430	,	O
430	b	O
430	##n	O
430	##f	O
430	for	O
430	c	O
430	##y	O
430	##p	O
430	##1	O
430	##a	O
430	##1	O
430	,	O
430	p	O
430	##b	O
430	for	O
430	c	O
430	##y	O
430	##p	O
430	##2	O
430	##b	O
430	##1	O
430	and	O
430	c	O
430	##y	O
430	##p	O
430	##2	O
430	##c	O
430	##6	O
430	and	O
430	c	O
430	##pa	O
430	for	O
430	c	O
430	##y	O
430	##p	O
430	##2	O
430	##c	O
430	##11	O
430	,	O
430	were	O
430	used	O
430	to	O
430	valid	O
430	##ate	O
430	the	O
430	ass	O
430	##ay	O
430	.	O
430	[SEP]	O
431	[CLS]	O
431	h	O
431	)	O
431	was	O
431	lower	O
431	(	O
431	p	O
431	<	O
431	0	O
431	.	O
431	05	O
431	)	O
431	in	O
431	m	O
431	##dr	O
431	##1	O
431	##a	O
431	/	O
431	1	O
431	##b	O
431	(	O
431	-	O
431	/	O
431	-	O
431	)	O
431	versus	O
431	m	O
431	##dr	O
431	##1	O
431	##a	O
431	/	O
431	1	O
431	##b	O
431	(	O
431	+	O
431	/	O
431	+	O
431	)	O
431	mice	O
431	,	O
431	respectively	O
431	.	O
431	[SEP]	O
432	[CLS]	O
432	g	O
432	##em	O
432	##ci	O
432	##ta	O
432	##bine	O
432	clearance	B-PK
432	(	O
432	l	O
432	/	O
432	h	O
432	)	O
432	was	O
432	obtained	O
432	by	O
432	dividing	O
432	the	O
432	given	O
432	dose	O
432	of	O
432	g	O
432	##em	O
432	##ci	O
432	##ta	O
432	##bine	O
432	(	O
432	μ	O
432	##mo	O
432	##l	O
432	/	O
432	patient	O
432	,	O
432	calculated	O
432	on	O
432	the	O
432	basis	O
432	of	O
432	a	O
432	molecular	O
432	weight	O
432	of	O
432	26	O
432	##3	O
432	.	O
432	198	O
432	)	O
432	by	O
432	the	O
432	au	B-PK
432	##c	I-PK
432	,	O
432	with	O
432	extra	O
432	##pol	O
432	##ation	O
432	to	O
432	in	O
432	##finity	O
432	(	O
432	dose	B-PK
432	/	I-PK
432	au	I-PK
432	##c	I-PK
432	)	O
432	.	O
432	[SEP]	O
433	[CLS]	O
433	no	O
433	significant	O
433	difference	O
433	existed	O
433	between	O
433	the	O
433	corrected	O
433	au	B-PK
433	##c	I-PK
433	(	I-PK
433	0	I-PK
433	-	I-PK
433	5	I-PK
433	)	I-PK
433	of	O
433	the	O
433	f	O
433	##ent	O
433	##any	O
433	##l	O
433	h	O
433	##c	O
433	##l	O
433	p	O
433	##cts	O
433	during	O
433	the	O
433	single	O
433	-	O
433	and	O
433	multiple	O
433	-	O
433	day	O
433	treatment	O
433	periods	O
433	(	O
433	0	O
433	.	O
433	40	O
433	and	O
433	0	O
433	.	O
433	54	O
433	micro	O
433	##g	O
433	x	O
433	h	O
433	/	O
433	l	O
433	,	O
433	respectively	O
433	;	O
433	p	O
433	=	O
433	0	O
433	.	O
433	133	O
433	)	O
433	.	O
433	[SEP]	O
434	[CLS]	O
434	after	O
434	im	O
434	##mu	O
434	##no	O
434	-	O
434	ch	O
434	##em	O
434	##otherapy	O
434	,	O
434	the	O
434	median	O
434	follow	O
434	-	O
434	up	O
434	was	O
434	55	O
434	.	O
434	5	O
434	months	O
434	[	O
434	24	O
434	–	O
434	108	O
434	months	O
434	]	O
434	,	O
434	median	O
434	time	O
434	to	O
434	re	O
434	##lap	O
434	##se	O
434	(	O
434	t	O
434	##tr	O
434	)	O
434	was	O
434	60	O
434	months	O
434	[	O
434	12	O
434	-	O
434	more	O
434	than	O
434	108	O
434	months	O
434	]	O
434	,	O
434	and	O
434	time	O
434	to	O
434	second	O
434	c	O
434	##ll	O
434	treatment	O
434	(	O
434	t	O
434	##st	O
434	)	O
434	was	O
434	84	O
434	months	O
434	[	O
434	24	O
434	-	O
434	more	O
434	than	O
434	108	O
434	months	O
434	]	O
434	.	O
434	[SEP]	O
435	[CLS]	O
435	how	O
435	this	O
435	might	O
435	change	O
435	clinical	O
435	p	O
435	##har	O
435	##ma	O
435	##cology	O
435	or	O
435	translation	O
435	##al	O
435	[UNK]	O
435	the	O
435	results	O
435	of	O
435	our	O
435	trial	O
435	indicate	O
435	substantially	O
435	altered	O
435	p	O
435	##ks	O
435	of	O
435	c	O
435	##yt	O
435	##och	O
435	##rome	O
435	‐	O
435	dependent	O
435	drugs	O
435	in	O
435	critically	O
435	ill	O
435	patients	O
435	.	O
435	[SEP]	O
436	[CLS]	O
436	grade	O
436	3	O
436	/	O
436	4	O
436	ne	O
436	##ut	O
436	##rop	O
436	##enia	O
436	was	O
436	observed	O
436	in	O
436	all	O
436	patients	O
436	,	O
436	but	O
436	not	O
436	associated	O
436	with	O
436	significant	O
436	complications	O
436	.	O
436	[SEP]	O
437	[CLS]	O
437	in	O
437	addition	O
437	,	O
437	c	O
437	##4	O
437	##n	O
437	##p	O
437	can	O
437	be	O
437	cleared	O
437	by	O
437	re	O
437	##nal	O
437	fi	O
437	##ltration	O
437	and	O
437	active	O
437	tub	O
437	##ular	O
437	secret	O
437	##ion	O
437	in	O
437	s	O
437	##pra	O
437	##gue	O
437	-	O
437	da	O
437	##wley	O
437	rats	O
437	.	O
437	[SEP]	O
438	[CLS]	O
438	cycle	O
438	1	O
438	d	O
438	##lts	O
438	were	O
438	grade	O
438	3	O
438	ne	O
438	##ut	O
438	##rop	O
438	##enia	O
438	,	O
438	anal	O
438	a	O
438	##bs	O
438	##cess	O
438	,	O
438	di	O
438	##ar	O
438	##r	O
438	##hea	O
438	,	O
438	and	O
438	th	O
438	##rom	O
438	##bo	O
438	##cy	O
438	##top	O
438	##enia	O
438	and	O
438	grade	O
438	4	O
438	my	O
438	##al	O
438	##gia	O
438	,	O
438	cell	O
438	##uli	O
438	##tis	O
438	,	O
438	ne	O
438	##ut	O
438	##rop	O
438	##enia	O
438	,	O
438	f	O
438	##eb	O
438	##ril	O
438	##e	O
438	ne	O
438	##ut	O
438	##rop	O
438	##enia	O
438	,	O
438	pulmonary	O
438	em	O
438	##bol	O
438	##ism	O
438	,	O
438	and	O
438	th	O
438	##rom	O
438	##bo	O
438	##cy	O
438	##top	O
438	##enia	O
438	.	O
438	[SEP]	O
439	[CLS]	O
439	the	O
439	ca	O
439	##li	O
439	##bra	O
439	##tion	O
439	curves	O
439	showed	O
439	good	O
439	linear	O
439	##ity	O
439	(	O
439	r	O
439	##2	O
439	>	O
439	0	O
439	.	O
439	99	O
439	)	O
439	over	O
439	the	O
439	ranges	O
439	of	O
439	50	O
439	-	O
439	800	O
439	##0	O
439	ng	O
439	/	O
439	m	O
439	##l	O
439	for	O
439	m	O
439	##dh	O
439	-	O
439	7	O
439	and	O
439	10	O
439	-	O
439	2000	O
439	ng	O
439	/	O
439	m	O
439	##l	O
439	for	O
439	5	O
439	-	O
439	f	O
439	##u	O
439	,	O
439	respectively	O
439	.	O
439	[SEP]	O
440	[CLS]	O
440	it	O
440	was	O
440	observed	O
440	that	O
440	r	O
440	##alo	O
440	##xi	O
440	##fen	O
440	##e	O
440	g	O
440	##lu	O
440	##cu	O
440	##ron	O
440	##ides	O
440	/	O
440	su	O
440	##lf	O
440	##ates	O
440	decreased	O
440	when	O
440	the	O
440	amount	O
440	of	O
440	a	O
440	##pi	O
440	##gen	O
440	##in	O
440	increased	O
440	.	O
440	[SEP]	O
441	[CLS]	O
441	we	O
441	used	O
441	the	O
441	following	O
441	diagnosis	O
441	s	O
441	##cat	O
441	##ter	O
441	plots	O
441	,	O
441	also	O
441	called	O
441	goodness	O
441	-	O
441	of	O
441	-	O
441	fit	O
441	plots	O
441	,	O
441	for	O
441	model	O
441	internal	O
441	qualification	O
441	:	O
441	observed	O
441	concentrations	O
441	vs	O
441	.	O
441	predicted	O
441	or	O
441	individual	O
441	-	O
441	predicted	O
441	concentrations	O
441	,	O
441	and	O
441	conditional	O
441	weighted	O
441	residual	O
441	##s	O
441	vs	O
441	.	O
441	predicted	O
441	concentrations	O
441	and	O
441	vs	O
441	.	O
441	time	O
441	.	O
441	[SEP]	O
442	[CLS]	O
442	in	O
442	which	O
442	s	O
442	is	O
442	the	O
442	spread	O
442	##ability	O
442	,	O
442	m	O
442	is	O
442	the	O
442	weight	O
442	(	O
442	g	O
442	)	O
442	tied	O
442	on	O
442	the	O
442	upper	O
442	plate	O
442	;	O
442	l	O
442	is	O
442	the	O
442	length	O
442	(	O
442	cm	O
442	)	O
442	of	O
442	the	O
442	glass	O
442	plates	O
442	,	O
442	and	O
442	t	O
442	is	O
442	the	O
442	time	O
442	taken	O
442	for	O
442	spreading	O
442	the	O
442	gel	O
442	[	O
442	14	O
442	,	O
442	19	O
442	]	O
442	.	O
442	[SEP]	O
443	[CLS]	O
443	nor	O
443	##eth	O
443	##ind	O
443	##rone	O
443	was	O
443	administered	O
443	by	O
443	i	O
443	##v	O
443	b	O
443	##ol	O
443	##us	O
443	injection	O
443	immediately	O
443	after	O
443	,	O
443	3	O
443	days	O
443	or	O
443	7	O
443	days	O
443	after	O
443	exposure	O
443	to	O
443	100	O
443	r	O
443	##ads	O
443	,	O
443	300	O
443	r	O
443	##ads	O
443	,	O
443	600	O
443	r	O
443	##ads	O
443	,	O
443	and	O
443	s	O
443	##ham	O
443	x	O
443	-	O
443	i	O
443	##rra	O
443	##diation	O
443	.	O
443	[SEP]	O
444	[CLS]	O
444	the	O
444	objective	O
444	of	O
444	this	O
444	study	O
444	was	O
444	to	O
444	assess	O
444	the	O
444	p	O
444	##har	O
444	##ma	O
444	##co	O
444	##kin	O
444	##etics	O
444	and	O
444	safety	O
444	of	O
444	a	O
444	single	O
444	up	O
444	##ada	O
444	##ci	O
444	##tin	O
444	##ib	O
444	dose	O
444	in	O
444	subjects	O
444	with	O
444	normal	O
444	re	O
444	##nal	O
444	function	O
444	and	O
444	in	O
444	subjects	O
444	with	O
444	re	O
444	##nal	O
444	imp	O
444	##air	O
444	##ment	O
444	.	O
444	[SEP]	O
445	[CLS]	O
445	in	O
445	contrast	O
445	,	O
445	the	O
445	signal	O
445	obtained	O
445	from	O
445	type	O
445	3	O
445	anti	O
445	##body	O
445	binding	O
445	increases	O
445	with	O
445	increasing	O
445	t	O
445	##n	O
445	##f	O
445	amounts	O
445	until	O
445	sat	O
445	##uration	O
445	is	O
445	reached	O
445	,	O
445	again	O
445	at	O
445	a	O
445	t	O
445	##n	O
445	##f	O
445	-	O
445	to	O
445	-	O
445	go	O
445	##lim	O
445	##uma	O
445	##b	O
445	ratio	O
445	of	O
445	about	O
445	1	O
445	:	O
445	2	O
445	.	O
445	[SEP]	O
446	[CLS]	O
446	dose	O
446	was	O
446	adjusted	O
446	based	O
446	on	O
446	side	O
446	effects	O
446	and	O
446	the	O
446	drug	O
446	level	O
446	was	O
446	measured	O
446	2	O
446	hours	O
446	after	O
446	the	O
446	morning	O
446	dose	O
446	(	O
446	c	O
446	##2	O
446	)	O
446	.	O
446	[SEP]	O
447	[CLS]	O
447	the	O
447	safety	O
447	profile	O
447	and	O
447	anti	O
447	##vir	O
447	##al	O
447	activity	O
447	of	O
447	the	O
447	combination	O
447	of	O
447	s	O
447	##ta	O
447	##vu	O
447	##dine	O
447	,	O
447	did	O
447	##ano	O
447	##sin	O
447	##e	O
447	,	O
447	and	O
447	ne	O
447	##lf	O
447	##ina	O
447	##vir	O
447	in	O
447	patients	O
447	with	O
447	hi	O
447	##v	O
447	infection	O
447	.	O
447	[SEP]	O
448	[CLS]	O
448	the	O
448	clinical	O
448	implications	O
448	of	O
448	these	O
448	observations	O
448	with	O
448	respect	O
448	to	O
448	the	O
448	dos	O
448	##ing	O
448	of	O
448	q	O
448	##p	O
448	are	O
448	discussed	O
448	.	O
448	[SEP]	O
449	[CLS]	O
449	the	O
449	only	O
449	age	O
449	-	O
449	dependent	O
449	significant	O
449	difference	O
449	in	O
449	p	O
449	##har	O
449	##ma	O
449	##co	O
449	##kin	O
449	##etic	O
449	behavior	O
449	between	O
449	young	O
449	and	O
449	old	O
449	be	O
449	##ag	O
449	##le	O
449	dogs	O
449	was	O
449	found	O
449	concerning	O
449	the	O
449	distribution	B-PK
449	rate	I-PK
449	constant	I-PK
449	##s	I-PK
449	.	O
449	[SEP]	O
450	[CLS]	O
450	the	O
450	p	O
450	##har	O
450	##ma	O
450	##co	O
450	##kin	O
450	##etic	O
450	parameters	O
450	were	O
450	expressed	O
450	as	O
450	mean	O
450	±	O
450	s	O
450	.	O
450	d	O
450	.	O
450	the	O
450	statistical	O
450	significance	O
450	of	O
450	the	O
450	results	O
450	was	O
450	analyzed	O
450	using	O
450	student	O
450	’	O
450	s	O
450	t	O
450	-	O
450	test	O
450	,	O
450	with	O
450	p	O
450	-	O
450	values	O
450	less	O
450	than	O
450	0	O
450	.	O
450	05	O
450	as	O
450	considered	O
450	statistical	O
450	##ly	O
450	significant	O
450	.	O
450	[SEP]	O
451	[CLS]	O
451	the	O
451	animal	O
451	ethics	O
451	committee	O
451	of	O
451	ma	O
451	##ast	O
451	##rich	O
451	##t	O
451	university	O
451	,	O
451	the	O
451	net	O
451	##her	O
451	##lands	O
451	approved	O
451	the	O
451	studies	O
451	:	O
451	2004	O
451	–	O
451	101	O
451	.	O
451	[SEP]	O
452	[CLS]	O
452	the	O
452	concentrations	O
452	read	O
452	from	O
452	the	O
452	standard	O
452	curve	O
452	were	O
452	multi	O
452	##plied	O
452	by	O
452	the	O
452	di	O
452	##lution	O
452	factor	O
452	.	O
452	[SEP]	O
453	[CLS]	O
453	none	O
453	of	O
453	these	O
453	models	O
453	resulted	O
453	in	O
453	an	O
453	acceptable	O
453	drug	O
453	-	O
453	effect	O
453	model	O
453	for	O
453	the	O
453	data	O
453	##set	O
453	under	O
453	evaluation	O
453	(	O
453	data	O
453	not	O
453	shown	O
453	)	O
453	.	O
453	[SEP]	O
454	[CLS]	O
454	the	O
454	results	O
454	indicated	O
454	our	O
454	success	O
454	in	O
454	such	O
454	an	O
454	enhance	O
454	##ment	O
454	.	O
454	[SEP]	O
455	[CLS]	O
455	the	O
455	in	O
455	##hibition	O
455	of	O
455	influx	O
455	transport	O
455	##ers	O
455	by	O
455	p	O
455	##b	O
455	led	O
455	to	O
455	a	O
455	reduction	O
455	of	O
455	free	O
455	q	O
455	##t	O
455	##p	O
455	brain	O
455	penetration	O
455	,	O
455	as	O
455	observed	O
455	by	O
455	the	O
455	reduction	O
455	of	O
455	penetration	B-PK
455	factor	I-PK
455	from	O
455	1	O
455	.	O
455	55	O
455	±	O
455	0	O
455	.	O
455	17	O
455	to	O
455	a	O
455	value	O
455	closer	O
455	to	O
455	unit	O
455	(	O
455	0	O
455	.	O
455	94	O
455	±	O
455	0	O
455	.	O
455	15	O
455	)	O
455	.	O
455	[SEP]	O
456	[CLS]	O
456	no	O
456	significant	O
456	differences	O
456	were	O
456	observed	O
456	in	O
456	the	O
456	drug	B-PK
456	elimination	I-PK
456	rate	I-PK
456	in	O
456	milk	O
456	or	O
456	in	O
456	serum	O
456	between	O
456	healthy	O
456	and	O
456	infected	O
456	cow	O
456	quarters	O
456	(	O
456	table	O
456	1	O
456	)	O
456	.	O
456	[SEP]	O
457	[CLS]	O
457	as	O
457	a	O
457	conclusion	O
457	,	O
457	the	O
457	present	O
457	method	O
457	proved	O
457	to	O
457	be	O
457	a	O
457	rapid	O
457	and	O
457	sensitive	O
457	analytical	O
457	tool	O
457	for	O
457	sofa	O
457	##l	O
457	##con	O
457	##e	O
457	in	O
457	human	O
457	plasma	O
457	or	O
457	urine	O
457	samples	O
457	and	O
457	has	O
457	been	O
457	successfully	O
457	applied	O
457	to	O
457	a	O
457	clinical	O
457	p	O
457	##har	O
457	##ma	O
457	##co	O
457	##kin	O
457	##etic	O
457	study	O
457	of	O
457	in	O
457	healthy	O
457	chin	O
457	##ese	O
457	subjects	O
457	.	O
457	[SEP]	O
458	[CLS]	O
458	when	O
458	ca	O
458	##ffe	O
458	##ine	O
458	was	O
458	co	O
458	##ad	O
458	##mini	O
458	##stered	O
458	the	O
458	cm	B-PK
458	##ax	I-PK
458	and	O
458	au	B-PK
458	##c	I-PK
458	of	O
458	me	O
458	##lat	O
458	##oni	O
458	##n	O
458	were	O
458	increased	O
458	on	O
458	average	O
458	by	O
458	142	O
458	%	O
458	(	O
458	p	O
458	=	O
458	0	O
458	.	O
458	00	O
458	##1	O
458	,	O
458	confidence	O
458	interval	O
458	on	O
458	the	O
458	difference	O
458	44	O
458	,	O
458	80	O
458	%	O
458	)	O
458	and	O
458	120	O
458	%	O
458	(	O
458	p	O
458	<	O
458	0	O
458	.	O
458	00	O
458	##1	O
458	,	O
458	confidence	O
458	interval	O
458	on	O
458	the	O
458	difference	O
458	63	O
458	,	O
458	178	O
458	%	O
458	)	O
458	,	O
458	respectively	O
458	.	O
458	[SEP]	O
459	[CLS]	O
459	both	O
459	compounds	O
459	were	O
459	tested	O
459	over	O
459	a	O
459	range	O
459	of	O
459	concentrations	O
459	up	O
459	to	O
459	and	O
459	including	O
459	5000	O
459	μ	O
459	##g	O
459	/	O
459	plate	O
459	.	O
459	[SEP]	O
460	[CLS]	O
460	mean	O
460	release	O
460	of	O
460	three	O
460	tablets	O
460	was	O
460	used	O
460	to	O
460	evaluate	O
460	the	O
460	drug	O
460	release	O
460	for	O
460	each	O
460	of	O
460	the	O
460	formulation	O
460	##s	O
460	(	O
460	17	O
460	)	O
460	.	O
460	[SEP]	O
461	[CLS]	O
461	the	O
461	two	O
461	genetic	O
461	fusion	O
461	##s	O
461	had	O
461	similar	O
461	p	O
461	##k	O
461	profiles	O
461	,	O
461	with	O
461	total	B-PK
461	body	I-PK
461	clearance	I-PK
461	of	O
461	~	O
461	0	O
461	.	O
461	9	O
461	-	O
461	1	O
461	.	O
461	0	O
461	m	O
461	##l	O
461	/	O
461	h	O
461	/	O
461	kg	O
461	,	O
461	volume	B-PK
461	of	I-PK
461	distribution	I-PK
461	at	I-PK
461	steady	I-PK
461	-	I-PK
461	state	I-PK
461	of	O
461	~	O
461	63	O
461	-	O
461	65	O
461	m	O
461	##l	O
461	/	O
461	kg	O
461	,	O
461	and	O
461	elimination	B-PK
461	half	I-PK
461	-	I-PK
461	life	I-PK
461	of	O
461	~	O
461	40	O
461	h	O
461	.	O
461	[SEP]	O
462	[CLS]	O
462	there	O
462	were	O
462	two	O
462	episodes	O
462	of	O
462	as	O
462	##ym	O
462	##pt	O
462	##oma	O
462	##tic	O
462	h	O
462	##y	O
462	##po	O
462	##cal	O
462	##ca	O
462	##emia	O
462	,	O
462	one	O
462	at	O
462	grade	O
462	ii	O
462	##i	O
462	and	O
462	one	O
462	grade	O
462	i	O
462	##v	O
462	,	O
462	which	O
462	were	O
462	recorded	O
462	in	O
462	early	O
462	follow	O
462	-	O
462	up	O
462	.	O
462	[SEP]	O
463	[CLS]	O
463	however	O
463	,	O
463	previous	O
463	studies	O
463	have	O
463	largely	O
463	treated	O
463	the	O
463	co	O
463	##lon	O
463	as	O
463	a	O
463	single	O
463	organ	O
463	or	O
463	looked	O
463	at	O
463	f	O
463	##eca	O
463	##l	O
463	profiles	O
463	,	O
463	and	O
463	differences	O
463	in	O
463	the	O
463	profiles	O
463	of	O
463	native	O
463	and	O
463	meta	O
463	##bol	O
463	##ite	O
463	compounds	O
463	between	O
463	regions	O
463	have	O
463	not	O
463	been	O
463	observed	O
463	.	O
463	[SEP]	O
464	[CLS]	O
464	an	O
464	hp	O
464	##l	O
464	##c	O
464	method	O
464	using	O
464	u	O
464	##v	O
464	detection	O
464	was	O
464	developed	O
464	to	O
464	assess	O
464	p	O
464	##hen	O
464	##ob	O
464	##ar	O
464	##bit	O
464	##al	O
464	in	O
464	plasma	O
464	of	O
464	the	O
464	subjects	O
464	.	O
464	[SEP]	O
465	[CLS]	O
465	×	O
465	3	O
465	factor	O
465	##ial	O
465	design	O
465	to	O
465	study	O
465	the	O
465	effect	O
465	of	O
465	polymer	O
465	and	O
465	plastic	O
465	##izer	O
465	type	O
465	and	O
465	concentration	O
465	on	O
465	mechanical	O
465	properties	O
465	and	O
465	in	O
465	v	O
465	##it	O
465	##ro	O
465	di	O
465	##sin	O
465	##te	O
465	##gration	O
465	time	O
465	of	O
465	the	O
465	plain	O
465	prepared	O
465	films	O
465	using	O
465	design	O
465	-	O
465	expert	O
465	##®	O
465	.	O
465	[SEP]	O
466	[CLS]	O
466	then	O
466	te	O
466	##os	O
466	(	O
466	8	O
466	.	O
466	65	O
466	g	O
466	)	O
466	was	O
466	added	O
466	and	O
466	the	O
466	system	O
466	was	O
466	stirred	O
466	for	O
466	another	O
466	20	O
466	h	O
466	at	O
466	80	O
466	°	O
466	##c	O
466	.	O
466	[SEP]	O
467	[CLS]	O
467	this	O
467	study	O
467	aimed	O
467	to	O
467	character	O
467	##ize	O
467	possible	O
467	relationships	O
467	between	O
467	p	O
467	##oly	O
467	##mor	O
467	##phism	O
467	##s	O
467	in	O
467	the	O
467	drug	O
467	transport	O
467	##er	O
467	genes	O
467	organic	O
467	an	O
467	##ion	O
467	transporting	O
467	p	O
467	##oly	O
467	##pe	O
467	##pt	O
467	##ide	O
467	-	O
467	c	O
467	(	O
467	o	O
467	##at	O
467	##p	O
467	-	O
467	c	O
467	,	O
467	s	O
467	##l	O
467	##co	O
467	##1	O
467	##b	O
467	##1	O
467	)	O
467	,	O
467	o	O
467	##at	O
467	##p	O
467	-	O
467	b	O
467	(	O
467	s	O
467	##l	O
467	##co	O
467	##2	O
467	##b	O
467	##1	O
467	)	O
467	,	O
467	multi	O
467	##dr	O
467	##ug	O
467	resistance	O
467	-	O
467	associated	O
467	protein	O
467	2	O
467	(	O
467	m	O
467	##rp	O
467	##2	O
467	,	O
467	a	O
467	##b	O
467	##cc	O
467	##2	O
467	)	O
467	and	O
467	multi	O
467	##dr	O
467	##ug	O
467	resistance	O
467	transport	O
467	##er	O
467	(	O
467	m	O
467	##dr	O
467	##1	O
467	,	O
467	a	O
467	##b	O
467	##c	O
467	##b	O
467	##1	O
467	)	O
467	and	O
467	the	O
467	p	O
467	##har	O
467	##ma	O
467	##co	O
467	##kin	O
467	##etics	O
467	of	O
467	p	O
467	##ra	O
467	##vas	O
467	##tat	O
467	##in	O
467	.	O
467	[SEP]	O
468	[CLS]	O
468	serum	O
468	exposure	O
468	of	O
468	me	O
468	##di	O
468	##48	O
468	##9	O
468	##3	O
468	increased	O
468	approximately	O
468	dose	O
468	proportional	O
468	##ly	O
468	;	O
468	the	O
468	maximum	B-PK
468	concentration	I-PK
468	of	I-PK
468	drug	I-PK
468	in	I-PK
468	serum	I-PK
468	(	I-PK
468	cm	I-PK
468	##ax	I-PK
468	)	I-PK
468	increased	O
468	from	O
468	77	O
468	μ	O
468	##g	O
468	/	O
468	m	O
468	##l	O
468	at	O
468	225	O
468	mg	O
468	to	O
468	1	O
468	,	O
468	78	O
468	##4	O
468	μ	O
468	##g	O
468	/	O
468	m	O
468	##l	O
468	at	O
468	5	O
468	,	O
468	000	O
468	mg	O
468	(	O
468	table	O
468	3	O
468	)	O
468	.	O
468	[SEP]	O
469	[CLS]	O
469	most	O
469	subjects	O
469	in	O
469	the	O
469	active	O
469	-	O
469	treatment	O
469	and	O
469	place	O
469	##bo	O
469	groups	O
469	reported	O
469	at	O
469	least	O
469	one	O
469	a	O
469	##e	O
469	during	O
469	the	O
469	treatment	O
469	period	O
469	(	O
469	org	O
469	265	O
469	##7	O
469	##6	O
469	:	O
469	97	O
469	%	O
469	;	O
469	place	O
469	##bo	O
469	:	O
469	89	O
469	%	O
469	)	O
469	.	O
469	[SEP]	O
470	[CLS]	O
470	its	O
470	human	O
470	half	B-PK
470	-	I-PK
470	life	I-PK
470	was	O
470	longer	O
470	than	O
470	those	O
470	of	O
470	ad	O
470	##ria	O
470	##my	O
470	##cin	O
470	,	O
470	mit	O
470	##omy	O
470	##cin	O
470	c	O
470	and	O
470	neo	O
470	##car	O
470	##zin	O
470	##ost	O
470	##ati	O
470	##n	O
470	,	O
470	and	O
470	a	O
470	little	O
470	shorter	O
470	than	O
470	that	O
470	of	O
470	b	O
470	##leo	O
470	##my	O
470	##cin	O
470	.	O
470	[SEP]	O
471	[CLS]	O
471	consequently	O
471	,	O
471	the	O
471	quality	O
471	of	O
471	pet	O
471	images	O
471	after	O
471	or	O
471	-	O
471	46	O
471	##2	O
471	was	O
471	better	O
471	,	O
471	which	O
471	has	O
471	implications	O
471	for	O
471	future	O
471	[	O
471	18	O
471	##f	O
471	]	O
471	6	O
471	-	O
471	flu	O
471	##oro	O
471	##do	O
471	##pa	O
471	studies	O
471	.	O
471	[SEP]	O
472	[CLS]	O
472	the	O
472	serum	O
472	concentration	O
472	of	O
472	ta	O
472	##mo	O
472	##xi	O
472	##fen	O
472	and	O
472	most	O
472	of	O
472	its	O
472	meta	O
472	##bol	O
472	##ites	O
472	(	O
472	[	O
472	trans	O
472	-	O
472	1	O
472	(	O
472	4	O
472	-	O
472	beta	O
472	-	O
472	h	O
472	##ydro	O
472	##xy	O
472	-	O
472	et	O
472	##ho	O
472	##xy	O
472	##phe	O
472	##ny	O
472	##l	O
472	)	O
472	-	O
472	1	O
472	,	O
472	2	O
472	-	O
472	dip	O
472	##hen	O
472	##yl	O
472	##but	O
472	-	O
472	1	O
472	-	O
472	en	O
472	##e	O
472	]	O
472	,	O
472	4	O
472	-	O
472	h	O
472	##ydro	O
472	##xy	O
472	##tam	O
472	##ox	O
472	##ife	O
472	##n	O
472	,	O
472	4	O
472	-	O
472	h	O
472	##ydro	O
472	##xy	O
472	-	O
472	n	O
472	-	O
472	des	O
472	##met	O
472	##hyl	O
472	##tam	O
472	##ox	O
472	##ife	O
472	##n	O
472	,	O
472	n	O
472	-	O
472	des	O
472	##met	O
472	##hyl	O
472	##tam	O
472	##ox	O
472	##ife	O
472	##n	O
472	,	O
472	and	O
472	n	O
472	-	O
472	des	O
472	##di	O
472	##met	O
472	##hyl	O
472	##tam	O
472	##ox	O
472	##ife	O
472	##n	O
472	)	O
472	were	O
472	marked	O
472	##ly	O
472	reduced	O
472	following	O
472	amino	O
472	##g	O
472	##lut	O
472	##eth	O
472	##im	O
472	##ide	O
472	administration	O
472	,	O
472	corresponding	O
472	to	O
472	an	O
472	increase	O
472	in	O
472	ta	O
472	##mo	O
472	##xi	O
472	##fen	O
472	clearance	B-PK
472	from	O
472	189	O
472	-	O
472	60	O
472	##8	O
472	m	O
472	##l	O
472	/	O
472	min	O
472	.	O
472	[SEP]	O
473	[CLS]	O
473	the	O
473	##op	O
473	##hyl	O
473	##line	O
473	clearance	B-PK
473	was	O
473	decreased	O
473	an	O
473	average	O
473	of	O
473	18	O
473	.	O
473	5	O
473	%	O
473	(	O
473	range	O
473	,	O
473	4	O
473	.	O
473	9	O
473	%	O
473	to	O
473	36	O
473	%	O
473	)	O
473	,	O
473	whereas	O
473	the	O
473	##op	O
473	##hyl	O
473	##line	O
473	volume	B-PK
473	of	I-PK
473	distribution	I-PK
473	was	O
473	unchanged	O
473	by	O
473	c	O
473	##ime	O
473	##ti	O
473	##dine	O
473	.	O
473	[SEP]	O
474	[CLS]	O
474	simple	O
474	and	O
474	multiple	O
474	re	O
474	##gression	O
474	analyses	O
474	were	O
474	performed	O
474	for	O
474	the	O
474	primary	O
474	metric	O
474	,	O
474	plasma	O
474	met	O
474	##had	O
474	##one	O
474	concentration	O
474	/	O
474	dose	O
474	.	O
474	[SEP]	O
475	[CLS]	O
475	a	O
475	##ver	O
475	##y	O
475	et	O
475	al	O
475	.	O
475	reported	O
475	that	O
475	the	O
475	un	O
475	##bound	O
475	e	O
475	##f	O
475	##v	O
475	concentrations	O
475	in	O
475	plasma	O
475	and	O
475	se	O
475	##men	O
475	(	O
475	a	O
475	##ver	O
475	##y	O
475	et	O
475	al	O
475	.	O
475	,	O
475	2011	O
475	)	O
475	and	O
475	in	O
475	plasma	O
475	and	O
475	c	O
475	##ere	O
475	##bro	O
475	##sp	O
475	##inal	O
475	fluid	O
475	are	O
475	nearly	O
475	identical	O
475	(	O
475	a	O
475	##ver	O
475	##y	O
475	et	O
475	al	O
475	.	O
475	,	O
475	2013	O
475	##a	O
475	)	O
475	.	O
475	[SEP]	O
476	[CLS]	O
476	the	O
476	recovery	O
476	of	O
476	b	O
476	##ava	O
476	##chal	O
476	##con	O
476	##e	O
476	ranged	O
476	from	O
476	84	O
476	.	O
476	1	O
476	to	O
476	87	O
476	.	O
476	0	O
476	%	O
476	.	O
476	[SEP]	O
477	[CLS]	O
477	pre	O
477	##ga	O
477	##bal	O
477	##in	O
477	is	O
477	an	O
477	alpha	O
477	(	O
477	2	O
477	)	O
477	-	O
477	delta	O
477	l	O
477	##igan	O
477	##d	O
477	that	O
477	has	O
477	an	O
477	##xi	O
477	##oly	O
477	##tic	O
477	,	O
477	anal	O
477	##ges	O
477	##ic	O
477	,	O
477	and	O
477	anti	O
477	##con	O
477	##vu	O
477	##ls	O
477	##ant	O
477	properties	O
477	.	O
477	[SEP]	O
478	[CLS]	O
478	one	O
478	-	O
478	way	O
478	(	O
478	o	O
478	##ws	O
478	##a	O
478	)	O
478	and	O
478	pro	O
478	##ba	O
478	##bil	O
478	##istic	O
478	sensitivity	O
478	analyses	O
478	(	O
478	ps	O
478	##a	O
478	)	O
478	were	O
478	conducted	O
478	to	O
478	assess	O
478	the	O
478	stability	O
478	of	O
478	the	O
478	results	O
478	beyond	O
478	the	O
478	100	O
478	-	O
478	day	O
478	period	O
478	under	O
478	the	O
478	uncertainty	O
478	arising	O
478	from	O
478	the	O
478	values	O
478	adopted	O
478	for	O
478	the	O
478	input	O
478	parameters	O
478	.	O
478	[SEP]	O
479	[CLS]	O
479	car	O
479	##ote	O
479	##no	O
479	##id	O
479	bio	B-PK
479	##ava	I-PK
479	##ila	I-PK
479	##bility	I-PK
479	in	O
479	humans	O
479	from	O
479	tomato	O
479	##es	O
479	processed	O
479	in	O
479	different	O
479	ways	O
479	determined	O
479	from	O
479	the	O
479	car	O
479	##ote	O
479	##no	O
479	##id	O
479	response	O
479	in	O
479	the	O
479	t	O
479	##rig	O
479	##ly	O
479	##cer	O
479	##ide	O
479	-	O
479	rich	O
479	lip	O
479	##op	O
479	##rote	O
479	##in	O
479	fraction	O
479	of	O
479	plasma	O
479	after	O
479	a	O
479	single	O
479	consumption	O
479	and	O
479	in	O
479	plasma	O
479	after	O
479	four	O
479	days	O
479	of	O
479	consumption	O
479	.	O
479	[SEP]	O
480	[CLS]	O
480	simulation	O
480	-	O
480	based	O
480	diagnostic	O
480	##s	O
480	and	O
480	re	O
480	-	O
480	est	O
480	##imation	O
480	methods	O
480	were	O
480	used	O
480	to	O
480	evaluate	O
480	the	O
480	performance	O
480	of	O
480	the	O
480	p	O
480	##k	O
480	and	O
480	p	O
480	##d	O
480	final	O
480	models	O
480	[	O
480	21	O
480	]	O
480	.	O
480	[SEP]	O
481	[CLS]	O
481	this	O
481	36	O
481	-	O
481	fold	O
481	increase	O
481	in	O
481	5	O
481	-	O
481	f	O
481	##u	O
481	dose	O
481	was	O
481	associated	O
481	with	O
481	a	O
481	greater	O
481	than	O
481	150	O
481	-	O
481	fold	O
481	increase	O
481	in	O
481	the	O
481	30	O
481	-	O
481	minute	O
481	plasma	O
481	concentration	O
481	of	O
481	5	O
481	-	O
481	f	O
481	##u	O
481	(	O
481	0	O
481	.	O
481	02	O
481	-	O
481	3	O
481	.	O
481	3	O
481	mm	O
481	)	O
481	.	O
481	[SEP]	O
482	[CLS]	O
482	the	O
482	plasma	O
482	concentration	O
482	time	O
482	curves	O
482	of	O
482	dans	O
482	##hen	O
482	##su	O
482	were	O
482	best	O
482	fitted	O
482	with	O
482	two	O
482	-	O
482	compartment	O
482	models	O
482	for	O
482	dans	O
482	##hen	O
482	##su	O
482	itself	O
482	and	O
482	for	O
482	sa	O
482	##l	O
482	##via	O
482	mi	O
482	##lt	O
482	##ior	O
482	##r	O
482	##hi	O
482	##za	O
482	injection	O
482	as	O
482	well	O
482	.	O
482	[SEP]	O
483	[CLS]	O
483	sa	O
483	##lm	O
483	##eter	O
483	##ol	O
483	distribution	O
483	is	O
483	en	O
483	##anti	O
483	##ose	O
483	##lect	O
483	##ive	O
483	in	O
483	the	O
483	central	O
483	lung	O
483	.	O
483	[SEP]	O
484	[CLS]	O
484	subjects	O
484	were	O
484	also	O
484	in	O
484	good	O
484	health	O
484	,	O
484	as	O
484	indicated	O
484	by	O
484	medical	O
484	history	O
484	and	O
484	physical	O
484	exam	O
484	,	O
484	and	O
484	able	O
484	to	O
484	speak	O
484	,	O
484	read	O
484	,	O
484	and	O
484	understand	O
484	en	O
484	##gli	O
484	##sh	O
484	.	O
484	[SEP]	O
485	[CLS]	O
485	a	O
485	value	O
485	of	O
485	p	O
485	<	O
485	0	O
485	.	O
485	05	O
485	was	O
485	considered	O
485	statistical	O
485	##ly	O
485	significant	O
485	.	O
485	[SEP]	O
486	[CLS]	O
486	t	O
486	##n	O
486	##bs	O
486	administration	O
486	substantially	O
486	increased	O
486	the	O
486	expression	O
486	of	O
486	n	O
486	##f	O
486	-	O
486	κ	O
486	##b	O
486	p	O
486	##65	O
486	(	O
486	p	O
486	<	O
486	0	O
486	.	O
486	01	O
486	;	O
486	figure	O
486	8	O
486	)	O
486	,	O
486	while	O
486	b	O
486	##d	O
486	-	O
486	s	O
486	##ned	O
486	##ds	O
486	marked	O
486	##ly	O
486	reversed	O
486	this	O
486	trend	O
486	(	O
486	p	O
486	<	O
486	0	O
486	.	O
486	01	O
486	vs	O
486	t	O
486	##n	O
486	##bs	O
486	group	O
486	)	O
486	in	O
486	a	O
486	dose	O
486	-	O
486	dependent	O
486	manner	O
486	.	O
486	[SEP]	O
487	[CLS]	O
487	the	O
487	mechanism	O
487	of	O
487	action	O
487	of	O
487	prop	O
487	##rano	O
487	##lo	O
487	##l	O
487	on	O
487	infant	O
487	##ile	O
487	hem	O
487	##ang	O
487	##io	O
487	##ma	O
487	is	O
487	not	O
487	well	O
487	understood	O
487	,	O
487	but	O
487	the	O
487	drug	O
487	was	O
487	proposed	O
487	to	O
487	regulate	O
487	hem	O
487	##ang	O
487	##io	O
487	##ma	O
487	cell	O
487	proliferation	O
487	through	O
487	cat	O
487	##ech	O
487	##ola	O
487	##mine	O
487	production	O
487	or	O
487	the	O
487	vascular	O
487	end	O
487	##oth	O
487	##eli	O
487	##al	O
487	growth	O
487	factor	O
487	pathway	O
487	.	O
487	2	O
487	[SEP]	O
488	[CLS]	O
488	during	O
488	the	O
488	trial	O
488	,	O
488	blinding	O
488	will	O
488	be	O
488	broken	O
488	by	O
488	the	O
488	investigator	O
488	for	O
488	emergency	O
488	purposes	O
488	only	O
488	,	O
488	where	O
488	knowledge	O
488	of	O
488	the	O
488	blinded	O
488	treatment	O
488	could	O
488	influence	O
488	further	O
488	patient	O
488	care	O
488	.	O
488	[SEP]	O
489	[CLS]	O
489	in	O
489	addition	O
489	,	O
489	it	O
489	appears	O
489	that	O
489	al	O
489	##ani	O
489	##ne	O
489	,	O
489	rather	O
489	than	O
489	g	O
489	##lut	O
489	##amine	O
489	,	O
489	is	O
489	the	O
489	predominant	O
489	n	O
489	carrier	O
489	involved	O
489	in	O
489	the	O
489	transfer	O
489	of	O
489	n	O
489	from	O
489	muscle	O
489	to	O
489	the	O
489	liver	O
489	during	O
489	moderate	O
489	intensity	O
489	exercise	O
489	.	O
489	[SEP]	O
490	[CLS]	O
490	the	O
490	ability	O
490	of	O
490	the	O
490	fabricated	O
490	x	O
490	##ep	O
490	##oma	O
490	##s	O
490	to	O
490	sustain	O
490	drug	O
490	release	O
490	and	O
490	enhance	O
490	bio	B-PK
490	##ava	I-PK
490	##ila	I-PK
490	##bility	I-PK
490	of	O
490	su	O
490	##l	O
490	##pi	O
490	##ride	O
490	in	O
490	v	O
490	##ivo	O
490	was	O
490	investigated	O
490	by	O
490	evaluating	O
490	the	O
490	plasma	O
490	drug	O
490	concentration	O
490	over	O
490	24	O
490	h	O
490	in	O
490	the	O
490	large	O
490	pig	O
490	model	O
490	.	O
490	[SEP]	O
491	[CLS]	O
491	the	O
491	convergence	O
491	criterion	O
491	of	O
491	the	O
491	implemented	O
491	algorithm	O
491	was	O
491	set	O
491	to	O
491	10	O
491	##−	O
491	##4	O
491	,	O
491	relative	O
491	and	O
491	absolute	O
491	error	O
491	to	O
491	0	O
491	.	O
491	01	O
491	and	O
491	0	O
491	.	O
491	1	O
491	,	O
491	respectively	O
491	.	O
491	[SEP]	O
492	[CLS]	O
492	quantitative	O
492	determination	O
492	of	O
492	t	O
492	##io	O
492	##p	O
492	##ron	O
492	##in	O
492	in	O
492	human	O
492	plasma	O
492	by	O
492	l	O
492	##c	O
492	-	O
492	m	O
492	##s	O
492	/	O
492	m	O
492	##s	O
492	without	O
492	der	O
492	##iva	O
492	##ti	O
492	##zation	O
492	.	O
492	[SEP]	O
493	[CLS]	O
493	the	O
493	effects	O
493	of	O
493	pro	O
493	##sta	O
493	##g	O
493	##land	O
493	##in	O
493	e	O
493	##1	O
493	(	O
493	p	O
493	##ge	O
493	##1	O
493	)	O
493	on	O
493	p	O
493	##har	O
493	##ma	O
493	##co	O
493	##kin	O
493	##etics	O
493	of	O
493	ve	O
493	##cu	O
493	##ron	O
493	##ium	O
493	and	O
493	f	O
493	##ent	O
493	##any	O
493	##l	O
493	were	O
493	studied	O
493	during	O
493	an	O
493	##est	O
493	##hesia	O
493	.	O
493	[SEP]	O
494	[CLS]	O
494	health	O
494	status	O
494	and	O
494	injection	O
494	-	O
494	site	O
494	reactions	O
494	were	O
494	monitored	O
494	daily	O
494	for	O
494	64	O
494	days	O
494	after	O
494	the	O
494	first	O
494	injection	O
494	.	O
494	[SEP]	O
495	[CLS]	O
495	three	O
495	discrete	O
495	retention	O
495	intervals	O
495	were	O
495	t	O
495	##it	O
495	##rated	O
495	for	O
495	each	O
495	subject	O
495	’	O
495	s	O
495	base	O
495	##line	O
495	performance	O
495	in	O
495	the	O
495	absence	O
495	of	O
495	compound	O
495	to	O
495	yield	O
495	performances	O
495	of	O
495	approximately	O
495	80	O
495	–	O
495	100	O
495	%	O
495	,	O
495	55	O
495	–	O
495	65	O
495	%	O
495	,	O
495	and	O
495	35	O
495	–	O
495	45	O
495	%	O
495	of	O
495	responses	O
495	being	O
495	correct	O
495	at	O
495	short	O
495	,	O
495	medium	O
495	,	O
495	and	O
495	long	O
495	retention	O
495	intervals	O
495	,	O
495	and	O
495	ranged	O
495	from	O
495	0	O
495	.	O
495	25	O
495	–	O
495	0	O
495	.	O
495	5	O
495	s	O
495	,	O
495	2	O
495	.	O
495	5	O
495	–	O
495	14	O
495	s	O
495	,	O
495	and	O
495	9	O
495	–	O
495	39	O
495	s	O
495	,	O
495	respectively	O
495	.	O
495	[SEP]	O
496	[CLS]	O
496	therapeutic	O
496	drug	O
496	monitoring	O
496	of	O
496	ta	O
496	##c	O
496	##rol	O
496	##imus	O
496	in	O
496	liver	O
496	transplant	O
496	##ation	O
496	,	O
496	phase	O
496	ii	O
496	##i	O
496	f	O
496	##k	O
496	##50	O
496	##6	O
496	multi	O
496	##cent	O
496	##er	O
496	span	O
496	##ish	O
496	study	O
496	group	O
496	:	O
496	a	O
496	two	O
496	-	O
496	year	O
496	follow	O
496	-	O
496	up	O
496	.	O
496	[SEP]	O
497	[CLS]	O
497	the	O
497	water	O
497	used	O
497	in	O
497	the	O
497	sample	O
497	preparation	O
497	,	O
497	high	O
497	-	O
497	performance	O
497	liquid	O
497	ch	O
497	##roma	O
497	##tography	O
497	(	O
497	hp	O
497	##l	O
497	##c	O
497	)	O
497	,	O
497	and	O
497	liquid	O
497	ch	O
497	##roma	O
497	##tography	O
497	-	O
497	mass	O
497	s	O
497	##pect	O
497	##rome	O
497	##try	O
497	(	O
497	l	O
497	##c	O
497	-	O
497	m	O
497	##s	O
497	/	O
497	m	O
497	##s	O
497	)	O
497	procedures	O
497	and	O
497	the	O
497	is	O
497	##op	O
497	##rop	O
497	##yl	O
497	alcohol	O
497	used	O
497	in	O
497	the	O
497	hp	O
497	##l	O
497	##c	O
497	procedure	O
497	were	O
497	of	O
497	hp	O
497	##l	O
497	##c	O
497	grade	O
497	and	O
497	were	O
497	purchased	O
497	from	O
497	the	O
497	##rm	O
497	##o	O
497	fish	O
497	##er	O
497	scientific	O
497	(	O
497	wa	O
497	##lt	O
497	##ham	O
497	,	O
497	ma	O
497	,	O
497	us	O
497	##a	O
497	)	O
497	.	O
497	[SEP]	O
498	[CLS]	O
498	art	O
498	##ica	O
498	##ine	O
498	is	O
498	a	O
498	safe	O
498	agent	O
498	for	O
498	in	O
498	##tra	O
498	##ven	O
498	##ous	O
498	regional	O
498	an	O
498	##ae	O
498	##st	O
498	##hesia	O
498	(	O
498	i	O
498	##v	O
498	##ra	O
498	)	O
498	with	O
498	rapid	O
498	onset	O
498	of	O
498	good	O
498	surgical	O
498	an	O
498	##ae	O
498	##st	O
498	##hesia	O
498	.	O
498	[SEP]	O
499	[CLS]	O
499	since	O
499	vitamin	O
499	k	O
499	antagonist	O
499	##s	O
499	are	O
499	associated	O
499	with	O
499	various	O
499	limitations	O
499	such	O
499	as	O
499	narrow	O
499	therapeutic	O
499	window	O
499	,	O
499	slow	O
499	onset	O
499	and	O
499	offset	O
499	of	O
499	effect	O
499	,	O
499	and	O
499	numerous	O
499	interactions	O
499	with	O
499	food	O
499	and	O
499	drugs	O
499	,	O
499	new	O
499	oral	O
499	anti	O
499	##coa	O
499	##gu	O
499	##lants	O
499	targeted	O
499	to	O
499	in	O
499	##hibit	O
499	th	O
499	##rom	O
499	##bin	O
499	or	O
499	factor	O
499	x	O
499	##a	O
499	(	O
499	f	O
499	##xa	O
499	)	O
499	have	O
499	been	O
499	developed	O
499	.	O
499	[SEP]	O
500	[CLS]	O
500	thanks	O
500	to	O
500	its	O
500	high	O
500	sensitivity	O
500	,	O
500	this	O
500	method	O
500	has	O
500	enabled	O
500	the	O
500	q	O
500	##uant	O
500	##itation	O
500	of	O
500	v	O
500	##ino	O
500	##rel	O
500	##bine	O
500	and	O
500	all	O
500	its	O
500	meta	O
500	##bol	O
500	##ites	O
500	in	O
500	whole	O
500	blood	O
500	over	O
500	168	O
500	h	O
500	(	O
500	i	O
500	.	O
500	e	O
500	.	O
500	,	O
500	4	O
500	-	O
500	5	O
500	elimination	B-PK
500	half	I-PK
500	lives	I-PK
500	)	O
500	whilst	O
500	the	O
500	previous	O
500	liquid	O
500	ch	O
500	##roma	O
500	##to	O
500	##graphic	O
500	methods	O
500	allowed	O
500	their	O
500	measurement	O
500	for	O
500	a	O
500	maximum	O
500	of	O
500	48	O
500	-	O
500	72	O
500	h	O
500	.	O
500	therefore	O
500	,	O
500	using	O
500	this	O
500	method	O
500	has	O
500	improved	O
500	the	O
500	reliability	O
500	of	O
500	the	O
500	p	O
500	##har	O
500	##ma	O
500	##co	O
500	##kin	O
500	##etic	O
500	data	O
500	analysis	O
500	of	O
500	v	O
500	##ino	O
500	##rel	O
500	##bine	O
500	.	O
500	[SEP]	O
501	[CLS]	O
501	effect	O
501	of	O
501	genetic	O
501	p	O
501	##oly	O
501	##mor	O
501	##phism	O
501	##s	O
501	in	O
501	u	O
501	##d	O
501	##p	O
501	-	O
501	g	O
501	##lu	O
501	##cu	O
501	##ron	O
501	##osy	O
501	##lt	O
501	##ran	O
501	##s	O
501	##fer	O
501	##ase	O
501	1	O
501	##a	O
501	##6	O
501	(	O
501	u	O
501	##gt	O
501	##1	O
501	##a	O
501	##6	O
501	)	O
501	on	O
501	ace	O
501	##ty	O
501	##ls	O
501	##ali	O
501	##cy	O
501	##lic	O
501	acid	O
501	metabolism	O
501	in	O
501	healthy	O
501	female	O
501	volunteers	O
501	.	O
501	[SEP]	O
502	[CLS]	O
502	there	O
502	is	O
502	also	O
502	an	O
502	increase	O
502	in	O
502	forecast	O
502	accuracy	O
502	(	O
502	de	O
502	##cre	O
502	##ment	O
502	in	O
502	mean	O
502	of	O
502	forecast	O
502	error	O
502	)	O
502	as	O
502	the	O
502	number	O
502	of	O
502	c	O
502	##ps	O
502	used	O
502	increases	O
502	.	O
502	[SEP]	O
503	[CLS]	O
503	t	B-PK
503	##rough	I-PK
503	level	I-PK
503	concentrations	I-PK
503	(	I-PK
503	c	I-PK
503	(	I-PK
503	12	I-PK
503	h	I-PK
503	)	I-PK
503	)	I-PK
503	showed	O
503	large	O
503	inter	O
503	-	O
503	individual	O
503	var	O
503	##iability	O
503	(	O
503	0	O
503	-	O
503	9	O
503	.	O
503	2	O
503	micro	O
503	##g	O
503	/	O
503	m	O
503	##l	O
503	)	O
503	.	O
503	[SEP]	O
504	[CLS]	O
504	it	O
504	is	O
504	also	O
504	suggested	O
504	that	O
504	mon	O
504	##ate	O
504	##pi	O
504	##l	O
504	male	O
504	##ate	O
504	improve	O
504	##s	O
504	plasma	O
504	lip	O
504	##id	O
504	metabolism	O
504	through	O
504	two	O
504	mechanisms	O
504	:	O
504	enhance	O
504	##ment	O
504	of	O
504	clearance	B-PK
504	of	O
504	plasma	O
504	l	O
504	##dl	O
504	,	O
504	which	O
504	may	O
504	be	O
504	mediated	O
504	by	O
504	up	O
504	-	O
504	regulation	O
504	of	O
504	he	O
504	##pa	O
504	##tic	O
504	l	O
504	##dl	O
504	receptors	O
504	,	O
504	and	O
504	acceleration	O
504	of	O
504	conversion	O
504	of	O
504	free	O
504	ch	O
504	##ole	O
504	##ster	O
504	##ol	O
504	to	O
504	bi	O
504	##le	O
504	acids	O
504	in	O
504	the	O
504	liver	O
504	.	O
504	[SEP]	O
505	[CLS]	O
505	[	O
505	consensus	O
505	document	O
505	of	O
505	g	O
505	##esi	O
505	##da	O
505	and	O
505	span	O
505	##ish	O
505	secret	O
505	##aria	O
505	##t	O
505	for	O
505	the	O
505	national	O
505	plan	O
505	on	O
505	aids	O
505	(	O
505	s	O
505	##p	O
505	##ns	O
505	)	O
505	regarding	O
505	combined	O
505	anti	O
505	##ret	O
505	##rov	O
505	##ira	O
505	##l	O
505	treatment	O
505	in	O
505	adults	O
505	infected	O
505	by	O
505	the	O
505	human	O
505	im	O
505	##mu	O
505	##no	O
505	##de	O
505	##ficiency	O
505	virus	O
505	(	O
505	j	O
505	##anu	O
505	##ary	O
505	2012	O
505	)	O
505	]	O
505	.	O
505	[SEP]	O
506	[CLS]	O
506	the	O
506	c	B-PK
506	##l	I-PK
506	,	O
506	vs	B-PK
506	##s	I-PK
506	,	O
506	and	O
506	v	B-PK
506	##z	I-PK
506	were	O
506	significantly	O
506	different	O
506	in	O
506	all	O
506	pair	O
506	##wise	O
506	group	O
506	comparisons	O
506	.	O
506	[SEP]	O
507	[CLS]	O
507	there	O
507	was	O
507	a	O
507	significant	O
507	correlation	O
507	between	O
507	these	O
507	two	O
507	rate	O
507	-	O
507	constant	O
507	ratios	O
507	(	O
507	r	O
507	=	O
507	0	O
507	.	O
507	96	O
507	,	O
507	p	O
507	less	O
507	than	O
507	0	O
507	.	O
507	05	O
507	)	O
507	,	O
507	although	O
507	the	O
507	values	O
507	observed	O
507	in	O
507	v	O
507	##it	O
507	##ro	O
507	were	O
507	higher	O
507	than	O
507	those	O
507	found	O
507	in	O
507	v	O
507	##ivo	O
507	.	O
507	[SEP]	O
508	[CLS]	O
508	changes	O
508	in	O
508	q	O
508	##ee	O
508	##g	O
508	and	O
508	co	O
508	##gnition	O
508	were	O
508	determined	O
508	for	O
508	8	O
508	hours	O
508	after	O
508	drug	O
508	administration	O
508	.	O
508	[SEP]	O
509	[CLS]	O
509	bio	O
509	##e	O
509	##qui	O
509	##valence	O
509	of	O
509	two	O
509	le	O
509	##uc	O
509	##ovo	O
509	##rin	O
509	calcium	O
509	tablet	O
509	formulation	O
509	##s	O
509	.	O
509	[SEP]	O
510	[CLS]	O
510	in	O
510	order	O
510	to	O
510	investigate	O
510	the	O
510	comparative	O
510	p	O
510	##har	O
510	##ma	O
510	##co	O
510	##kin	O
510	##etics	O
510	of	O
510	r	O
510	##hein	O
510	in	O
510	rats	O
510	,	O
510	a	O
510	sensitive	O
510	and	O
510	reliable	O
510	analytical	O
510	method	O
510	was	O
510	developed	O
510	and	O
510	valid	O
510	##ated	O
510	.	O
510	[SEP]	O
511	[CLS]	O
511	for	O
511	each	O
511	cancer	O
511	sub	O
511	##type	O
511	with	O
511	three	O
511	or	O
511	more	O
511	patients	O
511	,	O
511	the	O
511	median	O
511	p	O
511	##fs	O
511	was	O
511	7	O
511	.	O
511	1	O
511	months	O
511	for	O
511	re	O
511	##ct	O
511	##al	O
511	cancer	O
511	(	O
511	n	O
511	=	O
511	5	O
511	)	O
511	and	O
511	1	O
511	.	O
511	1	O
511	months	O
511	for	O
511	non	O
511	‐	O
511	small	O
511	‐	O
511	cell	O
511	lung	O
511	cancer	O
511	(	O
511	n	O
511	=	O
511	3	O
511	)	O
511	.	O
511	[SEP]	O
512	[CLS]	O
512	thirteen	O
512	participants	O
512	reported	O
512	a	O
512	total	O
512	of	O
512	78	O
512	a	O
512	##es	O
512	,	O
512	of	O
512	which	O
512	73	O
512	were	O
512	considered	O
512	drug	O
512	‐	O
512	related	O
512	(	O
512	three	O
512	a	O
512	##es	O
512	were	O
512	related	O
512	to	O
512	n	O
512	##t	O
512	##x	O
512	(	O
512	n	O
512	=	O
512	3	O
512	)	O
512	,	O
512	4	O
512	to	O
512	e	O
512	##b	O
512	##r	O
512	(	O
512	n	O
512	=	O
512	3	O
512	)	O
512	,	O
512	28	O
512	to	O
512	e	O
512	##b	O
512	##r	O
512	,	O
512	b	O
512	##up	O
512	/	O
512	na	O
512	##l	O
512	,	O
512	and	O
512	n	O
512	##t	O
512	##x	O
512	(	O
512	n	O
512	=	O
512	7	O
512	)	O
512	,	O
512	and	O
512	38	O
512	to	O
512	b	O
512	##up	O
512	/	O
512	na	O
512	##l	O
512	and	O
512	n	O
512	##t	O
512	##x	O
512	(	O
512	n	O
512	=	O
512	11	O
512	)	O
512	)	O
512	.	O
512	[SEP]	O
513	[CLS]	O
513	the	O
513	impact	O
513	of	O
513	age	O
513	on	O
513	line	O
513	##zo	O
513	##lid	O
513	disposition	O
513	during	O
513	the	O
513	first	O
513	few	O
513	months	O
513	of	O
513	life	O
513	has	O
513	not	O
513	been	O
513	previously	O
513	investigated	O
513	.	O
513	[SEP]	O
514	[CLS]	O
514	the	O
514	study	O
514	was	O
514	approved	O
514	by	O
514	the	O
514	local	O
514	human	O
514	research	O
514	and	O
514	ethics	O
514	committee	O
514	of	O
514	the	O
514	s	O
514	##t	O
514	.	O
514	ant	O
514	##oni	O
514	##us	O
514	hospital	O
514	(	O
514	v	O
514	##c	O
514	##mo	O
514	,	O
514	n	O
514	##l	O
514	##34	O
514	##6	O
514	##11	O
514	.	O
514	100	O
514	.	O
514	11	O
514	)	O
514	and	O
514	was	O
514	conducted	O
514	in	O
514	accordance	O
514	with	O
514	the	O
514	principles	O
514	of	O
514	the	O
514	declaration	O
514	of	O
514	he	O
514	##ls	O
514	##ink	O
514	##i	O
514	and	O
514	the	O
514	medical	O
514	research	O
514	involving	O
514	human	O
514	subjects	O
514	act	O
514	(	O
514	w	O
514	##mo	O
514	)	O
514	of	O
514	the	O
514	net	O
514	##her	O
514	##lands	O
514	.	O
514	[SEP]	O
515	[CLS]	O
515	p	O
515	##har	O
515	##ma	O
515	##co	O
515	##kin	O
515	##etic	O
515	properties	O
515	were	O
515	tuned	O
515	with	O
515	high	O
515	intrinsic	B-PK
515	clearance	I-PK
515	and	O
515	low	O
515	oral	B-PK
515	bio	I-PK
515	##ava	I-PK
515	##ila	I-PK
515	##bility	I-PK
515	in	O
515	mind	O
515	,	O
515	to	O
515	mini	O
515	##mise	O
515	systemic	O
515	exposure	O
515	and	O
515	reduce	O
515	systemic	O
515	##ally	O
515	driven	O
515	adverse	O
515	events	O
515	.	O
515	[SEP]	O
516	[CLS]	O
516	cat	O
516	##he	O
516	##ters	O
516	were	O
516	imp	O
516	##lanted	O
516	both	O
516	in	O
516	the	O
516	right	O
516	at	O
516	##rium	O
516	for	O
516	drug	O
516	in	O
516	##fusion	O
516	and	O
516	in	O
516	the	O
516	ascending	O
516	a	O
516	##ort	O
516	##a	O
516	for	O
516	blood	O
516	sampling	O
516	.	O
516	[SEP]	O
517	[CLS]	O
517	parameter	O
517	sets	O
517	achieving	O
517	ma	O
517	##ximal	O
517	model	O
517	agreement	O
517	with	O
517	experimental	O
517	training	O
517	data	O
517	were	O
517	selected	O
517	(	O
517	see	O
517	text	O
517	s	O
517	##1	O
517	,	O
517	tables	O
517	s	O
517	##1	O
517	-	O
517	s	O
517	##2	O
517	)	O
517	.	O
517	[SEP]	O
518	[CLS]	O
518	this	O
518	random	O
518	##ized	O
518	,	O
518	double	O
518	-	O
518	blind	O
518	,	O
518	place	O
518	##bo	O
518	-	O
518	controlled	O
518	study	O
518	assessed	O
518	the	O
518	safety	O
518	,	O
518	to	O
518	##ler	O
518	##ability	O
518	,	O
518	and	O
518	plasma	O
518	-	O
518	kinetic	O
518	behavior	O
518	of	O
518	94	O
518	%	O
518	pure	O
518	crystal	O
518	##line	O
518	e	O
518	##pi	O
518	##gall	O
518	##oc	O
518	##ate	O
518	##chin	O
518	gal	O
518	##late	O
518	(	O
518	e	O
518	##g	O
518	##c	O
518	##g	O
518	)	O
518	after	O
518	ten	O
518	days	O
518	'	O
518	repeated	O
518	dos	O
518	##ing	O
518	in	O
518	36	O
518	healthy	O
518	male	O
518	volunteers	O
518	.	O
518	[SEP]	O
519	[CLS]	O
519	the	O
519	bio	O
519	##dis	O
519	##tribution	O
519	of	O
519	99	O
519	##t	O
519	##c	O
519	##m	O
519	was	O
519	as	O
519	expected	O
519	for	O
519	a	O
519	labelled	O
519	f	O
519	##ab	O
519	'	O
519	fragment	O
519	:	O
519	relative	O
519	to	O
519	111	O
519	##in	O
519	,	O
519	99	O
519	##t	O
519	##c	O
519	##m	O
519	cleared	O
519	rapidly	O
519	from	O
519	circulation	O
519	and	O
519	into	O
519	kidney	O
519	##s	O
519	and	O
519	urine	O
519	.	O
519	[SEP]	O
520	[CLS]	O
520	the	O
520	recovery	O
520	of	O
520	to	O
520	##lf	O
520	##ena	O
520	##mic	O
520	acid	O
520	in	O
520	bi	O
520	##le	O
520	was	O
520	1	O
520	.	O
520	1	O
520	+	O
520	-	O
520	0	O
520	.	O
520	3	O
520	%	O
520	of	O
520	the	O
520	dose	O
520	,	O
520	whereas	O
520	the	O
520	recovery	O
520	of	O
520	total	O
520	14	O
520	##c	O
520	was	O
520	18	O
520	.	O
520	6	O
520	+	O
520	-	O
520	4	O
520	.	O
520	9	O
520	%	O
520	.	O
520	[SEP]	O
521	[CLS]	O
521	pool	O
521	##ing	O
521	t	O
521	##f	O
521	##g	O
521	3	O
521	data	O
521	from	O
521	the	O
521	5	O
521	,	O
521	7	O
521	.	O
521	5	O
521	and	O
521	10	O
521	mg	O
521	/	O
521	kg	O
521	groups	O
521	yielded	O
521	a	O
521	t	O
521	##im	O
521	##i	O
521	grade	O
521	3	O
521	flow	O
521	rate	O
521	of	O
521	34	O
521	%	O
521	(	O
521	n	O
521	=	O
521	10	O
521	/	O
521	29	O
521	;	O
521	range	O
521	29	O
521	-	O
521	43	O
521	%	O
521	)	O
521	.	O
521	[SEP]	O
522	[CLS]	O
522	in	O
522	summary	O
522	,	O
522	our	O
522	results	O
522	provide	O
522	evidence	O
522	of	O
522	b	O
522	##bb	O
522	passage	O
522	and	O
522	bio	B-PK
522	##ava	I-PK
522	##ila	I-PK
522	##bility	I-PK
522	of	O
522	i	O
522	##vi	O
522	##g	O
522	into	O
522	the	O
522	brain	O
522	in	O
522	the	O
522	absence	O
522	of	O
522	b	O
522	##bb	O
522	leak	O
522	##age	O
522	and	O
522	in	O
522	sufficient	O
522	concentration	O
522	to	O
522	interact	O
522	with	O
522	the	O
522	therapeutic	O
522	targets	O
522	.	O
522	[SEP]	O
523	[CLS]	O
523	the	O
523	in	O
523	v	O
523	##it	O
523	##ro	O
523	and	O
523	in	O
523	v	O
523	##ivo	O
523	p	O
523	##har	O
523	##ma	O
523	##co	O
523	##kin	O
523	##etic	O
523	,	O
523	t	O
523	##umour	O
523	delivery	O
523	and	O
523	efficacy	O
523	properties	O
523	of	O
523	lip	O
523	##oso	O
523	##mal	O
523	v	O
523	##in	O
523	##c	O
523	##rist	O
523	##ine	O
523	formulation	O
523	##s	O
523	based	O
523	on	O
523	s	O
523	##phi	O
523	##ngo	O
523	##my	O
523	##elin	O
523	(	O
523	s	O
523	##m	O
523	)	O
523	and	O
523	ch	O
523	##ole	O
523	##ster	O
523	##ol	O
523	were	O
523	compared	O
523	with	O
523	lip	O
523	##oso	O
523	##mes	O
523	composed	O
523	of	O
523	di	O
523	##ste	O
523	##aro	O
523	##yl	O
523	##ph	O
523	##os	O
523	##pha	O
523	##ti	O
523	##dy	O
523	##l	O
523	##cho	O
523	##line	O
523	(	O
523	d	O
523	##sp	O
523	##c	O
523	)	O
523	and	O
523	ch	O
523	##ole	O
523	##ster	O
523	##ol	O
523	.	O
523	[SEP]	O
524	[CLS]	O
524	following	O
524	in	O
524	##tra	O
524	##ven	O
524	##ous	O
524	administration	O
524	sum	O
524	##at	O
524	##rip	O
524	##tan	O
524	was	O
524	eliminated	O
524	from	O
524	plasma	O
524	with	O
524	a	O
524	half	B-PK
524	-	I-PK
524	life	I-PK
524	of	O
524	about	O
524	1	O
524	.	O
524	1	O
524	h	O
524	.	O
524	after	O
524	in	O
524	##tra	O
524	##nas	O
524	##al	O
524	administration	O
524	there	O
524	was	O
524	rapid	O
524	absorption	O
524	of	O
524	part	O
524	of	O
524	the	O
524	dose	O
524	and	O
524	two	O
524	peak	B-PK
524	plasma	I-PK
524	concentrations	I-PK
524	were	O
524	observed	O
524	,	O
524	initially	O
524	at	O
524	0	O
524	.	O
524	5	O
524	and	O
524	then	O
524	at	O
524	1	O
524	.	O
524	5	O
524	-	O
524	2	O
524	h	O
524	.	O
524	[SEP]	O
525	[CLS]	O
525	in	O
525	a	O
525	second	O
525	trial	O
525	,	O
525	3	O
525	g	O
525	##ilt	O
525	##s	O
525	were	O
525	fed	O
525	a	O
525	ratio	O
525	##n	O
525	containing	O
525	0	O
525	.	O
525	55	O
525	g	O
525	of	O
525	te	O
525	##tra	O
525	##cy	O
525	##cline	O
525	h	O
525	##ydro	O
525	##ch	O
525	##lor	O
525	##ide	O
525	/	O
525	kg	O
525	of	O
525	feed	O
525	.	O
525	[SEP]	O
526	[CLS]	O
526	c	O
526	##ef	O
526	##ove	O
526	##cin	O
526	mean	O
526	half	B-PK
526	-	I-PK
526	life	I-PK
526	,	O
526	volume	B-PK
526	of	I-PK
526	distribution	I-PK
526	at	I-PK
526	steady	I-PK
526	-	I-PK
526	state	I-PK
526	,	O
526	and	O
526	clearance	B-PK
526	after	O
526	in	O
526	##tra	O
526	##ven	O
526	##ous	O
526	administration	O
526	were	O
526	10	O
526	.	O
526	3	O
526	h	O
526	,	O
526	86	O
526	m	O
526	##l	O
526	/	O
526	kg	O
526	,	O
526	and	O
526	7	O
526	.	O
526	07	O
526	m	O
526	##l	O
526	·	O
526	h	O
526	/	O
526	kg	O
526	.	O
526	[SEP]	O
527	[CLS]	O
527	after	O
527	the	O
527	wash	O
527	##out	O
527	period	O
527	,	O
527	es	O
527	##rd	O
527	subjects	O
527	received	O
527	a	O
527	second	O
527	dose	O
527	of	O
527	o	O
527	##mada	O
527	##cy	O
527	##cline	O
527	(	O
527	the	O
527	second	O
527	treatment	O
527	period	O
527	)	O
527	approximately	O
527	60	O
527	to	O
527	90	O
527	min	O
527	before	O
527	dial	O
527	##ys	O
527	##is	O
527	.	O
527	[SEP]	O
528	[CLS]	O
528	no	O
528	rat	O
528	exhibited	O
528	evidence	O
528	of	O
528	ch	O
528	##rom	O
528	##oda	O
528	##c	O
528	##ryo	O
528	##rr	O
528	##hea	O
528	(	O
528	a	O
528	stress	O
528	indicator	O
528	)	O
528	or	O
528	other	O
528	health	O
528	problem	O
528	.	O
528	[SEP]	O
529	[CLS]	O
529	a	O
529	highly	O
529	significant	O
529	correlation	O
529	between	O
529	sa	O
529	##liva	O
529	and	O
529	plasma	O
529	a	O
529	##p	O
529	##c	O
529	##l	O
529	or	O
529	a	O
529	##pt	O
529	##1	O
529	/	O
529	2	O
529	was	O
529	found	O
529	in	O
529	young	O
529	subjects	O
529	.	O
529	[SEP]	O
530	[CLS]	O
530	however	O
530	,	O
530	for	O
530	reasons	O
530	stated	O
530	in	O
530	the	O
530	results	O
530	section	O
530	and	O
530	presented	O
530	in	O
530	detail	O
530	in	O
530	the	O
530	discussion	O
530	,	O
530	the	O
530	3	O
530	-	O
530	week	O
530	schedule	O
530	was	O
530	not	O
530	started	O
530	.	O
530	[SEP]	O
531	[CLS]	O
531	thus	O
531	,	O
531	p	O
531	##v	O
531	##p	O
531	/	O
531	e	O
531	##c	O
531	(	O
531	1	O
531	.	O
531	0	O
531	:	O
531	10	O
531	.	O
531	0	O
531	)	O
531	was	O
531	chosen	O
531	for	O
531	further	O
531	study	O
531	.	O
531	[SEP]	O
532	[CLS]	O
532	while	O
532	specific	O
532	g	O
532	##f	O
532	##r	O
532	function	O
532	was	O
532	parameter	O
532	##ized	O
532	using	O
532	the	O
532	observed	O
532	g	O
532	##f	O
532	##r	O
532	values	O
532	and	O
532	assuming	O
532	the	O
532	mean	O
532	kidney	O
532	weight	O
532	at	O
532	the	O
532	respective	O
532	age	O
532	,	O
532	the	O
532	var	O
532	##iability	O
532	was	O
532	entirely	O
532	dependent	O
532	on	O
532	the	O
532	de	O
532	##viation	O
532	in	O
532	kidney	O
532	weight	O
532	.	O
532	[SEP]	O
533	[CLS]	O
533	while	O
533	these	O
533	novel	O
533	est	O
533	##rad	O
533	##iol	O
533	-	O
533	releasing	O
533	combination	O
533	con	O
533	##tra	O
533	##ceptive	O
533	v	O
533	##agi	O
533	##nal	O
533	rings	O
533	provided	O
533	sustained	O
533	release	O
533	of	O
533	con	O
533	##tra	O
533	##ceptive	O
533	levels	O
533	of	O
533	nest	O
533	##oro	O
533	##ne	O
533	over	O
533	90	O
533	days	O
533	,	O
533	the	O
533	e	O
533	##2	O
533	levels	O
533	achieved	O
533	were	O
533	not	O
533	consistent	O
533	with	O
533	bone	O
533	protection	O
533	,	O
533	and	O
533	a	O
533	dose	O
533	-	O
533	response	O
533	was	O
533	not	O
533	observed	O
533	.	O
533	[SEP]	O
534	[CLS]	O
534	we	O
534	have	O
534	also	O
534	evaluated	O
534	its	O
534	potential	O
534	in	O
534	ch	O
534	##em	O
534	##ose	O
534	##ns	O
534	##iti	O
534	##zing	O
534	c	O
534	##er	O
534	##vic	O
534	##al	O
534	cancer	O
534	cells	O
534	to	O
534	p	O
534	##ac	O
534	##lit	O
534	##ax	O
534	##el	O
534	and	O
534	have	O
534	verified	O
534	the	O
534	results	O
534	using	O
534	c	O
534	##er	O
534	##vic	O
534	##al	O
534	cancer	O
534	x	O
534	##eno	O
534	##gra	O
534	##ft	O
534	model	O
534	in	O
534	nod	O
534	-	O
534	s	O
534	##cid	O
534	mice	O
534	.	O
534	[SEP]	O
535	[CLS]	O
535	this	O
535	plasma	O
535	ultra	O
535	##fi	O
535	##lt	O
535	##rate	O
535	was	O
535	immediately	O
535	frozen	O
535	and	O
535	stored	O
535	at	O
535	−	O
535	##20	O
535	##°	O
535	##c	O
535	.	O
535	[SEP]	O
536	[CLS]	O
536	for	O
536	phase	O
536	ii	O
536	enzymes	O
536	,	O
536	in	O
536	##test	O
536	##ine	O
536	expressed	O
536	more	O
536	u	O
536	##gt	O
536	##1	O
536	##a	O
536	##2	O
536	,	O
536	and	O
536	liver	O
536	expressed	O
536	a	O
536	greater	O
536	number	O
536	and	O
536	higher	O
536	levels	O
536	of	O
536	most	O
536	u	O
536	##gt	O
536	and	O
536	su	O
536	##lt	O
536	enzymes	O
536	.	O
536	[SEP]	O
537	[CLS]	O
537	no	O
537	radio	B-PK
537	##act	I-PK
537	##ivity	I-PK
537	was	O
537	exhaled	O
537	in	O
537	air	O
537	suggesting	O
537	that	O
537	elimination	O
537	through	O
537	re	O
537	##spiration	O
537	did	O
537	not	O
537	occur	O
537	.	O
537	[SEP]	O
538	[CLS]	O
538	the	O
538	complete	O
538	database	O
538	was	O
538	a	O
538	prior	O
538	##i	O
538	divided	O
538	into	O
538	“	O
538	training	O
538	data	O
538	##sets	O
538	”	O
538	for	O
538	model	O
538	parameter	O
538	est	O
538	##imation	O
538	,	O
538	and	O
538	“	O
538	valid	O
538	##ation	O
538	data	O
538	##sets	O
538	”	O
538	for	O
538	model	O
538	ve	O
538	##rification	O
538	.	O
538	[SEP]	O
539	[CLS]	O
539	bench	O
539	top	O
539	stability	O
539	experiment	O
539	was	O
539	conducted	O
539	to	O
539	keep	O
539	q	O
539	##c	O
539	samples	O
539	at	O
539	room	O
539	temperature	O
539	for	O
539	24	O
539	h	O
539	.	O
539	[SEP]	O
540	[CLS]	O
540	c	O
540	(	O
540	x	O
540	##1	O
540	,	O
540	x	O
540	##2	O
540	)	O
540	=	O
540	e	O
540	[	O
540	(	O
540	x	O
540	##1	O
540	##−	O
540	##u	O
540	##1	O
540	)	O
540	(	O
540	x	O
540	##2	O
540	##−	O
540	##u	O
540	##2	O
540	)	O
540	]	O
540	is	O
540	the	O
540	co	O
540	##var	O
540	##iance	O
540	,	O
540	e	O
540	is	O
540	the	O
540	mathematical	O
540	expectation	O
540	,	O
540	u	O
540	##i	O
540	=	O
540	e	O
540	[	O
540	x	O
540	##i	O
540	]	O
540	,	O
540	i	O
540	=	O
540	1	O
540	,	O
540	2	O
540	.	O
540	[SEP]	O
541	[CLS]	O
541	the	O
541	au	B-PK
541	##c	I-PK
541	of	O
541	mid	O
541	##az	O
541	##ola	O
541	##m	O
541	increased	O
541	1	O
541	.	O
541	4	O
541	‐	O
541	fold	O
541	by	O
541	b	O
541	##fe	O
541	##12	O
541	##24	O
541	co	O
541	##ad	O
541	##mini	O
541	##stra	O
541	##tion	O
541	(	O
541	table	O
541	##3	O
541	)	O
541	.	O
541	[SEP]	O
542	[CLS]	O
542	the	O
542	data	O
542	were	O
542	analyzed	O
542	using	O
542	micro	O
542	##so	O
542	##ft	O
542	ex	O
542	##cel	O
542	2010	O
542	and	O
542	i	O
542	##b	O
542	##m	O
542	s	O
542	##ps	O
542	##s	O
542	statistics	O
542	version	O
542	19	O
542	.	O
542	[SEP]	O
543	[CLS]	O
543	d	O
543	##sp	O
543	##c	O
543	:	O
543	ch	O
543	##ole	O
543	##ster	O
543	##ol	O
543	(	O
543	[UNK]	O
543	m	O
543	##ol	O
543	%	O
543	)	O
543	lip	O
543	##oso	O
543	##mes	O
543	were	O
543	prepared	O
543	as	O
543	previously	O
543	outlined	O
543	[	O
543	36	O
543	]	O
543	,	O
543	[	O
543	37	O
543	]	O
543	,	O
543	using	O
543	trace	O
543	amounts	O
543	of	O
543	the	O
543	non	O
543	-	O
543	meta	O
543	##bol	O
543	##iza	O
543	##ble	O
543	,	O
543	non	O
543	-	O
543	exchange	O
543	##able	O
543	lip	O
543	##id	O
543	trace	O
543	##r	O
543	[	O
543	3	O
543	##h	O
543	]	O
543	ch	O
543	##e	O
543	[	O
543	38	O
543	]	O
543	.	O
543	[SEP]	O
544	[CLS]	O
544	t	B-PK
544	##max	I-PK
544	was	O
544	4	O
544	.	O
544	2	O
544	and	O
544	4	O
544	.	O
544	3	O
544	hours	O
544	for	O
544	d	O
544	-	O
544	am	O
544	##phe	O
544	##tamine	O
544	to	O
544	l	O
544	-	O
544	am	O
544	##phe	O
544	##tamine	O
544	,	O
544	respectively	O
544	.	O
544	[SEP]	O
545	[CLS]	O
545	uh	O
545	##p	O
545	##l	O
545	##c	O
545	-	O
545	q	O
545	-	O
545	to	O
545	##f	O
545	/	O
545	m	O
545	##s	O
545	and	O
545	uh	O
545	##p	O
545	##l	O
545	##c	O
545	-	O
545	multi	O
545	##sta	O
545	##ge	O
545	tandem	O
545	m	O
545	##s	O
545	methods	O
545	were	O
545	developed	O
545	for	O
545	the	O
545	p	O
545	##har	O
545	##ma	O
545	##co	O
545	##kin	O
545	##etics	O
545	,	O
545	bio	B-PK
545	##ava	I-PK
545	##ila	I-PK
545	##bility	I-PK
545	and	O
545	metabolism	O
545	of	O
545	r	O
545	##ha	O
545	##pont	O
545	##ici	O
545	##n	O
545	in	O
545	rats	O
545	.	O
545	[SEP]	O
546	[CLS]	O
546	we	O
546	report	O
546	five	O
546	episodes	O
546	of	O
546	car	O
546	##ba	O
546	##ma	O
546	##ze	O
546	##pine	O
546	(	O
546	c	O
546	##b	O
546	##z	O
546	)	O
546	into	O
546	##xi	O
546	##cation	O
546	in	O
546	four	O
546	patients	O
546	.	O
546	[SEP]	O
547	[CLS]	O
547	3	O
547	.	O
547	co	O
547	##ad	O
547	##mini	O
547	##stra	O
547	##tion	O
547	of	O
547	dig	O
547	##ox	O
547	##in	O
547	and	O
547	ve	O
547	##net	O
547	##oc	O
547	##lax	O
547	increased	O
547	dig	O
547	##ox	O
547	##in	O
547	maximum	B-PK
547	observed	I-PK
547	plasma	I-PK
547	concentration	I-PK
547	(	I-PK
547	cm	I-PK
547	##ax	I-PK
547	)	I-PK
547	by	O
547	35	O
547	%	O
547	and	O
547	area	B-PK
547	under	I-PK
547	the	I-PK
547	plasma	I-PK
547	-	I-PK
547	concentration	I-PK
547	time	I-PK
547	curve	I-PK
547	(	I-PK
547	au	I-PK
547	##c	I-PK
547	##0	I-PK
547	-	I-PK
547	∞	I-PK
547	)	I-PK
547	by	O
547	9	O
547	%	O
547	.	O
547	[SEP]	O
548	[CLS]	O
548	two	O
548	patients	O
548	(	O
548	8	O
548	%	O
548	)	O
548	had	O
548	a	O
548	confirmed	O
548	partial	O
548	response	O
548	(	O
548	p	O
548	##r	O
548	)	O
548	;	O
548	15	O
548	(	O
548	60	O
548	%	O
548	)	O
548	had	O
548	stable	O
548	disease	O
548	(	O
548	s	O
548	##d	O
548	)	O
548	.	O
548	[SEP]	O
549	[CLS]	O
549	an	O
549	i	O
549	##gg	O
549	molecule	O
549	(	O
549	protein	O
549	-	O
549	01	O
549	)	O
549	and	O
549	a	O
549	40	O
549	k	O
549	##da	O
549	protein	O
549	(	O
549	protein	O
549	-	O
549	02	O
549	)	O
549	were	O
549	evaluated	O
549	.	O
549	[SEP]	O
550	[CLS]	O
550	results	O
550	were	O
550	expressed	O
550	as	O
550	stimulation	O
550	index	O
550	(	O
550	si	O
550	=	O
550	c	O
550	##pm	O
550	stimulate	O
550	##d	O
550	/	O
550	c	O
550	##pm	O
550	un	O
550	##st	O
550	##im	O
550	##ulated	O
550	)	O
550	and	O
550	reported	O
550	as	O
550	residual	O
550	proliferation	O
550	.	O
550	[SEP]	O
551	[CLS]	O
551	it	O
551	should	O
551	be	O
551	mentioned	O
551	,	O
551	however	O
551	,	O
551	that	O
551	c	O
551	##is	O
551	##p	O
551	##lat	O
551	##in	O
551	-	O
551	associated	O
551	ne	O
551	##ph	O
551	##rot	O
551	##ox	O
551	##icit	O
551	##y	O
551	was	O
551	not	O
551	increased	O
551	in	O
551	elderly	O
551	patients	O
551	,	O
551	whereas	O
551	increased	O
551	my	O
551	##elo	O
551	##su	O
551	##pp	O
551	##ression	O
551	was	O
551	seen	O
551	in	O
551	some	O
551	elderly	O
551	patients	O
551	receiving	O
551	c	O
551	##is	O
551	##p	O
551	##lat	O
551	##in	O
551	,	O
551	making	O
551	arbitrary	O
551	dose	O
551	reduction	O
551	##s	O
551	based	O
551	solely	O
551	on	O
551	aging	O
551	di	O
551	##sp	O
551	##uta	O
551	##ble	O
551	[	O
551	111	O
551	,	O
551	115	O
551	,	O
551	116	O
551	,	O
551	117	O
551	]	O
551	.	O
551	[SEP]	O
552	[CLS]	O
552	the	O
552	recovery	O
552	of	O
552	co	O
552	##lum	O
552	##bian	O
552	##adi	O
552	##n	O
552	was	O
552	calculated	O
552	by	O
552	comparing	O
552	the	O
552	peak	O
552	areas	O
552	obtained	O
552	from	O
552	spike	O
552	##d	O
552	plasma	O
552	samples	O
552	with	O
552	those	O
552	of	O
552	peak	O
552	areas	O
552	of	O
552	the	O
552	anal	O
552	##yte	O
552	spike	O
552	##d	O
552	post	O
552	-	O
552	treatment	O
552	at	O
552	corresponding	O
552	concentrations	O
552	.	O
552	[SEP]	O
553	[CLS]	O
553	urine	O
553	(	O
553	entire	O
553	volume	O
553	)	O
553	was	O
553	collected	O
553	during	O
553	3	O
553	sampling	O
553	periods	O
553	:	O
553	0	O
553	to	O
553	8	O
553	,	O
553	8	O
553	to	O
553	16	O
553	,	O
553	and	O
553	16	O
553	to	O
553	24	O
553	hours	O
553	after	O
553	l	O
553	##s	O
553	##d	O
553	administration	O
553	.	O
553	[SEP]	O
554	[CLS]	O
554	due	O
554	to	O
554	the	O
554	severity	O
554	of	O
554	p	O
554	.	O
554	a	O
554	##er	O
554	##ug	O
554	##ino	O
554	##sa	O
554	infection	O
554	,	O
554	a	O
554	lower	O
554	in	O
554	##oc	O
554	##ulum	O
554	was	O
554	used	O
554	so	O
554	as	O
554	to	O
554	reduce	O
554	mortality	O
554	;	O
554	treatment	O
554	was	O
554	started	O
554	2	O
554	h	O
554	post	O
554	##in	O
554	##fect	O
554	##ion	O
554	to	O
554	allow	O
554	c	O
554	##fu	O
554	counts	O
554	to	O
554	reach	O
554	a	O
554	higher	O
554	base	O
554	##line	O
554	level	O
554	.	O
554	[SEP]	O
555	[CLS]	O
555	si	O
555	between	O
555	rode	O
555	##nt	O
555	pairs	O
555	is	O
555	used	O
555	to	O
555	measure	O
555	anxiety	O
555	-	O
555	like	O
555	behaviour	O
555	##s	O
555	[	O
555	57	O
555	]	O
555	.	O
555	[SEP]	O
556	[CLS]	O
556	in	O
556	addition	O
556	,	O
556	t	O
556	##rol	O
556	##ean	O
556	##dom	O
556	##y	O
556	##cin	O
556	had	O
556	no	O
556	effect	O
556	on	O
556	er	O
556	##yt	O
556	##hr	O
556	##omy	O
556	##cin	O
556	transport	O
556	in	O
556	ca	O
556	##co	O
556	-	O
556	2	O
556	cells	O
556	(	O
556	p	O
556	>	O
556	or	O
556	=	O
556	.	O
556	20	O
556	)	O
556	.	O
556	[SEP]	O
557	[CLS]	O
557	sub	O
557	##ling	O
557	##ual	O
557	f	O
557	##ent	O
557	##any	O
557	##l	O
557	o	O
557	##dt	O
557	was	O
557	effective	O
557	and	O
557	well	O
557	tolerate	O
557	##d	O
557	for	O
557	the	O
557	long	O
557	-	O
557	term	O
557	treatment	O
557	of	O
557	b	O
557	##t	O
557	##c	O
557	##p	O
557	in	O
557	op	O
557	##io	O
557	##id	O
557	-	O
557	tolerant	O
557	cancer	O
557	patients	O
557	.	O
557	[SEP]	O
558	[CLS]	O
558	an	O
558	l	O
558	##c	O
558	–	O
558	es	O
558	##i	O
558	-	O
558	m	O
558	##s	O
558	/	O
558	m	O
558	##s	O
558	ass	O
558	##ay	O
558	for	O
558	δ	O
558	-	O
558	v	O
558	##ini	O
558	##fer	O
558	##in	O
558	(	O
558	r	O
558	##s	O
558	-	O
558	1	O
558	)	O
558	and	O
558	its	O
558	meta	O
558	##bol	O
558	##ites	O
558	in	O
558	rat	O
558	plasma	O
558	,	O
558	urine	O
558	and	O
558	f	O
558	##ec	O
558	##es	O
558	was	O
558	applied	O
558	in	O
558	p	O
558	##har	O
558	##ma	O
558	##co	O
558	##kin	O
558	##etics	O
558	of	O
558	r	O
558	##s	O
558	-	O
558	1	O
558	in	O
558	rats	O
558	.	O
558	[SEP]	O
559	[CLS]	O
559	[	O
559	t	O
559	##rud	O
559	##ell	O
559	medical	O
559	international	O
559	,	O
559	lo	O
559	##ndon	O
559	,	O
559	on	O
559	##tar	O
559	##io	O
559	,	O
559	can	O
559	##ada	O
559	]	O
559	)	O
559	.	O
559	[SEP]	O
560	[CLS]	O
560	in	O
560	this	O
560	paper	O
560	,	O
560	the	O
560	disposition	O
560	of	O
560	t	O
560	##re	O
560	##o	O
560	and	O
560	its	O
560	active	O
560	mon	O
560	##oe	O
560	##pox	O
560	##ide	O
560	(	O
560	s	O
560	,	O
560	s	O
560	-	O
560	e	O
560	##b	O
560	##d	O
560	##m	O
560	)	O
560	in	O
560	a	O
560	bone	O
560	ma	O
560	##rrow	O
560	,	O
560	liver	O
560	,	O
560	lungs	O
560	,	O
560	brain	O
560	,	O
560	and	O
560	q	O
560	##uad	O
560	##rice	O
560	##ps	O
560	f	O
560	##em	O
560	##oris	O
560	was	O
560	studied	O
560	in	O
560	an	O
560	animal	O
560	model	O
560	.	O
560	[SEP]	O
561	[CLS]	O
561	electron	O
561	micro	O
561	##sco	O
561	##py	O
561	revealed	O
561	sin	O
561	##us	O
561	##oid	O
561	destruction	O
561	and	O
561	changes	O
561	in	O
561	both	O
561	the	O
561	plasma	O
561	membrane	O
561	and	O
561	par	O
561	##en	O
561	##chy	O
561	##mal	O
561	cell	O
561	mit	O
561	##och	O
561	##ond	O
561	##ria	O
561	in	O
561	groups	O
561	a	O
561	and	O
561	b	O
561	,	O
561	while	O
561	in	O
561	group	O
561	c	O
561	these	O
561	structures	O
561	were	O
561	well	O
561	preserved	O
561	.	O
561	[SEP]	O
562	[CLS]	O
562	the	O
562	median	O
562	start	O
562	time	O
562	of	O
562	in	O
562	##tra	O
562	##ven	O
562	##ous	O
562	glucose	O
562	in	O
562	##fusion	O
562	post	O
562	‐	O
562	dos	O
562	##ing	O
562	to	O
562	treat	O
562	h	O
562	##y	O
562	##po	O
562	##gly	O
562	##ca	O
562	##emia	O
562	ranged	O
562	from	O
562	2	O
562	.	O
562	4	O
562	to	O
562	3	O
562	.	O
562	8	O
562	hours	O
562	for	O
562	das	O
562	##ig	O
562	##lu	O
562	##ca	O
562	##gon	O
562	versus	O
562	2	O
562	.	O
562	2	O
562	to	O
562	3	O
562	.	O
562	2	O
562	hours	O
562	for	O
562	commercial	O
562	g	O
562	##lu	O
562	##ca	O
562	##gon	O
562	(	O
562	post	O
562	ho	O
562	##c	O
562	analysis	O
562	;	O
562	table	O
562	s	O
562	##5	O
562	,	O
562	supporting	O
562	information	O
562	)	O
562	.	O
562	[SEP]	O
563	[CLS]	O
563	mean	O
563	cm	B-PK
563	##ax	I-PK
563	ranged	O
563	from	O
563	45	O
563	##4	O
563	-	O
563	10	O
563	,	O
563	333	O
563	ng	O
563	/	O
563	m	O
563	##l	O
563	and	O
563	mean	O
563	au	B-PK
563	##c	I-PK
563	(	I-PK
563	0	I-PK
563	-	I-PK
563	in	I-PK
563	##f	I-PK
563	)	I-PK
563	from	O
563	1	O
563	,	O
563	69	O
563	##0	O
563	-	O
563	43	O
563	,	O
563	37	O
563	##1	O
563	ng	O
563	x	O
563	h	O
563	/	O
563	m	O
563	##l	O
563	after	O
563	the	O
563	15	O
563	and	O
563	300	O
563	mg	O
563	single	O
563	doses	O
563	,	O
563	respectively	O
563	.	O
563	[SEP]	O
564	[CLS]	O
564	population	O
564	p	O
564	##k	O
564	and	O
564	p	O
564	##k	O
564	/	O
564	p	O
564	##d	O
564	models	O
564	were	O
564	developed	O
564	using	O
564	a	O
564	non	O
564	##linear	O
564	mixed	O
564	-	O
564	effects	O
564	approach	O
564	.	O
564	[SEP]	O
565	[CLS]	O
565	at	O
565	first	O
565	sight	O
565	,	O
565	the	O
565	proportion	O
565	of	O
565	patients	O
565	with	O
565	a	O
565	##es	O
565	occurring	O
565	under	O
565	c	O
565	##ic	O
565	##los	O
565	##por	O
565	##in	O
565	pro	O
565	appeared	O
565	higher	O
565	than	O
565	the	O
565	proportion	O
565	of	O
565	patients	O
565	with	O
565	a	O
565	##es	O
565	occurring	O
565	under	O
565	sand	O
565	##im	O
565	##mu	O
565	##n	O
565	##®	O
565	op	O
565	##tor	O
565	##al	O
565	.	O
565	[SEP]	O
566	[CLS]	O
566	three	O
566	other	O
566	patients	O
566	were	O
566	treated	O
566	with	O
566	3	O
566	mg	O
566	/	O
566	m	O
566	##2	O
566	v	O
566	##in	O
566	##blast	O
566	##ine	O
566	as	O
566	a	O
566	b	O
566	##ol	O
566	##us	O
566	injection	O
566	on	O
566	day	O
566	1	O
566	,	O
566	day	O
566	3	O
566	and	O
566	day	O
566	8	O
566	.	O
566	[SEP]	O
567	[CLS]	O
567	the	O
567	contents	O
567	were	O
567	stirred	O
567	and	O
567	cooled	O
567	in	O
567	an	O
567	ice	O
567	bath	O
567	(	O
567	30	O
567	minutes	O
567	)	O
567	.	O
567	[SEP]	O
568	[CLS]	O
568	the	O
568	disappearance	O
568	of	O
568	the	O
568	sharp	O
568	melting	O
568	end	O
568	##oth	O
568	##er	O
568	##mal	O
568	peak	O
568	of	O
568	ed	O
568	##r	O
568	in	O
568	the	O
568	the	O
568	##rm	O
568	##ogram	O
568	of	O
568	ne	O
568	##f	O
568	revealed	O
568	the	O
568	complete	O
568	alter	O
568	##ation	O
568	of	O
568	the	O
568	solid	O
568	state	O
568	of	O
568	ed	O
568	##r	O
568	from	O
568	crystal	O
568	##line	O
568	to	O
568	am	O
568	##or	O
568	##ph	O
568	##ous	O
568	.	O
568	[SEP]	O
569	[CLS]	O
569	day	O
569	1	O
569	pre	O
569	-	O
569	dose	O
569	procedures	O
569	and	O
569	assessments	O
569	included	O
569	vital	O
569	signs	O
569	and	O
569	collection	O
569	of	O
569	samples	O
569	for	O
569	base	O
569	##line	O
569	assessment	O
569	of	O
569	hem	O
569	##ato	O
569	##logy	O
569	,	O
569	chemistry	O
569	,	O
569	u	O
569	##rina	O
569	##lysis	O
569	,	O
569	and	O
569	ad	O
569	##as	O
569	.	O
569	[SEP]	O
570	[CLS]	O
570	the	O
570	analytical	O
570	method	O
570	developed	O
570	with	O
570	hp	O
570	##l	O
570	##c	O
570	was	O
570	successfully	O
570	valid	O
570	##ated	O
570	(	O
570	data	O
570	not	O
570	shown	O
570	)	O
570	.	O
570	[SEP]	O
571	[CLS]	O
571	the	O
571	range	O
571	of	O
571	re	O
571	##nal	O
571	function	O
571	was	O
571	relatively	O
571	wide	O
571	,	O
571	with	O
571	e	O
571	##g	O
571	##f	O
571	##r	O
571	values	O
571	as	O
571	low	O
571	as	O
571	4	O
571	.	O
571	1	O
571	m	O
571	##l	O
571	min	O
571	##−	O
571	##1	O
571	1	O
571	.	O
571	73	O
571	m	O
571	##−	O
571	##2	O
571	and	O
571	a	O
571	mean	O
571	of	O
571	88	O
571	.	O
571	7	O
571	(	O
571	31	O
571	.	O
571	4	O
571	)	O
571	m	O
571	##l	O
571	min	O
571	##−	O
571	##1	O
571	1	O
571	.	O
571	73	O
571	m	O
571	##−	O
571	##2	O
571	.	O
571	[SEP]	O
572	[CLS]	O
572	this	O
572	retrospective	O
572	analysis	O
572	was	O
572	conducted	O
572	to	O
572	identify	O
572	an	O
572	appropriate	O
572	s	O
572	##cal	O
572	##ing	O
572	method	O
572	to	O
572	predict	O
572	human	O
572	p	O
572	##k	O
572	for	O
572	ad	O
572	##cs	O
572	from	O
572	animal	O
572	p	O
572	##k	O
572	data	O
572	in	O
572	the	O
572	linear	O
572	range	O
572	.	O
572	[SEP]	O
573	[CLS]	O
573	m	O
573	##ln	O
573	##27	O
573	##0	O
573	##4	O
573	p	O
573	##har	O
573	##ma	O
573	##co	O
573	##kin	O
573	##etics	O
573	were	O
573	dose	O
573	-	O
573	linear	O
573	.	O
573	[SEP]	O
574	[CLS]	O
574	then	O
574	,	O
574	1	O
574	##e	O
574	##6	O
574	k	O
574	##b	O
574	cells	O
574	were	O
574	in	O
574	##cu	O
574	##bate	O
574	##d	O
574	with	O
574	0	O
574	.	O
574	1	O
574	,	O
574	1	O
574	.	O
574	0	O
574	,	O
574	2	O
574	.	O
574	5	O
574	,	O
574	5	O
574	.	O
574	0	O
574	,	O
574	or	O
574	10	O
574	.	O
574	0	O
574	μ	O
574	##m	O
574	of	O
574	e	O
574	##c	O
574	##17	O
574	and	O
574	o	O
574	##tl	O
574	##38	O
574	.	O
574	[SEP]	O
575	[CLS]	O
575	the	O
575	cartridge	O
575	was	O
575	se	O
575	##quential	O
575	##ly	O
575	washed	O
575	with	O
575	1	O
575	.	O
575	0	O
575	m	O
575	##l	O
575	up	O
575	##w	O
575	and	O
575	1	O
575	m	O
575	##l	O
575	of	O
575	5	O
575	%	O
575	a	O
575	##que	O
575	##ous	O
575	met	O
575	##han	O
575	##ol	O
575	.	O
575	[SEP]	O
576	[CLS]	O
576	seven	O
576	children	O
576	,	O
576	aged	O
576	3	O
576	-	O
576	16	O
576	years	O
576	,	O
576	in	O
576	second	O
576	or	O
576	subsequent	O
576	men	O
576	##inge	O
576	##al	O
576	re	O
576	##lap	O
576	##se	O
576	of	O
576	acute	O
576	l	O
576	##ymph	O
576	##ob	O
576	##lastic	O
576	le	O
576	##uka	O
576	##emia	O
576	(	O
576	all	O
576	)	O
576	,	O
576	have	O
576	been	O
576	treated	O
576	.	O
576	[SEP]	O
577	[CLS]	O
577	blood	O
577	samples	O
577	were	O
577	collected	O
577	over	O
577	15	O
577	days	O
577	post	O
577	-	O
577	treatment	O
577	and	O
577	drug	O
577	plasma	O
577	concentrations	O
577	measured	O
577	by	O
577	hp	O
577	##l	O
577	##c	O
577	.	O
577	[SEP]	O
578	[CLS]	O
578	increased	O
578	he	O
578	##pa	O
578	##tic	O
578	ni	O
578	##cot	O
578	##ine	O
578	elimination	O
578	after	O
578	p	O
578	##hen	O
578	##ob	O
578	##ar	O
578	##bit	O
578	##al	O
578	induction	O
578	in	O
578	the	O
578	conscious	O
578	rat	O
578	.	O
578	[SEP]	O
579	[CLS]	O
579	the	O
579	purpose	O
579	of	O
579	the	O
579	present	O
579	study	O
579	was	O
579	to	O
579	q	O
579	##uant	O
579	##ify	O
579	the	O
579	card	O
579	##iovascular	O
579	effects	O
579	of	O
579	the	O
579	2	O
579	'	O
579	-	O
579	,	O
579	3	O
579	'	O
579	-	O
579	,	O
579	5	O
579	'	O
579	-	O
579	de	O
579	##ox	O
579	##yr	O
579	##ib	O
579	##ose	O
579	analogue	O
579	##s	O
579	of	O
579	the	O
579	selective	O
579	ad	O
579	##eno	O
579	##sin	O
579	##e	O
579	a	O
579	##1	O
579	receptor	O
579	ago	O
579	##nist	O
579	,	O
579	n	O
579	##6	O
579	-	O
579	c	O
579	##y	O
579	##c	O
579	##lop	O
579	##ent	O
579	##yla	O
579	##den	O
579	##os	O
579	##ine	O
579	(	O
579	c	O
579	##pa	O
579	)	O
579	in	O
579	v	O
579	##ivo	O
579	.	O
579	[SEP]	O
580	[CLS]	O
580	hence	O
580	,	O
580	individual	O
580	##ised	O
580	dos	O
580	##ing	O
580	of	O
580	c	O
580	##is	O
580	##p	O
580	##lat	O
580	##in	O
580	using	O
580	au	B-PK
580	##c	I-PK
580	or	O
580	d	O
580	##na	O
580	-	O
580	add	O
580	##uc	O
580	##ts	O
580	should	O
580	lead	O
580	to	O
580	increased	O
580	response	O
580	rates	O
580	.	O
580	[SEP]	O
581	[CLS]	O
581	all	O
581	subjects	O
581	in	O
581	co	O
581	##hor	O
581	##ts	O
581	b	O
581	and	O
581	c	O
581	were	O
581	analyzed	O
581	for	O
581	p	O
581	##k	O
581	and	O
581	p	O
581	##d	O
581	parameters	O
581	.	O
581	[SEP]	O
582	[CLS]	O
582	the	O
582	volume	B-PK
582	of	I-PK
582	distribution	I-PK
582	decreased	O
582	with	O
582	increasing	O
582	doses	O
582	,	O
582	averaging	O
582	76	O
582	.	O
582	8	O
582	+	O
582	-	O
582	38	O
582	.	O
582	06	O
582	m	O
582	##l	O
582	/	O
582	kg	O
582	for	O
582	the	O
582	15	O
582	mg	O
582	/	O
582	kg	O
582	dose	O
582	and	O
582	falling	O
582	to	O
582	55	O
582	.	O
582	2	O
582	+	O
582	-	O
582	17	O
582	.	O
582	4	O
582	m	O
582	##l	O
582	/	O
582	kg	O
582	for	O
582	the	O
582	30	O
582	mg	O
582	/	O
582	kg	O
582	dose	O
582	.	O
582	[SEP]	O
583	[CLS]	O
583	the	O
583	au	B-PK
583	##c	I-PK
583	from	I-PK
583	the	I-PK
583	beginning	I-PK
583	to	I-PK
583	the	I-PK
583	last	I-PK
583	values	I-PK
583	(	I-PK
583	au	I-PK
583	##c	I-PK
583	##last	I-PK
583	)	I-PK
583	was	O
583	determined	O
583	using	O
583	the	O
583	linear	O
583	trap	O
583	##ez	O
583	##oid	O
583	##al	O
583	method	O
583	as	O
583	was	O
583	the	O
583	au	B-PK
583	##c	I-PK
583	##0	I-PK
583	–	I-PK
583	24	I-PK
583	h	I-PK
583	,	O
583	which	O
583	indicated	O
583	the	O
583	au	B-PK
583	##c	I-PK
583	from	I-PK
583	the	I-PK
583	beginning	I-PK
583	to	I-PK
583	24	I-PK
583	hours	I-PK
583	.	O
583	[SEP]	O
584	[CLS]	O
584	it	O
584	was	O
584	designed	O
584	as	O
584	a	O
584	window	O
584	study	O
584	in	O
584	order	O
584	to	O
584	test	O
584	o	O
584	##si	O
584	-	O
584	79	O
584	##0	O
584	##4	O
584	##l	O
584	in	O
584	first	O
584	-	O
584	line	O
584	patients	O
584	without	O
584	exposure	O
584	to	O
584	prior	O
584	flu	O
584	##oro	O
584	##py	O
584	##rim	O
584	##id	O
584	##ine	O
584	therapy	O
584	,	O
584	and	O
584	in	O
584	the	O
584	absence	O
584	of	O
584	clinical	O
584	benefit	O
584	,	O
584	more	O
584	commonly	O
584	used	O
584	combination	O
584	regime	O
584	##ns	O
584	could	O
584	be	O
584	introduced	O
584	without	O
584	negatively	O
584	impact	O
584	##ing	O
584	patient	O
584	care	O
584	.	O
584	[SEP]	O
585	[CLS]	O
585	the	O
585	ve	O
585	##si	O
585	##cle	O
585	suspension	O
585	was	O
585	pipe	O
585	##tte	O
585	into	O
585	a	O
585	bag	O
585	made	O
585	up	O
585	of	O
585	tub	O
585	##ing	O
585	and	O
585	sealed	O
585	followed	O
585	by	O
585	placing	O
585	the	O
585	dial	O
585	##ys	O
585	##is	O
585	bag	O
585	into	O
585	a	O
585	be	O
585	##aker	O
585	containing	O
585	200	O
585	m	O
585	##l	O
585	of	O
585	p	O
585	##bs	O
585	p	O
585	##h	O
585	7	O
585	.	O
585	4	O
585	.	O
585	[SEP]	O
586	[CLS]	O
586	i	O
586	##v	O
586	i	O
586	##rino	O
586	##teca	O
586	##n	O
586	(	O
586	15	O
586	or	O
586	20	O
586	mg	O
586	/	O
586	m	O
586	(	O
586	2	O
586	)	O
586	)	O
586	was	O
586	given	O
586	daily	O
586	for	O
586	5	O
586	days	O
586	of	O
586	2	O
586	consecutive	O
586	weeks	O
586	.	O
586	[SEP]	O
587	[CLS]	O
587	do	O
587	##pa	O
587	##mine	O
587	##rg	O
587	##ic	O
587	mechanisms	O
587	are	O
587	thought	O
587	to	O
587	play	O
587	a	O
587	central	O
587	role	O
587	in	O
587	the	O
587	re	O
587	##in	O
587	##forcing	O
587	effects	O
587	of	O
587	cocaine	O
587	.	O
587	[SEP]	O
588	[CLS]	O
588	blood	O
588	and	O
588	urine	O
588	samples	O
588	for	O
588	clinical	O
588	path	O
588	##ology	O
588	evaluation	O
588	##s	O
588	were	O
588	collected	O
588	from	O
588	all	O
588	animals	O
588	prior	O
588	to	O
588	the	O
588	terminal	O
588	ne	O
588	##c	O
588	##rops	O
588	##y	O
588	.	O
588	[SEP]	O
589	[CLS]	O
589	narrow	O
589	co	O
589	##lli	O
589	##mation	O
589	(	O
589	1	O
589	.	O
589	0	O
589	mm	O
589	)	O
589	was	O
589	used	O
589	as	O
589	before	O
589	,	O
589	with	O
589	a	O
589	1	O
589	.	O
589	0	O
589	mm	O
589	slice	O
589	width	O
589	and	O
589	a	O
589	medium	O
589	smooth	O
589	reconstruction	O
589	kernel	O
589	(	O
589	b	O
589	##30	O
589	##f	O
589	)	O
589	,	O
589	with	O
589	a	O
589	reconstruction	O
589	in	O
589	##cre	O
589	##ment	O
589	of	O
589	1	O
589	.	O
589	0	O
589	mm	O
589	.	O
589	[SEP]	O
590	[CLS]	O
590	the	O
590	area	B-PK
590	under	I-PK
590	the	I-PK
590	k	I-PK
590	##eto	I-PK
590	##p	I-PK
590	##ro	I-PK
590	##fen	I-PK
590	content	I-PK
590	-	I-PK
590	time	I-PK
590	curve	I-PK
590	(	I-PK
590	au	I-PK
590	##c	I-PK
590	##0	I-PK
590	-	I-PK
590	6	I-PK
590	h	I-PK
590	)	I-PK
590	for	O
590	the	O
590	ratio	O
590	photo	O
590	-	O
590	stab	O
590	##ilis	O
590	##ed	O
590	gel	O
590	/	O
590	transparent	O
590	gel	O
590	was	O
590	73	O
590	%	O
590	with	O
590	a	O
590	90	O
590	%	O
590	confidence	O
590	interval	O
590	(	O
590	c	O
590	##i	O
590	)	O
590	65	O
590	-	O
590	83	O
590	.	O
590	[SEP]	O
591	[CLS]	O
591	g	O
591	-	O
591	c	O
591	##s	O
591	##f	O
591	(	O
591	5	O
591	micro	O
591	##gram	O
591	##s	O
591	/	O
591	kg	O
591	/	O
591	day	O
591	)	O
591	was	O
591	administered	O
591	sub	O
591	##cut	O
591	##aneous	O
591	##ly	O
591	to	O
591	all	O
591	patients	O
591	from	O
591	day	O
591	3	O
591	until	O
591	the	O
591	w	O
591	##b	O
591	##c	O
591	>	O
591	or	O
591	=	O
591	1000	O
591	##0	O
591	/	O
591	micro	O
591	##lite	O
591	##rs	O
591	.	O
591	[SEP]	O
592	[CLS]	O
592	the	O
592	patient	O
592	died	O
592	suddenly	O
592	of	O
592	acute	O
592	heart	O
592	failure	O
592	before	O
592	the	O
592	operation	O
592	.	O
592	[SEP]	O
593	[CLS]	O
593	twenty	O
593	four	O
593	p	O
593	##har	O
593	##ma	O
593	##co	O
593	##kin	O
593	##etics	O
593	-	O
593	related	O
593	molecular	O
593	des	O
593	##cript	O
593	##ors	O
593	available	O
593	in	O
593	q	O
593	##ik	O
593	##p	O
593	##rop	O
593	[	O
593	21	O
593	]	O
593	,	O
593	which	O
593	character	O
593	##ize	O
593	a	O
593	wide	O
593	spectrum	O
593	of	O
593	molecular	O
593	properties	O
593	as	O
593	described	O
593	in	O
593	section	O
593	3	O
593	.	O
593	9	O
593	,	O
593	e	O
593	.	O
593	g	O
593	.	O
593	,	O
593	such	O
593	as	O
593	molecular	O
593	mass	O
593	,	O
593	total	O
593	solvent	O
593	-	O
593	accessible	O
593	molecular	O
593	surface	O
593	,	O
593	h	O
593	##ydro	O
593	##phobic	O
593	portion	O
593	of	O
593	the	O
593	solvent	O
593	-	O
593	accessible	O
593	molecular	O
593	surface	O
593	,	O
593	total	O
593	volume	O
593	of	O
593	molecule	O
593	enclosed	O
593	by	O
593	solvent	O
593	-	O
593	accessible	O
593	molecular	O
593	surface	O
593	,	O
593	number	O
593	of	O
593	non	O
593	-	O
593	trivial	O
593	non	O
593	-	O
593	hind	O
593	##ered	O
593	rot	O
593	##ata	O
593	##ble	O
593	bonds	O
593	,	O
593	estimated	O
593	number	O
593	of	O
593	hydrogen	O
593	bonds	O
593	that	O
593	would	O
593	be	O
593	donated	O
593	by	O
593	the	O
593	so	O
593	##lut	O
593	##e	O
593	to	O
593	water	O
593	molecules	O
593	in	O
593	an	O
593	a	O
593	##que	O
593	##ous	O
593	solution	O
593	,	O
593	estimated	O
593	number	O
593	of	O
593	hydrogen	O
593	bonds	O
593	that	O
593	would	O
593	be	O
593	accepted	O
593	by	O
593	the	O
593	so	O
593	##lut	O
593	##e	O
593	from	O
593	water	O
593	molecules	O
593	,	O
593	log	O
593	##ari	O
593	##th	O
593	##m	O
593	of	O
593	partition	O
593	##ing	O
593	coefficient	O
593	between	O
593	n	O
593	-	O
593	o	O
593	##ct	O
593	##ano	O
593	##l	O
593	and	O
593	water	O
593	phases	O
593	,	O
593	log	O
593	##ari	O
593	##th	O
593	##m	O
593	of	O
593	predicted	O
593	a	O
593	##que	O
593	##ous	O
593	so	O
593	##lub	O
593	##ility	O
593	,	O
593	log	O
593	##ari	O
593	##th	O
593	##m	O
593	of	O
593	predicted	O
593	binding	O
593	constant	O
593	to	O
593	human	O
593	serum	O
593	album	O
593	##in	O
593	,	O
593	log	O
593	##ari	O
593	##th	O
593	##m	O
593	of	O
593	predicted	O
593	brain	O
593	/	O
593	blood	O
593	partition	O
593	coefficient	O
593	,	O
593	apparent	O
593	ca	O
593	##co	O
593	-	O
593	2	O
593	cell	O
593	membrane	O
593	per	B-PK
593	##me	I-PK
593	##ability	I-PK
593	in	O
593	b	O
593	##oe	O
593	##hr	O
593	##inger	O
593	–	O
593	ing	O
593	##el	O
593	##heim	O
593	scale	O
593	,	O
593	number	O
593	of	O
593	likely	O
593	metabolic	O
593	reactions	O
593	,	O
593	percentage	O
593	of	O
593	human	O
593	oral	O
593	absorption	O
593	in	O
593	gas	O
593	##tro	O
593	##int	O
593	##est	O
593	##inal	O
593	tract	O
593	,	O
593	etc	O
593	.	O
593	[SEP]	O
594	[CLS]	O
594	however	O
594	,	O
594	due	O
594	to	O
594	its	O
594	short	O
594	half	B-PK
594	-	I-PK
594	life	I-PK
594	of	O
594	1	O
594	-	O
594	2	O
594	h	O
594	,	O
594	a	O
594	multiple	O
594	dose	O
594	regime	O
594	##n	O
594	is	O
594	required	O
594	for	O
594	oral	O
594	administration	O
594	.	O
594	[SEP]	O
595	[CLS]	O
595	as	O
595	shown	O
595	in	O
595	figure	O
595	s	O
595	##4	O
595	,	O
595	the	O
595	m	O
595	##or	O
595	##phological	O
595	properties	O
595	of	O
595	l	O
595	##c	O
595	##n	O
595	##p	O
595	-	O
595	#	O
595	8	O
595	and	O
595	#	O
595	11	O
595	in	O
595	the	O
595	acidic	O
595	condition	O
595	were	O
595	comparable	O
595	with	O
595	those	O
595	of	O
595	l	O
595	##c	O
595	##n	O
595	##p	O
595	-	O
595	#	O
595	8	O
595	and	O
595	#	O
595	11	O
595	in	O
595	the	O
595	neutral	O
595	condition	O
595	.	O
595	[SEP]	O
596	[CLS]	O
596	the	O
596	compound	O
596	was	O
596	eliminated	O
596	mainly	O
596	with	O
596	the	O
596	bi	O
596	##le	O
596	.	O
596	[SEP]	O
597	[CLS]	O
597	on	O
597	the	O
597	all	O
597	##o	O
597	-	O
597	h	O
597	##s	O
597	##ct	O
597	day	O
597	,	O
597	v	O
597	##p	O
597	-	O
597	16	O
597	was	O
597	detect	O
597	##able	O
597	in	O
597	the	O
597	plasma	O
597	samples	O
597	of	O
597	19	O
597	children	O
597	(	O
597	mean	O
597	±	O
597	s	O
597	##d	O
597	:	O
597	0	O
597	.	O
597	4	O
597	±	O
597	0	O
597	.	O
597	3	O
597	μ	O
597	##g	O
597	/	O
597	m	O
597	##l	O
597	)	O
597	.	O
597	[SEP]	O
598	[CLS]	O
598	both	O
598	trace	O
598	##rs	O
598	were	O
598	used	O
598	for	O
598	im	O
598	##mu	O
598	##no	O
598	##pet	O
598	imaging	O
598	of	O
598	the	O
598	b	O
598	cell	O
598	compartment	O
598	in	O
598	human	O
598	c	O
598	##d	O
598	##20	O
598	trans	O
598	##genic	O
598	mice	O
598	(	O
598	h	O
598	##c	O
598	##d	O
598	##20	O
598	##t	O
598	##m	O
598	)	O
598	.	O
598	[SEP]	O
599	[CLS]	O
599	em	O
599	images	O
599	were	O
599	acquired	O
599	at	O
599	27	O
599	,	O
599	500	O
599	##×	O
599	ma	O
599	##gni	O
599	##fication	O
599	(	O
599	p	O
599	##ixel	O
599	size	O
599	0	O
599	,	O
599	60	O
599	##2	O
599	nm	O
599	)	O
599	at	O
599	−	O
599	##12	O
599	,	O
599	−	O
599	##18	O
599	μ	O
599	##m	O
599	def	O
599	##oc	O
599	##us	O
599	.	O
599	[SEP]	O
600	[CLS]	O
600	in	O
600	##fluenza	O
600	is	O
600	a	O
600	respiratory	O
600	disease	O
600	that	O
600	causes	O
600	annual	O
600	epidemic	O
600	##s	O
600	.	O
600	[SEP]	O
601	[CLS]	O
601	patients	O
601	in	O
601	dose	O
601	level	O
601	(	O
601	d	O
601	##l	O
601	)	O
601	1	O
601	received	O
601	a	O
601	##xi	O
601	##tin	O
601	##ib	O
601	5	O
601	mg	O
601	twice	O
601	a	O
601	day	O
601	(	O
601	days	O
601	1	O
601	to	O
601	21	O
601	)	O
601	with	O
601	c	O
601	##is	O
601	##p	O
601	##lat	O
601	##in	O
601	80	O
601	mg	O
601	/	O
601	m	O
601	##2	O
601	(	O
601	day	O
601	1	O
601	)	O
601	and	O
601	cape	O
601	##ci	O
601	##ta	O
601	##bine	O
601	1	O
601	,	O
601	000	O
601	mg	O
601	/	O
601	m	O
601	##2	O
601	twice	O
601	a	O
601	day	O
601	(	O
601	days	O
601	1	O
601	to	O
601	14	O
601	)	O
601	in	O
601	21	O
601	-	O
601	day	O
601	cycles	O
601	.	O
601	[SEP]	O
602	[CLS]	O
602	the	O
602	‘	O
602	a	O
602	##ffy	O
602	##met	O
602	##rix	O
602	d	O
602	##met	O
602	-	O
602	plus	O
602	’	O
602	g	O
602	##eno	O
602	##ty	O
602	##ping	O
602	array	O
602	[	O
602	13	O
602	]	O
602	was	O
602	used	O
602	to	O
602	g	O
602	##eno	O
602	##type	O
602	common	O
602	genetic	O
602	variants	O
602	in	O
602	c	O
602	##y	O
602	##p	O
602	##3	O
602	##a	O
602	##4	O
602	/	O
602	3	O
602	##a	O
602	##5	O
602	,	O
602	c	O
602	##y	O
602	##p	O
602	##2	O
602	##c	O
602	##8	O
602	,	O
602	c	O
602	##y	O
602	##p	O
602	##2	O
602	##c	O
602	##19	O
602	,	O
602	s	O
602	##l	O
602	##co	O
602	##1	O
602	##b	O
602	##1	O
602	(	O
602	o	O
602	##at	O
602	##p	O
602	##1	O
602	##b	O
602	##1	O
602	)	O
602	and	O
602	a	O
602	##b	O
602	##c	O
602	##g	O
602	##2	O
602	(	O
602	b	O
602	##c	O
602	##rp	O
602	)	O
602	.	O
602	[SEP]	O
603	[CLS]	O
603	in	O
603	conclusion	O
603	,	O
603	y	O
603	##j	O
603	##c	O
603	-	O
603	105	O
603	##9	O
603	##2	O
603	showed	O
603	dose	O
603	-	O
603	dependent	O
603	p	O
603	##har	O
603	##ma	O
603	##co	O
603	##kin	O
603	##etics	O
603	and	O
603	low	O
603	f	B-PK
603	value	O
603	due	O
603	to	O
603	slower	O
603	elimination	O
603	and	O
603	incomplete	O
603	absorption	O
603	.	O
603	[SEP]	O
604	[CLS]	O
604	overall	O
604	,	O
604	2	O
604	%	O
604	of	O
604	patients	O
604	were	O
604	co	O
604	-	O
604	infected	O
604	with	O
604	he	O
604	##pa	O
604	##titis	O
604	b	O
604	and	O
604	3	O
604	%	O
604	with	O
604	he	O
604	##pa	O
604	##titis	O
604	c	O
604	virus	O
604	.	O
604	[SEP]	O
605	[CLS]	O
605	several	O
605	soluble	O
605	analogue	O
605	##s	O
605	with	O
605	similar	O
605	anti	O
605	##tum	O
605	##our	O
605	activity	O
605	are	O
605	currently	O
605	under	O
605	investigation	O
605	.	O
605	[SEP]	O
606	[CLS]	O
606	compared	O
606	with	O
606	healthy	O
606	matched	O
606	,	O
606	patients	O
606	with	O
606	moderate	O
606	-	O
606	severe	O
606	he	O
606	##pa	O
606	##tic	O
606	imp	O
606	##air	O
606	##ment	O
606	exhibited	O
606	small	O
606	increase	O
606	(	O
606	29	O
606	%	O
606	)	O
606	in	O
606	top	O
606	##ira	O
606	##mate	O
606	peak	B-PK
606	plasma	I-PK
606	concentrations	I-PK
606	and	O
606	au	B-PK
606	##c	I-PK
606	##0	I-PK
606	-	I-PK
606	∞	I-PK
606	values	O
606	,	O
606	consistent	O
606	with	O
606	lower	O
606	c	B-PK
606	##l	I-PK
606	/	I-PK
606	f	I-PK
606	(	O
606	26	O
606	%	O
606	)	O
606	.	O
606	[SEP]	O
607	[CLS]	O
607	mice	O
607	ex	O
607	##cre	O
607	##te	O
607	85	O
607	to	O
607	100	O
607	%	O
607	of	O
607	the	O
607	dose	O
607	in	O
607	24	O
607	h	O
607	.	O
607	rats	O
607	ex	O
607	##cre	O
607	##te	O
607	only	O
607	59	O
607	to	O
607	81	O
607	%	O
607	of	O
607	the	O
607	administered	O
607	radio	B-PK
607	##act	I-PK
607	##ivity	I-PK
607	in	O
607	the	O
607	same	O
607	time	O
607	,	O
607	primarily	O
607	in	O
607	urine	O
607	and	O
607	f	O
607	##ec	O
607	##es	O
607	,	O
607	with	O
607	a	O
607	trace	O
607	in	O
607	re	O
607	##sp	O
607	##ired	O
607	air	O
607	.	O
607	[SEP]	O
608	[CLS]	O
608	compared	O
608	to	O
608	the	O
608	a	O
608	##que	O
608	##ous	O
608	vehicle	O
608	,	O
608	the	O
608	extent	O
608	of	O
608	absorption	O
608	of	O
608	g	O
608	##reis	O
608	##eo	O
608	##ful	O
608	##vin	O
608	was	O
608	decreased	O
608	by	O
608	he	O
608	##xa	O
608	##de	O
608	##cane	O
608	,	O
608	o	O
608	##ley	O
608	##l	O
608	alcohol	O
608	,	O
608	and	O
608	trio	O
608	##lein	O
608	,	O
608	increased	O
608	by	O
608	p	O
608	##oly	O
608	##sor	O
608	##bate	O
608	80	O
608	,	O
608	and	O
608	not	O
608	affected	O
608	by	O
608	trio	O
608	##ct	O
608	##ano	O
608	##in	O
608	.	O
608	[SEP]	O
609	[CLS]	O
609	thus	O
609	,	O
609	including	O
609	disease	O
609	path	O
609	##ology	O
609	in	O
609	the	O
609	model	O
609	produced	O
609	better	O
609	predictions	O
609	of	O
609	p	O
609	##k	O
609	/	O
609	p	O
609	##d	O
609	relationships	O
609	for	O
609	both	O
609	r	O
609	##if	O
609	##am	O
609	##y	O
609	##cin	O
609	##s	O
609	.	O
609	[SEP]	O
610	[CLS]	O
610	the	O
610	maximum	B-PK
610	observed	I-PK
610	plasma	I-PK
610	concentration	I-PK
610	,	I-PK
610	cm	I-PK
610	##ax	I-PK
610	,	O
610	and	O
610	area	B-PK
610	under	I-PK
610	the	I-PK
610	plasma	I-PK
610	concentration	I-PK
610	-	I-PK
610	time	I-PK
610	curve	I-PK
610	from	I-PK
610	time	I-PK
610	zero	I-PK
610	to	I-PK
610	the	I-PK
610	last	I-PK
610	me	I-PK
610	##as	I-PK
610	##urable	I-PK
610	sampling	I-PK
610	time	I-PK
610	point	I-PK
610	(	I-PK
610	au	I-PK
610	##c	I-PK
610	##0	I-PK
610	–	I-PK
610	t	I-PK
610	)	I-PK
610	were	O
610	35	O
610	%	O
610	and	O
610	102	O
610	%	O
610	higher	O
610	than	O
610	those	O
610	of	O
610	en	O
610	##t	O
610	when	O
610	oral	O
610	##ly	O
610	administered	O
610	to	O
610	rats	O
610	(	O
610	10	O
610	mg	O
610	/	O
610	kg	O
610	)	O
610	.	O
610	[SEP]	O
611	[CLS]	O
611	wash	O
611	with	O
611	3	O
611	##x	O
611	##5	O
611	minutes	O
611	t	O
611	##bs	O
611	##t	O
611	,	O
611	then	O
611	secondary	O
611	anti	O
611	##body	O
611	in	O
611	##cu	O
611	##bation	O
611	for	O
611	2	O
611	hours	O
611	at	O
611	r	O
611	##t	O
611	with	O
611	shaking	O
611	(	O
611	goat	O
611	-	O
611	anti	O
611	-	O
611	rabbit	O
611	-	O
611	h	O
611	##rp	O
611	ca	O
611	##yman	O
611	1000	O
611	##43	O
611	##01	O
611	at	O
611	1	O
611	/	O
611	1000	O
611	in	O
611	15	O
611	m	O
611	##l	O
611	t	O
611	##bs	O
611	##t	O
611	)	O
611	.	O
611	[SEP]	O
612	[CLS]	O
612	p	O
612	##har	O
612	##ma	O
612	##co	O
612	##kin	O
612	##etic	O
612	parameters	O
612	were	O
612	calculated	O
612	for	O
612	plasma	O
612	and	O
612	tissues	O
612	.	O
612	[SEP]	O
613	[CLS]	O
613	although	O
613	o	O
613	##x	O
613	##1	O
613	##r	O
613	ant	O
613	##agon	O
613	##ism	O
613	blocked	O
613	expression	O
613	of	O
613	a	O
613	weak	O
613	ethanol	O
613	c	O
613	##pp	O
613	(	O
613	experiment	O
613	4	O
613	)	O
613	,	O
613	it	O
613	did	O
613	not	O
613	affect	O
613	expression	O
613	of	O
613	a	O
613	moderate	O
613	to	O
613	strong	O
613	c	O
613	##pp	O
613	(	O
613	experiment	O
613	5	O
613	)	O
613	.	O
613	[SEP]	O
614	[CLS]	O
614	the	O
614	mean	O
614	plasma	O
614	concentration	O
614	–	O
614	time	O
614	[SEP]	O
615	[CLS]	O
615	correlation	O
615	was	O
615	made	O
615	between	O
615	in	O
615	v	O
615	##it	O
615	##ro	O
615	release	O
615	and	O
615	in	O
615	v	O
615	##ivo	O
615	absorption	O
615	.	O
615	[SEP]	O
616	[CLS]	O
616	pro	O
616	-	O
616	and	O
616	anti	O
616	-	O
616	inflammatory	O
616	c	O
616	##yt	O
616	##oki	O
616	##nes	O
616	were	O
616	dose	O
616	-	O
616	dependent	O
616	##ly	O
616	but	O
616	trans	O
616	##ient	O
616	##ly	O
616	up	O
616	##re	O
616	##gu	O
616	##lated	O
616	only	O
616	after	O
616	the	O
616	first	O
616	dose	O
616	.	O
616	[SEP]	O
617	[CLS]	O
617	however	O
617	,	O
617	his	O
617	c	O
617	##d	O
617	##4	O
617	count	O
617	(	O
617	56	O
617	cells	O
617	/	O
617	μ	O
617	##l	O
617	)	O
617	and	O
617	plasma	O
617	viral	O
617	load	O
617	(	O
617	1	O
617	,	O
617	27	O
617	,	O
617	73	O
617	##4	O
617	/	O
617	mm	O
617	of	O
617	blood	O
617	)	O
617	failed	O
617	to	O
617	improve	O
617	.	O
617	[SEP]	O
618	[CLS]	O
618	the	O
618	overall	O
618	inter	O
618	-	O
618	ass	O
618	##ay	O
618	coefficient	O
618	of	O
618	variation	O
618	for	O
618	the	O
618	whole	O
618	blood	O
618	f	O
618	##olate	O
618	standard	O
618	was	O
618	9	O
618	.	O
618	1	O
618	%	O
618	with	O
618	a	O
618	mean	O
618	value	O
618	of	O
618	32	O
618	.	O
618	2	O
618	±	O
618	2	O
618	.	O
618	9	O
618	nm	O
618	##ol	O
618	/	O
618	l	O
618	(	O
618	14	O
618	.	O
618	2	O
618	±	O
618	1	O
618	.	O
618	3	O
618	ng	O
618	/	O
618	m	O
618	##l	O
618	)	O
618	.	O
618	[SEP]	O
619	[CLS]	O
619	the	O
619	study	O
619	schedule	O
619	included	O
619	a	O
619	screening	O
619	visit	O
619	,	O
619	a	O
619	2	O
619	-	O
619	day	O
619	in	O
619	##patient	O
619	pre	O
619	##tre	O
619	##at	O
619	##ment	O
619	base	O
619	##line	O
619	assessment	O
619	period	O
619	(	O
619	during	O
619	which	O
619	a	O
619	place	O
619	##bo	O
619	run	O
619	-	O
619	in	O
619	was	O
619	initiated	O
619	)	O
619	,	O
619	a	O
619	14	O
619	-	O
619	day	O
619	(	O
619	co	O
619	##hor	O
619	##ts	O
619	1	O
619	–	O
619	6	O
619	)	O
619	or	O
619	15	O
619	-	O
619	day	O
619	(	O
619	co	O
619	##hor	O
619	##t	O
619	7	O
619	)	O
619	in	O
619	##patient	O
619	treatment	O
619	period	O
619	,	O
619	and	O
619	a	O
619	6	O
619	-	O
619	day	O
619	(	O
619	co	O
619	##hor	O
619	##ts	O
619	1	O
619	–	O
619	6	O
619	)	O
619	or	O
619	5	O
619	-	O
619	day	O
619	(	O
619	co	O
619	##hor	O
619	##t	O
619	7	O
619	)	O
619	post	O
619	##dos	O
619	##ing	O
619	out	O
619	##patient	O
619	observation	O
619	period	O
619	.	O
619	[SEP]	O
620	[CLS]	O
620	apart	O
620	from	O
620	the	O
620	study	O
620	group	O
620	,	O
620	one	O
620	group	O
620	of	O
620	animals	O
620	received	O
620	the	O
620	respective	O
620	optical	O
620	probe	O
620	together	O
620	with	O
620	a	O
620	10	O
620	-	O
620	fold	O
620	excess	O
620	of	O
620	un	O
620	##la	O
620	##bell	O
620	##ed	O
620	mini	O
620	##gas	O
620	##tri	O
620	##n	O
620	to	O
620	induce	O
620	a	O
620	competition	O
620	for	O
620	cc	O
620	##k	O
620	##2	O
620	##r	O
620	binding	O
620	and	O
620	therefore	O
620	revealing	O
620	in	O
620	v	O
620	##ivo	O
620	specific	O
620	##ity	O
620	.	O
620	[SEP]	O
621	[CLS]	O
621	figure	O
621	6	O
621	shows	O
621	the	O
621	parameters	O
621	with	O
621	the	O
621	highest	O
621	sensitivity	O
621	index	O
621	##es	O
621	(	O
621	si	O
621	)	O
621	in	O
621	the	O
621	model	O
621	.	O
621	[SEP]	O
622	[CLS]	O
622	single	O
622	oral	O
622	doses	O
622	of	O
622	be	O
622	##vir	O
622	##ima	O
622	##t	O
622	were	O
622	well	O
622	tolerate	O
622	##d	O
622	and	O
622	demonstrated	O
622	a	O
622	dose	O
622	-	O
622	dependent	O
622	reduction	O
622	in	O
622	viral	O
622	load	O
622	.	O
622	[SEP]	O
623	[CLS]	O
623	these	O
623	data	O
623	suggest	O
623	that	O
623	ace	O
623	##ty	O
623	##lation	O
623	represents	O
623	a	O
623	means	O
623	of	O
623	increasing	O
623	the	O
623	biological	O
623	pot	O
623	##ency	O
623	in	O
623	v	O
623	##it	O
623	##ro	O
623	,	O
623	increasing	O
623	the	O
623	bio	B-PK
623	##ava	I-PK
623	##ila	I-PK
623	##bility	I-PK
623	of	O
623	e	O
623	##g	O
623	##c	O
623	##g	O
623	in	O
623	v	O
623	##ivo	O
623	,	O
623	and	O
623	may	O
623	improve	O
623	cancer	O
623	-	O
623	prevent	O
623	##ive	O
623	activity	O
623	.	O
623	[SEP]	O
624	[CLS]	O
624	internal	O
624	standards	O
624	were	O
624	f	O
624	##ent	O
624	##any	O
624	##l	O
624	c	O
624	##it	O
624	##rate	O
624	(	O
624	pro	O
624	##mo	O
624	##che	O
624	##m	O
624	,	O
624	we	O
624	##sel	O
624	,	O
624	g	O
624	##erman	O
624	##y	O
624	)	O
624	for	O
624	ass	O
624	##ay	O
624	of	O
624	un	O
624	##con	O
624	##ju	O
624	##gated	O
624	and	O
624	total	O
624	rot	O
624	##igo	O
624	##tine	O
624	and	O
624	n	O
624	-	O
624	des	O
624	##p	O
624	##rop	O
624	##yl	O
624	-	O
624	prop	O
624	##af	O
624	##eno	O
624	##ne	O
624	o	O
624	##xa	O
624	##late	O
624	for	O
624	ass	O
624	##ay	O
624	of	O
624	the	O
624	des	O
624	##alk	O
624	##yl	O
624	meta	O
624	##bol	O
624	##ites	O
624	.	O
624	[SEP]	O
625	[CLS]	O
625	larger	O
625	na	O
625	##no	O
625	##par	O
625	##tic	O
625	##les	O
625	(	O
625	150	O
625	–	O
625	200	O
625	nm	O
625	)	O
625	with	O
625	spherical	O
625	shapes	O
625	tend	O
625	to	O
625	be	O
625	trapped	O
625	by	O
625	the	O
625	liver	O
625	f	O
625	##ene	O
625	##stra	O
625	and	O
625	recognized	O
625	by	O
625	k	O
625	##up	O
625	##ffer	O
625	cells	O
625	.	O
625	42	O
625	smaller	O
625	particles	O
625	(	O
625	of	O
625	~	O
625	100	O
625	nm	O
625	in	O
625	diameter	O
625	)	O
625	with	O
625	elongated	O
625	shapes	O
625	may	O
625	be	O
625	se	O
625	##quest	O
625	##ered	O
625	by	O
625	the	O
625	s	O
625	##ple	O
625	##en	O
625	,	O
625	unless	O
625	being	O
625	def	O
625	##orm	O
625	##able	O
625	enough	O
625	to	O
625	cross	O
625	the	O
625	s	O
625	##ple	O
625	##en	O
625	re	O
625	##tic	O
625	##ular	O
625	network	O
625	.	O
625	[SEP]	O
626	[CLS]	O
626	to	O
626	100	O
626	μ	O
626	##l	O
626	al	O
626	##iq	O
626	##uo	O
626	##t	O
626	of	O
626	a	O
626	plasma	O
626	sample	O
626	,	O
626	20	O
626	μ	O
626	##l	O
626	met	O
626	##han	O
626	##ol	O
626	and	O
626	180	O
626	μ	O
626	##l	O
626	internal	O
626	standard	O
626	met	O
626	##han	O
626	##ol	O
626	solution	O
626	(	O
626	2	O
626	ng	O
626	/	O
626	m	O
626	##l	O
626	)	O
626	were	O
626	added	O
626	and	O
626	v	O
626	##ortex	O
626	##ed	O
626	for	O
626	60	O
626	s	O
626	to	O
626	mix	O
626	in	O
626	a	O
626	1	O
626	.	O
626	5	O
626	m	O
626	##l	O
626	p	O
626	##oly	O
626	##p	O
626	##rop	O
626	##yle	O
626	##ne	O
626	tube	O
626	,	O
626	and	O
626	then	O
626	cent	O
626	##ri	O
626	##fu	O
626	##ged	O
626	at	O
626	12	O
626	,	O
626	000	O
626	rpm	O
626	for	O
626	10	O
626	min	O
626	.	O
626	[SEP]	O
627	[CLS]	O
627	further	O
627	##more	O
627	,	O
627	the	O
627	enhance	O
627	##ment	O
627	of	O
627	the	O
627	ethanol	O
627	-	O
627	induced	O
627	lo	O
627	##rr	O
627	by	O
627	b	O
627	##c	O
627	##po	O
627	was	O
627	reversed	O
627	by	O
627	am	O
627	##6	O
627	##30	O
627	.	O
627	[SEP]	O
628	[CLS]	O
628	upon	O
628	the	O
628	recommendation	O
628	of	O
628	the	O
628	data	O
628	and	O
628	safety	O
628	monitoring	O
628	board	O
628	,	O
628	any	O
628	subject	O
628	with	O
628	hem	O
628	##og	O
628	##lo	O
628	##bin	O
628	levels	O
628	<	O
628	12	O
628	g	O
628	/	O
628	d	O
628	##l	O
628	at	O
628	study	O
628	exit	O
628	was	O
628	required	O
628	to	O
628	return	O
628	to	O
628	our	O
628	clinical	O
628	research	O
628	center	O
628	for	O
628	a	O
628	follow	O
628	-	O
628	up	O
628	safety	O
628	assessment	O
628	.	O
628	[SEP]	O
629	[CLS]	O
629	the	O
629	ch	O
629	##roma	O
629	##to	O
629	##graphic	O
629	total	O
629	run	O
629	time	O
629	was	O
629	10	O
629	min	O
629	.	O
629	[SEP]	O
630	[CLS]	O
630	for	O
630	the	O
630	principal	O
630	meta	O
630	##bol	O
630	##ite	O
630	p	O
630	##g	O
630	##l	O
630	##40	O
630	##0	O
630	##2	O
630	,	O
630	t	B-PK
630	##max	I-PK
630	and	O
630	plasma	B-PK
630	elimination	I-PK
630	half	I-PK
630	-	I-PK
630	life	I-PK
630	values	O
630	were	O
630	similar	O
630	to	O
630	those	O
630	of	O
630	up	O
630	##a	O
630	.	O
630	[SEP]	O
631	[CLS]	O
631	however	O
631	,	O
631	removal	O
631	of	O
631	b	O
631	##s	O
631	##v	O
631	for	O
631	v	B-PK
631	##1	I-PK
631	did	O
631	not	O
631	significantly	O
631	change	O
631	of	O
631	##v	O
631	(	O
631	increase	O
631	of	O
631	1	O
631	unit	O
631	)	O
631	.	O
631	[SEP]	O
632	[CLS]	O
632	the	O
632	distribution	B-PK
632	volume	I-PK
632	(	O
632	0	O
632	.	O
632	44	O
632	+	O
632	-	O
632	0	O
632	.	O
632	06	O
632	l	O
632	/	O
632	kg	O
632	in	O
632	control	O
632	vs	O
632	.	O
632	0	O
632	.	O
632	44	O
632	+	O
632	-	O
632	0	O
632	.	O
632	09	O
632	l	O
632	/	O
632	kg	O
632	oral	O
632	con	O
632	##tra	O
632	##ceptive	O
632	group	O
632	)	O
632	,	O
632	total	B-PK
632	body	I-PK
632	clearance	I-PK
632	(	O
632	0	O
632	.	O
632	78	O
632	+	O
632	-	O
632	0	O
632	.	O
632	13	O
632	m	O
632	##l	O
632	/	O
632	kg	O
632	/	O
632	min	O
632	vs	O
632	0	O
632	.	O
632	78	O
632	+	O
632	-	O
632	0	O
632	.	O
632	18	O
632	m	O
632	##l	O
632	/	O
632	kg	O
632	/	O
632	min	O
632	)	O
632	and	O
632	elimination	B-PK
632	t	I-PK
632	1	I-PK
632	/	I-PK
632	2	I-PK
632	(	O
632	40	O
632	##2	O
632	+	O
632	-	O
632	78	O
632	min	O
632	vs	O
632	.	O
632	40	O
632	##9	O
632	+	O
632	-	O
632	126	O
632	min	O
632	)	O
632	were	O
632	identical	O
632	in	O
632	the	O
632	two	O
632	groups	O
632	.	O
632	[SEP]	O
633	[CLS]	O
633	q	O
633	##uant	O
633	##itation	O
633	of	O
633	bi	O
633	##sp	O
633	##hen	O
633	##ol	O
633	a	O
633	and	O
633	bi	O
633	##sp	O
633	##hen	O
633	##ol	O
633	a	O
633	g	O
633	##lu	O
633	##cu	O
633	##ron	O
633	##ide	O
633	in	O
633	biological	O
633	samples	O
633	by	O
633	high	O
633	performance	O
633	liquid	O
633	ch	O
633	##roma	O
633	##tography	O
633	-	O
633	tandem	O
633	mass	O
633	s	O
633	##pect	O
633	##rome	O
633	##try	O
633	.	O
633	[SEP]	O
634	[CLS]	O
634	options	O
634	become	O
634	limited	O
634	in	O
634	cases	O
634	of	O
634	associated	O
634	systemic	O
634	com	O
634	##or	O
634	##bid	O
634	##ities	O
634	such	O
634	as	O
634	re	O
634	##nal	O
634	d	O
634	##ys	O
634	##function	O
634	,	O
634	h	O
634	##y	O
634	##pop	O
634	##rote	O
634	##inae	O
634	##mia	O
634	,	O
634	an	O
634	##ae	O
634	##mia	O
634	.	O
634	[SEP]	O
635	[CLS]	O
635	my	O
635	##co	O
635	##phe	O
635	##no	O
635	##lic	O
635	acid	O
635	p	O
635	##har	O
635	##ma	O
635	##co	O
635	##kin	O
635	##etics	O
635	in	O
635	stable	O
635	p	O
635	##ediatric	O
635	re	O
635	##nal	O
635	transplant	O
635	##ation	O
635	.	O
635	[SEP]	O
636	[CLS]	O
636	u	O
636	##d	O
636	##ca	O
636	at	O
636	a	O
636	50	O
636	mg	O
636	/	O
636	kg	O
636	dose	O
636	efficiently	O
636	decreased	O
636	the	O
636	serum	O
636	levels	O
636	of	O
636	t	O
636	##bil	O
636	,	O
636	t	O
636	##ba	O
636	,	O
636	and	O
636	d	O
636	##bil	O
636	to	O
636	43	O
636	.	O
636	8	O
636	%	O
636	(	O
636	p	O
636	<	O
636	0	O
636	.	O
636	01	O
636	)	O
636	,	O
636	30	O
636	.	O
636	9	O
636	%	O
636	(	O
636	p	O
636	<	O
636	0	O
636	.	O
636	00	O
636	##1	O
636	)	O
636	,	O
636	and	O
636	40	O
636	.	O
636	9	O
636	%	O
636	(	O
636	p	O
636	<	O
636	0	O
636	.	O
636	01	O
636	)	O
636	,	O
636	respectively	O
636	,	O
636	compared	O
636	with	O
636	the	O
636	control	O
636	group	O
636	.	O
636	[SEP]	O
637	[CLS]	O
637	nevertheless	O
637	,	O
637	collectively	O
637	our	O
637	micro	O
637	##arra	O
637	##y	O
637	and	O
637	c	O
637	##yt	O
637	##oki	O
637	##ne	O
637	analysis	O
637	confirmed	O
637	that	O
637	o	O
637	##ac	O
637	treatment	O
637	had	O
637	a	O
637	significant	O
637	and	O
637	systemic	O
637	impact	O
637	on	O
637	the	O
637	immune	O
637	and	O
637	inflammatory	O
637	response	O
637	in	O
637	mice	O
637	infected	O
637	with	O
637	p	O
637	##ba	O
637	.	O
637	[SEP]	O
638	[CLS]	O
638	the	O
638	p	O
638	##hy	O
638	##si	O
638	##co	O
638	##chemical	O
638	properties	O
638	,	O
638	p	O
638	##har	O
638	##ma	O
638	##co	O
638	##kin	O
638	##etic	O
638	and	O
638	anti	O
638	##plate	O
638	##let	O
638	a	O
638	##gg	O
638	##regation	O
638	activities	O
638	of	O
638	these	O
638	derivatives	O
638	were	O
638	measured	O
638	to	O
638	determine	O
638	whether	O
638	they	O
638	can	O
638	improve	O
638	the	O
638	defects	O
638	of	O
638	d	O
638	##ha	O
638	##p	O
638	.	O
638	[SEP]	O
639	[CLS]	O
639	in	O
639	v	O
639	##ivo	O
639	studies	O
639	were	O
639	carried	O
639	out	O
639	in	O
639	al	O
639	##bino	O
639	rabbit	O
639	eyes	O
639	of	O
639	either	O
639	sex	O
639	weighing	O
639	between	O
639	1	O
639	.	O
639	8	O
639	and	O
639	2	O
639	.	O
639	5	O
639	kg	O
639	.	O
639	[SEP]	O
640	[CLS]	O
640	treatment	O
640	of	O
640	cats	O
640	with	O
640	a	O
640	single	O
640	30	O
640	-	O
640	mg	O
640	/	O
640	kg	O
640	dose	O
640	of	O
640	m	O
640	##ps	O
640	##s	O
640	(	O
640	m	O
640	##ps	O
640	##s	O
640	/	O
640	v	O
640	)	O
640	provided	O
640	a	O
640	clear	O
640	,	O
640	although	O
640	not	O
640	significant	O
640	,	O
640	protection	O
640	against	O
640	ne	O
640	##uro	O
640	##fi	O
640	##lam	O
640	##ent	O
640	degradation	O
640	compared	O
640	with	O
640	v	O
640	/	O
640	v	O
640	-	O
640	treated	O
640	cats	O
640	when	O
640	measured	O
640	at	O
640	4	O
640	1	O
640	/	O
640	2	O
640	hours	O
640	after	O
640	injury	O
640	.	O
640	[SEP]	O
641	[CLS]	O
641	the	O
641	em	O
641	##etic	O
641	syrup	O
641	or	O
641	the	O
641	us	O
641	##p	O
641	i	O
641	##pec	O
641	##ac	O
641	syrup	O
641	was	O
641	then	O
641	administered	O
641	.	O
641	[SEP]	O
642	[CLS]	O
642	the	O
642	mean	O
642	terminal	B-PK
642	elimination	I-PK
642	half	I-PK
642	-	I-PK
642	life	I-PK
642	was	O
642	1	O
642	.	O
642	8	O
642	h	O
642	(	O
642	range	O
642	,	O
642	1	O
642	.	O
642	4	O
642	to	O
642	2	O
642	.	O
642	3	O
642	h	O
642	)	O
642	,	O
642	the	O
642	apparent	B-PK
642	volume	I-PK
642	of	I-PK
642	distribution	I-PK
642	at	I-PK
642	steady	I-PK
642	state	I-PK
642	was	O
642	17	O
642	liter	O
642	##s	O
642	,	O
642	and	O
642	the	O
642	total	B-PK
642	systemic	I-PK
642	clearance	I-PK
642	was	O
642	150	O
642	m	O
642	##l	O
642	/	O
642	min	O
642	.	O
642	[SEP]	O
643	[CLS]	O
643	the	O
643	in	O
643	##tra	O
643	##mus	O
643	##cular	O
643	group	O
643	was	O
643	dose	O
643	##d	O
643	with	O
643	i	O
643	##car	O
643	##ii	O
643	##n	O
643	(	O
643	20	O
643	mg	O
643	/	O
643	kg	O
643	)	O
643	by	O
643	in	O
643	##tra	O
643	##mus	O
643	##cular	O
643	injection	O
643	of	O
643	this	O
643	solution	O
643	.	O
643	[SEP]	O
644	[CLS]	O
644	the	O
644	volume	B-PK
644	of	I-PK
644	distribution	I-PK
644	in	I-PK
644	the	I-PK
644	per	I-PK
644	##ito	I-PK
644	##ne	I-PK
644	##um	I-PK
644	(	I-PK
644	v	I-PK
644	a	I-PK
644	)	I-PK
644	ex	O
644	##po	O
644	##nent	O
644	##ially	O
644	decreased	O
644	due	O
644	to	O
644	the	O
644	carrier	O
644	so	O
644	##lut	O
644	##e	O
644	absorption	O
644	.	O
644	[SEP]	O
645	[CLS]	O
645	the	O
645	results	O
645	indicate	O
645	that	O
645	two	O
645	different	O
645	therapeutic	O
645	schedules	O
645	of	O
645	me	O
645	##rop	O
645	##ene	O
645	##m	O
645	are	O
645	equally	O
645	applicable	O
645	to	O
645	patients	O
645	receiving	O
645	c	O
645	##v	O
645	##v	O
645	##h	O
645	##d	O
645	:	O
645	either	O
645	750	O
645	mg	O
645	t	O
645	##id	O
645	or	O
645	1500	O
645	bid	O
645	.	O
645	[SEP]	O
646	[CLS]	O
646	radio	O
646	##pha	O
646	##rma	O
646	##co	O
646	##kin	O
646	##etic	O
646	data	O
646	for	O
646	64	O
646	##cu	O
646	-	O
646	mm	O
646	-	O
646	302	O
646	in	O
646	naive	O
646	female	O
646	c	O
646	##d	O
646	-	O
646	1	O
646	mice	O
646	(	O
646	n	O
646	=	O
646	3	O
646	)	O
646	are	O
646	presented	O
646	in	O
646	figure	O
646	1	O
646	##a	O
646	.	O
646	[SEP]	O
647	[CLS]	O
647	between	O
647	cycles	O
647	3	O
647	and	O
647	4	O
647	,	O
647	the	O
647	patient	O
647	had	O
647	an	O
647	##emia	O
647	grade	O
647	2	O
647	,	O
647	probably	O
647	related	O
647	to	O
647	a	O
647	concurrent	O
647	infection	O
647	,	O
647	and	O
647	received	O
647	another	O
647	er	O
647	##yt	O
647	##hr	O
647	##oc	O
647	##yte	O
647	trans	O
647	##fusion	O
647	.	O
647	[SEP]	O
648	[CLS]	O
648	most	O
648	treatment	O
648	-	O
648	related	O
648	a	O
648	##es	O
648	were	O
648	mild	O
648	(	O
648	grade	O
648	1	O
648	/	O
648	2	O
648	)	O
648	,	O
648	with	O
648	higher	O
648	grade	O
648	treatment	O
648	-	O
648	related	O
648	a	O
648	##es	O
648	(	O
648	grade	O
648	3	O
648	/	O
648	4	O
648	)	O
648	observed	O
648	only	O
648	at	O
648	130	O
648	mg	O
648	,	O
648	the	O
648	highest	O
648	dose	O
648	administered	O
648	.	O
648	[SEP]	O
649	[CLS]	O
649	with	O
649	the	O
649	assumption	O
649	of	O
649	a	O
649	one	O
649	-	O
649	compartment	O
649	open	O
649	model	O
649	and	O
649	linear	O
649	p	O
649	##har	O
649	##ma	O
649	##co	O
649	##kin	O
649	##etics	O
649	,	O
649	analysis	O
649	of	O
649	the	O
649	data	O
649	determined	O
649	that	O
649	there	O
649	were	O
649	no	O
649	significant	O
649	differences	O
649	in	O
649	the	O
649	volume	B-PK
649	of	I-PK
649	distribution	I-PK
649	,	O
649	clearance	B-PK
649	,	O
649	elimination	B-PK
649	half	I-PK
649	-	I-PK
649	life	I-PK
649	,	O
649	and	O
649	serum	O
649	protein	O
649	binding	O
649	of	O
649	lid	O
649	##oc	O
649	##aine	O
649	among	O
649	these	O
649	racial	O
649	groups	O
649	.	O
649	[SEP]	O
650	[CLS]	O
650	a	O
650	90	O
650	%	O
650	c	O
650	##i	O
650	for	O
650	the	O
650	ratio	O
650	of	O
650	the	O
650	least	O
650	squares	O
650	means	O
650	of	O
650	the	O
650	multiple	O
650	-	O
650	dose	O
650	au	B-PK
650	##c	I-PK
650	##0	I-PK
650	–	I-PK
650	24	I-PK
650	relative	O
650	to	O
650	the	O
650	single	O
650	-	O
650	dose	O
650	au	B-PK
650	##c	I-PK
650	##0	I-PK
650	–	I-PK
650	∞	I-PK
650	was	O
650	derived	O
650	within	O
650	the	O
650	framework	O
650	of	O
650	an	O
650	##ova	O
650	.	O
650	[SEP]	O
651	[CLS]	O
651	according	O
651	to	O
651	the	O
651	who	O
651	,	O
651	m	O
651	##dr	O
651	and	O
651	x	O
651	##dr	O
651	tuberculosis	O
651	drive	O
651	25	O
651	%	O
651	of	O
651	global	O
651	tuberculosis	O
651	deaths	O
651	[	O
651	12	O
651	]	O
651	.	O
651	[SEP]	O
652	[CLS]	O
652	the	O
652	median	O
652	root	O
652	squared	O
652	percentage	O
652	of	O
652	the	O
652	prediction	O
652	error	O
652	was	O
652	18	O
652	%	O
652	(	O
652	drug	O
652	clearance	B-PK
652	)	O
652	and	O
652	12	O
652	%	O
652	(	O
652	half	B-PK
652	-	I-PK
652	life	I-PK
652	)	O
652	.	O
652	[SEP]	O
653	[CLS]	O
653	using	O
653	the	O
653	k	B-PK
653	(	I-PK
653	i	I-PK
653	)	I-PK
653	values	O
653	obtained	O
653	from	O
653	in	O
653	v	O
653	##it	O
653	##ro	O
653	in	O
653	##hibition	O
653	studies	O
653	,	O
653	the	O
653	degree	O
653	of	O
653	increase	O
653	in	O
653	to	O
653	##l	O
653	##but	O
653	##ami	O
653	##de	O
653	area	B-PK
653	under	I-PK
653	the	I-PK
653	plasma	I-PK
653	concentration	I-PK
653	-	I-PK
653	time	I-PK
653	curve	I-PK
653	(	I-PK
653	au	I-PK
653	##c	I-PK
653	)	I-PK
653	was	O
653	predicted	O
653	.	O
653	[SEP]	O
654	[CLS]	O
654	for	O
654	each	O
654	anal	O
654	##yte	O
654	,	O
654	the	O
654	two	O
654	highest	O
654	abundant	O
654	m	O
654	##rm	O
654	transitions	O
654	without	O
654	interference	O
654	in	O
654	sample	O
654	were	O
654	selected	O
654	—	O
654	one	O
654	for	O
654	q	O
654	##uant	O
654	##ification	O
654	and	O
654	the	O
654	other	O
654	for	O
654	confirmation	O
654	.	O
654	[SEP]	O
655	[CLS]	O
655	negative	O
655	ions	O
655	were	O
655	monitored	O
655	in	O
655	the	O
655	m	O
655	##rm	O
655	mode	O
655	with	O
655	mass	O
655	transitions	O
655	m	O
655	/	O
655	z	O
655	278	O
655	.	O
655	1	O
655	→	O
655	118	O
655	.	O
655	0	O
655	da	O
655	(	O
655	s	O
655	##nac	O
655	)	O
655	and	O
655	m	O
655	/	O
655	z	O
655	249	O
655	.	O
655	0	O
655	→	O
655	135	O
655	.	O
655	0	O
655	da	O
655	(	O
655	is	O
655	)	O
655	.	O
655	[SEP]	O
656	[CLS]	O
656	our	O
656	investigations	O
656	were	O
656	performed	O
656	after	O
656	approval	O
656	by	O
656	our	O
656	local	O
656	ethical	O
656	committee	O
656	at	O
656	p	O
656	##eking	O
656	union	O
656	medical	O
656	college	O
656	,	O
656	and	O
656	in	O
656	accordance	O
656	with	O
656	the	O
656	principles	O
656	of	O
656	laboratory	O
656	animal	O
656	care	O
656	.	O
656	[SEP]	O
657	[CLS]	O
657	β	O
657	-	O
657	g	O
657	##lu	O
657	##cu	O
657	##ron	O
657	##idas	O
657	##e	O
657	(	O
657	[UNK]	O
657	-	O
657	a	O
657	from	O
657	e	O
657	.	O
657	co	O
657	##li	O
657	)	O
657	was	O
657	purchased	O
657	from	O
657	si	O
657	##gma	O
657	-	O
657	al	O
657	##dric	O
657	##h	O
657	(	O
657	s	O
657	##hang	O
657	##hai	O
657	,	O
657	chin	O
657	##a	O
657	)	O
657	.	O
657	[SEP]	O
658	[CLS]	O
658	the	O
658	p	O
658	##b	O
658	##p	O
658	##k	O
658	models	O
658	of	O
658	p	O
658	##ra	O
658	##vas	O
658	##tat	O
658	##in	O
658	have	O
658	previously	O
658	been	O
658	developed	O
658	by	O
658	various	O
658	groups	O
658	##5	O
658	,	O
658	7	O
658	,	O
658	8	O
658	,	O
658	9	O
658	in	O
658	order	O
658	to	O
658	predict	O
658	the	O
658	p	O
658	##k	O
658	and	O
658	transported	O
658	mediated	O
658	drug	O
658	‐	O
658	drug	O
658	interactions	O
658	.	O
658	[SEP]	O
659	[CLS]	O
659	the	O
659	u	O
659	##rina	O
659	##ry	O
659	ex	O
659	##cre	O
659	##tion	O
659	of	O
659	the	O
659	in	O
659	##tra	O
659	##ven	O
659	##ous	O
659	dose	O
659	was	O
659	12	O
659	+	O
659	-	O
659	6	O
659	%	O
659	and	O
659	the	O
659	re	B-PK
659	##nal	I-PK
659	clearance	I-PK
659	10	O
659	+	O
659	-	O
659	5	O
659	m	O
659	##l	O
659	/	O
659	min	O
659	.	O
659	[SEP]	O
660	[CLS]	O
660	de	O
660	##x	O
660	##lan	O
660	##so	O
660	##pra	O
660	##zo	O
660	##le	O
660	plasma	O
660	concentrations	O
660	and	O
660	p	O
660	##har	O
660	##ma	O
660	##co	O
660	##kin	O
660	##etic	O
660	parameters	O
660	were	O
660	summarized	O
660	by	O
660	dose	O
660	group	O
660	.	O
660	[SEP]	O
661	[CLS]	O
661	in	O
661	##do	O
661	##l	O
661	##car	O
661	##box	O
661	##ami	O
661	##de	O
661	is	O
661	a	O
661	pre	O
661	##c	O
661	##lini	O
661	##cal	O
661	candidate	O
661	for	O
661	treating	O
661	multi	O
661	##dr	O
661	##ug	O
661	-	O
661	resistant	O
661	tuberculosis	O
661	.	O
661	[SEP]	O
662	[CLS]	O
662	we	O
662	previously	O
662	reported	O
662	es	O
662	##k	O
662	##1	O
662	,	O
662	a	O
662	high	O
662	avid	O
662	##ity	O
662	(	O
662	k	O
662	##d	O
662	<	O
662	0	O
662	.	O
662	2	O
662	nm	O
662	##ol	O
662	/	O
662	l	O
662	)	O
662	,	O
662	fully	O
662	-	O
662	human	O
662	mon	O
662	##oc	O
662	##lon	O
662	##al	O
662	anti	O
662	##body	O
662	(	O
662	ma	O
662	##b	O
662	)	O
662	specific	O
662	for	O
662	the	O
662	w	O
662	##t	O
662	##1	O
662	r	O
662	##m	O
662	##f	O
662	p	O
662	##eptide	O
662	/	O
662	h	O
662	##la	O
662	-	O
662	a	O
662	*	O
662	02	O
662	:	O
662	01	O
662	complex	O
662	,	O
662	which	O
662	selective	O
662	##ly	O
662	bound	O
662	and	O
662	killed	O
662	w	O
662	##t	O
662	##1	O
662	(	O
662	+	O
662	)	O
662	and	O
662	h	O
662	##la	O
662	-	O
662	a	O
662	*	O
662	02	O
662	:	O
662	01	O
662	(	O
662	+	O
662	)	O
662	le	O
662	##uke	O
662	##mia	O
662	and	O
662	solid	O
662	tumor	O
662	cell	O
662	lines	O
662	.	O
662	[SEP]	O
663	[CLS]	O
663	intact	O
663	doses	O
663	of	O
663	o	O
663	##xy	O
663	##co	O
663	##don	O
663	##e	O
663	de	O
663	##ter	O
663	##x	O
663	were	O
663	administered	O
663	with	O
663	50	O
663	m	O
663	##l	O
663	of	O
663	place	O
663	##bo	O
663	solution	O
663	(	O
663	micro	O
663	##c	O
663	##ry	O
663	##stal	O
663	##line	O
663	cell	O
663	##ulos	O
663	##e	O
663	mixed	O
663	with	O
663	room	O
663	temperature	O
663	,	O
663	non	O
663	##car	O
663	##bon	O
663	##ated	O
663	water	O
663	with	O
663	den	O
663	##aton	O
663	##ium	O
663	ben	O
663	##zo	O
663	##ate	O
663	to	O
663	create	O
663	a	O
663	1	O
663	‐	O
663	pp	O
663	##m	O
663	solution	O
663	added	O
663	for	O
663	blinding	O
663	purposes	O
663	)	O
663	.	O
663	[SEP]	O
664	[CLS]	O
664	the	O
664	influence	O
664	of	O
664	selective	O
664	se	O
664	##rot	O
664	##oni	O
664	##n	O
664	re	O
664	##up	O
664	##take	O
664	inhibitor	O
664	##s	O
664	on	O
664	the	O
664	plasma	O
664	and	O
664	brain	O
664	p	O
664	##har	O
664	##ma	O
664	##co	O
664	##kin	O
664	##etics	O
664	of	O
664	the	O
664	simplest	O
664	p	O
664	##hen	O
664	##oth	O
664	##ia	O
664	##zine	O
664	ne	O
664	##uro	O
664	##le	O
664	##ptic	O
664	pro	O
664	##ma	O
664	##zine	O
664	in	O
664	the	O
664	rat	O
664	.	O
664	[SEP]	O
665	[CLS]	O
665	size	O
665	(	O
665	37	O
665	.	O
665	8	O
665	%	O
665	)	O
665	and	O
665	pm	O
665	##a	O
665	(	O
665	27	O
665	.	O
665	3	O
665	%	O
665	)	O
665	contribute	O
665	to	O
665	this	O
665	var	O
665	##iability	O
665	.	O
665	[SEP]	O
666	[CLS]	O
666	thirteen	O
666	subjects	O
666	who	O
666	completed	O
666	the	O
666	study	O
666	received	O
666	a	O
666	single	O
666	120	O
666	mg	O
666	dose	O
666	of	O
666	te	O
666	##rf	O
666	##ena	O
666	##dine	O
666	alone	O
666	or	O
666	with	O
666	con	O
666	##com	O
666	##ita	O
666	##nt	O
666	20	O
666	mg	O
666	se	O
666	##rt	O
666	##ind	O
666	##ole	O
666	daily	O
666	.	O
666	[SEP]	O
667	[CLS]	O
667	the	O
667	sa	O
667	##r	O
667	suggested	O
667	##bot	O
667	##h	O
667	the	O
667	c	O
667	##yan	O
667	##o	O
667	group	O
667	and	O
667	perhaps	O
667	a	O
667	suitable	O
667	h	O
667	##ydro	O
667	##phobic	O
667	group	O
667	are	O
667	##re	O
667	##quire	O
667	##d	O
667	to	O
667	enhance	O
667	the	O
667	pot	O
667	##ency	O
667	.	O
667	[SEP]	O
668	[CLS]	O
668	with	O
668	the	O
668	goal	O
668	of	O
668	identifying	O
668	inhibitor	O
668	##s	O
668	of	O
668	he	O
668	##pa	O
668	##titis	O
668	c	O
668	virus	O
668	(	O
668	h	O
668	##c	O
668	##v	O
668	)	O
668	n	O
668	##s	O
668	##3	O
668	/	O
668	4	O
668	##a	O
668	pro	O
668	##te	O
668	##ase	O
668	that	O
668	are	O
668	potent	O
668	against	O
668	a	O
668	wide	O
668	range	O
668	of	O
668	g	O
668	##eno	O
668	##type	O
668	##s	O
668	and	O
668	clinical	O
668	##ly	O
668	relevant	O
668	mutant	O
668	viruses	O
668	,	O
668	several	O
668	sub	O
668	##ser	O
668	##ies	O
668	of	O
668	mac	O
668	##ro	O
668	##cycle	O
668	##s	O
668	were	O
668	investigated	O
668	based	O
668	on	O
668	observations	O
668	made	O
668	during	O
668	the	O
668	discovery	O
668	of	O
668	m	O
668	##k	O
668	-	O
668	51	O
668	##7	O
668	##2	O
668	.	O
668	[SEP]	O
669	[CLS]	O
669	the	O
669	dried	O
669	residue	O
669	was	O
669	dissolved	O
669	with	O
669	200	O
669	μ	O
669	##l	O
669	met	O
669	##han	O
669	##ol	O
669	and	O
669	cent	O
669	##ri	O
669	##fu	O
669	##ged	O
669	at	O
669	1500	O
669	##0	O
669	rpm	O
669	for	O
669	10	O
669	min	O
669	.	O
669	[SEP]	O
670	[CLS]	O
670	plasma	O
670	and	O
670	c	O
670	##s	O
670	##f	O
670	concentrations	O
670	were	O
670	in	O
670	the	O
670	range	O
670	that	O
670	has	O
670	been	O
670	shown	O
670	to	O
670	in	O
670	##hibit	O
670	par	O
670	##p	O
670	activity	O
670	in	O
670	v	O
670	##ivo	O
670	in	O
670	humans	O
670	.	O
670	[SEP]	O
671	[CLS]	O
671	previous	O
671	studies	O
671	have	O
671	found	O
671	that	O
671	a	O
671	##g	O
671	exhibits	O
671	potent	O
671	anti	O
671	-	O
671	inflammatory	O
671	activity	O
671	.	O
671	53	O
671	–	O
671	55	O
671	however	O
671	,	O
671	the	O
671	therapeutic	O
671	application	O
671	of	O
671	a	O
671	##g	O
671	is	O
671	restricted	O
671	by	O
671	its	O
671	low	O
671	so	O
671	##lub	O
671	##ility	O
671	in	O
671	water	O
671	,	O
671	which	O
671	results	O
671	in	O
671	low	O
671	bio	B-PK
671	##ava	I-PK
671	##ila	I-PK
671	##bility	I-PK
671	after	O
671	oral	O
671	administration	O
671	.	O
671	[SEP]	O
672	[CLS]	O
672	the	O
672	au	B-PK
672	##cs	I-PK
672	of	O
672	s	O
672	(	O
672	-	O
672	)	O
672	-	O
672	car	O
672	##v	O
672	were	O
672	significantly	O
672	lower	O
672	than	O
672	those	O
672	of	O
672	r	O
672	(	O
672	+	O
672	)	O
672	-	O
672	car	O
672	##v	O
672	after	O
672	both	O
672	i	O
672	.	O
672	v	O
672	.	O
672	and	O
672	p	O
672	.	O
672	o	O
672	.	O
672	administration	O
672	.	O
672	[SEP]	O
673	[CLS]	O
673	the	O
673	revised	O
673	who	O
673	guidelines	O
673	specify	O
673	replacement	O
673	of	O
673	d	O
673	##4	O
673	##t	O
673	with	O
673	less	O
673	toxic	O
673	but	O
673	more	O
673	expensive	O
673	drugs	O
673	when	O
673	feasible	O
673	,	O
673	and	O
673	that	O
673	d	O
673	##4	O
673	##t	O
673	doses	O
673	be	O
673	standardized	O
673	to	O
673	30	O
673	mg	O
673	twice	O
673	daily	O
673	(	O
673	bid	O
673	)	O
673	(	O
673	i	O
673	##rre	O
673	##spective	O
673	of	O
673	body	O
673	-	O
673	weight	O
673	)	O
673	,	O
673	from	O
673	the	O
673	approved	O
673	40	O
673	mg	O
673	bid	O
673	in	O
673	adults	O
673	(	O
673	body	O
673	-	O
673	weight	O
673	≥	O
673	##60	O
673	kg	O
673	)	O
673	.	O
673	[SEP]	O
674	[CLS]	O
674	initial	O
674	attempts	O
674	to	O
674	replace	O
674	the	O
674	4	O
674	-	O
674	p	O
674	##yr	O
674	##idy	O
674	##lf	O
674	##un	O
674	##ctional	O
674	group	O
674	at	O
674	r	O
674	##1	O
674	resulted	O
674	in	O
674	a	O
674	significant	O
674	loss	O
674	of	O
674	##anti	O
674	##mal	O
674	##aria	O
674	##l	O
674	activity	O
674	(	O
674	table	O
674	2	O
674	)	O
674	.	O
674	[SEP]	O
675	[CLS]	O
675	in	O
675	the	O
675	present	O
675	study	O
675	,	O
675	to	O
675	evaluate	O
675	the	O
675	app	O
675	##lica	O
675	##bility	O
675	of	O
675	t	O
675	##k	O
675	/	O
675	t	O
675	##d	O
675	analysis	O
675	based	O
675	on	O
675	free	O
675	drug	O
675	concentrations	O
675	,	O
675	we	O
675	investigated	O
675	the	O
675	t	O
675	##k	O
675	/	O
675	t	O
675	##d	O
675	of	O
675	c	O
675	##lo	O
675	##fi	O
675	##bra	O
675	##te	O
675	,	O
675	which	O
675	binds	O
675	to	O
675	album	O
675	##in	O
675	with	O
675	a	O
675	higher	O
675	ratio	O
675	,	O
675	using	O
675	an	O
675	album	O
675	##in	O
675	-	O
675	def	O
675	##icient	O
675	mutant	O
675	strain	O
675	,	O
675	na	O
675	##gas	O
675	##e	O
675	anal	O
675	##bu	O
675	##mine	O
675	##mia	O
675	rats	O
675	(	O
675	na	O
675	##r	O
675	)	O
675	.	O
675	[SEP]	O
676	[CLS]	O
676	internal	O
676	standard	O
676	ca	O
676	##li	O
676	##bra	O
676	##tion	O
676	was	O
676	used	O
676	with	O
676	the	O
676	analytical	O
676	signal	O
676	based	O
676	on	O
676	the	O
676	corrected	O
676	peak	O
676	area	O
676	obtained	O
676	from	O
676	the	O
676	integration	O
676	.	O
676	[SEP]	O
677	[CLS]	O
677	the	O
677	percentage	O
677	of	O
677	data	O
677	distributed	O
677	outside	O
677	the	O
677	95	O
677	%	O
677	prediction	O
677	intervals	O
677	of	O
677	the	O
677	predict	O
677	##ive	O
677	check	O
677	is	O
677	1	O
677	.	O
677	39	O
677	%	O
677	,	O
677	and	O
677	the	O
677	visual	O
677	predict	O
677	##ive	O
677	check	O
677	plots	O
677	are	O
677	shown	O
677	in	O
677	figure	O
677	5	O
677	##d	O
677	.	O
677	[SEP]	O
678	[CLS]	O
678	after	O
678	that	O
678	,	O
678	the	O
678	mixture	O
678	de	O
678	##co	O
678	##cted	O
678	for	O
678	30	O
678	min	O
678	and	O
678	filtered	O
678	.	O
678	[SEP]	O
679	[CLS]	O
679	human	O
679	plasma	O
679	obtained	O
679	from	O
679	the	O
679	phase	O
679	i	O
679	study	O
679	in	O
679	cancer	O
679	patients	O
679	were	O
679	also	O
679	analyzed	O
679	to	O
679	assess	O
679	the	O
679	metabolism	O
679	of	O
679	bi	O
679	##ib	O
679	##0	O
679	##21	O
679	in	O
679	humans	O
679	and	O
679	to	O
679	ensure	O
679	that	O
679	selected	O
679	animal	O
679	species	O
679	were	O
679	exposed	O
679	to	O
679	all	O
679	human	O
679	major	O
679	meta	O
679	##bol	O
679	##ites	O
679	.	O
679	[SEP]	O
680	[CLS]	O
680	however	O
680	,	O
680	more	O
680	studies	O
680	are	O
680	required	O
680	to	O
680	support	O
680	these	O
680	.	O
680	[SEP]	O
681	[CLS]	O
681	at	O
681	the	O
681	recommended	O
681	dose	O
681	,	O
681	an	O
681	extra	O
681	co	O
681	##hor	O
681	##t	O
681	of	O
681	patients	O
681	initially	O
681	received	O
681	g	O
681	##em	O
681	##ci	O
681	##ta	O
681	##bine	O
681	(	O
681	dose	O
681	level	O
681	ii	O
681	##ib	O
681	)	O
681	.	O
681	[SEP]	O
682	[CLS]	O
682	the	O
682	p	O
682	##har	O
682	##ma	O
682	##co	O
682	##kin	O
682	##etics	O
682	of	O
682	e	O
682	##pa	O
682	##ca	O
682	##dos	O
682	##tat	O
682	and	O
682	p	O
682	##em	O
682	##bro	O
682	##li	O
682	##zu	O
682	##ma	O
682	##b	O
682	and	O
682	anti	O
682	##dr	O
682	##ug	O
682	anti	O
682	##body	O
682	rate	O
682	were	O
682	comparable	O
682	to	O
682	historical	O
682	controls	O
682	for	O
682	mon	O
682	##oth	O
682	##era	O
682	##pies	O
682	.	O
682	[SEP]	O
683	[CLS]	O
683	the	O
683	reported	O
683	di	O
683	##sso	O
683	##ciation	O
683	constant	O
683	values	O
683	(	O
683	k	O
683	##i	O
683	)	O
683	are	O
683	42	O
683	##8	O
683	and	O
683	62	O
683	##6	O
683	nm	O
683	##ol	O
683	/	O
683	l	O
683	for	O
683	d	O
683	##1	O
683	and	O
683	d	O
683	##2	O
683	receptors	O
683	;	O
683	and	O
683	104	O
683	##0	O
683	and	O
683	38	O
683	nm	O
683	##ol	O
683	/	O
683	l	O
683	for	O
683	5	O
683	-	O
683	h	O
683	##t	O
683	##1	O
683	##a	O
683	and	O
683	5	O
683	-	O
683	h	O
683	##t	O
683	##2	O
683	##a	O
683	receptors	O
683	.	O
683	11	O
683	que	O
683	##tia	O
683	##pine	O
683	displays	O
683	affinity	O
683	for	O
683	α	O
683	##1	O
683	##b	O
683	and	O
683	α	O
683	##2	O
683	##b	O
683	-	O
683	ad	O
683	##ren	O
683	##oc	O
683	##ept	O
683	##ors	O
683	(	O
683	k	O
683	##i	O
683	14	O
683	.	O
683	6	O
683	and	O
683	61	O
683	##7	O
683	nm	O
683	##ol	O
683	/	O
683	l	O
683	)	O
683	,	O
683	his	O
683	##tamine	O
683	h	O
683	##1	O
683	receptors	O
683	(	O
683	k	O
683	##i	O
683	4	O
683	.	O
683	41	O
683	nm	O
683	##ol	O
683	/	O
683	l	O
683	)	O
683	but	O
683	lacks	O
683	significant	O
683	affinity	O
683	for	O
683	m	O
683	##us	O
683	##car	O
683	##ini	O
683	##c	O
683	ch	O
683	##olin	O
683	##ergic	O
683	(	O
683	m	O
683	##1	O
683	)	O
683	(	O
683	k	O
683	##i	O
683	108	O
683	##6	O
683	nm	O
683	##ol	O
683	/	O
683	l	O
683	)	O
683	or	O
683	ben	O
683	##zo	O
683	##dia	O
683	##ze	O
683	##pine	O
683	##s	O
683	receptors	O
683	(	O
683	k	O
683	##i	O
683	>	O
683	1000	O
683	##0	O
683	nm	O
683	##ol	O
683	/	O
683	l	O
683	)	O
683	.	O
683	12	O
683	[SEP]	O
684	[CLS]	O
684	repeat	O
684	-	O
684	dose	O
684	toxic	O
684	##ology	O
684	studies	O
684	in	O
684	mouse	O
684	,	O
684	rat	O
684	,	O
684	and	O
684	dog	O
684	have	O
684	demonstrated	O
684	that	O
684	induction	O
684	of	O
684	c	O
684	##yt	O
684	##och	O
684	##rome	O
684	p	O
684	##45	O
684	##0	O
684	by	O
684	v	O
684	##ori	O
684	##cona	O
684	##zo	O
684	##le	O
684	(	O
684	auto	O
684	##ind	O
684	##uction	O
684	of	O
684	metabolism	O
684	)	O
684	is	O
684	responsible	O
684	for	O
684	the	O
684	decreased	O
684	exposure	O
684	in	O
684	these	O
684	species	O
684	.	O
684	[SEP]	O
685	[CLS]	O
685	this	O
685	was	O
685	further	O
685	improved	O
685	to	O
685	95	O
685	%	O
685	when	O
685	si	O
685	##mulating	O
685	for	O
685	prolonged	O
685	in	O
685	##fusion	O
685	##s	O
685	.	O
685	[SEP]	O
686	[CLS]	O
686	thus	O
686	,	O
686	te	O
686	-	O
686	induced	O
686	suppression	O
686	of	O
686	l	O
686	##h	O
686	was	O
686	of	O
686	shorter	O
686	duration	O
686	,	O
686	but	O
686	of	O
686	greater	O
686	magnitude	O
686	compared	O
686	to	O
686	the	O
686	effect	O
686	caused	O
686	by	O
686	20	O
686	a	O
686	##et	O
686	-	O
686	1	O
686	.	O
686	[SEP]	O
687	[CLS]	O
687	in	O
687	conclusion	O
687	,	O
687	we	O
687	produced	O
687	p	O
687	##h	O
687	-	O
687	sensitive	O
687	lip	O
687	##oso	O
687	##me	O
687	-	O
687	en	O
687	##cap	O
687	##sul	O
687	##ated	O
687	mid	O
687	##az	O
687	##ola	O
687	##m	O
687	,	O
687	which	O
687	remained	O
687	stable	O
687	in	O
687	a	O
687	physiological	O
687	medium	O
687	and	O
687	showed	O
687	efficient	O
687	release	O
687	in	O
687	an	O
687	acidic	O
687	environment	O
687	.	O
687	[SEP]	O
688	[CLS]	O
688	3	O
688	.	O
688	co	O
688	-	O
688	administration	O
688	of	O
688	ten	O
688	##ida	O
688	##p	O
688	with	O
688	food	O
688	produced	O
688	a	O
688	statistical	O
688	##ly	O
688	significant	O
688	delay	O
688	in	O
688	the	O
688	rate	O
688	of	O
688	absorption	O
688	(	O
688	t	B-PK
688	##max	I-PK
688	,	O
688	4	O
688	.	O
688	4	O
688	h	O
688	)	O
688	(	O
688	p	O
688	<	O
688	0	O
688	.	O
688	00	O
688	##1	O
688	)	O
688	.	O
688	[SEP]	O
689	[CLS]	O
689	control	O
689	rats	O
689	(	O
689	n	O
689	=	O
689	5	O
689	)	O
689	received	O
689	sa	O
689	##line	O
689	at	O
689	the	O
689	same	O
689	time	O
689	.	O
689	[SEP]	O
690	[CLS]	O
690	his	O
690	##tamine	O
690	di	O
690	##hy	O
690	##dr	O
690	##och	O
690	##lor	O
690	##ide	O
690	administered	O
690	over	O
690	10	O
690	minutes	O
690	in	O
690	healthy	O
690	subjects	O
690	peaked	O
690	at	O
690	18	O
690	minutes	O
690	(	O
690	cm	B-PK
690	##ax	I-PK
690	38	O
690	nm	O
690	##ol	O
690	/	O
690	l	O
690	)	O
690	,	O
690	attained	O
690	a	O
690	distribution	B-PK
690	volume	I-PK
690	of	O
690	59	O
690	l	O
690	,	O
690	and	O
690	was	O
690	eliminated	O
690	at	O
690	6	O
690	%	O
690	/	O
690	min	O
690	.	O
690	[SEP]	O
691	[CLS]	O
691	plasma	O
691	concentration	O
691	–	O
691	time	O
691	curves	O
691	showed	O
691	a	O
691	decrease	O
691	in	O
691	a	O
691	##pta	O
691	##mer	O
691	concentration	O
691	with	O
691	a	O
691	half	B-PK
691	-	I-PK
691	life	I-PK
691	of	O
691	1	O
691	.	O
691	0	O
691	and	O
691	1	O
691	.	O
691	9	O
691	h	O
691	for	O
691	s	O
691	##l	O
691	##10	O
691	##26	O
691	and	O
691	s	O
691	##l	O
691	##10	O
691	##33	O
691	,	O
691	respectively	O
691	,	O
691	with	O
691	a	O
691	corresponding	O
691	clearance	B-PK
691	of	O
691	29	O
691	and	O
691	15	O
691	m	O
691	##l	O
691	/	O
691	(	O
691	h	O
691	*	O
691	kg	O
691	)	O
691	(	O
691	fi	O
691	##g	O
691	.	O
691	1	O
691	and	O
691	supplement	O
691	##ary	O
691	table	O
691	s	O
691	##2	O
691	)	O
691	.	O
691	[SEP]	O
692	[CLS]	O
692	the	O
692	via	O
692	##ls	O
692	were	O
692	kept	O
692	in	O
692	an	O
692	is	O
692	##oth	O
692	##er	O
692	##mal	O
692	shake	O
692	##r	O
692	(	O
692	g	O
692	##f	O
692	##l	O
692	##10	O
692	##9	O
692	##2	O
692	,	O
692	b	O
692	##urg	O
692	##wed	O
692	##el	O
692	,	O
692	g	O
692	##erman	O
692	##y	O
692	)	O
692	at	O
692	50	O
692	±	O
692	1	O
692	.	O
692	0	O
692	°	O
692	##c	O
692	for	O
692	72	O
692	h	O
692	until	O
692	ho	O
692	##mo	O
692	##gene	O
692	##ity	O
692	is	O
692	achieved	O
692	.	O
692	[SEP]	O
693	[CLS]	O
693	each	O
693	route	O
693	and	O
693	dose	O
693	combination	O
693	was	O
693	given	O
693	to	O
693	a	O
693	single	O
693	male	O
693	animal	O
693	,	O
693	blood	O
693	samples	O
693	were	O
693	collected	O
693	for	O
693	evaluation	O
693	of	O
693	bio	O
693	##mark	O
693	##ers	O
693	and	O
693	p	O
693	##har	O
693	##ma	O
693	##co	O
693	##kin	O
693	##etics	O
693	.	O
693	[SEP]	O
694	[CLS]	O
694	d	O
694	##t	O
694	##g	O
694	-	O
694	d	O
694	##3	O
694	and	O
694	my	O
694	##risto	O
694	##yla	O
694	##ted	O
694	cab	O
694	##ote	O
694	##gra	O
694	##vir	O
694	(	O
694	m	O
694	##ca	O
694	##b	O
694	)	O
694	were	O
694	used	O
694	as	O
694	is	O
694	for	O
694	d	O
694	##t	O
694	##g	O
694	and	O
694	m	O
694	##dt	O
694	##g	O
694	analysis	O
694	,	O
694	respectively	O
694	.	O
694	[SEP]	O
695	[CLS]	O
695	mean	O
695	recovery	O
695	of	O
695	radio	O
695	##car	O
695	##bon	O
695	in	O
695	urine	O
695	was	O
695	86	O
695	.	O
695	8	O
695	+	O
695	-	O
695	1	O
695	.	O
695	9	O
695	%	O
695	and	O
695	in	O
695	f	O
695	##ae	O
695	##ces	O
695	7	O
695	.	O
695	4	O
695	+	O
695	-	O
695	1	O
695	.	O
695	5	O
695	%	O
695	.	O
695	[SEP]	O
696	[CLS]	O
696	significant	O
696	differences	O
696	were	O
696	found	O
696	between	O
696	the	O
696	liver	O
696	up	O
696	##take	O
696	of	O
696	mice	O
696	injected	O
696	with	O
696	86	O
696	##y	O
696	-	O
696	ch	O
696	##x	O
696	-	O
696	a	O
696	’	O
696	’	O
696	-	O
696	d	O
696	##t	O
696	##pa	O
696	-	O
696	pan	O
696	##it	O
696	##um	O
696	##uma	O
696	##b	O
696	and	O
696	mice	O
696	injected	O
696	with	O
696	86	O
696	##y	O
696	-	O
696	ch	O
696	##x	O
696	-	O
696	a	O
696	’	O
696	’	O
696	-	O
696	d	O
696	##t	O
696	##pa	O
696	-	O
696	c	O
696	##et	O
696	##ux	O
696	##ima	O
696	##b	O
696	,	O
696	particularly	O
696	in	O
696	the	O
696	n	O
696	##ci	O
696	-	O
696	h	O
696	##22	O
696	##6	O
696	and	O
696	m	O
696	##sto	O
696	-	O
696	211	O
696	##h	O
696	tumor	O
696	models	O
696	.	O
696	[SEP]	O
697	[CLS]	O
697	t	O
697	##umour	O
697	volume	O
697	and	O
697	body	O
697	weight	O
697	values	O
697	are	O
697	presented	O
697	as	O
697	the	O
697	mean	O
697	±	O
697	standard	O
697	error	O
697	of	O
697	mean	O
697	(	O
697	se	O
697	##m	O
697	)	O
697	and	O
697	percent	O
697	change	O
697	,	O
697	respectively	O
697	.	O
697	[SEP]	O
698	[CLS]	O
698	dose	O
698	/	O
698	body	O
698	##weight	O
698	,	O
698	and	O
698	t	B-PK
698	##rough	I-PK
698	plasma	I-PK
698	concentrations	I-PK
698	of	O
698	(	O
698	r	O
698	)	O
698	-	O
698	or	O
698	(	O
698	r	O
698	,	O
698	s	O
698	)	O
698	-	O
698	met	O
698	##had	O
698	##one	O
698	were	O
698	no	O
698	better	O
698	predict	O
698	##ors	O
698	of	O
698	treatment	O
698	response	O
698	than	O
698	daily	O
698	dose	O
698	,	O
698	and	O
698	did	O
698	not	O
698	improve	O
698	the	O
698	fit	O
698	of	O
698	the	O
698	model	O
698	for	O
698	treatment	O
698	outcome	O
698	as	O
698	judged	O
698	by	O
698	the	O
698	likelihood	O
698	ratio	O
698	test	O
698	(	O
698	p	O
698	=	O
698	0	O
698	.	O
698	21	O
698	,	O
698	0	O
698	.	O
698	88	O
698	,	O
698	and	O
698	0	O
698	.	O
698	97	O
698	,	O
698	respectively	O
698	)	O
698	.	O
698	[SEP]	O
699	[CLS]	O
699	p	O
699	##t	O
699	concentrations	O
699	in	O
699	plasma	O
699	ultra	O
699	##fi	O
699	##lt	O
699	##rate	O
699	(	O
699	pu	O
699	##f	O
699	)	O
699	and	O
699	in	O
699	total	O
699	plasma	O
699	declined	O
699	in	O
699	parallel	O
699	and	O
699	became	O
699	barely	O
699	detect	O
699	##able	O
699	by	O
699	2	O
699	h	O
699	following	O
699	c	O
699	##b	O
699	##d	O
699	##ca	O
699	injection	O
699	.	O
699	[SEP]	O
700	[CLS]	O
700	to	O
700	determine	O
700	if	O
700	re	O
700	##bas	O
700	##tin	O
700	##ib	O
700	could	O
700	in	O
700	##hibit	O
700	b	O
700	##c	O
700	##r	O
700	-	O
700	a	O
700	##b	O
700	##l	O
700	##1	O
700	or	O
700	fl	O
700	##t	O
700	##3	O
700	in	O
700	samples	O
700	from	O
700	t	O
700	##ki	O
700	-	O
700	resistant	O
700	patients	O
700	,	O
700	blood	O
700	samples	O
700	were	O
700	in	O
700	##cu	O
700	##bate	O
700	##d	O
700	with	O
700	re	O
700	##bas	O
700	##tin	O
700	##ib	O
700	ex	O
700	v	O
700	##ivo	O
700	and	O
700	the	O
700	p	O
700	##hos	O
700	##ph	O
700	##ory	O
700	##lation	O
700	of	O
700	c	O
700	##rk	O
700	##l	O
700	or	O
700	fl	O
700	##t	O
700	##3	O
700	was	O
700	measured	O
700	.	O
700	[SEP]	O
701	[CLS]	O
701	peripheral	O
701	administration	O
701	of	O
701	a	O
701	novel	O
701	di	O
701	##ket	O
701	##op	O
701	##iper	O
701	##azi	O
701	##ne	O
701	,	O
701	n	O
701	##nz	O
701	25	O
701	##9	O
701	##1	O
701	,	O
701	prevents	O
701	brain	O
701	injury	O
701	and	O
701	improve	O
701	##s	O
701	so	O
701	##mat	O
701	##ose	O
701	##nso	O
701	##ry	O
701	-	O
701	motor	O
701	function	O
701	following	O
701	h	O
701	##y	O
701	##pox	O
701	##ia	O
701	-	O
701	is	O
701	##che	O
701	##mia	O
701	in	O
701	adult	O
701	rats	O
701	.	O
701	[SEP]	O
702	[CLS]	O
702	red	O
702	solid	O
702	.	O
702	[SEP]	O
703	[CLS]	O
703	main	O
703	outcome	O
703	measure	O
703	p	O
703	##har	O
703	##ma	O
703	##co	O
703	##kin	O
703	##etic	O
703	parameters	O
703	and	O
703	the	O
703	incidence	O
703	##s	O
703	of	O
703	ne	O
703	##ph	O
703	##rot	O
703	##ox	O
703	##icit	O
703	##y	O
703	were	O
703	compared	O
703	between	O
703	the	O
703	morning	O
703	,	O
703	afternoon	O
703	and	O
703	evening	O
703	groups	O
703	.	O
703	[SEP]	O
704	[CLS]	O
704	nevertheless	O
704	,	O
704	the	O
704	mechanisms	O
704	leading	O
704	to	O
704	the	O
704	targeted	O
704	long	O
704	-	O
704	acting	O
704	p	O
704	##har	O
704	##ma	O
704	##co	O
704	##kin	O
704	##etics	O
704	remain	O
704	el	O
704	##usive	O
704	.	O
704	[SEP]	O
705	[CLS]	O
705	p	O
705	##hy	O
705	##sio	O
705	##log	O
705	##ic	O
705	differences	O
705	suggest	O
705	the	O
705	need	O
705	for	O
705	g	O
705	##esta	O
705	##tional	O
705	age	O
705	-	O
705	appropriate	O
705	treatment	O
705	strategies	O
705	.	O
705	[SEP]	O
706	[CLS]	O
706	the	O
706	f	O
706	##em	O
706	##urs	O
706	were	O
706	th	O
706	##awed	O
706	prior	O
706	to	O
706	testing	O
706	,	O
706	and	O
706	the	O
706	bone	O
706	strength	O
706	of	O
706	the	O
706	intact	O
706	f	O
706	##em	O
706	##urs	O
706	was	O
706	measured	O
706	using	O
706	a	O
706	three	O
706	-	O
706	point	O
706	bending	O
706	test	O
706	.	O
706	[SEP]	O
707	[CLS]	O
707	the	O
707	mean	O
707	measured	O
707	g	O
707	##f	O
707	##r	O
707	was	O
707	87	O
707	m	O
707	##l	O
707	/	O
707	min	O
707	(	O
707	range	O
707	30	O
707	-	O
707	174	O
707	m	O
707	##l	O
707	/	O
707	min	O
707	)	O
707	.	O
707	[SEP]	O
708	[CLS]	O
708	an	O
708	in	O
708	v	O
708	##ivo	O
708	study	O
708	revealed	O
708	that	O
708	d	O
708	##m	O
708	-	O
708	beta	O
708	-	O
708	c	O
708	##yd	O
708	increased	O
708	the	O
708	bio	B-PK
708	##ava	I-PK
708	##ila	I-PK
708	##bility	I-PK
708	of	O
708	ta	O
708	##c	O
708	##rol	O
708	##imus	O
708	with	O
708	low	O
708	var	O
708	##iability	O
708	in	O
708	the	O
708	absorption	O
708	after	O
708	oral	O
708	administration	O
708	of	O
708	the	O
708	ta	O
708	##c	O
708	##rol	O
708	##imus	O
708	suspension	O
708	to	O
708	rats	O
708	.	O
708	[SEP]	O
709	[CLS]	O
709	all	O
709	plasma	O
709	samples	O
709	were	O
709	analyzed	O
709	for	O
709	m	O
709	##pa	O
709	and	O
709	m	O
709	##pa	O
709	##g	O
709	at	O
709	euro	O
709	##fin	O
709	##s	O
709	me	O
709	##dine	O
709	##t	O
709	laboratory	O
709	in	O
709	the	O
709	net	O
709	##her	O
709	##lands	O
709	by	O
709	a	O
709	specific	O
709	valid	O
709	##ated	O
709	liquid	O
709	ch	O
709	##roma	O
709	##tography	O
709	-	O
709	mass	O
709	s	O
709	##pect	O
709	##rome	O
709	##try	O
709	method	O
709	.	O
709	[SEP]	O
710	[CLS]	O
710	the	O
710	l	O
710	##qi	O
710	covers	O
710	four	O
710	domains	O
710	:	O
710	treatment	O
710	interference	O
710	,	O
710	therapy	O
710	‐	O
710	related	O
710	problems	O
710	,	O
710	therapy	O
710	settings	O
710	and	O
710	treatment	O
710	costs	O
710	.	O
710	[SEP]	O
711	[CLS]	O
711	compared	O
711	with	O
711	in	O
711	##tra	O
711	-	O
711	r	O
711	##umi	O
711	##nal	O
711	administration	O
711	,	O
711	in	O
711	##tra	O
711	-	O
711	a	O
711	##bo	O
711	##mas	O
711	##al	O
711	in	O
711	##fusion	O
711	of	O
711	f	O
711	##en	O
711	##ben	O
711	##da	O
711	##zo	O
711	##le	O
711	lowered	O
711	the	O
711	area	B-PK
711	under	I-PK
711	the	I-PK
711	concentration	I-PK
711	-	I-PK
711	time	I-PK
711	curve	I-PK
711	of	O
711	drug	O
711	in	O
711	both	O
711	plasma	O
711	and	O
711	a	O
711	##bo	O
711	##mas	O
711	##al	O
711	fluid	O
711	;	O
711	in	O
711	##tra	O
711	-	O
711	a	O
711	##bo	O
711	##mas	O
711	##al	O
711	in	O
711	##fusion	O
711	of	O
711	al	O
711	##ben	O
711	##da	O
711	##zo	O
711	##le	O
711	substantially	O
711	increased	O
711	maximum	B-PK
711	drug	I-PK
711	concentration	I-PK
711	and	O
711	the	O
711	concentration	O
711	-	O
711	time	O
711	curve	O
711	in	O
711	a	O
711	##bo	O
711	##mas	O
711	##al	O
711	fluid	O
711	and	O
711	lowered	O
711	the	O
711	plasma	O
711	concentration	O
711	time	O
711	curve	O
711	of	O
711	the	O
711	su	O
711	##l	O
711	##ph	O
711	##oxide	O
711	meta	O
711	##bol	O
711	##ite	O
711	;	O
711	in	O
711	##tra	O
711	-	O
711	a	O
711	##bo	O
711	##mas	O
711	##al	O
711	in	O
711	##fusion	O
711	of	O
711	o	O
711	##x	O
711	##fen	O
711	##da	O
711	##zo	O
711	##le	O
711	increased	O
711	maximum	B-PK
711	concentration	I-PK
711	and	O
711	the	O
711	concentration	O
711	-	O
711	time	O
711	curve	O
711	of	O
711	drug	O
711	in	O
711	plasma	O
711	and	O
711	a	O
711	##bo	O
711	##mas	O
711	##al	O
711	fluid	O
711	.	O
711	[SEP]	O
712	[CLS]	O
712	in	O
712	four	O
712	patients	O
712	who	O
712	achieved	O
712	partial	O
712	re	O
712	##mission	O
712	,	O
712	the	O
712	average	O
712	plasma	B-PK
712	half	I-PK
712	-	I-PK
712	life	I-PK
712	of	O
712	v	O
712	##l	O
712	##b	O
712	during	O
712	the	O
712	terminal	O
712	phase	O
712	was	O
712	29	O
712	.	O
712	4	O
712	+	O
712	-	O
712	14	O
712	.	O
712	6	O
712	days	O
712	,	O
712	with	O
712	a	O
712	total	B-PK
712	clearance	I-PK
712	of	O
712	36	O
712	+	O
712	-	O
712	8	O
712	m	O
712	##l	O
712	/	O
712	kg	O
712	/	O
712	h	O
712	##r	O
712	,	O
712	and	O
712	a	O
712	steady	B-PK
712	-	I-PK
712	state	I-PK
712	apparent	I-PK
712	volume	I-PK
712	of	I-PK
712	distribution	I-PK
712	of	O
712	28	O
712	.	O
712	1	O
712	+	O
712	-	O
712	8	O
712	.	O
712	5	O
712	liter	O
712	##s	O
712	/	O
712	kg	O
712	.	O
712	[SEP]	O
713	[CLS]	O
713	more	O
713	##over	O
713	,	O
713	despite	O
713	suppression	O
713	by	O
713	t	O
713	.	O
713	can	O
713	##is	O
713	anti	O
713	##gens	O
713	,	O
713	stimulation	O
713	of	O
713	the	O
713	immune	O
713	system	O
713	by	O
713	the	O
713	im	O
713	##mu	O
713	##no	O
713	##mo	O
713	##du	O
713	##lator	O
713	g	O
713	##lu	O
713	##can	O
713	potent	O
713	##iate	O
713	##s	O
713	the	O
713	effects	O
713	of	O
713	these	O
713	anti	O
713	##par	O
713	##asi	O
713	##tic	O
713	drugs	O
713	.	O
713	[SEP]	O
714	[CLS]	O
714	severe	O
714	pro	O
714	##stra	O
714	##tion	O
714	,	O
714	severe	O
714	acid	O
714	##osis	O
714	,	O
714	con	O
714	##vu	O
714	##ls	O
714	##ions	O
714	,	O
714	and	O
714	severe	O
714	an	O
714	##emia	O
714	were	O
714	the	O
714	most	O
714	common	O
714	severity	O
714	criteria	O
714	.	O
714	[SEP]	O
715	[CLS]	O
715	no	O
715	is	O
715	##oto	O
715	##pe	O
715	effects	O
715	were	O
715	observed	O
715	after	O
715	oral	O
715	administration	O
715	of	O
715	e	O
715	##qui	O
715	##mo	O
715	##lar	O
715	amounts	O
715	of	O
715	de	O
715	##uter	O
715	##ated	O
715	and	O
715	un	O
715	##la	O
715	##bell	O
715	##ed	O
715	(	O
715	s	O
715	)	O
715	-	O
715	f	O
715	##elo	O
715	##di	O
715	##pine	O
715	.	O
715	[SEP]	O
716	[CLS]	O
716	good	O
716	correlation	O
716	##s	O
716	of	O
716	the	O
716	a	O
716	##oz	O
716	concentration	O
716	were	O
716	found	O
716	between	O
716	plasma	O
716	and	O
716	muscle	O
716	,	O
716	plasma	O
716	and	O
716	liver	O
716	,	O
716	urine	O
716	and	O
716	liver	O
716	,	O
716	and	O
716	urine	O
716	and	O
716	kidney	O
716	in	O
716	the	O
716	de	O
716	##ple	O
716	##tion	O
716	period	O
716	of	O
716	7	O
716	-	O
716	63	O
716	or	O
716	21	O
716	-	O
716	63	O
716	days	O
716	,	O
716	with	O
716	correlation	O
716	coefficients	O
716	of	O
716	more	O
716	than	O
716	0	O
716	.	O
716	97	O
716	and	O
716	p	O
716	values	O
716	less	O
716	than	O
716	0	O
716	.	O
716	05	O
716	.	O
716	[SEP]	O
717	[CLS]	O
717	after	O
717	in	O
717	##tra	O
717	##mus	O
717	##cular	O
717	injection	O
717	and	O
717	re	O
717	##ct	O
717	##al	O
717	administration	O
717	of	O
717	an	O
717	a	O
717	##que	O
717	##ous	O
717	suspension	O
717	,	O
717	very	O
717	low	O
717	and	O
717	variable	O
717	art	O
717	##em	O
717	##isi	O
717	##nin	O
717	concentrations	O
717	in	O
717	serum	O
717	were	O
717	observed	O
717	,	O
717	probably	O
717	indicating	O
717	a	O
717	poor	O
717	and	O
717	erratic	O
717	absorption	O
717	.	O
717	[SEP]	O
718	[CLS]	O
718	the	O
718	current	O
718	study	O
718	investigated	O
718	the	O
718	p	O
718	##har	O
718	##ma	O
718	##co	O
718	##kin	O
718	##etics	O
718	(	O
718	p	O
718	##k	O
718	)	O
718	,	O
718	p	O
718	##har	O
718	##ma	O
718	##co	O
718	##dynamic	O
718	##s	O
718	(	O
718	p	O
718	##d	O
718	)	O
718	,	O
718	and	O
718	safety	O
718	of	O
718	combining	O
718	ve	O
718	##rin	O
718	##ura	O
718	##d	O
718	with	O
718	all	O
718	##op	O
718	##uri	O
718	##no	O
718	##l	O
718	in	O
718	adult	O
718	male	O
718	subjects	O
718	with	O
718	go	O
718	##ut	O
718	.	O
718	[SEP]	O
719	[CLS]	O
719	we	O
719	tested	O
719	the	O
719	effects	O
719	of	O
719	y	O
719	##m	O
719	-	O
719	35	O
719	##9	O
719	##44	O
719	##5	O
719	on	O
719	ve	O
719	##g	O
719	##f	O
719	##r	O
719	##2	O
719	t	O
719	##yr	O
719	##os	O
719	##ine	O
719	kinase	O
719	activity	O
719	,	O
719	cell	O
719	proliferation	O
719	,	O
719	and	O
719	an	O
719	##gio	O
719	##genesis	O
719	.	O
719	[SEP]	O
720	[CLS]	O
720	over	O
720	4	O
720	separate	O
720	study	O
720	days	O
720	,	O
720	synthetic	O
720	human	O
720	g	O
720	##ip	O
720	or	O
720	g	O
720	##l	O
720	##p	O
720	-	O
720	1	O
720	was	O
720	in	O
720	##fused	O
720	with	O
720	or	O
720	without	O
720	concurrent	O
720	in	O
720	##hibition	O
720	of	O
720	dip	O
720	##ept	O
720	##idy	O
720	##l	O
720	p	O
720	##ept	O
720	##idas	O
720	##e	O
720	4	O
720	using	O
720	sit	O
720	##ag	O
720	##lip	O
720	##tin	O
720	or	O
720	place	O
720	##bo	O
720	.	O
720	[SEP]	O
721	[CLS]	O
721	data	O
721	were	O
721	available	O
721	on	O
721	21	O
721	c	O
721	##y	O
721	##c	O
721	##lop	O
721	##hos	O
721	##pha	O
721	##mi	O
721	##de	O
721	courses	O
721	from	O
721	15	O
721	patients	O
721	.	O
721	[SEP]	O
722	[CLS]	O
722	mean	O
722	(	O
722	90	O
722	%	O
722	c	O
722	##i	O
722	)	O
722	treatment	O
722	differences	O
722	in	O
722	t	O
722	##ns	O
722	##s	O
722	over	O
722	0	O
722	-	O
722	4	O
722	hours	O
722	were	O
722	:	O
722	s	O
722	##b	O
722	-	O
722	70	O
722	##5	O
722	##4	O
722	##9	O
722	##8	O
722	-	O
722	place	O
722	##bo	O
722	:	O
722	-	O
722	0	O
722	.	O
722	2	O
722	(	O
722	-	O
722	0	O
722	.	O
722	9	O
722	,	O
722	0	O
722	.	O
722	4	O
722	)	O
722	;	O
722	s	O
722	##b	O
722	-	O
722	70	O
722	##5	O
722	##4	O
722	##9	O
722	##8	O
722	plus	O
722	f	O
722	##p	O
722	-	O
722	f	O
722	##p	O
722	:	O
722	0	O
722	.	O
722	7	O
722	(	O
722	0	O
722	.	O
722	2	O
722	,	O
722	1	O
722	.	O
722	2	O
722	)	O
722	;	O
722	f	O
722	##p	O
722	-	O
722	place	O
722	##bo	O
722	:	O
722	-	O
722	2	O
722	.	O
722	9	O
722	(	O
722	-	O
722	3	O
722	.	O
722	4	O
722	,	O
722	-	O
722	2	O
722	.	O
722	5	O
722	)	O
722	;	O
722	s	O
722	##b	O
722	-	O
722	70	O
722	##5	O
722	##4	O
722	##9	O
722	##8	O
722	plus	O
722	f	O
722	##p	O
722	-	O
722	place	O
722	##bo	O
722	:	O
722	-	O
722	2	O
722	.	O
722	3	O
722	(	O
722	-	O
722	2	O
722	.	O
722	8	O
722	,	O
722	-	O
722	1	O
722	.	O
722	8	O
722	)	O
722	.	O
722	[SEP]	O
723	[CLS]	O
723	previous	O
723	studies	O
723	have	O
723	revealed	O
723	that	O
723	the	O
723	me	O
723	##g	O
723	##x	O
723	test	O
723	is	O
723	an	O
723	effective	O
723	tool	O
723	for	O
723	assessing	O
723	liver	O
723	function	O
723	and	O
723	further	O
723	##more	O
723	,	O
723	this	O
723	test	O
723	has	O
723	a	O
723	high	O
723	reliability	O
723	when	O
723	repeated	O
723	(	O
723	o	O
723	##eller	O
723	##ich	O
723	and	O
723	arms	O
723	##tron	O
723	##g	O
723	2001	O
723	)	O
723	.	O
723	[SEP]	O
724	[CLS]	O
724	however	O
724	,	O
724	all	O
724	of	O
724	the	O
724	distinct	O
724	peaks	O
724	disappeared	O
724	in	O
724	the	O
724	s	O
724	##d	O
724	particles	O
724	’	O
724	di	O
724	##ff	O
724	##rac	O
724	##to	O
724	##gram	O
724	,	O
724	which	O
724	indicated	O
724	that	O
724	the	O
724	crystal	O
724	form	O
724	did	O
724	not	O
724	exist	O
724	in	O
724	the	O
724	s	O
724	##d	O
724	particles	O
724	.	O
724	28	O
724	this	O
724	result	O
724	suggested	O
724	that	O
724	it	O
724	##z	O
724	might	O
724	exist	O
724	in	O
724	the	O
724	am	O
724	##or	O
724	##ph	O
724	##ous	O
724	state	O
724	in	O
724	s	O
724	##d	O
724	particles	O
724	,	O
724	as	O
724	frequently	O
724	observed	O
724	for	O
724	s	O
724	##ds	O
724	.	O
724	[SEP]	O
725	[CLS]	O
725	additionally	O
725	children	O
725	weighing	O
725	≥	O
725	##39	O
725	kg	O
725	can	O
725	receive	O
725	the	O
725	adult	O
725	regime	O
725	##n	O
725	.	O
725	[SEP]	O
726	[CLS]	O
726	a	O
726	##f	O
726	##li	O
726	##ber	O
726	##ce	O
726	##pt	O
726	treatment	O
726	resulted	O
726	in	O
726	the	O
726	greatest	O
726	reduction	O
726	##s	O
726	in	O
726	plasma	O
726	free	O
726	-	O
726	ve	O
726	##g	O
726	##f	O
726	relative	O
726	to	O
726	base	O
726	##line	O
726	levels	O
726	,	O
726	whereas	O
726	ran	O
726	##ibi	O
726	##zu	O
726	##ma	O
726	##b	O
726	treatment	O
726	resulted	O
726	in	O
726	the	O
726	smallest	O
726	decreases	O
726	in	O
726	plasma	O
726	free	O
726	-	O
726	ve	O
726	##g	O
726	##f	O
726	.	O
726	[SEP]	O
727	[CLS]	O
727	per	O
727	##f	O
727	##lu	O
727	##oro	O
727	##alk	O
727	##yl	O
727	acid	O
727	car	O
727	##box	O
727	##yla	O
727	##tes	O
727	and	O
727	su	O
727	##lf	O
727	##ona	O
727	##tes	O
727	(	O
727	p	O
727	##fa	O
727	##a	O
727	)	O
727	have	O
727	many	O
727	consumer	O
727	and	O
727	industrial	O
727	applications	O
727	.	O
727	[SEP]	O
728	[CLS]	O
728	p	O
728	##har	O
728	##ma	O
728	##co	O
728	##gene	O
728	##tic	O
728	studies	O
728	[SEP]	O
729	[CLS]	O
729	subjects	O
729	with	O
729	a	O
729	lifetime	O
729	history	O
729	of	O
729	drug	O
729	or	O
729	alcohol	O
729	dependence	O
729	were	O
729	excluded	O
729	,	O
729	as	O
729	were	O
729	heavy	O
729	users	O
729	of	O
729	tobacco	O
729	products	O
729	(	O
729	e	O
729	##g	O
729	,	O
729	subjects	O
729	who	O
729	smoked	O
729	more	O
729	than	O
729	20	O
729	cigarettes	O
729	per	O
729	day	O
729	and	O
729	were	O
729	unable	O
729	to	O
729	a	O
729	##bs	O
729	##tain	O
729	from	O
729	smoking	O
729	for	O
729	at	O
729	least	O
729	5	O
729	hours	O
729	during	O
729	the	O
729	day	O
729	)	O
729	.	O
729	[SEP]	O
730	[CLS]	O
730	q	O
730	##con	O
730	##cat	O
730	-	O
730	based	O
730	data	O
730	revealed	O
730	generally	O
730	poor	O
730	correlation	O
730	with	O
730	activity	O
730	,	O
730	whereas	O
730	moderate	O
730	correlation	O
730	##s	O
730	were	O
730	shown	O
730	for	O
730	u	O
730	##gt	O
730	##s	O
730	1	O
730	##a	O
730	##1	O
730	,	O
730	1	O
730	##a	O
730	##3	O
730	,	O
730	and	O
730	2	O
730	##b	O
730	##7	O
730	.	O
730	[SEP]	O
731	[CLS]	O
731	the	O
731	combination	O
731	with	O
731	p	O
731	##yr	O
731	##ona	O
731	##rid	O
731	##ine	O
731	-	O
731	art	O
731	##es	O
731	##unate	O
731	resulted	O
731	in	O
731	significantly	O
731	higher	O
731	car	O
731	##box	O
731	##y	O
731	##p	O
731	##rima	O
731	##quin	O
731	##e	O
731	maximum	B-PK
731	concentrations	I-PK
731	(	O
731	p	O
731	=	O
731	0	O
731	.	O
731	01	O
731	##1	O
731	)	O
731	,	O
731	lower	O
731	volumes	B-PK
731	of	I-PK
731	distribution	I-PK
731	(	O
731	p	O
731	=	O
731	0	O
731	.	O
731	00	O
731	##1	O
731	)	O
731	,	O
731	and	O
731	shorter	O
731	terminal	B-PK
731	elimination	I-PK
731	half	I-PK
731	-	I-PK
731	life	I-PK
731	(	O
731	p	O
731	=	O
731	0	O
731	.	O
731	00	O
731	##1	O
731	)	O
731	than	O
731	when	O
731	p	O
731	##rima	O
731	##quin	O
731	##e	O
731	was	O
731	administered	O
731	alone	O
731	(	O
731	table	O
731	6	O
731	)	O
731	.	O
731	[SEP]	O
732	[CLS]	O
732	although	O
732	d	O
732	##p	O
732	##g	O
732	showed	O
732	p	O
732	##h	O
732	-	O
732	dependent	O
732	dissolution	O
732	behavior	O
732	,	O
732	d	O
732	##p	O
732	##g	O
732	with	O
732	t	O
732	##s	O
732	exhibited	O
732	a	O
732	high	O
732	rate	O
732	and	O
732	extent	O
732	of	O
732	dissolution	O
732	in	O
732	both	O
732	acidic	O
732	and	O
732	neutral	O
732	media	O
732	.	O
732	[SEP]	O
733	[CLS]	O
733	animals	O
733	used	O
733	for	O
733	micro	O
733	##dial	O
733	##ys	O
733	##is	O
733	experiments	O
733	also	O
733	received	O
733	micro	O
733	##dial	O
733	##ys	O
733	##is	O
733	guides	O
733	with	O
733	du	O
733	##mmy	O
733	probe	O
733	##s	O
733	(	O
733	cm	O
733	##a	O
733	,	O
733	so	O
733	##ln	O
733	##a	O
733	,	O
733	s	O
733	##wed	O
733	##en	O
733	)	O
733	in	O
733	the	O
733	ca	O
733	##uda	O
733	##te	O
733	put	O
733	##ame	O
733	##n	O
733	(	O
733	c	O
733	##p	O
733	;	O
733	coordinates	O
733	from	O
733	br	O
733	##eg	O
733	##ma	O
733	,	O
733	a	O
733	##p	O
733	-	O
733	1	O
733	.	O
733	0	O
733	mm	O
733	l	O
733	+	O
733	3	O
733	.	O
733	0	O
733	mm	O
733	v	O
733	-	O
733	3	O
733	.	O
733	4	O
733	mm	O
733	)	O
733	and	O
733	in	O
733	the	O
733	c	O
733	##ister	O
733	##na	O
733	ma	O
733	##gna	O
733	(	O
733	cm	O
733	;	O
733	coordinates	O
733	from	O
733	la	O
733	##mb	O
733	##da	O
733	,	O
733	a	O
733	##p	O
733	-	O
733	2	O
733	.	O
733	51	O
733	mm	O
733	l	O
733	+	O
733	2	O
733	.	O
733	04	O
733	mm	O
733	v	O
733	-	O
733	8	O
733	.	O
733	34	O
733	mm	O
733	,	O
733	at	O
733	an	O
733	angle	O
733	of	O
733	25	O
733	##°	O
733	anterior	O
733	from	O
733	the	O
733	do	O
733	##rs	O
733	##ove	O
733	##nt	O
733	##ral	O
733	axis	O
733	and	O
733	11	O
733	##°	O
733	lateral	O
733	from	O
733	the	O
733	ant	O
733	##ero	O
733	##post	O
733	##eri	O
733	##or	O
733	axis	O
733	)	O
733	(	O
733	17	O
733	)	O
733	.	O
733	[SEP]	O
734	[CLS]	O
734	the	O
734	vent	O
734	##ila	O
734	##tor	O
734	was	O
734	set	O
734	to	O
734	give	O
734	a	O
734	tidal	O
734	volume	O
734	of	O
734	8	O
734	m	O
734	##l	O
734	/	O
734	kg	O
734	at	O
734	a	O
734	rate	O
734	of	O
734	12	O
734	-	O
734	14	O
734	/	O
734	min	O
734	.	O
734	[SEP]	O
735	[CLS]	O
735	the	O
735	g	O
735	##eno	O
735	##ty	O
735	##ping	O
735	methods	O
735	are	O
735	based	O
735	on	O
735	the	O
735	5	O
735	′	O
735	-	O
735	n	O
735	##uc	O
735	##lea	O
735	##se	O
735	activity	O
735	method	O
735	(	O
735	ta	O
735	##q	O
735	##man	O
735	##®	O
735	)	O
735	employing	O
735	two	O
735	prime	O
735	##rs	O
735	and	O
735	two	O
735	fluorescent	O
735	labeled	O
735	probe	O
735	##s	O
735	in	O
735	a	O
735	real	O
735	-	O
735	time	O
735	based	O
735	ass	O
735	##ay	O
735	as	O
735	earlier	O
735	described	O
735	(	O
735	s	O
735	##chu	O
735	##l	O
735	##ze	O
735	et	O
735	al	O
735	.	O
735	,	O
735	2008	O
735	##a	O
735	)	O
735	.	O
735	[SEP]	O
736	[CLS]	O
736	the	O
736	aim	O
736	of	O
736	this	O
736	study	O
736	was	O
736	to	O
736	assess	O
736	the	O
736	p	O
736	##har	O
736	##ma	O
736	##co	O
736	##kin	O
736	##etics	O
736	and	O
736	subsequent	O
736	p	O
736	##har	O
736	##ma	O
736	##co	O
736	##dynamic	O
736	interaction	O
736	of	O
736	m	O
736	##p	O
736	##c	O
736	-	O
736	130	O
736	##4	O
736	,	O
736	a	O
736	di	O
736	##hy	O
736	##dr	O
736	##opy	O
736	##rid	O
736	##ine	O
736	ca	O
736	##2	O
736	+	O
736	antagonist	O
736	,	O
736	with	O
736	other	O
736	drugs	O
736	in	O
736	animal	O
736	experiments	O
736	.	O
736	[SEP]	O
737	[CLS]	O
737	de	O
737	##ox	O
737	##yn	O
737	##ival	O
737	##eno	O
737	##l	O
737	(	O
737	don	O
737	)	O
737	is	O
737	a	O
737	my	O
737	##cot	O
737	##ox	O
737	##in	O
737	frequently	O
737	found	O
737	as	O
737	a	O
737	con	O
737	##tam	O
737	##ina	O
737	##nt	O
737	of	O
737	cereal	O
737	crops	O
737	and	O
737	may	O
737	be	O
737	et	O
737	##iol	O
737	##ogical	O
737	##ly	O
737	associated	O
737	with	O
737	adverse	O
737	health	O
737	effects	O
737	in	O
737	developing	O
737	countries	O
737	where	O
737	considerable	O
737	quantities	O
737	of	O
737	contaminated	O
737	crops	O
737	are	O
737	consumed	O
737	.	O
737	[SEP]	O
738	[CLS]	O
738	the	O
738	aim	O
738	of	O
738	this	O
738	study	O
738	was	O
738	to	O
738	develop	O
738	and	O
738	valid	O
738	##ate	O
738	a	O
738	rapid	O
738	and	O
738	sensitive	O
738	liquid	O
738	ch	O
738	##roma	O
738	##tography	O
738	-	O
738	tandem	O
738	mass	O
738	s	O
738	##pect	O
738	##rome	O
738	##tric	O
738	(	O
738	l	O
738	##c	O
738	-	O
738	m	O
738	##s	O
738	/	O
738	m	O
738	##s	O
738	)	O
738	method	O
738	for	O
738	measuring	O
738	plasma	O
738	and	O
738	u	O
738	##ter	O
738	##ine	O
738	tissue	O
738	levels	O
738	of	O
738	in	O
738	##dom	O
738	##eth	O
738	##ac	O
738	##in	O
738	in	O
738	rabbits	O
738	after	O
738	insertion	O
738	of	O
738	in	O
738	##dom	O
738	##eth	O
738	##ac	O
738	##in	O
738	-	O
738	me	O
738	##dicated	O
738	cu	O
738	-	O
738	i	O
738	##uds	O
738	.	O
738	[SEP]	O
739	[CLS]	O
739	lo	O
739	##met	O
739	##re	O
739	##x	O
739	##ol	O
739	is	O
739	a	O
739	promising	O
739	,	O
739	anti	O
739	##can	O
739	##cer	O
739	agent	O
739	.	O
739	[SEP]	O
740	[CLS]	O
740	ex	O
740	##cre	O
740	##tion	O
740	of	O
740	cry	O
740	##pt	O
740	##ota	O
740	##ns	O
740	##hino	O
740	##ne	O
740	and	O
740	its	O
740	meta	O
740	##bol	O
740	##ites	O
740	into	O
740	urine	O
740	was	O
740	extremely	O
740	low	O
740	,	O
740	and	O
740	they	O
740	were	O
740	mainly	O
740	ex	O
740	##cre	O
740	##ted	O
740	into	O
740	f	O
740	##ae	O
740	##ces	O
740	and	O
740	bi	O
740	##le	O
740	.	O
740	[SEP]	O
741	[CLS]	O
741	p	O
741	##har	O
741	##ma	O
741	##co	O
741	##kin	O
741	##etics	O
741	of	O
741	the	O
741	novel	O
741	,	O
741	high	O
741	-	O
741	affinity	O
741	and	O
741	selective	O
741	do	O
741	##pa	O
741	##mine	O
741	d	O
741	##3	O
741	receptor	O
741	antagonist	O
741	s	O
741	##b	O
741	-	O
741	27	O
741	##70	O
741	##11	O
741	in	O
741	rat	O
741	,	O
741	dog	O
741	and	O
741	monkey	O
741	:	O
741	in	O
741	v	O
741	##it	O
741	##ro	O
741	/	O
741	in	O
741	v	O
741	##ivo	O
741	correlation	O
741	and	O
741	the	O
741	role	O
741	of	O
741	al	O
741	##de	O
741	##hy	O
741	##de	O
741	o	O
741	##xi	O
741	##das	O
741	##e	O
741	.	O
741	[SEP]	O
742	[CLS]	O
742	a	O
742	good	O
742	correlation	O
742	between	O
742	both	O
742	techniques	O
742	was	O
742	found	O
742	(	O
742	r	O
742	=	O
742	0	O
742	.	O
742	95	O
742	##3	O
742	)	O
742	when	O
742	tissue	O
742	samples	O
742	were	O
742	analyzed	O
742	with	O
742	both	O
742	methods	O
742	.	O
742	[SEP]	O
743	[CLS]	O
743	only	O
743	c	O
743	##sa	O
743	concentrations	O
743	that	O
743	were	O
743	greater	O
743	than	O
743	the	O
743	valid	O
743	##ated	O
743	lower	O
743	limit	O
743	of	O
743	q	O
743	##uant	O
743	##itation	O
743	(	O
743	ll	O
743	##o	O
743	##q	O
743	)	O
743	of	O
743	0	O
743	.	O
743	1	O
743	ng	O
743	/	O
743	m	O
743	##l	O
743	were	O
743	included	O
743	in	O
743	the	O
743	analysis	O
743	.	O
743	[SEP]	O
744	[CLS]	O
744	on	O
744	those	O
744	days	O
744	,	O
744	plasma	O
744	samples	O
744	were	O
744	obtained	O
744	before	O
744	the	O
744	daily	O
744	b	O
744	##udes	O
744	##oni	O
744	##de	O
744	administration	O
744	and	O
744	0	O
744	.	O
744	5	O
744	,	O
744	1	O
744	,	O
744	2	O
744	,	O
744	4	O
744	,	O
744	and	O
744	7	O
744	hours	O
744	after	O
744	drug	O
744	administration	O
744	,	O
744	whereas	O
744	urine	O
744	samples	O
744	were	O
744	obtained	O
744	after	O
744	collection	O
744	of	O
744	the	O
744	last	O
744	blood	O
744	sample	O
744	.	O
744	[SEP]	O
745	[CLS]	O
745	compared	O
745	to	O
745	healthy	O
745	adult	O
745	subjects	O
745	,	O
745	elderly	O
745	subjects	O
745	had	O
745	a	O
745	slightly	O
745	higher	O
745	exposure	O
745	to	O
745	a	O
745	##p	O
745	##ro	O
745	##cite	O
745	##nta	O
745	##n	O
745	in	O
745	terms	O
745	of	O
745	both	O
745	cm	B-PK
745	##ax	I-PK
745	and	O
745	au	B-PK
745	##c	I-PK
745	##τ	I-PK
745	both	O
745	on	O
745	day	O
745	1	O
745	and	O
745	day	O
745	10	O
745	.	O
745	[SEP]	O
746	[CLS]	O
746	to	O
746	evaluate	O
746	the	O
746	effectiveness	O
746	of	O
746	car	O
746	##ni	O
746	##tine	O
746	administration	O
746	in	O
746	aid	O
746	##ing	O
746	the	O
746	elimination	O
746	of	O
746	p	O
746	##ival	O
746	##ate	O
746	liberated	O
746	from	O
746	p	O
746	##iva	O
746	##mp	O
746	##ici	O
746	##llin	O
746	,	O
746	studies	O
746	were	O
746	undertaken	O
746	on	O
746	seven	O
746	p	O
746	##ae	O
746	##dia	O
746	##tric	O
746	patients	O
746	treated	O
746	for	O
746	7	O
746	days	O
746	with	O
746	combined	O
746	p	O
746	##iva	O
746	##mp	O
746	##ici	O
746	##llin	O
746	and	O
746	m	O
746	##olar	O
746	excess	O
746	of	O
746	car	O
746	##ni	O
746	##tine	O
746	.	O
746	[SEP]	O
747	[CLS]	O
747	the	O
747	selection	O
747	of	O
747	the	O
747	technique	O
747	was	O
747	made	O
747	based	O
747	on	O
747	the	O
747	evaluation	O
747	of	O
747	particle	O
747	size	O
747	,	O
747	p	O
747	##di	O
747	,	O
747	and	O
747	en	O
747	##tra	O
747	##pment	O
747	efficiency	O
747	of	O
747	the	O
747	na	O
747	##no	O
747	##par	O
747	##tic	O
747	##les	O
747	obtained	O
747	with	O
747	the	O
747	trial	O
747	batch	O
747	##es	O
747	using	O
747	the	O
747	commonly	O
747	used	O
747	and	O
747	reported	O
747	to	O
747	be	O
747	reliable	O
747	and	O
747	powerful	O
747	techniques	O
747	.	O
747	[SEP]	O
748	[CLS]	O
748	the	O
748	c	B-PK
748	##lt	I-PK
748	##ot	I-PK
748	of	O
748	a	O
748	##a	O
748	in	O
748	plasma	O
748	after	O
748	b	O
748	##ol	O
748	##us	O
748	injection	O
748	of	O
748	a	O
748	##a	O
748	(	O
748	4	O
748	mg	O
748	/	O
748	kg	O
748	body	O
748	w	O
748	##t	O
748	)	O
748	in	O
748	tumor	O
748	patients	O
748	was	O
748	compared	O
748	with	O
748	that	O
748	in	O
748	volunteers	O
748	.	O
748	[SEP]	O
749	[CLS]	O
749	to	O
749	##fo	O
749	##gli	O
749	##f	O
749	##lo	O
749	##zin	O
749	is	O
749	a	O
749	novel	O
749	selective	O
749	inhibitor	O
749	of	O
749	sodium	O
749	-	O
749	dependent	O
749	glucose	O
749	co	O
749	-	O
749	transport	O
749	##er	O
749	-	O
749	2	O
749	(	O
749	s	O
749	##g	O
749	##lt	O
749	##2	O
749	)	O
749	and	O
749	has	O
749	been	O
749	developed	O
749	for	O
749	the	O
749	treatment	O
749	of	O
749	patients	O
749	with	O
749	type	O
749	2	O
749	diabetes	O
749	me	O
749	##lli	O
749	##tus	O
749	.	O
749	[SEP]	O
750	[CLS]	O
750	the	O
750	standard	O
750	##ised	O
750	effect	O
750	size	O
750	of	O
750	g	O
750	##sk	O
750	##15	O
750	##21	O
750	##4	O
750	##9	O
750	##8	O
750	on	O
750	am	O
750	##y	O
750	##g	O
750	##dal	O
750	##ar	O
750	activation	O
750	(	O
750	−	O
750	##2	O
750	.	O
750	0	O
750	;	O
750	95	O
750	%	O
750	c	O
750	##i	O
750	−	O
750	##2	O
750	.	O
750	7	O
750	to	O
750	−	O
750	##1	O
750	.	O
750	2	O
750	)	O
750	was	O
750	greater	O
750	than	O
750	the	O
750	corresponding	O
750	effect	O
750	size	O
750	of	O
750	n	O
750	##t	O
750	##x	O
750	(	O
750	−	O
750	##0	O
750	.	O
750	1	O
750	;	O
750	95	O
750	%	O
750	c	O
750	##i	O
750	−	O
750	##0	O
750	.	O
750	9	O
750	to	O
750	0	O
750	.	O
750	7	O
750	)	O
750	;	O
750	although	O
750	the	O
750	difference	O
750	in	O
750	effect	O
750	sizes	O
750	(	O
750	0	O
750	.	O
750	6	O
750	)	O
750	was	O
750	not	O
750	quite	O
750	significantly	O
750	different	O
750	from	O
750	0	O
750	(	O
750	95	O
750	%	O
750	c	O
750	##i	O
750	,	O
750	−	O
750	##0	O
750	.	O
750	04	O
750	to	O
750	1	O
750	.	O
750	3	O
750	;	O
750	p	O
750	=	O
750	0	O
750	.	O
750	06	O
750	##2	O
750	;	O
750	see	O
750	supplement	O
750	##ary	O
750	tables	O
750	s	O
750	##2	O
750	,	O
750	s	O
750	##3	O
750	for	O
750	details	O
750	)	O
750	.	O
750	[SEP]	O
751	[CLS]	O
751	the	O
751	me	O
751	(	O
751	i	O
751	.	O
751	e	O
751	.	O
751	,	O
751	potential	O
751	ion	O
751	enhance	O
751	##ment	O
751	or	O
751	suppression	O
751	)	O
751	of	O
751	do	O
751	##ce	O
751	##ta	O
751	##xe	O
751	##l	O
751	,	O
751	calculated	O
751	as	O
751	the	O
751	area	O
751	ratio	O
751	with	O
751	and	O
751	without	O
751	matrix	O
751	ions	O
751	present	O
751	,	O
751	was	O
751	between	O
751	103	O
751	.	O
751	5	O
751	and	O
751	87	O
751	.	O
751	7	O
751	for	O
751	ultra	O
751	##fi	O
751	##lter	O
751	##ed	O
751	plasma	O
751	,	O
751	and	O
751	between	O
751	111	O
751	.	O
751	5	O
751	and	O
751	99	O
751	.	O
751	4	O
751	for	O
751	total	O
751	plasma	O
751	.	O
751	[SEP]	O
752	[CLS]	O
752	all	O
752	study	O
752	participants	O
752	indicated	O
752	that	O
752	the	O
752	opportunity	O
752	to	O
752	use	O
752	p	O
752	##n	O
752	su	O
752	##pp	O
752	##os	O
752	##itor	O
752	##ies	O
752	as	O
752	an	O
752	alternative	O
752	to	O
752	h	O
752	##c	O
752	self	O
752	-	O
752	injection	O
752	would	O
752	make	O
752	them	O
752	feel	O
752	safer	O
752	.	O
752	[SEP]	O
753	[CLS]	O
753	thus	O
753	,	O
753	with	O
753	respect	O
753	to	O
753	the	O
753	p	O
753	##har	O
753	##ma	O
753	##co	O
753	##kin	O
753	##etic	O
753	target	O
753	parameters	O
753	,	O
753	little	O
753	difference	O
753	can	O
753	be	O
753	found	O
753	between	O
753	the	O
753	two	O
753	su	O
753	##pp	O
753	##os	O
753	##itor	O
753	##y	O
753	forms	O
753	each	O
753	containing	O
753	20	O
753	mg	O
753	met	O
753	##oc	O
753	##lop	O
753	##ram	O
753	##ide	O
753	-	O
753	base	O
753	and	O
753	under	O
753	trial	O
753	in	O
753	this	O
753	study	O
753	.	O
753	(	O
753	abstract	O
753	t	O
753	##runcated	O
753	at	O
753	250	O
753	words	O
753	)	O
753	[SEP]	O
754	[CLS]	O
754	brains	O
754	were	O
754	im	O
754	##mers	O
754	##ed	O
754	in	O
754	modified	O
754	go	O
754	##l	O
754	##gi	O
754	-	O
754	co	O
754	##x	O
754	stain	O
754	##ing	O
754	solution	O
754	(	O
754	purchased	O
754	from	O
754	d	O
754	##rs	O
754	.	O
754	[SEP]	O
755	[CLS]	O
755	two	O
755	patients	O
755	developed	O
755	ha	O
755	##ha	O
755	of	O
755	uncertain	O
755	clinical	O
755	significance	O
755	.	O
755	[SEP]	O
756	[CLS]	O
756	in	O
756	contrast	O
756	,	O
756	patients	O
756	with	O
756	b	O
756	-	O
756	all	O
756	,	O
756	b	O
756	-	O
756	l	O
756	##ymph	O
756	##oma	O
756	,	O
756	acute	O
756	my	O
756	##elo	O
756	##gen	O
756	##ous	O
756	le	O
756	##uke	O
756	##mia	O
756	(	O
756	am	O
756	##i	O
756	)	O
756	,	O
756	or	O
756	t	O
756	-	O
756	c	O
756	##ll	O
756	did	O
756	not	O
756	respond	O
756	.	O
756	[SEP]	O
757	[CLS]	O
757	c	O
757	##yt	O
757	##ola	O
757	##se	O
757	p	O
757	##c	O
757	##l	O
757	##5	O
757	and	O
757	rapid	O
757	##ase	O
757	c	O
757	##80	O
757	##max	O
757	were	O
757	purchased	O
757	from	O
757	d	O
757	##sm	O
757	food	O
757	special	O
757	##ties	O
757	(	O
757	ma	O
757	del	O
757	##ft	O
757	,	O
757	net	O
757	##her	O
757	##lands	O
757	)	O
757	,	O
757	and	O
757	sum	O
757	##iz	O
757	##yme	O
757	a	O
757	##c	O
757	was	O
757	obtained	O
757	from	O
757	s	O
757	##hin	O
757	ni	O
757	##hon	O
757	chemical	O
757	(	O
757	a	O
757	##ichi	O
757	,	O
757	j	O
757	##apa	O
757	##n	O
757	)	O
757	.	O
757	[SEP]	O
758	[CLS]	O
758	the	O
758	appearance	O
758	of	O
758	14	O
758	##c	O
758	-	O
758	activity	O
758	in	O
758	the	O
758	neutral	O
758	lip	O
758	##id	O
758	fraction	O
758	(	O
758	fi	O
758	##g	O
758	1	O
758	,	O
758	panel	O
758	a	O
758	)	O
758	,	O
758	likely	O
758	est	O
758	##eri	O
758	##fied	O
758	d	O
758	##ha	O
758	in	O
758	the	O
758	form	O
758	of	O
758	t	O
758	##rig	O
758	##ly	O
758	##cer	O
758	##ide	O
758	,	O
758	was	O
758	delayed	O
758	by	O
758	about	O
758	20	O
758	min	O
758	,	O
758	probably	O
758	reflecting	O
758	transport	O
758	delay	O
758	of	O
758	ch	O
758	##yl	O
758	##omi	O
758	##c	O
758	##rons	O
758	via	O
758	the	O
758	l	O
758	##ymph	O
758	##atic	O
758	system	O
758	into	O
758	the	O
758	blood	O
758	.	O
758	[SEP]	O
759	[CLS]	O
759	a	O
759	pool	O
759	##ed	O
759	place	O
759	##bo	O
759	group	O
759	was	O
759	also	O
759	analyzed	O
759	in	O
759	the	O
759	same	O
759	manner	O
759	.	O
759	[SEP]	O
760	[CLS]	O
760	the	O
760	rate	O
760	of	O
760	m	O
760	##rna	O
760	synthesis	O
760	was	O
760	assumed	O
760	to	O
760	be	O
760	zero	O
760	‐	O
760	order	O
760	and	O
760	set	O
760	at	O
760	0	O
760	.	O
760	04	O
760	pm	O
760	##ol	O
760	/	O
760	hour	O
760	as	O
760	the	O
760	input	O
760	for	O
760	the	O
760	m	O
760	##rna	O
760	species	O
760	.	O
760	[SEP]	O
761	[CLS]	O
761	most	O
761	of	O
761	the	O
761	p	O
761	-	O
761	h	O
761	##ydro	O
761	##xy	O
761	##tri	O
761	##am	O
761	##ter	O
761	##ene	O
761	was	O
761	recovered	O
761	in	O
761	f	O
761	##ae	O
761	##ces	O
761	.	O
761	[SEP]	O
762	[CLS]	O
762	design	O
762	and	O
762	selection	O
762	of	O
762	d	O
762	##mp	O
762	850	O
762	and	O
762	d	O
762	##mp	O
762	85	O
762	##1	O
762	:	O
762	the	O
762	next	O
762	generation	O
762	of	O
762	c	O
762	##yclic	O
762	u	O
762	##rea	O
762	hi	O
762	##v	O
762	pro	O
762	##te	O
762	##ase	O
762	inhibitor	O
762	##s	O
762	.	O
762	[SEP]	O
763	[CLS]	O
763	the	O
763	anal	O
763	##yte	O
763	was	O
763	detect	O
763	##able	O
763	up	O
763	to	O
763	12	O
763	hours	O
763	in	O
763	the	O
763	mouse	O
763	plasma	O
763	.	O
763	[SEP]	O
764	[CLS]	O
764	additionally	O
764	,	O
764	the	O
764	changes	O
764	were	O
764	dose	O
764	-	O
764	dependent	O
764	.	O
764	[SEP]	O
765	[CLS]	O
765	the	O
765	values	O
765	of	O
765	m	B-PK
765	##rt	I-PK
765	and	O
765	vs	B-PK
765	##s	I-PK
765	were	O
765	much	O
765	decreased	O
765	in	O
765	the	O
765	mice	O
765	receiving	O
765	c	O
765	##f	O
765	##z	O
765	-	O
765	pm	O
765	compared	O
765	to	O
765	those	O
765	receiving	O
765	c	O
765	##f	O
765	##z	O
765	-	O
765	c	O
765	##d	O
765	.	O
765	[SEP]	O
766	[CLS]	O
766	concentrations	O
766	of	O
766	an	O
766	acidic	O
766	drug	O
766	,	O
766	i	O
766	##bu	O
766	##p	O
766	##ro	O
766	##fen	O
766	,	O
766	in	O
766	c	O
766	##er	O
766	##vic	O
766	##al	O
766	m	O
766	##uc	O
766	##us	O
766	and	O
766	serum	O
766	have	O
766	been	O
766	measured	O
766	by	O
766	hp	O
766	##l	O
766	##c	O
766	after	O
766	oral	O
766	administration	O
766	in	O
766	six	O
766	healthy	O
766	volunteers	O
766	.	O
766	[SEP]	O
767	[CLS]	O
767	linear	O
767	##ity	O
767	of	O
767	so	O
767	##f	O
767	and	O
767	da	O
767	##c	O
767	was	O
767	obtained	O
767	over	O
767	concentration	O
767	ranges	O
767	of	O
767	50	O
767	-	O
767	400	O
767	,	O
767	and	O
767	40	O
767	-	O
767	400	O
767	ng	O
767	/	O
767	m	O
767	##l	O
767	,	O
767	respectively	O
767	in	O
767	pure	O
767	form	O
767	,	O
767	60	O
767	-	O
767	300	O
767	and	O
767	50	O
767	-	O
767	300	O
767	ng	O
767	/	O
767	m	O
767	##l	O
767	,	O
767	respectively	O
767	for	O
767	human	O
767	plasma	O
767	and	O
767	over	O
767	50	O
767	-	O
767	400	O
767	,	O
767	and	O
767	40	O
767	-	O
767	400	O
767	ng	O
767	/	O
767	m	O
767	##l	O
767	,	O
767	respectively	O
767	for	O
767	human	O
767	urine	O
767	with	O
767	correlation	O
767	coefficient	O
767	>	O
767	0	O
767	.	O
767	99	O
767	##9	O
767	.	O
767	[SEP]	O
768	[CLS]	O
768	we	O
768	have	O
768	studied	O
768	the	O
768	p	O
768	##har	O
768	##ma	O
768	##co	O
768	##kin	O
768	##etics	O
768	of	O
768	met	O
768	##hot	O
768	##re	O
768	##xa	O
768	##te	O
768	in	O
768	patients	O
768	with	O
768	r	O
768	##he	O
768	##uma	O
768	##to	O
768	##id	O
768	art	O
768	##hr	O
768	##itis	O
768	concurrently	O
768	taking	O
768	the	O
768	most	O
768	commonly	O
768	used	O
768	non	O
768	-	O
768	s	O
768	##tero	O
768	##idal	O
768	anti	O
768	-	O
768	inflammatory	O
768	drugs	O
768	(	O
768	n	O
768	##sai	O
768	##ds	O
768	)	O
768	,	O
768	as	O
768	##pi	O
768	##rin	O
768	,	O
768	di	O
768	##c	O
768	##lo	O
768	##fen	O
768	##ac	O
768	,	O
768	nap	O
768	##ro	O
768	##xen	O
768	,	O
768	in	O
768	##dom	O
768	##eth	O
768	##ac	O
768	##in	O
768	,	O
768	and	O
768	i	O
768	##bu	O
768	##p	O
768	##ro	O
768	##fen	O
768	.	O
768	[SEP]	O
769	[CLS]	O
769	in	O
769	all	O
769	subjects	O
769	of	O
769	group	O
769	1	O
769	and	O
769	seven	O
769	subjects	O
769	(	O
769	88	O
769	%	O
769	)	O
769	of	O
769	group	O
769	2	O
769	,	O
769	therapeutic	O
769	levels	O
769	(	O
769	>	O
769	50	O
769	p	O
769	##g	O
769	/	O
769	m	O
769	##l	O
769	)	O
769	were	O
769	measured	O
769	during	O
769	the	O
769	first	O
769	2	O
769	.	O
769	5	O
769	h	O
769	,	O
769	compared	O
769	with	O
769	only	O
769	two	O
769	subjects	O
769	(	O
769	25	O
769	%	O
769	)	O
769	of	O
769	group	O
769	3	O
769	(	O
769	p	O
769	<	O
769	0	O
769	.	O
769	05	O
769	)	O
769	.	O
769	[SEP]	O
770	[CLS]	O
770	for	O
770	the	O
770	0	O
770	.	O
770	75	O
770	-	O
770	mg	O
770	dose	O
770	,	O
770	a	O
770	peak	B-PK
770	urine	I-PK
770	concentration	I-PK
770	of	O
770	1	O
770	,	O
770	100	O
770	mg	O
770	/	O
770	liter	O
770	was	O
770	reached	O
770	after	O
770	30	O
770	min	O
770	.	O
770	[SEP]	O
771	[CLS]	O
771	it	O
771	is	O
771	likely	O
771	that	O
771	long	O
771	-	O
771	term	O
771	treatment	O
771	with	O
771	as	O
771	##a	O
771	may	O
771	represent	O
771	a	O
771	ch	O
771	##em	O
771	##op	O
771	##re	O
771	##vent	O
771	##ive	O
771	option	O
771	for	O
771	l	O
771	##s	O
771	/	O
771	h	O
771	##n	O
771	##p	O
771	##cc	O
771	patients	O
771	.	O
771	[SEP]	O
772	[CLS]	O
772	the	O
772	primary	O
772	end	O
772	points	O
772	of	O
772	the	O
772	study	O
772	were	O
772	au	B-PK
772	##c	I-PK
772	(	I-PK
772	0	I-PK
772	-	I-PK
772	in	I-PK
772	##f	I-PK
772	)	I-PK
772	and	O
772	cm	B-PK
772	##ax	I-PK
772	.	O
772	[SEP]	O
773	[CLS]	O
773	b	O
773	##p	O
773	##c	O
773	was	O
773	successfully	O
773	prepared	O
773	under	O
773	the	O
773	op	O
773	##ti	O
773	##mum	O
773	conditions	O
773	[	O
773	temperature	O
773	=	O
773	60	O
773	degrees	O
773	c	O
773	,	O
773	drug	O
773	concentration	O
773	=	O
773	80	O
773	g	O
773	/	O
773	l	O
773	and	O
773	drug	O
773	-	O
773	to	O
773	-	O
773	p	O
773	##hos	O
773	##ph	O
773	##oli	O
773	##pid	O
773	##s	O
773	ratio	O
773	=	O
773	0	O
773	.	O
773	9	O
773	(	O
773	w	O
773	/	O
773	w	O
773	)	O
773	]	O
773	.	O
773	[SEP]	O
774	[CLS]	O
774	radio	B-PK
774	##act	I-PK
774	##ivity	I-PK
774	in	O
774	the	O
774	f	O
774	##em	O
774	##ur	O
774	34	O
774	##h	O
774	after	O
774	dos	O
774	##ing	O
774	was	O
774	the	O
774	highest	O
774	in	O
774	the	O
774	ca	O
774	-	O
774	as	O
774	##a	O
774	group	O
774	and	O
774	the	O
774	lowest	O
774	in	O
774	the	O
774	ca	O
774	##co	O
774	##3	O
774	group	O
774	.	O
774	[SEP]	O
775	[CLS]	O
775	for	O
775	accurate	O
775	description	O
775	of	O
775	the	O
775	p	O
775	##har	O
775	##ma	O
775	##co	O
775	##kin	O
775	##etic	O
775	profile	O
775	of	O
775	drugs	O
775	with	O
775	long	O
775	half	B-PK
775	-	I-PK
775	lives	I-PK
775	,	O
775	the	O
775	us	O
775	food	O
775	and	O
775	drug	O
775	administration	O
775	recommend	O
775	##s	O
775	a	O
775	sampling	O
775	period	O
775	covering	O
775	3	O
775	–	O
775	5	O
775	half	B-PK
775	-	I-PK
775	lives	I-PK
775	of	O
775	the	O
775	investigated	O
775	drug	O
775	[	O
775	24	O
775	]	O
775	.	O
775	[SEP]	O
776	[CLS]	O
776	male	O
776	s	O
776	##pra	O
776	##gue	O
776	-	O
776	da	O
776	##wley	O
776	(	O
776	s	O
776	##d	O
776	)	O
776	rats	O
776	of	O
776	weight	O
776	between	O
776	200	O
776	–	O
776	220	O
776	gram	O
776	were	O
776	provided	O
776	by	O
776	n	O
776	##la	O
776	##c	O
776	,	O
776	c	O
776	##sir	O
776	-	O
776	c	O
776	##dr	O
776	##i	O
776	,	O
776	luck	O
776	##no	O
776	##w	O
776	.	O
776	[SEP]	O
777	[CLS]	O
777	adverse	O
777	events	O
777	(	O
777	a	O
777	##es	O
777	)	O
777	such	O
777	as	O
777	a	O
777	##rr	O
777	##hy	O
777	##th	O
777	##mia	O
777	##s	O
777	have	O
777	not	O
777	been	O
777	associated	O
777	with	O
777	h	O
777	##no	O
777	donors	O
777	.	O
777	14	O
777	,	O
777	15	O
777	,	O
777	16	O
777	,	O
777	17	O
777	[SEP]	O
778	[CLS]	O
778	in	O
778	this	O
778	study	O
778	the	O
778	disposition	O
778	kinetic	O
778	##s	O
778	and	O
778	plasma	O
778	availability	O
778	of	O
778	m	O
778	##ox	O
778	##if	O
778	##lo	O
778	##xa	O
778	##cin	O
778	in	O
778	m	O
778	##us	O
778	##co	O
778	##vy	O
778	ducks	O
778	after	O
778	single	O
778	in	O
778	##tra	O
778	##ven	O
778	##ous	O
778	(	O
778	i	O
778	.	O
778	v	O
778	.	O
778	)	O
778	,	O
778	in	O
778	##tra	O
778	##mus	O
778	##cular	O
778	(	O
778	i	O
778	.	O
778	m	O
778	.	O
778	)	O
778	and	O
778	oral	O
778	(	O
778	p	O
778	.	O
778	o	O
778	.	O
778	)	O
778	administration	O
778	##s	O
778	of	O
778	5	O
778	mg	O
778	kg	O
778	(	O
778	-	O
778	1	O
778	)	O
778	b	O
778	.	O
778	w	O
778	##t	O
778	.	O
778	[SEP]	O
779	[CLS]	O
779	the	O
779	tablet	O
779	formulation	O
779	was	O
779	identified	O
779	by	O
779	determining	O
779	the	O
779	micro	O
779	##mer	O
779	##itic	O
779	properties	O
779	such	O
779	as	O
779	flow	O
779	##ability	O
779	and	O
779	com	O
779	##press	O
779	##ibility	O
779	of	O
779	the	O
779	powder	O
779	mixture	O
779	##s	O
779	composed	O
779	of	O
779	the	O
779	spray	O
779	dried	O
779	na	O
779	##no	O
779	##c	O
779	##ry	O
779	##stal	O
779	powder	O
779	and	O
779	other	O
779	commonly	O
779	used	O
779	direct	O
779	compression	O
779	ex	O
779	##ci	O
779	##pie	O
779	##nts	O
779	.	O
779	[SEP]	O
780	[CLS]	O
780	the	O
780	maximum	B-PK
780	plasma	I-PK
780	concentrations	I-PK
780	(	I-PK
780	cm	I-PK
780	##ax	I-PK
780	)	I-PK
780	were	O
780	99	O
780	##1	O
780	and	O
780	83	O
780	##9	O
780	ng	O
780	x	O
780	m	O
780	##l	O
780	(	O
780	-	O
780	1	O
780	)	O
780	for	O
780	seizure	O
780	terminated	O
780	and	O
780	not	O
780	terminated	O
780	,	O
780	respectively	O
780	.	O
780	[SEP]	O
781	[CLS]	O
781	su	O
781	##icidal	O
781	##ity	O
781	was	O
781	rated	O
781	and	O
781	monitored	O
781	using	O
781	the	O
781	co	O
781	##lum	O
781	##bia	O
781	-	O
781	suicide	O
781	severity	O
781	rating	O
781	scale	O
781	(	O
781	p	O
781	##os	O
781	##ner	O
781	et	O
781	al	O
781	.	O
781	,	O
781	2011	O
781	)	O
781	.	O
781	[SEP]	O
782	[CLS]	O
782	no	O
782	objective	O
782	responses	O
782	were	O
782	observed	O
782	.	O
782	[SEP]	O
783	[CLS]	O
783	in	O
783	the	O
783	nude	O
783	mouse	O
783	model	O
783	,	O
783	levels	O
783	of	O
783	radio	B-PK
783	##act	I-PK
783	##ivity	I-PK
783	in	O
783	tumor	O
783	reached	O
783	a	O
783	maximum	O
783	at	O
783	48	O
783	h	O
783	##r	O
783	after	O
783	i	O
783	.	O
783	v	O
783	.	O
783	administration	O
783	(	O
783	4	O
783	.	O
783	96	O
783	%	O
783	id	O
783	/	O
783	g	O
783	,	O
783	tumor	O
783	-	O
783	to	O
783	-	O
783	blood	O
783	5	O
783	.	O
783	5	O
783	)	O
783	.	O
783	[SEP]	O
784	[CLS]	O
784	a	O
784	##r	O
784	##9	O
784	##28	O
784	##1	O
784	,	O
784	a	O
784	potent	O
784	and	O
784	selective	O
784	inhibitor	O
784	of	O
784	soluble	O
784	e	O
784	##pox	O
784	##ide	O
784	h	O
784	##ydro	O
784	##lase	O
784	(	O
784	s	O
784	-	O
784	eh	O
784	)	O
784	,	O
784	is	O
784	in	O
784	clinical	O
784	development	O
784	targeting	O
784	h	O
784	##yper	O
784	##tens	O
784	##ion	O
784	and	O
784	type	O
784	2	O
784	diabetes	O
784	.	O
784	[SEP]	O
785	[CLS]	O
785	in	O
785	contrast	O
785	,	O
785	n	O
785	##ps	O
785	in	O
785	source	O
785	-	O
785	like	O
785	r	O
785	##ois	O
785	travel	O
785	through	O
785	the	O
785	v	O
785	##as	O
785	##cula	O
785	##ture	O
785	without	O
785	getting	O
785	trapped	O
785	##26	O
785	.	O
785	[SEP]	O
786	[CLS]	O
786	effects	O
786	of	O
786	da	O
786	##pa	O
786	##gli	O
786	##f	O
786	##lo	O
786	##zin	O
786	on	O
786	insulin	O
786	-	O
786	requirement	O
786	,	O
786	glucose	O
786	ex	O
786	##cre	O
786	##tion	O
786	and	O
786	ß	O
786	-	O
786	h	O
786	##ydro	O
786	##xy	O
786	##but	O
786	##yra	O
786	##te	O
786	levels	O
786	are	O
786	not	O
786	related	O
786	to	O
786	base	O
786	##line	O
786	h	O
786	##ba	O
786	##1	O
786	##c	O
786	in	O
786	youth	O
786	with	O
786	type	O
786	1	O
786	diabetes	O
786	.	O
786	[SEP]	O
787	[CLS]	O
787	ma	O
787	##gnesium	O
787	clearance	B-PK
787	was	O
787	estimated	O
787	via	O
787	p	O
787	##har	O
787	##ma	O
787	##co	O
787	##kin	O
787	##etic	O
787	modeling	O
787	to	O
787	be	O
787	48	O
787	.	O
787	1	O
787	##dl	O
787	/	O
787	h	O
787	,	O
787	volume	B-PK
787	of	I-PK
787	distribution	I-PK
787	156	O
787	##dl	O
787	and	O
787	im	O
787	bio	B-PK
787	##ava	I-PK
787	##ila	I-PK
787	##bility	I-PK
787	86	O
787	.	O
787	2	O
787	%	O
787	.	O
787	[SEP]	O
788	[CLS]	O
788	the	O
788	following	O
788	model	O
788	was	O
788	used	O
788	:	O
788	log	O
788	(	O
788	p	O
788	##k	O
788	parameter	O
788	)	O
788	=	O
788	α	O
788	+	O
788	β	O
788	·	O
788	log	O
788	(	O
788	dose	O
788	)	O
788	,	O
788	where	O
788	α	O
788	is	O
788	the	O
788	intercept	O
788	and	O
788	β	O
788	is	O
788	the	O
788	slope	O
788	of	O
788	the	O
788	model	O
788	.	O
788	[SEP]	O
789	[CLS]	O
789	the	O
789	p	O
789	##har	O
789	##ma	O
789	##co	O
789	##kin	O
789	##etics	O
789	and	O
789	safety	O
789	of	O
789	te	O
789	##lm	O
789	##isa	O
789	##rta	O
789	##n	O
789	were	O
789	assessed	O
789	in	O
789	subjects	O
789	with	O
789	he	O
789	##pa	O
789	##tic	O
789	imp	O
789	##air	O
789	##ment	O
789	in	O
789	a	O
789	single	O
789	-	O
789	center	O
789	,	O
789	open	O
789	-	O
789	label	O
789	study	O
789	.	O
789	[SEP]	O
790	[CLS]	O
790	the	O
790	in	O
790	##tra	O
790	##nas	O
790	##al	O
790	administration	O
790	of	O
790	ago	O
790	##mel	O
790	##ati	O
790	##ne	O
790	solid	O
790	lip	O
790	##id	O
790	na	O
790	##no	O
790	##par	O
790	##tic	O
790	##les	O
790	has	O
790	effectively	O
790	enhanced	O
790	both	O
790	the	O
790	absolute	B-PK
790	bio	I-PK
790	##ava	I-PK
790	##ila	I-PK
790	##bility	I-PK
790	and	O
790	the	O
790	brain	O
790	delivery	O
790	of	O
790	ago	O
790	##mel	O
790	##ati	O
790	##ne	O
790	.	O
790	[SEP]	O
791	[CLS]	O
791	the	O
791	results	O
791	indicated	O
791	that	O
791	the	O
791	e	O
791	##ff	O
791	##lux	O
791	activity	O
791	of	O
791	p	O
791	-	O
791	g	O
791	##p	O
791	was	O
791	qualified	O
791	for	O
791	the	O
791	experiment	O
791	.	O
791	[SEP]	O
792	[CLS]	O
792	a	O
792	blank	O
792	sample	O
792	was	O
792	also	O
792	taken	O
792	before	O
792	dos	O
792	##ing	O
792	.	O
792	[SEP]	O
793	[CLS]	O
793	g	O
793	##uan	O
793	##fa	O
793	##cine	O
793	h	O
793	##ydro	O
793	##ch	O
793	##lor	O
793	##ide	O
793	extended	O
793	-	O
793	release	O
793	tablet	O
793	(	O
793	g	O
793	##x	O
793	##r	O
793	)	O
793	is	O
793	approved	O
793	for	O
793	child	O
793	and	O
793	adolescent	O
793	patients	O
793	with	O
793	attention	O
793	-	O
793	deficit	O
793	/	O
793	h	O
793	##yper	O
793	##act	O
793	##ivity	O
793	disorder	O
793	(	O
793	ad	O
793	##h	O
793	##d	O
793	)	O
793	.	O
793	[SEP]	O
794	[CLS]	O
794	within	O
794	the	O
794	pairs	O
794	2	O
794	/	O
794	l	O
794	##p	O
794	-	O
794	2	O
794	and	O
794	3	O
794	/	O
794	l	O
794	##p	O
794	-	O
794	3	O
794	,	O
794	a	O
794	comparable	O
794	i	B-PK
794	##c	I-PK
794	##50	I-PK
794	value	O
794	between	O
794	each	O
794	drug	O
794	and	O
794	its	O
794	respective	O
794	lip	O
794	##oso	O
794	##mal	O
794	formulation	O
794	was	O
794	found	O
794	.	O
794	[SEP]	O
795	[CLS]	O
795	in	O
795	whole	O
795	blood	O
795	from	O
795	healthy	O
795	donors	O
795	,	O
795	ne	O
795	##ut	O
795	##rop	O
795	##hil	O
795	##s	O
795	were	O
795	induced	O
795	to	O
795	release	O
795	reactive	O
795	oxygen	O
795	species	O
795	(	O
795	r	O
795	##os	O
795	)	O
795	by	O
795	stimulation	O
795	with	O
795	op	O
795	##rb	O
795	##c	O
795	to	O
795	cross	O
795	‐	O
795	link	O
795	f	O
795	##c	O
795	##γ	O
795	##r	O
795	,	O
795	or	O
795	by	O
795	e	O
795	co	O
795	##li	O
795	to	O
795	induce	O
795	r	O
795	##os	O
795	via	O
795	s	O
795	##yk	O
795	‐	O
795	independent	O
795	toll	O
795	‐	O
795	like	O
795	receptor	O
795	mechanisms	O
795	.	O
795	[SEP]	O
796	[CLS]	O
796	naive	O
796	or	O
796	anti	O
796	##ret	O
796	##rov	O
796	##ira	O
796	##l	O
796	-	O
796	experienced	O
796	hi	O
796	##v	O
796	-	O
796	1	O
796	-	O
796	infected	O
796	subjects	O
796	were	O
796	included	O
796	in	O
796	a	O
796	non	O
796	-	O
796	random	O
796	##ized	O
796	,	O
796	observation	O
796	##al	O
796	co	O
796	##hor	O
796	##t	O
796	study	O
796	and	O
796	received	O
796	two	O
796	n	O
796	##uc	O
796	##leo	O
796	##side	O
796	r	O
796	##t	O
796	inhibitor	O
796	##s	O
796	+	O
796	n	O
796	##f	O
796	##v	O
796	(	O
796	750	O
796	mg	O
796	three	O
796	times	O
796	per	O
796	day	O
796	or	O
796	125	O
796	##0	O
796	mg	O
796	twice	O
796	per	O
796	day	O
796	)	O
796	.	O
796	[SEP]	O
797	[CLS]	O
797	although	O
797	recently	O
797	the	O
797	occurrence	O
797	of	O
797	a	O
797	ma	O
797	##li	O
797	##gnant	O
797	neo	O
797	##p	O
797	##las	O
797	##ma	O
797	as	O
797	a	O
797	com	O
797	##plication	O
797	of	O
797	u	O
797	##rem	O
797	##ia	O
797	is	O
797	becoming	O
797	more	O
797	frequently	O
797	,	O
797	p	O
797	##har	O
797	##ma	O
797	##co	O
797	##kin	O
797	##etics	O
797	of	O
797	anti	O
797	##tum	O
797	##or	O
797	agents	O
797	are	O
797	not	O
797	precisely	O
797	studied	O
797	in	O
797	patients	O
797	with	O
797	impaired	O
797	re	O
797	##nal	O
797	function	O
797	.	O
797	[SEP]	O
798	[CLS]	O
798	four	O
798	-	O
798	to	O
798	-	O
798	six	O
798	week	O
798	old	O
798	female	O
798	at	O
798	##hy	O
798	##mic	O
798	(	O
798	n	O
798	##u	O
798	+	O
798	/	O
798	n	O
798	##u	O
798	+	O
798	)	O
798	mice	O
798	were	O
798	obtained	O
798	from	O
798	ha	O
798	##rl	O
798	##an	O
798	laboratories	O
798	(	O
798	washing	O
798	##ton	O
798	d	O
798	##c	O
798	)	O
798	under	O
798	an	O
798	approved	O
798	research	O
798	protocol	O
798	by	O
798	the	O
798	institutional	O
798	animal	O
798	care	O
798	and	O
798	use	O
798	committee	O
798	.	O
798	[SEP]	O
799	[CLS]	O
799	au	B-PK
799	##c	I-PK
799	,	O
799	cm	B-PK
799	##ax	I-PK
799	and	O
799	t	B-PK
799	##1	I-PK
799	/	I-PK
799	2	I-PK
799	of	O
799	the	O
799	drug	O
799	after	O
799	repeated	O
799	oral	O
799	intake	O
799	were	O
799	not	O
799	significantly	O
799	different	O
799	when	O
799	compared	O
799	with	O
799	a	O
799	single	O
799	dose	O
799	at	O
799	either	O
799	20	O
799	mg	O
799	or	O
799	40	O
799	mg	O
799	.	O
799	[SEP]	O
800	[CLS]	O
800	this	O
800	study	O
800	examined	O
800	the	O
800	mechanical	O
800	(	O
800	gel	O
800	strength	O
800	,	O
800	ad	O
800	##hesive	O
800	##ness	O
800	)	O
800	and	O
800	r	O
800	##he	O
800	##ological	O
800	properties	O
800	of	O
800	c	O
800	##ress	O
800	seed	O
800	m	O
800	##uc	O
800	##ila	O
800	##ge	O
800	based	O
800	gel	O
800	##s	O
800	that	O
800	contain	O
800	different	O
800	ratios	O
800	of	O
800	car	O
800	##bo	O
800	##pol	O
800	93	O
800	##4	O
800	p	O
800	(	O
800	0	O
800	.	O
800	5	O
800	-	O
800	1	O
800	.	O
800	5	O
800	%	O
800	)	O
800	.	O
800	[SEP]	O
801	[CLS]	O
801	the	O
801	p	O
801	##k	O
801	data	O
801	from	O
801	clinical	O
801	p	O
801	##har	O
801	##ma	O
801	##cology	O
801	studies	O
801	were	O
801	combined	O
801	to	O
801	provide	O
801	a	O
801	single	O
801	data	O
801	set	O
801	that	O
801	would	O
801	allow	O
801	characterization	O
801	of	O
801	the	O
801	p	O
801	##k	O
801	of	O
801	each	O
801	insulin	O
801	product	O
801	.	O
801	[SEP]	O
802	[CLS]	O
802	mi	O
802	##cs	O
802	of	O
802	s	O
802	##y	O
802	##55	O
802	##55	O
802	against	O
802	s	O
802	.	O
802	au	O
802	##reus	O
802	,	O
802	c	O
802	##ns	O
802	,	O
802	s	O
802	.	O
802	pneumonia	O
802	##e	O
802	,	O
802	s	O
802	.	O
802	p	O
802	##yo	O
802	##gene	O
802	##s	O
802	,	O
802	h	O
802	.	O
802	in	O
802	##fluenza	O
802	##e	O
802	,	O
802	m	O
802	.	O
802	cat	O
802	##ar	O
802	##r	O
802	##hali	O
802	##s	O
802	,	O
802	e	O
802	.	O
802	co	O
802	##li	O
802	and	O
802	e	O
802	.	O
802	c	O
802	##lo	O
802	##aca	O
802	##e	O
802	were	O
802	0	O
802	.	O
802	2	O
802	,	O
802	0	O
802	.	O
802	2	O
802	,	O
802	0	O
802	.	O
802	2	O
802	,	O
802	<	O
802	or	O
802	=	O
802	0	O
802	.	O
802	02	O
802	##5	O
802	,	O
802	0	O
802	.	O
802	78	O
802	,	O
802	0	O
802	.	O
802	2	O
802	,	O
802	0	O
802	.	O
802	78	O
802	and	O
802	3	O
802	.	O
802	13	O
802	micro	O
802	##gram	O
802	##s	O
802	/	O
802	m	O
802	##l	O
802	,	O
802	respectively	O
802	,	O
802	showing	O
802	excellent	O
802	anti	O
802	##ba	O
802	##cter	O
802	##ial	O
802	effects	O
802	on	O
802	these	O
802	path	O
802	##ogen	O
802	##s	O
802	.	O
802	[SEP]	O
803	[CLS]	O
803	on	O
803	the	O
803	last	O
803	day	O
803	of	O
803	the	O
803	multiple	O
803	oral	O
803	dose	O
803	,	O
803	human	O
803	plasma	O
803	samples	O
803	(	O
803	3	O
803	m	O
803	##l	O
803	)	O
803	were	O
803	gathered	O
803	before	O
803	and	O
803	at	O
803	0	O
803	.	O
803	5	O
803	,	O
803	0	O
803	.	O
803	75	O
803	,	O
803	1	O
803	,	O
803	1	O
803	.	O
803	25	O
803	,	O
803	1	O
803	.	O
803	5	O
803	,	O
803	2	O
803	,	O
803	2	O
803	.	O
803	5	O
803	,	O
803	3	O
803	,	O
803	4	O
803	,	O
803	6	O
803	,	O
803	8	O
803	,	O
803	10	O
803	,	O
803	12	O
803	,	O
803	24	O
803	,	O
803	36	O
803	and	O
803	48	O
803	h	O
803	after	O
803	dos	O
803	##ing	O
803	,	O
803	and	O
803	this	O
803	phase	O
803	was	O
803	followed	O
803	by	O
803	a	O
803	single	O
803	oral	O
803	dose	O
803	.	O
803	[SEP]	O
804	[CLS]	O
804	the	O
804	ass	O
804	##ay	O
804	has	O
804	been	O
804	successfully	O
804	applied	O
804	to	O
804	measuring	O
804	plasma	O
804	concentrations	O
804	of	O
804	los	O
804	##art	O
804	##an	O
804	and	O
804	ex	O
804	##p	O
804	##31	O
804	##7	O
804	##4	O
804	in	O
804	patients	O
804	receiving	O
804	a	O
804	daily	O
804	dose	O
804	of	O
804	los	O
804	##art	O
804	##an	O
804	(	O
804	50	O
804	-	O
804	100	O
804	mg	O
804	)	O
804	.	O
804	[SEP]	O
805	[CLS]	O
805	the	O
805	present	O
805	series	O
805	of	O
805	studies	O
805	demonstrated	O
805	that	O
805	the	O
805	carrier	O
805	-	O
805	free	O
805	ultra	O
805	##tra	O
805	##ce	O
805	mi	O
805	##b	O
805	##g	O
805	radio	O
805	##la	O
805	##bel	O
805	##ed	O
805	with	O
805	either	O
805	(	O
805	123	O
805	)	O
805	i	O
805	or	O
805	(	O
805	131	O
805	)	O
805	i	O
805	exhibited	O
805	similar	O
805	tissue	O
805	distribution	O
805	to	O
805	the	O
805	carrier	O
805	-	O
805	added	O
805	radio	O
805	##la	O
805	##bel	O
805	##ed	O
805	mi	O
805	##b	O
805	##g	O
805	in	O
805	all	O
805	non	O
805	##tar	O
805	##get	O
805	tissues	O
805	.	O
805	[SEP]	O
806	[CLS]	O
806	to	O
806	compare	O
806	the	O
806	p	O
806	##har	O
806	##ma	O
806	##co	O
806	##kin	O
806	##etic	O
806	parameters	O
806	and	O
806	safety	O
806	of	O
806	the	O
806	pro	O
806	##ges	O
806	##tage	O
806	##n	O
806	,	O
806	org	O
806	306	O
806	##5	O
806	##9	O
806	,	O
806	(	O
806	17	O
806	##al	O
806	##pha	O
806	)	O
806	-	O
806	17	O
806	-	O
806	h	O
806	##ydro	O
806	##xy	O
806	-	O
806	11	O
806	-	O
806	met	O
806	##hyl	O
806	##ene	O
806	-	O
806	19	O
806	-	O
806	nor	O
806	##p	O
806	##re	O
806	##gna	O
806	-	O
806	4	O
806	,	O
806	15	O
806	-	O
806	die	O
806	##n	O
806	-	O
806	20	O
806	-	O
806	y	O
806	##n	O
806	-	O
806	3	O
806	-	O
806	one	O
806	)	O
806	,	O
806	and	O
806	et	O
806	##hin	O
806	##yl	O
806	est	O
806	##rad	O
806	##iol	O
806	(	O
806	e	O
806	##e	O
806	)	O
806	in	O
806	ca	O
806	##uca	O
806	##sian	O
806	and	O
806	j	O
806	##apa	O
806	##nese	O
806	women	O
806	after	O
806	single	O
806	and	O
806	multiple	O
806	doses	O
806	.	O
806	[SEP]	O
807	[CLS]	O
807	this	O
807	anti	O
807	##fu	O
807	##nga	O
807	##l	O
807	has	O
807	moderate	O
807	water	O
807	so	O
807	##lub	O
807	##ility	O
807	and	O
807	exhibits	O
807	a	O
807	non	O
807	##linear	O
807	p	O
807	##har	O
807	##ma	O
807	##co	O
807	##kin	O
807	##etic	O
807	(	O
807	p	O
807	##k	O
807	)	O
807	profile	O
807	.	O
807	[SEP]	O
808	[CLS]	O
808	v	O
808	##p	O
808	##cs	O
808	were	O
808	performed	O
808	using	O
808	ps	O
808	##n	O
808	[	O
808	6	O
808	,	O
808	7	O
808	]	O
808	and	O
808	plot	O
808	##ted	O
808	using	O
808	x	O
808	##pose	O
808	[	O
808	8	O
808	]	O
808	.	O
808	[SEP]	O
809	[CLS]	O
809	this	O
809	was	O
809	followed	O
809	by	O
809	a	O
809	clearance	B-PK
809	to	O
809	half	O
809	the	O
809	peak	O
809	value	O
809	at	O
809	about	O
809	25	O
809	minutes	O
809	with	O
809	the	O
809	overall	O
809	time	O
809	course	O
809	parallel	O
809	##ing	O
809	the	O
809	previously	O
809	documented	O
809	time	O
809	course	O
809	of	O
809	the	O
809	e	O
809	##up	O
809	##hor	O
809	##ia	O
809	experienced	O
809	after	O
809	in	O
809	##tra	O
809	##ven	O
809	##ous	O
809	cocaine	O
809	administration	O
809	.	O
809	[SEP]	O
810	[CLS]	O
810	no	O
810	significant	O
810	differences	O
810	were	O
810	observed	O
810	between	O
810	the	O
810	production	O
810	rates	O
810	of	O
810	t	O
810	and	O
810	e	O
810	##2	O
810	(	O
810	0	O
810	.	O
810	24	O
810	ng	O
810	/	O
810	kg	O
810	body	O
810	w	O
810	##t	O
810	/	O
810	h	O
810	##r	O
810	)	O
810	.	O
810	[SEP]	O
811	[CLS]	O
811	during	O
811	the	O
811	initial	O
811	period	O
811	of	O
811	45	O
811	-	O
811	60	O
811	min	O
811	,	O
811	a	O
811	very	O
811	rapid	O
811	fall	O
811	in	O
811	blood	O
811	level	O
811	of	O
811	radio	B-PK
811	##act	I-PK
811	##ivity	I-PK
811	was	O
811	noticed	O
811	.	O
811	[SEP]	O
812	[CLS]	O
812	the	O
812	s	O
812	##c	O
812	surface	O
812	was	O
812	arranged	O
812	more	O
812	irregular	O
812	##ly	O
812	and	O
812	disorder	O
812	##ly	O
812	.	O
812	[SEP]	O
813	[CLS]	O
813	for	O
813	group	O
813	1	O
813	,	O
813	232	O
813	samples	O
813	were	O
813	collected	O
813	from	O
813	healthy	O
813	ch	O
813	##ile	O
813	##an	O
813	children	O
813	who	O
813	attend	O
813	the	O
813	d	O
813	##r	O
813	.	O
813	l	O
813	##ui	O
813	##s	O
813	ca	O
813	##l	O
813	##vo	O
813	mac	O
813	##ken	O
813	##na	O
813	hospital	O
813	(	O
813	h	O
813	##l	O
813	##c	O
813	##m	O
813	)	O
813	for	O
813	routine	O
813	clinical	O
813	testing	O
813	.	O
813	[SEP]	O
814	[CLS]	O
814	the	O
814	anti	O
814	##no	O
814	##ci	O
814	##ceptive	O
814	activity	O
814	of	O
814	4	O
814	after	O
814	i	O
814	##p	O
814	administration	O
814	##was	O
814	assessed	O
814	in	O
814	the	O
814	mouse	O
814	warm	O
814	water	O
814	tail	O
814	withdrawal	O
814	(	O
814	w	O
814	##w	O
814	##t	O
814	##w	O
814	)	O
814	ass	O
814	##ay	O
814	.	O
814	[SEP]	O
815	[CLS]	O
815	to	O
815	##lter	O
815	##od	O
815	##ine	O
815	is	O
815	a	O
815	potent	O
815	m	O
815	##us	O
815	##car	O
815	##ini	O
815	##c	O
815	receptor	O
815	antagonist	O
815	and	O
815	has	O
815	been	O
815	used	O
815	for	O
815	the	O
815	treatment	O
815	of	O
815	over	O
815	##active	O
815	bladder	O
815	for	O
815	over	O
815	ten	O
815	years	O
815	.	O
815	[SEP]	O
816	[CLS]	O
816	the	O
816	aim	O
816	of	O
816	this	O
816	study	O
816	was	O
816	to	O
816	compare	O
816	the	O
816	p	O
816	##har	O
816	##ma	O
816	##co	O
816	##kin	O
816	##etics	O
816	and	O
816	p	O
816	##har	O
816	##ma	O
816	##co	O
816	##dynamic	O
816	##s	O
816	of	O
816	me	O
816	##rop	O
816	##ene	O
816	##m	O
816	when	O
816	administered	O
816	by	O
816	3	O
816	h	O
816	in	O
816	##fusion	O
816	or	O
816	b	O
816	##ol	O
816	##us	O
816	injection	O
816	regime	O
816	##ns	O
816	.	O
816	[SEP]	O
817	[CLS]	O
817	in	O
817	addition	O
817	,	O
817	the	O
817	area	O
817	of	O
817	its	O
817	h	O
817	##yster	O
817	##esis	O
817	loop	O
817	was	O
817	the	O
817	largest	O
817	indicating	O
817	a	O
817	better	O
817	th	O
817	##ix	O
817	##ot	O
817	##ropic	O
817	behavior	O
817	.	O
817	[SEP]	O
818	[CLS]	O
818	the	O
818	p	O
818	##har	O
818	##ma	O
818	##co	O
818	##kin	O
818	##etic	O
818	results	O
818	showed	O
818	that	O
818	the	O
818	average	O
818	cocaine	O
818	bio	B-PK
818	##ava	I-PK
818	##ila	I-PK
818	##bility	I-PK
818	after	O
818	i	O
818	.	O
818	p	O
818	.	O
818	administration	O
818	was	O
818	71	O
818	%	O
818	and	O
818	after	O
818	oral	O
818	administration	O
818	was	O
818	only	O
818	19	O
818	.	O
818	2	O
818	%	O
818	.	O
818	[SEP]	O
819	[CLS]	O
819	the	O
819	area	B-PK
819	under	I-PK
819	the	I-PK
819	concentration	I-PK
819	vs	I-PK
819	time	I-PK
819	curve	I-PK
819	(	I-PK
819	au	I-PK
819	##c	I-PK
819	)	I-PK
819	,	O
819	but	O
819	not	O
819	the	O
819	maximum	B-PK
819	concentration	I-PK
819	(	I-PK
819	cm	I-PK
819	##ax	I-PK
819	)	I-PK
819	,	O
819	increased	O
819	in	O
819	a	O
819	dose	O
819	-	O
819	proportional	O
819	manner	O
819	.	O
819	[SEP]	O
820	[CLS]	O
820	neon	O
820	##ata	O
820	##l	O
820	mice	O
820	[	O
820	post	O
820	##nat	O
820	##al	O
820	day	O
820	10	O
820	(	O
820	p	O
820	##nd	O
820	##10	O
820	)	O
820	]	O
820	were	O
820	dose	O
820	##d	O
820	i	O
820	##p	O
820	due	O
820	to	O
820	the	O
820	difficulty	O
820	in	O
820	accurately	O
820	dos	O
820	##ing	O
820	neon	O
820	##ata	O
820	##l	O
820	mice	O
820	by	O
820	oral	O
820	g	O
820	##ava	O
820	##ge	O
820	.	O
820	[SEP]	O
821	[CLS]	O
821	also	O
821	,	O
821	the	O
821	matrix	O
821	effect	O
821	for	O
821	er	O
821	##l	O
821	(	O
821	is	O
821	)	O
821	was	O
821	also	O
821	determined	O
821	at	O
821	the	O
821	concentration	O
821	level	O
821	specified	O
821	in	O
821	actual	O
821	analysis	O
821	and	O
821	it	O
821	was	O
821	found	O
821	to	O
821	be	O
821	2	O
821	.	O
821	63	O
821	%	O
821	.	O
821	[SEP]	O
822	[CLS]	O
822	this	O
822	method	O
822	provides	O
822	a	O
822	platform	O
822	to	O
822	evaluate	O
822	effects	O
822	at	O
822	##tri	O
822	##but	O
822	##able	O
822	to	O
822	the	O
822	route	O
822	of	O
822	administration	O
822	on	O
822	the	O
822	response	O
822	to	O
822	alcohol	O
822	,	O
822	as	O
822	well	O
822	as	O
822	the	O
822	influence	O
822	of	O
822	de	O
822	##ter	O
822	##mina	O
822	##nts	O
822	such	O
822	as	O
822	family	O
822	history	O
822	of	O
822	alcohol	O
822	##ism	O
822	on	O
822	the	O
822	alcohol	O
822	response	O
822	.	O
822	[SEP]	O
823	[CLS]	O
823	sub	O
823	##op	O
823	##ti	O
823	##mal	O
823	dos	O
823	##ing	O
823	with	O
823	flu	O
823	##cona	O
823	##zo	O
823	##le	O
823	is	O
823	pre	O
823	##vale	O
823	##n	O
823	;	O
823	33	O
823	%	O
823	of	O
823	patients	O
823	receiving	O
823	flu	O
823	##cona	O
823	##zo	O
823	##le	O
823	did	O
823	not	O
823	achieve	O
823	the	O
823	desired	O
823	p	O
823	##k	O
823	/	O
823	p	O
823	##d	O
823	index	O
823	required	O
823	for	O
823	optimal	O
823	outcome	O
823	.	O
823	[SEP]	O
824	[CLS]	O
824	im	O
824	##mu	O
824	##no	O
824	##his	O
824	##to	O
824	##chemistry	O
824	and	O
824	quantitative	O
824	analyses	O
824	were	O
824	performed	O
824	according	O
824	to	O
824	established	O
824	protocols	O
824	[	O
824	17	O
824	,	O
824	28	O
824	]	O
824	using	O
824	primary	O
824	antibodies	O
824	against	O
824	t	O
824	##yr	O
824	##os	O
824	##ine	O
824	h	O
824	##ydro	O
824	##xy	O
824	##lase	O
824	[	O
824	32	O
824	]	O
824	(	O
824	rabbit	O
824	anti	O
824	-	O
824	th	O
824	anti	O
824	##ser	O
824	##um	O
824	from	O
824	p	O
824	##el	O
824	-	O
824	free	O
824	##z	O
824	,	O
824	r	O
824	##og	O
824	##ers	O
824	,	O
824	a	O
824	##r	O
824	,	O
824	1	O
824	:	O
824	1000	O
824	)	O
824	and	O
824	cluster	O
824	of	O
824	differentiation	O
824	68	O
824	(	O
824	c	O
824	##d	O
824	##6	O
824	##8	O
824	)	O
824	(	O
824	rat	O
824	anti	O
824	-	O
824	c	O
824	##d	O
824	##6	O
824	##8	O
824	anti	O
824	##ser	O
824	##um	O
824	from	O
824	a	O
824	##b	O
824	##d	O
824	se	O
824	##rote	O
824	##c	O
824	,	O
824	kid	O
824	##lington	O
824	,	O
824	o	O
824	##x	O
824	##ford	O
824	##shire	O
824	,	O
824	uk	O
824	;	O
824	1	O
824	:	O
824	1000	O
824	)	O
824	.	O
824	[SEP]	O
825	[CLS]	O
825	the	O
825	ratio	B-PK
825	of	I-PK
825	un	I-PK
825	##bound	I-PK
825	c	I-PK
825	##s	I-PK
825	##f	I-PK
825	:	I-PK
825	plasma	I-PK
825	ni	O
825	##lot	O
825	##ini	O
825	##b	O
825	(	O
825	figure	O
825	2	O
825	##c	O
825	)	O
825	appears	O
825	to	O
825	be	O
825	the	O
825	same	O
825	in	O
825	all	O
825	dose	O
825	groups	O
825	and	O
825	an	O
825	average	O
825	of	O
825	0	O
825	.	O
825	5	O
825	‐	O
825	1	O
825	%	O
825	ni	O
825	##lot	O
825	##ini	O
825	##b	O
825	is	O
825	detected	O
825	in	O
825	the	O
825	c	O
825	##s	O
825	##f	O
825	,	O
825	suggesting	O
825	that	O
825	ni	O
825	##lot	O
825	##ini	O
825	##b	O
825	crosses	O
825	the	O
825	b	O
825	##bb	O
825	and	O
825	is	O
825	detected	O
825	as	O
825	free	O
825	or	O
825	un	O
825	##bound	O
825	in	O
825	the	O
825	c	O
825	##s	O
825	##f	O
825	at	O
825	low	O
825	concentrations	O
825	.	O
825	[SEP]	O
826	[CLS]	O
826	the	O
826	second	O
826	study	O
826	was	O
826	a	O
826	random	O
826	##ized	O
826	,	O
826	double	O
826	-	O
826	blind	O
826	,	O
826	place	O
826	##bo	O
826	-	O
826	controlled	O
826	study	O
826	of	O
826	i	O
826	##v	O
826	del	O
826	##af	O
826	##lo	O
826	##xa	O
826	##cin	O
826	(	O
826	300	O
826	mg	O
826	)	O
826	given	O
826	as	O
826	a	O
826	single	O
826	dose	O
826	on	O
826	day	O
826	1	O
826	,	O
826	followed	O
826	by	O
826	twice	O
826	-	O
826	daily	O
826	dos	O
826	##ing	O
826	on	O
826	days	O
826	2	O
826	through	O
826	14	O
826	;	O
826	12	O
826	(	O
826	8	O
826	active	O
826	,	O
826	4	O
826	place	O
826	##bo	O
826	)	O
826	healthy	O
826	volunteers	O
826	were	O
826	enrolled	O
826	.	O
826	[SEP]	O
827	[CLS]	O
827	analysis	O
827	was	O
827	performed	O
827	using	O
827	rotor	O
827	gene	O
827	real	O
827	-	O
827	time	O
827	p	O
827	##c	O
827	##r	O
827	system	O
827	(	O
827	q	O
827	##ia	O
827	##gen	O
827	,	O
827	stock	O
827	##holm	O
827	,	O
827	s	O
827	##wed	O
827	##en	O
827	)	O
827	by	O
827	means	O
827	of	O
827	the	O
827	v	O
827	##ic	O
827	and	O
827	f	O
827	##am	O
827	dye	O
827	-	O
827	label	O
827	##ing	O
827	system	O
827	according	O
827	to	O
827	the	O
827	manufacturer	O
827	’	O
827	s	O
827	instructions	O
827	.	O
827	[SEP]	O
828	[CLS]	O
828	single	O
828	-	O
828	dose	O
828	and	O
828	steady	O
828	-	O
828	state	O
828	p	O
828	##har	O
828	##ma	O
828	##co	O
828	##kin	O
828	##etic	O
828	parameters	O
828	were	O
828	determined	O
828	for	O
828	each	O
828	individual	O
828	.	O
828	[SEP]	O
829	[CLS]	O
829	the	O
829	change	O
829	in	O
829	m	O
829	##rna	O
829	levels	O
829	of	O
829	p	O
829	##c	O
829	##na	O
829	in	O
829	whole	O
829	blood	O
829	as	O
829	a	O
829	sur	O
829	##rogate	O
829	tissue	O
829	was	O
829	determined	O
829	in	O
829	response	O
829	to	O
829	r	O
829	##onic	O
829	##ic	O
829	##li	O
829	##b	O
829	treatment	O
829	.	O
829	[SEP]	O
830	[CLS]	O
830	subsequently	O
830	,	O
830	the	O
830	i	O
830	.	O
830	v	O
830	.	O
830	r	O
830	##uca	O
830	##par	O
830	##ib	O
830	arms	O
830	were	O
830	discontinued	O
830	and	O
830	three	O
830	of	O
830	the	O
830	ch	O
830	##em	O
830	##otherapy	O
830	arms	O
830	(	O
830	b	O
830	,	O
830	c	O
830	,	O
830	and	O
830	d	O
830	)	O
830	were	O
830	closed	O
830	to	O
830	further	O
830	en	O
830	##rol	O
830	##ment	O
830	.	O
830	[SEP]	O
831	[CLS]	O
831	[	O
831	the	O
831	art	O
831	##eri	O
831	##oly	O
831	##mp	O
831	##hat	O
831	##ic	O
831	administration	O
831	of	O
831	anti	O
831	##biotics	O
831	in	O
831	treating	O
831	patients	O
831	with	O
831	su	O
831	##pp	O
831	##ura	O
831	##tive	O
831	-	O
831	inflammatory	O
831	diseases	O
831	of	O
831	the	O
831	abdominal	O
831	cavity	O
831	organs	O
831	]	O
831	.	O
831	[SEP]	O
832	[CLS]	O
832	the	O
832	plasma	O
832	ca	O
832	##li	O
832	##bra	O
832	##tion	O
832	curves	O
832	were	O
832	prepared	O
832	at	O
832	concentrations	O
832	of	O
832	6	O
832	.	O
832	25	O
832	,	O
832	3	O
832	.	O
832	12	O
832	,	O
832	1	O
832	.	O
832	56	O
832	,	O
832	0	O
832	.	O
832	78	O
832	and	O
832	0	O
832	.	O
832	39	O
832	ng	O
832	/	O
832	m	O
832	##l	O
832	by	O
832	s	O
832	##pi	O
832	##king	O
832	190	O
832	µ	O
832	##l	O
832	of	O
832	rat	O
832	plasma	O
832	with	O
832	10	O
832	##µ	O
832	##l	O
832	of	O
832	working	O
832	standard	O
832	and	O
832	200	O
832	µ	O
832	##l	O
832	of	O
832	dei	O
832	##onized	O
832	water	O
832	.	O
832	[SEP]	O
833	[CLS]	O
833	a	O
833	rapid	O
833	and	O
833	sensitive	O
833	liquid	O
833	ch	O
833	##roma	O
833	##tography	O
833	tandem	O
833	mass	O
833	s	O
833	##pect	O
833	##rome	O
833	##try	O
833	detection	O
833	using	O
833	selected	O
833	reaction	O
833	monitoring	O
833	in	O
833	positive	O
833	ion	O
833	##ization	O
833	mode	O
833	was	O
833	developed	O
833	and	O
833	valid	O
833	##ated	O
833	for	O
833	the	O
833	q	O
833	##uant	O
833	##ification	O
833	of	O
833	nod	O
833	##ake	O
833	##nin	O
833	in	O
833	rat	O
833	plasma	O
833	and	O
833	brain	O
833	.	O
833	[SEP]	O
834	[CLS]	O
834	a	O
834	uniform	O
834	volume	O
834	per	O
834	administration	O
834	(	O
834	200	O
834	μ	O
834	##l	O
834	)	O
834	was	O
834	used	O
834	for	O
834	each	O
834	group	O
834	.	O
834	[SEP]	O
835	[CLS]	O
835	co	O
835	##x	O
835	multi	O
835	##var	O
835	##iable	O
835	modelling	O
835	investigated	O
835	the	O
835	effect	O
835	of	O
835	sa	O
835	##m	O
835	and	O
835	other	O
835	co	O
835	##fa	O
835	##ctors	O
835	(	O
835	study	O
835	site	O
835	,	O
835	base	O
835	##line	O
835	parasite	O
835	density	O
835	,	O
835	child	O
835	’	O
835	s	O
835	age	O
835	,	O
835	and	O
835	all	O
835	co	O
835	##var	O
835	##iate	O
835	##s	O
835	with	O
835	a	O
835	statistical	O
835	##ly	O
835	significant	O
835	difference	O
835	at	O
835	base	O
835	##line	O
835	between	O
835	the	O
835	sa	O
835	##m	O
835	and	O
835	non	O
835	-	O
835	sa	O
835	##m	O
835	groups	O
835	)	O
835	on	O
835	malaria	O
835	-	O
835	free	O
835	survival	O
835	.	O
835	[SEP]	O
836	[CLS]	O
836	similar	O
836	results	O
836	were	O
836	obtained	O
836	in	O
836	v	O
836	##ivo	O
836	using	O
836	a	O
836	delayed	O
836	end	O
836	##oto	O
836	##xin	O
836	challenge	O
836	.	O
836	[SEP]	O
837	[CLS]	O
837	the	O
837	residue	O
837	##was	O
837	dissolved	O
837	in	O
837	me	O
837	##oh	O
837	/	O
837	d	O
837	##c	O
837	##m	O
837	and	O
837	pu	O
837	##rified	O
837	by	O
837	s	O
837	##c	O
837	##x	O
837	2	O
837	g	O
837	column	O
837	el	O
837	##uti	O
837	##ng	O
837	with	O
837	##me	O
837	##oh	O
837	and	O
837	then	O
837	2	O
837	m	O
837	n	O
837	##h	O
837	##3	O
837	in	O
837	me	O
837	##oh	O
837	.	O
837	[SEP]	O
838	[CLS]	O
838	l	O
838	##t	O
838	##d	O
838	,	O
838	s	O
838	##yd	O
838	##ney	O
838	,	O
838	au	O
838	##stra	O
838	##lia	O
838	)	O
838	.	O
838	[SEP]	O
839	[CLS]	O
839	d	O
839	##s	O
839	-	O
839	104	O
839	##0	O
839	did	O
839	not	O
839	affect	O
839	plate	O
839	##let	O
839	a	O
839	##gg	O
839	##regation	O
839	and	O
839	co	O
839	##agu	O
839	##lation	O
839	time	O
839	.	O
839	[SEP]	O
840	[CLS]	O
840	with	O
840	respect	O
840	to	O
840	g	O
840	##h	O
840	and	O
840	p	O
840	##rl	O
840	secret	O
840	##ion	O
840	,	O
840	mi	O
840	##rta	O
840	##za	O
840	##pine	O
840	did	O
840	not	O
840	show	O
840	any	O
840	effects	O
840	in	O
840	comparison	O
840	with	O
840	place	O
840	##bo	O
840	.	O
840	[SEP]	O
841	[CLS]	O
841	pp	O
841	##x	O
841	did	O
841	not	O
841	alter	O
841	l	O
841	##d	O
841	bio	B-PK
841	##ava	I-PK
841	##ila	I-PK
841	##bility	I-PK
841	,	O
841	and	O
841	pp	O
841	##x	O
841	p	O
841	##har	O
841	##ma	O
841	##co	O
841	##kin	O
841	##etics	O
841	were	O
841	equivalent	O
841	in	O
841	men	O
841	and	O
841	women	O
841	.	O
841	[SEP]	O
842	[CLS]	O
842	no	O
842	serious	O
842	adverse	O
842	events	O
842	occurred	O
842	.	O
842	[SEP]	O
843	[CLS]	O
843	in	O
843	our	O
843	systematic	O
843	review	O
843	of	O
843	the	O
843	literature	O
843	,	O
843	we	O
843	investigated	O
843	the	O
843	potential	O
843	for	O
843	drug	O
843	interactions	O
843	between	O
843	oral	O
843	anti	O
843	##coa	O
843	##gu	O
843	##lants	O
843	and	O
843	r	O
843	##il	O
843	-	O
843	2	O
843	by	O
843	assessing	O
843	the	O
843	influence	O
843	of	O
843	r	O
843	##il	O
843	-	O
843	2	O
843	administration	O
843	on	O
843	transport	O
843	##ers	O
843	and	O
843	c	O
843	##yt	O
843	##och	O
843	##rome	O
843	##s	O
843	determining	O
843	the	O
843	p	O
843	##har	O
843	##ma	O
843	##co	O
843	##kin	O
843	##etics	O
843	of	O
843	(	O
843	direct	O
843	)	O
843	oral	O
843	anti	O
843	##coa	O
843	##gu	O
843	##lants	O
843	.	O
843	[SEP]	O
844	[CLS]	O
844	fl	O
844	##orf	O
844	##eni	O
844	##co	O
844	##l	O
844	,	O
844	a	O
844	mon	O
844	##of	O
844	##lu	O
844	##ori	O
844	##nated	O
844	analogue	O
844	of	O
844	th	O
844	##iam	O
844	##phe	O
844	##nic	O
844	##ol	O
844	,	O
844	has	O
844	a	O
844	broad	O
844	anti	O
844	##ba	O
844	##cter	O
844	##ial	O
844	spectrum	O
844	.	O
844	[SEP]	O
845	[CLS]	O
845	z	O
845	##of	O
845	##eno	O
845	##p	O
845	##ril	O
845	‐	O
845	mediated	O
845	card	O
845	##io	O
845	##p	O
845	##rote	O
845	##ction	O
845	during	O
845	i	O
845	/	O
845	r	O
845	is	O
845	associated	O
845	with	O
845	an	O
845	increase	O
845	in	O
845	h	O
845	##2	O
845	##s	O
845	and	O
845	no	O
845	signaling	O
845	.	O
845	[SEP]	O
846	[CLS]	O
846	blood	O
846	was	O
846	collected	O
846	at	O
846	various	O
846	time	O
846	points	O
846	between	O
846	0	O
846	and	O
846	600	O
846	minutes	O
846	and	O
846	then	O
846	analyzed	O
846	with	O
846	high	O
846	-	O
846	performance	O
846	liquid	O
846	ch	O
846	##roma	O
846	##tography	O
846	to	O
846	determine	O
846	levels	O
846	of	O
846	tram	O
846	##ado	O
846	##l	O
846	and	O
846	m	O
846	##1	O
846	,	O
846	the	O
846	pre	O
846	##dom	O
846	##inate	O
846	active	O
846	meta	O
846	##bol	O
846	##ite	O
846	.	O
846	[SEP]	O
847	[CLS]	O
847	it	O
847	is	O
847	also	O
847	known	O
847	as	O
847	an	O
847	inhibitor	O
847	of	O
847	the	O
847	c	O
847	##yt	O
847	##och	O
847	##rome	O
847	p	O
847	##45	O
847	##0	O
847	(	O
847	c	O
847	##y	O
847	##p	O
847	)	O
847	is	O
847	##oe	O
847	##nz	O
847	##yme	O
847	3	O
847	##a	O
847	##4	O
847	.	O
847	[SEP]	O
848	[CLS]	O
848	s	O
848	##yne	O
848	##rg	O
848	##ism	O
848	with	O
848	p	O
848	##ac	O
848	##lit	O
848	##ax	O
848	##el	O
848	and	O
848	derivative	O
848	3	O
848	was	O
848	also	O
848	observed	O
848	in	O
848	co	O
848	##lon	O
848	cancer	O
848	cell	O
848	line	O
848	h	O
848	##ct	O
848	##11	O
848	##6	O
848	(	O
848	fi	O
848	##g	O
848	.	O
848	6	O
848	)	O
848	.	O
848	[SEP]	O
849	[CLS]	O
849	smoking	O
849	does	O
849	not	O
849	contribute	O
849	significantly	O
849	to	O
849	the	O
849	var	O
849	##iability	O
849	in	O
849	ni	O
849	##fe	O
849	##di	O
849	##pine	O
849	p	O
849	##har	O
849	##ma	O
849	##co	O
849	##kin	O
849	##etics	O
849	.	O
849	[SEP]	O
850	[CLS]	O
850	during	O
850	do	O
850	##but	O
850	##amine	O
850	in	O
850	##fusion	O
850	##s	O
850	,	O
850	there	O
850	were	O
850	significant	O
850	increases	O
850	in	O
850	cardiac	O
850	output	O
850	measurements	O
850	above	O
850	per	O
850	##in	O
850	##fusion	O
850	values	O
850	.	O
850	[SEP]	O
851	[CLS]	O
851	the	O
851	time	O
851	required	O
851	to	O
851	reach	O
851	clinical	O
851	##ly	O
851	effective	O
851	blood	O
851	levels	O
851	of	O
851	pseudo	O
851	##ep	O
851	##hed	O
851	##rine	O
851	was	O
851	longer	O
851	,	O
851	starting	O
851	at	O
851	approximately	O
851	2	O
851	h	O
851	.	O
851	however	O
851	,	O
851	the	O
851	plasma	O
851	levels	O
851	predicted	O
851	that	O
851	the	O
851	clinical	O
851	effect	O
851	would	O
851	then	O
851	last	O
851	for	O
851	at	O
851	least	O
851	a	O
851	further	O
851	12	O
851	h	O
851	.	O
851	t	B-PK
851	##rough	I-PK
851	levels	I-PK
851	from	O
851	the	O
851	multiple	O
851	-	O
851	dose	O
851	study	O
851	showed	O
851	that	O
851	clinical	O
851	##ly	O
851	relevant	O
851	anal	O
851	##ges	O
851	##ic	O
851	and	O
851	de	O
851	##con	O
851	##ges	O
851	##tant	O
851	plasma	O
851	levels	O
851	were	O
851	maintained	O
851	for	O
851	24	O
851	h	O
851	during	O
851	twice	O
851	-	O
851	daily	O
851	dos	O
851	##ing	O
851	.	O
851	[SEP]	O
852	[CLS]	O
852	the	O
852	e	O
852	‐	O
852	r	O
852	models	O
852	for	O
852	das	O
852	##28	O
852	and	O
852	a	O
852	##c	O
852	##r	O
852	##20	O
852	/	O
852	50	O
852	/	O
852	70	O
852	were	O
852	developed	O
852	using	O
852	data	O
852	from	O
852	3	O
852	trials	O
852	(	O
852	1	O
852	phase	O
852	2	O
852	,	O
852	2	O
852	phase	O
852	3	O
852	)	O
852	in	O
852	patients	O
852	with	O
852	r	O
852	##a	O
852	.	O
852	[SEP]	O
853	[CLS]	O
853	diet	O
853	##ary	O
853	protein	O
853	deficiency	O
853	was	O
853	associated	O
853	with	O
853	a	O
853	decrease	O
853	in	O
853	body	O
853	weight	O
853	gain	O
853	,	O
853	vent	O
853	##ric	O
853	##ular	O
853	weight	O
853	,	O
853	total	O
853	plasma	O
853	proteins	O
853	and	O
853	plasma	O
853	album	O
853	##in	O
853	,	O
853	he	O
853	##pa	O
853	##tic	O
853	total	O
853	and	O
853	micro	O
853	##so	O
853	##mal	O
853	proteins	O
853	,	O
853	c	O
853	##yt	O
853	##och	O
853	##rome	O
853	p	O
853	-	O
853	450	O
853	,	O
853	and	O
853	protein	O
853	:	O
853	d	O
853	##na	O
853	ratios	O
853	;	O
853	serum	O
853	potassium	O
853	was	O
853	slightly	O
853	but	O
853	ins	O
853	##ign	O
853	##ificant	O
853	##ly	O
853	decreased	O
853	.	O
853	[SEP]	O
854	[CLS]	O
854	two	O
854	sub	O
854	##pop	O
854	##ulation	O
854	##s	O
854	of	O
854	women	O
854	emerged	O
854	based	O
854	on	O
854	the	O
854	rate	O
854	of	O
854	increase	O
854	in	O
854	l	O
854	##t	O
854	##g	O
854	c	B-PK
854	##l	I-PK
854	/	I-PK
854	f	I-PK
854	during	O
854	pregnancy	O
854	.	O
854	[SEP]	O
855	[CLS]	O
855	patients	O
855	with	O
855	a	O
855	previous	O
855	tuberculosis	O
855	episode	O
855	within	O
855	three	O
855	years	O
855	prior	O
855	to	O
855	the	O
855	current	O
855	episode	O
855	,	O
855	a	O
855	history	O
855	of	O
855	prior	O
855	treatment	O
855	for	O
855	m	O
855	##dr	O
855	tuberculosis	O
855	,	O
855	con	O
855	##com	O
855	##ita	O
855	##nt	O
855	op	O
855	##port	O
855	##uni	O
855	##stic	O
855	infection	O
855	requiring	O
855	additional	O
855	anti	O
855	-	O
855	micro	O
855	##bial	O
855	treatment	O
855	,	O
855	a	O
855	formal	O
855	con	O
855	##tra	O
855	##ind	O
855	##ica	O
855	##tion	O
855	to	O
855	any	O
855	trial	O
855	medication	O
855	,	O
855	diabetes	O
855	me	O
855	##lli	O
855	##tus	O
855	requiring	O
855	treatment	O
855	,	O
855	recreational	O
855	drug	O
855	or	O
855	alcohol	O
855	abuse	O
855	,	O
855	mental	O
855	illness	O
855	,	O
855	total	O
855	ne	O
855	##ut	O
855	##rop	O
855	##hil	O
855	count	O
855	<	O
855	1200	O
855	cells	O
855	/	O
855	l	O
855	,	O
855	hem	O
855	##og	O
855	##lo	O
855	##bin	O
855	<	O
855	6	O
855	.	O
855	8	O
855	g	O
855	/	O
855	d	O
855	##l	O
855	,	O
855	or	O
855	liver	O
855	function	O
855	tests	O
855	>	O
855	grade	O
855	2	O
855	,	O
855	pregnancy	O
855	or	O
855	la	O
855	##ct	O
855	##ating	O
855	women	O
855	were	O
855	excluded	O
855	.	O
855	[SEP]	O
856	[CLS]	O
856	if	O
856	the	O
856	concentration	O
856	of	O
856	the	O
856	chemical	O
856	in	O
856	the	O
856	free	B-PK
856	fraction	I-PK
856	was	O
856	below	O
856	,	O
856	this	O
856	value	O
856	or	O
856	below	O
856	the	O
856	analytical	O
856	limits	O
856	of	O
856	detection	O
856	,	O
856	a	O
856	default	O
856	f	B-PK
856	##u	I-PK
856	of	O
856	0	O
856	.	O
856	00	O
856	##5	O
856	was	O
856	assumed	O
856	.	O
856	[SEP]	O
857	[CLS]	O
857	the	O
857	rats	O
857	were	O
857	fast	O
857	##ed	O
857	overnight	O
857	before	O
857	the	O
857	day	O
857	of	O
857	the	O
857	experiment	O
857	.	O
857	[SEP]	O
858	[CLS]	O
858	p	O
858	##b	O
858	##p	O
858	##k	O
858	model	O
858	simulation	O
858	suggested	O
858	that	O
858	the	O
858	distribution	O
858	of	O
858	flu	O
858	##cona	O
858	##zo	O
858	##le	O
858	into	O
858	sub	O
858	##cut	O
858	##aneous	O
858	inter	O
858	##st	O
858	##iti	O
858	##al	O
858	fluid	O
858	is	O
858	dependent	O
858	on	O
858	tissue	O
858	blood	B-PK
858	flow	I-PK
858	.	O
858	[SEP]	O
859	[CLS]	O
859	limited	O
859	information	O
859	about	O
859	the	O
859	p	O
859	##har	O
859	##ma	O
859	##co	O
859	##kin	O
859	##etics	O
859	of	O
859	mi	O
859	##ca	O
859	##fu	O
859	##ng	O
859	##in	O
859	in	O
859	the	O
859	per	O
859	##ito	O
859	##nea	O
859	##l	O
859	cavity	O
859	is	O
859	available	O
859	.	O
859	[SEP]	O
860	[CLS]	O
860	compared	O
860	with	O
860	control	O
860	group	O
860	,	O
860	the	O
860	co	O
860	##ad	O
860	##mini	O
860	##stra	O
860	##tion	O
860	of	O
860	be	O
860	##rber	O
860	##ine	O
860	resulted	O
860	in	O
860	a	O
860	decrease	O
860	of	O
860	cm	B-PK
860	##ax	I-PK
860	(	O
860	p	O
860	<	O
860	0	O
860	.	O
860	05	O
860	)	O
860	.	O
860	[SEP]	O
861	[CLS]	O
861	$	O
861	$	O
861	\	O
861	end	O
861	{	O
861	document	O
861	}	O
861	base	O
861	##line	O
861	al	O
861	##t	O
861	=	O
861	21	O
861	.	O
861	2	O
861	##×	O
861	##b	O
861	##w	O
861	##t	O
861	/	O
861	77	O
861	.	O
861	30	O
861	.	O
861	37	O
861	##6	O
861	.	O
861	[SEP]	O
862	[CLS]	O
862	acute	O
862	-	O
862	toxicity	O
862	testing	O
862	also	O
862	showed	O
862	that	O
862	mi	O
862	##l	O
862	had	O
862	no	O
862	devastating	O
862	effect	O
862	on	O
862	mice	O
862	behaviors	O
862	.	O
862	[SEP]	O
863	[CLS]	O
863	predict	O
863	##ing	O
863	need	O
863	for	O
863	p	O
863	##har	O
863	##ma	O
863	##co	O
863	##kin	O
863	##etic	O
863	consultation	O
863	follow	O
863	-	O
863	up	O
863	using	O
863	disc	O
863	##rim	O
863	##ina	O
863	##nt	O
863	analysis	O
863	.	O
863	[SEP]	O
864	[CLS]	O
864	when	O
864	b	O
864	##ms	O
864	-	O
864	1811	O
864	##01	O
864	was	O
864	administered	O
864	with	O
864	food	O
864	,	O
864	cm	B-PK
864	##ax	I-PK
864	was	O
864	reduced	O
864	by	O
864	about	O
864	25	O
864	%	O
864	and	O
864	t	B-PK
864	##max	I-PK
864	was	O
864	prolonged	O
864	by	O
864	1	O
864	h	O
864	.	O
864	however	O
864	,	O
864	au	B-PK
864	##ct	I-PK
864	##au	I-PK
864	,	O
864	t	B-PK
864	##1	I-PK
864	/	I-PK
864	2	I-PK
864	,	O
864	and	O
864	time	B-PK
864	to	I-PK
864	attain	I-PK
864	steady	I-PK
864	state	I-PK
864	of	O
864	b	O
864	##ms	O
864	-	O
864	1811	O
864	##01	O
864	were	O
864	not	O
864	altered	O
864	by	O
864	ing	O
864	##est	O
864	##ion	O
864	of	O
864	food	O
864	.	O
864	[SEP]	O
865	[CLS]	O
865	the	O
865	is	O
865	##onia	O
865	##zi	O
865	##d	O
865	peak	B-PK
865	≤	O
865	##4	O
865	.	O
865	29	O
865	mg	O
865	/	O
865	l	O
865	score	O
865	was	O
865	49	O
865	%	O
865	,	O
865	while	O
865	that	O
865	for	O
865	the	O
865	au	B-PK
865	##c	I-PK
865	##0	I-PK
865	–	I-PK
865	24	I-PK
865	was	O
865	35	O
865	%	O
865	;	O
865	however	O
865	,	O
865	for	O
865	both	O
865	parameters	O
865	higher	O
865	is	O
865	##onia	O
865	##zi	O
865	##d	O
865	concentration	O
865	selected	O
865	nodes	O
865	with	O
865	greater	O
865	proportions	O
865	of	O
865	dead	O
865	children	O
865	,	O
865	and	O
865	in	O
865	un	O
865	##p	O
865	##run	O
865	##ed	O
865	trees	O
865	were	O
865	ranked	O
865	even	O
865	higher	O
865	.	O
865	[SEP]	O
866	[CLS]	O
866	a	O
866	phase	O
866	i	O
866	study	O
866	of	O
866	p	O
866	##ac	O
866	##lit	O
866	##ax	O
866	##el	O
866	and	O
866	do	O
866	##x	O
866	##or	O
866	##ubi	O
866	##cin	O
866	administered	O
866	as	O
866	concurrent	O
866	96	O
866	-	O
866	h	O
866	continuous	O
866	i	O
866	.	O
866	v	O
866	.	O
866	in	O
866	##fusion	O
866	was	O
866	performed	O
866	to	O
866	determine	O
866	the	O
866	maximum	O
866	tolerate	O
866	##d	O
866	dose	O
866	(	O
866	m	O
866	##t	O
866	##d	O
866	)	O
866	,	O
866	principal	O
866	toxic	O
866	##ities	O
866	,	O
866	and	O
866	p	O
866	##har	O
866	##ma	O
866	##co	O
866	##kin	O
866	##etics	O
866	of	O
866	this	O
866	combination	O
866	in	O
866	women	O
866	with	O
866	re	O
866	##lap	O
866	##sed	O
866	e	O
866	##pit	O
866	##hel	O
866	##ial	O
866	o	O
866	##var	O
866	##ian	O
866	cancer	O
866	.	O
866	[SEP]	O
867	[CLS]	O
867	one	O
867	child	O
867	in	O
867	group	O
867	in	O
867	experienced	O
867	rapid	O
867	and	O
867	high	O
867	level	O
867	s	O
867	-	O
867	k	O
867	##eta	O
867	##mine	O
867	absorption	O
867	with	O
867	a	O
867	peak	B-PK
867	plasma	I-PK
867	concentration	I-PK
867	of	O
867	73	O
867	##2	O
867	ng	O
867	x	O
867	m	O
867	##l	O
867	(	O
867	-	O
867	1	O
867	)	O
867	after	O
867	2	O
867	min	O
867	,	O
867	which	O
867	decreased	O
867	to	O
867	27	O
867	##4	O
867	ng	O
867	x	O
867	m	O
867	##l	O
867	(	O
867	-	O
867	1	O
867	)	O
867	after	O
867	60	O
867	min	O
867	.	O
867	[SEP]	O
868	[CLS]	O
868	thus	O
868	,	O
868	we	O
868	analyzed	O
868	the	O
868	stab	O
868	##ili	O
868	##zing	O
868	effect	O
868	of	O
868	sodium	O
868	de	O
868	##ox	O
868	##ych	O
868	##olate	O
868	when	O
868	incorporated	O
868	into	O
868	na	O
868	##no	O
868	-	O
868	sized	O
868	lip	O
868	##oso	O
868	##mes	O
868	.	O
868	[SEP]	O
869	[CLS]	O
869	a	O
869	p	O
869	##har	O
869	##ma	O
869	##co	O
869	##kin	O
869	##etic	O
869	investigation	O
869	showed	O
869	the	O
869	mean	O
869	elimination	B-PK
869	half	I-PK
869	life	I-PK
869	of	O
869	z	O
869	##d	O
869	-	O
869	169	O
869	##4	O
869	plasma	O
869	concentration	O
869	was	O
869	91	O
869	.	O
869	5	O
869	hours	O
869	in	O
869	the	O
869	single	O
869	-	O
869	dose	O
869	group	O
869	and	O
869	119	O
869	.	O
869	1	O
869	hours	O
869	in	O
869	the	O
869	repeated	O
869	dose	O
869	group	O
869	.	O
869	[SEP]	O
870	[CLS]	O
870	where	O
870	em	B-PK
870	##ax	I-PK
870	is	O
870	the	O
870	maximum	B-PK
870	effect	I-PK
870	and	O
870	e	B-PK
870	##c	I-PK
870	##50	I-PK
870	is	O
870	the	O
870	if	O
870	##n	O
870	-	O
870	α	O
870	concentration	B-PK
870	that	I-PK
870	produces	I-PK
870	50	I-PK
870	%	I-PK
870	of	I-PK
870	the	I-PK
870	maximum	I-PK
870	effect	I-PK
870	.	O
870	[SEP]	O
871	[CLS]	O
871	the	O
871	low	O
871	cumulative	O
871	curves	O
871	of	O
871	the	O
871	two	O
871	su	O
871	##cci	O
871	##ny	O
871	##l	O
871	-	O
871	s	O
871	##n	O
871	##38	O
871	derivatives	O
871	in	O
871	50	O
871	%	O
871	plasma	O
871	and	O
871	25	O
871	%	O
871	liver	O
871	ho	O
871	##mo	O
871	##gen	O
871	##ate	O
871	reflected	O
871	fast	O
871	in	O
871	v	O
871	##ivo	O
871	elimination	O
871	.	O
871	[SEP]	O
872	[CLS]	O
872	the	O
872	prepared	O
872	films	O
872	were	O
872	evaluated	O
872	for	O
872	their	O
872	tens	O
872	##ile	O
872	strength	O
872	,	O
872	thickness	O
872	uniform	O
872	##ity	O
872	,	O
872	di	O
872	##sin	O
872	##te	O
872	##gration	O
872	time	O
872	(	O
872	in	O
872	v	O
872	##it	O
872	##ro	O
872	and	O
872	in	O
872	v	O
872	##ivo	O
872	)	O
872	,	O
872	in	O
872	v	O
872	##it	O
872	##ro	O
872	dissolution	O
872	,	O
872	and	O
872	moisture	O
872	content	O
872	.	O
872	[SEP]	O
873	[CLS]	O
873	dos	O
873	##age	O
873	,	O
873	dos	O
873	##ing	O
873	regime	O
873	##n	O
873	,	O
873	and	O
873	the	O
873	last	O
873	blood	O
873	sampling	O
873	time	O
873	were	O
873	set	O
873	to	O
873	match	O
873	the	O
873	actual	O
873	clinical	O
873	trial	O
873	in	O
873	phase	O
873	i	O
873	studies	O
873	in	O
873	j	O
873	##apa	O
873	##nese	O
873	and	O
873	non	O
873	‐	O
873	j	O
873	##apa	O
873	##nese	O
873	healthy	O
873	subjects	O
873	.	O
873	[SEP]	O
874	[CLS]	O
874	in	O
874	this	O
874	report	O
874	,	O
874	we	O
874	describe	O
874	the	O
874	development	O
874	and	O
874	valid	O
874	##ation	O
874	of	O
874	a	O
874	limited	O
874	-	O
874	sampling	O
874	model	O
874	for	O
874	car	O
874	##bo	O
874	##p	O
874	##lat	O
874	##in	O
874	from	O
874	77	O
874	p	O
874	##har	O
874	##ma	O
874	##co	O
874	##kin	O
874	##etic	O
874	curves	O
874	,	O
874	when	O
874	car	O
874	##bo	O
874	##p	O
874	##lat	O
874	##in	O
874	is	O
874	used	O
874	in	O
874	combination	O
874	with	O
874	p	O
874	##ac	O
874	##lit	O
874	##ax	O
874	##el	O
874	.	O
874	[SEP]	O
875	[CLS]	O
875	d	O
875	##l	O
875	was	O
875	obtained	O
875	from	O
875	ca	O
875	##di	O
875	##la	O
875	pharmaceutical	O
875	##s	O
875	,	O
875	in	O
875	##dia	O
875	.	O
875	[SEP]	O
876	[CLS]	O
876	such	O
876	a	O
876	process	O
876	compares	O
876	well	O
876	to	O
876	the	O
876	estimated	O
876	di	O
876	##sso	O
876	##ciation	O
876	rate	O
876	constant	O
876	(	O
876	k	O
876	(	O
876	off	O
876	)	O
876	)	O
876	of	O
876	the	O
876	com	O
876	##t	O
876	-	O
876	op	O
876	##ica	O
876	##po	O
876	##ne	O
876	molecular	O
876	complex	O
876	(	O
876	k	O
876	(	O
876	off	O
876	)	O
876	=	O
876	1	O
876	.	O
876	9	O
876	×	O
876	10	O
876	(	O
876	-	O
876	6	O
876	)	O
876	s	O
876	(	O
876	-	O
876	1	O
876	)	O
876	)	O
876	.	O
876	[SEP]	O
877	[CLS]	O
877	this	O
877	analysis	O
877	was	O
877	performed	O
877	on	O
877	patients	O
877	diagnosed	O
877	with	O
877	pulmonary	O
877	tuberculosis	O
877	from	O
877	two	O
877	clinical	O
877	studies	O
877	:	O
877	the	O
877	phase	O
877	ii	O
877	##i	O
877	r	O
877	##if	O
877	##aq	O
877	##uin	O
877	study	O
877	(	O
877	registration	O
877	number	O
877	is	O
877	##rc	O
877	##t	O
877	##n	O
877	##44	O
877	##15	O
877	##30	O
877	##44	O
877	)	O
877	(	O
877	26	O
877	)	O
877	and	O
877	the	O
877	two	O
877	-	O
877	stage	O
877	activity	O
877	-	O
877	safety	O
877	study	O
877	of	O
877	daily	O
877	r	O
877	##if	O
877	##ap	O
877	##ent	O
877	##ine	O
877	(	O
877	27	O
877	)	O
877	,	O
877	referred	O
877	to	O
877	here	O
877	as	O
877	the	O
877	daily	O
877	r	O
877	##pe	O
877	study	O
877	(	O
877	clinical	O
877	##tri	O
877	##als	O
877	.	O
877	go	O
877	##v	O
877	registration	O
877	number	O
877	n	O
877	##ct	O
877	##00	O
877	##8	O
877	##14	O
877	##6	O
877	##7	O
877	##1	O
877	)	O
877	.	O
877	[SEP]	O
878	[CLS]	O
878	there	O
878	is	O
878	sufficient	O
878	evidence	O
878	supporting	O
878	the	O
878	protective	O
878	role	O
878	of	O
878	the	O
878	n	O
878	##rf	O
878	##2	O
878	-	O
878	mediated	O
878	pathway	O
878	against	O
878	o	O
878	##xi	O
878	##da	O
878	##tive	O
878	stress	O
878	and	O
878	inflammation	O
878	.	O
878	28	O
878	recent	O
878	research	O
878	has	O
878	shown	O
878	that	O
878	n	O
878	##rf	O
878	##2	O
878	has	O
878	multiple	O
878	functions	O
878	,	O
878	including	O
878	acute	O
878	and	O
878	trans	O
878	##ient	O
878	stress	O
878	responses	O
878	to	O
878	o	O
878	##xi	O
878	##da	O
878	##tive	O
878	insults	O
878	.	O
878	29	O
878	ho	O
878	-	O
878	1	O
878	gene	O
878	expression	O
878	is	O
878	mainly	O
878	regulated	O
878	by	O
878	the	O
878	n	O
878	##rf	O
878	##2	O
878	anti	O
878	##ox	O
878	##ida	O
878	##nt	O
878	response	O
878	element	O
878	(	O
878	are	O
878	)	O
878	pathway	O
878	,	O
878	and	O
878	induction	O
878	of	O
878	this	O
878	enzyme	O
878	protects	O
878	cells	O
878	from	O
878	injury	O
878	and	O
878	death	O
878	caused	O
878	by	O
878	o	O
878	##xi	O
878	##da	O
878	##tive	O
878	stress	O
878	.	O
878	30	O
878	n	O
878	##rf	O
878	##2	O
878	expression	O
878	was	O
878	found	O
878	to	O
878	have	O
878	increased	O
878	post	O
878	-	O
878	c	O
878	##sa	O
878	administration	O
878	,	O
878	parallel	O
878	##ing	O
878	the	O
878	enhanced	O
878	anti	O
878	##ox	O
878	##ida	O
878	##nt	O
878	capacity	O
878	,	O
878	but	O
878	surprisingly	O
878	not	O
878	the	O
878	inflammatory	O
878	changes	O
878	in	O
878	re	O
878	##nal	O
878	tissues	O
878	.	O
878	[SEP]	O
879	[CLS]	O
879	therapeutic	O
879	intervention	O
879	controls	O
879	increased	O
879	i	O
879	##op	O
879	,	O
879	but	O
879	ne	O
879	##uro	O
879	##p	O
879	##rote	O
879	##ction	O
879	is	O
879	unavailable	O
879	.	O
879	[SEP]	O
880	[CLS]	O
880	the	O
880	au	B-PK
880	##c	I-PK
880	ratio	I-PK
880	(	O
880	-	O
880	)	O
880	/	O
880	(	O
880	+	O
880	)	O
880	was	O
880	1	O
880	.	O
880	52	O
880	+	O
880	-	O
880	0	O
880	.	O
880	36	O
880	and	O
880	1	O
880	.	O
880	32	O
880	+	O
880	-	O
880	0	O
880	.	O
880	17	O
880	after	O
880	single	O
880	doses	O
880	and	O
880	steady	O
880	-	O
880	state	O
880	,	O
880	respectively	O
880	(	O
880	p	O
880	greater	O
880	than	O
880	0	O
880	.	O
880	05	O
880	)	O
880	.	O
880	[SEP]	O
881	[CLS]	O
881	p	O
881	##har	O
881	##ma	O
881	##co	O
881	##kin	O
881	##etics	O
881	and	O
881	milk	O
881	penetration	O
881	of	O
881	di	O
881	##f	O
881	##lo	O
881	##xa	O
881	##cin	O
881	after	O
881	a	O
881	long	O
881	-	O
881	acting	O
881	formulation	O
881	for	O
881	sub	O
881	##cut	O
881	##aneous	O
881	administration	O
881	to	O
881	la	O
881	##ct	O
881	##ating	O
881	goats	O
881	.	O
881	[SEP]	O
882	[CLS]	O
882	to	O
882	further	O
882	investigate	O
882	the	O
882	effect	O
882	of	O
882	the	O
882	p	O
882	##h	O
882	on	O
882	the	O
882	h	O
882	##ydro	O
882	##lysis	O
882	of	O
882	d	O
882	##m	O
882	##f	O
882	to	O
882	mm	O
882	##f	O
882	,	O
882	0	O
882	.	O
882	1	O
882	m	O
882	sodium	O
882	phosphate	O
882	buffer	O
882	##s	O
882	with	O
882	p	O
882	##h	O
882	values	O
882	ranging	O
882	from	O
882	6	O
882	.	O
882	5	O
882	–	O
882	8	O
882	were	O
882	spike	O
882	##d	O
882	with	O
882	d	O
882	##m	O
882	##f	O
882	and	O
882	the	O
882	combination	O
882	of	O
882	d	O
882	##m	O
882	##f	O
882	and	O
882	me	O
882	##f	O
882	.	O
882	[SEP]	O
883	[CLS]	O
883	to	O
883	estimate	O
883	the	O
883	population	O
883	p	O
883	##har	O
883	##ma	O
883	##co	O
883	##kin	O
883	##etics	O
883	of	O
883	low	O
883	-	O
883	dose	O
883	met	O
883	##hot	O
883	##re	O
883	##xa	O
883	##te	O
883	(	O
883	m	O
883	##t	O
883	##x	O
883	)	O
883	in	O
883	j	O
883	##apa	O
883	##nese	O
883	patients	O
883	using	O
883	non	O
883	##me	O
883	##m	O
883	,	O
883	a	O
883	computer	O
883	program	O
883	designed	O
883	for	O
883	anal	O
883	##ys	O
883	##ing	O
883	drug	O
883	p	O
883	##har	O
883	##ma	O
883	##co	O
883	##kin	O
883	##etics	O
883	in	O
883	study	O
883	populations	O
883	through	O
883	pool	O
883	##ing	O
883	of	O
883	data	O
883	.	O
883	[SEP]	O
884	[CLS]	O
884	safety	O
884	and	O
884	efficacy	O
884	were	O
884	evaluated	O
884	in	O
884	all	O
884	patients	O
884	who	O
884	received	O
884	one	O
884	or	O
884	more	O
884	doses	O
884	of	O
884	study	O
884	treatment	O
884	.	O
884	[SEP]	O
885	[CLS]	O
885	using	O
885	a	O
885	perfect	O
885	##si	O
885	##l	O
885	c	O
885	##18	O
885	column	O
885	(	O
885	4	O
885	.	O
885	6	O
885	×	O
885	150	O
885	mm	O
885	,	O
885	5	O
885	μ	O
885	##m	O
885	particle	O
885	size	O
885	)	O
885	,	O
885	a	O
885	variety	O
885	of	O
885	mobile	O
885	phases	O
885	comprising	O
885	several	O
885	combinations	O
885	of	O
885	a	O
885	##que	O
885	##ous	O
885	(	O
885	0	O
885	.	O
885	01	O
885	m	O
885	potassium	O
885	di	O
885	##hy	O
885	##dr	O
885	##ogen	O
885	phosphate	O
885	buffer	O
885	or	O
885	dei	O
885	##onized	O
885	water	O
885	)	O
885	and	O
885	organic	O
885	solvent	O
885	##s	O
885	(	O
885	met	O
885	##han	O
885	##ol	O
885	or	O
885	ace	O
885	##ton	O
885	##it	O
885	##ril	O
885	##e	O
885	)	O
885	were	O
885	tested	O
885	to	O
885	provide	O
885	sufficient	O
885	resolution	O
885	between	O
885	do	O
885	##x	O
885	##or	O
885	##ubi	O
885	##cin	O
885	,	O
885	is	O
885	and	O
885	plasma	O
885	interfering	O
885	peaks	O
885	.	O
885	[SEP]	O
886	[CLS]	O
886	hence	O
886	,	O
886	o	O
886	##x	O
886	##car	O
886	##ba	O
886	##ze	O
886	##pine	O
886	can	O
886	be	O
886	generally	O
886	applied	O
886	using	O
886	the	O
886	same	O
886	dos	O
886	##age	O
886	and	O
886	administration	O
886	for	O
886	the	O
886	treatment	O
886	of	O
886	partial	O
886	onset	O
886	seizure	O
886	##s	O
886	in	O
886	p	O
886	##ediatric	O
886	patients	O
886	,	O
886	regardless	O
886	of	O
886	ethnicity	O
886	.	O
886	[SEP]	O
887	[CLS]	O
887	in	O
887	v	O
887	##ivo	O
887	,	O
887	the	O
887	album	O
887	##in	O
887	binding	O
887	m	O
887	##oi	O
887	##ety	O
887	resulted	O
887	in	O
887	prolonged	O
887	circulation	O
887	and	O
887	higher	O
887	α	O
887	##v	O
887	##β	O
887	##6	O
887	-	O
887	targeted	O
887	up	O
887	##take	O
887	.	O
887	[SEP]	O
888	[CLS]	O
888	e	O
888	##c	O
888	##g	O
888	parameters	O
888	for	O
888	any	O
888	patient	O
888	and	O
888	time	O
888	##point	O
888	were	O
888	considered	O
888	valid	O
888	if	O
888	they	O
888	were	O
888	based	O
888	on	O
888	at	O
888	least	O
888	two	O
888	valid	O
888	replica	O
888	##te	O
888	e	O
888	##c	O
888	##gs	O
888	.	O
888	[SEP]	O
889	[CLS]	O
889	the	O
889	area	B-PK
889	under	I-PK
889	the	I-PK
889	curve	I-PK
889	(	I-PK
889	au	I-PK
889	##c	I-PK
889	##0	I-PK
889	-	I-PK
889	180	I-PK
889	)	I-PK
889	for	O
889	m	O
889	##3	O
889	##g	O
889	and	O
889	m	O
889	##6	O
889	##g	O
889	were	O
889	similar	O
889	in	O
889	the	O
889	two	O
889	patient	O
889	groups	O
889	,	O
889	as	O
889	were	O
889	the	O
889	peak	B-PK
889	meta	I-PK
889	##bol	I-PK
889	##ite	I-PK
889	concentrations	I-PK
889	and	O
889	times	B-PK
889	to	I-PK
889	peak	I-PK
889	concentrations	I-PK
889	.	O
889	[SEP]	O
890	[CLS]	O
890	side	O
890	-	O
890	effects	O
890	were	O
890	frequent	O
890	,	O
890	but	O
890	neither	O
890	their	O
890	severity	O
890	nor	O
890	their	O
890	occurrence	O
890	could	O
890	be	O
890	related	O
890	to	O
890	plasma	O
890	levels	O
890	or	O
890	to	O
890	the	O
890	rate	O
890	of	O
890	increase	O
890	in	O
890	plasma	O
890	concentration	O
890	of	O
890	the	O
890	drug	O
890	.	O
890	[SEP]	O
891	[CLS]	O
891	blood	O
891	samples	O
891	were	O
891	collected	O
891	by	O
891	re	O
891	##tro	O
891	-	O
891	orbital	O
891	bleeding	O
891	from	O
891	the	O
891	two	O
891	groups	O
891	at	O
891	the	O
891	indicated	O
891	time	O
891	intervals	O
891	.	O
891	[SEP]	O
892	[CLS]	O
892	these	O
892	results	O
892	directly	O
892	support	O
892	our	O
892	observation	O
892	that	O
892	do	O
892	##xy	O
892	##cy	O
892	##cline	O
892	potent	O
892	##ly	O
892	in	O
892	##hibit	O
892	##s	O
892	ma	O
892	##mm	O
892	##os	O
892	##phere	O
892	formation	O
892	,	O
892	by	O
892	blocking	O
892	the	O
892	c	O
892	##lon	O
892	##al	O
892	expansion	O
892	of	O
892	c	O
892	##s	O
892	##cs	O
892	and	O
892	reduces	O
892	an	O
892	##oi	O
892	##kis	O
892	-	O
892	resistance	O
892	.	O
892	[SEP]	O
893	[CLS]	O
893	my	O
893	##oto	O
893	##nia	O
893	was	O
893	induced	O
893	in	O
893	the	O
893	rat	O
893	by	O
893	injection	O
893	of	O
893	ant	O
893	##hra	O
893	##ce	O
893	##n	O
893	-	O
893	9	O
893	-	O
893	car	O
893	##box	O
893	##yl	O
893	##ic	O
893	acid	O
893	,	O
893	a	O
893	muscle	O
893	chloride	O
893	channel	O
893	block	O
893	##er	O
893	.	O
893	[SEP]	O
894	[CLS]	O
894	in	O
894	a	O
894	double	O
894	‐	O
894	blind	O
894	,	O
894	random	O
894	##ized	O
894	,	O
894	multiple	O
894	‐	O
894	ascending	O
894	‐	O
894	dose	O
894	(	O
894	mad	O
894	)	O
894	study	O
894	,	O
894	8	O
894	healthy	O
894	subjects	O
894	per	O
894	panel	O
894	(	O
894	3	O
894	active	O
894	:	O
894	1	O
894	place	O
894	##bo	O
894	)	O
894	received	O
894	5	O
894	weekly	O
894	s	O
894	##c	O
894	doses	O
894	of	O
894	l	O
894	##uli	O
894	##zu	O
894	##ma	O
894	##b	O
894	at	O
894	6	O
894	.	O
894	25	O
894	,	O
894	12	O
894	.	O
894	5	O
894	,	O
894	or	O
894	37	O
894	.	O
894	5	O
894	mg	O
894	(	O
894	all	O
894	6	O
894	.	O
894	25	O
894	‐	O
894	mg	O
894	panel	O
894	subjects	O
894	received	O
894	place	O
894	##bo	O
894	in	O
894	weeks	O
894	2	O
894	and	O
894	4	O
894	)	O
894	,	O
894	or	O
894	place	O
894	##bo	O
894	.	O
894	[SEP]	O
895	[CLS]	O
895	flow	O
895	rate	O
895	of	O
895	100	O
895	μ	O
895	##l	O
895	/	O
895	min	O
895	was	O
895	maintained	O
895	.	O
895	[SEP]	O
896	[CLS]	O
896	peak	B-PK
896	concentrations	I-PK
896	of	O
896	sts	O
896	for	O
896	the	O
896	250	O
896	mg	O
896	/	O
896	m	O
896	##l	O
896	dose	O
896	was	O
896	found	O
896	to	O
896	be	O
896	7	O
896	.	O
896	27	O
896	mg	O
896	/	O
896	m	O
896	##l	O
896	with	O
896	a	O
896	standard	O
896	de	O
896	##viation	O
896	of	O
896	0	O
896	.	O
896	83	O
896	.	O
896	[SEP]	O
897	[CLS]	O
897	the	O
897	steady	B-PK
897	-	I-PK
897	state	I-PK
897	maximum	I-PK
897	plasma	I-PK
897	concentrations	I-PK
897	(	I-PK
897	c	I-PK
897	(	I-PK
897	ma	I-PK
897	##x	I-PK
897	,	I-PK
897	s	I-PK
897	##s	I-PK
897	)	I-PK
897	;	O
897	mean	O
897	±	O
897	standard	O
897	de	O
897	##viation	O
897	)	O
897	of	O
897	lobe	O
897	##gli	O
897	##ta	O
897	##zone	O
897	and	O
897	met	O
897	##form	O
897	##in	O
897	alone	O
897	were	O
897	29	O
897	.	O
897	38	O
897	±	O
897	5	O
897	.	O
897	25	O
897	ng	O
897	/	O
897	m	O
897	##l	O
897	and	O
897	1661	O
897	.	O
897	84	O
897	±	O
897	47	O
897	##1	O
897	.	O
897	88	O
897	ng	O
897	/	O
897	m	O
897	##l	O
897	,	O
897	respectively	O
897	;	O
897	the	O
897	c	B-PK
897	(	I-PK
897	ma	I-PK
897	##x	I-PK
897	,	I-PK
897	s	I-PK
897	##s	I-PK
897	)	I-PK
897	during	O
897	co	O
897	-	O
897	administration	O
897	were	O
897	27	O
897	.	O
897	15	O
897	±	O
897	5	O
897	.	O
897	75	O
897	ng	O
897	/	O
897	m	O
897	##l	O
897	and	O
897	1779	O
897	.	O
897	92	O
897	±	O
897	405	O
897	.	O
897	20	O
897	ng	O
897	/	O
897	m	O
897	##l	O
897	,	O
897	respectively	O
897	.	O
897	[SEP]	O
898	[CLS]	O
898	physiological	O
898	##ly	O
898	based	O
898	p	O
898	##har	O
898	##ma	O
898	##co	O
898	##kin	O
898	##etic	O
898	modeling	O
898	of	O
898	sa	O
898	##liva	O
898	##ry	O
898	concentrations	O
898	for	O
898	non	O
898	##in	O
898	##vasive	O
898	bio	O
898	##mon	O
898	##itor	O
898	##ing	O
898	of	O
898	2	O
898	,	O
898	4	O
898	-	O
898	di	O
898	##ch	O
898	##lor	O
898	##op	O
898	##hen	O
898	##ox	O
898	##ya	O
898	##ce	O
898	##tic	O
898	acid	O
898	(	O
898	2	O
898	,	O
898	4	O
898	-	O
898	d	O
898	)	O
898	.	O
898	[SEP]	O
899	[CLS]	O
899	all	O
899	subjects	O
899	received	O
899	a	O
899	single	O
899	dose	O
899	of	O
899	study	O
899	drug	O
899	according	O
899	to	O
899	their	O
899	assigned	O
899	treatment	O
899	.	O
899	[SEP]	O
900	[CLS]	O
900	results	O
900	differed	O
900	only	O
900	moderately	O
900	between	O
900	the	O
900	injection	O
900	sites	O
900	(	O
900	right	O
900	and	O
900	left	O
900	g	O
900	##lut	O
900	##eal	O
900	mass	O
900	)	O
900	in	O
900	the	O
900	same	O
900	animal	O
900	.	O
900	[SEP]	O
901	[CLS]	O
901	a	O
901	non	O
901	##sign	O
901	##ificant	O
901	delay	O
901	in	O
901	t	B-PK
901	##max	I-PK
901	.	O
901	[SEP]	O
902	[CLS]	O
902	the	O
902	ca	O
902	##li	O
902	##bra	O
902	##tion	O
902	plot	O
902	revealed	O
902	linear	O
902	##ity	O
902	in	O
902	the	O
902	concentration	O
902	range	O
902	of	O
902	1	O
902	–	O
902	300	O
902	μ	O
902	##g	O
902	/	O
902	m	O
902	##l	O
902	with	O
902	the	O
902	correlation	O
902	coefficient	O
902	of	O
902	0	O
902	.	O
902	99	O
902	##9	O
902	##6	O
902	.	O
902	[SEP]	O
903	[CLS]	O
903	comparisons	O
903	of	O
903	ethnic	O
903	and	O
903	gender	O
903	differences	O
903	in	O
903	the	O
903	distribution	O
903	of	O
903	all	O
903	##eli	O
903	##c	O
903	frequencies	O
903	among	O
903	g	O
903	##eno	O
903	##type	O
903	##s	O
903	,	O
903	and	O
903	/	O
903	or	O
903	gender	O
903	differences	O
903	and	O
903	tests	O
903	for	O
903	hard	O
903	##y	O
903	-	O
903	we	O
903	##in	O
903	##berg	O
903	equilibrium	O
903	were	O
903	carried	O
903	out	O
903	using	O
903	the	O
903	ch	O
903	##i	O
903	-	O
903	square	O
903	test	O
903	.	O
903	[SEP]	O
904	[CLS]	O
904	the	O
904	re	O
904	##gression	O
904	equation	O
904	for	O
904	the	O
904	ca	O
904	##li	O
904	##bra	O
904	##tion	O
904	curve	O
904	of	O
904	e	O
904	##chin	O
904	##os	O
904	##ide	O
904	a	O
904	in	O
904	h	O
904	##bs	O
904	##s	O
904	and	O
904	plasma	O
904	were	O
904	,	O
904	respectively	O
904	,	O
904	y	O
904	=	O
904	52	O
904	##8	O
904	##8	O
904	##8	O
904	##4	O
904	##x	O
904	−	O
904	231	O
904	##8	O
904	.	O
904	7	O
904	(	O
904	r	O
904	##2	O
904	=	O
904	0	O
904	.	O
904	99	O
904	##8	O
904	##8	O
904	)	O
904	and	O
904	y	O
904	=	O
904	306	O
904	##6	O
904	##8	O
904	##x	O
904	+	O
904	30	O
904	.	O
904	70	O
904	##7	O
904	(	O
904	r	O
904	##2	O
904	=	O
904	0	O
904	.	O
904	99	O
904	##9	O
904	##1	O
904	)	O
904	.	O
904	[SEP]	O
905	[CLS]	O
905	to	O
905	improve	O
905	therapeutic	O
905	effects	O
905	and	O
905	pro	O
905	##long	O
905	the	O
905	systemic	O
905	circulation	O
905	time	O
905	of	O
905	sa	O
905	##l	O
905	b	O
905	,	O
905	lip	O
905	##oso	O
905	##mes	O
905	,	O
905	composed	O
905	of	O
905	so	O
905	##y	O
905	##be	O
905	##an	O
905	p	O
905	##hos	O
905	##pha	O
905	##ti	O
905	##dy	O
905	##l	O
905	##cho	O
905	##line	O
905	and	O
905	ch	O
905	##ole	O
905	##ster	O
905	##ol	O
905	were	O
905	prepared	O
905	by	O
905	reverse	O
905	-	O
905	phase	O
905	e	O
905	##va	O
905	##por	O
905	##ation	O
905	method	O
905	.	O
905	[SEP]	O
906	[CLS]	O
906	mean	O
906	r	B-PK
906	##au	I-PK
906	##c	I-PK
906	values	O
906	for	O
906	r	O
906	##d	O
906	##c	O
906	-	O
906	99	O
906	##86	O
906	/	O
906	sa	O
906	##m	O
906	were	O
906	0	O
906	.	O
906	31	O
906	##4	O
906	,	O
906	0	O
906	.	O
906	81	O
906	##8	O
906	,	O
906	and	O
906	0	O
906	.	O
906	98	O
906	##1	O
906	following	O
906	in	O
906	##tra	O
906	##ven	O
906	##ous	O
906	,	O
906	sub	O
906	##ling	O
906	##ual	O
906	,	O
906	and	O
906	oral	O
906	administration	O
906	of	O
906	sa	O
906	##m	O
906	,	O
906	respectively	O
906	.	O
906	[SEP]	O
907	[CLS]	O
907	c	O
907	##y	O
907	##c	O
907	##los	O
907	##por	O
907	##in	O
907	a	O
907	treatment	O
907	resulted	O
907	in	O
907	a	O
907	significant	O
907	increase	O
907	in	O
907	elimination	B-PK
907	half	I-PK
907	-	I-PK
907	life	I-PK
907	,	O
907	mean	B-PK
907	residence	I-PK
907	time	I-PK
907	and	O
907	area	B-PK
907	under	I-PK
907	the	I-PK
907	concentration	I-PK
907	versus	I-PK
907	time	I-PK
907	curve	I-PK
907	(	I-PK
907	au	I-PK
907	##c	I-PK
907	)	I-PK
907	of	O
907	un	O
907	##bound	O
907	b	O
907	##aic	O
907	##ale	O
907	##in	O
907	in	O
907	the	O
907	brain	O
907	.	O
907	[SEP]	O
908	[CLS]	O
908	the	O
908	ad	O
908	##van	O
908	##4	O
908	sub	O
908	##rout	O
908	##ine	O
908	was	O
908	used	O
908	during	O
908	the	O
908	model	O
908	development	O
908	process	O
908	.	O
908	[SEP]	O
909	[CLS]	O
909	sodium	O
909	or	O
909	##th	O
909	##ova	O
909	##na	O
909	##date	O
909	(	O
909	na	O
909	##3	O
909	##vo	O
909	##4	O
909	)	O
909	was	O
909	used	O
909	as	O
909	a	O
909	at	O
909	##pas	O
909	##e	O
909	inhibitor	O
909	.	O
909	[SEP]	O
910	[CLS]	O
910	serum	O
910	concentrations	O
910	after	O
910	the	O
910	first	O
910	480	O
910	mg	O
910	in	O
910	##fusion	O
910	(	O
910	month	O
910	4	O
910	)	O
910	rapidly	O
910	approached	O
910	steady	B-PK
910	-	I-PK
910	state	I-PK
910	concentration	I-PK
910	levels	I-PK
910	(	O
910	≥	O
910	##90	O
910	%	O
910	)	O
910	of	O
910	480	O
910	mg	O
910	q	O
910	##4	O
910	##w	O
910	and	O
910	were	O
910	maintained	O
910	for	O
910	the	O
910	entire	O
910	treatment	O
910	duration	O
910	(	O
910	figure	O
910	2	O
910	and	O
910	supplement	O
910	##ary	O
910	table	O
910	s	O
910	##1	O
910	,	O
910	available	O
910	at	O
910	an	O
910	##nal	O
910	##s	O
910	of	O
910	on	O
910	##cology	O
910	online	O
910	)	O
910	.	O
910	[SEP]	O
911	[CLS]	O
911	the	O
911	six	O
911	liquid	O
911	preparation	O
911	were	O
911	a	O
911	##que	O
911	##ous	O
911	solution	O
911	,	O
911	an	O
911	organic	O
911	solvent	O
911	complex	O
911	(	O
911	la	O
911	##no	O
911	##xi	O
911	##cap	O
911	##s	O
911	fill	O
911	)	O
911	for	O
911	which	O
911	solvent	O
911	assisted	O
911	absorption	O
911	has	O
911	been	O
911	suggested	O
911	,	O
911	dig	O
911	##ox	O
911	##in	O
911	el	O
911	##ix	O
911	##ir	O
911	,	O
911	and	O
911	three	O
911	different	O
911	solutions	O
911	each	O
911	comprising	O
911	a	O
911	single	O
911	organic	O
911	solvent	O
911	in	O
911	the	O
911	concentration	O
911	used	O
911	in	O
911	la	O
911	##no	O
911	##xi	O
911	##cap	O
911	##s	O
911	plus	O
911	water	O
911	to	O
911	make	O
911	up	O
911	the	O
911	balance	O
911	.	O
911	[SEP]	O
912	[CLS]	O
912	the	O
912	predict	O
912	##ive	O
912	performance	O
912	of	O
912	each	O
912	model	O
912	was	O
912	evaluated	O
912	using	O
912	the	O
912	model	O
912	prediction	O
912	error	O
912	(	O
912	p	O
912	##e	O
912	)	O
912	,	O
912	mean	O
912	prediction	O
912	error	O
912	(	O
912	m	O
912	##pe	O
912	)	O
912	,	O
912	mean	O
912	absolute	O
912	prediction	O
912	error	O
912	(	O
912	map	O
912	##e	O
912	)	O
912	,	O
912	prediction	O
912	-	O
912	corrected	O
912	visual	O
912	predict	O
912	##ive	O
912	check	O
912	(	O
912	p	O
912	##c	O
912	##v	O
912	##p	O
912	##c	O
912	)	O
912	,	O
912	and	O
912	normal	O
912	##ized	O
912	prediction	O
912	distribution	O
912	errors	O
912	(	O
912	n	O
912	##p	O
912	##de	O
912	)	O
912	.	O
912	[SEP]	O
913	[CLS]	O
913	it	O
913	is	O
913	possible	O
913	that	O
913	no	O
913	unchanged	O
913	k	O
913	##eto	O
913	##p	O
913	##ro	O
913	##fen	O
913	,	O
913	nap	O
913	##ro	O
913	##xen	O
913	,	O
913	or	O
913	probe	O
913	##ne	O
913	##cid	O
913	is	O
913	ex	O
913	##cre	O
913	##ted	O
913	in	O
913	urine	O
913	.	O
913	[SEP]	O
914	[CLS]	O
914	to	O
914	determine	O
914	p	O
914	##har	O
914	##ma	O
914	##co	O
914	##kin	O
914	##etic	O
914	parameters	O
914	for	O
914	me	O
914	##lo	O
914	##xi	O
914	##cam	O
914	,	O
914	a	O
914	non	O
914	##ster	O
914	##oid	O
914	##al	O
914	anti	O
914	-	O
914	inflammatory	O
914	drug	O
914	,	O
914	in	O
914	horses	O
914	.	O
914	[SEP]	O
915	[CLS]	O
915	in	O
915	a	O
915	similar	O
915	manner	O
915	,	O
915	simple	O
915	all	O
915	##ome	O
915	##try	O
915	predicted	O
915	the	O
915	human	O
915	p	O
915	##har	O
915	##ma	O
915	##co	O
915	##kin	O
915	##etic	O
915	parameters	O
915	of	O
915	des	O
915	-	O
915	c	O
915	##icles	O
915	##oni	O
915	##de	O
915	(	O
915	c	B-PK
915	##l	I-PK
915	/	I-PK
915	f	I-PK
915	,	O
915	v	B-PK
915	##d	I-PK
915	/	I-PK
915	f	I-PK
915	,	O
915	t	B-PK
915	(	I-PK
915	½	I-PK
915	)	I-PK
915	,	O
915	and	O
915	k	B-PK
915	##el	I-PK
915	)	O
915	within	O
915	a	O
915	two	O
915	-	O
915	to	O
915	three	O
915	##fold	O
915	range	O
915	of	O
915	the	O
915	observed	O
915	values	O
915	.	O
915	[SEP]	O
916	[CLS]	O
916	a	O
916	total	O
916	of	O
916	100	O
916	µ	O
916	##l	O
916	micro	O
916	##so	O
916	##mal	O
916	protein	O
916	and	O
916	100	O
916	µ	O
916	##l	O
916	probe	O
916	drugs	O
916	were	O
916	added	O
916	with	O
916	250	O
916	µ	O
916	##l	O
916	phosphate	O
916	buffer	O
916	in	O
916	a	O
916	brown	O
916	cent	O
916	##ri	O
916	##fu	O
916	##ge	O
916	tube	O
916	,	O
916	v	O
916	##ortex	O
916	-	O
916	mixed	O
916	for	O
916	1	O
916	min	O
916	,	O
916	and	O
916	in	O
916	##cu	O
916	##bate	O
916	##d	O
916	at	O
916	37	O
916	°	O
916	##c	O
916	water	O
916	.	O
916	[SEP]	O
917	[CLS]	O
917	(	O
917	this	O
917	study	O
917	has	O
917	been	O
917	registered	O
917	at	O
917	clinical	O
917	##tri	O
917	##als	O
917	.	O
917	go	O
917	##v	O
917	under	O
917	registration	O
917	no	O
917	.	O
917	n	O
917	##ct	O
917	##00	O
917	##64	O
917	##0	O
917	##8	O
917	##8	O
917	##7	O
917	.	O
917	)	O
917	.	O
917	[SEP]	O
918	[CLS]	O
918	trans	O
918	##c	O
918	##rani	O
918	##al	O
918	magnetic	O
918	stimulation	O
918	was	O
918	used	O
918	to	O
918	probe	O
918	the	O
918	acute	O
918	effect	O
918	of	O
918	a	O
918	single	O
918	oral	O
918	dose	O
918	of	O
918	various	O
918	do	O
918	##pa	O
918	##mine	O
918	##rg	O
918	##ic	O
918	(	O
918	le	O
918	##vo	O
918	##do	O
918	##pa	O
918	,	O
918	se	O
918	##leg	O
918	##ili	O
918	##ne	O
918	,	O
918	br	O
918	##omo	O
918	##cript	O
918	##ine	O
918	)	O
918	and	O
918	anti	O
918	##do	O
918	##pa	O
918	##mine	O
918	##rg	O
918	##ic	O
918	drugs	O
918	(	O
918	su	O
918	##l	O
918	##pi	O
918	##ride	O
918	,	O
918	ha	O
918	##lop	O
918	##eri	O
918	##do	O
918	##l	O
918	)	O
918	on	O
918	motor	O
918	cortex	O
918	ex	O
918	##ci	O
918	##ta	O
918	##bility	O
918	in	O
918	healthy	O
918	volunteers	O
918	.	O
918	[SEP]	O
919	[CLS]	O
919	met	O
919	##form	O
919	##in	O
919	anti	O
919	##tum	O
919	##or	O
919	effects	O
919	were	O
919	tested	O
919	by	O
919	i	O
919	##vis	O
919	.	O
919	[SEP]	O
920	[CLS]	O
920	following	O
920	i	O
920	##v	O
920	administration	O
920	of	O
920	s	O
920	##ch	O
920	59	O
920	##8	O
920	##8	O
920	##4	O
920	,	O
920	the	O
920	compound	O
920	is	O
920	rapidly	O
920	de	O
920	##ph	O
920	##os	O
920	##ph	O
920	##ory	O
920	##lated	O
920	to	O
920	s	O
920	##ch	O
920	207	O
920	##9	O
920	##6	O
920	##2	O
920	which	O
920	is	O
920	then	O
920	h	O
920	##ydro	O
920	##ly	O
920	##zed	O
920	to	O
920	s	O
920	##ch	O
920	56	O
920	##5	O
920	##9	O
920	##2	O
920	.	O
920	[SEP]	O
921	[CLS]	O
921	p	O
921	##har	O
921	##ma	O
921	##co	O
921	##kin	O
921	##etic	O
921	parameters	O
921	were	O
921	analyzed	O
921	by	O
921	p	O
921	##ks	O
921	##ol	O
921	##ver	O
921	following	O
921	the	O
921	instruction	O
921	.	O
921	[SEP]	O
922	[CLS]	O
922	hp	O
922	##l	O
922	##c	O
922	grade	O
922	ace	O
922	##ton	O
922	##it	O
922	##ril	O
922	##e	O
922	,	O
922	met	O
922	##han	O
922	##ol	O
922	,	O
922	or	O
922	##th	O
922	##op	O
922	##hos	O
922	##ph	O
922	##ori	O
922	##c	O
922	acid	O
922	,	O
922	and	O
922	water	O
922	were	O
922	obtained	O
922	from	O
922	me	O
922	##rc	O
922	##k	O
922	kg	O
922	##aa	O
922	(	O
922	g	O
922	##erman	O
922	##y	O
922	)	O
922	.	O
922	[SEP]	O
923	[CLS]	O
923	regulatory	O
923	activities	O
923	of	O
923	2	O
923	beta	O
923	-	O
923	(	O
923	3	O
923	-	O
923	h	O
923	##ydro	O
923	##xy	O
923	##p	O
923	##rop	O
923	##ox	O
923	##y	O
923	)	O
923	-	O
923	1	O
923	alpha	O
923	,	O
923	25	O
923	-	O
923	di	O
923	##hy	O
923	##dr	O
923	##ox	O
923	##y	O
923	##vi	O
923	##tam	O
923	##in	O
923	d	O
923	##3	O
923	[	O
923	ed	O
923	-	O
923	71	O
923	]	O
923	,	O
923	a	O
923	novel	O
923	synthetic	O
923	vitamin	O
923	d	O
923	##3	O
923	derivative	O
923	,	O
923	on	O
923	calcium	O
923	metabolism	O
923	were	O
923	investigated	O
923	.	O
923	[SEP]	O
924	[CLS]	O
924	the	O
924	amounts	O
924	of	O
924	g	O
924	##c	O
924	##v	O
924	en	O
924	##tra	O
924	##pped	O
924	in	O
924	the	O
924	micro	O
924	##sp	O
924	##here	O
924	##s	O
924	were	O
924	sufficient	O
924	to	O
924	administer	O
924	therapeutic	O
924	##ally	O
924	relevant	O
924	doses	O
924	in	O
924	60	O
924	micro	O
924	##l	O
924	of	O
924	the	O
924	formulation	O
924	.	O
924	[SEP]	O
925	[CLS]	O
925	di	O
925	##ar	O
925	##r	O
925	##hea	O
925	was	O
925	observed	O
925	at	O
925	similar	O
925	rates	O
925	in	O
925	both	O
925	o	O
925	##xa	O
925	##lip	O
925	##lat	O
925	##in	O
925	(	O
925	6	O
925	/	O
925	48	O
925	patients	O
925	,	O
925	13	O
925	%	O
925	)	O
925	and	O
925	i	O
925	##rino	O
925	##teca	O
925	##n	O
925	treated	O
925	patients	O
925	(	O
925	4	O
925	/	O
925	30	O
925	patients	O
925	,	O
925	13	O
925	%	O
925	)	O
925	.	O
925	[SEP]	O
926	[CLS]	O
926	they	O
926	were	O
926	im	O
926	##mers	O
926	##ed	O
926	in	O
926	100	O
926	m	O
926	##l	O
926	of	O
926	medium	O
926	at	O
926	37	O
926	±	O
926	0	O
926	.	O
926	5	O
926	°	O
926	##c	O
926	under	O
926	stirring	O
926	(	O
926	150	O
926	rpm	O
926	)	O
926	.	O
926	[SEP]	O
927	[CLS]	O
927	est	O
927	##imation	O
927	errors	O
927	on	O
927	clearance	B-PK
927	were	O
927	within	O
927	+	O
927	-	O
927	8	O
927	%	O
927	for	O
927	adults	O
927	and	O
927	+	O
927	-	O
927	13	O
927	%	O
927	for	O
927	children	O
927	(	O
927	95	O
927	%	O
927	limits	O
927	of	O
927	agreement	O
927	)	O
927	.	O
927	[SEP]	O
928	[CLS]	O
928	in	O
928	v	O
928	##ivo	O
928	kinetic	O
928	studies	O
928	in	O
928	rats	O
928	indicated	O
928	53	O
928	%	O
928	release	O
928	of	O
928	nor	O
928	##f	O
928	##lo	O
928	##xa	O
928	##cin	O
928	in	O
928	plasma	O
928	at	O
928	the	O
928	end	O
928	of	O
928	8	O
928	##h	O
928	.	O
928	[SEP]	O
929	[CLS]	O
929	this	O
929	was	O
929	a	O
929	single	O
929	-	O
929	center	O
929	study	O
929	with	O
929	an	O
929	open	O
929	,	O
929	random	O
929	##ized	O
929	double	O
929	-	O
929	way	O
929	crossover	O
929	design	O
929	.	O
929	[SEP]	O
930	[CLS]	O
930	for	O
930	the	O
930	preliminary	O
930	toxicity	O
930	test	O
930	,	O
930	at	O
930	least	O
930	500	O
930	cells	O
930	were	O
930	evaluated	O
930	to	O
930	determine	O
930	the	O
930	c	O
930	##yt	O
930	##oki	O
930	##nes	O
930	##is	O
930	-	O
930	blocked	O
930	proliferation	O
930	index	O
930	(	O
930	c	O
930	##b	O
930	##pi	O
930	)	O
930	at	O
930	each	O
930	dose	O
930	level	O
930	and	O
930	the	O
930	control	O
930	.	O
930	[SEP]	O
931	[CLS]	O
931	administration	O
931	of	O
931	e	O
931	##a	O
931	‐	O
931	230	O
931	is	O
931	safe	O
931	and	O
931	results	O
931	in	O
931	at	O
931	##ten	O
931	##uation	O
931	of	O
931	the	O
931	systemic	O
931	inflammatory	O
931	response	O
931	in	O
931	humans	O
931	.	O
931	[SEP]	O
932	[CLS]	O
932	in	O
932	further	O
932	studies	O
932	using	O
932	pre	O
932	##c	O
932	##lini	O
932	##cal	O
932	models	O
932	,	O
932	in	O
932	v	O
932	##ivo	O
932	administration	O
932	of	O
932	y	O
932	##s	O
932	##11	O
932	##0	O
932	resulted	O
932	in	O
932	in	O
932	##hibition	O
932	of	O
932	t	O
932	##umour	O
932	cell	O
932	growth	O
932	,	O
932	migration	O
932	and	O
932	invasion	O
932	,	O
932	and	O
932	enhanced	O
932	survival	O
932	of	O
932	mouse	O
932	x	O
932	##eno	O
932	##gra	O
932	##ft	O
932	models	O
932	in	O
932	##oc	O
932	##ulated	O
932	with	O
932	r	O
932	##cc	O
932	or	O
932	m	O
932	##pm	O
932	(	O
932	in	O
932	##amo	O
932	##to	O
932	,	O
932	et	O
932	al	O
932	,	O
932	2007	O
932	;	O
932	ok	O
932	##amo	O
932	##to	O
932	et	O
932	al	O
932	,	O
932	2014	O
932	;	O
932	ya	O
932	##mamoto	O
932	et	O
932	al	O
932	,	O
932	2014	O
932	)	O
932	.	O
932	[SEP]	O
933	[CLS]	O
933	among	O
933	the	O
933	10	O
933	patients	O
933	with	O
933	re	O
933	##nal	O
933	imp	O
933	##air	O
933	##ment	O
933	,	O
933	three	O
933	had	O
933	moderate	O
933	imp	O
933	##air	O
933	##ment	O
933	and	O
933	three	O
933	had	O
933	severe	O
933	imp	O
933	##air	O
933	##ment	O
933	.	O
933	[SEP]	O
934	[CLS]	O
934	that	O
934	is	O
934	when	O
934	i	O
934	would	O
934	forget	O
934	to	O
934	drink	O
934	them	O
934	,	O
934	but	O
934	when	O
934	i	O
934	was	O
934	home	O
934	i	O
934	was	O
934	able	O
934	to	O
934	drink	O
934	them	O
934	every	O
934	day	O
934	.	O
934	[SEP]	O
935	[CLS]	O
935	our	O
935	results	O
935	indicate	O
935	the	O
935	efficacy	O
935	of	O
935	c	O
935	##ef	O
935	##tri	O
935	##ax	O
935	##one	O
935	against	O
935	experimental	O
935	c	O
935	##ep	O
935	##hal	O
935	##os	O
935	##por	O
935	##in	O
935	-	O
935	resistant	O
935	p	O
935	##ne	O
935	##um	O
935	##oc	O
935	##oc	O
935	##cal	O
935	o	O
935	##titis	O
935	and	O
935	provide	O
935	a	O
935	basis	O
935	for	O
935	the	O
935	clinical	O
935	use	O
935	of	O
935	single	O
935	-	O
935	dose	O
935	c	O
935	##ef	O
935	##tri	O
935	##ax	O
935	##one	O
935	against	O
935	p	O
935	##ne	O
935	##um	O
935	##oc	O
935	##oc	O
935	##cal	O
935	o	O
935	##titis	O
935	media	O
935	.	O
935	[SEP]	O
936	[CLS]	O
936	at	O
936	8	O
936	mg	O
936	kg	O
936	-	O
936	1	O
936	in	O
936	the	O
936	multiple	O
936	-	O
936	dose	O
936	co	O
936	##hor	O
936	##t	O
936	,	O
936	the	O
936	day	O
936	4	O
936	geometric	O
936	mean	O
936	au	B-PK
936	##c	I-PK
936	##0	I-PK
936	-	I-PK
936	24	I-PK
936	was	O
936	57	O
936	.	O
936	9	O
936	μ	O
936	##g	O
936	*	O
936	h	O
936	m	O
936	##l	O
936	-	O
936	1	O
936	.	O
936	[SEP]	O
937	[CLS]	O
937	according	O
937	to	O
937	a	O
937	previous	O
937	report	O
937	[	O
937	28	O
937	]	O
937	,	O
937	m	O
937	##21	O
937	was	O
937	in	O
937	##ferred	O
937	to	O
937	be	O
937	3	O
937	-	O
937	h	O
937	##ydro	O
937	##xy	O
937	##hip	O
937	##uri	O
937	##c	O
937	acid	O
937	.	O
937	[SEP]	O
938	[CLS]	O
938	compared	O
938	with	O
938	base	O
938	##line	O
938	,	O
938	the	O
938	median	O
938	plasma	O
938	4	O
938	##β	O
938	-	O
938	oh	O
938	##c	O
938	/	O
938	ch	O
938	##ol	O
938	ratio	O
938	increased	O
938	at	O
938	the	O
938	4th	O
938	(	O
938	257	O
938	%	O
938	)	O
938	,	O
938	16th	O
938	(	O
938	29	O
938	##1	O
938	%	O
938	)	O
938	and	O
938	48	O
938	##th	O
938	(	O
938	165	O
938	%	O
938	)	O
938	week	O
938	(	O
938	p	O
938	<	O
938	0	O
938	.	O
938	000	O
938	##1	O
938	)	O
938	.	O
938	[SEP]	O
939	[CLS]	O
939	dose	O
939	-	O
939	limiting	O
939	toxic	O
939	##ities	O
939	included	O
939	r	O
939	##ash	O
939	,	O
939	fatigue	O
939	and	O
939	vomit	O
939	##ing	O
939	.	O
939	[SEP]	O
940	[CLS]	O
940	to	O
940	investigate	O
940	the	O
940	p	O
940	##har	O
940	##ma	O
940	##co	O
940	##kin	O
940	##etics	O
940	of	O
940	10	O
940	micro	O
940	##g	O
940	and	O
940	25	O
940	micro	O
940	##g	O
940	17	O
940	##bet	O
940	##a	O
940	-	O
940	est	O
940	##rad	O
940	##iol	O
940	(	O
940	e	O
940	##2	O
940	)	O
940	v	O
940	##agi	O
940	##nal	O
940	tablets	O
940	in	O
940	post	O
940	##men	O
940	##op	O
940	##aus	O
940	##al	O
940	women	O
940	with	O
940	v	O
940	##agi	O
940	##nal	O
940	at	O
940	##rop	O
940	##hy	O
940	.	O
940	[SEP]	O
941	[CLS]	O
941	the	O
941	first	O
941	and	O
941	last	O
941	authors	O
941	of	O
941	identified	O
941	studies	O
941	were	O
941	contacted	O
941	and	O
941	invited	O
941	to	O
941	join	O
941	this	O
941	pool	O
941	##ed	O
941	analysis	O
941	by	O
941	contributing	O
941	individual	O
941	patient	O
941	data	O
941	to	O
941	the	O
941	worldwide	O
941	anti	O
941	##mal	O
941	##aria	O
941	##l	O
941	resistance	O
941	network	O
941	(	O
941	w	O
941	##war	O
941	##n	O
941	)	O
941	re	O
941	##pository	O
941	as	O
941	part	O
941	of	O
941	a	O
941	study	O
941	group	O
941	if	O
941	their	O
941	studies	O
941	were	O
941	prospective	O
941	su	O
941	##lf	O
941	##ado	O
941	##xin	O
941	##e	O
941	and	O
941	p	O
941	##yr	O
941	##ime	O
941	##tham	O
941	##ine	O
941	studies	O
941	of	O
941	non	O
941	##p	O
941	##re	O
941	##gnant	O
941	a	O
941	##f	O
941	##rica	O
941	##n	O
941	patients	O
941	with	O
941	un	O
941	##com	O
941	##plicate	O
941	##d	O
941	p	O
941	.	O
941	f	O
941	##al	O
941	##ci	O
941	##par	O
941	##um	O
941	infection	O
941	,	O
941	especially	O
941	children	O
941	under	O
941	the	O
941	age	O
941	of	O
941	5	O
941	years	O
941	.	O
941	[SEP]	O
942	[CLS]	O
942	this	O
942	study	O
942	was	O
942	a	O
942	random	O
942	##ized	O
942	2	O
942	‐	O
942	way	O
942	cross	O
942	‐	O
942	over	O
942	clinical	O
942	trial	O
942	utilizing	O
942	4	O
942	adult	O
942	an	O
942	##gus	O
942	steer	O
942	##s	O
942	fitted	O
942	previously	O
942	with	O
942	surgical	O
942	##ly	O
942	imp	O
942	##lanted	O
942	duo	O
942	##den	O
942	##al	O
942	can	O
942	##nu	O
942	##la	O
942	##e	O
942	placed	O
942	or	O
942	##ad	O
942	to	O
942	the	O
942	bi	O
942	##lia	O
942	##ry	O
942	and	O
942	pan	O
942	##cre	O
942	##atic	O
942	duct	O
942	##s	O
942	.	O
942	[SEP]	O
943	[CLS]	O
943	comparative	O
943	p	O
943	##har	O
943	##ma	O
943	##co	O
943	##kin	O
943	##etics	O
943	of	O
943	pipe	O
943	##rac	O
943	##ill	O
943	##in	O
943	in	O
943	normal	O
943	##s	O
943	and	O
943	in	O
943	patients	O
943	with	O
943	re	O
943	##nal	O
943	failure	O
943	.	O
943	[SEP]	O
944	[CLS]	O
944	mi	O
944	##son	O
944	##ida	O
944	##zo	O
944	##le	O
944	,	O
944	a	O
944	h	O
944	##y	O
944	##pox	O
944	##ic	O
944	cell	O
944	se	O
944	##ns	O
944	##iti	O
944	##zer	O
944	,	O
944	enhance	O
944	##s	O
944	the	O
944	anti	O
944	##tum	O
944	##or	O
944	effects	O
944	of	O
944	c	O
944	##y	O
944	##c	O
944	##lop	O
944	##hos	O
944	##pha	O
944	##mi	O
944	##de	O
944	in	O
944	pre	O
944	##c	O
944	##lini	O
944	##cal	O
944	studies	O
944	.	O
944	[SEP]	O
945	[CLS]	O
945	samples	O
945	were	O
945	analyzed	O
945	on	O
945	a	O
945	the	O
945	##rm	O
945	##o	O
945	scientific	O
945	t	O
945	##s	O
945	##q	O
945	quantum	O
945	ultra	O
945	mass	O
945	s	O
945	##pect	O
945	##rome	O
945	##ter	O
945	(	O
945	wa	O
945	##lt	O
945	##ham	O
945	,	O
945	ma	O
945	,	O
945	us	O
945	##a	O
945	)	O
945	interface	O
945	##d	O
945	to	O
945	a	O
945	waters	O
945	a	O
945	##c	O
945	##qui	O
945	##ty	O
945	up	O
945	##l	O
945	##c	O
945	system	O
945	(	O
945	mi	O
945	##lf	O
945	##ord	O
945	,	O
945	ma	O
945	,	O
945	us	O
945	##a	O
945	)	O
945	.	O
945	[SEP]	O
946	[CLS]	O
946	co	O
946	##agu	O
946	##lation	O
946	was	O
946	activated	O
946	using	O
946	commercially	O
946	available	O
946	re	O
946	##age	O
946	##nts	O
946	containing	O
946	re	O
946	##comb	O
946	##ina	O
946	##nt	O
946	tissue	O
946	factor	O
946	(	O
946	t	O
946	##f	O
946	,	O
946	final	O
946	concentration	O
946	5	O
946	pm	O
946	)	O
946	,	O
946	p	O
946	##hos	O
946	##ph	O
946	##oli	O
946	##pid	O
946	##s	O
946	(	O
946	final	O
946	concentration	O
946	4	O
946	µ	O
946	##m	O
946	)	O
946	,	O
946	in	O
946	the	O
946	presence	O
946	or	O
946	absence	O
946	of	O
946	soluble	O
946	th	O
946	##rom	O
946	##bo	O
946	##mo	O
946	##du	O
946	##lin	O
946	(	O
946	t	O
946	##m	O
946	,	O
946	the	O
946	concentration	O
946	of	O
946	which	O
946	is	O
946	not	O
946	revealed	O
946	by	O
946	the	O
946	manufacturer	O
946	)	O
946	.	O
946	[SEP]	O
947	[CLS]	O
947	in	O
947	both	O
947	sessions	O
947	,	O
947	art	O
947	##erial	O
947	plasma	O
947	samples	O
947	were	O
947	obtained	O
947	.	O
947	[SEP]	O
948	[CLS]	O
948	the	O
948	total	O
948	amount	O
948	of	O
948	q	O
948	##c	O
948	samples	O
948	was	O
948	no	O
948	less	O
948	than	O
948	5	O
948	%	O
948	of	O
948	the	O
948	test	O
948	samples	O
948	in	O
948	the	O
948	same	O
948	batch	O
948	.	O
948	[SEP]	O
949	[CLS]	O
949	administration	O
949	of	O
949	a	O
949	single	O
949	in	O
949	##tra	O
949	##ven	O
949	##ous	O
949	b	O
949	##ol	O
949	##us	O
949	dose	O
949	of	O
949	f	O
949	##xa	O
949	##i	O
949	##16	O
949	##l	O
949	was	O
949	safe	O
949	and	O
949	tolerate	O
949	##d	O
949	at	O
949	all	O
949	dose	O
949	levels	O
949	tested	O
949	,	O
949	with	O
949	no	O
949	dose	O
949	-	O
949	limiting	O
949	toxicity	O
949	or	O
949	serious	O
949	adverse	O
949	events	O
949	.	O
949	[SEP]	O
950	[CLS]	O
950	compared	O
950	to	O
950	the	O
950	three	O
950	-	O
950	compartment	O
950	model	O
950	,	O
950	clearance	B-PK
950	values	O
950	were	O
950	over	O
950	##est	O
950	##imated	O
950	by	O
950	the	O
950	s	O
950	##ch	O
950	##wart	O
950	##z	O
950	approach	O
950	(	O
950	bias	O
950	6	O
950	.	O
950	5	O
950	m	O
950	##l	O
950	/	O
950	min	O
950	)	O
950	,	O
950	resulting	O
950	in	O
950	limited	O
950	effects	O
950	on	O
950	re	O
950	##gression	O
950	coefficients	O
950	of	O
950	the	O
950	bi	O
950	##s	O
950	equations	O
950	(	O
950	e	O
950	.	O
950	g	O
950	.	O
950	,	O
950	proportional	O
950	##ity	O
950	factor	O
950	of	O
950	bi	O
950	##s	O
950	##2	O
950	changed	O
950	from	O
950	76	O
950	##7	O
950	to	O
950	720	O
950	)	O
950	.	O
950	[SEP]	O
951	[CLS]	O
951	the	O
951	results	O
951	are	O
951	similar	O
951	to	O
951	those	O
951	obtained	O
951	with	O
951	c	O
951	##q	O
951	(	O
951	figure	O
951	2	O
951	##c	O
951	,	O
951	d	O
951	)	O
951	.	O
951	[SEP]	O
952	[CLS]	O
952	plasma	O
952	concentration	O
952	-	O
952	time	O
952	curves	O
952	were	O
952	plot	O
952	##ted	O
952	.	O
952	[SEP]	O
953	[CLS]	O
953	we	O
953	suggest	O
953	that	O
953	the	O
953	described	O
953	method	O
953	is	O
953	suitable	O
953	to	O
953	analyze	O
953	sa	O
953	##liva	O
953	and	O
953	plasma	O
953	samples	O
953	of	O
953	small	O
953	volumes	O
953	for	O
953	therapeutic	O
953	drug	O
953	monitoring	O
953	(	O
953	t	O
953	##d	O
953	##m	O
953	)	O
953	and	O
953	p	O
953	##har	O
953	##ma	O
953	##co	O
953	##kin	O
953	##etic	O
953	studies	O
953	in	O
953	p	O
953	##ediatric	O
953	patients	O
953	.	O
953	[SEP]	O
954	[CLS]	O
954	however	O
954	,	O
954	35	O
954	-	O
954	40	O
954	million	O
954	people	O
954	bear	O
954	the	O
954	infection	O
954	worldwide	O
954	.	O
954	[SEP]	O
955	[CLS]	O
955	p	O
955	##har	O
955	##ma	O
955	##co	O
955	##kin	O
955	##etic	O
955	parameters	O
955	of	O
955	ve	O
955	##rap	O
955	##ami	O
955	##l	O
955	and	O
955	its	O
955	active	O
955	meta	O
955	##bol	O
955	##ite	O
955	nor	O
955	##ver	O
955	##apa	O
955	##mi	O
955	##l	O
955	in	O
955	patients	O
955	with	O
955	he	O
955	##pa	O
955	##top	O
955	##athy	O
955	.	O
955	[SEP]	O
956	[CLS]	O
956	in	O
956	##hibition	O
956	of	O
956	notch	O
956	pathway	O
956	signaling	O
956	was	O
956	demonstrated	O
956	at	O
956	these	O
956	doses	O
956	.	O
956	[SEP]	O
957	[CLS]	O
957	in	O
957	addition	O
957	,	O
957	g	O
957	##l	O
957	##p	O
957	‐	O
957	1	O
957	suppress	O
957	##es	O
957	g	O
957	##lu	O
957	##ca	O
957	##gon	O
957	release	O
957	from	O
957	pan	O
957	##cre	O
957	##atic	O
957	α	O
957	‐	O
957	cells	O
957	and	O
957	slow	O
957	##s	O
957	gas	O
957	##tric	O
957	empty	O
957	##ing	O
957	.	O
957	[SEP]	O
958	[CLS]	O
958	a	O
958	graphic	O
958	approach	O
958	provides	O
958	the	O
958	recommended	O
958	dose	O
958	for	O
958	any	O
958	selected	O
958	probability	O
958	of	O
958	attain	O
958	##ing	O
958	the	O
958	p	O
958	##k	O
958	/	O
958	p	O
958	##d	O
958	efficacy	O
958	target	O
958	or	O
958	to	O
958	evaluate	O
958	the	O
958	cumulative	O
958	fraction	O
958	of	O
958	response	O
958	for	O
958	any	O
958	dos	O
958	##ing	O
958	regime	O
958	##n	O
958	in	O
958	this	O
958	population	O
958	.	O
958	[SEP]	O
959	[CLS]	O
959	no	O
959	in	O
959	##tra	O
959	##patient	O
959	dose	O
959	es	O
959	##cal	O
959	##ation	O
959	beyond	O
959	the	O
959	original	O
959	assigned	O
959	co	O
959	##hor	O
959	##t	O
959	was	O
959	permitted	O
959	.	O
959	[SEP]	O
960	[CLS]	O
960	the	O
960	effect	O
960	of	O
960	ch	O
960	##lor	O
960	##ine	O
960	substitution	O
960	on	O
960	the	O
960	disposition	O
960	of	O
960	p	O
960	##oly	O
960	##ch	O
960	##lor	O
960	##inated	O
960	bi	O
960	##phe	O
960	##ny	O
960	##ls	O
960	following	O
960	der	O
960	##mal	O
960	administration	O
960	.	O
960	[SEP]	O
961	[CLS]	O
961	the	O
961	mobile	O
961	phase	O
961	consisted	O
961	of	O
961	0	O
961	.	O
961	1	O
961	%	O
961	form	O
961	##ic	O
961	acid	O
961	:	O
961	ace	O
961	##ton	O
961	##it	O
961	##ril	O
961	##e	O
961	(	O
961	25	O
961	:	O
961	75	O
961	,	O
961	v	O
961	/	O
961	v	O
961	)	O
961	.	O
961	[SEP]	O
962	[CLS]	O
962	the	O
962	primary	O
962	d	O
962	##lt	O
962	and	O
962	m	O
962	##t	O
962	##d	O
962	analysis	O
962	was	O
962	performed	O
962	on	O
962	all	O
962	e	O
962	##val	O
962	##ua	O
962	##ble	O
962	patients	O
962	who	O
962	signed	O
962	the	O
962	informed	O
962	consent	O
962	and	O
962	who	O
962	did	O
962	not	O
962	miss	O
962	≥	O
962	##7	O
962	days	O
962	of	O
962	treatment	O
962	during	O
962	the	O
962	first	O
962	cycle	O
962	of	O
962	treatment	O
962	or	O
962	had	O
962	a	O
962	d	O
962	##lt	O
962	.	O
962	[SEP]	O
963	[CLS]	O
963	the	O
963	majority	O
963	of	O
963	infections	O
963	were	O
963	mild	O
963	respiratory	O
963	infections	O
963	.	O
963	[SEP]	O
964	[CLS]	O
964	each	O
964	formulation	O
964	contained	O
964	800	O
964	mg	O
964	i	O
964	##bu	O
964	##p	O
964	##ro	O
964	##fen	O
964	.	O
964	[SEP]	O
965	[CLS]	O
965	our	O
965	results	O
965	showed	O
965	that	O
965	this	O
965	immune	O
965	prop	O
965	##hyl	O
965	##actic	O
965	strategy	O
965	influences	O
965	the	O
965	p	O
965	##har	O
965	##ma	O
965	##co	O
965	##kin	O
965	##etic	O
965	of	O
965	b	O
965	[	O
965	a	O
965	]	O
965	p	O
965	and	O
965	further	O
965	studies	O
965	to	O
965	investigate	O
965	their	O
965	effects	O
965	on	O
965	chemical	O
965	car	O
965	##cin	O
965	##ogen	O
965	##esis	O
965	are	O
965	warrant	O
965	##ed	O
965	.	O
965	[SEP]	O
966	[CLS]	O
966	delta	O
966	##met	O
966	##hr	O
966	##in	O
966	,	O
966	a	O
966	widely	O
966	used	O
966	type	O
966	ii	O
966	p	O
966	##yre	O
966	##th	O
966	##roid	O
966	insect	O
966	##icide	O
966	,	O
966	is	O
966	a	O
966	relatively	O
966	potent	O
966	ne	O
966	##uro	O
966	##to	O
966	##xi	O
966	##can	O
966	##t	O
966	.	O
966	[SEP]	O
967	[CLS]	O
967	f	O
967	##ent	O
967	##any	O
967	##l	O
967	(	O
967	20	O
967	μ	O
967	##g	O
967	/	O
967	kg	O
967	)	O
967	was	O
967	administered	O
967	i	O
967	##v	O
967	,	O
967	and	O
967	blood	O
967	samples	O
967	were	O
967	collected	O
967	over	O
967	time	O
967	to	O
967	measure	O
967	plasma	O
967	f	O
967	##ent	O
967	##any	O
967	##l	O
967	concentrations	O
967	for	O
967	p	O
967	##har	O
967	##ma	O
967	##co	O
967	##kin	O
967	##etic	O
967	calculations	O
967	.	O
967	[SEP]	O
968	[CLS]	O
968	adverse	O
968	events	O
968	(	O
968	a	O
968	##es	O
968	)	O
968	were	O
968	assessed	O
968	per	O
968	common	O
968	terminology	O
968	criteria	O
968	for	O
968	adverse	O
968	events	O
968	v	O
968	##3	O
968	.	O
968	0	O
968	;	O
968	tumor	O
968	responses	O
968	were	O
968	assessed	O
968	by	O
968	response	O
968	evaluation	O
968	criteria	O
968	in	O
968	solid	O
968	tumors	O
968	.	O
968	[SEP]	O
969	[CLS]	O
969	en	O
969	##roll	O
969	##ees	O
969	were	O
969	male	O
969	or	O
969	female	O
969	ages	O
969	≥	O
969	6	O
969	and	O
969	≤	O
969	75	O
969	years	O
969	with	O
969	a	O
969	confirmed	O
969	diagnosis	O
969	of	O
969	primary	O
969	im	O
969	##mu	O
969	##no	O
969	##de	O
969	##ficiency	O
969	,	O
969	a	O
969	history	O
969	of	O
969	h	O
969	##y	O
969	##po	O
969	##gam	O
969	##ma	O
969	##g	O
969	##lo	O
969	##bul	O
969	##ine	O
969	##mia	O
969	(	O
969	i	O
969	.	O
969	e	O
969	.	O
969	,	O
969	i	O
969	##gg	O
969	<	O
969	500	O
969	mg	O
969	/	O
969	d	O
969	##l	O
969	)	O
969	or	O
969	def	O
969	##icient	O
969	anti	O
969	##body	O
969	production	O
969	prior	O
969	to	O
969	i	O
969	##gg	O
969	replacement	O
969	therapy	O
969	.	O
969	[SEP]	O
970	[CLS]	O
970	the	O
970	plasma	O
970	levels	O
970	of	O
970	the	O
970	unchanged	O
970	drug	O
970	showed	O
970	that	O
970	do	O
970	##xa	O
970	##min	O
970	##ol	O
970	was	O
970	very	O
970	rapidly	O
970	eliminated	O
970	and	O
970	meta	O
970	##bol	O
970	##ized	O
970	.	O
970	[SEP]	O
971	[CLS]	O
971	a	O
971	reproductive	O
971	screening	O
971	test	O
971	of	O
971	ha	O
971	##wth	O
971	##orn	O
971	.	O
971	[SEP]	O
972	[CLS]	O
972	met	O
972	##han	O
972	##ol	O
972	toxic	O
972	##oki	O
972	##net	O
972	##ics	O
972	were	O
972	examined	O
972	in	O
972	pregnant	O
972	s	O
972	##pra	O
972	##gue	O
972	-	O
972	da	O
972	##wley	O
972	rats	O
972	and	O
972	c	O
972	##d	O
972	-	O
972	1	O
972	mice	O
972	to	O
972	explore	O
972	the	O
972	possibility	O
972	of	O
972	g	O
972	##esta	O
972	##tional	O
972	-	O
972	associated	O
972	alterations	O
972	in	O
972	metabolism	O
972	and	O
972	disposition	O
972	.	O
972	[SEP]	O
973	[CLS]	O
973	sixty	O
973	-	O
973	nine	O
973	patients	O
973	were	O
973	enrolled	O
973	,	O
973	including	O
973	20	O
973	patients	O
973	at	O
973	the	O
973	m	O
973	##t	O
973	##d	O
973	.	O
973	[SEP]	O
974	[CLS]	O
974	the	O
974	mean	O
974	au	B-PK
974	##c	I-PK
974	(	I-PK
974	0	I-PK
974	-	I-PK
974	48	I-PK
974	)	I-PK
974	were	O
974	13	O
974	.	O
974	6	O
974	+	O
974	-	O
974	5	O
974	.	O
974	0	O
974	ng	O
974	.	O
974	h	O
974	/	O
974	m	O
974	##l	O
974	and	O
974	13	O
974	.	O
974	3	O
974	+	O
974	-	O
974	4	O
974	.	O
974	7	O
974	ng	O
974	.	O
974	h	O
974	/	O
974	m	O
974	##l	O
974	for	O
974	the	O
974	test	O
974	and	O
974	reference	O
974	treatment	O
974	,	O
974	respectively	O
974	;	O
974	the	O
974	corresponding	O
974	estimated	O
974	treatment	O
974	ratio	O
974	for	O
974	test	O
974	:	O
974	reference	O
974	was	O
974	1	O
974	.	O
974	01	O
974	##1	O
974	,	O
974	95	O
974	%	O
974	c	O
974	##i	O
974	:	O
974	0	O
974	.	O
974	86	O
974	##6	O
974	to	O
974	1	O
974	.	O
974	142	O
974	.	O
974	[SEP]	O
975	[CLS]	O
975	total	O
975	protein	O
975	was	O
975	measured	O
975	by	O
975	the	O
975	bra	O
975	##dford	O
975	ass	O
975	##ay	O
975	(	O
975	bio	O
975	‐	O
975	r	O
975	##ad	O
975	,	O
975	her	O
975	##cule	O
975	##s	O
975	,	O
975	ca	O
975	)	O
975	using	O
975	b	O
975	##ov	O
975	##ine	O
975	serum	O
975	album	O
975	##in	O
975	as	O
975	a	O
975	standard	O
975	.	O
975	[SEP]	O
976	[CLS]	O
976	similarly	O
976	,	O
976	a	O
976	bi	O
976	##pha	O
976	##si	O
976	##c	O
976	model	O
976	best	O
976	described	O
976	the	O
976	data	O
976	for	O
976	the	O
976	formation	O
976	of	O
976	pen	O
976	##to	O
976	##xi	O
976	##fy	O
976	##llin	O
976	##e	O
976	from	O
976	l	O
976	##s	O
976	##f	O
976	.	O
976	[SEP]	O
977	[CLS]	O
977	the	O
977	presence	O
977	of	O
977	ve	O
977	##g	O
977	##f	O
977	in	O
977	samples	O
977	,	O
977	at	O
977	expected	O
977	physiological	O
977	concentrations	O
977	,	O
977	did	O
977	not	O
977	marked	O
977	##ly	O
977	interfere	O
977	in	O
977	the	O
977	q	O
977	##uant	O
977	##ification	O
977	of	O
977	be	O
977	##va	O
977	##ci	O
977	##zu	O
977	##ma	O
977	##b	O
977	.	O
977	[SEP]	O
978	[CLS]	O
978	the	O
978	injection	O
978	schemes	O
978	are	O
978	presented	O
978	in	O
978	figure	O
978	1	O
978	.	O
978	[SEP]	O
979	[CLS]	O
979	briefly	O
979	,	O
979	200	O
979	μ	O
979	##l	O
979	of	O
979	plasma	O
979	was	O
979	extracted	O
979	twice	O
979	with	O
979	200	O
979	-	O
979	μ	O
979	##l	O
979	te	O
979	##rt	O
979	-	O
979	but	O
979	##yl	O
979	met	O
979	##hyl	O
979	et	O
979	##her	O
979	.	O
979	[SEP]	O
980	[CLS]	O
980	thus	O
980	,	O
980	age	O
980	is	O
980	a	O
980	de	O
980	##ter	O
980	##mina	O
980	##nt	O
980	of	O
980	the	O
980	steady	B-PK
980	-	I-PK
980	state	I-PK
980	concentrations	I-PK
980	of	O
980	sa	O
980	##lic	O
980	##yla	O
980	##te	O
980	m	O
980	##oi	O
980	##eti	O
980	##es	O
980	but	O
980	ace	O
980	##ty	O
980	##lator	O
980	p	O
980	##hen	O
980	##otype	O
980	plays	O
980	a	O
980	greater	O
980	role	O
980	in	O
980	determining	O
980	the	O
980	serum	O
980	concentration	O
980	of	O
980	su	O
980	##lf	O
980	##ap	O
980	##yr	O
980	##id	O
980	##ine	O
980	,	O
980	which	O
980	has	O
980	greater	O
980	therapeutic	O
980	implications	O
980	in	O
980	r	O
980	##he	O
980	##uma	O
980	##tology	O
980	.	O
980	[SEP]	O
981	[CLS]	O
981	atom	O
981	##ox	O
981	##eti	O
981	##ne	O
981	has	O
981	been	O
981	considered	O
981	as	O
981	an	O
981	ago	O
981	##nist	O
981	replacement	O
981	therapy	O
981	for	O
981	cocaine	O
981	.	O
981	[SEP]	O
982	[CLS]	O
982	therefore	O
982	,	O
982	it	O
982	is	O
982	important	O
982	to	O
982	examine	O
982	the	O
982	antagonist	O
982	##ic	O
982	effects	O
982	on	O
982	u	O
982	##rina	O
982	##tion	O
982	associated	O
982	with	O
982	me	O
982	##det	O
982	##omi	O
982	##dine	O
982	use	O
982	.	O
982	[SEP]	O
983	[CLS]	O
983	the	O
983	composition	O
983	started	O
983	out	O
983	at	O
983	5	O
983	%	O
983	mobile	O
983	phase	O
983	b	O
983	and	O
983	increased	O
983	linear	O
983	##ly	O
983	to	O
983	70	O
983	%	O
983	mobile	O
983	phase	O
983	b	O
983	by	O
983	7	O
983	min	O
983	.	O
983	[SEP]	O
984	[CLS]	O
984	q	O
984	##uant	O
984	##ification	O
984	of	O
984	p	O
984	##x	O
984	in	O
984	rat	O
984	plasma	O
984	:	O
984	an	O
984	l	O
984	##c	O
984	-	O
984	m	O
984	##s	O
984	/	O
984	m	O
984	##s	O
984	ass	O
984	##ay	O
984	was	O
984	developed	O
984	to	O
984	determine	O
984	the	O
984	concentrations	O
984	of	O
984	p	O
984	##x	O
984	in	O
984	rat	O
984	plasma	O
984	.	O
984	[SEP]	O
985	[CLS]	O
985	when	O
985	the	O
985	b	O
985	##16	O
985	##f	O
985	##10	O
985	tumors	O
985	had	O
985	reached	O
985	a	O
985	volume	O
985	of	O
985	about	O
985	500	O
985	mm	O
985	##3	O
985	,	O
985	the	O
985	c	O
985	##5	O
985	##7	O
985	##b	O
985	##l	O
985	/	O
985	6	O
985	j	O
985	tumor	O
985	-	O
985	bearing	O
985	mice	O
985	were	O
985	randomly	O
985	and	O
985	equally	O
985	divided	O
985	into	O
985	three	O
985	groups	O
985	,	O
985	which	O
985	received	O
985	free	O
985	p	O
985	##ac	O
985	##lit	O
985	##ax	O
985	##el	O
985	solution	O
985	,	O
985	c	O
985	##l	O
985	-	O
985	p	O
985	##t	O
985	##x	O
985	,	O
985	or	O
985	t	O
985	##l	O
985	-	O
985	p	O
985	##t	O
985	##x	O
985	administered	O
985	as	O
985	a	O
985	single	O
985	dose	O
985	of	O
985	10	O
985	mg	O
985	p	O
985	##ac	O
985	##lit	O
985	##ax	O
985	##el	O
985	/	O
985	kg	O
985	body	O
985	weight	O
985	via	O
985	the	O
985	tail	O
985	vein	O
985	.	O
985	[SEP]	O
986	[CLS]	O
986	children	O
986	had	O
986	been	O
986	referred	O
986	from	O
986	their	O
986	general	O
986	practitioners	O
986	(	O
986	g	O
986	##ps	O
986	)	O
986	,	O
986	school	O
986	‐	O
986	and	O
986	community	O
986	‐	O
986	based	O
986	doctors	O
986	,	O
986	or	O
986	p	O
986	##ediatric	O
986	##ians	O
986	.	O
986	[SEP]	O
987	[CLS]	O
987	however	O
987	,	O
987	the	O
987	increase	O
987	was	O
987	ins	O
987	##ign	O
987	##ificant	O
987	when	O
987	compared	O
987	to	O
987	animals	O
987	treated	O
987	with	O
987	fl	O
987	##x	O
987	alone	O
987	.	O
987	[SEP]	O
988	[CLS]	O
988	the	O
988	potential	O
988	for	O
988	a	O
988	drug	O
988	interaction	O
988	between	O
988	c	O
988	##y	O
988	##c	O
988	##los	O
988	##por	O
988	##in	O
988	a	O
988	and	O
988	p	O
988	##hen	O
988	##yt	O
988	##oi	O
988	##n	O
988	was	O
988	investigated	O
988	in	O
988	rats	O
988	.	O
988	[SEP]	O
989	[CLS]	O
989	thus	O
989	,	O
989	the	O
989	anti	O
989	-	O
989	em	O
989	##t	O
989	pathway	O
989	or	O
989	the	O
989	method	O
989	of	O
989	in	O
989	##hibit	O
989	##ing	O
989	of	O
989	t	O
989	##g	O
989	##f	O
989	-	O
989	β	O
989	##1	O
989	signaling	O
989	could	O
989	provide	O
989	a	O
989	novel	O
989	potential	O
989	target	O
989	for	O
989	the	O
989	treatment	O
989	of	O
989	pulmonary	O
989	fi	O
989	##bro	O
989	##sis	O
989	.	O
989	[SEP]	O
990	[CLS]	O
990	sixteen	O
990	healthy	O
990	subjects	O
990	(	O
990	8	O
990	men	O
990	and	O
990	8	O
990	women	O
990	;	O
990	mean	O
990	age	O
990	##±	O
990	##s	O
990	##d	O
990	:	O
990	28	O
990	.	O
990	6	O
990	##±	O
990	##6	O
990	.	O
990	2	O
990	years	O
990	;	O
990	range	O
990	:	O
990	25	O
990	–	O
990	51	O
990	years	O
990	)	O
990	were	O
990	included	O
990	.	O
990	[SEP]	O
991	[CLS]	O
991	generally	O
991	,	O
991	the	O
991	optimization	O
991	of	O
991	particle	O
991	size	O
991	is	O
991	dependent	O
991	on	O
991	the	O
991	therapeutic	O
991	purpose	O
991	.	O
991	[SEP]	O
992	[CLS]	O
992	on	O
992	the	O
992	morning	O
992	of	O
992	day	O
992	9	O
992	,	O
992	subjects	O
992	completed	O
992	a	O
992	24	O
992	-	O
992	hour	O
992	p	O
992	##k	O
992	study	O
992	after	O
992	receiving	O
992	1000	O
992	mg	O
992	n	O
992	##r	O
992	at	O
992	t	O
992	=	O
992	0	O
992	.	O
992	[SEP]	O
993	[CLS]	O
993	differences	O
993	between	O
993	treatment	O
993	groups	O
993	were	O
993	anal	O
993	##ys	O
993	##ed	O
993	by	O
993	analysis	O
993	of	O
993	variance	O
993	.	O
993	[SEP]	O
994	[CLS]	O
994	the	O
994	entire	O
994	data	O
994	set	O
994	was	O
994	best	O
994	described	O
994	by	O
994	a	O
994	one	O
994	-	O
994	compartment	O
994	model	O
994	,	O
994	with	O
994	a	O
994	first	O
994	-	O
994	order	O
994	absorption	O
994	and	O
994	la	O
994	##g	O
994	phase	O
994	.	O
994	[SEP]	O
995	[CLS]	O
995	all	O
995	an	O
995	##ova	O
995	##s	O
995	were	O
995	additionally	O
995	adjusted	O
995	for	O
995	visit	O
995	to	O
995	control	O
995	for	O
995	within	O
995	subject	O
995	var	O
995	##iability	O
995	.	O
995	[SEP]	O
996	[CLS]	O
996	base	O
996	##line	O
996	may	O
996	##o	O
996	and	O
996	pu	O
996	##ca	O
996	##i	O
996	scores	O
996	were	O
996	8	O
996	.	O
996	0	O
996	(	O
996	6	O
996	.	O
996	0	O
996	-	O
996	9	O
996	.	O
996	0	O
996	)	O
996	and	O
996	45	O
996	(	O
996	35	O
996	.	O
996	0	O
996	-	O
996	65	O
996	.	O
996	0	O
996	)	O
996	,	O
996	respectively	O
996	.	O
996	[SEP]	O
997	[CLS]	O
997	two	O
997	patients	O
997	with	O
997	radio	O
997	##log	O
997	##ic	O
997	signs	O
997	of	O
997	gas	O
997	##tro	O
997	##par	O
997	##esis	O
997	had	O
997	no	O
997	peak	B-PK
997	c	I-PK
997	##y	I-PK
997	##c	I-PK
997	##los	I-PK
997	##por	I-PK
997	##ine	I-PK
997	levels	I-PK
997	at	O
997	all	O
997	and	O
997	were	O
997	excluded	O
997	from	O
997	the	O
997	correlation	O
997	analysis	O
997	.	O
997	[SEP]	O
998	[CLS]	O
998	din	O
998	##ut	O
998	##ux	O
998	##ima	O
998	##b	O
998	(	O
998	[UNK]	O
998	;	O
998	ch	O
998	##14	O
998	.	O
998	18	O
998	)	O
998	,	O
998	a	O
998	mon	O
998	##oc	O
998	##lon	O
998	##al	O
998	anti	O
998	##body	O
998	against	O
998	di	O
998	##sia	O
998	##log	O
998	##ang	O
998	##lio	O
998	##side	O
998	,	O
998	improved	O
998	survival	O
998	as	O
998	part	O
998	of	O
998	post	O
998	-	O
998	consolidation	O
998	therapy	O
998	for	O
998	high	O
998	-	O
998	risk	O
998	ne	O
998	##uro	O
998	##blast	O
998	##oma	O
998	.	O
998	[SEP]	O
999	[CLS]	O
999	the	O
999	p	O
999	##har	O
999	##ma	O
999	##co	O
999	##kin	O
999	##etics	O
999	was	O
999	estimated	O
999	according	O
999	to	O
999	a	O
999	two	O
999	-	O
999	compartment	O
999	open	O
999	model	O
999	.	O
999	[SEP]	O
1000	[CLS]	O
1000	subsequent	O
1000	administration	O
1000	of	O
1000	na	O
1000	##lo	O
1000	##xon	O
1000	##e	O
1000	(	O
1000	1	O
1000	mg	O
1000	/	O
1000	kg	O
1000	,	O
1000	i	O
1000	.	O
1000	v	O
1000	.	O
1000	)	O
1000	significantly	O
1000	increased	O
1000	ca	O
1000	levels	O
1000	in	O
1000	both	O
1000	groups	O
1000	.	O
1000	[SEP]	O
1001	[CLS]	O
1001	the	O
1001	m	O
1001	##olar	O
1001	excess	O
1001	of	O
1001	d	O
1001	##b	O
1001	##p	O
1001	to	O
1001	25	O
1001	(	O
1001	oh	O
1001	)	O
1001	d	O
1001	##3	O
1001	in	O
1001	plasma	O
1001	,	O
1001	and	O
1001	the	O
1001	relatively	O
1001	rapid	O
1001	turnover	O
1001	of	O
1001	d	O
1001	##b	O
1001	##p	O
1001	indicate	O
1001	that	O
1001	a	O
1001	high	O
1001	capacity	O
1001	,	O
1001	high	O
1001	affinity	O
1001	,	O
1001	and	O
1001	dynamic	O
1001	transport	O
1001	mechanism	O
1001	for	O
1001	vitamin	O
1001	d	O
1001	s	O
1001	##tero	O
1001	##ls	O
1001	exists	O
1001	in	O
1001	rabbit	O
1001	plasma	O
1001	.	O
1001	[SEP]	O
1002	[CLS]	O
1002	plasma	O
1002	concentrations	O
1002	that	O
1002	were	O
1002	below	O
1002	the	O
1002	lower	O
1002	limit	O
1002	of	O
1002	q	O
1002	##uant	O
1002	##itation	O
1002	were	O
1002	set	O
1002	to	O
1002	zero	O
1002	when	O
1002	calculating	O
1002	summary	O
1002	statistics	O
1002	for	O
1002	plasma	O
1002	concentration	O
1002	at	O
1002	a	O
1002	given	O
1002	nominal	O
1002	time	O
1002	point	O
1002	,	O
1002	except	O
1002	when	O
1002	a	O
1002	single	O
1002	value	O
1002	fell	O
1002	between	O
1002	two	O
1002	me	O
1002	##as	O
1002	##urable	O
1002	concentrations	O
1002	,	O
1002	then	O
1002	this	O
1002	value	O
1002	was	O
1002	set	O
1002	to	O
1002	be	O
1002	missing	O
1002	.	O
1002	[SEP]	O
1003	[CLS]	O
1003	the	O
1003	important	O
1003	aspect	O
1003	of	O
1003	the	O
1003	study	O
1003	is	O
1003	the	O
1003	effect	O
1003	of	O
1003	treatment	O
1003	with	O
1003	the	O
1003	so	O
1003	##fo	O
1003	##s	O
1003	##bu	O
1003	##vir	O
1003	–	O
1003	rib	O
1003	##avi	O
1003	##rin	O
1003	combination	O
1003	regime	O
1003	##n	O
1003	on	O
1003	the	O
1003	c	O
1003	##ni	O
1003	au	B-PK
1003	##c	I-PK
1003	levels	O
1003	,	O
1003	which	O
1003	resulted	O
1003	in	O
1003	a	O
1003	reduction	O
1003	in	O
1003	the	O
1003	c	O
1003	##ni	O
1003	au	B-PK
1003	##c	I-PK
1003	.	O
1003	[SEP]	O
1004	[CLS]	O
1004	similar	O
1004	physical	O
1004	instability	O
1004	was	O
1004	also	O
1004	observed	O
1004	in	O
1004	real	O
1004	-	O
1004	time	O
1004	ch	O
1004	##e	O
1004	##q	O
1004	##sol	O
1004	so	O
1004	##lub	O
1004	##ility	O
1004	ass	O
1004	##ay	O
1004	.	O
1004	[SEP]	O
1005	[CLS]	O
1005	the	O
1005	profile	O
1005	is	O
1005	dominated	O
1005	by	O
1005	the	O
1005	elimination	O
1005	(	O
1005	beta	O
1005	)	O
1005	phase	O
1005	with	O
1005	a	O
1005	half	B-PK
1005	-	I-PK
1005	life	I-PK
1005	of	O
1005	5	O
1005	.	O
1005	2	O
1005	+	O
1005	-	O
1005	0	O
1005	.	O
1005	6	O
1005	h	O
1005	.	O
1005	consequently	O
1005	,	O
1005	24	O
1005	h	O
1005	after	O
1005	the	O
1005	injection	O
1005	(	O
1005	approximately	O
1005	5	O
1005	half	B-PK
1005	-	I-PK
1005	life	I-PK
1005	)	O
1005	97	O
1005	%	O
1005	of	O
1005	the	O
1005	product	O
1005	was	O
1005	eliminated	O
1005	.	O
1005	[SEP]	O
1006	[CLS]	O
1006	vent	O
1006	##ila	O
1006	##tor	O
1006	parameters	O
1006	remained	O
1006	unchanged	O
1006	throughout	O
1006	the	O
1006	protocol	O
1006	.	O
1006	[SEP]	O
1007	[CLS]	O
1007	only	O
1007	one	O
1007	response	O
1007	differed	O
1007	significantly	O
1007	according	O
1007	to	O
1007	sex	O
1007	:	O
1007	the	O
1007	47	O
1007	males	O
1007	receiving	O
1007	da	O
1007	##bi	O
1007	##gat	O
1007	##ran	O
1007	were	O
1007	more	O
1007	sensitive	O
1007	to	O
1007	he	O
1007	##par	O
1007	##in	O
1007	than	O
1007	the	O
1007	corresponding	O
1007	19	O
1007	females	O
1007	(	O
1007	p	O
1007	<	O
1007	0	O
1007	.	O
1007	05	O
1007	)	O
1007	.	O
1007	[SEP]	O
1008	[CLS]	O
1008	mi	O
1008	##rta	O
1008	##za	O
1008	##pine	O
1008	decreases	O
1008	s	O
1008	##ti	O
1008	##mu	O
1008	##lator	O
1008	##y	O
1008	effects	O
1008	of	O
1008	re	O
1008	##box	O
1008	##eti	O
1008	##ne	O
1008	on	O
1008	co	O
1008	##rt	O
1008	##is	O
1008	##ol	O
1008	,	O
1008	ad	O
1008	##ren	O
1008	##oc	O
1008	##ort	O
1008	##ico	O
1008	##tro	O
1008	##pin	O
1008	and	O
1008	pro	O
1008	##la	O
1008	##ct	O
1008	##in	O
1008	secret	O
1008	##ion	O
1008	in	O
1008	healthy	O
1008	male	O
1008	subjects	O
1008	.	O
1008	[SEP]	O
1009	[CLS]	O
1009	exclusion	O
1009	criteria	O
1009	included	O
1009	re	O
1009	##ceipt	O
1009	of	O
1009	any	O
1009	transplant	O
1009	##ed	O
1009	organ	O
1009	other	O
1009	than	O
1009	the	O
1009	kidney	O
1009	,	O
1009	white	O
1009	blood	O
1009	count	O
1009	2	O
1009	.	O
1009	8	O
1009	##×	O
1009	##10	O
1009	##9	O
1009	/	O
1009	l	O
1009	or	O
1009	less	O
1009	,	O
1009	total	O
1009	pro	O
1009	##gra	O
1009	##f	O
1009	dose	O
1009	for	O
1009	24	O
1009	h	O
1009	##r	O
1009	of	O
1009	less	O
1009	than	O
1009	3	O
1009	mg	O
1009	,	O
1009	taking	O
1009	any	O
1009	drug	O
1009	interfering	O
1009	with	O
1009	ta	O
1009	##c	O
1009	##rol	O
1009	##imus	O
1009	metabolism	O
1009	,	O
1009	had	O
1009	taken	O
1009	sir	O
1009	##oli	O
1009	##mus	O
1009	within	O
1009	3	O
1009	months	O
1009	before	O
1009	screening	O
1009	,	O
1009	had	O
1009	acute	O
1009	rejection	O
1009	requiring	O
1009	anti	O
1009	##body	O
1009	therapy	O
1009	within	O
1009	6	O
1009	months	O
1009	before	O
1009	en	O
1009	##rol	O
1009	##ment	O
1009	,	O
1009	had	O
1009	been	O
1009	treated	O
1009	for	O
1009	acute	O
1009	rejection	O
1009	within	O
1009	30	O
1009	days	O
1009	before	O
1009	en	O
1009	##rol	O
1009	##ment	O
1009	,	O
1009	or	O
1009	any	O
1009	gas	O
1009	##tro	O
1009	##int	O
1009	##est	O
1009	##inal	O
1009	disorder	O
1009	that	O
1009	may	O
1009	have	O
1009	affected	O
1009	the	O
1009	absorption	O
1009	of	O
1009	ta	O
1009	##c	O
1009	##rol	O
1009	##imus	O
1009	.	O
1009	[SEP]	O
1010	[CLS]	O
1010	a	O
1010	bio	O
1010	##e	O
1010	##qui	O
1010	##valence	O
1010	study	O
1010	of	O
1010	two	O
1010	ta	O
1010	##ms	O
1010	##ulos	O
1010	##in	O
1010	sustained	O
1010	-	O
1010	release	O
1010	tablets	O
1010	in	O
1010	in	O
1010	##don	O
1010	##esi	O
1010	##an	O
1010	healthy	O
1010	volunteers	O
1010	.	O
1010	[SEP]	O
1011	[CLS]	O
1011	the	O
1011	recover	O
1011	##ies	O
1011	of	O
1011	the	O
1011	anal	O
1011	##yte	O
1011	and	O
1011	is	O
1011	were	O
1011	determined	O
1011	by	O
1011	comparing	O
1011	the	O
1011	peak	O
1011	areas	O
1011	of	O
1011	extracted	O
1011	standard	O
1011	samples	O
1011	with	O
1011	the	O
1011	peak	O
1011	areas	O
1011	of	O
1011	post	O
1011	-	O
1011	extraction	O
1011	plasma	O
1011	blank	O
1011	##s	O
1011	spike	O
1011	##d	O
1011	at	O
1011	the	O
1011	corresponding	O
1011	concentrations	O
1011	.	O
1011	[SEP]	O
1012	[CLS]	O
1012	pro	O
1012	##sta	O
1012	##g	O
1012	##land	O
1012	##in	O
1012	e	O
1012	##1	O
1012	(	O
1012	p	O
1012	##ge	O
1012	##1	O
1012	)	O
1012	was	O
1012	administered	O
1012	in	O
1012	##tra	O
1012	##ven	O
1012	##ously	O
1012	to	O
1012	conscious	O
1012	be	O
1012	##ag	O
1012	##les	O
1012	and	O
1012	the	O
1012	plasma	O
1012	concentrations	O
1012	of	O
1012	its	O
1012	pulmonary	O
1012	meta	O
1012	##bol	O
1012	##ite	O
1012	13	O
1012	,	O
1012	14	O
1012	-	O
1012	di	O
1012	##hy	O
1012	##dr	O
1012	##o	O
1012	-	O
1012	15	O
1012	-	O
1012	k	O
1012	##eto	O
1012	-	O
1012	p	O
1012	##ge	O
1012	##1	O
1012	were	O
1012	q	O
1012	##uant	O
1012	##itated	O
1012	at	O
1012	various	O
1012	times	O
1012	after	O
1012	dos	O
1012	##ing	O
1012	.	O
1012	[SEP]	O
1013	[CLS]	O
1013	although	O
1013	o	O
1013	##besity	O
1013	was	O
1013	found	O
1013	to	O
1013	be	O
1013	associated	O
1013	with	O
1013	an	O
1013	increased	O
1013	v	B-PK
1013	##1	I-PK
1013	,	O
1013	dose	O
1013	adjustment	O
1013	based	O
1013	on	O
1013	c	O
1013	##l	O
1013	##c	O
1013	##r	O
1013	appears	O
1013	to	O
1013	be	O
1013	more	O
1013	important	O
1013	than	O
1013	patient	O
1013	b	O
1013	##mi	O
1013	.	O
1013	[SEP]	O
1014	[CLS]	O
1014	more	O
1014	##over	O
1014	,	O
1014	the	O
1014	sustained	O
1014	circulation	O
1014	behavior	O
1014	of	O
1014	r	O
1014	##h	O
1014	##2	O
1014	-	O
1014	lip	O
1014	##o	O
1014	was	O
1014	similar	O
1014	to	O
1014	that	O
1014	of	O
1014	p	O
1014	##eg	O
1014	-	O
1014	c	O
1014	-	O
1014	lip	O
1014	##o	O
1014	.	O
1014	[SEP]	O
1015	[CLS]	O
1015	β	O
1015	-	O
1015	el	O
1015	##emon	O
1015	##ic	O
1015	acid	O
1015	in	O
1015	##hibit	O
1015	##s	O
1015	the	O
1015	growth	O
1015	of	O
1015	human	O
1015	o	O
1015	##ste	O
1015	##osa	O
1015	##rc	O
1015	##oma	O
1015	through	O
1015	end	O
1015	##op	O
1015	##las	O
1015	##mic	O
1015	re	O
1015	##tic	O
1015	##ulum	O
1015	(	O
1015	er	O
1015	)	O
1015	stress	O
1015	-	O
1015	mediated	O
1015	per	O
1015	##k	O
1015	/	O
1015	e	O
1015	##if	O
1015	##2	O
1015	##α	O
1015	/	O
1015	at	O
1015	##f	O
1015	##4	O
1015	/	O
1015	ch	O
1015	##op	O
1015	activation	O
1015	and	O
1015	w	O
1015	##nt	O
1015	/	O
1015	β	O
1015	-	O
1015	cat	O
1015	##eni	O
1015	##n	O
1015	signal	O
1015	suppression	O
1015	.	O
1015	[SEP]	O
1016	[CLS]	O
1016	this	O
1016	score	O
1016	predicted	O
1016	w	O
1016	##12	O
1016	failure	O
1016	with	O
1016	94	O
1016	%	O
1016	sensitivity	O
1016	,	O
1016	versus	O
1016	31	O
1016	%	O
1016	for	O
1016	the	O
1016	an	O
1016	##rs	O
1016	2005	O
1016	algorithm	O
1016	.	O
1016	[SEP]	O
1017	[CLS]	O
1017	ma	O
1017	##rb	O
1017	##of	O
1017	##lo	O
1017	##xa	O
1017	##cin	O
1017	was	O
1017	not	O
1017	detected	O
1017	in	O
1017	any	O
1017	samples	O
1017	from	O
1017	control	O
1017	dogs	O
1017	.	O
1017	[SEP]	O
1018	[CLS]	O
1018	influence	O
1018	of	O
1018	re	O
1018	##nal	O
1018	imp	O
1018	##air	O
1018	##ment	O
1018	on	O
1018	the	O
1018	p	O
1018	##har	O
1018	##ma	O
1018	##co	O
1018	##kin	O
1018	##etics	O
1018	and	O
1018	p	O
1018	##har	O
1018	##ma	O
1018	##co	O
1018	##dynamic	O
1018	##s	O
1018	of	O
1018	oral	O
1018	da	O
1018	##bi	O
1018	##gat	O
1018	##ran	O
1018	et	O
1018	##ex	O
1018	##ila	O
1018	##te	O
1018	:	O
1018	an	O
1018	open	O
1018	-	O
1018	label	O
1018	,	O
1018	parallel	O
1018	-	O
1018	group	O
1018	,	O
1018	single	O
1018	-	O
1018	centre	O
1018	study	O
1018	.	O
1018	[SEP]	O
1019	[CLS]	O
1019	a	O
1019	full	O
1019	list	O
1019	is	O
1019	provided	O
1019	in	O
1019	supplement	O
1019	##ary	O
1019	material	O
1019	d	O
1019	.	O
1019	[SEP]	O
1020	[CLS]	O
1020	similarly	O
1020	,	O
1020	o	O
1020	##c	O
1020	and	O
1020	o	O
1020	##xy	O
1020	a	O
1020	##pi	O
1020	were	O
1020	associated	O
1020	with	O
1020	mean	O
1020	(	O
1020	s	O
1020	##d	O
1020	)	O
1020	s	O
1020	##d	O
1020	##v	O
1020	em	B-PK
1020	##ax	I-PK
1020	of	O
1020	$	O
1020	27	O
1020	.	O
1020	95	O
1020	(	O
1020	16	O
1020	.	O
1020	03	O
1020	)	O
1020	and	O
1020	$	O
1020	27	O
1020	.	O
1020	30	O
1020	(	O
1020	17	O
1020	.	O
1020	40	O
1020	)	O
1020	,	O
1020	respectively	O
1020	,	O
1020	whereas	O
1020	mean	O
1020	s	O
1020	##d	O
1020	##v	O
1020	em	B-PK
1020	##ax	I-PK
1020	for	O
1020	coarse	O
1020	##ly	O
1020	and	O
1020	finely	O
1020	crushed	O
1020	or	O
1020	##f	O
1020	were	O
1020	lower	O
1020	(	O
1020	$	O
1020	17	O
1020	.	O
1020	25	O
1020	[	O
1020	$	O
1020	17	O
1020	.	O
1020	93	O
1020	]	O
1020	and	O
1020	$	O
1020	17	O
1020	.	O
1020	01	O
1020	[	O
1020	$	O
1020	16	O
1020	.	O
1020	39	O
1020	]	O
1020	,	O
1020	respectively	O
1020	)	O
1020	,	O
1020	and	O
1020	o	O
1020	##c	O
1020	place	O
1020	##bo	O
1020	was	O
1020	the	O
1020	lowest	O
1020	(	O
1020	$	O
1020	0	O
1020	.	O
1020	37	O
1020	[	O
1020	$	O
1020	0	O
1020	.	O
1020	60	O
1020	]	O
1020	)	O
1020	.	O
1020	[SEP]	O
1021	[CLS]	O
1021	one	O
1021	of	O
1021	them	O
1021	experienced	O
1021	d	O
1021	##lt	O
1021	in	O
1021	the	O
1021	form	O
1021	of	O
1021	grade	O
1021	1	O
1021	ex	O
1021	##tre	O
1021	##mity	O
1021	t	O
1021	##rem	O
1021	##ors	O
1021	,	O
1021	superior	O
1021	limb	O
1021	extra	O
1021	##py	O
1021	##ram	O
1021	##idal	O
1021	h	O
1021	##yper	O
1021	##tro	O
1021	##pia	O
1021	and	O
1021	d	O
1021	##ys	O
1021	##met	O
1021	##ria	O
1021	;	O
1021	grade	O
1021	2	O
1021	at	O
1021	##ax	O
1021	##ia	O
1021	,	O
1021	confusion	O
1021	and	O
1021	visual	O
1021	hall	O
1021	##uc	O
1021	##ination	O
1021	.	O
1021	[SEP]	O
1022	[CLS]	O
1022	blood	O
1022	and	O
1022	urine	O
1022	were	O
1022	collected	O
1022	at	O
1022	intervals	O
1022	over	O
1022	8	O
1022	h	O
1022	and	O
1022	urine	O
1022	alone	O
1022	for	O
1022	a	O
1022	further	O
1022	16	O
1022	h	O
1022	.	O
1022	the	O
1022	study	O
1022	was	O
1022	then	O
1022	repeated	O
1022	in	O
1022	nine	O
1022	healthy	O
1022	volunteers	O
1022	using	O
1022	in	O
1022	##tra	O
1022	##ven	O
1022	##ous	O
1022	and	O
1022	oral	O
1022	b	O
1022	##ume	O
1022	##tani	O
1022	##de	O
1022	2	O
1022	mg	O
1022	.	O
1022	[SEP]	O
1023	[CLS]	O
1023	sixteen	O
1023	patients	O
1023	did	O
1023	not	O
1023	respond	O
1023	to	O
1023	c	O
1023	##pt	O
1023	(	O
1023	no	O
1023	change	O
1023	and	O
1023	progressive	O
1023	disease	O
1023	)	O
1023	.	O
1023	[SEP]	O
1024	[CLS]	O
1024	assessing	O
1024	bio	O
1024	##e	O
1024	##qui	O
1024	##valence	O
1024	of	O
1024	generic	O
1024	modified	O
1024	-	O
1024	release	O
1024	anti	O
1024	##ep	O
1024	##ile	O
1024	##ptic	O
1024	drugs	O
1024	.	O
1024	[SEP]	O
1025	[CLS]	O
1025	protein	O
1025	concentrations	O
1025	were	O
1025	measured	O
1025	using	O
1025	a	O
1025	bra	O
1025	##dford	O
1025	method	O
1025	(	O
1025	bio	O
1025	-	O
1025	r	O
1025	##ad	O
1025	laboratories	O
1025	in	O
1025	##c	O
1025	.	O
1025	,	O
1025	her	O
1025	##cule	O
1025	##s	O
1025	,	O
1025	ca	O
1025	,	O
1025	us	O
1025	##a	O
1025	)	O
1025	.	O
1025	[SEP]	O
1026	[CLS]	O
1026	in	O
1026	patients	O
1026	with	O
1026	open	O
1026	s	O
1026	##tr	O
1026	##s	O
1026	,	O
1026	the	O
1026	mean	O
1026	au	B-PK
1026	##c	I-PK
1026	of	O
1026	m	O
1026	##t	O
1026	##x	O
1026	in	O
1026	c	O
1026	##s	O
1026	##f	O
1026	was	O
1026	4	O
1026	.	O
1026	44	O
1026	%	O
1026	of	O
1026	that	O
1026	found	O
1026	in	O
1026	plasma	O
1026	,	O
1026	while	O
1026	in	O
1026	patients	O
1026	with	O
1026	closed	O
1026	s	O
1026	##tr	O
1026	##s	O
1026	,	O
1026	the	O
1026	mean	O
1026	was	O
1026	61	O
1026	.	O
1026	2	O
1026	%	O
1026	of	O
1026	that	O
1026	found	O
1026	in	O
1026	plasma	O
1026	.	O
1026	[SEP]	O
1027	[CLS]	O
1027	a	O
1027	75	O
1027	mg	O
1027	/	O
1027	kg	O
1027	dose	O
1027	of	O
1027	the	O
1027	t	O
1027	##ica	O
1027	##rc	O
1027	##ill	O
1027	##in	O
1027	component	O
1027	was	O
1027	used	O
1027	.	O
1027	[SEP]	O
1028	[CLS]	O
1028	in	O
1028	both	O
1028	studies	O
1028	,	O
1028	all	O
1028	participants	O
1028	were	O
1028	ca	O
1028	##uca	O
1028	##sian	O
1028	and	O
1028	the	O
1028	majority	O
1028	were	O
1028	women	O
1028	.	O
1028	[SEP]	O
1029	[CLS]	O
1029	body	O
1029	weight	O
1029	in	O
1029	mice	O
1029	of	O
1029	t	O
1029	##p	O
1029	##gs	O
1029	-	O
1029	p	O
1029	##n	O
1029	was	O
1029	almost	O
1029	as	O
1029	the	O
1029	same	O
1029	as	O
1029	control	O
1029	group	O
1029	,	O
1029	which	O
1029	may	O
1029	explained	O
1029	as	O
1029	the	O
1029	safety	O
1029	of	O
1029	the	O
1029	t	O
1029	##p	O
1029	##gs	O
1029	-	O
1029	p	O
1029	##n	O
1029	.	O
1029	[SEP]	O
1030	[CLS]	O
1030	we	O
1030	conclude	O
1030	that	O
1030	3	O
1030	concentration	O
1030	time	O
1030	points	O
1030	may	O
1030	be	O
1030	all	O
1030	that	O
1030	are	O
1030	required	O
1030	for	O
1030	est	O
1030	##imation	O
1030	of	O
1030	p	O
1030	##har	O
1030	##ma	O
1030	##co	O
1030	##kin	O
1030	##etic	O
1030	parameters	O
1030	sufficiently	O
1030	accurate	O
1030	for	O
1030	practical	O
1030	purposes	O
1030	in	O
1030	neon	O
1030	##ates	O
1030	.	O
1030	[SEP]	O
1031	[CLS]	O
1031	this	O
1031	random	O
1031	##ized	O
1031	,	O
1031	multi	O
1031	##cent	O
1031	##er	O
1031	,	O
1031	double	O
1031	-	O
1031	du	O
1031	##mmy	O
1031	,	O
1031	parallel	O
1031	-	O
1031	group	O
1031	phase	O
1031	ii	O
1031	##i	O
1031	trial	O
1031	evaluated	O
1031	the	O
1031	efficacy	O
1031	and	O
1031	safety	O
1031	of	O
1031	a	O
1031	##pf	O
1031	##53	O
1031	##0	O
1031	in	O
1031	ch	O
1031	##em	O
1031	##otherapy	O
1031	-	O
1031	naive	O
1031	and	O
1031	non	O
1031	-	O
1031	naive	O
1031	patients	O
1031	with	O
1031	cancer	O
1031	receiving	O
1031	single	O
1031	-	O
1031	day	O
1031	administration	O
1031	##s	O
1031	of	O
1031	either	O
1031	me	O
1031	##c	O
1031	or	O
1031	he	O
1031	##c	O
1031	(	O
1031	as	O
1031	defined	O
1031	by	O
1031	he	O
1031	##sket	O
1031	##h	O
1031	)	O
1031	.	O
1031	18	O
1031	patients	O
1031	were	O
1031	random	O
1031	##ized	O
1031	to	O
1031	receive	O
1031	p	O
1031	##alo	O
1031	##nose	O
1031	##tron	O
1031	0	O
1031	.	O
1031	25	O
1031	mg	O
1031	in	O
1031	##tra	O
1031	##ven	O
1031	##ously	O
1031	(	O
1031	i	O
1031	##v	O
1031	)	O
1031	,	O
1031	a	O
1031	##pf	O
1031	##53	O
1031	##0	O
1031	250	O
1031	mg	O
1031	s	O
1031	##c	O
1031	,	O
1031	or	O
1031	a	O
1031	##pf	O
1031	##53	O
1031	##0	O
1031	500	O
1031	mg	O
1031	s	O
1031	##c	O
1031	,	O
1031	all	O
1031	in	O
1031	combination	O
1031	with	O
1031	matching	O
1031	place	O
1031	##bo	O
1031	and	O
1031	standardized	O
1031	doses	O
1031	of	O
1031	de	O
1031	##xa	O
1031	##met	O
1031	##has	O
1031	##one	O
1031	during	O
1031	their	O
1031	first	O
1031	cycle	O
1031	of	O
1031	ch	O
1031	##em	O
1031	##otherapy	O
1031	in	O
1031	this	O
1031	study	O
1031	.	O
1031	[SEP]	O
1032	[CLS]	O
1032	the	O
1032	contribution	O
1032	of	O
1032	debris	O
1032	##o	O
1032	##quin	O
1032	##e	O
1032	p	O
1032	##oly	O
1032	##mor	O
1032	##phism	O
1032	to	O
1032	the	O
1032	metabolism	O
1032	and	O
1032	action	O
1032	of	O
1032	beta	O
1032	-	O
1032	ad	O
1032	##ren	O
1032	##oc	O
1032	##ept	O
1032	##or	O
1032	antagonist	O
1032	##s	O
1032	(	O
1032	beta	O
1032	-	O
1032	block	O
1032	##ers	O
1032	)	O
1032	varies	O
1032	widely	O
1032	between	O
1032	drugs	O
1032	.	O
1032	[SEP]	O
1033	[CLS]	O
1033	after	O
1033	21	O
1033	days	O
1033	of	O
1033	exposure	O
1033	to	O
1033	b	O
1033	##d	O
1033	##p	O
1033	,	O
1033	fish	O
1033	were	O
1033	terminal	O
1033	##ly	O
1033	an	O
1033	##ae	O
1033	##st	O
1033	##he	O
1033	##tised	O
1033	using	O
1033	et	O
1033	##hyl	O
1033	3	O
1033	-	O
1033	amino	O
1033	##ben	O
1033	##zo	O
1033	##ate	O
1033	met	O
1033	##hane	O
1033	##sul	O
1033	##fo	O
1033	##nate	O
1033	salt	O
1033	(	O
1033	m	O
1033	##s	O
1033	-	O
1033	222	O
1033	,	O
1033	0	O
1033	.	O
1033	5	O
1033	g	O
1033	/	O
1033	l	O
1033	;	O
1033	adjusted	O
1033	to	O
1033	p	O
1033	##h	O
1033	7	O
1033	.	O
1033	5	O
1033	with	O
1033	1	O
1033	m	O
1033	na	O
1033	##oh	O
1033	)	O
1033	(	O
1033	si	O
1033	##gma	O
1033	,	O
1033	pool	O
1033	##e	O
1033	,	O
1033	uk	O
1033	;	O
1033	ca	O
1033	##s	O
1033	no	O
1033	:	O
1033	144	O
1033	-	O
1033	55	O
1033	-	O
1033	8	O
1033	)	O
1033	.	O
1033	[SEP]	O
1034	[CLS]	O
1034	the	O
1034	time	O
1034	course	O
1034	disposition	O
1034	of	O
1034	14	O
1034	##c	O
1034	was	O
1034	examined	O
1034	over	O
1034	a	O
1034	48	O
1034	-	O
1034	h	O
1034	##r	O
1034	period	O
1034	in	O
1034	12	O
1034	-	O
1034	and	O
1034	18	O
1034	-	O
1034	day	O
1034	pregnant	O
1034	rats	O
1034	after	O
1034	a	O
1034	single	O
1034	oral	O
1034	dose	O
1034	of	O
1034	1	O
1034	.	O
1034	6	O
1034	mm	O
1034	##ol	O
1034	[	O
1034	14	O
1034	##c	O
1034	]	O
1034	d	O
1034	##ce	O
1034	kg	O
1034	-	O
1034	1	O
1034	.	O
1034	[SEP]	O
1035	[CLS]	O
1035	the	O
1035	cm	B-PK
1035	##ax	I-PK
1035	of	O
1035	br	O
1035	##oms	O
1035	##ite	O
1035	##®	O
1035	bid	O
1035	was	O
1035	similar	O
1035	to	O
1035	br	O
1035	##oms	O
1035	##ite	O
1035	##®	O
1035	q	O
1035	##d	O
1035	(	O
1035	geometric	O
1035	means	O
1035	ratio	O
1035	=	O
1035	1	O
1035	.	O
1035	04	O
1035	)	O
1035	,	O
1035	but	O
1035	2	O
1035	.	O
1035	7	O
1035	-	O
1035	,	O
1035	and	O
1035	2	O
1035	.	O
1035	5	O
1035	-	O
1035	fold	O
1035	greater	O
1035	than	O
1035	that	O
1035	of	O
1035	pro	O
1035	##len	O
1035	##sa	O
1035	##®	O
1035	,	O
1035	and	O
1035	il	O
1035	##ev	O
1035	##ro	O
1035	##®	O
1035	,	O
1035	respectively	O
1035	.	O
1035	[SEP]	O
1036	[CLS]	O
1036	the	O
1036	##p	O
1036	##rog	O
1036	##ression	O
1036	-	O
1036	free	O
1036	survival	O
1036	(	O
1036	p	O
1036	##fs	O
1036	)	O
1036	were	O
1036	estimated	O
1036	with	O
1036	the	O
1036	ka	O
1036	##p	O
1036	##lan	O
1036	–	O
1036	me	O
1036	##ier	O
1036	method	O
1036	.	O
1036	[SEP]	O
1037	[CLS]	O
1037	quality	O
1037	control	O
1037	(	O
1037	q	O
1037	##c	O
1037	)	O
1037	samples	O
1037	were	O
1037	prepared	O
1037	at	O
1037	low	O
1037	(	O
1037	5	O
1037	ng	O
1037	/	O
1037	m	O
1037	##l	O
1037	)	O
1037	,	O
1037	medium	O
1037	(	O
1037	50	O
1037	ng	O
1037	/	O
1037	m	O
1037	##l	O
1037	)	O
1037	,	O
1037	and	O
1037	high	O
1037	concentration	O
1037	(	O
1037	150	O
1037	ng	O
1037	/	O
1037	m	O
1037	##l	O
1037	)	O
1037	in	O
1037	the	O
1037	same	O
1037	way	O
1037	as	O
1037	the	O
1037	plasma	O
1037	ca	O
1037	##li	O
1037	##bra	O
1037	##tion	O
1037	samples	O
1037	.	O
1037	[SEP]	O
1038	[CLS]	O
1038	a	O
1038	phase	O
1038	i	O
1038	trial	O
1038	was	O
1038	designed	O
1038	to	O
1038	examine	O
1038	the	O
1038	f	O
1038	##eas	O
1038	##ibility	O
1038	of	O
1038	combining	O
1038	inter	O
1038	##fer	O
1038	##on	O
1038	and	O
1038	tax	O
1038	##ol	O
1038	with	O
1038	in	O
1038	##tra	O
1038	##per	O
1038	##ito	O
1038	##nea	O
1038	##l	O
1038	radio	O
1038	##im	O
1038	##mu	O
1038	##not	O
1038	##her	O
1038	##ap	O
1038	##y	O
1038	(	O
1038	177	O
1038	##lu	O
1038	-	O
1038	cc	O
1038	##4	O
1038	##9	O
1038	)	O
1038	.	O
1038	[SEP]	O
1039	[CLS]	O
1039	the	O
1039	addition	O
1039	of	O
1039	an	O
1039	f	O
1039	##c	O
1039	domain	O
1039	,	O
1039	human	O
1039	i	O
1039	##gg	O
1039	##1	O
1039	in	O
1039	the	O
1039	case	O
1039	of	O
1039	currently	O
1039	licensed	O
1039	f	O
1039	##c	O
1039	-	O
1039	fusion	O
1039	##s	O
1039	,	O
1039	has	O
1039	multiple	O
1039	benefits	O
1039	in	O
1039	construction	O
1039	of	O
1039	novel	O
1039	biological	O
1039	agents	O
1039	.	O
1039	[SEP]	O
1040	[CLS]	O
1040	additional	O
1040	24	O
1040	hours	O
1040	collection	O
1040	periods	O
1040	at	O
1040	day	O
1040	20	O
1040	–	O
1040	21	O
1040	and	O
1040	at	O
1040	day	O
1040	29	O
1040	–	O
1040	30	O
1040	were	O
1040	needed	O
1040	to	O
1040	follow	O
1040	the	O
1040	complete	O
1040	profile	O
1040	of	O
1040	net	O
1040	##up	O
1040	##ita	O
1040	##nt	O
1040	ex	O
1040	##cre	O
1040	##tion	O
1040	.	O
1040	[SEP]	O
1041	[CLS]	O
1041	p	O
1041	##har	O
1041	##ma	O
1041	##co	O
1041	##kin	O
1041	##etic	O
1041	and	O
1041	p	O
1041	##rand	O
1041	##ial	O
1041	p	O
1041	##har	O
1041	##ma	O
1041	##co	O
1041	##dynamic	O
1041	properties	O
1041	of	O
1041	insulin	O
1041	de	O
1041	##g	O
1041	##lude	O
1041	##c	O
1041	/	O
1041	insulin	O
1041	as	O
1041	##par	O
1041	##t	O
1041	in	O
1041	children	O
1041	,	O
1041	adolescent	O
1041	##s	O
1041	,	O
1041	and	O
1041	adults	O
1041	with	O
1041	type	O
1041	1	O
1041	diabetes	O
1041	.	O
1041	[SEP]	O
1042	[CLS]	O
1042	the	O
1042	concentrations	O
1042	of	O
1042	the	O
1042	agent	O
1042	were	O
1042	found	O
1042	to	O
1042	be	O
1042	considerably	O
1042	lower	O
1042	in	O
1042	the	O
1042	brain	O
1042	than	O
1042	in	O
1042	the	O
1042	plasma	O
1042	.	O
1042	[SEP]	O
1043	[CLS]	O
1043	early	O
1043	results	O
1043	with	O
1043	sir	O
1043	##oli	O
1043	##mus	O
1043	-	O
1043	el	O
1043	##uti	O
1043	##ng	O
1043	s	O
1043	##ten	O
1043	##ts	O
1043	have	O
1043	demonstrated	O
1043	a	O
1043	favorable	O
1043	outcome	O
1043	for	O
1043	reducing	O
1043	rest	O
1043	##eno	O
1043	##sis	O
1043	post	O
1043	co	O
1043	##rona	O
1043	##ry	O
1043	intervention	O
1043	.	O
1043	[SEP]	O
1044	[CLS]	O
1044	after	O
1044	three	O
1044	consecutive	O
1044	administration	O
1044	##s	O
1044	of	O
1044	c	O
1044	##eti	O
1044	##riz	O
1044	##ine	O
1044	(	O
1044	0	O
1044	.	O
1044	2	O
1044	mg	O
1044	/	O
1044	kg	O
1044	body	O
1044	weight	O
1044	,	O
1044	b	O
1044	##w	O
1044	)	O
1044	every	O
1044	12	O
1044	##h	O
1044	,	O
1044	the	O
1044	t	B-PK
1044	##rough	I-PK
1044	plasma	I-PK
1044	concentration	I-PK
1044	of	O
1044	c	O
1044	##eti	O
1044	##riz	O
1044	##ine	O
1044	was	O
1044	16	O
1044	+	O
1044	-	O
1044	4	O
1044	ng	O
1044	/	O
1044	m	O
1044	##l	O
1044	(	O
1044	mean	O
1044	+	O
1044	-	O
1044	s	O
1044	##d	O
1044	)	O
1044	and	O
1044	the	O
1044	w	O
1044	##hea	O
1044	##l	O
1044	formation	O
1044	was	O
1044	in	O
1044	##hibit	O
1044	##ed	O
1044	by	O
1044	45	O
1044	+	O
1044	-	O
1044	23	O
1044	%	O
1044	.	O
1044	[SEP]	O
1045	[CLS]	O
1045	in	O
1045	this	O
1045	species	O
1045	,	O
1045	there	O
1045	was	O
1045	rapid	O
1045	accumulation	O
1045	of	O
1045	drug	O
1045	in	O
1045	all	O
1045	tissue	O
1045	.	O
1045	[SEP]	O
1046	[CLS]	O
1046	hi	O
1046	##v	O
1046	plasma	O
1046	viral	O
1046	load	O
1046	(	O
1046	co	O
1046	##bas	O
1046	am	O
1046	##p	O
1046	##lip	O
1046	##re	O
1046	##p	O
1046	ta	O
1046	##q	O
1046	##man	O
1046	hi	O
1046	##v	O
1046	-	O
1046	1	O
1046	ass	O
1046	##ay	O
1046	,	O
1046	r	O
1046	##och	O
1046	##e	O
1046	diagnostic	O
1046	##s	O
1046	systems	O
1046	,	O
1046	lava	O
1046	##l	O
1046	,	O
1046	que	O
1046	##be	O
1046	##c	O
1046	,	O
1046	can	O
1046	##ada	O
1046	)	O
1046	was	O
1046	measured	O
1046	at	O
1046	base	O
1046	##line	O
1046	,	O
1046	at	O
1046	weeks	O
1046	2	O
1046	and	O
1046	4	O
1046	,	O
1046	then	O
1046	every	O
1046	4	O
1046	weeks	O
1046	throughout	O
1046	the	O
1046	study	O
1046	.	O
1046	[SEP]	O
1047	[CLS]	O
1047	bi	O
1047	##so	O
1047	##p	O
1047	##rol	O
1047	##ol	O
1047	concentrations	O
1047	in	O
1047	plasma	O
1047	and	O
1047	most	O
1047	eye	O
1047	tissues	O
1047	were	O
1047	considerably	O
1047	higher	O
1047	after	O
1047	oral	O
1047	than	O
1047	after	O
1047	con	O
1047	##junct	O
1047	##ival	O
1047	treatment	O
1047	.	O
1047	[SEP]	O
1048	[CLS]	O
1048	to	O
1048	determine	O
1048	the	O
1048	maximum	O
1048	-	O
1048	tolerate	O
1048	##d	O
1048	dose	O
1048	,	O
1048	toxicity	O
1048	,	O
1048	p	O
1048	##har	O
1048	##ma	O
1048	##co	O
1048	##kin	O
1048	##etics	O
1048	,	O
1048	and	O
1048	bio	O
1048	##log	O
1048	##ic	O
1048	effects	O
1048	of	O
1048	g	O
1048	##31	O
1048	##39	O
1048	when	O
1048	administered	O
1048	with	O
1048	do	O
1048	##x	O
1048	##or	O
1048	##ubi	O
1048	##cin	O
1048	and	O
1048	c	O
1048	##y	O
1048	##c	O
1048	##lop	O
1048	##hos	O
1048	##pha	O
1048	##mi	O
1048	##de	O
1048	to	O
1048	children	O
1048	with	O
1048	re	O
1048	##lap	O
1048	##sed	O
1048	solid	O
1048	tumors	O
1048	.	O
1048	[SEP]	O
1049	[CLS]	O
1049	the	O
1049	area	B-PK
1049	under	I-PK
1049	the	I-PK
1049	plasma	I-PK
1049	concentration	I-PK
1049	-	I-PK
1049	time	I-PK
1049	curve	I-PK
1049	(	I-PK
1049	au	I-PK
1049	##c	I-PK
1049	##0	I-PK
1049	-	I-PK
1049	48	I-PK
1049	)	I-PK
1049	of	O
1049	do	O
1049	##ce	O
1049	##ta	O
1049	##xe	O
1049	##l	O
1049	at	O
1049	the	O
1049	r	O
1049	##p	O
1049	##2	O
1049	##d	O
1049	of	O
1049	once	O
1049	-	O
1049	weekly	O
1049	60	O
1049	-	O
1049	mg	O
1049	m	O
1049	##od	O
1049	##rado	O
1049	##c	O
1049	##00	O
1049	##1	O
1049	capsule	O
1049	with	O
1049	100	O
1049	-	O
1049	mg	O
1049	r	O
1049	##ito	O
1049	##na	O
1049	##vir	O
1049	was	O
1049	1	O
1049	,	O
1049	000	O
1049	±	O
1049	68	O
1049	##7	O
1049	ng	O
1049	/	O
1049	m	O
1049	##l	O
1049	/	O
1049	hour	O
1049	and	O
1049	for	O
1049	once	O
1049	-	O
1049	weekly	O
1049	60	O
1049	-	O
1049	mg	O
1049	m	O
1049	##od	O
1049	##rado	O
1049	##c	O
1049	##00	O
1049	##6	O
1049	tablet	O
1049	with	O
1049	100	O
1049	-	O
1049	mg	O
1049	r	O
1049	##ito	O
1049	##na	O
1049	##vir	O
1049	,	O
1049	the	O
1049	au	B-PK
1049	##c	I-PK
1049	##0	I-PK
1049	-	I-PK
1049	48	I-PK
1049	was	O
1049	1	O
1049	,	O
1049	79	O
1049	##0	O
1049	±	O
1049	81	O
1049	##9	O
1049	ng	O
1049	/	O
1049	m	O
1049	##l	O
1049	/	O
1049	hour	O
1049	.	O
1049	[SEP]	O
1050	[CLS]	O
1050	the	O
1050	total	O
1050	energies	O
1050	and	O
1050	the	O
1050	distances	O
1050	of	O
1050	hydrogen	O
1050	bonds	O
1050	of	O
1050	the	O
1050	four	O
1050	op	O
1050	##ti	O
1050	##mized	O
1050	conform	O
1050	##ation	O
1050	were	O
1050	calculated	O
1050	(	O
1050	table	O
1050	1	O
1050	##s	O
1050	)	O
1050	.	O
1050	[SEP]	O
1051	[CLS]	O
1051	the	O
1051	patient	O
1051	was	O
1051	subsequently	O
1051	treated	O
1051	off	O
1051	-	O
1051	study	O
1051	with	O
1051	another	O
1051	four	O
1051	courses	O
1051	at	O
1051	reduced	O
1051	dose	O
1051	and	O
1051	achieved	O
1051	a	O
1051	complete	O
1051	response	O
1051	.	O
1051	[SEP]	O
1052	[CLS]	O
1052	mice	O
1052	were	O
1052	randomly	O
1052	divided	O
1052	into	O
1052	five	O
1052	groups	O
1052	(	O
1052	n	O
1052	=	O
1052	4	O
1052	)	O
1052	.	O
1052	[SEP]	O
1053	[CLS]	O
1053	surface	O
1053	area	O
1053	(	O
1053	s	O
1053	##t	O
1053	)	O
1053	per	O
1053	gram	O
1053	of	O
1053	cardiac	O
1053	tissue	O
1053	,	O
1053	only	O
1053	available	O
1053	for	O
1053	humans	O
1053	or	O
1053	q	O
1053	##uant	O
1053	##ifiable	O
1053	from	O
1053	human	O
1053	data	O
1053	[	O
1053	36	O
1053	,	O
1053	37	O
1053	]	O
1053	,	O
1053	were	O
1053	applied	O
1053	to	O
1053	mice	O
1053	.	O
1053	[SEP]	O
1054	[CLS]	O
1054	p	O
1054	##har	O
1054	##ma	O
1054	##co	O
1054	##kin	O
1054	##etic	O
1054	parameters	O
1054	were	O
1054	calculated	O
1054	by	O
1054	a	O
1054	non	O
1054	-	O
1054	compartment	O
1054	method	O
1054	using	O
1054	win	O
1054	##non	O
1054	##lin	O
1054	6	O
1054	.	O
1054	3	O
1054	software	O
1054	(	O
1054	p	O
1054	##har	O
1054	-	O
1054	sight	O
1054	corporation	O
1054	,	O
1054	sunny	O
1054	##vale	O
1054	,	O
1054	ca	O
1054	,	O
1054	us	O
1054	##a	O
1054	)	O
1054	.	O
1054	[SEP]	O
1055	[CLS]	O
1055	cm	B-PK
1055	##ax	I-PK
1055	increased	O
1055	in	O
1055	a	O
1055	dose	O
1055	-	O
1055	proportional	O
1055	manner	O
1055	and	O
1055	au	B-PK
1055	##c	I-PK
1055	##∞	I-PK
1055	increased	O
1055	in	O
1055	a	O
1055	more	O
1055	than	O
1055	dose	O
1055	-	O
1055	proportional	O
1055	manner	O
1055	.	O
1055	[SEP]	O
1056	[CLS]	O
1056	the	O
1056	two	O
1056	types	O
1056	of	O
1056	drug	O
1056	administration	O
1056	were	O
1056	used	O
1056	alternatively	O
1056	with	O
1056	the	O
1056	same	O
1056	patient	O
1056	.	O
1056	[SEP]	O
1057	[CLS]	O
1057	ace	O
1057	##ty	O
1057	##l	O
1057	##car	O
1057	##ni	O
1057	##tine	O
1057	(	O
1057	con	O
1057	,	O
1057	4	O
1057	.	O
1057	8	O
1057	+	O
1057	-	O
1057	1	O
1057	.	O
1057	8	O
1057	;	O
1057	ch	O
1057	##o	O
1057	,	O
1057	1	O
1057	.	O
1057	5	O
1057	+	O
1057	-	O
1057	0	O
1057	.	O
1057	9	O
1057	mm	O
1057	##ol	O
1057	(	O
1057	kg	O
1057	dry	O
1057	mass	O
1057	(	O
1057	d	O
1057	.	O
1057	m	O
1057	.	O
1057	)	O
1057	)	O
1057	(	O
1057	-	O
1057	1	O
1057	)	O
1057	,	O
1057	p	O
1057	<	O
1057	0	O
1057	.	O
1057	05	O
1057	)	O
1057	and	O
1057	ace	O
1057	##ty	O
1057	##l	O
1057	co	O
1057	##a	O
1057	(	O
1057	con	O
1057	,	O
1057	13	O
1057	.	O
1057	2	O
1057	+	O
1057	-	O
1057	2	O
1057	.	O
1057	3	O
1057	;	O
1057	ch	O
1057	##o	O
1057	,	O
1057	6	O
1057	.	O
1057	3	O
1057	+	O
1057	-	O
1057	0	O
1057	.	O
1057	6	O
1057	micro	O
1057	##mo	O
1057	##l	O
1057	(	O
1057	kg	O
1057	d	O
1057	.	O
1057	m	O
1057	.	O
1057	)	O
1057	(	O
1057	-	O
1057	1	O
1057	)	O
1057	,	O
1057	p	O
1057	<	O
1057	0	O
1057	.	O
1057	05	O
1057	)	O
1057	were	O
1057	lower	O
1057	at	O
1057	rest	O
1057	,	O
1057	whereas	O
1057	p	O
1057	##yr	O
1057	##u	O
1057	##vate	O
1057	de	O
1057	##hy	O
1057	##dr	O
1057	##ogen	O
1057	##ase	O
1057	activation	O
1057	(	O
1057	p	O
1057	##dha	O
1057	)	O
1057	was	O
1057	greater	O
1057	in	O
1057	ch	O
1057	##o	O
1057	compared	O
1057	with	O
1057	con	O
1057	(	O
1057	con	O
1057	,	O
1057	0	O
1057	.	O
1057	78	O
1057	+	O
1057	-	O
1057	0	O
1057	.	O
1057	07	O
1057	;	O
1057	ch	O
1057	##o	O
1057	,	O
1057	1	O
1057	.	O
1057	44	O
1057	+	O
1057	-	O
1057	0	O
1057	.	O
1057	19	O
1057	mm	O
1057	##ol	O
1057	min	O
1057	(	O
1057	-	O
1057	1	O
1057	)	O
1057	(	O
1057	kg	O
1057	wet	O
1057	mass	O
1057	(	O
1057	w	O
1057	.	O
1057	m	O
1057	.	O
1057	)	O
1057	)	O
1057	(	O
1057	-	O
1057	1	O
1057	)	O
1057	)	O
1057	.	O
1057	[SEP]	O
1058	[CLS]	O
1058	part	O
1058	3	O
1058	was	O
1058	designed	O
1058	to	O
1058	compare	O
1058	the	O
1058	p	O
1058	##har	O
1058	##ma	O
1058	##co	O
1058	##kin	O
1058	##etic	O
1058	parameters	O
1058	of	O
1058	i	O
1058	##gu	O
1058	##rat	O
1058	##imo	O
1058	##d	O
1058	between	O
1058	single	O
1058	-	O
1058	dose	O
1058	and	O
1058	multiple	O
1058	-	O
1058	dose	O
1058	administration	O
1058	;	O
1058	subjects	O
1058	were	O
1058	divided	O
1058	into	O
1058	two	O
1058	groups	O
1058	,	O
1058	with	O
1058	one	O
1058	group	O
1058	receiving	O
1058	a	O
1058	single	O
1058	dose	O
1058	of	O
1058	50	O
1058	mg	O
1058	on	O
1058	day	O
1058	1	O
1058	and	O
1058	the	O
1058	other	O
1058	group	O
1058	receiving	O
1058	a	O
1058	multiple	O
1058	dose	O
1058	of	O
1058	50	O
1058	mg	O
1058	,	O
1058	once	O
1058	every	O
1058	day	O
1058	,	O
1058	until	O
1058	a	O
1058	stable	O
1058	plasma	O
1058	concentration	O
1058	had	O
1058	been	O
1058	achieved	O
1058	.	O
1058	[SEP]	O
1059	[CLS]	O
1059	the	O
1059	limit	O
1059	of	O
1059	q	O
1059	##uant	O
1059	##ification	O
1059	(	O
1059	lo	O
1059	##q	O
1059	)	O
1059	was	O
1059	20	O
1059	ng	O
1059	/	O
1059	m	O
1059	##l	O
1059	for	O
1059	vitamin	O
1059	d	O
1059	##3	O
1059	and	O
1059	40	O
1059	ng	O
1059	/	O
1059	m	O
1059	##l	O
1059	for	O
1059	k	O
1059	##1	O
1059	.	O
1059	[SEP]	O
1060	[CLS]	O
1060	relative	B-PK
1060	bio	I-PK
1060	##ava	I-PK
1060	##ila	I-PK
1060	##bility	I-PK
1060	of	O
1060	commercial	O
1060	am	O
1060	##pic	O
1060	##ill	O
1060	##in	O
1060	formulation	O
1060	##s	O
1060	in	O
1060	man	O
1060	.	O
1060	[SEP]	O
1061	[CLS]	O
1061	this	O
1061	valid	O
1061	##ated	O
1061	method	O
1061	was	O
1061	applied	O
1061	for	O
1061	an	O
1061	open	O
1061	label	O
1061	,	O
1061	balanced	O
1061	,	O
1061	random	O
1061	##ized	O
1061	,	O
1061	two	O
1061	-	O
1061	treatment	O
1061	,	O
1061	two	O
1061	period	O
1061	,	O
1061	two	O
1061	sequence	O
1061	,	O
1061	single	O
1061	dose	O
1061	,	O
1061	crossover	O
1061	bio	B-PK
1061	##ava	I-PK
1061	##ila	I-PK
1061	##bility	I-PK
1061	study	O
1061	comparing	O
1061	a	O
1061	car	O
1061	##bo	O
1061	##cist	O
1061	##ein	O
1061	##e	O
1061	capsule	O
1061	in	O
1061	35	O
1061	healthy	O
1061	,	O
1061	adult	O
1061	,	O
1061	human	O
1061	subjects	O
1061	under	O
1061	fast	O
1061	##ing	O
1061	conditions	O
1061	.	O
1061	[SEP]	O
1062	[CLS]	O
1062	preliminary	O
1062	data	O
1062	of	O
1062	the	O
1062	phase	O
1062	i	O
1062	study	O
1062	of	O
1062	p	O
1062	##f	O
1062	##l	O
1062	(	O
1062	c	O
1062	##is	O
1062	##p	O
1062	##lat	O
1062	##in	O
1062	,	O
1062	le	O
1062	##uc	O
1062	##ovo	O
1062	##rin	O
1062	and	O
1062	5	O
1062	##fu	O
1062	)	O
1062	and	O
1062	mat	O
1062	##uz	O
1062	##uma	O
1062	##b	O
1062	(	O
1062	at	O
1062	doses	O
1062	of	O
1062	400	O
1062	or	O
1062	800	O
1062	mg	O
1062	weekly	O
1062	)	O
1062	in	O
1062	advanced	O
1062	og	O
1062	cancer	O
1062	indicate	O
1062	good	O
1062	to	O
1062	##ler	O
1062	##ability	O
1062	at	O
1062	the	O
1062	400	O
1062	mg	O
1062	dose	O
1062	level	O
1062	(	O
1062	d	O
1062	##l	O
1062	)	O
1062	(	O
1062	t	O
1062	##rar	O
1062	##bach	O
1062	et	O
1062	al	O
1062	,	O
1062	2005	O
1062	)	O
1062	.	O
1062	[SEP]	O
1063	[CLS]	O
1063	d	O
1063	study	O
1063	discharge	O
1063	,	O
1063	mad	O
1063	multiple	O
1063	ascending	O
1063	dose	O
1063	,	O
1063	r	O
1063	random	O
1063	##ization	O
1063	,	O
1063	s	O
1063	screening	O
1063	,	O
1063	sad	O
1063	single	O
1063	ascending	O
1063	dose	O
1063	,	O
1063	s	O
1063	##dd	O
1063	spray	O
1063	dried	O
1063	di	O
1063	##sper	O
1063	##sion	O
1063	,	O
1063	w	O
1063	wash	O
1063	##out	O
1063	(	O
1063	g	O
1063	##if	O
1063	74	O
1063	k	O
1063	##b	O
1063	)	O
1063	[SEP]	O
1064	[CLS]	O
1064	card	O
1064	##iovascular	O
1064	safety	O
1064	results	O
1064	indicated	O
1064	no	O
1064	instances	O
1064	of	O
1064	a	O
1064	q	O
1064	##t	O
1064	##c	O
1064	##f	O
1064	value	O
1064	exceeding	O
1064	500	O
1064	m	O
1064	##se	O
1064	##c	O
1064	.	O
1064	[SEP]	O
1065	[CLS]	O
1065	lo	O
1065	##iz	O
1065	##ou	O
1065	et	O
1065	al	O
1065	.	O
1065	[	O
1065	20	O
1065	]	O
1065	developed	O
1065	a	O
1065	detailed	O
1065	p	O
1065	##b	O
1065	##p	O
1065	##k	O
1065	in	O
1065	the	O
1065	rat	O
1065	with	O
1065	the	O
1065	ha	O
1065	##lot	O
1065	##hane	O
1065	metabolism	O
1065	described	O
1065	by	O
1065	a	O
1065	4	O
1065	parameter	O
1065	function	O
1065	that	O
1065	included	O
1065	both	O
1065	mi	O
1065	##cha	O
1065	##eli	O
1065	##s	O
1065	-	O
1065	men	O
1065	##ten	O
1065	and	O
1065	in	O
1065	##act	O
1065	##ivation	O
1065	components	O
1065	.	O
1065	[SEP]	O
1066	[CLS]	O
1066	im	O
1066	##mu	O
1066	##no	O
1066	##genic	O
1066	##ity	O
1066	was	O
1066	measured	O
1066	by	O
1066	the	O
1066	incidence	O
1066	of	O
1066	ad	O
1066	##as	O
1066	,	O
1066	including	O
1066	neutral	O
1066	##ising	O
1066	antibodies	O
1066	(	O
1066	na	O
1066	##bs	O
1066	)	O
1066	.	O
1066	[SEP]	O
1067	[CLS]	O
1067	a	O
1067	phase	O
1067	i	O
1067	trial	O
1067	of	O
1067	mon	O
1067	##oc	O
1067	##lon	O
1067	##al	O
1067	anti	O
1067	##body	O
1067	m	O
1067	##19	O
1067	##5	O
1067	in	O
1067	acute	O
1067	my	O
1067	##elo	O
1067	##gen	O
1067	##ous	O
1067	le	O
1067	##uke	O
1067	##mia	O
1067	:	O
1067	specific	O
1067	bone	O
1067	ma	O
1067	##rrow	O
1067	targeting	O
1067	and	O
1067	internal	O
1067	##ization	O
1067	of	O
1067	radio	O
1067	##nu	O
1067	##c	O
1067	##lide	O
1067	.	O
1067	[SEP]	O
1068	[CLS]	O
1068	the	O
1068	multiple	O
1068	dose	O
1068	phase	O
1068	showed	O
1068	increasing	O
1068	plasma	O
1068	levels	O
1068	up	O
1068	to	O
1068	7	O
1068	days	O
1068	after	O
1068	the	O
1068	start	O
1068	of	O
1068	administration	O
1068	,	O
1068	and	O
1068	sustained	O
1068	high	O
1068	concentrations	O
1068	during	O
1068	the	O
1068	all	O
1068	administration	O
1068	period	O
1068	.	O
1068	[SEP]	O
1069	[CLS]	O
1069	to	O
1069	examine	O
1069	extinction	O
1069	s	O
1069	##pect	O
1069	##ra	O
1069	,	O
1069	we	O
1069	used	O
1069	a	O
1069	u	O
1069	##v	O
1069	–	O
1069	v	O
1069	##is	O
1069	s	O
1069	##pect	O
1069	##rop	O
1069	##hot	O
1069	##ometer	O
1069	(	O
1069	u	O
1069	##v	O
1069	–	O
1069	260	O
1069	##0	O
1069	,	O
1069	s	O
1069	##hima	O
1069	##d	O
1069	##zu	O
1069	)	O
1069	.	O
1069	[SEP]	O
1070	[CLS]	O
1070	subject	O
1070	exclusion	O
1070	criteria	O
1070	were	O
1070	:	O
1070	(	O
1070	a	O
1070	)	O
1070	patients	O
1070	with	O
1070	significant	O
1070	he	O
1070	##pa	O
1070	##tic	O
1070	disease	O
1070	,	O
1070	un	O
1070	##con	O
1070	##tro	O
1070	##lled	O
1070	h	O
1070	##yper	O
1070	##tens	O
1070	##ion	O
1070	/	O
1070	diabetes	O
1070	me	O
1070	##lli	O
1070	##tus	O
1070	(	O
1070	b	O
1070	)	O
1070	patients	O
1070	on	O
1070	con	O
1070	##com	O
1070	##ita	O
1070	##nt	O
1070	drug	O
1070	therapy	O
1070	which	O
1070	is	O
1070	likely	O
1070	to	O
1070	increase	O
1070	or	O
1070	decrease	O
1070	c	O
1070	##y	O
1070	##c	O
1070	##los	O
1070	##por	O
1070	##ine	O
1070	levels	O
1070	or	O
1070	enhance	O
1070	its	O
1070	ne	O
1070	##ph	O
1070	##rot	O
1070	##ox	O
1070	##icit	O
1070	##y	O
1070	(	O
1070	c	O
1070	)	O
1070	patients	O
1070	with	O
1070	severe	O
1070	or	O
1070	unstable	O
1070	an	O
1070	##gin	O
1070	##a	O
1070	p	O
1070	##ector	O
1070	##is	O
1070	within	O
1070	the	O
1070	previous	O
1070	one	O
1070	month	O
1070	(	O
1070	d	O
1070	)	O
1070	history	O
1070	of	O
1070	h	O
1070	##yper	O
1070	##sen	O
1070	##si	O
1070	##ti	O
1070	##vity	O
1070	to	O
1070	the	O
1070	trial	O
1070	medication	O
1070	(	O
1070	e	O
1070	)	O
1070	doubts	O
1070	on	O
1070	patient	O
1070	compliance	O
1070	.	O
1070	[SEP]	O
1071	[CLS]	O
1071	this	O
1071	trial	O
1071	is	O
1071	funded	O
1071	by	O
1071	the	O
1071	centre	O
1071	for	O
1071	collaborative	O
1071	drug	O
1071	research	O
1071	at	O
1071	the	O
1071	university	O
1071	of	O
1071	to	O
1071	##ron	O
1071	##to	O
1071	,	O
1071	and	O
1071	will	O
1071	be	O
1071	conducted	O
1071	in	O
1071	accordance	O
1071	with	O
1071	the	O
1071	ethical	O
1071	principles	O
1071	outlined	O
1071	by	O
1071	the	O
1071	can	O
1071	##adia	O
1071	##n	O
1071	t	O
1071	##ri	O
1071	-	O
1071	council	O
1071	policy	O
1071	statement	O
1071	:	O
1071	ethical	O
1071	conduct	O
1071	for	O
1071	research	O
1071	involving	O
1071	humans	O
1071	##5	O
1071	##9	O
1071	and	O
1071	the	O
1071	declaration	O
1071	of	O
1071	he	O
1071	##ls	O
1071	##ink	O
1071	##i	O
1071	.	O
1071	[SEP]	O
1072	[CLS]	O
1072	[	O
1072	α	O
1072	]	O
1072	d	O
1072	##20	O
1072	(	O
1072	ch	O
1072	##c	O
1072	##l	O
1072	##3	O
1072	;	O
1072	c	O
1072	=	O
1072	0	O
1072	.	O
1072	02	O
1072	##8	O
1072	)	O
1072	:	O
1072	35	O
1072	.	O
1072	71	O
1072	.	O
1072	[SEP]	O
1073	[CLS]	O
1073	the	O
1073	au	B-PK
1073	##c	I-PK
1073	was	O
1073	also	O
1073	slightly	O
1073	higher	O
1073	in	O
1073	cycle	O
1073	2	O
1073	(	O
1073	mean	O
1073	1689	O
1073	μ	O
1073	##g	O
1073	h	O
1073	m	O
1073	##l	O
1073	##−	O
1073	##1	O
1073	,	O
1073	range	O
1073	49	O
1073	##2	O
1073	–	O
1073	625	O
1073	##7	O
1073	μ	O
1073	##g	O
1073	h	O
1073	m	O
1073	##l	O
1073	##−	O
1073	##1	O
1073	)	O
1073	than	O
1073	in	O
1073	cycle	O
1073	1	O
1073	(	O
1073	mean	O
1073	108	O
1073	##7	O
1073	μ	O
1073	##g	O
1073	h	O
1073	m	O
1073	##l	O
1073	##−	O
1073	##1	O
1073	,	O
1073	range	O
1073	34	O
1073	##3	O
1073	–	O
1073	240	O
1073	##8	O
1073	μ	O
1073	##g	O
1073	h	O
1073	m	O
1073	##l	O
1073	##−	O
1073	##1	O
1073	;	O
1073	p	O
1073	=	O
1073	0	O
1073	.	O
1073	04	O
1073	)	O
1073	.	O
1073	[SEP]	O
1074	[CLS]	O
1074	the	O
1074	z	O
1074	##eta	O
1074	potential	O
1074	method	O
1074	was	O
1074	used	O
1074	to	O
1074	confirm	O
1074	the	O
1074	optimal	O
1074	ratio	O
1074	for	O
1074	formation	O
1074	of	O
1074	ins	O
1074	-	O
1074	s	O
1074	##d	O
1074	-	O
1074	com	O
1074	##p	O
1074	.	O
1074	[SEP]	O
1075	[CLS]	O
1075	human	O
1075	a	O
1075	##po	O
1075	##a	O
1075	-	O
1075	i	O
1075	isolated	O
1075	as	O
1075	previously	O
1075	described	O
1075	[	O
1075	25	O
1075	]	O
1075	was	O
1075	labeled	O
1075	with	O
1075	ale	O
1075	##xa	O
1075	-	O
1075	64	O
1075	##7	O
1075	as	O
1075	per	O
1075	the	O
1075	manufacturer	O
1075	’	O
1075	s	O
1075	instructions	O
1075	(	O
1075	in	O
1075	##vi	O
1075	##tro	O
1075	##gen	O
1075	)	O
1075	.	O
1075	[SEP]	O
1076	[CLS]	O
1076	the	O
1076	p	O
1076	##har	O
1076	##ma	O
1076	##co	O
1076	##kin	O
1076	##etic	O
1076	parameters	O
1076	showed	O
1076	large	O
1076	inter	O
1076	##ind	O
1076	##iv	O
1076	##id	O
1076	##ual	O
1076	variations	O
1076	,	O
1076	with	O
1076	a	O
1076	mean	O
1076	half	B-PK
1076	-	I-PK
1076	life	I-PK
1076	of	O
1076	2	O
1076	h	O
1076	and	O
1076	a	O
1076	mean	O
1076	volume	B-PK
1076	of	I-PK
1076	distribution	I-PK
1076	of	O
1076	0	O
1076	.	O
1076	36	O
1076	l	O
1076	/	O
1076	kg	O
1076	.	O
1076	[SEP]	O
1077	[CLS]	O
1077	1	O
1077	8	O
1077	3	O
1077	3	O
1077	$	O
1077	$	O
1077	\	O
1077	end	O
1077	{	O
1077	document	O
1077	}	O
1077	t	O
1077	##b	O
1077	##v	O
1077	,	O
1077	female	O
1077	=	O
1077	0	O
1077	.	O
1077	35	O
1077	##6	O
1077	##1	O
1077	##∗	O
1077	##he	O
1077	##ight	O
1077	+	O
1077	0	O
1077	.	O
1077	03	O
1077	##30	O
1077	##8	O
1077	##∗	O
1077	##weight	O
1077	+	O
1077	0	O
1077	.	O
1077	1833	O
1077	##where	O
1077	height	O
1077	and	O
1077	weight	O
1077	must	O
1077	be	O
1077	in	O
1077	units	O
1077	of	O
1077	meter	O
1077	and	O
1077	k	O
1077	##ilo	O
1077	##gram	O
1077	but	O
1077	are	O
1077	considered	O
1077	in	O
1077	the	O
1077	formula	O
1077	as	O
1077	unit	O
1077	-	O
1077	less	O
1077	quantities	O
1077	.	O
1077	[SEP]	O
1078	[CLS]	O
1078	the	O
1078	time	O
1078	course	O
1078	of	O
1078	radio	B-PK
1078	##act	I-PK
1078	##ivity	I-PK
1078	in	O
1078	plasma	O
1078	and	O
1078	urine	O
1078	after	O
1078	oral	O
1078	administration	O
1078	of	O
1078	a	O
1078	single	O
1078	dose	O
1078	of	O
1078	(	O
1078	1	O
1078	-	O
1078	14	O
1078	##c	O
1078	)	O
1078	as	O
1078	##cor	O
1078	##bic	O
1078	acid	O
1078	has	O
1078	been	O
1078	followed	O
1078	in	O
1078	healthy	O
1078	non	O
1078	##smo	O
1078	##king	O
1078	male	O
1078	volunteers	O
1078	.	O
1078	[SEP]	O
1079	[CLS]	O
1079	the	O
1079	study	O
1079	was	O
1079	performed	O
1079	in	O
1079	eight	O
1079	patients	O
1079	with	O
1079	re	O
1079	##current	O
1079	g	O
1079	##lio	O
1079	##blast	O
1079	##oma	O
1079	,	O
1079	all	O
1079	of	O
1079	whom	O
1079	had	O
1079	previously	O
1079	undergone	O
1079	surgery	O
1079	and	O
1079	been	O
1079	treated	O
1079	with	O
1079	radio	O
1079	##ther	O
1079	##ap	O
1079	##y	O
1079	and	O
1079	ch	O
1079	##em	O
1079	##otherapy	O
1079	,	O
1079	who	O
1079	received	O
1079	50	O
1079	mg	O
1079	of	O
1079	da	O
1079	##uno	O
1079	##x	O
1079	##ome	O
1079	as	O
1079	a	O
1079	1	O
1079	-	O
1079	h	O
1079	in	O
1079	##fusion	O
1079	.	O
1079	[SEP]	O
1080	[CLS]	O
1080	the	O
1080	p	O
1080	##har	O
1080	##ma	O
1080	##co	O
1080	##kin	O
1080	##etic	O
1080	properties	O
1080	of	O
1080	a	O
1080	new	O
1080	re	O
1080	##comb	O
1080	##ina	O
1080	##nt	O
1080	er	O
1080	##yt	O
1080	##hr	O
1080	##op	O
1080	##oi	O
1080	##eti	O
1080	##n	O
1080	preparation	O
1080	(	O
1080	e	O
1080	##po	O
1080	##eti	O
1080	##n	O
1080	z	O
1080	##eta	O
1080	,	O
1080	ca	O
1080	##s	O
1080	60	O
1080	##48	O
1080	##0	O
1080	##2	O
1080	-	O
1080	70	O
1080	-	O
1080	2	O
1080	)	O
1080	compared	O
1080	to	O
1080	a	O
1080	reference	O
1080	product	O
1080	(	O
1080	e	O
1080	##po	O
1080	##eti	O
1080	##n	O
1080	al	O
1080	##fa	O
1080	,	O
1080	ca	O
1080	##s	O
1080	113	O
1080	##42	O
1080	##7	O
1080	-	O
1080	24	O
1080	-	O
1080	0	O
1080	)	O
1080	were	O
1080	analyzed	O
1080	after	O
1080	a	O
1080	single	O
1080	in	O
1080	##tra	O
1080	##ven	O
1080	##ous	O
1080	b	O
1080	##ol	O
1080	##us	O
1080	injection	O
1080	of	O
1080	10	O
1080	,	O
1080	000	O
1080	i	O
1080	##u	O
1080	in	O
1080	a	O
1080	two	O
1080	-	O
1080	period	O
1080	crossover	O
1080	design	O
1080	in	O
1080	24	O
1080	healthy	O
1080	volunteers	O
1080	.	O
1080	[SEP]	O
1081	[CLS]	O
1081	in	O
1081	bone	O
1081	marker	O
1081	assessments	O
1081	,	O
1081	33	O
1081	of	O
1081	38	O
1081	(	O
1081	87	O
1081	%	O
1081	)	O
1081	and	O
1081	26	O
1081	of	O
1081	34	O
1081	(	O
1081	76	O
1081	%	O
1081	)	O
1081	had	O
1081	decreases	O
1081	in	O
1081	u	O
1081	##rina	O
1081	##ry	O
1081	n	O
1081	-	O
1081	te	O
1081	##lop	O
1081	##eptide	O
1081	or	O
1081	bone	O
1081	-	O
1081	specific	O
1081	al	O
1081	##kal	O
1081	##ine	O
1081	p	O
1081	##hos	O
1081	##pha	O
1081	##tase	O
1081	levels	O
1081	,	O
1081	respectively	O
1081	.	O
1081	[SEP]	O
1082	[CLS]	O
1082	clinical	O
1082	##ly	O
1082	,	O
1082	fever	O
1082	resolved	O
1082	within	O
1082	3	O
1082	days	O
1082	of	O
1082	g	O
1082	##rn	O
1082	##x	O
1082	administration	O
1082	and	O
1082	c	O
1082	-	O
1082	reactive	O
1082	protein	O
1082	levels	O
1082	returned	O
1082	to	O
1082	normal	O
1082	14	O
1082	days	O
1082	after	O
1082	administration	O
1082	.	O
1082	[SEP]	O
1083	[CLS]	O
1083	median	O
1083	p	O
1083	##fs	O
1083	was	O
1083	62	O
1083	days	O
1083	(	O
1083	95	O
1083	%	O
1083	c	O
1083	##i	O
1083	,	O
1083	57	O
1083	to	O
1083	177	O
1083	)	O
1083	in	O
1083	the	O
1083	300	O
1083	mg	O
1083	group	O
1083	and	O
1083	34	O
1083	days	O
1083	(	O
1083	95	O
1083	%	O
1083	c	O
1083	##i	O
1083	,	O
1083	33	O
1083	to	O
1083	37	O
1083	)	O
1083	in	O
1083	the	O
1083	100	O
1083	mg	O
1083	group	O
1083	.	O
1083	[SEP]	O
1084	[CLS]	O
1084	the	O
1084	values	O
1084	for	O
1084	the	O
1084	distribution	B-PK
1084	rate	I-PK
1084	constant	I-PK
1084	##s	I-PK
1084	as	O
1084	well	O
1084	as	O
1084	for	O
1084	the	O
1084	elimination	B-PK
1084	half	I-PK
1084	-	I-PK
1084	lives	I-PK
1084	of	O
1084	the	O
1084	two	O
1084	en	O
1084	##anti	O
1084	##omer	O
1084	##s	O
1084	were	O
1084	similar	O
1084	but	O
1084	the	O
1084	au	B-PK
1084	##c	I-PK
1084	of	O
1084	the	O
1084	s	O
1084	-	O
1084	(	O
1084	+	O
1084	)	O
1084	-	O
1084	en	O
1084	##anti	O
1084	##omer	O
1084	was	O
1084	always	O
1084	significantly	O
1084	higher	O
1084	(	O
1084	p	O
1084	less	O
1084	than	O
1084	0	O
1084	.	O
1084	01	O
1084	)	O
1084	than	O
1084	that	O
1084	of	O
1084	the	O
1084	opposite	O
1084	en	O
1084	##anti	O
1084	##omer	O
1084	.	O
1084	[SEP]	O
1085	[CLS]	O
1085	g	O
1085	##c	O
1085	and	O
1085	m	O
1085	##c	O
1085	transcription	O
1085	##al	O
1085	activity	O
1085	was	O
1085	tested	O
1085	by	O
1085	l	O
1085	##uc	O
1085	##ifer	O
1085	##ase	O
1085	ass	O
1085	##ay	O
1085	in	O
1085	c	O
1085	##v	O
1085	-	O
1085	1	O
1085	cells	O
1085	trans	O
1085	##fected	O
1085	with	O
1085	human	O
1085	g	O
1085	##c	O
1085	or	O
1085	m	O
1085	##c	O
1085	receptor	O
1085	expression	O
1085	vectors	O
1085	.	O
1085	[SEP]	O
1086	[CLS]	O
1086	the	O
1086	most	O
1086	common	O
1086	nervous	O
1086	system	O
1086	disorder	O
1086	was	O
1086	headache	O
1086	,	O
1086	with	O
1086	a	O
1086	total	O
1086	of	O
1086	15	O
1086	mild	O
1086	tea	O
1086	##es	O
1086	reported	O
1086	by	O
1086	11	O
1086	subjects	O
1086	overall	O
1086	(	O
1086	19	O
1086	.	O
1086	6	O
1086	%	O
1086	)	O
1086	.	O
1086	[SEP]	O
1087	[CLS]	O
1087	p	O
1087	##har	O
1087	##ma	O
1087	##co	O
1087	##kin	O
1087	##etics	O
1087	of	O
1087	b	O
1087	##c	O
1087	##p	O
1087	in	O
1087	man	O
1087	following	O
1087	oral	O
1087	administration	O
1087	.	O
1087	[SEP]	O
1088	[CLS]	O
1088	comparison	O
1088	of	O
1088	the	O
1088	release	O
1088	profile	O
1088	and	O
1088	p	O
1088	##har	O
1088	##ma	O
1088	##co	O
1088	##kin	O
1088	##etics	O
1088	of	O
1088	intact	O
1088	and	O
1088	fragment	O
1088	##ed	O
1088	de	O
1088	##xa	O
1088	##met	O
1088	##has	O
1088	##one	O
1088	in	O
1088	##tra	O
1088	##vi	O
1088	##tre	O
1088	##al	O
1088	imp	O
1088	##lants	O
1088	in	O
1088	rabbit	O
1088	eyes	O
1088	.	O
1088	[SEP]	O
1089	[CLS]	O
1089	this	O
1089	is	O
1089	particularly	O
1089	true	O
1089	with	O
1089	c	O
1089	##d	O
1089	##47	O
1089	,	O
1089	which	O
1089	is	O
1089	expressed	O
1089	on	O
1089	virtually	O
1089	every	O
1089	cell	O
1089	.	O
1089	[SEP]	O
1090	[CLS]	O
1090	to	O
1090	test	O
1090	the	O
1090	hypothesis	O
1090	that	O
1090	oral	O
1090	administration	O
1090	of	O
1090	a	O
1090	##c	O
1090	might	O
1090	have	O
1090	a	O
1090	beneficial	O
1090	effect	O
1090	on	O
1090	the	O
1090	outcome	O
1090	of	O
1090	severe	O
1090	malaria	O
1090	,	O
1090	we	O
1090	used	O
1090	the	O
1090	model	O
1090	of	O
1090	e	O
1090	##c	O
1090	##m	O
1090	caused	O
1090	by	O
1090	p	O
1090	##las	O
1090	##mo	O
1090	##dium	O
1090	be	O
1090	##rg	O
1090	##he	O
1090	##i	O
1090	an	O
1090	##ka	O
1090	(	O
1090	p	O
1090	##ba	O
1090	)	O
1090	infection	O
1090	in	O
1090	c	O
1090	##5	O
1090	##7	O
1090	##b	O
1090	##l	O
1090	/	O
1090	6	O
1090	mice	O
1090	.	O
1090	[SEP]	O
1091	[CLS]	O
1091	the	O
1091	results	O
1091	showed	O
1091	that	O
1091	the	O
1091	total	O
1091	concentration	O
1091	of	O
1091	all	O
1091	the	O
1091	anal	O
1091	##yte	O
1091	##s	O
1091	(	O
1091	range	O
1091	,	O
1091	200	O
1091	–	O
1091	2000	O
1091	ng	O
1091	/	O
1091	m	O
1091	##l	O
1091	)	O
1091	in	O
1091	human	O
1091	plasma	O
1091	samples	O
1091	was	O
1091	stable	O
1091	throughout	O
1091	the	O
1091	duration	O
1091	of	O
1091	a	O
1091	typical	O
1091	sequence	O
1091	of	O
1091	ch	O
1091	##roma	O
1091	##to	O
1091	##graphic	O
1091	analyses	O
1091	and	O
1091	for	O
1091	at	O
1091	least	O
1091	two	O
1091	months	O
1091	of	O
1091	storage	O
1091	at	O
1091	−	O
1091	##80	O
1091	##°	O
1091	##c	O
1091	as	O
1091	well	O
1091	as	O
1091	after	O
1091	two	O
1091	cycles	O
1091	of	O
1091	th	O
1091	##aw	O
1091	-	O
1091	freeze	O
1091	.	O
1091	[SEP]	O
1092	[CLS]	O
1092	safety	O
1092	data	O
1092	were	O
1092	presented	O
1092	in	O
1092	ta	O
1092	##bula	O
1092	##r	O
1092	format	O
1092	and	O
1092	summarized	O
1092	descriptive	O
1092	##ly	O
1092	,	O
1092	where	O
1092	appropriate	O
1092	.	O
1092	[SEP]	O
1093	[CLS]	O
1093	however	O
1093	,	O
1093	the	O
1093	most	O
1093	significant	O
1093	increase	O
1093	in	O
1093	plasma	O
1093	oxygen	O
1093	transport	O
1093	took	O
1093	place	O
1093	in	O
1093	patients	O
1093	supplemented	O
1093	with	O
1093	l	O
1093	##y	O
1093	##cos	O
1093	##ome	O
1093	formulation	O
1093	of	O
1093	d	O
1093	##ha	O
1093	when	O
1093	median	O
1093	##s	O
1093	of	O
1093	plasma	O
1093	oxygen	O
1093	transport	O
1093	spike	O
1093	##d	O
1093	by	O
1093	45	O
1093	##4	O
1093	points	O
1093	.	O
1093	[SEP]	O
1094	[CLS]	O
1094	m	O
1094	##z	O
1094	##mine	O
1094	software	O
1094	v	O
1094	##2	O
1094	.	O
1094	2	O
1094	(	O
1094	ok	O
1094	##ina	O
1094	##wa	O
1094	institute	O
1094	of	O
1094	science	O
1094	and	O
1094	technology	O
1094	)	O
1094	was	O
1094	used	O
1094	to	O
1094	identify	O
1094	##fe	O
1094	##ature	O
1094	##s	O
1094	characterized	O
1094	by	O
1094	retention	O
1094	time	O
1094	and	O
1094	m	O
1094	/	O
1094	z	O
1094	from	O
1094	each	O
1094	l	O
1094	##c	O
1094	/	O
1094	m	O
1094	##s	O
1094	run	O
1094	and	O
1094	to	O
1094	assign	O
1094	##amp	O
1094	##lit	O
1094	##udes	O
1094	to	O
1094	these	O
1094	features	O
1094	based	O
1094	on	O
1094	integration	O
1094	of	O
1094	the	O
1094	ion	O
1094	current	O
1094	values	O
1094	(	O
1094	37	O
1094	)	O
1094	.	O
1094	[SEP]	O
1095	[CLS]	O
1095	the	O
1095	p	O
1095	##har	O
1095	##ma	O
1095	##co	O
1095	##kin	O
1095	##etics	O
1095	and	O
1095	tissue	O
1095	distribution	O
1095	of	O
1095	q	O
1095	##3	O
1095	##g	O
1095	is	O
1095	limited	O
1095	.	O
1095	[SEP]	O
1096	[CLS]	O
1096	concentrations	O
1096	of	O
1096	pre	O
1096	##dn	O
1096	##is	O
1096	##olo	O
1096	##ne	O
1096	and	O
1096	co	O
1096	##rt	O
1096	##is	O
1096	##ol	O
1096	in	O
1096	plasma	O
1096	over	O
1096	a	O
1096	24	O
1096	-	O
1096	h	O
1096	##r	O
1096	test	O
1096	period	O
1096	were	O
1096	measured	O
1096	by	O
1096	high	O
1096	-	O
1096	performance	O
1096	liquid	O
1096	ch	O
1096	##roma	O
1096	##tography	O
1096	.	O
1096	[SEP]	O
1097	[CLS]	O
1097	the	O
1097	greater	O
1097	negative	O
1097	bias	O
1097	found	O
1097	for	O
1097	the	O
1097	latter	O
1097	three	O
1097	estimates	O
1097	of	O
1097	car	O
1097	##bo	O
1097	##p	O
1097	##lat	O
1097	##in	O
1097	clearance	B-PK
1097	could	O
1097	result	O
1097	in	O
1097	under	O
1097	##dos	O
1097	##ing	O
1097	of	O
1097	car	O
1097	##bo	O
1097	##p	O
1097	##lat	O
1097	##in	O
1097	.	O
1097	[SEP]	O
1098	[CLS]	O
1098	the	O
1098	blood	O
1098	sample	O
1098	was	O
1098	collected	O
1098	at	O
1098	2	O
1098	,	O
1098	5	O
1098	,	O
1098	15	O
1098	,	O
1098	and	O
1098	30	O
1098	min	O
1098	as	O
1098	well	O
1098	as	O
1098	1	O
1098	,	O
1098	2	O
1098	,	O
1098	4	O
1098	,	O
1098	and	O
1098	6	O
1098	h	O
1098	post	O
1098	-	O
1098	dose	O
1098	,	O
1098	and	O
1098	a	O
1098	single	O
1098	blood	O
1098	sample	O
1098	was	O
1098	collected	O
1098	from	O
1098	a	O
1098	single	O
1098	mouse	O
1098	.	O
1098	[SEP]	O
1099	[CLS]	O
1099	still	O
1099	,	O
1099	all	O
1099	strains	O
1099	were	O
1099	estimated	O
1099	to	O
1099	have	O
1099	a	O
1099	greater	O
1099	metabolic	O
1099	flux	O
1099	through	O
1099	oxidation	O
1099	compared	O
1099	with	O
1099	g	O
1099	##lut	O
1099	##ath	O
1099	##ione	O
1099	con	O
1099	##ju	O
1099	##gation	O
1099	;	O
1099	median	O
1099	estimates	O
1099	for	O
1099	their	O
1099	ratio	O
1099	varied	O
1099	about	O
1099	30	O
1099	-	O
1099	fold	O
1099	(	O
1099	from	O
1099	620	O
1099	to	O
1099	19	O
1099	,	O
1099	000	O
1099	)	O
1099	.	O
1099	[SEP]	O
1100	[CLS]	O
1100	this	O
1100	treatment	O
1100	cycle	O
1100	was	O
1100	repeated	O
1100	every	O
1100	4	O
1100	weeks	O
1100	until	O
1100	disease	O
1100	progression	O
1100	or	O
1100	an	O
1100	unacceptable	O
1100	toxicity	O
1100	was	O
1100	observed	O
1100	.	O
1100	[SEP]	O
1101	[CLS]	O
1101	there	O
1101	were	O
1101	no	O
1101	dose	O
1101	-	O
1101	limiting	O
1101	toxic	O
1101	##ities	O
1101	(	O
1101	d	O
1101	##lts	O
1101	)	O
1101	in	O
1101	co	O
1101	##hor	O
1101	##ts	O
1101	1	O
1101	-	O
1101	3	O
1101	.	O
1101	[SEP]	O
1102	[CLS]	O
1102	after	O
1102	drying	O
1102	the	O
1102	organic	O
1102	layer	O
1102	over	O
1102	sodium	O
1102	su	O
1102	##lf	O
1102	##ate	O
1102	,	O
1102	the	O
1102	##vo	O
1102	##lat	O
1102	##iles	O
1102	were	O
1102	removed	O
1102	under	O
1102	reduced	O
1102	pressure	O
1102	,	O
1102	fur	O
1102	##nish	O
1102	##ing	O
1102	the	O
1102	product	O
1102	##as	O
1102	yellowish	O
1102	oil	O
1102	.	O
1102	[SEP]	O
1103	[CLS]	O
1103	p	O
1103	##har	O
1103	##ma	O
1103	##co	O
1103	##kin	O
1103	##etic	O
1103	analysis	O
1103	revealed	O
1103	first	O
1103	-	O
1103	order	O
1103	kinetic	O
1103	##s	O
1103	for	O
1103	the	O
1103	clearance	B-PK
1103	of	O
1103	a	O
1103	##po	O
1103	##b	O
1103	-	O
1103	48	O
1103	in	O
1103	d	O
1103	<	O
1103	1	O
1103	.	O
1103	00	O
1103	##6	O
1103	g	O
1103	/	O
1103	m	O
1103	##l	O
1103	fraction	O
1103	##s	O
1103	,	O
1103	but	O
1103	zero	O
1103	-	O
1103	order	O
1103	kinetic	O
1103	##s	O
1103	for	O
1103	a	O
1103	##po	O
1103	##b	O
1103	-	O
1103	100	O
1103	clearance	B-PK
1103	.	O
1103	[SEP]	O
1104	[CLS]	O
1104	m	O
1104	##or	O
1104	##phine	O
1104	was	O
1104	administered	O
1104	in	O
1104	a	O
1104	series	O
1104	of	O
1104	b	O
1104	##ol	O
1104	##us	O
1104	doses	O
1104	until	O
1104	p	O
1104	##aco	O
1104	##2	O
1104	was	O
1104	elevated	O
1104	greater	O
1104	than	O
1104	50	O
1104	mm	O
1104	h	O
1104	##g	O
1104	.	O
1104	[SEP]	O
1105	[CLS]	O
1105	fortification	O
1105	of	O
1105	common	O
1105	salt	O
1105	with	O
1105	iron	O
1105	:	O
1105	effect	O
1105	of	O
1105	chemical	O
1105	add	O
1105	##itive	O
1105	##s	O
1105	on	O
1105	stability	O
1105	and	O
1105	bio	B-PK
1105	##ava	I-PK
1105	##ila	I-PK
1105	##bility	I-PK
1105	.	O
1105	[SEP]	O
1106	[CLS]	O
1106	with	O
1106	the	O
1106	recent	O
1106	findings	O
1106	that	O
1106	clinical	O
1106	outcomes	O
1106	are	O
1106	related	O
1106	to	O
1106	c	O
1106	##ep	O
1106	##m	O
1106	au	B-PK
1106	##c	I-PK
1106	,	O
1106	further	O
1106	data	O
1106	are	O
1106	needed	O
1106	regarding	O
1106	the	O
1106	p	O
1106	##har	O
1106	##ma	O
1106	##co	O
1106	##kin	O
1106	##etics	O
1106	of	O
1106	c	O
1106	##y	O
1106	##c	O
1106	##lop	O
1106	##hos	O
1106	##pha	O
1106	##mi	O
1106	##de	O
1106	and	O
1106	relevant	O
1106	meta	O
1106	##bol	O
1106	##ites	O
1106	in	O
1106	an	O
1106	##ep	O
1106	##hr	O
1106	##ic	O
1106	children	O
1106	.	O
1106	[SEP]	O
1107	[CLS]	O
1107	the	O
1107	e	O
1107	##2	O
1107	/	O
1107	e	O
1107	##1	O
1107	ratio	O
1107	increased	O
1107	from	O
1107	the	O
1107	post	O
1107	##men	O
1107	##op	O
1107	##aus	O
1107	##al	O
1107	values	O
1107	lower	O
1107	than	O
1107	0	O
1107	.	O
1107	2	O
1107	found	O
1107	before	O
1107	the	O
1107	application	O
1107	of	O
1107	patch	O
1107	7	O
1107	##d	O
1107	to	O
1107	average	O
1107	values	O
1107	of	O
1107	0	O
1107	.	O
1107	67	O
1107	,	O
1107	i	O
1107	.	O
1107	e	O
1107	.	O
1107	,	O
1107	to	O
1107	values	O
1107	that	O
1107	are	O
1107	normally	O
1107	found	O
1107	during	O
1107	the	O
1107	fertile	O
1107	life	O
1107	of	O
1107	the	O
1107	woman	O
1107	.	O
1107	[SEP]	O
1108	[CLS]	O
1108	s	O
1108	##r	O
1108	is	O
1108	considered	O
1108	advantage	O
1108	##ous	O
1108	to	O
1108	i	O
1108	##r	O
1108	for	O
1108	the	O
1108	chronic	O
1108	treatment	O
1108	of	O
1108	h	O
1108	##yper	O
1108	##tensive	O
1108	patients	O
1108	.	O
1108	[SEP]	O
1109	[CLS]	O
1109	response	O
1109	to	O
1109	met	O
1109	##had	O
1109	##one	O
1109	maintenance	O
1109	treatment	O
1109	is	O
1109	associated	O
1109	with	O
1109	the	O
1109	my	O
1109	##oc	O
1109	##d	O
1109	and	O
1109	g	O
1109	##rm	O
1109	##6	O
1109	genes	O
1109	.	O
1109	[SEP]	O
1110	[CLS]	O
1110	the	O
1110	ca	O
1110	##li	O
1110	##bra	O
1110	##tion	O
1110	curve	O
1110	was	O
1110	obtained	O
1110	by	O
1110	plotting	O
1110	the	O
1110	ratio	O
1110	of	O
1110	the	O
1110	ch	O
1110	##roma	O
1110	##to	O
1110	##graphic	O
1110	peak	O
1110	area	O
1110	(	O
1110	met	O
1110	##form	O
1110	##in	O
1110	h	O
1110	##c	O
1110	##l	O
1110	)	O
1110	versus	O
1110	concentration	O
1110	of	O
1110	met	O
1110	##form	O
1110	##in	O
1110	h	O
1110	##c	O
1110	##l	O
1110	.	O
1110	[SEP]	O
1111	[CLS]	O
1111	however	O
1111	,	O
1111	limited	O
1111	progress	O
1111	has	O
1111	been	O
1111	made	O
1111	##in	O
1111	developing	O
1111	m	O
1111	##s	O
1111	##n	O
1111	-	O
1111	based	O
1111	multi	O
1111	##mo	O
1111	##dal	O
1111	##ity	O
1111	imaging	O
1111	agents	O
1111	to	O
1111	image	O
1111	tumors	O
1111	.	O
1111	[SEP]	O
1112	[CLS]	O
1112	concentration	O
1112	-	O
1112	effect	O
1112	and	O
1112	time	O
1112	-	O
1112	course	O
1112	studies	O
1112	were	O
1112	performed	O
1112	in	O
1112	the	O
1112	presence	O
1112	of	O
1112	free	O
1112	l	O
1112	##y	O
1112	,	O
1112	s	O
1112	##f	O
1112	n	O
1112	##ps	O
1112	,	O
1112	and	O
1112	s	O
1112	##f	O
1112	-	O
1112	l	O
1112	##y	O
1112	n	O
1112	##ps	O
1112	.	O
1112	[SEP]	O
1113	[CLS]	O
1113	statistical	O
1113	analysis	O
1113	was	O
1113	performed	O
1113	using	O
1113	k	O
1113	##rus	O
1113	##kal	O
1113	–	O
1113	wall	O
1113	##is	O
1113	one	O
1113	-	O
1113	way	O
1113	analysis	O
1113	of	O
1113	variance	O
1113	.	O
1113	[SEP]	O
1114	[CLS]	O
1114	following	O
1114	##eth	O
1114	##yl	O
1114	ace	O
1114	##tate	O
1114	extraction	O
1114	and	O
1114	re	O
1114	##con	O
1114	##st	O
1114	##itution	O
1114	with	O
1114	50	O
1114	:	O
1114	50	O
1114	met	O
1114	##han	O
1114	##ol	O
1114	/	O
1114	water	O
1114	(	O
1114	v	O
1114	/	O
1114	v	O
1114	)	O
1114	used	O
1114	for	O
1114	am	O
1114	##s	O
1114	analysis	O
1114	(	O
1114	described	O
1114	below	O
1114	)	O
1114	,	O
1114	the	O
1114	recovery	O
1114	was	O
1114	51	O
1114	##±	O
1114	10	O
1114	%	O
1114	(	O
1114	n	O
1114	=	O
1114	3	O
1114	)	O
1114	as	O
1114	determined	O
1114	by	O
1114	am	O
1114	##s	O
1114	.	O
1114	[SEP]	O
1115	[CLS]	O
1115	the	O
1115	full	O
1115	co	O
1115	##var	O
1115	##iate	O
1115	model	O
1115	including	O
1115	all	O
1115	plausible	O
1115	co	O
1115	##var	O
1115	##iate	O
1115	##s	O
1115	included	O
1115	in	O
1115	a	O
1115	single	O
1115	step	O
1115	showed	O
1115	no	O
1115	impact	O
1115	on	O
1115	s	O
1115	##ym	O
1115	##00	O
1115	##4	O
1115	exposure	O
1115	of	O
1115	age	O
1115	,	O
1115	as	O
1115	##ian	O
1115	race	O
1115	,	O
1115	re	O
1115	##nal	O
1115	and	O
1115	he	O
1115	##pa	O
1115	##tic	O
1115	function	O
1115	,	O
1115	tumor	O
1115	type	O
1115	and	O
1115	previous	O
1115	anti	O
1115	-	O
1115	e	O
1115	##g	O
1115	##f	O
1115	##r	O
1115	treatments	O
1115	.	O
1115	[SEP]	O
1116	[CLS]	O
1116	these	O
1116	results	O
1116	suggest	O
1116	that	O
1116	i	O
1116	##p	O
1116	injection	O
1116	might	O
1116	decrease	O
1116	the	O
1116	systemic	O
1116	toxicity	O
1116	of	O
1116	p	O
1116	##ac	O
1116	##lit	O
1116	##ax	O
1116	##el	O
1116	.	O
1116	[SEP]	O
1117	[CLS]	O
1117	the	O
1117	(	O
1117	au	B-PK
1117	##c	I-PK
1117	##0	I-PK
1117	-	I-PK
1117	in	I-PK
1117	##f	I-PK
1117	)	O
1117	and	O
1117	c	O
1117	##30	O
1117	##s	O
1117	of	O
1117	c	O
1117	##11	O
1117	##8	O
1117	##p	O
1117	at	O
1117	50	O
1117	mg	O
1117	/	O
1117	kg	O
1117	in	O
1117	rats	O
1117	and	O
1117	6	O
1117	mg	O
1117	/	O
1117	kg	O
1117	in	O
1117	dogs	O
1117	,	O
1117	and	O
1117	the	O
1117	c	O
1117	##2	O
1117	##min	O
1117	of	O
1117	c	O
1117	##11	O
1117	##8	O
1117	at	O
1117	6	O
1117	mg	O
1117	/	O
1117	kg	O
1117	in	O
1117	dogs	O
1117	increased	O
1117	less	O
1117	than	O
1117	the	O
1117	dos	O
1117	##age	O
1117	increase	O
1117	,	O
1117	suggested	O
1117	non	O
1117	##linear	O
1117	p	O
1117	##har	O
1117	##ma	O
1117	##co	O
1117	##kin	O
1117	##etic	O
1117	occurred	O
1117	at	O
1117	high	O
1117	dose	O
1117	.	O
1117	[SEP]	O
1118	[CLS]	O
1118	in	O
1118	the	O
1118	new	O
1118	era	O
1118	of	O
1118	effective	O
1118	maintenance	O
1118	im	O
1118	##mu	O
1118	##nos	O
1118	##up	O
1118	##press	O
1118	##ion	O
1118	,	O
1118	a	O
1118	limited	O
1118	dos	O
1118	##ing	O
1118	regime	O
1118	##n	O
1118	of	O
1118	da	O
1118	##c	O
1118	##li	O
1118	##zu	O
1118	##ma	O
1118	##b	O
1118	may	O
1118	be	O
1118	desired	O
1118	,	O
1118	practical	O
1118	and	O
1118	economical	O
1118	.	O
1118	[SEP]	O
1119	[CLS]	O
1119	the	O
1119	model	O
1119	was	O
1119	developed	O
1119	using	O
1119	a	O
1119	three	O
1119	-	O
1119	step	O
1119	approach	O
1119	involving	O
1119	bay	O
1119	##esi	O
1119	##an	O
1119	est	O
1119	##imation	O
1119	of	O
1119	p	O
1119	##har	O
1119	##ma	O
1119	##co	O
1119	##kin	O
1119	##etic	O
1119	parameters	O
1119	,	O
1119	selection	O
1119	of	O
1119	co	O
1119	##var	O
1119	##iate	O
1119	##s	O
1119	by	O
1119	principal	O
1119	component	O
1119	analysis	O
1119	,	O
1119	and	O
1119	final	O
1119	selection	O
1119	of	O
1119	co	O
1119	##var	O
1119	##iate	O
1119	##s	O
1119	by	O
1119	step	O
1119	##wise	O
1119	multiple	O
1119	linear	O
1119	re	O
1119	##gression	O
1119	.	O
1119	[SEP]	O
1120	[CLS]	O
1120	ass	O
1120	##ay	O
1120	linear	O
1120	##ity	O
1120	was	O
1120	verified	O
1120	for	O
1120	v	O
1120	##rd	O
1120	at	O
1120	a	O
1120	concentration	O
1120	range	O
1120	of	O
1120	3	O
1120	–	O
1120	350	O
1120	ng	O
1120	/	O
1120	m	O
1120	##l	O
1120	with	O
1120	re	O
1120	##gression	O
1120	coefficients	O
1120	(	O
1120	r	O
1120	##2	O
1120	)	O
1120	of	O
1120	0	O
1120	.	O
1120	99	O
1120	##6	O
1120	and	O
1120	0	O
1120	.	O
1120	99	O
1120	##4	O
1120	for	O
1120	v	O
1120	##rd	O
1120	.	O
1120	[SEP]	O
1121	[CLS]	O
1121	the	O
1121	final	O
1121	model	O
1121	was	O
1121	able	O
1121	to	O
1121	accurately	O
1121	describe	O
1121	c	O
1121	##ef	O
1121	##uro	O
1121	##xi	O
1121	##me	O
1121	exposure	O
1121	after	O
1121	b	O
1121	##ol	O
1121	##us	O
1121	and	O
1121	extended	O
1121	in	O
1121	##fusion	O
1121	##s	O
1121	for	O
1121	the	O
1121	literature	O
1121	c	O
1121	##t	O
1121	curves	O
1121	.	O
1121	[SEP]	O
1122	[CLS]	O
1122	do	O
1122	##pa	O
1122	##mine	O
1122	concentrations	O
1122	were	O
1122	all	O
1122	below	O
1122	the	O
1122	limit	O
1122	of	O
1122	detection	O
1122	.	O
1122	[SEP]	O
1123	[CLS]	O
1123	ne	O
1123	##vir	O
1123	##ap	O
1123	##ine	O
1123	(	O
1123	n	O
1123	##v	O
1123	##p	O
1123	)	O
1123	is	O
1123	a	O
1123	key	O
1123	component	O
1123	of	O
1123	anti	O
1123	##ret	O
1123	##rov	O
1123	##ira	O
1123	##l	O
1123	prop	O
1123	##hyl	O
1123	##ax	O
1123	##is	O
1123	and	O
1123	treatment	O
1123	for	O
1123	neon	O
1123	##ates	O
1123	.	O
1123	[SEP]	O
1124	[CLS]	O
1124	we	O
1124	also	O
1124	compared	O
1124	se	O
1124	##ns	O
1124	##iti	O
1124	##vi	O
1124	##ties	O
1124	and	O
1124	specific	O
1124	##ities	O
1124	by	O
1124	gender	O
1124	,	O
1124	using	O
1124	an	O
1124	interaction	O
1124	term	O
1124	in	O
1124	generalized	O
1124	est	O
1124	##imating	O
1124	equations	O
1124	with	O
1124	a	O
1124	bin	O
1124	##omi	O
1124	##al	O
1124	distribution	O
1124	to	O
1124	account	O
1124	for	O
1124	repeated	O
1124	observations	O
1124	.	O
1124	[SEP]	O
1125	[CLS]	O
1125	briefly	O
1125	,	O
1125	each	O
1125	p	O
1125	##c	O
1125	##r	O
1125	reaction	O
1125	contained	O
1125	1	O
1125	μ	O
1125	##l	O
1125	of	O
1125	d	O
1125	##na	O
1125	template	O
1125	and	O
1125	15	O
1125	pm	O
1125	of	O
1125	each	O
1125	prime	O
1125	##r	O
1125	as	O
1125	well	O
1125	as	O
1125	2	O
1125	μ	O
1125	##l	O
1125	of	O
1125	5	O
1125	##×	O
1125	hot	O
1125	fire	O
1125	##pole	O
1125	##va	O
1125	##green	O
1125	q	O
1125	##p	O
1125	##c	O
1125	##r	O
1125	mix	O
1125	plus	O
1125	in	O
1125	a	O
1125	final	O
1125	volume	O
1125	of	O
1125	10	O
1125	μ	O
1125	##l	O
1125	.	O
1125	[SEP]	O
1126	[CLS]	O
1126	the	O
1126	t	O
1126	##ci	O
1126	was	O
1126	given	O
1126	by	O
1126	a	O
1126	ha	O
1126	##rva	O
1126	##rd	O
1126	22	O
1126	pump	O
1126	controlled	O
1126	by	O
1126	s	O
1126	##tan	O
1126	##pu	O
1126	##mp	O
1126	software	O
1126	running	O
1126	on	O
1126	a	O
1126	personal	O
1126	computer	O
1126	.	O
1126	[SEP]	O
1127	[CLS]	O
1127	protein	O
1127	##ase	O
1127	k	O
1127	l	O
1127	##ys	O
1127	##is	O
1127	buffer	O
1127	was	O
1127	prepared	O
1127	by	O
1127	adding	O
1127	2	O
1127	%	O
1127	(	O
1127	v	O
1127	/	O
1127	v	O
1127	)	O
1127	protein	O
1127	##ase	O
1127	k	O
1127	(	O
1127	life	O
1127	technologies	O
1127	car	O
1127	##ls	O
1127	##bad	O
1127	,	O
1127	ca	O
1127	)	O
1127	to	O
1127	epic	O
1127	##ent	O
1127	##re	O
1127	tissue	O
1127	and	O
1127	cell	O
1127	l	O
1127	##ys	O
1127	##is	O
1127	solution	O
1127	for	O
1127	master	O
1127	##pur	O
1127	##e	O
1127	kit	O
1127	(	O
1127	epic	O
1127	##ent	O
1127	##re	O
1127	,	O
1127	mad	O
1127	##ison	O
1127	,	O
1127	w	O
1127	##i	O
1127	,	O
1127	us	O
1127	##a	O
1127	)	O
1127	.	O
1127	[SEP]	O
1128	[CLS]	O
1128	the	O
1128	major	O
1128	pathways	O
1128	of	O
1128	metabolism	O
1128	of	O
1128	delta	O
1128	4	O
1128	-	O
1128	v	O
1128	##pa	O
1128	were	O
1128	found	O
1128	to	O
1128	be	O
1128	est	O
1128	##er	O
1128	g	O
1128	##lu	O
1128	##cu	O
1128	##ron	O
1128	##ide	O
1128	formation	O
1128	and	O
1128	beta	O
1128	-	O
1128	oxidation	O
1128	,	O
1128	whereas	O
1128	o	O
1128	##me	O
1128	##ga	O
1128	-	O
1128	and	O
1128	(	O
1128	o	O
1128	##me	O
1128	##ga	O
1128	-	O
1128	1	O
1128	)	O
1128	-	O
1128	oxidation	O
1128	processes	O
1128	were	O
1128	of	O
1128	minor	O
1128	quantitative	O
1128	importance	O
1128	.	O
1128	[SEP]	O
1129	[CLS]	O
1129	in	O
1129	urine	O
1129	,	O
1129	the	O
1129	p	O
1129	##hage	O
1129	survival	O
1129	was	O
1129	decreased	O
1129	by	O
1129	44	O
1129	%	O
1129	after	O
1129	5	O
1129	min	O
1129	of	O
1129	in	O
1129	##cu	O
1129	##bation	O
1129	(	O
1129	p	O
1129	=	O
1129	0	O
1129	.	O
1129	00	O
1129	##4	O
1129	)	O
1129	.	O
1129	[SEP]	O
1130	[CLS]	O
1130	the	O
1130	final	O
1130	concentration	O
1130	of	O
1130	t	O
1130	##rc	O
1130	##10	O
1130	##5	O
1130	(	O
1130	f	O
1130	##ab	O
1130	)	O
1130	-	O
1130	s	O
1130	##h	O
1130	was	O
1130	found	O
1130	##to	O
1130	be	O
1130	about	O
1130	1	O
1130	.	O
1130	7	O
1130	mg	O
1130	/	O
1130	m	O
1130	##l	O
1130	(	O
1130	[UNK]	O
1130	μ	O
1130	##l	O
1130	)	O
1130	.	O
1130	[SEP]	O
1131	[CLS]	O
1131	the	O
1131	scan	O
1131	showed	O
1131	maximum	O
1131	absorb	O
1131	##ance	O
1131	at	O
1131	34	O
1131	##1	O
1131	nm	O
1131	,	O
1131	which	O
1131	was	O
1131	selected	O
1131	as	O
1131	the	O
1131	working	O
1131	##wave	O
1131	##len	O
1131	##gth	O
1131	for	O
1131	the	O
1131	detector	O
1131	of	O
1131	hp	O
1131	##l	O
1131	##c	O
1131	.	O
1131	[SEP]	O
1132	[CLS]	O
1132	this	O
1132	observation	O
1132	suggests	O
1132	that	O
1132	the	O
1132	killing	O
1132	function	O
1132	with	O
1132	the	O
1132	greatest	O
1132	p	O
1132	##har	O
1132	##ma	O
1132	##co	O
1132	##dy	O
1132	##ami	O
1132	##c	O
1132	impact	O
1132	for	O
1132	da	O
1132	##pt	O
1132	##omy	O
1132	##cin	O
1132	is	O
1132	the	O
1132	in	O
1132	##hibition	O
1132	of	O
1132	the	O
1132	probability	O
1132	of	O
1132	successful	O
1132	replication	O
1132	.	O
1132	[SEP]	O
1133	[CLS]	O
1133	the	O
1133	best	O
1133	anti	O
1133	##tum	O
1133	##or	O
1133	activity	O
1133	,	O
1133	with	O
1133	more	O
1133	than	O
1133	50	O
1133	%	O
1133	of	O
1133	treated	O
1133	animals	O
1133	cured	O
1133	,	O
1133	was	O
1133	achieved	O
1133	with	O
1133	2	O
1133	lo	O
1133	##core	O
1133	##gion	O
1133	##al	O
1133	treatments	O
1133	of	O
1133	in	O
1133	##tra	O
1133	##per	O
1133	##ito	O
1133	##nea	O
1133	##lly	O
1133	growing	O
1133	tumors	O
1133	on	O
1133	days	O
1133	2	O
1133	and	O
1133	9	O
1133	.	O
1133	[SEP]	O
1134	[CLS]	O
1134	the	O
1134	mean	O
1134	n	O
1134	##tz	O
1134	mi	O
1134	##c	O
1134	for	O
1134	my	O
1134	##co	O
1134	##ba	O
1134	##cter	O
1134	##ium	O
1134	tuberculosis	O
1134	is	O
1134	##olate	O
1134	##s	O
1134	was	O
1134	12	O
1134	.	O
1134	3	O
1134	μ	O
1134	##g	O
1134	/	O
1134	m	O
1134	##l	O
1134	;	O
1134	the	O
1134	mean	O
1134	n	O
1134	##tz	O
1134	maximum	B-PK
1134	concentration	I-PK
1134	(	I-PK
1134	cm	I-PK
1134	##ax	I-PK
1134	)	I-PK
1134	in	I-PK
1134	plasma	I-PK
1134	was	O
1134	10	O
1134	.	O
1134	2	O
1134	μ	O
1134	##g	O
1134	/	O
1134	m	O
1134	##l	O
1134	.	O
1134	[SEP]	O
1135	[CLS]	O
1135	these	O
1135	are	O
1135	largely	O
1135	a	O
1135	result	O
1135	of	O
1135	poor	O
1135	c	O
1135	##d	O
1135	p	O
1135	##har	O
1135	##ma	O
1135	##co	O
1135	##kin	O
1135	##etics	O
1135	and	O
1135	bio	B-PK
1135	##ava	I-PK
1135	##ila	I-PK
1135	##bility	I-PK
1135	,	O
1135	particularly	O
1135	in	O
1135	brain	O
1135	since	O
1135	hp	O
1135	-	O
1135	β	O
1135	-	O
1135	c	O
1135	##d	O
1135	does	O
1135	not	O
1135	effectively	O
1135	cross	O
1135	the	O
1135	blood	O
1135	-	O
1135	brain	O
1135	barrier	O
1135	.	O
1135	[SEP]	O
1136	[CLS]	O
1136	these	O
1136	samples	O
1136	were	O
1136	th	O
1136	##awed	O
1136	on	O
1136	the	O
1136	day	O
1136	of	O
1136	testing	O
1136	and	O
1136	run	O
1136	together	O
1136	with	O
1136	freshly	O
1136	prepared	O
1136	ca	O
1136	##li	O
1136	##bra	O
1136	##tion	O
1136	standards	O
1136	and	O
1136	quality	O
1136	controls	O
1136	and	O
1136	the	O
1136	values	O
1136	were	O
1136	calculated	O
1136	from	O
1136	the	O
1136	resulting	O
1136	ca	O
1136	##li	O
1136	##bra	O
1136	##tion	O
1136	curve	O
1136	obtained	O
1136	from	O
1136	the	O
1136	ca	O
1136	##li	O
1136	##bra	O
1136	##tion	O
1136	standards	O
1136	.	O
1136	[SEP]	O
1137	[CLS]	O
1137	m	O
1137	##r	O
1137	-	O
1137	trans	O
1137	##fected	O
1137	fi	O
1137	##bro	O
1137	##blast	O
1137	cells	O
1137	internal	O
1137	##ize	O
1137	m	O
1137	##fe	O
1137	##c	O
1137	##p	O
1137	##1	O
1137	as	O
1137	revealed	O
1137	by	O
1137	flow	O
1137	c	O
1137	##yt	O
1137	##ome	O
1137	##try	O
1137	and	O
1137	con	O
1137	##fo	O
1137	##cal	O
1137	micro	O
1137	##sco	O
1137	##py	O
1137	.	O
1137	[SEP]	O
1138	[CLS]	O
1138	in	O
1138	addition	O
1138	,	O
1138	s	O
1138	##ds	O
1138	were	O
1138	prepared	O
1138	with	O
1138	or	O
1138	without	O
1138	amino	O
1138	##c	O
1138	##lay	O
1138	,	O
1138	a	O
1138	p	O
1138	##h	O
1138	m	O
1138	##od	O
1138	##ulator	O
1138	,	O
1138	at	O
1138	different	O
1138	weight	O
1138	ratios	O
1138	.	O
1138	[SEP]	O
1139	[CLS]	O
1139	administration	O
1139	of	O
1139	hp	O
1139	##c	O
1139	by	O
1139	s	O
1139	##c	O
1139	injection	O
1139	of	O
1139	1	O
1139	.	O
1139	1	O
1139	m	O
1139	##l	O
1139	(	O
1139	275	O
1139	mg	O
1139	)	O
1139	via	O
1139	auto	O
1139	##in	O
1139	##ject	O
1139	##or	O
1139	is	O
1139	bio	O
1139	##e	O
1139	##qui	O
1139	##valent	O
1139	to	O
1139	im	O
1139	injection	O
1139	of	O
1139	1	O
1139	.	O
1139	0	O
1139	m	O
1139	##l	O
1139	(	O
1139	250	O
1139	mg	O
1139	)	O
1139	.	O
1139	[SEP]	O
1140	[CLS]	O
1140	we	O
1140	conclude	O
1140	that	O
1140	the	O
1140	disposition	O
1140	kinetic	O
1140	##s	O
1140	of	O
1140	c	O
1140	##y	O
1140	##c	O
1140	##los	O
1140	##por	O
1140	##in	O
1140	in	O
1140	patients	O
1140	with	O
1140	c	O
1140	##ro	O
1140	##hn	O
1140	'	O
1140	s	O
1140	disease	O
1140	are	O
1140	comparable	O
1140	to	O
1140	those	O
1140	of	O
1140	other	O
1140	groups	O
1140	,	O
1140	whereas	O
1140	the	O
1140	bio	B-PK
1140	##ava	I-PK
1140	##ila	I-PK
1140	##bility	I-PK
1140	may	O
1140	be	O
1140	decreased	O
1140	.	O
1140	[SEP]	O
1141	[CLS]	O
1141	it	O
1141	was	O
1141	found	O
1141	that	O
1141	the	O
1141	lower	O
1141	sa	O
1141	##lic	O
1141	##yla	O
1141	##te	O
1141	clearance	B-PK
1141	in	O
1141	fi	O
1141	##c	O
1141	cats	O
1141	was	O
1141	due	O
1141	in	O
1141	part	O
1141	to	O
1141	a	O
1141	decreased	O
1141	metabolism	O
1141	in	O
1141	the	O
1141	disease	O
1141	state	O
1141	and	O
1141	also	O
1141	involved	O
1141	slower	O
1141	drug	O
1141	elimination	O
1141	at	O
1141	the	O
1141	higher	O
1141	plasma	O
1141	concentrations	O
1141	secondary	O
1141	to	O
1141	the	O
1141	more	O
1141	extensive	O
1141	absorption	O
1141	of	O
1141	the	O
1141	in	O
1141	##tra	O
1141	##ves	O
1141	##ical	O
1141	dose	O
1141	.	O
1141	(	O
1141	abstract	O
1141	t	O
1141	##runcated	O
1141	at	O
1141	250	O
1141	words	O
1141	)	O
1141	[SEP]	O
1142	[CLS]	O
1142	detection	O
1142	was	O
1142	performed	O
1142	using	O
1142	positive	O
1142	m	O
1142	##rm	O
1142	mode	O
1142	on	O
1142	a	O
1142	t	O
1142	##ur	O
1142	##bo	O
1142	##ions	O
1142	##pra	O
1142	##y	O
1142	source	O
1142	.	O
1142	[SEP]	O
1143	[CLS]	O
1143	among	O
1143	the	O
1143	36	O
1143	enrolled	O
1143	subjects	O
1143	,	O
1143	34	O
1143	completed	O
1143	the	O
1143	study	O
1143	(	O
1143	mean	O
1143	[	O
1143	range	O
1143	]	O
1143	age	O
1143	,	O
1143	28	O
1143	.	O
1143	6	O
1143	[	O
1143	23	O
1143	-	O
1143	49	O
1143	]	O
1143	y	O
1143	;	O
1143	mean	O
1143	[	O
1143	range	O
1143	]	O
1143	weight	O
1143	,	O
1143	66	O
1143	.	O
1143	4	O
1143	[	O
1143	52	O
1143	.	O
1143	2	O
1143	-	O
1143	78	O
1143	.	O
1143	7	O
1143	]	O
1143	kg	O
1143	)	O
1143	.	O
1143	[SEP]	O
1144	[CLS]	O
1144	area	B-PK
1144	under	I-PK
1144	the	I-PK
1144	plasma	I-PK
1144	concentration	I-PK
1144	-	I-PK
1144	time	I-PK
1144	curve	I-PK
1144	did	O
1144	not	O
1144	differ	O
1144	for	O
1144	the	O
1144	various	O
1144	dos	O
1144	##ing	O
1144	volumes	O
1144	.	O
1144	[SEP]	O
1145	[CLS]	O
1145	therapeutic	O
1145	regime	O
1145	##ns	O
1145	(	O
1145	m	O
1145	##ox	O
1145	##if	O
1145	##lo	O
1145	##xa	O
1145	##cin	O
1145	:	O
1145	peak	B-PK
1145	,	O
1145	4	O
1145	.	O
1145	5	O
1145	micro	O
1145	g	O
1145	/	O
1145	m	O
1145	##l	O
1145	;	O
1145	half	B-PK
1145	-	I-PK
1145	life	I-PK
1145	[	I-PK
1145	t	I-PK
1145	(	I-PK
1145	1	I-PK
1145	/	I-PK
1145	2	I-PK
1145	)	I-PK
1145	]	I-PK
1145	,	O
1145	12	O
1145	h	O
1145	;	O
1145	and	O
1145	le	O
1145	##vo	O
1145	##f	O
1145	##lo	O
1145	##xa	O
1145	##cin	O
1145	:	O
1145	peak	B-PK
1145	,	O
1145	6	O
1145	micro	O
1145	g	O
1145	/	O
1145	m	O
1145	##l	O
1145	;	O
1145	t	B-PK
1145	(	I-PK
1145	1	I-PK
1145	/	I-PK
1145	2	I-PK
1145	)	I-PK
1145	,	O
1145	6	O
1145	h	O
1145	)	O
1145	were	O
1145	tested	O
1145	against	O
1145	two	O
1145	flu	O
1145	##oro	O
1145	##quin	O
1145	##olo	O
1145	##ne	O
1145	-	O
1145	susceptible	O
1145	is	O
1145	##olate	O
1145	##s	O
1145	(	O
1145	strains	O
1145	79	O
1145	and	O
1145	at	O
1145	##cc	O
1145	49	O
1145	##6	O
1145	##19	O
1145	)	O
1145	and	O
1145	k	O
1145	##d	O
1145	##21	O
1145	##38	O
1145	and	O
1145	k	O
1145	##d	O
1145	##21	O
1145	##39	O
1145	(	O
1145	par	O
1145	##c	O
1145	and	O
1145	g	O
1145	##yra	O
1145	mutant	O
1145	##s	O
1145	,	O
1145	respectively	O
1145	,	O
1145	of	O
1145	at	O
1145	##cc	O
1145	49	O
1145	##6	O
1145	##19	O
1145	)	O
1145	.	O
1145	[SEP]	O
1146	[CLS]	O
1146	over	O
1146	300	O
1146	plasma	O
1146	samples	O
1146	were	O
1146	analyzed	O
1146	by	O
1146	this	O
1146	method	O
1146	without	O
1146	any	O
1146	significant	O
1146	loss	O
1146	of	O
1146	resolution	O
1146	.	O
1146	[SEP]	O
1147	[CLS]	O
1147	v	O
1147	##ita	O
1147	##co	O
1147	##xi	O
1147	##b	O
1147	and	O
1147	internal	O
1147	standard	O
1147	(	O
1147	is	O
1147	,	O
1147	c	O
1147	##ele	O
1147	##co	O
1147	##xi	O
1147	##b	O
1147	)	O
1147	were	O
1147	detected	O
1147	under	O
1147	the	O
1147	multiple	O
1147	-	O
1147	reaction	O
1147	monitoring	O
1147	mode	O
1147	by	O
1147	mass	O
1147	s	O
1147	##pect	O
1147	##rome	O
1147	##ter	O
1147	with	O
1147	es	O
1147	##i	O
1147	+	O
1147	(	O
1147	m	O
1147	/	O
1147	z	O
1147	34	O
1147	##7	O
1147	.	O
1147	9	O
1147	/	O
1147	26	O
1147	##9	O
1147	.	O
1147	03	O
1147	for	O
1147	v	O
1147	##ita	O
1147	##co	O
1147	##xi	O
1147	##b	O
1147	and	O
1147	m	O
1147	/	O
1147	z	O
1147	38	O
1147	##2	O
1147	.	O
1147	0	O
1147	/	O
1147	36	O
1147	##2	O
1147	.	O
1147	0	O
1147	for	O
1147	is	O
1147	,	O
1147	respectively	O
1147	)	O
1147	.	O
1147	[SEP]	O
1148	[CLS]	O
1148	this	O
1148	patient	O
1148	received	O
1148	maintenance	O
1148	parent	O
1148	##eral	O
1148	fluid	O
1148	therapy	O
1148	,	O
1148	likely	O
1148	mask	O
1148	##ing	O
1148	the	O
1148	rise	O
1148	in	O
1148	ha	O
1148	##ema	O
1148	##to	O
1148	##c	O
1148	##rit	O
1148	usually	O
1148	seen	O
1148	in	O
1148	association	O
1148	with	O
1148	such	O
1148	a	O
1148	reduction	O
1148	in	O
1148	plasma	O
1148	album	O
1148	##in	O
1148	.	O
1148	[SEP]	O
1149	[CLS]	O
1149	maximum	O
1149	decrease	O
1149	and	O
1149	level	O
1149	##ing	O
1149	of	O
1149	l	O
1149	##ymph	O
1149	##ocytes	O
1149	concentrations	O
1149	occurred	O
1149	within	O
1149	hours	O
1149	of	O
1149	the	O
1149	onset	O
1149	of	O
1149	p	O
1149	##nt	O
1149	##22	O
1149	##5	O
1149	##8	O
1149	in	O
1149	##fusion	O
1149	.	O
1149	[SEP]	O
1150	[CLS]	O
1150	the	O
1150	disposition	O
1150	of	O
1150	h	O
1150	-	O
1150	z	O
1150	##t	O
1150	/	O
1150	g	O
1150	##4	O
1150	-	O
1150	mm	O
1150	##ae	O
1150	was	O
1150	studied	O
1150	in	O
1150	c	O
1150	##yn	O
1150	##omo	O
1150	##l	O
1150	##gus	O
1150	monkey	O
1150	since	O
1150	this	O
1150	model	O
1150	is	O
1150	clinical	O
1150	##ly	O
1150	relevant	O
1150	due	O
1150	to	O
1150	h	O
1150	-	O
1150	z	O
1150	##t	O
1150	/	O
1150	g	O
1150	##4	O
1150	specific	O
1150	binding	O
1150	to	O
1150	monkey	O
1150	r	O
1150	##on	O
1150	.	O
1150	[SEP]	O
1151	[CLS]	O
1151	this	O
1151	study	O
1151	consisted	O
1151	of	O
1151	an	O
1151	initial	O
1151	dose	O
1151	-	O
1151	es	O
1151	##cal	O
1151	##ation	O
1151	and	O
1151	subsequent	O
1151	##ex	O
1151	##pan	O
1151	##sion	O
1151	phase	O
1151	.	O
1151	[SEP]	O
1152	[CLS]	O
1152	the	O
1152	m	O
1152	##ox	O
1152	##if	O
1152	##lo	O
1152	##xa	O
1152	##cin	O
1152	mi	O
1152	##c	O
1152	distribution	O
1152	was	O
1152	from	O
1152	the	O
1152	same	O
1152	234	O
1152	is	O
1152	##olate	O
1152	##s	O
1152	from	O
1152	rod	O
1152	##rig	O
1152	##ue	O
1152	##z	O
1152	et	O
1152	al	O
1152	[	O
1152	35	O
1152	]	O
1152	.	O
1152	[SEP]	O
1153	[CLS]	O
1153	the	O
1153	meal	O
1153	accompanying	O
1153	ten	O
1153	##of	O
1153	##ov	O
1153	##ir	O
1153	/	O
1153	em	O
1153	##tric	O
1153	##ita	O
1153	##bine	O
1153	/	O
1153	r	O
1153	##il	O
1153	##pi	O
1153	##vir	O
1153	##ine	O
1153	intake	O
1153	satisfied	O
1153	food	O
1153	requirements	O
1153	in	O
1153	81	O
1153	%	O
1153	of	O
1153	cases	O
1153	.	O
1153	[SEP]	O
1154	[CLS]	O
1154	the	O
1154	select	O
1154	##ivity	O
1154	of	O
1154	the	O
1154	method	O
1154	was	O
1154	evaluated	O
1154	by	O
1154	analyzing	O
1154	blank	O
1154	plasma	O
1154	and	O
1154	plasma	O
1154	samples	O
1154	collected	O
1154	from	O
1154	six	O
1154	rats	O
1154	to	O
1154	investigate	O
1154	the	O
1154	potential	O
1154	interference	O
1154	##s	O
1154	at	O
1154	the	O
1154	peak	O
1154	region	O
1154	of	O
1154	anal	O
1154	##yte	O
1154	##s	O
1154	and	O
1154	i	O
1154	.	O
1154	s	O
1154	.	O
1154	using	O
1154	the	O
1154	proposed	O
1154	extraction	O
1154	procedure	O
1154	and	O
1154	analytical	O
1154	conditions	O
1154	.	O
1154	[SEP]	O
1155	[CLS]	O
1155	comparative	O
1155	study	O
1155	of	O
1155	p	O
1155	##har	O
1155	##ma	O
1155	##co	O
1155	##kin	O
1155	##etics	O
1155	of	O
1155	once	O
1155	daily	O
1155	and	O
1155	continuous	O
1155	in	O
1155	##tra	O
1155	##per	O
1155	##ito	O
1155	##nea	O
1155	##l	O
1155	net	O
1155	##il	O
1155	##my	O
1155	##cin	O
1155	in	O
1155	continuous	O
1155	am	O
1155	##bula	O
1155	##tory	O
1155	per	O
1155	##ito	O
1155	##nea	O
1155	##l	O
1155	dial	O
1155	##ys	O
1155	##is	O
1155	patients	O
1155	with	O
1155	per	O
1155	##ito	O
1155	##ni	O
1155	##tis	O
1155	.	O
1155	[SEP]	O
1156	[CLS]	O
1156	these	O
1156	data	O
1156	illustrate	O
1156	that	O
1156	r	O
1156	##u	O
1156	-	O
1156	th	O
1156	##io	O
1156	-	O
1156	ch	O
1156	##ry	O
1156	##sin	O
1156	and	O
1156	ch	O
1156	##ry	O
1156	##sin	O
1156	affect	O
1156	ha	O
1156	##em	O
1156	##ost	O
1156	##asis	O
1156	with	O
1156	similar	O
1156	efficacy	O
1156	in	O
1156	mice	O
1156	.	O
1156	[SEP]	O
1157	[CLS]	O
1157	each	O
1157	sample	O
1157	,	O
1157	properly	O
1157	loaded	O
1157	onto	O
1157	the	O
1157	sample	O
1157	disc	O
1157	,	O
1157	was	O
1157	scanned	O
1157	in	O
1157	the	O
1157	range	O
1157	of	O
1157	400	O
1157	–	O
1157	4	O
1157	,	O
1157	000	O
1157	cm	O
1157	##−	O
1157	##1	O
1157	.	O
1157	[SEP]	O
1158	[CLS]	O
1158	subjects	O
1158	included	O
1158	in	O
1158	the	O
1158	study	O
1158	had	O
1158	at	O
1158	least	O
1158	2	O
1158	detect	O
1158	##able	O
1158	th	O
1158	##c	O
1158	and	O
1158	related	O
1158	meta	O
1158	##bol	O
1158	##ite	O
1158	plasma	O
1158	concentrations	O
1158	during	O
1158	serial	O
1158	blood	O
1158	draw	O
1158	over	O
1158	a	O
1158	10	O
1158	-	O
1158	12	O
1158	h	O
1158	study	O
1158	period	O
1158	.	O
1158	[SEP]	O
1159	[CLS]	O
1159	although	O
1159	this	O
1159	study	O
1159	was	O
1159	not	O
1159	designed	O
1159	to	O
1159	assess	O
1159	efficacy	O
1159	,	O
1159	repeat	O
1159	imaging	O
1159	was	O
1159	performed	O
1159	and	O
1159	evaluated	O
1159	using	O
1159	re	O
1159	##cist	O
1159	every	O
1159	two	O
1159	cycles	O
1159	.	O
1159	[SEP]	O
1160	[CLS]	O
1160	win	O
1160	##non	O
1160	##lin	O
1160	was	O
1160	used	O
1160	for	O
1160	non	O
1160	##com	O
1160	##par	O
1160	##tment	O
1160	##al	O
1160	analysis	O
1160	,	O
1160	compartment	O
1160	##al	O
1160	modeling	O
1160	,	O
1160	and	O
1160	statistics	O
1160	,	O
1160	and	O
1160	non	O
1160	##me	O
1160	##m	O
1160	was	O
1160	used	O
1160	for	O
1160	visual	O
1160	predict	O
1160	##ive	O
1160	checks	O
1160	.	O
1160	[SEP]	O
1161	[CLS]	O
1161	inter	O
1161	-	O
1161	and	O
1161	in	O
1161	##tra	O
1161	##ind	O
1161	##iv	O
1161	##id	O
1161	##ual	O
1161	var	O
1161	##iability	O
1161	was	O
1161	assessed	O
1161	,	O
1161	and	O
1161	the	O
1161	effects	O
1161	of	O
1161	co	O
1161	##var	O
1161	##iate	O
1161	##s	O
1161	were	O
1161	q	O
1161	##uant	O
1161	##ified	O
1161	using	O
1161	a	O
1161	non	O
1161	##linear	O
1161	mixed	O
1161	-	O
1161	effects	O
1161	modeling	O
1161	approach	O
1161	(	O
1161	non	O
1161	##me	O
1161	##m	O
1161	)	O
1161	.	O
1161	[SEP]	O
1162	[CLS]	O
1162	the	O
1162	%	O
1162	bias	O
1162	in	O
1162	recovery	O
1162	calculation	O
1162	at	O
1162	ll	O
1162	##o	O
1162	##q	O
1162	level	O
1162	was	O
1162	least	O
1162	(	O
1162	<	O
1162	15	O
1162	%	O
1162	)	O
1162	for	O
1162	un	O
1162	##weight	O
1162	##ed	O
1162	and	O
1162	weighted	O
1162	ca	O
1162	##li	O
1162	##bra	O
1162	##tion	O
1162	curve	O
1162	when	O
1162	a	O
1162	weight	O
1162	of	O
1162	1	O
1162	/	O
1162	x	O
1162	and	O
1162	1	O
1162	/	O
1162	x	O
1162	##2	O
1162	was	O
1162	applied	O
1162	.	O
1162	[SEP]	O
1163	[CLS]	O
1163	as	O
1163	a	O
1163	result	O
1163	,	O
1163	11	O
1163	meta	O
1163	##bol	O
1163	##ites	O
1163	of	O
1163	act	O
1163	##eo	O
1163	##side	O
1163	,	O
1163	7	O
1163	meta	O
1163	##bol	O
1163	##ites	O
1163	of	O
1163	is	O
1163	##oa	O
1163	##ct	O
1163	##eo	O
1163	##side	O
1163	,	O
1163	and	O
1163	11	O
1163	meta	O
1163	##bol	O
1163	##ites	O
1163	of	O
1163	2	O
1163	'	O
1163	-	O
1163	ace	O
1163	##ty	O
1163	##la	O
1163	##ct	O
1163	##eo	O
1163	##side	O
1163	were	O
1163	identified	O
1163	respectively	O
1163	.	O
1163	[SEP]	O
1164	[CLS]	O
1164	tribe	O
1164	##ndi	O
1164	##mi	O
1164	##dine	O
1164	is	O
1164	a	O
1164	broad	O
1164	-	O
1164	spectrum	O
1164	ant	O
1164	##hel	O
1164	##min	O
1164	##thi	O
1164	##c	O
1164	available	O
1164	in	O
1164	chin	O
1164	##a	O
1164	,	O
1164	which	O
1164	is	O
1164	currently	O
1164	being	O
1164	pursued	O
1164	for	O
1164	u	O
1164	.	O
1164	s	O
1164	.	O
1164	food	O
1164	and	O
1164	drug	O
1164	administration	O
1164	approval	O
1164	for	O
1164	soil	O
1164	-	O
1164	transmitted	O
1164	helm	O
1164	##int	O
1164	##h	O
1164	infections	O
1164	.	O
1164	[SEP]	O
1165	[CLS]	O
1165	development	O
1165	,	O
1165	optimization	O
1165	,	O
1165	and	O
1165	evaluation	O
1165	of	O
1165	carved	O
1165	##ilo	O
1165	##l	O
1165	-	O
1165	loaded	O
1165	solid	O
1165	lip	O
1165	##id	O
1165	na	O
1165	##no	O
1165	##par	O
1165	##tic	O
1165	##les	O
1165	for	O
1165	in	O
1165	##tra	O
1165	##nas	O
1165	##al	O
1165	drug	O
1165	delivery	O
1165	.	O
1165	[SEP]	O
1166	[CLS]	O
1166	subgroup	O
1166	comparisons	O
1166	were	O
1166	made	O
1166	using	O
1166	the	O
1166	new	O
1166	##man	O
1166	–	O
1166	k	O
1166	##eu	O
1166	##ls	O
1166	multiple	O
1166	comparisons	O
1166	.	O
1166	[SEP]	O
1167	[CLS]	O
1167	the	O
1167	solid	O
1167	s	O
1167	##med	O
1167	##ds	O
1167	was	O
1167	formulated	O
1167	by	O
1167	spray	O
1167	drying	O
1167	liquid	O
1167	s	O
1167	##med	O
1167	##ds	O
1167	with	O
1167	the	O
1167	solid	O
1167	carrier	O
1167	(	O
1167	calcium	O
1167	si	O
1167	##lica	O
1167	##te	O
1167	)	O
1167	.	O
1167	[SEP]	O
1168	[CLS]	O
1168	since	O
1168	the	O
1168	binding	O
1168	of	O
1168	drugs	O
1168	to	O
1168	plasma	O
1168	proteins	O
1168	can	O
1168	significantly	O
1168	after	O
1168	the	O
1168	intensity	O
1168	of	O
1168	p	O
1168	##har	O
1168	##ma	O
1168	##cological	O
1168	and	O
1168	toxic	O
1168	##ological	O
1168	effects	O
1168	of	O
1168	drugs	O
1168	,	O
1168	we	O
1168	studied	O
1168	the	O
1168	p	O
1168	##har	O
1168	##ma	O
1168	##co	O
1168	##kin	O
1168	##etics	O
1168	of	O
1168	three	O
1168	drugs	O
1168	in	O
1168	patients	O
1168	with	O
1168	h	O
1168	##y	O
1168	##po	O
1168	##al	O
1168	##bu	O
1168	##mine	O
1168	##mia	O
1168	secondary	O
1168	to	O
1168	the	O
1168	ne	O
1168	##ph	O
1168	##rot	O
1168	##ic	O
1168	syndrome	O
1168	,	O
1168	but	O
1168	with	O
1168	relatively	O
1168	normal	O
1168	re	O
1168	##nal	O
1168	function	O
1168	.	O
1168	[SEP]	O
1169	[CLS]	O
1169	total	O
1169	exposure	O
1169	,	O
1169	measured	O
1169	by	O
1169	area	B-PK
1169	under	I-PK
1169	the	I-PK
1169	plasma	I-PK
1169	concentration	I-PK
1169	-	I-PK
1169	time	I-PK
1169	curve	I-PK
1169	(	I-PK
1169	au	I-PK
1169	##c	I-PK
1169	)	I-PK
1169	,	O
1169	was	O
1169	generated	O
1169	for	O
1169	the	O
1169	da	O
1169	##as	O
1169	,	O
1169	r	O
1169	##ito	O
1169	##na	O
1169	##vir	O
1169	,	O
1169	and	O
1169	rib	O
1169	##avi	O
1169	##rin	O
1169	using	O
1169	population	O
1169	p	O
1169	##har	O
1169	##ma	O
1169	##co	O
1169	##kin	O
1169	##etic	O
1169	modeling	O
1169	of	O
1169	data	O
1169	(	O
1169	n	O
1169	=	O
1169	209	O
1169	##3	O
1169	patients	O
1169	)	O
1169	from	O
1169	6	O
1169	phase	O
1169	3	O
1169	studies	O
1169	and	O
1169	1	O
1169	phase	O
1169	2	O
1169	study	O
1169	.	O
1169	[SEP]	O
1170	[CLS]	O
1170	one	O
1170	patient	O
1170	in	O
1170	the	O
1170	1200	O
1170	mg	O
1170	q	O
1170	##d	O
1170	dose	O
1170	level	O
1170	(	O
1170	p	O
1170	##ic	O
1170	)	O
1170	experienced	O
1170	2	O
1170	d	O
1170	##lts	O
1170	(	O
1170	grade	O
1170	3	O
1170	d	O
1170	##ys	O
1170	##art	O
1170	##hr	O
1170	##ia	O
1170	and	O
1170	muscular	O
1170	weakness	O
1170	)	O
1170	.	O
1170	[SEP]	O
1171	[CLS]	O
1171	to	O
1171	assess	O
1171	the	O
1171	effects	O
1171	of	O
1171	c	O
1171	##y	O
1171	##p	O
1171	##3	O
1171	##a	O
1171	##5	O
1171	gene	O
1171	p	O
1171	##oly	O
1171	##mor	O
1171	##phism	O
1171	##s	O
1171	on	O
1171	drug	O
1171	metabolism	O
1171	,	O
1171	the	O
1171	present	O
1171	study	O
1171	constructed	O
1171	a	O
1171	p	O
1171	##k	O
1171	prediction	O
1171	model	O
1171	by	O
1171	expressing	O
1171	c	O
1171	##y	O
1171	##p	O
1171	##3	O
1171	##a	O
1171	##5	O
1171	gene	O
1171	p	O
1171	##oly	O
1171	##mor	O
1171	##phism	O
1171	vectors	O
1171	in	O
1171	sa	O
1171	##cc	O
1171	##har	O
1171	##omy	O
1171	##ces	O
1171	c	O
1171	##ere	O
1171	##vis	O
1171	##iae	O
1171	.	O
1171	[SEP]	O
1172	[CLS]	O
1172	the	O
1172	clinical	O
1172	efficacy	O
1172	was	O
1172	evaluated	O
1172	based	O
1172	on	O
1172	the	O
1172	clinical	O
1172	response	O
1172	,	O
1172	categorized	O
1172	into	O
1172	a	O
1172	clinical	O
1172	success	O
1172	and	O
1172	clinical	O
1172	failure	O
1172	.	O
1172	[SEP]	O
1173	[CLS]	O
1173	to	O
1173	improve	O
1173	the	O
1173	poor	O
1173	so	O
1173	##lub	O
1173	##ility	O
1173	of	O
1173	f	O
1173	##v	O
1173	##s	O
1173	,	O
1173	f	O
1173	.	O
1173	ve	O
1173	##lut	O
1173	##ip	O
1173	##es	O
1173	s	O
1173	##tero	O
1173	##l	O
1173	lip	O
1173	##oso	O
1173	##me	O
1173	(	O
1173	f	O
1173	##v	O
1173	##s	O
1173	##l	O
1173	)	O
1173	was	O
1173	originally	O
1173	prepared	O
1173	.	O
1173	[SEP]	O
1174	[CLS]	O
1174	blood	O
1174	samples	O
1174	were	O
1174	collected	O
1174	daily	O
1174	in	O
1174	the	O
1174	morning	O
1174	(	O
1174	08	O
1174	##00	O
1174	hours	O
1174	)	O
1174	beginning	O
1174	the	O
1174	day	O
1174	after	O
1174	surgery	O
1174	.	O
1174	[SEP]	O
1175	[CLS]	O
1175	cocaine	O
1175	and	O
1175	its	O
1175	meta	O
1175	##bol	O
1175	##ites	O
1175	were	O
1175	determined	O
1175	using	O
1175	3	O
1175	##h	O
1175	-	O
1175	cocaine	O
1175	as	O
1175	a	O
1175	trace	O
1175	##r	O
1175	,	O
1175	followed	O
1175	by	O
1175	ho	O
1175	##mo	O
1175	##gen	O
1175	##ization	O
1175	and	O
1175	solvent	O
1175	extraction	O
1175	of	O
1175	tissues	O
1175	,	O
1175	and	O
1175	quantitative	O
1175	analysis	O
1175	by	O
1175	hp	O
1175	##tl	O
1175	##c	O
1175	and	O
1175	l	O
1175	##s	O
1175	##c	O
1175	.	O
1175	[SEP]	O
1176	[CLS]	O
1176	even	O
1176	though	O
1176	individual	O
1176	monitoring	O
1176	of	O
1176	serum	O
1176	if	O
1176	##n	O
1176	t	O
1176	##iter	O
1176	##s	O
1176	emphasized	O
1176	,	O
1176	for	O
1176	a	O
1176	given	O
1176	dose	O
1176	,	O
1176	marked	O
1176	quantitative	O
1176	variations	O
1176	of	O
1176	the	O
1176	observed	B-PK
1176	maximum	I-PK
1176	concentrations	I-PK
1176	,	O
1176	their	O
1176	mean	O
1176	values	O
1176	were	O
1176	found	O
1176	to	O
1176	be	O
1176	dose	O
1176	-	O
1176	dependent	O
1176	(	O
1176	35	O
1176	##8	O
1176	+	O
1176	-	O
1176	167	O
1176	u	O
1176	/	O
1176	m	O
1176	##l	O
1176	at	O
1176	30	O
1176	.	O
1176	10	O
1176	(	O
1176	6	O
1176	)	O
1176	u	O
1176	and	O
1176	104	O
1176	##4	O
1176	+	O
1176	-	O
1176	59	O
1176	##9	O
1176	u	O
1176	/	O
1176	m	O
1176	##l	O
1176	at	O
1176	100	O
1176	.	O
1176	10	O
1176	(	O
1176	6	O
1176	)	O
1176	u	O
1176	doses	O
1176	)	O
1176	.	O
1176	[SEP]	O
1177	[CLS]	O
1177	the	O
1177	mean	O
1177	diameter	O
1177	of	O
1177	the	O
1177	s	O
1177	##ma	O
1177	-	O
1177	p	O
1177	##t	O
1177	##x	O
1177	mice	O
1177	##lle	O
1177	was	O
1177	195	O
1177	##±	O
1177	##12	O
1177	.	O
1177	3	O
1177	nm	O
1177	as	O
1177	determined	O
1177	by	O
1177	dynamic	O
1177	light	O
1177	scattering	O
1177	.	O
1177	[SEP]	O
1178	[CLS]	O
1178	brain	O
1178	accumulation	O
1178	of	O
1178	sun	O
1178	##iti	O
1178	##ni	O
1178	##b	O
1178	is	O
1178	effectively	O
1178	restricted	O
1178	by	O
1178	both	O
1178	m	O
1178	##ua	O
1178	##b	O
1178	##c	O
1178	##b	O
1178	##1	O
1178	and	O
1178	m	O
1178	##ua	O
1178	##b	O
1178	##c	O
1178	##g	O
1178	##2	O
1178	activity	O
1178	.	O
1178	[SEP]	O
1179	[CLS]	O
1179	the	O
1179	effect	O
1179	of	O
1179	the	O
1179	day	O
1179	(	O
1179	day	O
1179	22	O
1179	versus	O
1179	day	O
1179	1	O
1179	)	O
1179	or	O
1179	the	O
1179	cycle	O
1179	(	O
1179	cycle	O
1179	2	O
1179	versus	O
1179	cycle	O
1179	1	O
1179	)	O
1179	on	O
1179	the	O
1179	exposure	O
1179	(	O
1179	cm	B-PK
1179	##ax	I-PK
1179	and	O
1179	au	B-PK
1179	##c	I-PK
1179	##0	I-PK
1179	-	I-PK
1179	t	I-PK
1179	)	O
1179	after	O
1179	dose	O
1179	normal	O
1179	##isation	O
1179	and	O
1179	log	O
1179	transformation	O
1179	was	O
1179	assessed	O
1179	using	O
1179	a	O
1179	pro	O
1179	##c	O
1179	mixed	O
1179	procedure	O
1179	of	O
1179	sa	O
1179	##s	O
1179	software	O
1179	with	O
1179	the	O
1179	patient	O
1179	taken	O
1179	as	O
1179	random	O
1179	effect	O
1179	and	O
1179	with	O
1179	day	O
1179	and	O
1179	cycle	O
1179	as	O
1179	fixed	O
1179	effects	O
1179	.	O
1179	[SEP]	O
1180	[CLS]	O
1180	the	O
1180	valid	O
1180	##ated	O
1180	ass	O
1180	##ay	O
1180	has	O
1180	been	O
1180	successfully	O
1180	applied	O
1180	to	O
1180	the	O
1180	p	O
1180	##har	O
1180	##ma	O
1180	##co	O
1180	##kin	O
1180	##etic	O
1180	study	O
1180	of	O
1180	c	O
1180	##li	O
1180	##gos	O
1180	##iba	O
1180	##n	O
1180	in	O
1180	rat	O
1180	plasma	O
1180	after	O
1180	in	O
1180	##tra	O
1180	##ven	O
1180	##ous	O
1180	and	O
1180	oral	O
1180	administration	O
1180	.	O
1180	[SEP]	O
1181	[CLS]	O
1181	in	O
1181	the	O
1181	course	O
1181	of	O
1181	method	O
1181	development	O
1181	,	O
1181	the	O
1181	main	O
1181	focus	O
1181	was	O
1181	the	O
1181	optimal	O
1181	detection	O
1181	and	O
1181	q	O
1181	##uant	O
1181	##ification	O
1181	of	O
1181	the	O
1181	meta	O
1181	##bol	O
1181	##ite	O
1181	m	O
1181	##1	O
1181	.	O
1181	[SEP]	O
1182	[CLS]	O
1182	compared	O
1182	with	O
1182	other	O
1182	ace	O
1182	inhibitor	O
1182	##s	O
1182	,	O
1182	which	O
1182	are	O
1182	mainly	O
1182	ex	O
1182	##cre	O
1182	##ted	O
1182	through	O
1182	the	O
1182	kidney	O
1182	,	O
1182	the	O
1182	plasma	O
1182	concentration	O
1182	of	O
1182	the	O
1182	active	O
1182	di	O
1182	##ac	O
1182	##id	O
1182	meta	O
1182	##bol	O
1182	##ite	O
1182	was	O
1182	hardly	O
1182	influenced	O
1182	by	O
1182	re	O
1182	##nal	O
1182	function	O
1182	.	O
1182	[SEP]	O
1183	[CLS]	O
1183	routine	O
1183	his	O
1183	##to	O
1183	##logical	O
1183	methodology	O
1183	was	O
1183	undertaken	O
1183	which	O
1183	involved	O
1183	may	O
1183	##er	O
1183	'	O
1183	s	O
1183	hem	O
1183	##ato	O
1183	##xy	O
1183	##lin	O
1183	and	O
1183	e	O
1183	##os	O
1183	##in	O
1183	stain	O
1183	##ing	O
1183	procedure	O
1183	.	O
1183	[SEP]	O
1184	[CLS]	O
1184	following	O
1184	an	O
1184	overnight	O
1184	fast	O
1184	of	O
1184	at	O
1184	least	O
1184	10	O
1184	h	O
1184	,	O
1184	all	O
1184	subjects	O
1184	received	O
1184	a	O
1184	single	O
1184	oral	O
1184	dose	O
1184	of	O
1184	33	O
1184	mg	O
1184	kg	O
1184	##−	O
1184	##1	O
1184	of	O
1184	d	O
1184	##f	O
1184	##p	O
1184	,	O
1184	provided	O
1184	as	O
1184	500	O
1184	mg	O
1184	f	O
1184	##er	O
1184	##rip	O
1184	##ro	O
1184	##x	O
1184	tablets	O
1184	rounded	O
1184	to	O
1184	the	O
1184	nearest	O
1184	half	O
1184	‐	O
1184	tablet	O
1184	(	O
1184	250	O
1184	mg	O
1184	)	O
1184	.	O
1184	[SEP]	O
1185	[CLS]	O
1185	the	O
1185	ad	O
1185	##r	O
1185	was	O
1185	local	O
1185	adverse	O
1185	reaction	O
1185	in	O
1185	four	O
1185	subjects	O
1185	,	O
1185	that	O
1185	is	O
1185	,	O
1185	mild	O
1185	injection	O
1185	site	O
1185	h	O
1185	##yper	O
1185	##ae	O
1185	##mia	O
1185	,	O
1185	which	O
1185	started	O
1185	within	O
1185	16	O
1185	–	O
1185	45	O
1185	min	O
1185	since	O
1185	in	O
1185	##tra	O
1185	##ven	O
1185	##ous	O
1185	in	O
1185	##fusion	O
1185	,	O
1185	and	O
1185	resolved	O
1185	30	O
1185	min	O
1185	after	O
1185	the	O
1185	end	O
1185	of	O
1185	in	O
1185	##tra	O
1185	##ven	O
1185	##ous	O
1185	in	O
1185	##fusion	O
1185	.	O
1185	[SEP]	O
1186	[CLS]	O
1186	overall	O
1186	,	O
1186	drug	O
1186	exposure	O
1186	was	O
1186	reduced	O
1186	(	O
1186	l	O
1186	##p	O
1186	##v	O
1186	-	O
1186	33	O
1186	%	O
1186	,	O
1186	e	O
1186	##f	O
1186	##v	O
1186	-	O
1186	15	O
1186	%	O
1186	,	O
1186	r	O
1186	##ito	O
1186	##na	O
1186	##vir	O
1186	-	O
1186	17	O
1186	%	O
1186	)	O
1186	compared	O
1186	to	O
1186	well	O
1186	-	O
1186	no	O
1186	##uri	O
1186	##shed	O
1186	controls	O
1186	(	O
1186	p	O
1186	<	O
1186	0	O
1186	.	O
1186	00	O
1186	##1	O
1186	)	O
1186	,	O
1186	at	O
1186	##tri	O
1186	##but	O
1186	##able	O
1186	to	O
1186	decreased	O
1186	bio	B-PK
1186	##ava	I-PK
1186	##ila	I-PK
1186	##bility	I-PK
1186	.	O
1186	[SEP]	O
1187	[CLS]	O
1187	thereafter	O
1187	,	O
1187	the	O
1187	ratio	O
1187	increased	O
1187	to	O
1187	0	O
1187	.	O
1187	79	O
1187	at	O
1187	48	O
1187	h	O
1187	post	O
1187	-	O
1187	dose	O
1187	,	O
1187	the	O
1187	last	O
1187	e	O
1187	##val	O
1187	##ua	O
1187	##ble	O
1187	time	O
1187	point	O
1187	.	O
1187	[SEP]	O
1188	[CLS]	O
1188	all	O
1188	physiological	O
1188	parameters	O
1188	for	O
1188	a	O
1188	reference	O
1188	man	O
1188	,	O
1188	woman	O
1188	and	O
1188	rat	O
1188	that	O
1188	are	O
1188	independent	O
1188	of	O
1188	the	O
1188	chemical	O
1188	and	O
1188	constitute	O
1188	a	O
1188	constant	O
1188	part	O
1188	of	O
1188	the	O
1188	model	O
1188	equations	O
1188	(	O
1188	app	O
1188	##end	O
1188	##ix	O
1188	a	O
1188	##1	O
1188	in	O
1188	supplement	O
1188	##ary	O
1188	material	O
1188	)	O
1188	.	O
1188	[SEP]	O
1189	[CLS]	O
1189	the	O
1189	data	O
1189	was	O
1189	fitted	O
1189	into	O
1189	k	O
1189	##ors	O
1189	##meyer	O
1189	-	O
1189	p	O
1189	##ep	O
1189	##pas	O
1189	equation	O
1189	.	O
1189	[SEP]	O
1190	[CLS]	O
1190	of	O
1190	the	O
1190	62	O
1190	random	O
1190	##ized	O
1190	subjects	O
1190	(	O
1190	74	O
1190	%	O
1190	male	O
1190	)	O
1190	,	O
1190	59	O
1190	completed	O
1190	the	O
1190	study	O
1190	and	O
1190	three	O
1190	subjects	O
1190	discontinued	O
1190	(	O
1190	all	O
1190	during	O
1190	the	O
1190	place	O
1190	##bo	O
1190	+	O
1190	am	O
1190	##ox	O
1190	##ici	O
1190	##llin	O
1190	arm	O
1190	)	O
1190	,	O
1190	including	O
1190	one	O
1190	due	O
1190	to	O
1190	an	O
1190	a	O
1190	##e	O
1190	.	O
1190	[SEP]	O
1191	[CLS]	O
1191	together	O
1191	,	O
1191	these	O
1191	results	O
1191	demonstrate	O
1191	that	O
1191	f	O
1191	##etal	O
1191	mouse	O
1191	and	O
1191	rat	O
1191	p	O
1191	##ht	O
1191	##hala	O
1191	##te	O
1191	exposure	O
1191	both	O
1191	induce	O
1191	immediate	O
1191	early	O
1191	gene	O
1191	expression	O
1191	and	O
1191	disrupt	O
1191	semi	O
1191	##nife	O
1191	##rous	O
1191	cord	O
1191	and	O
1191	go	O
1191	##no	O
1191	##cy	O
1191	##te	O
1191	development	O
1191	.	O
1191	[SEP]	O
1192	[CLS]	O
1192	events	O
1192	were	O
1192	regarded	O
1192	generally	O
1192	“	O
1192	related	O
1192	”	O
1192	to	O
1192	b	O
1192	##c	O
1192	-	O
1192	81	O
1192	##9	O
1192	in	O
1192	case	O
1192	their	O
1192	time	O
1192	relationship	O
1192	to	O
1192	b	O
1192	##c	O
1192	-	O
1192	81	O
1192	##9	O
1192	treatment	O
1192	was	O
1192	not	O
1192	in	O
1192	##com	O
1192	##pa	O
1192	##tible	O
1192	or	O
1192	making	O
1192	a	O
1192	casual	O
1192	connection	O
1192	imp	O
1192	##ro	O
1192	##ba	O
1192	##ble	O
1192	.	O
1192	[SEP]	O
1193	[CLS]	O
1193	separation	O
1193	was	O
1193	carried	O
1193	out	O
1193	applying	O
1193	-	O
1193	20	O
1193	k	O
1193	##v	O
1193	in	O
1193	50	O
1193	mm	O
1193	phosphate	O
1193	buffer	O
1193	,	O
1193	p	O
1193	##h	O
1193	3	O
1193	.	O
1193	5	O
1193	,	O
1193	containing	O
1193	10	O
1193	%	O
1193	v	O
1193	/	O
1193	v	O
1193	a	O
1193	##c	O
1193	##n	O
1193	and	O
1193	30	O
1193	mg	O
1193	/	O
1193	m	O
1193	##l	O
1193	su	O
1193	##lf	O
1193	##ated	O
1193	-	O
1193	β	O
1193	-	O
1193	c	O
1193	##y	O
1193	##c	O
1193	##lo	O
1193	##de	O
1193	##x	O
1193	##tri	O
1193	##n	O
1193	(	O
1193	s	O
1193	-	O
1193	β	O
1193	-	O
1193	c	O
1193	##d	O
1193	)	O
1193	.	O
1193	[SEP]	O
1194	[CLS]	O
1194	it	O
1194	is	O
1194	concluded	O
1194	that	O
1194	the	O
1194	ace	O
1194	##ty	O
1194	##lation	O
1194	of	O
1194	h	O
1194	##yd	O
1194	##ral	O
1194	##azi	O
1194	##ne	O
1194	in	O
1194	man	O
1194	is	O
1194	a	O
1194	capacity	O
1194	-	O
1194	limited	O
1194	process	O
1194	.	O
1194	[SEP]	O
1195	[CLS]	O
1195	the	O
1195	time	O
1195	intervals	O
1195	of	O
1195	blood	O
1195	collection	O
1195	were	O
1195	identical	O
1195	for	O
1195	all	O
1195	groups	O
1195	:	O
1195	5	O
1195	min	O
1195	before	O
1195	the	O
1195	first	O
1195	injection	O
1195	of	O
1195	the	O
1195	sample	O
1195	,	O
1195	and	O
1195	7	O
1195	,	O
1195	15	O
1195	,	O
1195	30	O
1195	,	O
1195	45	O
1195	,	O
1195	65	O
1195	,	O
1195	and	O
1195	90	O
1195	min	O
1195	after	O
1195	.	O
1195	[SEP]	O
1196	[CLS]	O
1196	automated	O
1196	radios	O
1196	##ynth	O
1196	##esis	O
1196	afforded	O
1196	radio	O
1196	##tra	O
1196	##cer	O
1196	[	O
1196	18	O
1196	##f	O
1196	]	O
1196	d	O
1196	##c	O
1196	##f	O
1196	##py	O
1196	##l	O
1196	in	O
1196	decay	O
1196	-	O
1196	corrected	O
1196	radio	O
1196	##chemical	O
1196	yields	O
1196	of	O
1196	23	O
1196	±	O
1196	5	O
1196	%	O
1196	(	O
1196	n	O
1196	=	O
1196	10	O
1196	)	O
1196	within	O
1196	55	O
1196	min	O
1196	,	O
1196	including	O
1196	hp	O
1196	##l	O
1196	##c	O
1196	pu	O
1196	##rification	O
1196	.	O
1196	[SEP]	O
1197	[CLS]	O
1197	m	O
1197	##f	O
1197	,	O
1197	c	O
1197	##pm	O
1197	,	O
1197	e	O
1197	##p	O
1197	,	O
1197	em	O
1197	,	O
1197	m	O
1197	##p	O
1197	,	O
1197	s	O
1197	##m	O
1197	,	O
1197	s	O
1197	##b	O
1197	,	O
1197	s	O
1197	##r	O
1197	and	O
1197	j	O
1197	##r	O
1197	##h	O
1197	have	O
1197	been	O
1197	engaged	O
1197	by	O
1197	f	O
1197	##ae	O
1197	##s	O
1197	farm	O
1197	##a	O
1197	s	O
1197	.	O
1197	a	O
1197	.	O
1197	as	O
1197	experts	O
1197	for	O
1197	various	O
1197	aspects	O
1197	of	O
1197	the	O
1197	studies	O
1197	(	O
1197	pet	O
1197	technique	O
1197	,	O
1197	p	O
1197	##har	O
1197	##ma	O
1197	##co	O
1197	##kin	O
1197	##etic	O
1197	and	O
1197	statistical	O
1197	methods	O
1197	)	O
1197	.	O
1197	[SEP]	O
1198	[CLS]	O
1198	the	O
1198	mass	O
1198	transitions	O
1198	for	O
1198	α	O
1198	-	O
1198	mg	O
1198	was	O
1198	m	O
1198	/	O
1198	z	O
1198	41	O
1198	##1	O
1198	.	O
1198	21	O
1198	→	O
1198	35	O
1198	##4	O
1198	.	O
1198	85	O
1198	(	O
1198	collision	O
1198	energy	O
1198	of	O
1198	20	O
1198	e	O
1198	##v	O
1198	and	O
1198	collision	O
1198	cell	O
1198	exit	O
1198	potential	O
1198	of	O
1198	25	O
1198	e	O
1198	##v	O
1198	,	O
1198	respectively	O
1198	)	O
1198	.	O
1198	[SEP]	O
1199	[CLS]	O
1199	for	O
1199	the	O
1199	10	O
1199	-	O
1199	mg	O
1199	es	O
1199	##ome	O
1199	##pra	O
1199	##zo	O
1199	##le	O
1199	dose	O
1199	,	O
1199	the	O
1199	geometric	O
1199	mean	O
1199	body	O
1199	-	O
1199	weight	O
1199	-	O
1199	normal	B-PK
1199	##ized	I-PK
1199	apparent	I-PK
1199	oral	I-PK
1199	clearance	I-PK
1199	was	O
1199	approximately	O
1199	50	O
1199	%	O
1199	higher	O
1199	in	O
1199	the	O
1199	younger	O
1199	group	O
1199	compared	O
1199	with	O
1199	the	O
1199	older	O
1199	group	O
1199	(	O
1199	0	O
1199	.	O
1199	40	O
1199	and	O
1199	0	O
1199	.	O
1199	25	O
1199	l	O
1199	/	O
1199	h	O
1199	x	O
1199	kg	O
1199	(	O
1199	-	O
1199	1	O
1199	)	O
1199	,	O
1199	respectively	O
1199	)	O
1199	.	O
1199	[SEP]	O
1200	[CLS]	O
1200	given	O
1200	the	O
1200	early	O
1200	disco	O
1200	##ntin	O
1200	##uation	O
1200	of	O
1200	the	O
1200	first	O
1200	three	O
1200	patients	O
1200	,	O
1200	the	O
1200	protocol	O
1200	was	O
1200	amended	O
1200	to	O
1200	short	O
1200	##en	O
1200	the	O
1200	first	O
1200	cycle	O
1200	to	O
1200	a	O
1200	14	O
1200	-	O
1200	day	O
1200	cycle	O
1200	to	O
1200	obtain	O
1200	a	O
1200	p	O
1200	##har	O
1200	##ma	O
1200	##co	O
1200	##kin	O
1200	##etic	O
1200	profile	O
1200	after	O
1200	14	O
1200	days	O
1200	of	O
1200	multiple	O
1200	dos	O
1200	##ing	O
1200	of	O
1200	l	O
1200	##y	O
1200	##24	O
1200	##5	O
1200	##75	O
1200	##46	O
1200	.	O
1200	[SEP]	O
1201	[CLS]	O
1201	the	O
1201	mechanism	O
1201	of	O
1201	von	O
1201	will	O
1201	##eb	O
1201	##rand	O
1201	factor	O
1201	(	O
1201	v	O
1201	##w	O
1201	##f	O
1201	)	O
1201	clearance	B-PK
1201	is	O
1201	not	O
1201	fully	O
1201	understood	O
1201	.	O
1201	[SEP]	O
1202	[CLS]	O
1202	it	O
1202	is	O
1202	shown	O
1202	,	O
1202	that	O
1202	for	O
1202	oral	O
1202	administration	O
1202	the	O
1202	most	O
1202	appropriate	O
1202	is	O
1202	an	O
1202	am	O
1202	##or	O
1202	##ph	O
1202	##ous	O
1202	form	O
1202	obtained	O
1202	by	O
1202	rapid	O
1202	e	O
1202	##va	O
1202	##por	O
1202	##ation	O
1202	of	O
1202	a	O
1202	solvent	O
1202	from	O
1202	solution	O
1202	of	O
1202	the	O
1202	est	O
1202	##er	O
1202	.	O
1202	[SEP]	O
1203	[CLS]	O
1203	post	O
1203	ho	O
1203	##c	O
1203	ex	O
1203	##p	O
1203	##lora	O
1203	##tory	O
1203	parameters	O
1203	were	O
1203	the	O
1203	au	B-PK
1203	##c	I-PK
1203	(	I-PK
1203	0	I-PK
1203	-	I-PK
1203	16	I-PK
1203	)	I-PK
1203	and	O
1203	the	O
1203	au	B-PK
1203	##c	I-PK
1203	(	I-PK
1203	0	I-PK
1203	-	I-PK
1203	in	I-PK
1203	##finity	I-PK
1203	)	I-PK
1203	assuming	O
1203	a	O
1203	16	O
1203	-	O
1203	hour	O
1203	application	O
1203	time	O
1203	for	O
1203	the	O
1203	21	O
1203	-	O
1203	mg	O
1203	patch	O
1203	.	O
1203	[SEP]	O
1204	[CLS]	O
1204	by	O
1204	contrast	O
1204	,	O
1204	a	O
1204	significant	O
1204	period	O
1204	effect	O
1204	was	O
1204	found	O
1204	for	O
1204	glucose	O
1204	(	O
1204	p	O
1204	<	O
1204	0	O
1204	.	O
1204	05	O
1204	)	O
1204	,	O
1204	suggesting	O
1204	that	O
1204	the	O
1204	changes	O
1204	relative	O
1204	to	O
1204	day	O
1204	−	O
1204	##1	O
1204	may	O
1204	be	O
1204	only	O
1204	partially	O
1204	explained	O
1204	by	O
1204	l	O
1204	##x	O
1204	##42	O
1204	##11	O
1204	treatment	O
1204	,	O
1204	because	O
1204	they	O
1204	were	O
1204	con	O
1204	##founded	O
1204	with	O
1204	time	O
1204	.	O
1204	[SEP]	O
1205	[CLS]	O
1205	z	O
1205	##b	O
1205	-	O
1205	16	O
1205	group	O
1205	showed	O
1205	blood	O
1205	glucose	O
1205	levels	O
1205	by	O
1205	27	O
1205	%	O
1205	lower	O
1205	than	O
1205	in	O
1205	sa	O
1205	##line	O
1205	group	O
1205	30	O
1205	min	O
1205	after	O
1205	oral	O
1205	glucose	O
1205	administration	O
1205	(	O
1205	3	O
1205	mg	O
1205	/	O
1205	kg	O
1205	)	O
1205	.	O
1205	[SEP]	O
1206	[CLS]	O
1206	ca	O
1206	##lve	O
1206	##rt	O
1206	et	O
1206	al	O
1206	(	O
1206	1989	O
1206	)	O
1206	demonstrated	O
1206	that	O
1206	the	O
1206	total	B-PK
1206	plasma	I-PK
1206	clearance	I-PK
1206	of	O
1206	car	O
1206	##bo	O
1206	##p	O
1206	##lat	O
1206	##in	O
1206	was	O
1206	linear	O
1206	##ly	O
1206	related	O
1206	to	O
1206	the	O
1206	g	O
1206	##lo	O
1206	##mer	O
1206	##ular	O
1206	fi	O
1206	##ltration	O
1206	rate	O
1206	(	O
1206	g	O
1206	##f	O
1206	##r	O
1206	)	O
1206	and	O
1206	that	O
1206	the	O
1206	non	B-PK
1206	-	I-PK
1206	re	I-PK
1206	##nal	I-PK
1206	clearance	I-PK
1206	was	O
1206	25	O
1206	m	O
1206	##l	O
1206	min	O
1206	##−	O
1206	##1	O
1206	.	O
1206	[SEP]	O
1207	[CLS]	O
1207	his	O
1207	##to	O
1207	##logical	O
1207	##ly	O
1207	,	O
1207	brain	O
1207	and	O
1207	spinal	O
1207	cord	O
1207	sections	O
1207	revealed	O
1207	scattered	O
1207	micro	O
1207	##in	O
1207	##far	O
1207	##cts	O
1207	and	O
1207	minimal	O
1207	g	O
1207	##lio	O
1207	##sis	O
1207	consistent	O
1207	with	O
1207	post	O
1207	##p	O
1207	##ro	O
1207	##ced	O
1207	##ure	O
1207	changes	O
1207	in	O
1207	all	O
1207	four	O
1207	s	O
1207	##ten	O
1207	##t	O
1207	-	O
1207	treatment	O
1207	groups	O
1207	.	O
1207	[SEP]	O
1208	[CLS]	O
1208	79	O
1208	patients	O
1208	were	O
1208	on	O
1208	mon	O
1208	##otherapy	O
1208	of	O
1208	either	O
1208	c	O
1208	##b	O
1208	##z	O
1208	or	O
1208	o	O
1208	##x	O
1208	##c	O
1208	,	O
1208	63	O
1208	were	O
1208	on	O
1208	either	O
1208	c	O
1208	##b	O
1208	##z	O
1208	or	O
1208	o	O
1208	##x	O
1208	##c	O
1208	plus	O
1208	another	O
1208	anti	O
1208	ne	O
1208	##uro	O
1208	##pathic	O
1208	/	O
1208	anal	O
1208	##ges	O
1208	##ic	O
1208	medication	O
1208	which	O
1208	were	O
1208	included	O
1208	in	O
1208	the	O
1208	analysis	O
1208	.	O
1208	[SEP]	O
1209	[CLS]	O
1209	finally	O
1209	,	O
1209	the	O
1209	op	O
1209	##ti	O
1209	##mized	O
1209	v	O
1209	##rd	O
1209	-	O
1209	o	O
1209	##dt	O
1209	##s	O
1209	exhibited	O
1209	increased	O
1209	oral	O
1209	absorption	O
1209	of	O
1209	v	O
1209	##rd	O
1209	and	O
1209	subsequent	O
1209	decrease	O
1209	in	O
1209	the	O
1209	time	O
1209	of	O
1209	onset	O
1209	of	O
1209	clinical	O
1209	effect	O
1209	and	O
1209	mask	O
1209	##ing	O
1209	the	O
1209	unpleasant	O
1209	taste	O
1209	.	O
1209	[SEP]	O
1210	[CLS]	O
1210	a	O
1210	total	O
1210	of	O
1210	151	O
1210	participants	O
1210	were	O
1210	included	O
1210	in	O
1210	the	O
1210	analysis	O
1210	under	O
1210	fast	O
1210	##ed	O
1210	conditions	O
1210	,	O
1210	and	O
1210	31	O
1210	participants	O
1210	were	O
1210	included	O
1210	in	O
1210	the	O
1210	fed	O
1210	analysis	O
1210	.	O
1210	[SEP]	O
1211	[CLS]	O
1211	the	O
1211	matrix	O
1211	effect	O
1211	and	O
1211	recovery	O
1211	yield	O
1211	were	O
1211	all	O
1211	within	O
1211	±	O
1211	##15	O
1211	%	O
1211	,	O
1211	which	O
1211	was	O
1211	generally	O
1211	accepted	O
1211	to	O
1211	carry	O
1211	out	O
1211	the	O
1211	analysis	O
1211	of	O
1211	biological	O
1211	samples	O
1211	containing	O
1211	the	O
1211	drug	O
1211	.	O
1211	[SEP]	O
1212	[CLS]	O
1212	the	O
1212	s	O
1212	:	O
1212	r	O
1212	ratio	O
1212	of	O
1212	nor	O
1212	concentration	O
1212	was	O
1212	also	O
1212	input	O
1212	rate	O
1212	-	O
1212	dependent	O
1212	.	O
1212	[SEP]	O
1213	[CLS]	O
1213	a	O
1213	full	O
1213	method	O
1213	valid	O
1213	##ation	O
1213	of	O
1213	the	O
1213	ass	O
1213	##ay	O
1213	for	O
1213	the	O
1213	anal	O
1213	##yte	O
1213	determination	O
1213	in	O
1213	rat	O
1213	plasma	O
1213	was	O
1213	performed	O
1213	according	O
1213	to	O
1213	the	O
1213	chin	O
1213	##a	O
1213	food	O
1213	and	O
1213	drug	O
1213	administration	O
1213	guidelines	O
1213	for	O
1213	the	O
1213	pre	O
1213	##c	O
1213	##lini	O
1213	##cal	O
1213	p	O
1213	##har	O
1213	##ma	O
1213	##co	O
1213	##kin	O
1213	##etic	O
1213	study	O
1213	with	O
1213	respect	O
1213	to	O
1213	select	O
1213	##ivity	O
1213	,	O
1213	linear	O
1213	##ity	O
1213	,	O
1213	precision	O
1213	,	O
1213	accuracy	O
1213	,	O
1213	recovery	O
1213	,	O
1213	matrix	O
1213	effect	O
1213	,	O
1213	stability	O
1213	,	O
1213	and	O
1213	di	O
1213	##lution	O
1213	integrity	O
1213	[	O
1213	11	O
1213	]	O
1213	.	O
1213	[SEP]	O
1214	[CLS]	O
1214	the	O
1214	data	O
1214	from	O
1214	the	O
1214	dose	O
1214	-	O
1214	dependence	O
1214	study	O
1214	showed	O
1214	that	O
1214	n	O
1214	##l	O
1214	##g	O
1214	##9	O
1214	##19	O
1214	at	O
1214	100	O
1214	mg	O
1214	/	O
1214	kg	O
1214	demonstrated	O
1214	the	O
1214	maximum	O
1214	anti	O
1214	##tum	O
1214	##or	O
1214	efficacy	O
1214	.	O
1214	[SEP]	O
1215	[CLS]	O
1215	only	O
1215	a	O
1215	few	O
1215	high	O
1215	-	O
1215	purity	O
1215	v	O
1215	##w	O
1215	##f	O
1215	/	O
1215	f	O
1215	##vi	O
1215	##ii	O
1215	concentrate	O
1215	##s	O
1215	have	O
1215	been	O
1215	extensively	O
1215	evaluated	O
1215	in	O
1215	p	O
1215	##har	O
1215	##ma	O
1215	##co	O
1215	##kin	O
1215	##etic	O
1215	(	O
1215	p	O
1215	##k	O
1215	)	O
1215	trials	O
1215	as	O
1215	well	O
1215	as	O
1215	in	O
1215	retrospective	O
1215	or	O
1215	prospective	O
1215	efficacy	O
1215	studies	O
1215	in	O
1215	v	O
1215	##w	O
1215	##d	O
1215	.	O
1215	[SEP]	O
1216	[CLS]	O
1216	in	O
1216	addition	O
1216	,	O
1216	the	O
1216	anti	O
1216	##can	O
1216	##cer	O
1216	effect	O
1216	of	O
1216	am	O
1216	##b	O
1216	pre	O
1216	##tre	O
1216	##ated	O
1216	with	O
1216	t	O
1216	##ce	O
1216	##e	O
1216	was	O
1216	evaluated	O
1216	.	O
1216	[SEP]	O
1217	[CLS]	O
1217	m	O
1217	##d	O
1217	##ma	O
1217	reversed	O
1217	the	O
1217	subjective	O
1217	se	O
1217	##dation	O
1217	induced	O
1217	by	O
1217	alcohol	O
1217	but	O
1217	did	O
1217	not	O
1217	reduce	O
1217	drunken	O
1217	##ness	O
1217	feelings	O
1217	.	O
1217	[SEP]	O
1218	[CLS]	O
1218	the	O
1218	third	O
1218	phase	O
1218	appears	O
1218	to	O
1218	involve	O
1218	a	O
1218	slow	O
1218	turnover	O
1218	of	O
1218	se	O
1218	##quest	O
1218	##ered	O
1218	zinc	O
1218	(	O
1218	t	B-PK
1218	(	I-PK
1218	1	I-PK
1218	/	I-PK
1218	2	I-PK
1218	)	I-PK
1218	greater	O
1218	than	O
1218	1	O
1218	year	O
1218	)	O
1218	.	O
1218	[SEP]	O
1219	[CLS]	O
1219	ft	O
1219	##ir	O
1219	s	O
1219	##pect	O
1219	##ra	O
1219	showed	O
1219	chemical	O
1219	group	O
1219	of	O
1219	each	O
1219	component	O
1219	and	O
1219	interaction	O
1219	between	O
1219	components	O
1219	.	O
1219	[SEP]	O
1220	[CLS]	O
1220	samples	O
1220	were	O
1220	re	O
1220	##con	O
1220	##stituted	O
1220	in	O
1220	sample	O
1220	loading	O
1220	buffer	O
1220	of	O
1220	s	O
1220	##ds	O
1220	-	O
1220	p	O
1220	##oly	O
1220	##ac	O
1220	##ryl	O
1220	##ami	O
1220	##de	O
1220	gel	O
1220	electro	O
1220	##ph	O
1220	##ores	O
1220	##is	O
1220	and	O
1220	boiled	O
1220	for	O
1220	5	O
1220	min	O
1220	for	O
1220	protein	O
1220	den	O
1220	##at	O
1220	##uration	O
1220	.	O
1220	[SEP]	O
1221	[CLS]	O
1221	after	O
1221	1	O
1221	h	O
1221	##r	O
1221	,	O
1221	three	O
1221	test	O
1221	groups	O
1221	including	O
1221	##2	O
1221	.	O
1221	5	O
1221	,	O
1221	5	O
1221	and	O
1221	10	O
1221	mg	O
1221	/	O
1221	kg	O
1221	of	O
1221	en	O
1221	##ro	O
1221	##f	O
1221	##lo	O
1221	##xa	O
1221	##cin	O
1221	were	O
1221	administered	O
1221	oral	O
1221	##ly	O
1221	once	O
1221	a	O
1221	day	O
1221	for	O
1221	three	O
1221	##con	O
1221	##se	O
1221	##cut	O
1221	##ive	O
1221	days	O
1221	,	O
1221	respectively	O
1221	.	O
1221	[SEP]	O
1222	[CLS]	O
1222	in	O
1222	clinical	O
1222	trials	O
1222	,	O
1222	both	O
1222	agents	O
1222	have	O
1222	shown	O
1222	some	O
1222	activity	O
1222	as	O
1222	second	O
1222	-	O
1222	line	O
1222	agents	O
1222	(	O
1222	measured	O
1222	by	O
1222	clinical	O
1222	benefit	O
1222	as	O
1222	well	O
1222	as	O
1222	reduction	O
1222	in	O
1222	ps	O
1222	##a	O
1222	)	O
1222	,	O
1222	supporting	O
1222	the	O
1222	concept	O
1222	of	O
1222	a	O
1222	more	O
1222	selective	O
1222	inhibitor	O
1222	of	O
1222	the	O
1222	17	O
1222	##α	O
1222	-	O
1222	h	O
1222	##ydro	O
1222	##xy	O
1222	##lase	O
1222	/	O
1222	c	O
1222	##17	O
1222	,	O
1222	20	O
1222	-	O
1222	l	O
1222	##yas	O
1222	##e	O
1222	enzyme	O
1222	(	O
1222	oh	O
1222	,	O
1222	2002	O
1222	)	O
1222	.	O
1222	[SEP]	O
1223	[CLS]	O
1223	three	O
1223	aids	O
1223	patients	O
1223	experienced	O
1223	severe	O
1223	di	O
1223	##ar	O
1223	##r	O
1223	##hea	O
1223	following	O
1223	the	O
1223	oral	O
1223	dose	O
1223	;	O
1223	four	O
1223	patients	O
1223	had	O
1223	mild	O
1223	di	O
1223	##ar	O
1223	##r	O
1223	##hea	O
1223	following	O
1223	the	O
1223	i	O
1223	.	O
1223	v	O
1223	.	O
1223	dose	O
1223	.	O
1223	[SEP]	O
1224	[CLS]	O
1224	the	O
1224	mice	O
1224	were	O
1224	sacrificed	O
1224	at	O
1224	72	O
1224	days	O
1224	after	O
1224	the	O
1224	6th	O
1224	injection	O
1224	.	O
1224	[SEP]	O
1225	[CLS]	O
1225	twenty	O
1225	-	O
1225	five	O
1225	volunteers	O
1225	were	O
1225	screened	O
1225	,	O
1225	and	O
1225	17	O
1225	of	O
1225	them	O
1225	were	O
1225	random	O
1225	##ized	O
1225	.	O
1225	[SEP]	O
1226	[CLS]	O
1226	du	O
1226	##14	O
1226	##5	O
1226	and	O
1226	ca	O
1226	##co	O
1226	-	O
1226	2	O
1226	cells	O
1226	were	O
1226	culture	O
1226	##d	O
1226	in	O
1226	eagle	O
1226	'	O
1226	s	O
1226	minimum	O
1226	essential	O
1226	medium	O
1226	(	O
1226	em	O
1226	##em	O
1226	)	O
1226	.	O
1226	[SEP]	O
1227	[CLS]	O
1227	of	O
1227	these	O
1227	patients	O
1227	,	O
1227	29	O
1227	(	O
1227	69	O
1227	%	O
1227	)	O
1227	had	O
1227	r	O
1227	##ai	O
1227	stage	O
1227	i	O
1227	to	O
1227	ii	O
1227	disease	O
1227	.	O
1227	[SEP]	O
1228	[CLS]	O
1228	data	O
1228	from	O
1228	three	O
1228	studies	O
1228	of	O
1228	healthy	O
1228	individuals	O
1228	with	O
1228	p	O
1228	##k	O
1228	measurements	O
1228	of	O
1228	plasma	O
1228	and	O
1228	urine	O
1228	after	O
1228	single	O
1228	dose	O
1228	or	O
1228	at	O
1228	steady	O
1228	-	O
1228	state	O
1228	were	O
1228	used	O
1228	in	O
1228	this	O
1228	study	O
1228	.	O
1228	[SEP]	O
1229	[CLS]	O
1229	ethanol	O
1229	did	O
1229	not	O
1229	modify	O
1229	the	O
1229	effect	O
1229	of	O
1229	am	O
1229	##is	O
1229	##ulp	O
1229	##ride	O
1229	on	O
1229	plasma	O
1229	pro	O
1229	##la	O
1229	##ct	O
1229	##in	O
1229	,	O
1229	and	O
1229	the	O
1229	plasma	O
1229	concentrations	O
1229	of	O
1229	am	O
1229	##is	O
1229	##ulp	O
1229	##ride	O
1229	were	O
1229	little	O
1229	changed	O
1229	by	O
1229	ethanol	O
1229	.	O
1229	[SEP]	O
1230	[CLS]	O
1230	animals	O
1230	were	O
1230	kept	O
1230	in	O
1230	a	O
1230	temperature	O
1230	-	O
1230	controlled	O
1230	environment	O
1230	with	O
1230	a	O
1230	12	O
1230	-	O
1230	hour	O
1230	light	O
1230	/	O
1230	12	O
1230	-	O
1230	hour	O
1230	dark	O
1230	cycle	O
1230	.	O
1230	[SEP]	O
1231	[CLS]	O
1231	p	O
1231	##har	O
1231	##ma	O
1231	##co	O
1231	##kin	O
1231	##etic	O
1231	parameters	O
1231	,	O
1231	including	O
1231	area	B-PK
1231	under	I-PK
1231	the	I-PK
1231	curve	I-PK
1231	from	I-PK
1231	0	I-PK
1231	##h	I-PK
1231	to	I-PK
1231	the	I-PK
1231	last	I-PK
1231	measured	I-PK
1231	point	I-PK
1231	24	I-PK
1231	##h	I-PK
1231	[	I-PK
1231	au	I-PK
1231	##c	I-PK
1231	(	I-PK
1231	(	I-PK
1231	0	I-PK
1231	-	I-PK
1231	24	I-PK
1231	)	I-PK
1231	)	I-PK
1231	]	I-PK
1231	,	O
1231	area	B-PK
1231	under	I-PK
1231	the	I-PK
1231	curve	I-PK
1231	from	I-PK
1231	0	I-PK
1231	##h	I-PK
1231	to	I-PK
1231	infinite	I-PK
1231	time	I-PK
1231	[	I-PK
1231	au	I-PK
1231	##c	I-PK
1231	(	I-PK
1231	(	I-PK
1231	0	I-PK
1231	-	I-PK
1231	∞	I-PK
1231	)	I-PK
1231	)	I-PK
1231	]	I-PK
1231	,	O
1231	peak	B-PK
1231	plasma	I-PK
1231	concentration	I-PK
1231	(	I-PK
1231	c	I-PK
1231	(	I-PK
1231	ma	I-PK
1231	##x	I-PK
1231	)	I-PK
1231	)	I-PK
1231	,	O
1231	time	B-PK
1231	to	I-PK
1231	reach	I-PK
1231	c	I-PK
1231	(	I-PK
1231	ma	I-PK
1231	##x	I-PK
1231	)	I-PK
1231	(	I-PK
1231	t	I-PK
1231	(	I-PK
1231	ma	I-PK
1231	##x	I-PK
1231	)	I-PK
1231	)	I-PK
1231	,	O
1231	oral	B-PK
1231	clearance	I-PK
1231	(	I-PK
1231	c	I-PK
1231	##l	I-PK
1231	)	I-PK
1231	,	O
1231	oral	B-PK
1231	volume	I-PK
1231	of	I-PK
1231	distribution	I-PK
1231	(	I-PK
1231	v	I-PK
1231	(	I-PK
1231	d	I-PK
1231	)	I-PK
1231	)	I-PK
1231	and	O
1231	elimination	B-PK
1231	half	I-PK
1231	-	I-PK
1231	life	I-PK
1231	(	I-PK
1231	t	I-PK
1231	(	I-PK
1231	1	I-PK
1231	/	I-PK
1231	2	I-PK
1231	)	I-PK
1231	)	I-PK
1231	,	O
1231	were	O
1231	determined	O
1231	following	O
1231	a	O
1231	single	O
1231	oral	O
1231	dose	O
1231	of	O
1231	los	O
1231	##art	O
1231	##an	O
1231	.	O
1231	[SEP]	O
1232	[CLS]	O
1232	at	O
1232	about	O
1232	84	O
1232	minutes	O
1232	after	O
1232	a	O
1232	b	O
1232	##ol	O
1232	##us	O
1232	injection	O
1232	of	O
1232	1	O
1232	g	O
1232	dose	O
1232	of	O
1232	c	O
1232	##d	O
1232	##z	O
1232	##m	O
1232	,	O
1232	the	O
1232	drug	O
1232	was	O
1232	transferred	O
1232	well	O
1232	into	O
1232	tissues	O
1232	of	O
1232	internal	O
1232	g	O
1232	##eni	O
1232	##tal	O
1232	organs	O
1232	and	O
1232	remained	O
1232	there	O
1232	at	O
1232	therapeutic	O
1232	levels	O
1232	for	O
1232	285	O
1232	minutes	O
1232	.	O
1232	[SEP]	O
1233	[CLS]	O
1233	we	O
1233	prepared	O
1233	r	O
1233	##t	O
1233	##v	O
1233	isn	O
1233	##p	O
1233	g	O
1233	##ran	O
1233	##ules	O
1233	by	O
1233	using	O
1233	our	O
1233	novel	O
1233	isn	O
1233	##p	O
1233	na	O
1233	##note	O
1233	##ch	O
1233	##nology	O
1233	,	O
1233	as	O
1233	shown	O
1233	in	O
1233	figure	O
1233	1	O
1233	##b	O
1233	.	O
1233	[SEP]	O
1234	[CLS]	O
1234	applications	O
1234	of	O
1234	surf	O
1234	##act	O
1234	##ant	O
1234	in	O
1234	ni	O
1234	##oso	O
1234	##mal	O
1234	drug	O
1234	delivery	O
1234	were	O
1234	explored	O
1234	using	O
1234	c	O
1234	##ef	O
1234	##ix	O
1234	##ime	O
1234	as	O
1234	model	O
1234	.	O
1234	[SEP]	O
1235	[CLS]	O
1235	the	O
1235	super	O
1235	##nat	O
1235	##ant	O
1235	was	O
1235	collected	O
1235	,	O
1235	and	O
1235	its	O
1235	concentration	O
1235	was	O
1235	determined	O
1235	using	O
1235	high	O
1235	performance	O
1235	liquid	O
1235	ch	O
1235	##roma	O
1235	##tography	O
1235	at	O
1235	270	O
1235	nm	O
1235	.	O
1235	[SEP]	O
1236	[CLS]	O
1236	o	O
1236	##xy	O
1236	##co	O
1236	##don	O
1236	##e	O
1236	is	O
1236	an	O
1236	op	O
1236	##io	O
1236	##id	O
1236	ago	O
1236	##nist	O
1236	largely	O
1236	prescribed	O
1236	for	O
1236	the	O
1236	treatment	O
1236	of	O
1236	moderate	O
1236	to	O
1236	severe	O
1236	pain	O
1236	.	O
1236	[SEP]	O
1237	[CLS]	O
1237	in	O
1237	this	O
1237	single	O
1237	-	O
1237	dose	O
1237	study	O
1237	,	O
1237	when	O
1237	p	O
1237	##elle	O
1237	##ts	O
1237	from	O
1237	m	O
1237	##s	O
1237	-	O
1237	s	O
1237	##nt	O
1237	were	O
1237	crushed	O
1237	,	O
1237	na	O
1237	##lt	O
1237	##re	O
1237	##xon	O
1237	##e	O
1237	appeared	O
1237	to	O
1237	be	O
1237	completely	O
1237	released	O
1237	and	O
1237	available	O
1237	to	O
1237	mit	O
1237	##igate	O
1237	m	O
1237	##or	O
1237	##phine	O
1237	-	O
1237	induced	O
1237	effects	O
1237	.	O
1237	[SEP]	O
1238	[CLS]	O
1238	our	O
1238	in	O
1238	v	O
1238	##it	O
1238	##ro	O
1238	studies	O
1238	had	O
1238	demonstrated	O
1238	that	O
1238	bi	O
1238	##l	O
1238	##r	O
1238	35	O
1238	##5	O
1238	was	O
1238	extensively	O
1238	meta	O
1238	##bol	O
1238	##ized	O
1238	by	O
1238	c	O
1238	##yt	O
1238	##och	O
1238	##rome	O
1238	p	O
1238	##45	O
1238	##0	O
1238	3	O
1238	##a	O
1238	.	O
1238	[SEP]	O
1239	[CLS]	O
1239	the	O
1239	associated	O
1239	apparent	B-PK
1239	terminal	I-PK
1239	elimination	I-PK
1239	half	I-PK
1239	-	I-PK
1239	life	I-PK
1239	(	I-PK
1239	t	I-PK
1239	##1	I-PK
1239	/	I-PK
1239	2	I-PK
1239	)	I-PK
1239	was	O
1239	calculated	O
1239	as	O
1239	t	O
1239	##1	O
1239	/	O
1239	2	O
1239	=	O
1239	l	O
1239	##n	O
1239	##2	O
1239	/	O
1239	l	O
1239	##z	O
1239	.	O
1239	[SEP]	O
1240	[CLS]	O
1240	competitive	O
1240	binding	O
1240	ass	O
1240	##ays	O
1240	were	O
1240	performed	O
1240	to	O
1240	examine	O
1240	direct	O
1240	binding	O
1240	of	O
1240	fl	O
1240	##av	O
1240	##ono	O
1240	##id	O
1240	g	O
1240	##lu	O
1240	##cu	O
1240	##ron	O
1240	##ides	O
1240	and	O
1240	a	O
1240	##gly	O
1240	##con	O
1240	##es	O
1240	to	O
1240	human	O
1240	er	O
1240	##s	O
1240	.	O
1240	[SEP]	O
1241	[CLS]	O
1241	serum	O
1241	bio	O
1241	##chemical	O
1241	parameters	O
1241	indicate	O
1241	that	O
1241	liver	O
1241	and	O
1241	kidney	O
1241	function	O
1241	were	O
1241	not	O
1241	remarkably	O
1241	affected	O
1241	,	O
1241	and	O
1241	m	O
1241	##or	O
1241	##phological	O
1241	changes	O
1241	in	O
1241	the	O
1241	liver	O
1241	and	O
1241	s	O
1241	##ple	O
1241	##en	O
1241	were	O
1241	ne	O
1241	##gli	O
1241	##gible	O
1241	.	O
1241	[SEP]	O
1242	[CLS]	O
1242	the	O
1242	recommended	O
1242	oral	O
1242	di	O
1242	##f	O
1242	##lo	O
1242	##mote	O
1242	##can	O
1242	dose	O
1242	for	O
1242	phase	O
1242	ii	O
1242	studies	O
1242	is	O
1242	0	O
1242	.	O
1242	27	O
1242	mg	O
1242	/	O
1242	day	O
1242	x	O
1242	5	O
1242	every	O
1242	3	O
1242	weeks	O
1242	.	O
1242	[SEP]	O
1243	[CLS]	O
1243	cellular	O
1243	distribution	O
1243	of	O
1243	drugs	O
1243	was	O
1243	observed	O
1243	by	O
1243	c	O
1243	##ls	O
1243	##m	O
1243	imaging	O
1243	.	O
1243	[SEP]	O
1244	[CLS]	O
1244	eleven	O
1244	rats	O
1244	contributed	O
1244	p	O
1244	##k	O
1244	data	O
1244	.	O
1244	[SEP]	O
1245	[CLS]	O
1245	this	O
1245	study	O
1245	demonstrated	O
1245	that	O
1245	p	O
1245	##b	O
1245	##p	O
1245	##k	O
1245	is	O
1245	a	O
1245	useful	O
1245	tool	O
1245	to	O
1245	predict	O
1245	human	O
1245	p	O
1245	##k	O
1245	when	O
1245	inter	O
1245	##sp	O
1245	##ec	O
1245	##ies	O
1245	extra	O
1245	##pol	O
1245	##ation	O
1245	is	O
1245	not	O
1245	applicable	O
1245	.	O
1245	[SEP]	O
1246	[CLS]	O
1246	experiments	O
1246	were	O
1246	performed	O
1246	on	O
1246	a	O
1246	q	O
1246	-	O
1246	to	O
1246	##f	O
1246	instrument	O
1246	,	O
1246	operated	O
1246	in	O
1246	the	O
1246	m	O
1246	##s	O
1246	/	O
1246	m	O
1246	##s	O
1246	mode	O
1246	.	O
1246	[SEP]	O
1247	[CLS]	O
1247	co	O
1247	##bal	O
1247	##ami	O
1247	##n	O
1247	and	O
1247	ho	O
1247	##lot	O
1247	##c	O
1247	declined	O
1247	on	O
1247	average	O
1247	with	O
1247	47	O
1247	and	O
1247	56	O
1247	%	O
1247	relative	O
1247	to	O
1247	concentrations	O
1247	at	O
1247	the	O
1247	end	O
1247	of	O
1247	supplement	O
1247	##ation	O
1247	for	O
1247	the	O
1247	group	O
1247	assessed	O
1247	at	O
1247	7	O
1247	months	O
1247	post	O
1247	-	O
1247	supplement	O
1247	##ation	O
1247	.	O
1247	[SEP]	O
1248	[CLS]	O
1248	the	O
1248	in	O
1248	v	O
1248	##ivo	O
1248	and	O
1248	in	O
1248	v	O
1248	##it	O
1248	##ro	O
1248	experiments	O
1248	showed	O
1248	good	O
1248	relevance	O
1248	and	O
1248	consistency	O
1248	.	O
1248	[SEP]	O
1249	[CLS]	O
1249	all	O
1249	statistical	O
1249	analyses	O
1249	were	O
1249	performed	O
1249	using	O
1249	s	O
1249	##ys	O
1249	##tat	O
1249	13	O
1249	(	O
1249	s	O
1249	##ys	O
1249	##tat	O
1249	software	O
1249	in	O
1249	##c	O
1249	,	O
1249	ch	O
1249	##ica	O
1249	##go	O
1249	,	O
1249	us	O
1249	##a	O
1249	)	O
1249	.	O
1249	[SEP]	O
1250	[CLS]	O
1250	a	O
1250	pool	O
1250	##ed	O
1250	re	O
1250	##gression	O
1250	of	O
1250	the	O
1250	combined	O
1250	cc	O
1250	##ip	O
1250	and	O
1250	zero	O
1250	-	O
1250	order	O
1250	data	O
1250	confirmed	O
1250	that	O
1250	the	O
1250	co	O
1250	##var	O
1250	##iate	O
1250	,	O
1250	height	O
1250	(	O
1250	cm	O
1250	)	O
1250	,	O
1250	was	O
1250	related	O
1250	in	O
1250	linear	O
1250	fashion	O
1250	to	O
1250	c	B-PK
1250	##l	I-PK
1250	##1	I-PK
1250	.	O
1250	[SEP]	O
1251	[CLS]	O
1251	oral	O
1251	m	O
1251	##r	O
1251	##x	O
1251	-	O
1251	i	O
1251	was	O
1251	well	O
1251	tolerate	O
1251	##d	O
1251	at	O
1251	single	O
1251	doses	O
1251	of	O
1251	up	O
1251	to	O
1251	1	O
1251	,	O
1251	200	O
1251	and	O
1251	800	O
1251	mg	O
1251	q	O
1251	##12	O
1251	##h	O
1251	for	O
1251	up	O
1251	to	O
1251	28	O
1251	days	O
1251	;	O
1251	all	O
1251	adverse	O
1251	events	O
1251	were	O
1251	mild	O
1251	to	O
1251	moderate	O
1251	in	O
1251	severity	O
1251	,	O
1251	and	O
1251	there	O
1251	was	O
1251	no	O
1251	drug	O
1251	disco	O
1251	##ntin	O
1251	##uation	O
1251	due	O
1251	to	O
1251	adverse	O
1251	events	O
1251	.	O
1251	[SEP]	O
1252	[CLS]	O
1252	the	O
1252	matrix	O
1252	effect	O
1252	was	O
1252	evaluated	O
1252	by	O
1252	comparing	O
1252	the	O
1252	anal	O
1252	##yte	O
1252	/	O
1252	internal	O
1252	standard	O
1252	peak	O
1252	ratios	O
1252	dissolved	O
1252	with	O
1252	blank	O
1252	matrix	O
1252	extract	O
1252	against	O
1252	those	O
1252	dissolved	O
1252	with	O
1252	the	O
1252	mobile	O
1252	phase	O
1252	at	O
1252	high	O
1252	,	O
1252	medium	O
1252	and	O
1252	low	O
1252	levels	O
1252	.	O
1252	[SEP]	O
1253	[CLS]	O
1253	the	O
1253	literature	O
1253	search	O
1253	identified	O
1253	a	O
1253	total	O
1253	of	O
1253	35	O
1253	pub	O
1253	##med	O
1253	records	O
1253	,	O
1253	148	O
1253	em	O
1253	##base	O
1253	records	O
1253	and	O
1253	70	O
1253	clinical	O
1253	trials	O
1253	(	O
1253	figure	O
1253	1	O
1253	)	O
1253	.	O
1253	[SEP]	O
1254	[CLS]	O
1254	a	O
1254	significant	O
1254	linear	O
1254	correlation	O
1254	in	O
1254	the	O
1254	values	O
1254	of	O
1254	f	O
1254	##e	O
1254	p	O
1254	##hen	O
1254	##ols	O
1254	and	O
1254	f	O
1254	##eh	O
1254	##2	O
1254	##o	O
1254	and	O
1254	those	O
1254	of	O
1254	f	O
1254	##e	O
1254	p	O
1254	##hen	O
1254	##ols	O
1254	and	O
1254	f	O
1254	##e	O
1254	u	O
1254	##rea	O
1254	was	O
1254	documented	O
1254	.	O
1254	[SEP]	O
1255	[CLS]	O
1255	the	O
1255	highest	O
1255	enzyme	O
1255	levels	O
1255	were	O
1255	found	O
1255	after	O
1255	4	O
1255	d	O
1255	of	O
1255	starvation	O
1255	following	O
1255	the	O
1255	7	O
1255	d	O
1255	of	O
1255	treatment	O
1255	and	O
1255	6	O
1255	d	O
1255	of	O
1255	recovery	O
1255	.	O
1255	[SEP]	O
1256	[CLS]	O
1256	no	O
1256	acute	O
1256	rejection	O
1256	or	O
1256	mortality	O
1256	occurred	O
1256	during	O
1256	the	O
1256	follow	O
1256	-	O
1256	up	O
1256	period	O
1256	.	O
1256	[SEP]	O
1257	[CLS]	O
1257	thus	O
1257	,	O
1257	at	O
1257	low	O
1257	concentrations	O
1257	very	O
1257	small	O
1257	differences	O
1257	in	O
1257	population	O
1257	‐	O
1257	predicted	O
1257	and	O
1257	observed	O
1257	times	O
1257	of	O
1257	reaching	O
1257	the	O
1257	ll	O
1257	##o	O
1257	##q	O
1257	level	O
1257	led	O
1257	to	O
1257	very	O
1257	large	O
1257	fold	O
1257	differences	O
1257	between	O
1257	the	O
1257	observed	O
1257	(	O
1257	d	O
1257	##v	O
1257	)	O
1257	and	O
1257	predicted	O
1257	concentrations	O
1257	(	O
1257	pre	O
1257	##d	O
1257	)	O
1257	,	O
1257	which	O
1257	may	O
1257	look	O
1257	like	O
1257	out	O
1257	##liers	O
1257	in	O
1257	log	O
1257	–	O
1257	log	O
1257	figures	O
1257	.	O
1257	[SEP]	O
1258	[CLS]	O
1258	the	O
1258	t	B-PK
1258	##1	I-PK
1258	/	I-PK
1258	2	I-PK
1258	,	O
1258	ca	B-PK
1258	##v	I-PK
1258	,	I-PK
1258	s	I-PK
1258	##s	I-PK
1258	,	O
1258	and	O
1258	au	B-PK
1258	##c	I-PK
1258	##τ	I-PK
1258	,	I-PK
1258	s	I-PK
1258	##s	I-PK
1258	for	O
1258	en	O
1258	##zas	O
1258	##ta	O
1258	##uri	O
1258	##n	O
1258	and	O
1258	its	O
1258	primary	O
1258	active	O
1258	meta	O
1258	##bol	O
1258	##ite	O
1258	l	O
1258	##s	O
1258	##n	O
1258	##32	O
1258	##60	O
1258	##20	O
1258	were	O
1258	14	O
1258	and	O
1258	42	O
1258	h	O
1258	,	O
1258	1	O
1258	,	O
1258	210	O
1258	and	O
1258	90	O
1258	##7	O
1258	nm	O
1258	##ol	O
1258	/	O
1258	l	O
1258	,	O
1258	and	O
1258	29	O
1258	,	O
1258	100	O
1258	and	O
1258	21	O
1258	,	O
1258	800	O
1258	nm	O
1258	##ol	O
1258	•	O
1258	h	O
1258	/	O
1258	l	O
1258	,	O
1258	respectively	O
1258	.	O
1258	[SEP]	O
1259	[CLS]	O
1259	results	O
1259	were	O
1259	correlated	O
1259	to	O
1259	explain	O
1259	the	O
1259	p	O
1259	##har	O
1259	##ma	O
1259	##co	O
1259	##kin	O
1259	##etics	O
1259	of	O
1259	the	O
1259	main	O
1259	drugs	O
1259	administered	O
1259	.	O
1259	[SEP]	O
1260	[CLS]	O
1260	the	O
1260	animals	O
1260	were	O
1260	divided	O
1260	into	O
1260	four	O
1260	experimental	O
1260	groups	O
1260	(	O
1260	n	O
1260	=	O
1260	6	O
1260	/	O
1260	group	O
1260	)	O
1260	.	O
1260	[SEP]	O
1261	[CLS]	O
1261	anti	O
1261	-	O
1261	an	O
1261	##gio	O
1261	##genic	O
1261	drugs	O
1261	that	O
1261	target	O
1261	vascular	O
1261	end	O
1261	##oth	O
1261	##eli	O
1261	##al	O
1261	growth	O
1261	factor	O
1261	(	O
1261	ve	O
1261	##g	O
1261	##f	O
1261	)	O
1261	signaling	O
1261	pathways	O
1261	caused	O
1261	h	O
1261	##yper	O
1261	##tens	O
1261	##ion	O
1261	as	O
1261	an	O
1261	adverse	O
1261	effect	O
1261	in	O
1261	clinical	O
1261	studies	O
1261	.	O
1261	[SEP]	O
1262	[CLS]	O
1262	to	O
1262	##xin	O
1262	##s	O
1262	complex	O
1262	were	O
1262	prepared	O
1262	from	O
1262	concentrated	O
1262	super	O
1262	##nat	O
1262	##ants	O
1262	of	O
1262	cultures	O
1262	grown	O
1262	for	O
1262	6	O
1262	days	O
1262	in	O
1262	an	O
1262	##ae	O
1262	##ro	O
1262	##bic	O
1262	culture	O
1262	tubes	O
1262	.	O
1262	[SEP]	O
1263	[CLS]	O
1263	on	O
1263	the	O
1263	basis	O
1263	of	O
1263	the	O
1263	in	O
1263	##tra	O
1263	##ven	O
1263	##ous	O
1263	injection	O
1263	study	O
1263	,	O
1263	systemic	B-PK
1263	bio	I-PK
1263	##ava	I-PK
1263	##ila	I-PK
1263	##bility	I-PK
1263	averaged	O
1263	66	O
1263	%	O
1263	and	O
1263	70	O
1263	%	O
1263	for	O
1263	the	O
1263	75	O
1263	mg	O
1263	and	O
1263	three	O
1263	25	O
1263	mg	O
1263	tablets	O
1263	respectively	O
1263	.	O
1263	[SEP]	O
1264	[CLS]	O
1264	the	O
1264	ch	O
1264	##roma	O
1264	##to	O
1264	##graphic	O
1264	conditions	O
1264	were	O
1264	modified	O
1264	from	O
1264	our	O
1264	recent	O
1264	methods	O
1264	for	O
1264	the	O
1264	q	O
1264	##uant	O
1264	##ification	O
1264	of	O
1264	various	O
1264	s	O
1264	##til	O
1264	##ben	O
1264	##es	O
1264	[	O
1264	8	O
1264	,	O
1264	9	O
1264	,	O
1264	10	O
1264	,	O
1264	11	O
1264	,	O
1264	12	O
1264	,	O
1264	13	O
1264	,	O
1264	14	O
1264	]	O
1264	.	O
1264	[SEP]	O
1265	[CLS]	O
1265	drug	O
1265	and	O
1265	statistics	O
1265	(	O
1265	das	O
1265	)	O
1265	software	O
1265	(	O
1265	version	O
1265	3	O
1265	.	O
1265	0	O
1265	)	O
1265	was	O
1265	used	O
1265	to	O
1265	calculate	O
1265	the	O
1265	p	O
1265	##har	O
1265	##ma	O
1265	##co	O
1265	##kin	O
1265	##etic	O
1265	parameters	O
1265	.	O
1265	[SEP]	O
1266	[CLS]	O
1266	the	O
1266	absorption	B-PK
1266	half	I-PK
1266	-	I-PK
1266	time	I-PK
1266	for	O
1266	total	O
1266	p	O
1266	##oly	O
1266	##ch	O
1266	##lor	O
1266	##inated	O
1266	bi	O
1266	##phe	O
1266	##ny	O
1266	##l	O
1266	in	O
1266	s	O
1266	##wine	O
1266	was	O
1266	1	O
1266	.	O
1266	13	O
1266	h	O
1266	##r	O
1266	while	O
1266	that	O
1266	for	O
1266	sheep	O
1266	was	O
1266	3	O
1266	.	O
1266	83	O
1266	h	O
1266	##r	O
1266	.	O
1266	[SEP]	O
1267	[CLS]	O
1267	v	O
1267	##al	O
1267	-	O
1267	g	O
1267	##c	O
1267	##v	O
1267	and	O
1267	v	O
1267	##al	O
1267	-	O
1267	v	O
1267	##al	O
1267	-	O
1267	g	O
1267	##c	O
1267	##v	O
1267	in	O
1267	##hibit	O
1267	##ed	O
1267	re	O
1267	##tina	O
1267	##l	O
1267	up	O
1267	##take	O
1267	of	O
1267	[	O
1267	3	O
1267	##h	O
1267	]	O
1267	g	O
1267	##ly	O
1267	-	O
1267	sa	O
1267	##r	O
1267	by	O
1267	43	O
1267	%	O
1267	and	O
1267	37	O
1267	%	O
1267	,	O
1267	respectively	O
1267	,	O
1267	suggesting	O
1267	that	O
1267	these	O
1267	pro	O
1267	##dr	O
1267	##ugs	O
1267	may	O
1267	be	O
1267	substrates	O
1267	of	O
1267	the	O
1267	re	O
1267	##tina	O
1267	##l	O
1267	p	O
1267	##eptide	O
1267	transport	O
1267	system	O
1267	.	O
1267	[SEP]	O
1268	[CLS]	O
1268	we	O
1268	therefore	O
1268	undertook	O
1268	the	O
1268	development	O
1268	of	O
1268	a	O
1268	radio	O
1268	##im	O
1268	##mu	O
1268	##no	O
1268	##ass	O
1268	##ay	O
1268	(	O
1268	r	O
1268	##ia	O
1268	)	O
1268	.	O
1268	[SEP]	O
1269	[CLS]	O
1269	twenty	O
1269	healthy	O
1269	subjects	O
1269	(	O
1269	10	O
1269	male	O
1269	and	O
1269	10	O
1269	female	O
1269	)	O
1269	of	O
1269	east	O
1269	as	O
1269	##ian	O
1269	heritage	O
1269	and	O
1269	resident	O
1269	in	O
1269	chin	O
1269	##a	O
1269	were	O
1269	enrolled	O
1269	.	O
1269	[SEP]	O
1270	[CLS]	O
1270	video	O
1270	recordings	O
1270	of	O
1270	ca	O
1270	##lves	O
1270	walking	O
1270	through	O
1270	a	O
1270	1	O
1270	x	O
1270	3	O
1270	m	O
1270	alley	O
1270	were	O
1270	collected	O
1270	on	O
1270	d	O
1270	-	O
1270	2	O
1270	,	O
1270	-	O
1270	1	O
1270	,	O
1270	immediately	O
1270	after	O
1270	cast	O
1270	##ration	O
1270	,	O
1270	30	O
1270	,	O
1270	60	O
1270	,	O
1270	90	O
1270	,	O
1270	120	O
1270	,	O
1270	150	O
1270	,	O
1270	240	O
1270	min	O
1270	and	O
1270	on	O
1270	d	O
1270	1	O
1270	,	O
1270	2	O
1270	,	O
1270	3	O
1270	,	O
1270	5	O
1270	,	O
1270	7	O
1270	,	O
1270	10	O
1270	,	O
1270	14	O
1270	,	O
1270	21	O
1270	and	O
1270	28	O
1270	after	O
1270	cast	O
1270	##ration	O
1270	.	O
1270	[SEP]	O
1271	[CLS]	O
1271	results	O
1271	obtained	O
1271	show	O
1271	that	O
1271	1	O
1271	)	O
1271	in	O
1271	##test	O
1271	##inal	O
1271	absorption	O
1271	kinetic	O
1271	##s	O
1271	of	O
1271	am	O
1271	##ox	O
1271	##ici	O
1271	##llin	O
1271	follows	O
1271	a	O
1271	zero	O
1271	-	O
1271	order	O
1271	process	O
1271	,	O
1271	which	O
1271	further	O
1271	sub	O
1271	##stant	O
1271	##iate	O
1271	##s	O
1271	the	O
1271	existence	O
1271	of	O
1271	a	O
1271	sat	O
1271	##urable	O
1271	carrier	O
1271	-	O
1271	mediated	O
1271	process	O
1271	for	O
1271	this	O
1271	anti	O
1271	##biotic	O
1271	in	O
1271	humans	O
1271	and	O
1271	2	O
1271	)	O
1271	calcium	O
1271	channel	O
1271	blockade	O
1271	significantly	O
1271	enhance	O
1271	##s	O
1271	both	O
1271	absorption	B-PK
1271	rate	I-PK
1271	(	O
1271	by	O
1271	70	O
1271	%	O
1271	)	O
1271	and	O
1271	bio	B-PK
1271	##ava	I-PK
1271	##ila	I-PK
1271	##bility	I-PK
1271	of	O
1271	am	O
1271	##ox	O
1271	##ici	O
1271	##llin	O
1271	(	O
1271	by	O
1271	21	O
1271	.	O
1271	4	O
1271	%	O
1271	)	O
1271	without	O
1271	modify	O
1271	##ing	O
1271	its	O
1271	distribution	O
1271	or	O
1271	elimination	O
1271	.	O
1271	[SEP]	O
1272	[CLS]	O
1272	compound	O
1272	5	O
1272	(	O
1272	35	O
1272	mg	O
1272	,	O
1272	quantitative	O
1272	yield	O
1272	)	O
1272	was	O
1272	obtained	O
1272	using	O
1272	the	O
1272	compound	O
1272	4	O
1272	(	O
1272	35	O
1272	mg	O
1272	,	O
1272	0	O
1272	.	O
1272	1	O
1272	mm	O
1272	##ol	O
1272	)	O
1272	as	O
1272	starting	O
1272	material	O
1272	in	O
1272	the	O
1272	same	O
1272	experimental	O
1272	conditions	O
1272	previously	O
1272	described	O
1272	for	O
1272	compound	O
1272	2	O
1272	.	O
1272	[SEP]	O
1273	[CLS]	O
1273	if	O
1273	no	O
1273	acute	O
1273	all	O
1273	##ergic	O
1273	reaction	O
1273	occurred	O
1273	after	O
1273	the	O
1273	first	O
1273	in	O
1273	##fusion	O
1273	,	O
1273	patients	O
1273	received	O
1273	subsequent	O
1273	in	O
1273	##fusion	O
1273	##s	O
1273	without	O
1273	pre	O
1273	##med	O
1273	##ica	O
1273	##tion	O
1273	,	O
1273	at	O
1273	the	O
1273	investigator	O
1273	'	O
1273	s	O
1273	discretion	O
1273	.	O
1273	[SEP]	O
1274	[CLS]	O
1274	additional	O
1274	samples	O
1274	were	O
1274	obtained	O
1274	on	O
1274	day	O
1274	8	O
1274	,	O
1274	15	O
1274	,	O
1274	22	O
1274	and	O
1274	28	O
1274	of	O
1274	cycle	O
1274	1	O
1274	.	O
1274	[SEP]	O
1275	[CLS]	O
1275	s	O
1275	##tero	O
1275	##id	O
1275	and	O
1275	mm	O
1275	##f	O
1275	therapy	O
1275	was	O
1275	the	O
1275	same	O
1275	as	O
1275	the	O
1275	ta	O
1275	##c	O
1275	##rol	O
1275	##imus	O
1275	regime	O
1275	##n	O
1275	.	O
1275	[SEP]	O
1276	[CLS]	O
1276	tissues	O
1276	(	O
1276	brain	O
1276	,	O
1276	liver	O
1276	and	O
1276	s	O
1276	##ple	O
1276	##en	O
1276	)	O
1276	and	O
1276	serum	O
1276	were	O
1276	obtained	O
1276	from	O
1276	the	O
1276	surviving	O
1276	g	O
1276	##uin	O
1276	##ea	O
1276	pigs	O
1276	at	O
1276	the	O
1276	end	O
1276	of	O
1276	the	O
1276	study	O
1276	for	O
1276	j	O
1276	##un	O
1276	##v	O
1276	-	O
1276	specific	O
1276	r	O
1276	##t	O
1276	-	O
1276	p	O
1276	##c	O
1276	##r	O
1276	analysis	O
1276	,	O
1276	as	O
1276	well	O
1276	as	O
1276	his	O
1276	##top	O
1276	##ath	O
1276	##ology	O
1276	.	O
1276	[SEP]	O
1277	[CLS]	O
1277	kidney	O
1277	ex	O
1277	##cre	O
1277	##tion	O
1277	of	O
1277	h	O
1277	##bo	O
1277	##cs	O
1277	is	O
1277	greatly	O
1277	diminished	O
1277	compared	O
1277	to	O
1277	that	O
1277	of	O
1277	un	O
1277	##mo	O
1277	##dified	O
1277	h	O
1277	##b	O
1277	,	O
1277	but	O
1277	the	O
1277	liver	O
1277	remains	O
1277	a	O
1277	primary	O
1277	site	O
1277	of	O
1277	cat	O
1277	##ab	O
1277	##olis	O
1277	##m	O
1277	.	O
1277	[SEP]	O
1278	[CLS]	O
1278	ni	O
1278	##rap	O
1278	##ari	O
1278	##b	O
1278	-	O
1278	be	O
1278	##va	O
1278	##ci	O
1278	##zu	O
1278	##ma	O
1278	##b	O
1278	showed	O
1278	promising	O
1278	activity	O
1278	;	O
1278	part	O
1278	2	O
1278	(	O
1278	vs	O
1278	be	O
1278	##va	O
1278	##ci	O
1278	##zu	O
1278	##ma	O
1278	##b	O
1278	)	O
1278	was	O
1278	recently	O
1278	reported	O
1278	and	O
1278	phase	O
1278	ii	O
1278	##i	O
1278	comparison	O
1278	with	O
1278	standard	O
1278	-	O
1278	of	O
1278	-	O
1278	care	O
1278	therapy	O
1278	is	O
1278	planned	O
1278	.	O
1278	[SEP]	O
1279	[CLS]	O
1279	the	O
1279	er	O
1279	##yt	O
1279	##hr	O
1279	##op	O
1279	##oi	O
1279	##eti	O
1279	##n	O
1279	mi	O
1279	##met	O
1279	##ic	O
1279	anti	O
1279	##body	O
1279	fusion	O
1279	protein	O
1279	c	O
1279	##nto	O
1279	52	O
1279	##8	O
1279	was	O
1279	developed	O
1279	as	O
1279	a	O
1279	novel	O
1279	anti	O
1279	##body	O
1279	fusion	O
1279	protein	O
1279	by	O
1279	constructing	O
1279	an	O
1279	active	O
1279	hem	O
1279	##ato	O
1279	##po	O
1279	##iet	O
1279	##ic	O
1279	p	O
1279	##eptide	O
1279	onto	O
1279	an	O
1279	i	O
1279	##gg	O
1279	##1	O
1279	-	O
1279	based	O
1279	s	O
1279	##ca	O
1279	##ff	O
1279	##old	O
1279	.	O
1279	[SEP]	O
1280	[CLS]	O
1280	the	O
1280	hem	O
1280	##og	O
1280	##lo	O
1280	##bin	O
1280	de	O
1280	##ple	O
1280	##tion	O
1280	-	O
1280	re	O
1280	##ple	O
1280	##tion	O
1280	method	O
1280	was	O
1280	used	O
1280	in	O
1280	w	O
1280	##ista	O
1280	##r	O
1280	rats	O
1280	.	O
1280	[SEP]	O
1281	[CLS]	O
1281	the	O
1281	tubes	O
1281	were	O
1281	v	O
1281	##ortex	O
1281	##ed	O
1281	for	O
1281	1	O
1281	min	O
1281	,	O
1281	and	O
1281	cent	O
1281	##ri	O
1281	##fu	O
1281	##ged	O
1281	at	O
1281	10	O
1281	,	O
1281	000	O
1281	rpm	O
1281	for	O
1281	10	O
1281	min	O
1281	.	O
1281	[SEP]	O
1282	[CLS]	O
1282	dogs	O
1282	(	O
1282	n	O
1282	=	O
1282	7	O
1282	)	O
1282	were	O
1282	an	O
1282	##est	O
1282	##he	O
1282	##tized	O
1282	with	O
1282	ha	O
1282	##lot	O
1282	##hane	O
1282	(	O
1282	1	O
1282	.	O
1282	5	O
1282	%	O
1282	)	O
1282	in	O
1282	oxygen	O
1282	.	O
1282	[SEP]	O
1283	[CLS]	O
1283	this	O
1283	study	O
1283	confirms	O
1283	that	O
1283	lip	O
1283	##oso	O
1283	##me	O
1283	charge	O
1283	is	O
1283	critical	O
1283	to	O
1283	promote	O
1283	its	O
1283	accumulation	O
1283	in	O
1283	the	O
1283	brain	O
1283	in	O
1283	##far	O
1283	##ct	O
1283	after	O
1283	m	O
1283	##ca	O
1283	##ot	O
1283	.	O
1283	[SEP]	O
1284	[CLS]	O
1284	plasma	O
1284	and	O
1284	er	O
1284	##yt	O
1284	##hr	O
1284	##oc	O
1284	##yte	O
1284	concentrations	O
1284	of	O
1284	me	O
1284	##rca	O
1284	##pt	O
1284	##op	O
1284	##uri	O
1284	##ne	O
1284	after	O
1284	oral	O
1284	administration	O
1284	in	O
1284	children	O
1284	.	O
1284	[SEP]	O
1285	[CLS]	O
1285	the	O
1285	instrument	O
1285	system	O
1285	was	O
1285	a	O
1285	waters	O
1285	a	O
1285	##c	O
1285	##qui	O
1285	##ty	O
1285	series	O
1285	up	O
1285	##l	O
1285	##c	O
1285	equipped	O
1285	with	O
1285	an	O
1285	auto	O
1285	##sa	O
1285	##mple	O
1285	##r	O
1285	,	O
1285	a	O
1285	column	O
1285	heat	O
1285	##er	O
1285	,	O
1285	a	O
1285	binary	O
1285	pump	O
1285	coupled	O
1285	to	O
1285	a	O
1285	x	O
1285	##evo	O
1285	t	O
1285	##q	O
1285	-	O
1285	s	O
1285	triple	O
1285	-	O
1285	q	O
1285	##uad	O
1285	##rup	O
1285	##ole	O
1285	mass	O
1285	s	O
1285	##pect	O
1285	##rome	O
1285	##ter	O
1285	with	O
1285	an	O
1285	electro	O
1285	##sp	O
1285	##ray	O
1285	ion	O
1285	##ization	O
1285	source	O
1285	(	O
1285	waters	O
1285	,	O
1285	mi	O
1285	##lf	O
1285	##ord	O
1285	,	O
1285	ma	O
1285	)	O
1285	.	O
1285	[SEP]	O
1286	[CLS]	O
1286	the	O
1286	flow	O
1286	rate	O
1286	was	O
1286	set	O
1286	at	O
1286	1	O
1286	.	O
1286	0	O
1286	m	O
1286	##l	O
1286	/	O
1286	min	O
1286	.	O
1286	[SEP]	O
1287	[CLS]	O
1287	met	O
1287	##hyl	O
1287	5	O
1287	-	O
1287	ni	O
1287	##tro	O
1287	-	O
1287	1	O
1287	##h	O
1287	-	O
1287	in	O
1287	##do	O
1287	##le	O
1287	-	O
1287	3	O
1287	-	O
1287	car	O
1287	##box	O
1287	##yla	O
1287	##te	O
1287	(	O
1287	200	O
1287	mg	O
1287	,	O
1287	0	O
1287	.	O
1287	91	O
1287	mm	O
1287	##ol	O
1287	)	O
1287	used	O
1287	h	O
1287	##ydro	O
1287	##lysis	O
1287	reaction	O
1287	(	O
1287	2	O
1287	n	O
1287	na	O
1287	##oh	O
1287	water	O
1287	solution	O
1287	)	O
1287	to	O
1287	afford	O
1287	d	O
1287	##x	O
1287	-	O
1287	01	O
1287	-	O
1287	04	O
1287	(	O
1287	white	O
1287	solid	O
1287	,	O
1287	172	O
1287	mg	O
1287	,	O
1287	yield	O
1287	92	O
1287	%	O
1287	)	O
1287	.	O
1287	[SEP]	O
1288	[CLS]	O
1288	m	O
1288	##1	O
1288	was	O
1288	the	O
1288	major	O
1288	drug	O
1288	-	O
1288	related	O
1288	component	O
1288	in	O
1288	plasma	O
1288	and	O
1288	urine	O
1288	,	O
1288	accounting	O
1288	for	O
1288	up	O
1288	to	O
1288	95	O
1288	.	O
1288	8	O
1288	%	O
1288	of	O
1288	radio	B-PK
1288	##act	I-PK
1288	##ivity	I-PK
1288	in	O
1288	plasma	O
1288	.	O
1288	[SEP]	O
1289	[CLS]	O
1289	there	O
1289	were	O
1289	no	O
1289	local	O
1289	reactions	O
1289	(	O
1289	in	O
1289	##fusion	O
1289	site	O
1289	)	O
1289	or	O
1289	evidence	O
1289	of	O
1289	th	O
1289	##rom	O
1289	##bos	O
1289	##is	O
1289	at	O
1289	high	O
1289	doses	O
1289	in	O
1289	rats	O
1289	and	O
1289	monkeys	O
1289	.	O
1289	[SEP]	O
1290	[CLS]	O
1290	con	O
1290	##com	O
1290	##ita	O
1290	##nt	O
1290	im	O
1290	##mu	O
1290	##nos	O
1290	##up	O
1290	##press	O
1290	##ion	O
1290	may	O
1290	affect	O
1290	the	O
1290	my	O
1290	##co	O
1290	##phe	O
1290	##no	O
1290	##late	O
1290	m	O
1290	##of	O
1290	##eti	O
1290	##l	O
1290	exposure	O
1290	.	O
1290	[SEP]	O
1291	[CLS]	O
1291	the	O
1291	average	O
1291	elimination	B-PK
1291	half	I-PK
1291	-	I-PK
1291	life	I-PK
1291	after	O
1291	p	O
1291	##o	O
1291	dos	O
1291	##ing	O
1291	was	O
1291	4	O
1291	.	O
1291	6	O
1291	hours	O
1291	and	O
1291	similar	O
1291	to	O
1291	the	O
1291	half	B-PK
1291	-	I-PK
1291	life	I-PK
1291	observed	O
1291	after	O
1291	i	O
1291	##v	O
1291	dos	O
1291	##ing	O
1291	.	O
1291	[SEP]	O
1292	[CLS]	O
1292	in	O
1292	this	O
1292	study	O
1292	,	O
1292	we	O
1292	examined	O
1292	the	O
1292	potential	O
1292	of	O
1292	dynamic	O
1292	contrast	O
1292	-	O
1292	enhanced	O
1292	magnetic	O
1292	resonance	O
1292	imaging	O
1292	(	O
1292	d	O
1292	##ce	O
1292	-	O
1292	m	O
1292	##ri	O
1292	)	O
1292	for	O
1292	assessment	O
1292	of	O
1292	radiation	O
1292	injury	O
1292	to	O
1292	the	O
1292	par	O
1292	##ot	O
1292	##id	O
1292	glands	O
1292	.	O
1292	[SEP]	O
1293	[CLS]	O
1293	a	O
1293	valid	O
1293	##ated	O
1293	liquid	O
1293	ch	O
1293	##roma	O
1293	##tography	O
1293	–	O
1293	tandem	O
1293	mass	O
1293	s	O
1293	##pect	O
1293	##rome	O
1293	##try	O
1293	method	O
1293	was	O
1293	used	O
1293	for	O
1293	the	O
1293	ex	O
1293	##ci	O
1293	##pie	O
1293	##nt	O
1293	p	O
1293	##eptide	O
1293	(	O
1293	m	O
1293	##l	O
1293	##p	O
1293	)	O
1293	.	O
1293	[SEP]	O
1294	[CLS]	O
1294	the	O
1294	mean	O
1294	plasma	B-PK
1294	elimination	I-PK
1294	half	I-PK
1294	-	I-PK
1294	lives	I-PK
1294	of	O
1294	the	O
1294	various	O
1294	dos	O
1294	##age	O
1294	forms	O
1294	were	O
1294	in	O
1294	the	O
1294	range	O
1294	24	O
1294	.	O
1294	5	O
1294	-	O
1294	25	O
1294	.	O
1294	4	O
1294	h	O
1294	.	O
1294	[SEP]	O
1295	[CLS]	O
1295	after	O
1295	surgery	O
1295	,	O
1295	each	O
1295	rat	O
1295	was	O
1295	given	O
1295	0	O
1295	.	O
1295	25	O
1295	m	O
1295	##l	O
1295	of	O
1295	s	O
1295	##c	O
1295	2	O
1295	.	O
1295	27	O
1295	%	O
1295	en	O
1295	##rol	O
1295	##f	O
1295	##lo	O
1295	##xa	O
1295	##cine	O
1295	once	O
1295	daily	O
1295	for	O
1295	three	O
1295	days	O
1295	as	O
1295	pre	O
1295	##ca	O
1295	##ution	O
1295	against	O
1295	infection	O
1295	.	O
1295	[SEP]	O
1296	[CLS]	O
1296	safety	O
1296	,	O
1296	to	O
1296	##ler	O
1296	##ability	O
1296	,	O
1296	p	O
1296	##har	O
1296	##ma	O
1296	##co	O
1296	##kin	O
1296	##etics	O
1296	,	O
1296	and	O
1296	p	O
1296	##har	O
1296	##ma	O
1296	##co	O
1296	##dynamic	O
1296	##s	O
1296	of	O
1296	the	O
1296	novel	O
1296	γ	O
1296	-	O
1296	secret	O
1296	##ase	O
1296	m	O
1296	##od	O
1296	##ulator	O
1296	,	O
1296	e	O
1296	##22	O
1296	##12	O
1296	,	O
1296	in	O
1296	healthy	O
1296	human	O
1296	subjects	O
1296	.	O
1296	[SEP]	O
1297	[CLS]	O
1297	influence	O
1297	of	O
1297	racial	O
1297	differences	O
1297	on	O
1297	effects	O
1297	of	O
1297	ran	O
1297	##iti	O
1297	##dine	O
1297	and	O
1297	c	O
1297	##ime	O
1297	##ti	O
1297	##dine	O
1297	on	O
1297	i	O
1297	##bu	O
1297	##p	O
1297	##ro	O
1297	##fen	O
1297	p	O
1297	##har	O
1297	##ma	O
1297	##co	O
1297	##kin	O
1297	##etics	O
1297	.	O
1297	[SEP]	O
1298	[CLS]	O
1298	results	O
1298	:	O
1298	the	O
1298	p	O
1298	##hy	O
1298	##si	O
1298	##co	O
1298	##chemical	O
1298	studies	O
1298	showed	O
1298	that	O
1298	the	O
1298	r	O
1298	##ca	O
1298	/	O
1298	c	O
1298	##d	O
1298	complexes	O
1298	were	O
1298	well	O
1298	incorporated	O
1298	into	O
1298	c	O
1298	##p	O
1298	##ns	O
1298	resulted	O
1298	in	O
1298	na	O
1298	##nos	O
1298	##ized	O
1298	particles	O
1298	(	O
1298	215	O
1298	.	O
1298	22	O
1298	and	O
1298	189	O
1298	.	O
1298	13	O
1298	nm	O
1298	)	O
1298	with	O
1298	ho	O
1298	##mo	O
1298	##gen	O
1298	##ous	O
1298	size	O
1298	distribution	O
1298	(	O
1298	p	O
1298	##di	O
1298	:	O
1298	0	O
1298	.	O
1298	203	O
1298	and	O
1298	0	O
1298	.	O
1298	182	O
1298	)	O
1298	with	O
1298	relatively	O
1298	high	O
1298	incorporation	O
1298	capacity	O
1298	(	O
1298	76	O
1298	.	O
1298	11	O
1298	and	O
1298	68	O
1298	.	O
1298	18	O
1298	%	O
1298	)	O
1298	for	O
1298	the	O
1298	c	O
1298	##p	O
1298	##n	O
1298	##1	O
1298	and	O
1298	c	O
1298	##p	O
1298	##n	O
1298	##2	O
1298	formulation	O
1298	##s	O
1298	respectively	O
1298	.	O
1298	[SEP]	O
1299	[CLS]	O
1299	r	O
1299	##adi	O
1299	##x	O
1299	in	O
1299	##ula	O
1299	##e	O
1299	is	O
1299	endemic	O
1299	to	O
1299	chin	O
1299	##a	O
1299	and	O
1299	has	O
1299	been	O
1299	used	O
1299	in	O
1299	traditional	O
1299	medicine	O
1299	to	O
1299	treat	O
1299	upper	O
1299	body	O
1299	pain	O
1299	,	O
1299	em	O
1299	##esis	O
1299	and	O
1299	di	O
1299	##ar	O
1299	##r	O
1299	##hoe	O
1299	##a	O
1299	,	O
1299	and	O
1299	to	O
1299	eliminate	O
1299	parasite	O
1299	##s	O
1299	.	O
1299	[SEP]	O
1300	[CLS]	O
1300	mean	O
1300	c	O
1300	##ef	O
1300	##uro	O
1300	##xi	O
1300	##me	O
1300	levels	O
1300	in	O
1300	serum	O
1300	were	O
1300	greater	O
1300	than	O
1300	8	O
1300	micro	O
1300	##gram	O
1300	/	O
1300	m	O
1300	##l	O
1300	for	O
1300	3	O
1300	h	O
1300	in	O
1300	group	O
1300	1	O
1300	,	O
1300	for	O
1300	6	O
1300	h	O
1300	in	O
1300	group	O
1300	2	O
1300	,	O
1300	and	O
1300	for	O
1300	30	O
1300	h	O
1300	in	O
1300	group	O
1300	3	O
1300	.	O
1300	[SEP]	O
1301	[CLS]	O
1301	the	O
1301	lip	O
1301	##id	O
1301	em	O
1301	##ul	O
1301	##sions	O
1301	contained	O
1301	radio	O
1301	##la	O
1301	##bel	O
1301	##ed	O
1301	trio	O
1301	##lein	O
1301	(	O
1301	to	O
1301	)	O
1301	and	O
1301	ch	O
1301	##ole	O
1301	##ster	O
1301	##yl	O
1301	o	O
1301	##lea	O
1301	##te	O
1301	(	O
1301	co	O
1301	)	O
1301	to	O
1301	trace	O
1301	plasma	B-PK
1301	clearance	I-PK
1301	##s	I-PK
1301	.	O
1301	[SEP]	O
1302	[CLS]	O
1302	further	O
1302	studies	O
1302	are	O
1302	required	O
1302	to	O
1302	explore	O
1302	the	O
1302	efficacy	O
1302	and	O
1302	op	O
1302	##ti	O
1302	##mized	O
1302	dos	O
1302	##age	O
1302	regime	O
1302	##n	O
1302	of	O
1302	this	O
1302	promising	O
1302	combination	O
1302	.	O
1302	[SEP]	O
1303	[CLS]	O
1303	the	O
1303	column	O
1303	e	O
1303	##ff	O
1303	##lue	O
1303	##nt	O
1303	was	O
1303	monitored	O
1303	using	O
1303	a	O
1303	4000	O
1303	q	O
1303	##tra	O
1303	##p	O
1303	##®	O
1303	##l	O
1303	##c	O
1303	/	O
1303	m	O
1303	##s	O
1303	/	O
1303	m	O
1303	##s	O
1303	(	O
1303	a	O
1303	##b	O
1303	s	O
1303	##cie	O
1303	##x	O
1303	,	O
1303	to	O
1303	##ron	O
1303	##to	O
1303	,	O
1303	on	O
1303	,	O
1303	can	O
1303	##ada	O
1303	)	O
1303	.	O
1303	[SEP]	O
1304	[CLS]	O
1304	for	O
1304	each	O
1304	subject	O
1304	,	O
1304	adverse	O
1304	events	O
1304	(	O
1304	a	O
1304	##es	O
1304	)	O
1304	were	O
1304	recorded	O
1304	throughout	O
1304	the	O
1304	post	O
1304	-	O
1304	dos	O
1304	##ing	O
1304	period	O
1304	.	O
1304	[SEP]	O
1305	[CLS]	O
1305	nineteen	O
1305	healthy	O
1305	male	O
1305	volunteers	O
1305	were	O
1305	given	O
1305	daily	O
1305	160	O
1305	mg	O
1305	prop	O
1305	##rano	O
1305	##lo	O
1305	##l	O
1305	h	O
1305	##ydro	O
1305	##ch	O
1305	##lor	O
1305	##ide	O
1305	in	O
1305	divided	O
1305	doses	O
1305	,	O
1305	either	O
1305	four	O
1305	40	O
1305	-	O
1305	mg	O
1305	tablets	O
1305	or	O
1305	two	O
1305	80	O
1305	-	O
1305	mg	O
1305	tablets	O
1305	,	O
1305	and	O
1305	the	O
1305	plasma	O
1305	prop	O
1305	##rano	O
1305	##lo	O
1305	##l	O
1305	concentration	O
1305	profiles	O
1305	were	O
1305	compared	O
1305	after	O
1305	one	O
1305	and	O
1305	seven	O
1305	consecutive	O
1305	days	O
1305	of	O
1305	drug	O
1305	administration	O
1305	.	O
1305	[SEP]	O
1306	[CLS]	O
1306	thereafter	O
1306	,	O
1306	the	O
1306	di	O
1306	##sper	O
1306	##sion	O
1306	was	O
1306	ultra	O
1306	##cent	O
1306	##ri	O
1306	##fu	O
1306	##ged	O
1306	at	O
1306	20	O
1306	,	O
1306	000	O
1306	rpm	O
1306	for	O
1306	30	O
1306	min	O
1306	at	O
1306	10	O
1306	##°	O
1306	##c	O
1306	,	O
1306	and	O
1306	aggregate	O
1306	##s	O
1306	were	O
1306	pu	O
1306	##rified	O
1306	by	O
1306	dial	O
1306	##ys	O
1306	##is	O
1306	bag	O
1306	and	O
1306	re	O
1306	-	O
1306	suspended	O
1306	in	O
1306	10	O
1306	m	O
1306	##l	O
1306	of	O
1306	a	O
1306	##que	O
1306	##ous	O
1306	phase	O
1306	containing	O
1306	2	O
1306	.	O
1306	5	O
1306	%	O
1306	l	O
1306	##ut	O
1306	##rol	O
1306	127	O
1306	as	O
1306	a	O
1306	na	O
1306	##no	O
1306	##par	O
1306	##tic	O
1306	##le	O
1306	stab	O
1306	##ilizer	O
1306	with	O
1306	stirring	O
1306	at	O
1306	1000	O
1306	rpm	O
1306	for	O
1306	30	O
1306	min	O
1306	.	O
1306	[SEP]	O
1307	[CLS]	O
1307	s	O
1307	##rc	O
1307	##d	O
1307	supplement	O
1307	##ation	O
1307	significantly	O
1307	increased	O
1307	c	O
1307	##ec	O
1307	##um	O
1307	mass	O
1307	,	O
1307	whereas	O
1307	it	O
1307	significantly	O
1307	decreased	O
1307	the	O
1307	c	O
1307	##eca	O
1307	##l	O
1307	but	O
1307	##yra	O
1307	##te	O
1307	and	O
1307	short	O
1307	-	O
1307	chain	O
1307	fatty	O
1307	acid	O
1307	(	O
1307	sum	O
1307	of	O
1307	the	O
1307	ace	O
1307	##tate	O
1307	,	O
1307	but	O
1307	##yra	O
1307	##te	O
1307	,	O
1307	and	O
1307	prop	O
1307	##ion	O
1307	##ate	O
1307	)	O
1307	concentrations	O
1307	.	O
1307	[SEP]	O
1308	[CLS]	O
1308	the	O
1308	duration	O
1308	of	O
1308	the	O
1308	muscle	O
1308	relax	O
1308	##ant	O
1308	effect	O
1308	was	O
1308	proportional	O
1308	to	O
1308	the	O
1308	log	O
1308	##ari	O
1308	##th	O
1308	##m	O
1308	of	O
1308	the	O
1308	dose	O
1308	of	O
1308	c	O
1308	##z	O
1308	##x	O
1308	.	O
1308	[SEP]	O
1309	[CLS]	O
1309	et	O
1309	##oz	O
1309	##olin	O
1309	and	O
1309	its	O
1309	meta	O
1309	##bol	O
1309	##ite	O
1309	are	O
1309	extracted	O
1309	from	O
1309	the	O
1309	plasma	O
1309	into	O
1309	di	O
1309	##ch	O
1309	##lor	O
1309	##ome	O
1309	##than	O
1309	##e	O
1309	at	O
1309	p	O
1309	##h	O
1309	9	O
1309	and	O
1309	p	O
1309	##h	O
1309	5	O
1309	,	O
1309	respectively	O
1309	,	O
1309	and	O
1309	the	O
1309	resulting	O
1309	residues	O
1309	are	O
1309	analyzed	O
1309	on	O
1309	a	O
1309	si	O
1309	##lica	O
1309	gel	O
1309	column	O
1309	.	O
1309	[SEP]	O
1310	[CLS]	O
1310	the	O
1310	plasma	O
1310	concentrations	O
1310	of	O
1310	5	O
1310	-	O
1310	f	O
1310	##u	O
1310	and	O
1310	c	O
1310	##dd	O
1310	##p	O
1310	were	O
1310	not	O
1310	significantly	O
1310	different	O
1310	between	O
1310	respond	O
1310	##ers	O
1310	and	O
1310	non	O
1310	-	O
1310	respond	O
1310	##ers	O
1310	.	O
1310	[SEP]	O
1311	[CLS]	O
1311	from	O
1311	48	O
1311	%	O
1311	to	O
1311	62	O
1311	%	O
1311	of	O
1311	the	O
1311	dose	O
1311	was	O
1311	ex	O
1311	##cre	O
1311	##ted	O
1311	in	O
1311	the	O
1311	urine	O
1311	during	O
1311	the	O
1311	first	O
1311	48	O
1311	hours	O
1311	after	O
1311	in	O
1311	##fusion	O
1311	.	O
1311	[SEP]	O
1312	[CLS]	O
1312	the	O
1312	study	O
1312	protocol	O
1312	was	O
1312	approved	O
1312	by	O
1312	the	O
1312	research	O
1312	ethics	O
1312	committee	O
1312	of	O
1312	be	O
1312	##iji	O
1312	##ng	O
1312	friendship	O
1312	hospital	O
1312	.	O
1312	[SEP]	O
1313	[CLS]	O
1313	the	O
1313	ace	O
1313	##ton	O
1313	##it	O
1313	##ril	O
1313	##e	O
1313	used	O
1313	was	O
1313	of	O
1313	s	O
1313	##pect	O
1313	##ros	O
1313	##copic	O
1313	grade	O
1313	and	O
1313	purchased	O
1313	from	O
1313	honey	O
1313	##well	O
1313	(	O
1313	am	O
1313	##eric	O
1313	##a	O
1313	)	O
1313	.	O
1313	[SEP]	O
1314	[CLS]	O
1314	thirty	O
1314	-	O
1314	day	O
1314	,	O
1314	open	O
1314	-	O
1314	label	O
1314	,	O
1314	fixed	O
1314	-	O
1314	sequence	O
1314	,	O
1314	p	O
1314	##har	O
1314	##ma	O
1314	##co	O
1314	##kin	O
1314	##etic	O
1314	drug	O
1314	-	O
1314	drug	O
1314	interaction	O
1314	study	O
1314	.	O
1314	[SEP]	O
1315	[CLS]	O
1315	the	O
1315	solution	O
1315	was	O
1315	cent	O
1315	##ri	O
1315	##fu	O
1315	##ged	O
1315	at	O
1315	12	O
1315	,	O
1315	000	O
1315	rpm	O
1315	for	O
1315	5	O
1315	min	O
1315	to	O
1315	obtain	O
1315	the	O
1315	super	O
1315	##nat	O
1315	##ant	O
1315	.	O
1315	[SEP]	O
1316	[CLS]	O
1316	this	O
1316	disc	O
1316	##lose	O
1316	##s	O
1316	that	O
1316	such	O
1316	compounds	O
1316	may	O
1316	have	O
1316	greater	O
1316	safety	O
1316	in	O
1316	use	O
1316	,	O
1316	according	O
1316	to	O
1316	the	O
1316	data	O
1316	shown	O
1316	in	O
1316	table	O
1316	5	O
1316	.	O
1316	[SEP]	O
1317	[CLS]	O
1317	phase	O
1317	i	O
1317	study	O
1317	of	O
1317	in	O
1317	##tra	O
1317	##ven	O
1317	##ous	O
1317	vascular	O
1317	end	O
1317	##oth	O
1317	##eli	O
1317	##al	O
1317	growth	O
1317	factor	O
1317	trap	O
1317	,	O
1317	a	O
1317	##f	O
1317	##li	O
1317	##ber	O
1317	##ce	O
1317	##pt	O
1317	,	O
1317	in	O
1317	patients	O
1317	with	O
1317	advanced	O
1317	solid	O
1317	tumors	O
1317	.	O
1317	[SEP]	O
1318	[CLS]	O
1318	during	O
1318	withdrawal	O
1318	animals	O
1318	showed	O
1318	tolerance	O
1318	as	O
1318	estimated	O
1318	with	O
1318	both	O
1318	the	O
1318	em	B-PK
1318	##ax	I-PK
1318	and	O
1318	au	B-PK
1318	##c	I-PK
1318	.	O
1318	[SEP]	O
1319	[CLS]	O
1319	four	O
1319	3	O
1319	-	O
1319	mm	O
1319	t	O
1319	##re	O
1319	##phi	O
1319	##nation	O
1319	##s	O
1319	were	O
1319	created	O
1319	with	O
1319	a	O
1319	high	O
1319	-	O
1319	speed	O
1319	nitrogen	O
1319	-	O
1319	driven	O
1319	surgical	O
1319	drill	O
1319	(	O
1319	hall	O
1319	sur	O
1319	##gai	O
1319	##rt	O
1319	##ome	O
1319	ii	O
1319	;	O
1319	con	O
1319	##med	O
1319	l	O
1319	##in	O
1319	##vate	O
1319	##c	O
1319	,	O
1319	la	O
1319	##rgo	O
1319	,	O
1319	fl	O
1319	)	O
1319	,	O
1319	marking	O
1319	the	O
1319	corners	O
1319	of	O
1319	a	O
1319	square	O
1319	with	O
1319	sides	O
1319	2	O
1319	cm	O
1319	in	O
1319	length	O
1319	.	O
1319	[SEP]	O
1320	[CLS]	O
1320	p	O
1320	##har	O
1320	##ma	O
1320	##co	O
1320	##kin	O
1320	##etic	O
1320	/	O
1320	p	O
1320	##har	O
1320	##ma	O
1320	##co	O
1320	##dynamic	O
1320	models	O
1320	were	O
1320	developed	O
1320	from	O
1320	full	O
1320	p	O
1320	##har	O
1320	##ma	O
1320	##co	O
1320	##kin	O
1320	##etic	O
1320	and	O
1320	i	O
1320	##g	O
1320	##f	O
1320	-	O
1320	i	O
1320	profiles	O
1320	following	O
1320	so	O
1320	##ma	O
1320	##pa	O
1320	##ci	O
1320	##tan	O
1320	dos	O
1320	##ing	O
1320	(	O
1320	table	O
1320	1	O
1320	)	O
1320	.	O
1320	[SEP]	O
1321	[CLS]	O
1321	in	O
1321	the	O
1321	bi	O
1321	##lia	O
1321	##ry	O
1321	ex	O
1321	##cre	O
1321	##tion	O
1321	,	O
1321	about	O
1321	10	O
1321	per	O
1321	cent	O
1321	of	O
1321	the	O
1321	radio	B-PK
1321	##act	I-PK
1321	##ivity	I-PK
1321	administered	O
1321	was	O
1321	ex	O
1321	##cre	O
1321	##ted	O
1321	in	O
1321	bi	O
1321	##le	O
1321	within	O
1321	24	O
1321	h	O
1321	##r	O
1321	.	O
1321	[SEP]	O
1322	[CLS]	O
1322	p	O
1322	##eptide	O
1322	separation	O
1322	was	O
1322	performed	O
1322	on	O
1322	a	O
1322	waters	O
1322	a	O
1322	##c	O
1322	##qui	O
1322	##ty	O
1322	up	O
1322	##l	O
1322	##c	O
1322	system	O
1322	with	O
1322	a	O
1322	reverse	O
1322	phase	O
1322	x	O
1322	##bridge	O
1322	be	O
1322	##h	O
1322	c	O
1322	##18	O
1322	column	O
1322	(	O
1322	2	O
1322	.	O
1322	1	O
1322	##x	O
1322	##15	O
1322	##0	O
1322	mm	O
1322	,	O
1322	3	O
1322	.	O
1322	5	O
1322	µ	O
1322	##m	O
1322	,	O
1322	300	O
1322	##a	O
1322	,	O
1322	waters	O
1322	)	O
1322	at	O
1322	a	O
1322	flow	O
1322	rate	O
1322	of	O
1322	300	O
1322	µ	O
1322	##l	O
1322	min	O
1322	##−	O
1322	##1	O
1322	in	O
1322	a	O
1322	step	O
1322	-	O
1322	wise	O
1322	gradient	O
1322	of	O
1322	0	O
1322	.	O
1322	1	O
1322	%	O
1322	form	O
1322	##ic	O
1322	acid	O
1322	in	O
1322	water	O
1322	and	O
1322	0	O
1322	.	O
1322	1	O
1322	%	O
1322	form	O
1322	##ic	O
1322	acid	O
1322	in	O
1322	ace	O
1322	##ton	O
1322	##it	O
1322	##ril	O
1322	##e	O
1322	.	O
1322	[SEP]	O
1323	[CLS]	O
1323	in	O
1323	##tra	O
1323	-	O
1323	and	O
1323	inter	O
1323	-	O
1323	day	O
1323	variation	O
1323	was	O
1323	calculated	O
1323	for	O
1323	all	O
1323	the	O
1323	five	O
1323	concentrations	O
1323	spike	O
1323	##d	O
1323	with	O
1323	blank	O
1323	plasma	O
1323	anal	O
1323	##ys	O
1323	##ed	O
1323	for	O
1323	three	O
1323	consecutive	O
1323	days	O
1323	.	O
1323	[SEP]	O
1324	[CLS]	O
1324	the	O
1324	p	O
1324	##har	O
1324	##ma	O
1324	##co	O
1324	##kin	O
1324	##etics	O
1324	of	O
1324	et	O
1324	##hyl	O
1324	##ene	O
1324	and	O
1324	1	O
1324	,	O
1324	3	O
1324	-	O
1324	but	O
1324	##adi	O
1324	##ene	O
1324	were	O
1324	studied	O
1324	in	O
1324	male	O
1324	s	O
1324	##pra	O
1324	##gue	O
1324	-	O
1324	da	O
1324	##wley	O
1324	rats	O
1324	by	O
1324	use	O
1324	of	O
1324	a	O
1324	closed	O
1324	in	O
1324	##hala	O
1324	##tion	O
1324	chamber	O
1324	system	O
1324	.	O
1324	[SEP]	O
1325	[CLS]	O
1325	excluding	O
1325	children	O
1325	with	O
1325	other	O
1325	,	O
1325	un	O
1325	##con	O
1325	##tro	O
1325	##lled	O
1325	,	O
1325	potentially	O
1325	my	O
1325	##elo	O
1325	##su	O
1325	##pp	O
1325	##ress	O
1325	##ive	O
1325	influences	O
1325	the	O
1325	correlation	O
1325	between	O
1325	6	O
1325	-	O
1325	th	O
1325	##io	O
1325	##gua	O
1325	##nine	O
1325	n	O
1325	##uc	O
1325	##leo	O
1325	##tide	O
1325	concentration	O
1325	and	O
1325	ne	O
1325	##ut	O
1325	##rop	O
1325	##enia	O
1325	improved	O
1325	(	O
1325	r	O
1325	=	O
1325	-	O
1325	0	O
1325	.	O
1325	6	O
1325	;	O
1325	p	O
1325	less	O
1325	than	O
1325	0	O
1325	.	O
1325	00	O
1325	##1	O
1325	;	O
1325	n	O
1325	=	O
1325	37	O
1325	)	O
1325	.	O
1325	[SEP]	O
1326	[CLS]	O
1326	stereo	O
1326	##sel	O
1326	##ec	O
1326	##tive	O
1326	p	O
1326	##har	O
1326	##ma	O
1326	##co	O
1326	##kin	O
1326	##etics	O
1326	of	O
1326	te	O
1326	##tra	O
1326	##hy	O
1326	##dr	O
1326	##op	O
1326	##al	O
1326	##mat	O
1326	##ine	O
1326	after	O
1326	oral	O
1326	administration	O
1326	of	O
1326	(	O
1326	-	O
1326	)	O
1326	-	O
1326	en	O
1326	##anti	O
1326	##omer	O
1326	and	O
1326	the	O
1326	race	O
1326	##mate	O
1326	.	O
1326	[SEP]	O
1327	[CLS]	O
1327	a	O
1327	single	O
1327	p	O
1327	##ka	O
1327	value	O
1327	of	O
1327	9	O
1327	.	O
1327	51	O
1327	(	O
1327	moderate	O
1327	base	O
1327	)	O
1327	,	O
1327	a	O
1327	log	O
1327	##p	O
1327	value	O
1327	of	O
1327	2	O
1327	.	O
1327	31	O
1327	,	O
1327	and	O
1327	a	O
1327	log	O
1327	##d	O
1327	value	O
1327	of	O
1327	0	O
1327	.	O
1327	24	O
1327	at	O
1327	p	O
1327	##h	O
1327	7	O
1327	.	O
1327	4	O
1327	were	O
1327	predicted	O
1327	for	O
1327	mph	O
1327	using	O
1327	the	O
1327	a	O
1327	##c	O
1327	##d	O
1327	lab	O
1327	so	O
1327	##lub	O
1327	##ility	O
1327	suite	O
1327	(	O
1327	advanced	O
1327	chemistry	O
1327	development	O
1327	,	O
1327	in	O
1327	##c	O
1327	.	O
1327	,	O
1327	to	O
1327	##ron	O
1327	##to	O
1327	,	O
1327	on	O
1327	##tar	O
1327	##io	O
1327	,	O
1327	can	O
1327	##ada	O
1327	)	O
1327	.	O
1327	[SEP]	O
1328	[CLS]	O
1328	the	O
1328	estimated	O
1328	half	B-PK
1328	-	I-PK
1328	life	I-PK
1328	ranged	O
1328	from	O
1328	5	O
1328	.	O
1328	59	O
1328	to	O
1328	6	O
1328	.	O
1328	03	O
1328	d	O
1328	,	O
1328	and	O
1328	statistical	O
1328	##ly	O
1328	non	O
1328	##sign	O
1328	##ificant	O
1328	en	O
1328	##anti	O
1328	##ose	O
1328	##lect	O
1328	##ive	O
1328	degradation	O
1328	was	O
1328	observed	O
1328	.	O
1328	[SEP]	O
1329	[CLS]	O
1329	effect	O
1329	of	O
1329	varying	O
1329	doses	O
1329	of	O
1329	ch	O
1329	##eno	O
1329	##de	O
1329	##ox	O
1329	##ych	O
1329	##olic	O
1329	acid	O
1329	on	O
1329	bi	O
1329	##le	O
1329	lip	O
1329	##id	O
1329	and	O
1329	bi	O
1329	##lia	O
1329	##ry	O
1329	bi	O
1329	##le	O
1329	acid	O
1329	composition	O
1329	in	O
1329	gal	O
1329	##lston	O
1329	##e	O
1329	patients	O
1329	:	O
1329	a	O
1329	dose	O
1329	-	O
1329	response	O
1329	study	O
1329	.	O
1329	[SEP]	O
1330	[CLS]	O
1330	the	O
1330	bi	O
1330	##spect	O
1330	##ral	O
1330	index	O
1330	(	O
1330	bi	O
1330	##s	O
1330	)	O
1330	was	O
1330	recorded	O
1330	##with	O
1330	a	O
1330	bi	O
1330	##s	O
1330	monitor	O
1330	.	O
1330	[SEP]	O
1331	[CLS]	O
1331	the	O
1331	most	O
1331	frequently	O
1331	reported	O
1331	r	O
1331	##omi	O
1331	##de	O
1331	##ps	O
1331	##in	O
1331	‐	O
1331	related	O
1331	tea	O
1331	##es	O
1331	were	O
1331	nausea	O
1331	,	O
1331	decreased	O
1331	appetite	O
1331	,	O
1331	fatigue	O
1331	,	O
1331	vomit	O
1331	##ing	O
1331	,	O
1331	di	O
1331	##ar	O
1331	##r	O
1331	##hea	O
1331	,	O
1331	th	O
1331	##rom	O
1331	##bo	O
1331	##cy	O
1331	##top	O
1331	##enia	O
1331	,	O
1331	an	O
1331	##emia	O
1331	,	O
1331	d	O
1331	##ys	O
1331	##ge	O
1331	##us	O
1331	##ia	O
1331	,	O
1331	and	O
1331	h	O
1331	##y	O
1331	##po	O
1331	##kal	O
1331	##emia	O
1331	.	O
1331	[SEP]	O
1332	[CLS]	O
1332	the	O
1332	area	B-PK
1332	under	I-PK
1332	the	I-PK
1332	plasma	I-PK
1332	concentration	I-PK
1332	time	I-PK
1332	curve	I-PK
1332	(	I-PK
1332	au	I-PK
1332	##c	I-PK
1332	)	I-PK
1332	value	O
1332	was	O
1332	calculated	O
1332	to	O
1332	the	O
1332	last	O
1332	q	O
1332	##uant	O
1332	##ifiable	O
1332	sample	O
1332	(	O
1332	au	B-PK
1332	##c	I-PK
1332	##last	I-PK
1332	)	O
1332	by	O
1332	use	O
1332	of	O
1332	the	O
1332	log	O
1332	-	O
1332	linear	O
1332	trap	O
1332	##ez	O
1332	##oid	O
1332	##al	O
1332	rule	O
1332	.	O
1332	[SEP]	O
1333	[CLS]	O
1333	a	O
1333	dual	O
1333	pp	O
1333	##ar	O
1333	alpha	O
1333	/	O
1333	gamma	O
1333	ago	O
1333	##nist	O
1333	increases	O
1333	ad	O
1333	##ip	O
1333	##one	O
1333	##ct	O
1333	##in	O
1333	and	O
1333	improve	O
1333	##s	O
1333	plasma	O
1333	lip	O
1333	##id	O
1333	profiles	O
1333	in	O
1333	healthy	O
1333	subjects	O
1333	.	O
1333	[SEP]	O
1334	[CLS]	O
1334	p	O
1334	##har	O
1334	##ma	O
1334	##co	O
1334	##kin	O
1334	##etic	O
1334	/	O
1334	p	O
1334	##har	O
1334	##ma	O
1334	##co	O
1334	##dynamic	O
1334	(	O
1334	p	O
1334	##k	O
1334	/	O
1334	p	O
1334	##d	O
1334	)	O
1334	simulation	O
1334	##s	O
1334	were	O
1334	performed	O
1334	to	O
1334	explore	O
1334	the	O
1334	ability	O
1334	of	O
1334	different	O
1334	dos	O
1334	##age	O
1334	regime	O
1334	##ns	O
1334	to	O
1334	achieve	O
1334	the	O
1334	p	O
1334	##har	O
1334	##ma	O
1334	##co	O
1334	##dynamic	O
1334	targets	O
1334	.	O
1334	[SEP]	O
1335	[CLS]	O
1335	phase	O
1335	i	O
1335	study	O
1335	of	O
1335	the	O
1335	anti	O
1335	##fo	O
1335	##late	O
1335	n	O
1335	##10	O
1335	-	O
1335	prop	O
1335	##ar	O
1335	##gy	O
1335	##l	O
1335	-	O
1335	5	O
1335	,	O
1335	8	O
1335	-	O
1335	did	O
1335	##ea	O
1335	##za	O
1335	##fo	O
1335	##lic	O
1335	acid	O
1335	,	O
1335	c	O
1335	##b	O
1335	37	O
1335	##17	O
1335	.	O
1335	[SEP]	O
1336	[CLS]	O
1336	with	O
1336	a	O
1336	very	O
1336	small	O
1336	sample	O
1336	size	O
1336	,	O
1336	and	O
1336	low	O
1336	rate	O
1336	of	O
1336	respond	O
1336	##ers	O
1336	,	O
1336	no	O
1336	correlation	O
1336	of	O
1336	mutation	O
1336	profile	O
1336	to	O
1336	response	O
1336	was	O
1336	seen	O
1336	in	O
1336	an	O
1336	analysis	O
1336	of	O
1336	arch	O
1336	##ival	O
1336	tumor	O
1336	bio	O
1336	##ps	O
1336	##ies	O
1336	(	O
1336	data	O
1336	not	O
1336	shown	O
1336	)	O
1336	.	O
1336	[SEP]	O
1337	[CLS]	O
1337	the	O
1337	accumulation	O
1337	of	O
1337	[	O
1337	111	O
1337	##in	O
1337	]	O
1337	us	O
1337	##2	O
1337	in	O
1337	the	O
1337	m	O
1337	##da	O
1337	-	O
1337	m	O
1337	##b	O
1337	-	O
1337	231	O
1337	tumor	O
1337	was	O
1337	consistent	O
1337	with	O
1337	the	O
1337	distribution	O
1337	of	O
1337	ca	O
1337	-	O
1337	i	O
1337	##x	O
1337	and	O
1337	h	O
1337	##y	O
1337	##pox	O
1337	##ic	O
1337	regions	O
1337	,	O
1337	but	O
1337	not	O
1337	blood	O
1337	vessels	O
1337	,	O
1337	suggesting	O
1337	the	O
1337	detection	O
1337	of	O
1337	ca	O
1337	-	O
1337	i	O
1337	##x	O
1337	and	O
1337	h	O
1337	##y	O
1337	##pox	O
1337	##ia	O
1337	within	O
1337	the	O
1337	m	O
1337	##da	O
1337	-	O
1337	m	O
1337	##b	O
1337	-	O
1337	231	O
1337	tumor	O
1337	by	O
1337	[	O
1337	111	O
1337	##in	O
1337	]	O
1337	us	O
1337	##2	O
1337	.	O
1337	[SEP]	O
1338	[CLS]	O
1338	the	O
1338	diagnostic	O
1338	plots	O
1338	of	O
1338	the	O
1338	final	O
1338	population	O
1338	p	O
1338	##k	O
1338	model	O
1338	revealed	O
1338	no	O
1338	systematic	O
1338	bias	O
1338	.	O
1338	[SEP]	O
1339	[CLS]	O
1339	the	O
1339	nuclear	O
1339	p	O
1339	##elle	O
1339	##ts	O
1339	were	O
1339	re	O
1339	##sus	O
1339	##pen	O
1339	##ded	O
1339	in	O
1339	nuclear	O
1339	extraction	O
1339	re	O
1339	##age	O
1339	##nt	O
1339	(	O
1339	provided	O
1339	in	O
1339	the	O
1339	kit	O
1339	)	O
1339	,	O
1339	and	O
1339	the	O
1339	tubes	O
1339	were	O
1339	vigorously	O
1339	rocked	O
1339	at	O
1339	4	O
1339	##°	O
1339	##c	O
1339	for	O
1339	30	O
1339	min	O
1339	on	O
1339	a	O
1339	shaking	O
1339	platform	O
1339	.	O
1339	[SEP]	O
1340	[CLS]	O
1340	patients	O
1340	with	O
1340	the	O
1340	age	O
1340	of	O
1340	more	O
1340	than	O
1340	18	O
1340	years	O
1340	old	O
1340	in	O
1340	any	O
1340	ward	O
1340	at	O
1340	ram	O
1340	##ath	O
1340	##ib	O
1340	##od	O
1340	##i	O
1340	hospital	O
1340	,	O
1340	ma	O
1340	##hi	O
1340	##do	O
1340	##l	O
1340	university	O
1340	,	O
1340	bang	O
1340	##ko	O
1340	##k	O
1340	,	O
1340	th	O
1340	##ail	O
1340	##and	O
1340	who	O
1340	received	O
1340	van	O
1340	##com	O
1340	##y	O
1340	##cin	O
1340	with	O
1340	complete	O
1340	data	O
1340	regarding	O
1340	dos	O
1340	##age	O
1340	regime	O
1340	##ns	O
1340	,	O
1340	serum	O
1340	drug	O
1340	concentration	O
1340	,	O
1340	and	O
1340	precise	O
1340	timing	O
1340	of	O
1340	dose	O
1340	administration	O
1340	and	O
1340	blood	O
1340	sampling	O
1340	over	O
1340	the	O
1340	entire	O
1340	course	O
1340	of	O
1340	van	O
1340	##com	O
1340	##y	O
1340	##cin	O
1340	therapy	O
1340	during	O
1340	j	O
1340	##anu	O
1340	##ary	O
1340	,	O
1340	2007	O
1340	till	O
1340	j	O
1340	##une	O
1340	,	O
1340	2010	O
1340	were	O
1340	included	O
1340	.	O
1340	[SEP]	O
1341	[CLS]	O
1341	study	O
1341	2	O
1341	was	O
1341	conducted	O
1341	at	O
1341	a	O
1341	single	O
1341	center	O
1341	in	O
1341	two	O
1341	parallel	O
1341	parts	O
1341	as	O
1341	depicted	O
1341	in	O
1341	fi	O
1341	##g	O
1341	.	O
1341	3	O
1341	.	O
1341	[SEP]	O
1342	[CLS]	O
1342	a	O
1342	total	O
1342	of	O
1342	24	O
1342	subjects	O
1342	(	O
1342	12	O
1342	in	O
1342	each	O
1342	co	O
1342	##hor	O
1342	##t	O
1342	)	O
1342	were	O
1342	enrolled	O
1342	in	O
1342	the	O
1342	study	O
1342	,	O
1342	and	O
1342	21	O
1342	completed	O
1342	the	O
1342	study	O
1342	as	O
1342	planned	O
1342	.	O
1342	[SEP]	O
1343	[CLS]	O
1343	the	O
1343	study	O
1343	was	O
1343	conducted	O
1343	at	O
1343	q	O
1343	##uin	O
1343	##tile	O
1343	##s	O
1343	drug	O
1343	research	O
1343	unit	O
1343	at	O
1343	guy	O
1343	'	O
1343	s	O
1343	hospital	O
1343	,	O
1343	lo	O
1343	##ndon	O
1343	and	O
1343	hammer	O
1343	##smith	O
1343	medicines	O
1343	research	O
1343	,	O
1343	h	O
1343	##m	O
1343	##r	O
1343	l	O
1343	##t	O
1343	##d	O
1343	,	O
1343	lo	O
1343	##ndon	O
1343	,	O
1343	uk	O
1343	.	O
1343	[SEP]	O
1344	[CLS]	O
1344	16	O
1344	as	O
1344	##a	O
1344	physical	O
1344	status	O
1344	i	O
1344	and	O
1344	ii	O
1344	patients	O
1344	scheduled	O
1344	for	O
1344	or	O
1344	##th	O
1344	##oped	O
1344	##ic	O
1344	surgery	O
1344	with	O
1344	p	O
1344	##ne	O
1344	##umatic	O
1344	tour	O
1344	##ni	O
1344	##quet	O
1344	use	O
1344	.	O
1344	[SEP]	O
1345	[CLS]	O
1345	in	O
1345	study	O
1345	1	O
1345	,	O
1345	the	O
1345	f	O
1345	##d	O
1345	##c	O
1345	ta	O
1345	##ms	O
1345	##ulos	O
1345	##in	O
1345	had	O
1345	a	O
1345	slower	O
1345	release	O
1345	than	O
1345	commercial	O
1345	ha	O
1345	##rnal	O
1345	-	O
1345	[UNK]	O
1345	tablets	O
1345	co	O
1345	##ad	O
1345	##mini	O
1345	##stered	O
1345	with	O
1345	du	O
1345	##tas	O
1345	##ter	O
1345	##ide	O
1345	(	O
1345	fed	O
1345	and	O
1345	fast	O
1345	##ed	O
1345	state	O
1345	)	O
1345	.	O
1345	[SEP]	O
1346	[CLS]	O
1346	pen	O
1346	##but	O
1346	##olo	O
1346	##l	O
1346	:	O
1346	a	O
1346	preliminary	O
1346	review	O
1346	of	O
1346	its	O
1346	p	O
1346	##har	O
1346	##ma	O
1346	##cological	O
1346	properties	O
1346	and	O
1346	therapeutic	O
1346	efficacy	O
1346	in	O
1346	h	O
1346	##yper	O
1346	##tens	O
1346	##ion	O
1346	and	O
1346	an	O
1346	##gin	O
1346	##a	O
1346	p	O
1346	##ector	O
1346	##is	O
1346	.	O
1346	[SEP]	O
1347	[CLS]	O
1347	figure	O
1347	1	O
1347	illustrate	O
1347	##s	O
1347	mean	O
1347	p	O
1347	##har	O
1347	##ma	O
1347	##co	O
1347	##kin	O
1347	##etic	O
1347	profiles	O
1347	of	O
1347	c	O
1347	##l	O
1347	##p	O
1347	and	O
1347	each	O
1347	meta	O
1347	##bol	O
1347	##ite	O
1347	—	O
1347	c	O
1347	##l	O
1347	##pm	O
1347	,	O
1347	h	O
1347	##3	O
1347	and	O
1347	h	O
1347	##4	O
1347	in	O
1347	patients	O
1347	with	O
1347	w	O
1347	##t	O
1347	/	O
1347	w	O
1347	##t	O
1347	and	O
1347	w	O
1347	##t	O
1347	/	O
1347	*	O
1347	1	O
1347	##g	O
1347	g	O
1347	##eno	O
1347	##type	O
1347	##s	O
1347	.	O
1347	[SEP]	O
1348	[CLS]	O
1348	forty	O
1348	-	O
1348	two	O
1348	were	O
1348	random	O
1348	##ized	O
1348	to	O
1348	c	O
1348	##dd	O
1348	##p	O
1348	given	O
1348	before	O
1348	5	O
1348	-	O
1348	f	O
1348	##u	O
1348	and	O
1348	41	O
1348	to	O
1348	c	O
1348	##dd	O
1348	##p	O
1348	given	O
1348	after	O
1348	5	O
1348	-	O
1348	f	O
1348	##u	O
1348	.	O
1348	[SEP]	O
1349	[CLS]	O
1349	p	O
1349	##ira	O
1349	##na	O
1349	was	O
1349	used	O
1349	as	O
1349	the	O
1349	modeling	O
1349	environment	O
1349	[	O
1349	23	O
1349	]	O
1349	and	O
1349	r	O
1349	(	O
1349	version	O
1349	3	O
1349	.	O
1349	3	O
1349	.	O
1349	1	O
1349	)	O
1349	was	O
1349	used	O
1349	for	O
1349	graphical	O
1349	interpretation	O
1349	of	O
1349	the	O
1349	data	O
1349	.	O
1349	[SEP]	O
1350	[CLS]	O
1350	patients	O
1350	were	O
1350	given	O
1350	an	O
1350	oral	O
1350	solution	O
1350	of	O
1350	c	O
1350	##y	O
1350	##g	O
1350	in	O
1350	period	O
1350	ii	O
1350	(	O
1350	weeks	O
1350	2	O
1350	-	O
1350	3	O
1350	)	O
1350	,	O
1350	and	O
1350	a	O
1350	micro	O
1350	##em	O
1350	##ul	O
1350	##sion	O
1350	capsule	O
1350	formulation	O
1350	of	O
1350	c	O
1350	##y	O
1350	##g	O
1350	in	O
1350	period	O
1350	ii	O
1350	##i	O
1350	(	O
1350	weeks	O
1350	4	O
1350	-	O
1350	5	O
1350	)	O
1350	,	O
1350	with	O
1350	dose	O
1350	t	O
1350	##it	O
1350	##ration	O
1350	as	O
1350	necessary	O
1350	to	O
1350	achieve	O
1350	t	B-PK
1350	##rough	I-PK
1350	concentrations	I-PK
1350	in	O
1350	a	O
1350	pre	O
1350	##de	O
1350	##fine	O
1350	##d	O
1350	range	O
1350	,	O
1350	as	O
1350	measured	O
1350	by	O
1350	f	O
1350	##pia	O
1350	.	O
1350	[SEP]	O
1351	[CLS]	O
1351	the	O
1351	genetic	O
1351	or	O
1351	chemical	O
1351	imp	O
1351	##air	O
1351	##ment	O
1351	of	O
1351	o	O
1351	##ct	O
1351	##2	O
1351	or	O
1351	mate	O
1351	##2	O
1351	-	O
1351	k	O
1351	caused	O
1351	a	O
1351	significant	O
1351	increase	O
1351	in	O
1351	the	O
1351	plasma	O
1351	m	O
1351	##1	O
1351	##a	O
1351	concentration	O
1351	in	O
1351	mice	O
1351	and	O
1351	c	O
1351	##yn	O
1351	##omo	O
1351	##l	O
1351	##gus	O
1351	monkeys	O
1351	due	O
1351	to	O
1351	the	O
1351	high	O
1351	contribution	O
1351	of	O
1351	tub	O
1351	##ular	O
1351	secret	O
1351	##ion	O
1351	to	O
1351	the	O
1351	net	O
1351	elimination	O
1351	of	O
1351	m	O
1351	##1	O
1351	##a	O
1351	.	O
1351	[SEP]	O
1352	[CLS]	O
1352	blood	O
1352	samples	O
1352	were	O
1352	collected	O
1352	to	O
1352	0	O
1352	,	O
1352	5	O
1352	,	O
1352	10	O
1352	,	O
1352	15	O
1352	,	O
1352	45	O
1352	,	O
1352	and	O
1352	60	O
1352	minutes	O
1352	and	O
1352	at	O
1352	1	O
1352	.	O
1352	5	O
1352	,	O
1352	2	O
1352	,	O
1352	2	O
1352	.	O
1352	5	O
1352	,	O
1352	3	O
1352	,	O
1352	3	O
1352	.	O
1352	5	O
1352	,	O
1352	4	O
1352	,	O
1352	5	O
1352	,	O
1352	6	O
1352	,	O
1352	8	O
1352	,	O
1352	12	O
1352	,	O
1352	24	O
1352	,	O
1352	26	O
1352	,	O
1352	28	O
1352	,	O
1352	30	O
1352	,	O
1352	40	O
1352	,	O
1352	48	O
1352	,	O
1352	50	O
1352	,	O
1352	53	O
1352	,	O
1352	and	O
1352	60	O
1352	hours	O
1352	after	O
1352	i	O
1352	.	O
1352	v	O
1352	.	O
1352	administration	O
1352	of	O
1352	4	O
1352	.	O
1352	5	O
1352	mg	O
1352	of	O
1352	p	O
1352	##hen	O
1352	##yl	O
1352	##but	O
1352	##az	O
1352	##one	O
1352	per	O
1352	kg	O
1352	of	O
1352	body	O
1352	weight	O
1352	.	O
1352	[SEP]	O
1353	[CLS]	O
1353	during	O
1353	direct	O
1353	in	O
1353	##fusion	O
1353	,	O
1353	the	O
1353	mass	O
1353	s	O
1353	##pect	O
1353	##ra	O
1353	of	O
1353	the	O
1353	major	O
1353	product	O
1353	ions	O
1353	in	O
1353	the	O
1353	positive	O
1353	mode	O
1353	for	O
1353	bi	O
1353	##s	O
1353	##de	O
1353	##met	O
1353	##ho	O
1353	##xy	O
1353	##cu	O
1353	##rc	O
1353	##umi	O
1353	##n	O
1353	m	O
1353	/	O
1353	z	O
1353	30	O
1353	##9	O
1353	.	O
1353	09	O
1353	##6	O
1353	##8	O
1353	[	O
1353	m	O
1353	+	O
1353	h	O
1353	]	O
1353	+	O
1353	to	O
1353	the	O
1353	product	O
1353	ion	O
1353	225	O
1353	.	O
1353	07	O
1353	##90	O
1353	(	O
1353	figure	O
1353	2	O
1353	##a	O
1353	)	O
1353	dem	O
1353	##eth	O
1353	##ox	O
1353	##y	O
1353	##cu	O
1353	##rc	O
1353	##umi	O
1353	##n	O
1353	m	O
1353	/	O
1353	z	O
1353	33	O
1353	##9	O
1353	.	O
1353	102	O
1353	##3	O
1353	(	O
1353	m	O
1353	+	O
1353	h	O
1353	)	O
1353	to	O
1353	255	O
1353	.	O
1353	08	O
1353	##48	O
1353	(	O
1353	figure	O
1353	2	O
1353	##b	O
1353	)	O
1353	and	O
1353	of	O
1353	cu	O
1353	##rc	O
1353	##umi	O
1353	##n	O
1353	m	O
1353	/	O
1353	z	O
1353	39	O
1353	##1	O
1353	.	O
1353	08	O
1353	##64	O
1353	[	O
1353	m	O
1353	+	O
1353	na	O
1353	]	O
1353	,	O
1353	36	O
1353	##9	O
1353	.	O
1353	106	O
1353	##6	O
1353	(	O
1353	m	O
1353	+	O
1353	h	O
1353	)	O
1353	to	O
1353	285	O
1353	.	O
1353	09	O
1353	##12	O
1353	(	O
1353	figure	O
1353	2	O
1353	##c	O
1353	)	O
1353	.	O
1353	[SEP]	O
1354	[CLS]	O
1354	the	O
1354	final	O
1354	concentrations	O
1354	of	O
1354	n	O
1354	##hp	O
1354	##p	O
1354	##c	O
1354	working	O
1354	solution	O
1354	was	O
1354	20	O
1354	,	O
1354	50	O
1354	,	O
1354	100	O
1354	,	O
1354	250	O
1354	,	O
1354	500	O
1354	,	O
1354	1000	O
1354	,	O
1354	2000	O
1354	,	O
1354	5000	O
1354	,	O
1354	10	O
1354	,	O
1354	000	O
1354	,	O
1354	and	O
1354	20	O
1354	,	O
1354	000	O
1354	ng	O
1354	/	O
1354	m	O
1354	##l	O
1354	for	O
1354	standard	O
1354	ca	O
1354	##li	O
1354	##bra	O
1354	##tion	O
1354	,	O
1354	and	O
1354	40	O
1354	,	O
1354	2000	O
1354	,	O
1354	and	O
1354	16	O
1354	,	O
1354	000	O
1354	ng	O
1354	/	O
1354	m	O
1354	##l	O
1354	for	O
1354	quality	O
1354	control	O
1354	samples	O
1354	.	O
1354	[SEP]	O
1355	[CLS]	O
1355	van	O
1355	bell	O
1355	##e	O
1355	et	O
1355	al	O
1355	.	O
1355	[	O
1355	33	O
1355	]	O
1355	reported	O
1355	car	O
1355	##ba	O
1355	##ma	O
1355	##ze	O
1355	##pine	O
1355	hip	O
1355	##po	O
1355	##cam	O
1355	##pus	O
1355	p	O
1355	##har	O
1355	##ma	O
1355	##co	O
1355	##kin	O
1355	##etics	O
1355	following	O
1355	a	O
1355	single	O
1355	dose	O
1355	to	O
1355	rats	O
1355	and	O
1355	this	O
1355	was	O
1355	used	O
1355	as	O
1355	a	O
1355	basis	O
1355	to	O
1355	further	O
1355	valid	O
1355	##ate	O
1355	the	O
1355	regional	O
1355	brain	O
1355	p	O
1355	##b	O
1355	##p	O
1355	##k	O
1355	model	O
1355	.	O
1355	[SEP]	O
1356	[CLS]	O
1356	concentrations	O
1356	following	O
1356	storage	O
1356	were	O
1356	compared	O
1356	with	O
1356	freshly	O
1356	prepared	O
1356	samples	O
1356	of	O
1356	the	O
1356	same	O
1356	concentrations	O
1356	.	O
1356	[SEP]	O
1357	[CLS]	O
1357	a	O
1357	blood	O
1357	specimen	O
1357	was	O
1357	obtained	O
1357	just	O
1357	before	O
1357	drug	O
1357	administration	O
1357	and	O
1357	at	O
1357	the	O
1357	time	O
1357	of	O
1357	tons	O
1357	##ille	O
1357	##ct	O
1357	##omy	O
1357	,	O
1357	together	O
1357	with	O
1357	a	O
1357	specimen	O
1357	of	O
1357	tons	O
1357	##il	O
1357	tissue	O
1357	.	O
1357	[SEP]	O
1358	[CLS]	O
1358	during	O
1358	the	O
1358	elimination	O
1358	phase	O
1358	,	O
1358	a	O
1358	secondary	O
1358	rise	O
1358	in	O
1358	met	O
1358	##hyl	O
1358	##p	O
1358	##red	O
1358	##nis	O
1358	##olo	O
1358	##ne	O
1358	concentration	O
1358	occurred	O
1358	which	O
1358	may	O
1358	be	O
1358	related	O
1358	to	O
1358	enter	O
1358	##oh	O
1358	##ep	O
1358	##atic	O
1358	circulation	O
1358	.	O
1358	[SEP]	O
1359	[CLS]	O
1359	from	O
1359	2009	O
1359	to	O
1359	2014	O
1359	,	O
1359	we	O
1359	conducted	O
1359	a	O
1359	d	O
1359	##b	O
1359	##rc	O
1359	##t	O
1359	including	O
1359	60	O
1359	patients	O
1359	with	O
1359	primary	O
1359	m	O
1359	##h	O
1359	##g	O
1359	##pin	O
1359	and	O
1359	/	O
1359	or	O
1359	as	O
1359	##ap	O
1359	receiving	O
1359	daily	O
1359	l	O
1359	##y	O
1359	##cope	O
1359	##ne	O
1359	35	O
1359	mg	O
1359	,	O
1359	se	O
1359	##len	O
1359	##ium	O
1359	55	O
1359	µ	O
1359	##g	O
1359	,	O
1359	and	O
1359	g	O
1359	##t	O
1359	##cs	O
1359	600	O
1359	mg	O
1359	,	O
1359	or	O
1359	place	O
1359	##bo	O
1359	for	O
1359	6	O
1359	months	O
1359	.	O
1359	[SEP]	O
1360	[CLS]	O
1360	for	O
1360	concentrating	O
1360	,	O
1360	this	O
1360	process	O
1360	was	O
1360	repeated	O
1360	ten	O
1360	times	O
1360	,	O
1360	and	O
1360	the	O
1360	components	O
1360	of	O
1360	the	O
1360	g	O
1360	##ins	O
1360	##eno	O
1360	##side	O
1360	##s	O
1360	in	O
1360	the	O
1360	k	O
1360	##ore	O
1360	##an	O
1360	red	O
1360	g	O
1360	##ins	O
1360	##eng	O
1360	extract	O
1360	are	O
1360	shown	O
1360	in	O
1360	table	O
1360	1	O
1360	.	O
1360	[SEP]	O
1361	[CLS]	O
1361	out	O
1361	of	O
1361	180	O
1361	eligible	O
1361	patients	O
1361	110	O
1361	were	O
1361	random	O
1361	##ized	O
1361	,	O
1361	57	O
1361	(	O
1361	51	O
1361	.	O
1361	8	O
1361	%	O
1361	)	O
1361	to	O
1361	top	O
1361	##ira	O
1361	##mate	O
1361	and	O
1361	53	O
1361	(	O
1361	48	O
1361	.	O
1361	2	O
1361	%	O
1361	)	O
1361	to	O
1361	place	O
1361	##bo	O
1361	.	O
1361	[SEP]	O
1362	[CLS]	O
1362	the	O
1362	na	O
1362	##te	O
1362	##gli	O
1362	##ni	O
1362	##de	O
1362	meta	O
1362	##bol	O
1362	##ite	O
1362	caused	O
1362	severe	O
1362	h	O
1362	##y	O
1362	##po	O
1362	##gly	O
1362	##ce	O
1362	##mia	O
1362	in	O
1362	this	O
1362	case	O
1362	.	O
1362	[SEP]	O
1363	[CLS]	O
1363	the	O
1363	organic	O
1363	phase	O
1363	containing	O
1363	polymer	O
1363	(	O
1363	15	O
1363	mg	O
1363	/	O
1363	m	O
1363	##l	O
1363	)	O
1363	and	O
1363	d	O
1363	##t	O
1363	##x	O
1363	(	O
1363	5	O
1363	w	O
1363	##t	O
1363	%	O
1363	)	O
1363	was	O
1363	added	O
1363	into	O
1363	the	O
1363	a	O
1363	##que	O
1363	##ous	O
1363	phase	O
1363	with	O
1363	a	O
1363	certain	O
1363	amount	O
1363	of	O
1363	surf	O
1363	##act	O
1363	##ant	O
1363	by	O
1363	magnetic	O
1363	stirring	O
1363	to	O
1363	get	O
1363	the	O
1363	coarse	O
1363	em	O
1363	##ul	O
1363	##sions	O
1363	.	O
1363	[SEP]	O
1364	[CLS]	O
1364	i	O
1364	##bo	O
1364	##pa	O
1364	##mine	O
1364	produces	O
1364	a	O
1364	dose	O
1364	-	O
1364	dependent	O
1364	my	O
1364	##dr	O
1364	##ias	O
1364	##is	O
1364	endowed	O
1364	with	O
1364	very	O
1364	interesting	O
1364	characteristics	O
1364	:	O
1364	rapid	O
1364	onset	O
1364	,	O
1364	marked	O
1364	pupil	O
1364	di	O
1364	##lation	O
1364	and	O
1364	rapid	O
1364	return	O
1364	to	O
1364	normal	O
1364	pupil	O
1364	##lary	O
1364	diameter	O
1364	.	O
1364	[SEP]	O
1365	[CLS]	O
1365	the	O
1365	limit	O
1365	of	O
1365	q	O
1365	##uant	O
1365	##ification	O
1365	and	O
1365	linear	O
1365	quantitative	O
1365	range	O
1365	for	O
1365	the	O
1365	six	O
1365	si	O
1365	##ly	O
1365	##mar	O
1365	##in	O
1365	fl	O
1365	##av	O
1365	##ono	O
1365	##li	O
1365	##gna	O
1365	##ns	O
1365	was	O
1365	5	O
1365	ng	O
1365	/	O
1365	m	O
1365	##l	O
1365	,	O
1365	and	O
1365	5	O
1365	to	O
1365	1000	O
1365	ng	O
1365	/	O
1365	m	O
1365	##l	O
1365	,	O
1365	respectively	O
1365	.	O
1365	[SEP]	O
1366	[CLS]	O
1366	p	O
1366	##k	O
1366	exposure	O
1366	##s	O
1366	revealed	O
1366	a	O
1366	c	O
1366	##s	O
1366	##f	O
1366	median	O
1366	(	O
1366	i	O
1366	##q	O
1366	##r	O
1366	)	O
1366	au	B-PK
1366	##c	I-PK
1366	##0	I-PK
1366	–	I-PK
1366	24	I-PK
1366	of	O
1366	26	O
1366	.	O
1366	3	O
1366	(	O
1366	16	O
1366	.	O
1366	6	O
1366	to	O
1366	43	O
1366	.	O
1366	1	O
1366	)	O
1366	mg	O
1366	·	O
1366	h	O
1366	/	O
1366	liter	O
1366	and	O
1366	cm	B-PK
1366	##ax	I-PK
1366	0	I-PK
1366	–	I-PK
1366	24	I-PK
1366	of	O
1366	6	O
1366	.	O
1366	8	O
1366	(	O
1366	5	O
1366	.	O
1366	2	O
1366	to	O
1366	9	O
1366	.	O
1366	4	O
1366	)	O
1366	μ	O
1366	##g	O
1366	/	O
1366	m	O
1366	##l	O
1366	.	O
1366	[SEP]	O
1367	[CLS]	O
1367	the	O
1367	precision	O
1367	was	O
1367	calculated	O
1367	using	O
1367	the	O
1367	relative	O
1367	standard	O
1367	de	O
1367	##viation	O
1367	(	O
1367	r	O
1367	##s	O
1367	##d	O
1367	)	O
1367	with	O
1367	r	O
1367	##s	O
1367	##d	O
1367	%	O
1367	=	O
1367	(	O
1367	standard	O
1367	de	O
1367	##viation	O
1367	of	O
1367	the	O
1367	mean	O
1367	/	O
1367	mean	O
1367	)	O
1367	×	O
1367	100	O
1367	%	O
1367	.	O
1367	[SEP]	O
1368	[CLS]	O
1368	these	O
1368	correspond	O
1368	to	O
1368	an	O
1368	average	O
1368	half	B-PK
1368	-	I-PK
1368	life	I-PK
1368	of	O
1368	8	O
1368	.	O
1368	0	O
1368	h	O
1368	for	O
1368	c	O
1368	##b	O
1368	##ze	O
1368	and	O
1368	12	O
1368	.	O
1368	4	O
1368	h	O
1368	for	O
1368	c	O
1368	##b	O
1368	##z	O
1368	##d	O
1368	,	O
1368	which	O
1368	suggest	O
1368	elimination	O
1368	-	O
1368	rate	O
1368	-	O
1368	limited	O
1368	disappearance	O
1368	of	O
1368	c	O
1368	##b	O
1368	##z	O
1368	##d	O
1368	.	O
1368	[SEP]	O
1369	[CLS]	O
1369	systematic	O
1369	review	O
1369	:	O
1369	b	O
1369	##ace	O
1369	-	O
1369	1	O
1369	is	O
1369	an	O
1369	emerging	O
1369	target	O
1369	for	O
1369	potential	O
1369	treatment	O
1369	of	O
1369	al	O
1369	##z	O
1369	##heimer	O
1369	'	O
1369	s	O
1369	disease	O
1369	(	O
1369	ad	O
1369	)	O
1369	.	O
1369	[SEP]	O
1370	[CLS]	O
1370	from	O
1370	the	O
1370	results	O
1370	shown	O
1370	in	O
1370	fi	O
1370	##g	O
1370	.	O
1370	6	O
1370	,	O
1370	there	O
1370	is	O
1370	good	O
1370	evidence	O
1370	for	O
1370	sustained	O
1370	plasma	O
1370	concentrations	O
1370	of	O
1370	1	O
1370	up	O
1370	to	O
1370	around	O
1370	1	O
1370	h	O
1370	at	O
1370	the	O
1370	two	O
1370	higher	O
1370	dose	O
1370	levels	O
1370	and	O
1370	that	O
1370	the	O
1370	o	O
1370	##li	O
1370	##gos	O
1370	##ac	O
1370	##cha	O
1370	##ride	O
1370	is	O
1370	well	O
1370	retained	O
1370	in	O
1370	the	O
1370	plasma	O
1370	at	O
1370	these	O
1370	concentrations	O
1370	.	O
1370	[SEP]	O
1371	[CLS]	O
1371	to	O
1371	obtain	O
1371	acute	O
1371	therapy	O
1371	for	O
1371	a	O
1371	drug	O
1371	with	O
1371	narrow	O
1371	therapeutic	O
1371	window	O
1371	,	O
1371	attention	O
1371	should	O
1371	be	O
1371	given	O
1371	to	O
1371	the	O
1371	dos	O
1371	##ing	O
1371	time	O
1371	and	O
1371	food	O
1371	intake	O
1371	interactions	O
1371	.	O
1371	[SEP]	O
1372	[CLS]	O
1372	p	O
1372	##har	O
1372	##ma	O
1372	##co	O
1372	##kin	O
1372	##etic	O
1372	profile	O
1372	of	O
1372	plasma	O
1372	to	O
1372	##co	O
1372	##pher	O
1372	##ol	O
1372	following	O
1372	in	O
1372	##tra	O
1372	##mus	O
1372	##cular	O
1372	administration	O
1372	of	O
1372	ace	O
1372	##ty	O
1372	##lated	O
1372	alpha	O
1372	-	O
1372	to	O
1372	##co	O
1372	##pher	O
1372	##ol	O
1372	to	O
1372	sheep	O
1372	.	O
1372	[SEP]	O
1373	[CLS]	O
1373	disposition	O
1373	of	O
1373	nap	O
1373	##20	O
1373	-	O
1373	h	O
1373	##sa	O
1373	was	O
1373	studied	O
1373	in	O
1373	rats	O
1373	and	O
1373	compared	O
1373	to	O
1373	that	O
1373	of	O
1373	equivalent	O
1373	doses	O
1373	of	O
1373	mixture	O
1373	##s	O
1373	of	O
1373	un	O
1373	##co	O
1373	##up	O
1373	##led	O
1373	drug	O
1373	and	O
1373	protein	O
1373	.	O
1373	[SEP]	O
1374	[CLS]	O
1374	the	O
1374	descending	O
1374	phase	O
1374	of	O
1374	the	O
1374	plasma	O
1374	concentration	O
1374	–	O
1374	time	O
1374	curves	O
1374	appeared	O
1374	to	O
1374	be	O
1374	bi	O
1374	##pha	O
1374	##si	O
1374	##c	O
1374	,	O
1374	characterized	O
1374	by	O
1374	a	O
1374	relatively	O
1374	rapid	O
1374	initial	O
1374	phase	O
1374	followed	O
1374	by	O
1374	a	O
1374	slower	O
1374	terminal	O
1374	phase	O
1374	(	O
1374	figure	O
1374	1	O
1374	##a	O
1374	,	O
1374	b	O
1374	)	O
1374	.	O
1374	[SEP]	O
1375	[CLS]	O
1375	additional	O
1375	visits	O
1375	for	O
1375	screening	O
1375	procedures	O
1375	and	O
1375	/	O
1375	or	O
1375	follow	O
1375	-	O
1375	up	O
1375	were	O
1375	scheduled	O
1375	as	O
1375	necessary	O
1375	.	O
1375	[SEP]	O
1376	[CLS]	O
1376	ne	O
1376	##rat	O
1376	##ini	O
1376	##b	O
1376	is	O
1376	a	O
1376	potent	O
1376	i	O
1376	##rre	O
1376	##versible	O
1376	pan	O
1376	-	O
1376	er	O
1376	##bb	O
1376	t	O
1376	##yr	O
1376	##os	O
1376	##ine	O
1376	kinase	O
1376	inhibitor	O
1376	that	O
1376	has	O
1376	demonstrated	O
1376	anti	O
1376	##tum	O
1376	##our	O
1376	activity	O
1376	and	O
1376	an	O
1376	acceptable	O
1376	safety	O
1376	profile	O
1376	in	O
1376	patients	O
1376	with	O
1376	human	O
1376	e	O
1376	##pid	O
1376	##er	O
1376	##mal	O
1376	growth	O
1376	factor	O
1376	receptor	O
1376	(	O
1376	her	O
1376	)	O
1376	-	O
1376	2	O
1376	-	O
1376	positive	O
1376	breast	O
1376	cancer	O
1376	and	O
1376	other	O
1376	solid	O
1376	t	O
1376	##umour	O
1376	##s	O
1376	.	O
1376	[SEP]	O
1377	[CLS]	O
1377	owing	O
1377	to	O
1377	data	O
1377	below	O
1377	the	O
1377	limit	O
1377	of	O
1377	q	O
1377	##uant	O
1377	##ification	O
1377	(	O
1377	lo	O
1377	##q	O
1377	)	O
1377	of	O
1377	the	O
1377	p	O
1377	##k	O
1377	ass	O
1377	##ay	O
1377	or	O
1377	a	O
1377	non	O
1377	-	O
1377	credible	O
1377	p	O
1377	##k	O
1377	profile	O
1377	,	O
1377	parameters	O
1377	of	O
1377	r	O
1377	##if	O
1377	##amp	O
1377	##ici	O
1377	##n	O
1377	,	O
1377	is	O
1377	##onia	O
1377	##zi	O
1377	##d	O
1377	,	O
1377	p	O
1377	##yra	O
1377	##zin	O
1377	##ami	O
1377	##de	O
1377	and	O
1377	et	O
1377	##ham	O
1377	##but	O
1377	##ol	O
1377	could	O
1377	only	O
1377	be	O
1377	estimated	O
1377	for	O
1377	28	O
1377	,	O
1377	30	O
1377	,	O
1377	29	O
1377	and	O
1377	28	O
1377	of	O
1377	the	O
1377	children	O
1377	with	O
1377	mean	O
1377	percentage	O
1377	extra	O
1377	##pol	O
1377	##ation	O
1377	of	O
1377	the	O
1377	au	B-PK
1377	##c	I-PK
1377	##0	I-PK
1377	–	I-PK
1377	∞	I-PK
1377	of	O
1377	28	O
1377	.	O
1377	6	O
1377	%	O
1377	,	O
1377	3	O
1377	.	O
1377	2	O
1377	%	O
1377	,	O
1377	30	O
1377	.	O
1377	8	O
1377	%	O
1377	and	O
1377	10	O
1377	.	O
1377	9	O
1377	%	O
1377	,	O
1377	respectively	O
1377	;	O
1377	54	O
1377	.	O
1377	4	O
1377	%	O
1377	,	O
1377	11	O
1377	.	O
1377	1	O
1377	%	O
1377	,	O
1377	21	O
1377	.	O
1377	1	O
1377	%	O
1377	and	O
1377	10	O
1377	.	O
1377	3	O
1377	%	O
1377	of	O
1377	data	O
1377	##points	O
1377	for	O
1377	r	O
1377	##if	O
1377	##amp	O
1377	##ici	O
1377	##n	O
1377	,	O
1377	is	O
1377	##onia	O
1377	##zi	O
1377	##d	O
1377	,	O
1377	p	O
1377	##yra	O
1377	##zin	O
1377	##ami	O
1377	##de	O
1377	and	O
1377	et	O
1377	##ham	O
1377	##but	O
1377	##ol	O
1377	,	O
1377	respectively	O
1377	,	O
1377	were	O
1377	below	O
1377	the	O
1377	lo	O
1377	##q	O
1377	and	O
1377	were	O
1377	omitted	O
1377	from	O
1377	the	O
1377	analysis	O
1377	.	O
1377	[SEP]	O
1378	[CLS]	O
1378	tumors	O
1378	were	O
1378	processed	O
1378	and	O
1378	labeled	O
1378	with	O
1378	tandem	O
1378	-	O
1378	mass	O
1378	tag	O
1378	(	O
1378	t	O
1378	##m	O
1378	##t	O
1378	)	O
1378	−	O
1378	##10	O
1378	-	O
1378	p	O
1378	##lex	O
1378	mass	O
1378	tag	O
1378	label	O
1378	##ing	O
1378	kits	O
1378	(	O
1378	the	O
1378	##rm	O
1378	##o	O
1378	)	O
1378	44	O
1378	.	O
1378	[SEP]	O
1379	[CLS]	O
1379	figure	O
1379	2	O
1379	shows	O
1379	the	O
1379	change	O
1379	in	O
1379	these	O
1379	factors	O
1379	for	O
1379	each	O
1379	patient	O
1379	.	O
1379	[SEP]	O
1380	[CLS]	O
1380	since	O
1380	activation	O
1380	and	O
1380	proliferation	O
1380	of	O
1380	he	O
1380	##pa	O
1380	##tic	O
1380	s	O
1380	##tel	O
1380	##late	O
1380	cells	O
1380	(	O
1380	h	O
1380	##s	O
1380	##cs	O
1380	)	O
1380	is	O
1380	key	O
1380	in	O
1380	progression	O
1380	of	O
1380	na	O
1380	##sh	O
1380	-	O
1380	related	O
1380	liver	O
1380	fi	O
1380	##bro	O
1380	##sis	O
1380	,	O
1380	24	O
1380	,	O
1380	25	O
1380	the	O
1380	activated	O
1380	h	O
1380	##s	O
1380	##c	O
1380	cell	O
1380	line	O
1380	h	O
1380	##s	O
1380	##c	O
1380	-	O
1380	t	O
1380	##6	O
1380	was	O
1380	used	O
1380	to	O
1380	investigate	O
1380	the	O
1380	efficacy	O
1380	of	O
1380	p	O
1380	##b	O
1380	##mm	O
1380	/	O
1380	s	O
1380	##k	O
1380	##l	O
1380	##b	O
1380	##0	O
1380	##23	O
1380	in	O
1380	v	O
1380	##it	O
1380	##ro	O
1380	.	O
1380	[SEP]	O
1381	[CLS]	O
1381	for	O
1381	the	O
1381	determination	O
1381	of	O
1381	les	O
1381	##in	O
1381	##ura	O
1381	##d	O
1381	and	O
1381	is	O
1381	,	O
1381	the	O
1381	positive	O
1381	-	O
1381	ion	O
1381	mode	O
1381	was	O
1381	used	O
1381	according	O
1381	to	O
1381	the	O
1381	conditions	O
1381	shown	O
1381	in	O
1381	table	O
1381	1	O
1381	.	O
1381	[SEP]	O
1382	[CLS]	O
1382	the	O
1382	overall	O
1382	re	B-PK
1382	##nal	I-PK
1382	clearance	I-PK
1382	(	I-PK
1382	c	I-PK
1382	##l	I-PK
1382	##r	I-PK
1382	)	I-PK
1382	for	O
1382	c	O
1382	##ef	O
1382	##az	O
1382	##olin	O
1382	was	O
1382	3	O
1382	.	O
1382	6	O
1382	times	O
1382	as	O
1382	large	O
1382	as	O
1382	c	B-PK
1382	##l	I-PK
1382	##r	I-PK
1382	for	O
1382	c	O
1382	##ef	O
1382	##pi	O
1382	##ram	O
1382	##ide	O
1382	,	O
1382	being	O
1382	in	O
1382	good	O
1382	agreement	O
1382	with	O
1382	the	O
1382	c	O
1382	##ef	O
1382	##az	O
1382	##olin	O
1382	/	O
1382	c	O
1382	##ef	O
1382	##pi	O
1382	##ram	O
1382	##ide	O
1382	ratios	O
1382	of	O
1382	c	B-PK
1382	##lt	I-PK
1382	and	O
1382	c	B-PK
1382	##l	I-PK
1382	##r	I-PK
1382	.	O
1382	therefore	O
1382	,	O
1382	the	O
1382	long	O
1382	-	O
1382	lasting	O
1382	p	O
1382	##har	O
1382	##ma	O
1382	##co	O
1382	##kin	O
1382	##etic	O
1382	properties	O
1382	of	O
1382	c	O
1382	##ef	O
1382	##pi	O
1382	##ram	O
1382	##ide	O
1382	was	O
1382	suggested	O
1382	to	O
1382	be	O
1382	due	O
1382	to	O
1382	the	O
1382	fact	O
1382	that	O
1382	c	O
1382	##ef	O
1382	##pi	O
1382	##ram	O
1382	##ide	O
1382	undergo	O
1382	##es	O
1382	re	O
1382	##nal	O
1382	tub	O
1382	##ular	O
1382	secret	O
1382	##ion	O
1382	to	O
1382	less	O
1382	extent	O
1382	.	O
1382	[SEP]	O
1383	[CLS]	O
1383	here	O
1383	,	O
1383	we	O
1383	comparatively	O
1383	evaluated	O
1383	in	O
1383	v	O
1383	##ivo	O
1383	efficacy	O
1383	of	O
1383	g	O
1383	##e	O
1383	with	O
1383	an	O
1383	artificial	O
1383	quasi	O
1383	-	O
1383	mixture	O
1383	(	O
1383	mix	O
1383	)	O
1383	formulated	O
1383	by	O
1383	combining	O
1383	four	O
1383	most	O
1383	active	O
1383	g	O
1383	##inger	O
1383	constituents	O
1383	at	O
1383	concentrations	O
1383	equivalent	O
1383	to	O
1383	those	O
1383	present	O
1383	in	O
1383	whole	O
1383	extract	O
1383	.	O
1383	[SEP]	O
1384	[CLS]	O
1384	the	O
1384	b	O
1384	##p	O
1384	‐	O
1384	lowering	O
1384	effect	O
1384	reached	O
1384	a	O
1384	plateau	O
1384	in	O
1384	~	O
1384	2	O
1384	hours	O
1384	and	O
1384	lasted	O
1384	for	O
1384	up	O
1384	to	O
1384	20	O
1384	hours	O
1384	.	O
1384	[SEP]	O
1385	[CLS]	O
1385	the	O
1385	plasma	B-PK
1385	beta	I-PK
1385	t	I-PK
1385	/	I-PK
1385	2	I-PK
1385	of	O
1385	p	O
1385	##hen	O
1385	##yt	O
1385	##oi	O
1385	##n	O
1385	decreased	O
1385	dramatically	O
1385	with	O
1385	age	O
1385	,	O
1385	a	O
1385	10	O
1385	-	O
1385	fold	O
1385	difference	O
1385	occurring	O
1385	between	O
1385	4	O
1385	-	O
1385	and	O
1385	60	O
1385	-	O
1385	day	O
1385	-	O
1385	old	O
1385	pu	O
1385	##ps	O
1385	.	O
1385	[SEP]	O
1386	[CLS]	O
1386	steps	O
1386	1	O
1386	to	O
1386	5	O
1386	are	O
1386	explained	O
1386	into	O
1386	detail	O
1386	below	O
1386	.	O
1386	[SEP]	O
1387	[CLS]	O
1387	separation	O
1387	and	O
1387	q	O
1387	##uant	O
1387	##itation	O
1387	of	O
1387	di	O
1387	##c	O
1387	##lo	O
1387	##fen	O
1387	##ac	O
1387	in	O
1387	the	O
1387	bi	O
1387	##le	O
1387	dial	O
1387	##ys	O
1387	##ates	O
1387	were	O
1387	achieved	O
1387	using	O
1387	a	O
1387	micro	O
1387	##bor	O
1387	##e	O
1387	reversed	O
1387	-	O
1387	phase	O
1387	c	O
1387	##18	O
1387	column	O
1387	(	O
1387	150	O
1387	##x	O
1387	##1	O
1387	.	O
1387	0	O
1387	mm	O
1387	i	O
1387	.	O
1387	d	O
1387	.	O
1387	;	O
1387	particle	O
1387	size	O
1387	5	O
1387	micro	O
1387	##m	O
1387	)	O
1387	maintained	O
1387	at	O
1387	ambient	O
1387	temperature	O
1387	.	O
1387	[SEP]	O
1388	[CLS]	O
1388	the	O
1388	kinetic	O
1388	##s	O
1388	of	O
1388	the	O
1388	three	O
1388	molecules	O
1388	fitted	O
1388	a	O
1388	bi	O
1388	##com	O
1388	##par	O
1388	##tment	O
1388	##al	O
1388	model	O
1388	.	O
1388	[SEP]	O
1389	[CLS]	O
1389	healthy	O
1389	volunteers	O
1389	were	O
1389	required	O
1389	to	O
1389	be	O
1389	in	O
1389	good	O
1389	health	O
1389	on	O
1389	physical	O
1389	examination	O
1389	and	O
1389	to	O
1389	have	O
1389	normal	O
1389	vital	O
1389	sign	O
1389	measurements	O
1389	and	O
1389	were	O
1389	excluded	O
1389	if	O
1389	they	O
1389	had	O
1389	a	O
1389	positive	O
1389	test	O
1389	result	O
1389	for	O
1389	he	O
1389	##pa	O
1389	##titis	O
1389	b	O
1389	surface	O
1389	anti	O
1389	##gen	O
1389	or	O
1389	he	O
1389	##pa	O
1389	##titis	O
1389	c	O
1389	virus	O
1389	anti	O
1389	##body	O
1389	.	O
1389	[SEP]	O
1390	[CLS]	O
1390	steady	O
1390	‐	O
1390	state	O
1390	pre	O
1390	##dos	O
1390	##e	O
1390	to	O
1390	##ci	O
1390	##li	O
1390	##zu	O
1390	##ma	O
1390	##b	O
1390	concentration	O
1390	in	O
1390	week	O
1390	24	O
1390	was	O
1390	approximately	O
1390	18	O
1390	μ	O
1390	##g	O
1390	/	O
1390	m	O
1390	##l	O
1390	,	O
1390	with	O
1390	every	O
1390	‐	O
1390	4	O
1390	‐	O
1390	week	O
1390	in	O
1390	##tra	O
1390	##ven	O
1390	##ous	O
1390	dos	O
1390	##ing	O
1390	.	O
1390	[SEP]	O
1391	[CLS]	O
1391	p	O
1391	##har	O
1391	##ma	O
1391	##co	O
1391	##kin	O
1391	##etics	O
1391	and	O
1391	p	O
1391	##har	O
1391	##ma	O
1391	##co	O
1391	##dynamic	O
1391	##s	O
1391	of	O
1391	g	O
1391	##lip	O
1391	##iz	O
1391	##ide	O
1391	in	O
1391	healthy	O
1391	volunteers	O
1391	.	O
1391	[SEP]	O
1392	[CLS]	O
1392	population	O
1392	p	O
1392	##k	O
1392	analysis	O
1392	was	O
1392	performed	O
1392	using	O
1392	a	O
1392	linear	O
1392	one	O
1392	-	O
1392	compartment	O
1392	model	O
1392	involving	O
1392	total	B-PK
1392	body	I-PK
1392	clearance	I-PK
1392	(	I-PK
1392	c	I-PK
1392	##l	I-PK
1392	)	I-PK
1392	and	O
1392	volume	B-PK
1392	of	I-PK
1392	distribution	I-PK
1392	with	O
1392	an	O
1392	inter	O
1392	-	O
1392	individual	O
1392	random	O
1392	effect	O
1392	on	O
1392	c	B-PK
1392	##l	I-PK
1392	and	O
1392	a	O
1392	proportional	O
1392	residual	O
1392	errors	O
1392	to	O
1392	describe	O
1392	57	O
1392	##8	O
1392	plasma	O
1392	se	O
1392	##pan	O
1392	##tron	O
1392	##ium	O
1392	concentrations	O
1392	obtained	O
1392	from	O
1392	a	O
1392	total	O
1392	of	O
1392	96	O
1392	patients	O
1392	by	O
1392	non	O
1392	##me	O
1392	##m	O
1392	version	O
1392	v	O
1392	##i	O
1392	.	O
1392	[SEP]	O
1393	[CLS]	O
1393	o	O
1393	##xa	O
1393	##ce	O
1393	##p	O
1393	##rol	O
1393	was	O
1393	not	O
1393	meta	O
1393	##bol	O
1393	##ized	O
1393	.	O
1393	[SEP]	O
1394	[CLS]	O
1394	that	O
1394	is	O
1394	widely	O
1394	used	O
1394	for	O
1394	the	O
1394	treatment	O
1394	of	O
1394	h	O
1394	##yper	O
1394	##tens	O
1394	##ion	O
1394	,	O
1394	vascular	O
1394	dem	O
1394	##ent	O
1394	##ia	O
1394	,	O
1394	and	O
1394	stroke	O
1394	.	O
1394	[SEP]	O
1395	[CLS]	O
1395	easy	O
1395	‐	O
1395	to	O
1395	‐	O
1395	use	O
1395	na	O
1395	##lo	O
1395	##xon	O
1395	##e	O
1395	formulation	O
1395	##s	O
1395	are	O
1395	needed	O
1395	to	O
1395	help	O
1395	address	O
1395	the	O
1395	op	O
1395	##io	O
1395	##id	O
1395	over	O
1395	##dos	O
1395	##e	O
1395	epidemic	O
1395	.	O
1395	[SEP]	O
1396	[CLS]	O
1396	dose	O
1396	and	O
1396	route	O
1396	of	O
1396	administration	O
1396	were	O
1396	selected	O
1396	on	O
1396	the	O
1396	basis	O
1396	of	O
1396	the	O
1396	effectiveness	O
1396	of	O
1396	a	O
1396	##r	O
1396	-	O
1396	t	O
1396	##ur	O
1396	##mer	O
1396	##one	O
1396	to	O
1396	control	O
1396	seizure	O
1396	generation	O
1396	in	O
1396	the	O
1396	6	O
1396	-	O
1396	h	O
1396	##z	O
1396	ps	O
1396	##ych	O
1396	##omo	O
1396	##tor	O
1396	seizure	O
1396	test	O
1396	.	O
1396	[SEP]	O
1397	[CLS]	O
1397	the	O
1397	major	O
1397	bio	O
1397	##tra	O
1397	##ns	O
1397	##formation	O
1397	products	O
1397	are	O
1397	bi	O
1397	##phe	O
1397	##ny	O
1397	##lace	O
1397	##tate	O
1397	(	O
1397	b	O
1397	##pa	O
1397	)	O
1397	,	O
1397	which	O
1397	is	O
1397	p	O
1397	##har	O
1397	##ma	O
1397	##cological	O
1397	##ly	O
1397	active	O
1397	,	O
1397	p	O
1397	-	O
1397	h	O
1397	##ydro	O
1397	##xy	O
1397	-	O
1397	bi	O
1397	##phe	O
1397	##ny	O
1397	##lace	O
1397	##tate	O
1397	(	O
1397	p	O
1397	-	O
1397	h	O
1397	##b	O
1397	##pa	O
1397	)	O
1397	and	O
1397	alpha	O
1397	-	O
1397	amino	O
1397	##py	O
1397	##rid	O
1397	##ine	O
1397	(	O
1397	a	O
1397	##p	O
1397	)	O
1397	.	O
1397	[SEP]	O
1398	[CLS]	O
1398	the	O
1398	disposition	O
1398	of	O
1398	re	O
1398	##mo	O
1398	##xi	O
1398	##p	O
1398	##ride	O
1398	was	O
1398	evaluated	O
1398	in	O
1398	13	O
1398	male	O
1398	chronic	O
1398	s	O
1398	##chi	O
1398	##zo	O
1398	##ph	O
1398	##ren	O
1398	##ic	O
1398	patients	O
1398	.	O
1398	[SEP]	O
1399	[CLS]	O
1399	plasma	O
1399	level	O
1399	of	O
1399	these	O
1399	drugs	O
1399	were	O
1399	analyzed	O
1399	by	O
1399	using	O
1399	flu	O
1399	##ores	O
1399	##cence	O
1399	polar	O
1399	##ization	O
1399	im	O
1399	##mu	O
1399	##no	O
1399	ass	O
1399	##ay	O
1399	(	O
1399	f	O
1399	##pia	O
1399	)	O
1399	technique	O
1399	.	O
1399	[SEP]	O
1400	[CLS]	O
1400	a	O
1400	linear	O
1400	least	O
1400	-	O
1400	squares	O
1400	re	O
1400	##gression	O
1400	analysis	O
1400	using	O
1400	1	O
1400	/	O
1400	x	O
1400	##2	O
1400	as	O
1400	weight	O
1400	##ing	O
1400	factor	O
1400	will	O
1400	be	O
1400	conducted	O
1400	to	O
1400	determine	O
1400	the	O
1400	linear	O
1400	##ity	O
1400	of	O
1400	the	O
1400	ca	O
1400	##li	O
1400	##bra	O
1400	##tion	O
1400	curve	O
1400	.	O
1400	[SEP]	O
1401	[CLS]	O
1401	the	O
1401	bias	O
1401	was	O
1401	>	O
1401	20	O
1401	%	O
1401	in	O
1401	1	O
1401	.	O
1401	8	O
1401	%	O
1401	of	O
1401	patients	O
1401	.	O
1401	[SEP]	O
1402	[CLS]	O
1402	about	O
1402	half	O
1402	of	O
1402	the	O
1402	patients	O
1402	were	O
1402	male	O
1402	and	O
1402	the	O
1402	median	O
1402	age	O
1402	was	O
1402	56	O
1402	years	O
1402	(	O
1402	range	O
1402	,	O
1402	36	O
1402	–	O
1402	73	O
1402	years	O
1402	)	O
1402	.	O
1402	[SEP]	O
1403	[CLS]	O
1403	to	O
1403	achieve	O
1403	this	O
1403	goal	O
1403	,	O
1403	first	O
1403	,	O
1403	we	O
1403	incorporated	O
1403	a	O
1403	2	O
1403	k	O
1403	##da	O
1403	di	O
1403	##thi	O
1403	##ol	O
1403	p	O
1403	##oly	O
1403	##eth	O
1403	##yle	O
1403	##ne	O
1403	g	O
1403	##ly	O
1403	##co	O
1403	##l	O
1403	(	O
1403	p	O
1403	##eg	O
1403	)	O
1403	to	O
1403	the	O
1403	a	O
1403	##c	O
1403	##g	O
1403	##44	O
1403	na	O
1403	##no	O
1403	##con	O
1403	##ju	O
1403	##gate	O
1403	##s	O
1403	,	O
1403	producing	O
1403	a	O
1403	##c	O
1403	##g	O
1403	##44	O
1403	##p	O
1403	##2	O
1403	##k	O
1403	.	O
1403	[SEP]	O
1404	[CLS]	O
1404	the	O
1404	particle	O
1404	size	O
1404	determined	O
1404	by	O
1404	differential	O
1404	light	O
1404	scattering	O
1404	(	O
1404	d	O
1404	##ls	O
1404	)	O
1404	for	O
1404	the	O
1404	same	O
1404	batch	O
1404	was	O
1404	found	O
1404	to	O
1404	be	O
1404	158	O
1404	.	O
1404	5	O
1404	nm	O
1404	.	O
1404	[SEP]	O
1405	[CLS]	O
1405	we	O
1405	evaluated	O
1405	ta	O
1405	##iji	O
1405	##a	O
1405	and	O
1405	p	O
1405	##lav	O
1405	##ix	O
1405	##®	O
1405	in	O
1405	128	O
1405	subjects	O
1405	,	O
1405	with	O
1405	64	O
1405	in	O
1405	a	O
1405	fast	O
1405	##ed	O
1405	state	O
1405	and	O
1405	64	O
1405	receiving	O
1405	a	O
1405	high	O
1405	-	O
1405	fat	O
1405	diet	O
1405	,	O
1405	and	O
1405	com	O
1405	##puted	O
1405	cm	B-PK
1405	##ax	I-PK
1405	,	O
1405	au	B-PK
1405	##c	I-PK
1405	##0	I-PK
1405	-	I-PK
1405	∞	I-PK
1405	,	O
1405	and	O
1405	au	B-PK
1405	##c	I-PK
1405	##0	I-PK
1405	-	I-PK
1405	t	I-PK
1405	.	O
1405	[SEP]	O
1406	[CLS]	O
1406	this	O
1406	p	O
1406	##eg	O
1406	-	O
1406	pro	O
1406	##dr	O
1406	##ug	O
1406	technology	O
1406	could	O
1406	provide	O
1406	precisely	O
1406	tuned	O
1406	long	O
1406	-	O
1406	acting	O
1406	anti	O
1406	-	O
1406	di	O
1406	##abe	O
1406	##tic	O
1406	and	O
1406	anti	O
1406	-	O
1406	o	O
1406	##besity	O
1406	the	O
1406	##rap	O
1406	##ies	O
1406	and	O
1406	even	O
1406	once	O
1406	-	O
1406	monthly	O
1406	administration	O
1406	intervals	O
1406	when	O
1406	combined	O
1406	with	O
1406	other	O
1406	formulation	O
1406	strategies	O
1406	.	O
1406	[SEP]	O
1407	[CLS]	O
1407	the	O
1407	prolonged	O
1407	high	O
1407	t	O
1407	##umes	O
1407	##cent	O
1407	anti	O
1407	##biotics	O
1407	concentrations	O
1407	in	O
1407	sub	O
1407	##cut	O
1407	##aneous	O
1407	tissue	O
1407	may	O
1407	reduce	O
1407	the	O
1407	need	O
1407	to	O
1407	precisely	O
1407	give	O
1407	i	O
1407	##v	O
1407	anti	O
1407	##biotics	O
1407	30	O
1407	–	O
1407	60	O
1407	minutes	O
1407	before	O
1407	an	O
1407	in	O
1407	##cision	O
1407	.	O
1407	[SEP]	O
1408	[CLS]	O
1408	this	O
1408	will	O
1408	improve	O
1408	the	O
1408	translation	O
1408	##al	O
1408	value	O
1408	of	O
1408	this	O
1408	ve	O
1408	##rte	O
1408	##bra	O
1408	##te	O
1408	model	O
1408	organism	O
1408	in	O
1408	drug	O
1408	discovery	O
1408	and	O
1408	development	O
1408	.	O
1408	[SEP]	O
1409	[CLS]	O
1409	clinical	O
1409	laboratory	O
1409	measurements	O
1409	and	O
1409	12	O
1409	-	O
1409	lead	O
1409	electro	O
1409	##card	O
1409	##io	O
1409	##gram	O
1409	intervals	O
1409	were	O
1409	assessed	O
1409	for	O
1409	general	O
1409	health	O
1409	during	O
1409	the	O
1409	21	O
1409	-	O
1409	day	O
1409	screening	O
1409	period	O
1409	.	O
1409	[SEP]	O
1410	[CLS]	O
1410	in	O
1410	the	O
1410	control	O
1410	un	O
1410	##les	O
1410	##ioned	O
1410	un	O
1410	##tre	O
1410	##ated	O
1410	cats	O
1410	,	O
1410	the	O
1410	basal	O
1410	number	O
1410	of	O
1410	h	O
1410	##d	O
1410	##c	O
1410	im	O
1410	##mu	O
1410	##nor	O
1410	##ea	O
1410	##ctive	O
1410	neurons	O
1410	was	O
1410	moderate	O
1410	and	O
1410	symmetrical	O
1410	in	O
1410	the	O
1410	bilateral	O
1410	t	O
1410	##m	O
1410	##n	O
1410	.	O
1410	[SEP]	O
1411	[CLS]	O
1411	at	O
1411	the	O
1411	end	O
1411	of	O
1411	each	O
1411	period	O
1411	,	O
1411	blood	O
1411	was	O
1411	taken	O
1411	pre	O
1411	##dos	O
1411	##ing	O
1411	and	O
1411	for	O
1411	up	O
1411	to	O
1411	24	O
1411	h	O
1411	post	O
1411	##dos	O
1411	##ing	O
1411	to	O
1411	measure	O
1411	the	O
1411	drug	O
1411	concentrations	O
1411	.	O
1411	[SEP]	O
1412	[CLS]	O
1412	oral	O
1412	dos	O
1412	##age	O
1412	significantly	O
1412	influenced	O
1412	maximum	B-PK
1412	plasma	I-PK
1412	concentration	I-PK
1412	(	O
1412	ng	O
1412	/	O
1412	m	O
1412	##l	O
1412	,	O
1412	s	O
1412	:	O
1412	126	O
1412	##7	O
1412	,	O
1412	r	O
1412	:	O
1412	135	O
1412	##5	O
1412	at	O
1412	0	O
1412	.	O
1412	5	O
1412	mg	O
1412	/	O
1412	kg	O
1412	;	O
1412	s	O
1412	:	O
1412	61	O
1412	##4	O
1412	.	O
1412	9	O
1412	,	O
1412	r	O
1412	:	O
1412	67	O
1412	##9	O
1412	.	O
1412	4	O
1412	at	O
1412	0	O
1412	.	O
1412	25	O
1412	mg	O
1412	/	O
1412	kg	O
1412	;	O
1412	s	O
1412	:	O
1412	250	O
1412	.	O
1412	5	O
1412	,	O
1412	r	O
1412	:	O
1412	36	O
1412	##7	O
1412	.	O
1412	6	O
1412	at	O
1412	0	O
1412	.	O
1412	1	O
1412	mg	O
1412	/	O
1412	kg	O
1412	)	O
1412	,	O
1412	au	B-PK
1412	##c	I-PK
1412	(	O
1412	h	O
1412	*	O
1412	micro	O
1412	##g	O
1412	/	O
1412	m	O
1412	##l	O
1412	,	O
1412	s	O
1412	:	O
1412	45	O
1412	.	O
1412	12	O
1412	,	O
1412	r	O
1412	:	O
1412	30	O
1412	.	O
1412	91	O
1412	at	O
1412	0	O
1412	.	O
1412	5	O
1412	mg	O
1412	/	O
1412	kg	O
1412	;	O
1412	s	O
1412	:	O
1412	22	O
1412	.	O
1412	98	O
1412	:	O
1412	,	O
1412	r	O
1412	:	O
1412	18	O
1412	.	O
1412	99	O
1412	at	O
1412	0	O
1412	.	O
1412	25	O
1412	mg	O
1412	/	O
1412	kg	O
1412	;	O
1412	s	O
1412	:	O
1412	3	O
1412	.	O
1412	92	O
1412	##2	O
1412	,	O
1412	r	O
1412	:	O
1412	3	O
1412	.	O
1412	570	O
1412	at	O
1412	0	O
1412	.	O
1412	1	O
1412	mg	O
1412	/	O
1412	kg	O
1412	)	O
1412	and	O
1412	au	B-PK
1412	##m	I-PK
1412	##c	I-PK
1412	(	O
1412	h	O
1412	*	O
1412	h	O
1412	*	O
1412	micro	O
1412	##g	O
1412	/	O
1412	m	O
1412	##l	O
1412	,	O
1412	s	O
1412	:	O
1412	213	O
1412	##5	O
1412	,	O
1412	r	O
1412	:	O
1412	106	O
1412	##2	O
1412	at	O
1412	0	O
1412	.	O
1412	5	O
1412	mg	O
1412	/	O
1412	kg	O
1412	;	O
1412	s	O
1412	:	O
1412	94	O
1412	##3	O
1412	.	O
1412	1	O
1412	,	O
1412	r	O
1412	:	O
1412	59	O
1412	##9	O
1412	.	O
1412	9	O
1412	at	O
1412	0	O
1412	.	O
1412	25	O
1412	mg	O
1412	/	O
1412	kg	O
1412	;	O
1412	s	O
1412	:	O
1412	132	O
1412	.	O
1412	2	O
1412	,	O
1412	r	O
1412	:	O
1412	59	O
1412	.	O
1412	03	O
1412	at	O
1412	0	O
1412	.	O
1412	1	O
1412	mg	O
1412	/	O
1412	kg	O
1412	)	O
1412	,	O
1412	but	O
1412	not	O
1412	t	B-PK
1412	##1	I-PK
1412	/	I-PK
1412	2	I-PK
1412	(	O
1412	s	O
1412	:	O
1412	23	O
1412	.	O
1412	5	O
1412	,	O
1412	r	O
1412	:	O
1412	11	O
1412	.	O
1412	6	O
1412	h	O
1412	)	O
1412	nor	O
1412	m	B-PK
1412	##rt	I-PK
1412	(	O
1412	s	O
1412	:	O
1412	26	O
1412	.	O
1412	3	O
1412	,	O
1412	r	O
1412	:	O
1412	13	O
1412	.	O
1412	5	O
1412	h	O
1412	)	O
1412	.	O
1412	[SEP]	O
1413	[CLS]	O
1413	mass	O
1413	transfer	O
1413	within	O
1413	the	O
1413	plasma	O
1413	(	O
1413	r	O
1413	##1	O
1413	)	O
1413	between	O
1413	organs	O
1413	is	O
1413	calculated	O
1413	as	O
1413	organ	O
1413	specific	O
1413	blood	B-PK
1413	flow	I-PK
1413	(	I-PK
1413	q	I-PK
1413	##or	I-PK
1413	##gan	I-PK
1413	)	I-PK
1413	times	O
1413	the	O
1413	drug	O
1413	concentration	O
1413	within	O
1413	the	O
1413	plasma	O
1413	of	O
1413	the	O
1413	respective	O
1413	organ	O
1413	(	O
1413	c	O
1413	##p	O
1413	##ls	O
1413	_	O
1413	organ	O
1413	)	O
1413	times	O
1413	the	O
1413	overall	O
1413	plasma	O
1413	fraction	O
1413	(	O
1413	1	O
1413	−	O
1413	h	O
1413	##ct	O
1413	)	O
1413	which	O
1413	is	O
1413	one	O
1413	sub	O
1413	##tracted	O
1413	by	O
1413	the	O
1413	hem	O
1413	##ato	O
1413	##c	O
1413	##rit	O
1413	(	O
1413	h	O
1413	##ct	O
1413	)	O
1413	value	O
1413	.	O
1413	[SEP]	O
1414	[CLS]	O
1414	in	O
1414	a	O
1414	multi	O
1414	##var	O
1414	##iable	O
1414	log	O
1414	##istic	O
1414	re	O
1414	##gression	O
1414	analysis	O
1414	,	O
1414	using	O
1414	factors	O
1414	shown	O
1414	to	O
1414	be	O
1414	statistical	O
1414	##ly	O
1414	significant	O
1414	through	O
1414	un	O
1414	##iva	O
1414	##ria	O
1414	##te	O
1414	analysis	O
1414	,	O
1414	only	O
1414	con	O
1414	##com	O
1414	##ita	O
1414	##nt	O
1414	h	O
1414	##2	O
1414	##ra	O
1414	/	O
1414	pp	O
1414	##i	O
1414	use	O
1414	was	O
1414	an	O
1414	independent	O
1414	de	O
1414	##ter	O
1414	##mina	O
1414	##nt	O
1414	of	O
1414	a	O
1414	non	O
1414	-	O
1414	therapeutic	O
1414	p	O
1414	##osa	O
1414	##cona	O
1414	##zo	O
1414	##le	O
1414	drug	O
1414	level	O
1414	(	O
1414	p	O
1414	=	O
1414	0	O
1414	.	O
1414	04	O
1414	)	O
1414	(	O
1414	table	O
1414	6	O
1414	)	O
1414	.	O
1414	[SEP]	O
1415	[CLS]	O
1415	however	O
1415	,	O
1415	au	B-PK
1415	##c	I-PK
1415	##0	I-PK
1415	-	I-PK
1415	12	I-PK
1415	tended	O
1415	to	O
1415	be	O
1415	higher	O
1415	for	O
1415	all	O
1415	seven	O
1415	anal	O
1415	##yte	O
1415	##s	O
1415	in	O
1415	the	O
1415	p	O
1415	-	O
1415	s	O
1415	##c	O
1415	group	O
1415	.	O
1415	[SEP]	O
1416	[CLS]	O
1416	all	O
1416	random	O
1416	##ized	O
1416	subjects	O
1416	completed	O
1416	the	O
1416	study	O
1416	.	O
1416	[SEP]	O
1417	[CLS]	O
1417	stability	O
1417	studies	O
1417	were	O
1417	performed	O
1417	according	O
1417	to	O
1417	previously	O
1417	reported	O
1417	method	O
1417	.	O
1417	[SEP]	O
1418	[CLS]	O
1418	kinetic	O
1418	analysis	O
1418	of	O
1418	the	O
1418	interactions	O
1418	of	O
1418	the	O
1418	different	O
1418	na	O
1418	##nob	O
1418	##ody	O
1418	variants	O
1418	with	O
1418	il	O
1418	-	O
1418	6	O
1418	##r	O
1418	was	O
1418	performed	O
1418	on	O
1418	a	O
1418	bi	O
1418	##aco	O
1418	##re	O
1418	t	O
1418	##100	O
1418	instrument	O
1418	(	O
1418	bi	O
1418	##aco	O
1418	##re	O
1418	international	O
1418	a	O
1418	##b	O
1418	,	O
1418	up	O
1418	##ps	O
1418	##ala	O
1418	,	O
1418	s	O
1418	##wed	O
1418	##en	O
1418	)	O
1418	.	O
1418	[SEP]	O
1419	[CLS]	O
1419	all	O
1419	three	O
1419	drugs	O
1419	were	O
1419	extensively	O
1419	(	O
1419	greater	O
1419	than	O
1419	99	O
1419	%	O
1419	)	O
1419	bound	O
1419	to	O
1419	plasma	O
1419	proteins	O
1419	and	O
1419	the	O
1419	plasma	O
1419	concentration	O
1419	/	O
1419	time	O
1419	curve	O
1419	was	O
1419	best	O
1419	described	O
1419	by	O
1419	a	O
1419	t	O
1419	##ri	O
1419	-	O
1419	ex	O
1419	##po	O
1419	##nent	O
1419	##ial	O
1419	equation	O
1419	.	O
1419	[SEP]	O
1420	[CLS]	O
1420	healthy	O
1420	volunteers	O
1420	were	O
1420	recruited	O
1420	(	O
1420	through	O
1420	advertisements	O
1420	posted	O
1420	around	O
1420	the	O
1420	medical	O
1420	center	O
1420	)	O
1420	and	O
1420	assessed	O
1420	for	O
1420	inclusion	O
1420	in	O
1420	the	O
1420	study	O
1420	.	O
1420	[SEP]	O
1421	[CLS]	O
1421	the	O
1421	total	O
1421	ch	O
1421	##roma	O
1421	##to	O
1421	##graphic	O
1421	run	O
1421	time	O
1421	was	O
1421	10	O
1421	.	O
1421	5	O
1421	min	O
1421	with	O
1421	the	O
1421	retention	O
1421	time	O
1421	of	O
1421	7	O
1421	.	O
1421	1	O
1421	min	O
1421	and	O
1421	6	O
1421	.	O
1421	2	O
1421	min	O
1421	for	O
1421	lo	O
1421	##r	O
1421	and	O
1421	d	O
1421	##p	O
1421	,	O
1421	respectively	O
1421	,	O
1421	and	O
1421	2	O
1421	.	O
1421	2	O
1421	min	O
1421	for	O
1421	both	O
1421	of	O
1421	p	O
1421	##es	O
1421	and	O
1421	pp	O
1421	##a	O
1421	.	O
1421	[SEP]	O
1422	[CLS]	O
1422	time	O
1422	for	O
1422	plasma	O
1422	al	O
1422	##fa	O
1422	##xa	O
1422	##lone	O
1422	concentration	O
1422	to	O
1422	decrease	O
1422	by	O
1422	90	O
1422	%	O
1422	was	O
1422	predicted	O
1422	to	O
1422	range	O
1422	from	O
1422	7	O
1422	to	O
1422	120	O
1422	or	O
1422	113	O
1422	minutes	O
1422	following	O
1422	a	O
1422	b	O
1422	##ol	O
1422	##us	O
1422	to	O
1422	an	O
1422	8	O
1422	hour	O
1422	target	O
1422	-	O
1422	controlled	O
1422	or	O
1422	continuous	O
1422	rate	O
1422	in	O
1422	##fusion	O
1422	,	O
1422	respectively	O
1422	.	O
1422	[SEP]	O
1423	[CLS]	O
1423	the	O
1423	bio	B-PK
1423	##ava	I-PK
1423	##ila	I-PK
1423	##bility	I-PK
1423	of	O
1423	the	O
1423	drug	O
1423	was	O
1423	greater	O
1423	than	O
1423	or	O
1423	equal	O
1423	to	O
1423	95	O
1423	%	O
1423	after	O
1423	im	O
1423	injection	O
1423	.	O
1423	[SEP]	O
1424	[CLS]	O
1424	in	O
1424	addition	O
1424	,	O
1424	the	O
1424	gradient	O
1424	el	O
1424	##uti	O
1424	##ng	O
1424	mode	O
1424	was	O
1424	op	O
1424	##ti	O
1424	##mized	O
1424	to	O
1424	make	O
1424	the	O
1424	tested	O
1424	compounds	O
1424	completely	O
1424	separated	O
1424	and	O
1424	have	O
1424	good	O
1424	peak	O
1424	shapes	O
1424	,	O
1424	and	O
1424	the	O
1424	interference	O
1424	between	O
1424	the	O
1424	anal	O
1424	##yte	O
1424	and	O
1424	the	O
1424	is	O
1424	was	O
1424	avoided	O
1424	.	O
1424	[SEP]	O
1425	[CLS]	O
1425	dependence	O
1425	of	O
1425	correlation	O
1425	on	O
1425	stirring	O
1425	rate	O
1425	indicated	O
1425	the	O
1425	value	O
1425	of	O
1425	100	O
1425	rpm	O
1425	as	O
1425	the	O
1425	most	O
1425	appropriate	O
1425	both	O
1425	in	O
1425	cases	O
1425	of	O
1425	m	O
1425	##1	O
1425	and	O
1425	m	O
1425	##5	O
1425	meta	O
1425	##bol	O
1425	##ites	O
1425	.	O
1425	[SEP]	O
1426	[CLS]	O
1426	on	O
1426	day	O
1426	−	O
1426	##1	O
1426	,	O
1426	blood	O
1426	samples	O
1426	were	O
1426	collected	O
1426	at	O
1426	time	O
1426	0	O
1426	and	O
1426	at	O
1426	15	O
1426	,	O
1426	30	O
1426	,	O
1426	45	O
1426	,	O
1426	and	O
1426	60	O
1426	min	O
1426	following	O
1426	the	O
1426	morning	O
1426	dose	O
1426	and	O
1426	every	O
1426	30	O
1426	min	O
1426	thereafter	O
1426	for	O
1426	12	O
1426	h	O
1426	.	O
1426	on	O
1426	day	O
1426	21	O
1426	,	O
1426	blood	O
1426	samples	O
1426	were	O
1426	collected	O
1426	at	O
1426	the	O
1426	same	O
1426	time	O
1426	##points	O
1426	as	O
1426	for	O
1426	day	O
1426	−	O
1426	##1	O
1426	and	O
1426	every	O
1426	2	O
1426	h	O
1426	from	O
1426	hours	O
1426	12	O
1426	to	O
1426	16	O
1426	relative	O
1426	to	O
1426	the	O
1426	start	O
1426	of	O
1426	the	O
1426	in	O
1426	##fusion	O
1426	.	O
1426	[SEP]	O
1427	[CLS]	O
1427	the	O
1427	composition	O
1427	of	O
1427	the	O
1427	prepared	O
1427	a	O
1427	##e	O
1427	-	O
1427	l	O
1427	##c	O
1427	##n	O
1427	##p	O
1427	formulation	O
1427	##s	O
1427	(	O
1427	f	O
1427	##1	O
1427	–	O
1427	f	O
1427	##14	O
1427	)	O
1427	is	O
1427	given	O
1427	in	O
1427	table	O
1427	1	O
1427	.	O
1427	[SEP]	O
1428	[CLS]	O
1428	plasma	O
1428	samples	O
1428	having	O
1428	bi	O
1428	##so	O
1428	##p	O
1428	##rol	O
1428	##ol	O
1428	theoretical	O
1428	##s	O
1428	concentrations	O
1428	of	O
1428	3	O
1428	ng	O
1428	/	O
1428	m	O
1428	##l	O
1428	,	O
1428	25	O
1428	ng	O
1428	/	O
1428	m	O
1428	##l	O
1428	and	O
1428	75	O
1428	ng	O
1428	/	O
1428	m	O
1428	##l	O
1428	were	O
1428	considered	O
1428	to	O
1428	be	O
1428	appropriate	O
1428	to	O
1428	be	O
1428	used	O
1428	to	O
1428	valid	O
1428	##ate	O
1428	the	O
1428	bio	O
1428	##ana	O
1428	##ly	O
1428	##tical	O
1428	method	O
1428	.	O
1428	[SEP]	O
1429	[CLS]	O
1429	since	O
1429	the	O
1429	in	O
1429	v	O
1429	##ivo	O
1429	recovery	O
1429	of	O
1429	d	O
1429	##f	O
1429	##c	O
1429	##r	O
1429	and	O
1429	d	O
1429	##fu	O
1429	##r	O
1429	could	O
1429	not	O
1429	be	O
1429	evaluated	O
1429	and	O
1429	considering	O
1429	that	O
1429	both	O
1429	meta	O
1429	##bol	O
1429	##ites	O
1429	behave	O
1429	similar	O
1429	to	O
1429	f	O
1429	##u	O
1429	(	O
1429	no	O
1429	plasma	O
1429	protein	O
1429	binding	O
1429	as	O
1429	shown	O
1429	below	O
1429	and	O
1429	in	O
1429	v	O
1429	##it	O
1429	##ro	O
1429	recover	O
1429	##ies	O
1429	similar	O
1429	to	O
1429	f	O
1429	##u	O
1429	)	O
1429	,	O
1429	d	O
1429	##f	O
1429	##c	O
1429	##r	O
1429	and	O
1429	d	O
1429	##fu	O
1429	##r	O
1429	were	O
1429	calculated	O
1429	using	O
1429	the	O
1429	in	O
1429	v	O
1429	##ivo	O
1429	recovery	O
1429	of	O
1429	f	O
1429	##u	O
1429	.	O
1429	[SEP]	O
1430	[CLS]	O
1430	participants	O
1430	of	O
1430	this	O
1430	project	O
1430	will	O
1430	not	O
1430	be	O
1430	identified	O
1430	in	O
1430	any	O
1430	reports	O
1430	or	O
1430	publications	O
1430	.	O
1430	[SEP]	O
1431	[CLS]	O
1431	four	O
1431	patients	O
1431	had	O
1431	grade	O
1431	2	O
1431	th	O
1431	##rom	O
1431	##bo	O
1431	##cy	O
1431	##top	O
1431	##enia	O
1431	including	O
1431	2	O
1431	patients	O
1431	each	O
1431	at	O
1431	4	O
1431	.	O
1431	34	O
1431	and	O
1431	6	O
1431	.	O
1431	5	O
1431	mg	O
1431	/	O
1431	kg	O
1431	.	O
1431	[SEP]	O
1432	[CLS]	O
1432	this	O
1432	study	O
1432	evaluated	O
1432	daily	O
1432	las	O
1432	##of	O
1432	##ox	O
1432	##ife	O
1432	##ne	O
1432	for	O
1432	14	O
1432	days	O
1432	in	O
1432	healthy	O
1432	post	O
1432	##men	O
1432	##op	O
1432	##aus	O
1432	##al	O
1432	women	O
1432	.	O
1432	[SEP]	O
1433	[CLS]	O
1433	the	O
1433	selection	O
1433	was	O
1433	based	O
1433	on	O
1433	particle	O
1433	size	O
1433	distribution	O
1433	and	O
1433	short	O
1433	-	O
1433	term	O
1433	stability	O
1433	of	O
1433	the	O
1433	result	O
1433	##ant	O
1433	c	O
1433	##l	O
1433	##x	O
1433	-	O
1433	n	O
1433	##c	O
1433	.	O
1433	[SEP]	O
1434	[CLS]	O
1434	alcohol	O
1434	,	O
1434	0	O
1434	.	O
1434	8	O
1434	g	O
1434	/	O
1434	kg	O
1434	,	O
1434	caused	O
1434	the	O
1434	greatest	O
1434	performance	O
1434	imp	O
1434	##air	O
1434	##ment	O
1434	,	O
1434	followed	O
1434	closely	O
1434	by	O
1434	di	O
1434	##az	O
1434	##ep	O
1434	##am	O
1434	.	O
1434	[SEP]	O
1435	[CLS]	O
1435	3	O
1435	-	O
1435	(	O
1435	5	O
1435	-	O
1435	amino	O
1435	-	O
1435	1	O
1435	,	O
1435	3	O
1435	,	O
1435	4	O
1435	-	O
1435	th	O
1435	##ia	O
1435	##dia	O
1435	##zo	O
1435	##l	O
1435	-	O
1435	2	O
1435	-	O
1435	y	O
1435	##l	O
1435	)	O
1435	-	O
1435	1	O
1435	-	O
1435	c	O
1435	##y	O
1435	##c	O
1435	##lop	O
1435	##rop	O
1435	##yl	O
1435	-	O
1435	7	O
1435	-	O
1435	(	O
1435	4	O
1435	-	O
1435	(	O
1435	2	O
1435	,	O
1435	4	O
1435	-	O
1435	di	O
1435	##ch	O
1435	##lor	O
1435	##obe	O
1435	##nz	O
1435	##oy	O
1435	##l	O
1435	)	O
1435	pipe	O
1435	##raz	O
1435	##in	O
1435	-	O
1435	1	O
1435	-	O
1435	y	O
1435	##l	O
1435	)	O
1435	-	O
1435	6	O
1435	-	O
1435	flu	O
1435	##oro	O
1435	##quin	O
1435	##olin	O
1435	-	O
1435	4	O
1435	(	O
1435	1	O
1435	##h	O
1435	)	O
1435	-	O
1435	one	O
1435	(	O
1435	3	O
1435	##i	O
1435	)	O
1435	.	O
1435	[SEP]	O
1436	[CLS]	O
1436	this	O
1436	finding	O
1436	was	O
1436	reproduced	O
1436	(	O
1436	p	O
1436	=	O
1436	0	O
1436	.	O
1436	01	O
1436	##3	O
1436	)	O
1436	after	O
1436	withdrawal	O
1436	of	O
1436	two	O
1436	patients	O
1436	with	O
1436	bleeding	O
1436	p	O
1436	##hen	O
1436	##otype	O
1436	related	O
1436	to	O
1436	their	O
1436	advanced	O
1436	art	O
1436	##hr	O
1436	##op	O
1436	##athy	O
1436	but	O
1436	normal	O
1436	t	B-PK
1436	##1	I-PK
1436	/	I-PK
1436	2	I-PK
1436	and	O
1436	t	B-PK
1436	##rough	I-PK
1436	levels	I-PK
1436	.	O
1436	[SEP]	O
1437	[CLS]	O
1437	mean	O
1437	i	O
1437	##g	O
1437	##p	O
1437	##ro	O
1437	##20	O
1437	:	O
1437	i	O
1437	##g	O
1437	##p	O
1437	##ro	O
1437	##10	O
1437	dose	O
1437	ratio	O
1437	(	O
1437	dose	O
1437	adjustment	O
1437	coefficient	O
1437	)	O
1437	was	O
1437	1	O
1437	.	O
1437	53	O
1437	(	O
1437	range	O
1437	1	O
1437	.	O
1437	26	O
1437	-	O
1437	1	O
1437	.	O
1437	87	O
1437	)	O
1437	.	O
1437	[SEP]	O
1438	[CLS]	O
1438	pre	O
1438	##tar	O
1438	##get	O
1438	##ed	O
1438	radio	O
1438	##im	O
1438	##mu	O
1438	##not	O
1438	##her	O
1438	##ap	O
1438	##y	O
1438	(	O
1438	p	O
1438	##rit	O
1438	)	O
1438	based	O
1438	on	O
1438	the	O
1438	inverse	O
1438	electron	O
1438	demand	O
1438	die	O
1438	##ls	O
1438	-	O
1438	al	O
1438	##der	O
1438	(	O
1438	i	O
1438	##edd	O
1438	##a	O
1438	)	O
1438	reaction	O
1438	between	O
1438	te	O
1438	##tra	O
1438	##zine	O
1438	(	O
1438	t	O
1438	##z	O
1438	)	O
1438	and	O
1438	trans	O
1438	-	O
1438	c	O
1438	##y	O
1438	##c	O
1438	##lo	O
1438	##oc	O
1438	##ten	O
1438	##e	O
1438	(	O
1438	t	O
1438	##co	O
1438	)	O
1438	represents	O
1438	a	O
1438	promising	O
1438	strategy	O
1438	for	O
1438	lever	O
1438	##aging	O
1438	the	O
1438	affinity	O
1438	and	O
1438	specific	O
1438	##ity	O
1438	of	O
1438	antibodies	O
1438	without	O
1438	their	O
1438	p	O
1438	##har	O
1438	##ma	O
1438	##co	O
1438	##kin	O
1438	##etic	O
1438	draw	O
1438	##backs	O
1438	.	O
1438	[SEP]	O
1439	[CLS]	O
1439	however	O
1439	because	O
1439	the	O
1439	absolute	O
1439	dose	O
1439	received	O
1439	by	O
1439	the	O
1439	infant	O
1439	is	O
1439	dependent	O
1439	on	O
1439	the	O
1439	maternal	O
1439	dose	O
1439	rate	O
1439	,	O
1439	the	O
1439	risk	O
1439	-	O
1439	benefit	O
1439	ratio	O
1439	should	O
1439	be	O
1439	considered	O
1439	for	O
1439	each	O
1439	individual	O
1439	case	O
1439	.	O
1439	[SEP]	O
1440	[CLS]	O
1440	car	O
1440	##ip	O
1440	##raz	O
1440	##ine	O
1440	is	O
1440	in	O
1440	phase	O
1440	ii	O
1440	##i	O
1440	clinical	O
1440	trials	O
1440	in	O
1440	patients	O
1440	with	O
1440	s	O
1440	##chi	O
1440	##zophrenia	O
1440	and	O
1440	in	O
1440	patients	O
1440	with	O
1440	bi	O
1440	##pol	O
1440	##ar	O
1440	disorder	O
1440	.	O
1440	[SEP]	O
1441	[CLS]	O
1441	the	O
1441	in	O
1441	##hibition	O
1441	of	O
1441	clearance	B-PK
1441	through	O
1441	cross	O
1441	-	O
1441	linking	O
1441	occurs	O
1441	only	O
1441	under	O
1441	conditions	O
1441	that	O
1441	produce	O
1441	partial	O
1441	cross	O
1441	-	O
1441	linking	O
1441	of	O
1441	the	O
1441	fi	O
1441	##bri	O
1441	##n	O
1441	.	O
1441	[SEP]	O
1442	[CLS]	O
1442	the	O
1442	ma	B-PK
1442	##ximal	I-PK
1442	g	I-PK
1442	##ent	I-PK
1442	##ami	I-PK
1442	##cin	I-PK
1442	level	I-PK
1442	for	O
1442	any	O
1442	patient	O
1442	was	O
1442	2	O
1442	.	O
1442	36	O
1442	μ	O
1442	##g	O
1442	/	O
1442	m	O
1442	##l	O
1442	at	O
1442	6	O
1442	h	O
1442	,	O
1442	which	O
1442	was	O
1442	well	O
1442	below	O
1442	the	O
1442	pre	O
1442	##sp	O
1442	##ec	O
1442	##ified	O
1442	stopping	O
1442	criterion	O
1442	of	O
1442	12	O
1442	μ	O
1442	##g	O
1442	/	O
1442	m	O
1442	##l	O
1442	at	O
1442	6	O
1442	h	O
1442	.	O
1442	the	O
1442	ma	B-PK
1442	##ximal	I-PK
1442	van	I-PK
1442	##com	I-PK
1442	##y	I-PK
1442	##cin	I-PK
1442	level	I-PK
1442	for	O
1442	any	O
1442	patient	O
1442	was	O
1442	0	O
1442	.	O
1442	68	O
1442	##4	O
1442	μ	O
1442	##g	O
1442	/	O
1442	m	O
1442	##l	O
1442	at	O
1442	6	O
1442	h	O
1442	,	O
1442	well	O
1442	below	O
1442	the	O
1442	pre	O
1442	##sp	O
1442	##ec	O
1442	##ified	O
1442	stopping	O
1442	criterion	O
1442	of	O
1442	20	O
1442	μ	O
1442	##g	O
1442	/	O
1442	m	O
1442	##l	O
1442	.	O
1442	p	O
1442	##har	O
1442	##ma	O
1442	##co	O
1442	##kin	O
1442	##etic	O
1442	data	O
1442	are	O
1442	shown	O
1442	in	O
1442	table	O
1442	2	O
1442	and	O
1442	fi	O
1442	##gs	O
1442	.	O
1442	1	O
1442	and	O
1442	2	O
1442	.	O
1442	[SEP]	O
1443	[CLS]	O
1443	inter	O
1443	##fer	O
1443	##on	O
1443	β	O
1443	-	O
1443	1	O
1443	##a	O
1443	was	O
1443	labelled	O
1443	with	O
1443	125	O
1443	##i	O
1443	by	O
1443	an	O
1443	##awa	O
1443	(	O
1443	wa	O
1443	##nge	O
1443	##n	O
1443	,	O
1443	s	O
1443	##witz	O
1443	##erland	O
1443	)	O
1443	and	O
1443	prepared	O
1443	in	O
1443	l	O
1443	##yo	O
1443	##phi	O
1443	##li	O
1443	##zed	O
1443	al	O
1443	##iq	O
1443	##uo	O
1443	##ts	O
1443	of	O
1443	2	O
1443	.	O
1443	5	O
1443	μ	O
1443	##ci	O
1443	,	O
1443	each	O
1443	containing	O
1443	25	O
1443	ng	O
1443	of	O
1443	inter	O
1443	##fer	O
1443	##on	O
1443	β	O
1443	-	O
1443	1	O
1443	##a	O
1443	.	O
1443	[SEP]	O
1444	[CLS]	O
1444	the	O
1444	potential	O
1444	impact	O
1444	of	O
1444	co	O
1444	##ad	O
1444	##mini	O
1444	##stra	O
1444	##tion	O
1444	of	O
1444	b	O
1444	##up	O
1444	##ar	O
1444	##lis	O
1444	##ib	O
1444	on	O
1444	bin	O
1444	##ime	O
1444	##tin	O
1444	##ib	O
1444	was	O
1444	assessed	O
1444	by	O
1444	examining	O
1444	maximum	B-PK
1444	plasma	I-PK
1444	concentration	I-PK
1444	(	I-PK
1444	cm	I-PK
1444	##ax	I-PK
1444	)	I-PK
1444	and	O
1444	area	B-PK
1444	under	I-PK
1444	the	I-PK
1444	concentration	I-PK
1444	curve	I-PK
1444	(	I-PK
1444	au	I-PK
1444	##ct	I-PK
1444	##au	I-PK
1444	)	I-PK
1444	at	O
1444	the	O
1444	same	O
1444	level	O
1444	of	O
1444	bin	O
1444	##ime	O
1444	##tin	O
1444	##ib	O
1444	across	O
1444	doses	O
1444	of	O
1444	b	O
1444	##up	O
1444	##ar	O
1444	##lis	O
1444	##ib	O
1444	on	O
1444	day	O
1444	15	O
1444	.	O
1444	[SEP]	O
1445	[CLS]	O
1445	each	O
1445	rat	O
1445	was	O
1445	deemed	O
1445	to	O
1445	be	O
1445	im	O
1445	##mobile	O
1445	when	O
1445	it	O
1445	stopped	O
1445	s	O
1445	##c	O
1445	##rab	O
1445	##bling	O
1445	,	O
1445	remained	O
1445	floating	O
1445	still	O
1445	##y	O
1445	in	O
1445	the	O
1445	water	O
1445	and	O
1445	only	O
1445	made	O
1445	necessary	O
1445	struggling	O
1445	to	O
1445	maintain	O
1445	its	O
1445	head	O
1445	over	O
1445	water	O
1445	.	O
1445	[SEP]	O
1446	[CLS]	O
1446	of	O
1446	205	O
1446	patients	O
1446	,	O
1446	19	O
1446	,	O
1446	82	O
1446	,	O
1446	and	O
1446	104	O
1446	carried	O
1446	0	O
1446	,	O
1446	1	O
1446	,	O
1446	and	O
1446	2	O
1446	active	O
1446	o	O
1446	##ct	O
1446	##1	O
1446	all	O
1446	##ele	O
1446	##s	O
1446	,	O
1446	respectively	O
1446	.	O
1446	[SEP]	O
1447	[CLS]	O
1447	the	O
1447	d	O
1447	##ys	O
1447	##re	O
1447	##gu	O
1447	##lation	O
1447	of	O
1447	p	O
1447	##hos	O
1447	##pha	O
1447	##ti	O
1447	##dy	O
1447	##lino	O
1447	##si	O
1447	##to	O
1447	##l	O
1447	3	O
1447	-	O
1447	kinase	O
1447	(	O
1447	p	O
1447	##i	O
1447	##3	O
1447	##k	O
1447	)	O
1447	-	O
1447	dependent	O
1447	pathways	O
1447	is	O
1447	implicated	O
1447	in	O
1447	several	O
1447	human	O
1447	cancer	O
1447	##s	O
1447	making	O
1447	it	O
1447	an	O
1447	attractive	O
1447	target	O
1447	for	O
1447	small	O
1447	molecule	O
1447	p	O
1447	##i	O
1447	##3	O
1447	##k	O
1447	inhibitor	O
1447	##s	O
1447	.	O
1447	[SEP]	O
1448	[CLS]	O
1448	to	O
1448	assess	O
1448	the	O
1448	effects	O
1448	of	O
1448	food	O
1448	,	O
1448	the	O
1448	subjects	O
1448	in	O
1448	the	O
1448	10	O
1448	-	O
1448	mg	O
1448	dose	O
1448	group	O
1448	received	O
1448	a	O
1448	single	O
1448	dose	O
1448	of	O
1448	da	O
1448	-	O
1448	122	O
1448	##9	O
1448	10	O
1448	mg	O
1448	after	O
1448	a	O
1448	high	O
1448	-	O
1448	fat	O
1448	meal	O
1448	,	O
1448	crossing	O
1448	over	O
1448	from	O
1448	the	O
1448	administration	O
1448	of	O
1448	da	O
1448	-	O
1448	122	O
1448	##9	O
1448	under	O
1448	a	O
1448	fast	O
1448	##ing	O
1448	state	O
1448	,	O
1448	after	O
1448	a	O
1448	7	O
1448	-	O
1448	day	O
1448	wash	O
1448	##out	O
1448	period	O
1448	.	O
1448	[SEP]	O
1449	[CLS]	O
1449	then	O
1449	,	O
1449	an	O
1449	##nex	O
1449	##in	O
1449	v	O
1449	-	O
1449	fit	O
1449	##c	O
1449	and	O
1449	p	O
1449	##i	O
1449	were	O
1449	added	O
1449	,	O
1449	followed	O
1449	by	O
1449	a	O
1449	10	O
1449	-	O
1449	min	O
1449	in	O
1449	##cu	O
1449	##bation	O
1449	at	O
1449	room	O
1449	temperature	O
1449	,	O
1449	and	O
1449	were	O
1449	analyzed	O
1449	using	O
1449	a	O
1449	flow	O
1449	c	O
1449	##yt	O
1449	##ometer	O
1449	(	O
1449	a	O
1449	##cc	O
1449	##uri	O
1449	c	O
1449	##6	O
1449	;	O
1449	b	O
1449	##d	O
1449	company	O
1449	,	O
1449	f	O
1449	##rank	O
1449	##lin	O
1449	lakes	O
1449	,	O
1449	n	O
1449	##j	O
1449	)	O
1449	.	O
1449	[SEP]	O
1450	[CLS]	O
1450	the	O
1450	number	O
1450	of	O
1450	recruited	O
1450	mon	O
1450	##ocytes	O
1450	was	O
1450	reduced	O
1450	by	O
1450	64	O
1450	%	O
1450	,	O
1450	whereas	O
1450	no	O
1450	significant	O
1450	effect	O
1450	on	O
1450	ne	O
1450	##ut	O
1450	##rop	O
1450	##hil	O
1450	recruitment	O
1450	was	O
1450	observed	O
1450	(	O
1450	fi	O
1450	##g	O
1450	.	O
1450	4	O
1450	##g	O
1450	and	O
1450	supplement	O
1450	##ary	O
1450	figure	O
1450	3	O
1450	)	O
1450	.	O
1450	[SEP]	O
1451	[CLS]	O
1451	as	O
1451	shown	O
1451	in	O
1451	figure	O
1451	2	O
1451	,	O
1451	figure	O
1451	3	O
1451	,	O
1451	no	O
1451	significant	O
1451	direct	O
1451	interference	O
1451	in	O
1451	the	O
1451	blank	O
1451	plasma	O
1451	traces	O
1451	was	O
1451	observed	O
1451	from	O
1451	end	O
1451	##ogen	O
1451	##ous	O
1451	substances	O
1451	in	O
1451	drug	O
1451	-	O
1451	free	O
1451	plasma	O
1451	at	O
1451	the	O
1451	retention	O
1451	time	O
1451	of	O
1451	the	O
1451	anal	O
1451	##yte	O
1451	##s	O
1451	.	O
1451	[SEP]	O
1452	[CLS]	O
1452	the	O
1452	demographic	O
1452	characteristics	O
1452	of	O
1452	the	O
1452	patients	O
1452	are	O
1452	shown	O
1452	in	O
1452	table	O
1452	1	O
1452	.	O
1452	[SEP]	O
1453	[CLS]	O
1453	the	O
1453	o	O
1453	##ih	O
1453	/	O
1453	(	O
1453	99	O
1453	##m	O
1453	)	O
1453	t	O
1453	##c	O
1453	-	O
1453	ma	O
1453	##g	O
1453	##3	O
1453	re	B-PK
1453	##nal	I-PK
1453	clearance	I-PK
1453	ratio	I-PK
1453	was	O
1453	2	O
1453	.	O
1453	47	O
1453	.	O
1453	[SEP]	O
1454	[CLS]	O
1454	further	O
1454	studies	O
1454	are	O
1454	needed	O
1454	to	O
1454	determine	O
1454	the	O
1454	full	O
1454	p	O
1454	##har	O
1454	##ma	O
1454	##co	O
1454	##kin	O
1454	##etics	O
1454	of	O
1454	a	O
1454	.	O
1454	f	O
1454	##rag	O
1454	##ran	O
1454	##s	O
1454	activity	O
1454	in	O
1454	v	O
1454	##ivo	O
1454	.	O
1454	[SEP]	O
1455	[CLS]	O
1455	with	O
1455	one	O
1455	-	O
1455	fourth	O
1455	of	O
1455	the	O
1455	population	O
1455	absorbing	O
1455	as	O
1455	little	O
1455	as	O
1455	30	O
1455	%	O
1455	of	O
1455	the	O
1455	drug	O
1455	relative	O
1455	to	O
1455	others	O
1455	,	O
1455	low	O
1455	drug	O
1455	exposure	O
1455	##s	O
1455	might	O
1455	be	O
1455	responsible	O
1455	for	O
1455	treatment	O
1455	failures	O
1455	.	O
1455	[SEP]	O
1456	[CLS]	O
1456	the	O
1456	observed	O
1456	values	O
1456	were	O
1456	used	O
1456	to	O
1456	calculate	O
1456	the	O
1456	em	B-PK
1456	##ax	I-PK
1456	,	I-PK
1456	s	I-PK
1456	##s	I-PK
1456	.	O
1456	[SEP]	O
1457	[CLS]	O
1457	in	O
1457	##hibition	O
1457	of	O
1457	ni	O
1457	##fe	O
1457	##di	O
1457	##pine	O
1457	metabolism	O
1457	in	O
1457	dogs	O
1457	by	O
1457	er	O
1457	##yt	O
1457	##hr	O
1457	##omy	O
1457	##cin	O
1457	:	O
1457	difference	O
1457	between	O
1457	the	O
1457	gut	O
1457	wall	O
1457	and	O
1457	the	O
1457	liver	O
1457	.	O
1457	[SEP]	O
1458	[CLS]	O
1458	the	O
1458	is	O
1458	##oc	O
1458	##ratic	O
1458	mobile	O
1458	phase	O
1458	,	O
1458	0	O
1458	.	O
1458	01	O
1458	m	O
1458	potassium	O
1458	di	O
1458	##hy	O
1458	##dr	O
1458	##ogen	O
1458	or	O
1458	##th	O
1458	##o	O
1458	phosphate	O
1458	(	O
1458	p	O
1458	##h	O
1458	3	O
1458	.	O
1458	2	O
1458	)	O
1458	and	O
1458	ace	O
1458	##ton	O
1458	##it	O
1458	##ril	O
1458	##e	O
1458	(	O
1458	50	O
1458	:	O
1458	50	O
1458	,	O
1458	v	O
1458	/	O
1458	v	O
1458	)	O
1458	was	O
1458	run	O
1458	at	O
1458	a	O
1458	flow	O
1458	rate	O
1458	of	O
1458	1	O
1458	m	O
1458	##l	O
1458	/	O
1458	min	O
1458	.	O
1458	[SEP]	O
1459	[CLS]	O
1459	p	O
1459	##har	O
1459	##ma	O
1459	##co	O
1459	##kin	O
1459	##etic	O
1459	study	O
1459	of	O
1459	radioactive	O
1459	anti	O
1459	##ne	O
1459	##op	O
1459	##last	O
1459	##on	O
1459	a	O
1459	##10	O
1459	following	O
1459	oral	O
1459	administration	O
1459	in	O
1459	rats	O
1459	.	O
1459	[SEP]	O
1460	[CLS]	O
1460	performance	O
1460	of	O
1460	computer	O
1460	simulated	O
1460	in	O
1460	##hala	O
1460	##tional	O
1460	an	O
1460	##est	O
1460	##hetic	O
1460	up	O
1460	##take	O
1460	model	O
1460	in	O
1460	comparison	O
1460	with	O
1460	real	O
1460	time	O
1460	is	O
1460	##of	O
1460	##lu	O
1460	##rane	O
1460	concentration	O
1460	.	O
1460	[SEP]	O
1461	[CLS]	O
1461	no	O
1461	evidence	O
1461	of	O
1461	acute	O
1461	card	O
1461	##iot	O
1461	##ox	O
1461	##icit	O
1461	##y	O
1461	or	O
1461	of	O
1461	acute	O
1461	or	O
1461	delayed	O
1461	systemic	O
1461	toxicity	O
1461	was	O
1461	observed	O
1461	.	O
1461	[SEP]	O
1462	[CLS]	O
1462	for	O
1462	day	O
1462	1	O
1462	,	O
1462	m	O
1462	##ds	O
1462	-	O
1462	up	O
1462	##dr	O
1462	##s	O
1462	assessments	O
1462	after	O
1462	rescue	O
1462	were	O
1462	imp	O
1462	##uted	O
1462	as	O
1462	base	O
1462	##line	O
1462	observation	O
1462	carried	O
1462	forward	O
1462	and	O
1462	motor	O
1462	state	O
1462	assessments	O
1462	were	O
1462	imp	O
1462	##uted	O
1462	as	O
1462	off	O
1462	.	O
1462	[SEP]	O
1463	[CLS]	O
1463	patients	O
1463	weighing	O
1463	<	O
1463	50	O
1463	kg	O
1463	or	O
1463	>	O
1463	90	O
1463	kg	O
1463	were	O
1463	excluded	O
1463	.	O
1463	[SEP]	O
1464	[CLS]	O
1464	c	O
1464	##t	O
1464	##26	O
1464	was	O
1464	used	O
1464	to	O
1464	determine	O
1464	the	O
1464	in	O
1464	v	O
1464	##it	O
1464	##ro	O
1464	c	O
1464	##yt	O
1464	##oto	O
1464	##xi	O
1464	##city	O
1464	.	O
1464	[SEP]	O
1465	[CLS]	O
1465	the	O
1465	purpose	O
1465	of	O
1465	this	O
1465	study	O
1465	was	O
1465	to	O
1465	establish	O
1465	the	O
1465	p	O
1465	##har	O
1465	##ma	O
1465	##co	O
1465	##kin	O
1465	##etics	O
1465	of	O
1465	en	O
1465	##ro	O
1465	##f	O
1465	##lo	O
1465	##xa	O
1465	##cin	O
1465	and	O
1465	its	O
1465	meta	O
1465	##bol	O
1465	##ite	O
1465	c	O
1465	##ip	O
1465	##ro	O
1465	##f	O
1465	##lo	O
1465	##xa	O
1465	##cin	O
1465	in	O
1465	the	O
1465	plasma	O
1465	and	O
1465	inter	O
1465	##st	O
1465	##iti	O
1465	##al	O
1465	fluid	O
1465	(	O
1465	is	O
1465	##f	O
1465	)	O
1465	following	O
1465	sub	O
1465	##cut	O
1465	##aneous	O
1465	(	O
1465	s	O
1465	.	O
1465	c	O
1465	.	O
1465	)	O
1465	administration	O
1465	of	O
1465	en	O
1465	##ro	O
1465	##f	O
1465	##lo	O
1465	##xa	O
1465	##cin	O
1465	.	O
1465	[SEP]	O
1466	[CLS]	O
1466	phase	O
1466	i	O
1466	evaluation	O
1466	of	O
1466	continuous	O
1466	5	O
1466	-	O
1466	flu	O
1466	##oro	O
1466	##ura	O
1466	##ci	O
1466	##l	O
1466	in	O
1466	##fusion	O
1466	followed	O
1466	by	O
1466	weekly	O
1466	p	O
1466	##ac	O
1466	##lit	O
1466	##ax	O
1466	##el	O
1466	in	O
1466	patients	O
1466	with	O
1466	advanced	O
1466	or	O
1466	re	O
1466	##current	O
1466	gas	O
1466	##tric	O
1466	cancer	O
1466	.	O
1466	[SEP]	O
1467	[CLS]	O
1467	p	O
1467	##eptide	O
1467	##s	O
1467	were	O
1467	initially	O
1467	evaluated	O
1467	using	O
1467	a	O
1467	competitive	O
1467	enzyme	O
1467	-	O
1467	linked	O
1467	im	O
1467	##mu	O
1467	##nos	O
1467	##or	O
1467	##bent	O
1467	ass	O
1467	##ay	O
1467	(	O
1467	el	O
1467	##isa	O
1467	)	O
1467	.	O
1467	[SEP]	O
1468	[CLS]	O
1468	a	O
1468	se	O
1468	##rous	O
1468	-	O
1468	a	O
1468	##cin	O
1468	##ar	O
1468	chemical	O
1468	transport	O
1468	ass	O
1468	##ay	O
1468	was	O
1468	established	O
1468	to	O
1468	measure	O
1468	chemical	O
1468	transport	O
1468	with	O
1468	non	O
1468	##phy	O
1468	##sio	O
1468	##logical	O
1468	(	O
1468	standard	O
1468	cell	O
1468	culture	O
1468	medium	O
1468	)	O
1468	and	O
1468	physiological	O
1468	(	O
1468	using	O
1468	sur	O
1468	##rogate	O
1468	plasma	O
1468	and	O
1468	sa	O
1468	##liva	O
1468	medium	O
1468	)	O
1468	conditions	O
1468	using	O
1468	3	O
1468	,	O
1468	5	O
1468	,	O
1468	6	O
1468	-	O
1468	t	O
1468	##rich	O
1468	##lor	O
1468	##o	O
1468	-	O
1468	2	O
1468	-	O
1468	p	O
1468	##yr	O
1468	##id	O
1468	##ino	O
1468	##l	O
1468	(	O
1468	t	O
1468	##c	O
1468	##py	O
1468	)	O
1468	a	O
1468	meta	O
1468	##bol	O
1468	##ite	O
1468	of	O
1468	the	O
1468	p	O
1468	##est	O
1468	##icide	O
1468	ch	O
1468	##lor	O
1468	##py	O
1468	##ri	O
1468	##fo	O
1468	##s	O
1468	.	O
1468	[SEP]	O
1469	[CLS]	O
1469	the	O
1469	onset	O
1469	times	O
1469	were	O
1469	the	O
1469	same	O
1469	for	O
1469	both	O
1469	the	O
1469	elderly	O
1469	and	O
1469	younger	O
1469	control	O
1469	group	O
1469	,	O
1469	but	O
1469	the	O
1469	duration	O
1469	of	O
1469	action	O
1469	of	O
1469	r	O
1469	##oc	O
1469	##uron	O
1469	##ium	O
1469	was	O
1469	significantly	O
1469	prolonged	O
1469	in	O
1469	the	O
1469	elderly	O
1469	patients	O
1469	.	O
1469	[SEP]	O
1470	[CLS]	O
1470	by	O
1470	comparing	O
1470	approximately	O
1470	e	O
1470	##qui	O
1470	##pot	O
1470	##ent	O
1470	doses	O
1470	,	O
1470	time	O
1470	to	O
1470	peak	O
1470	ant	O
1470	##agon	O
1470	##ism	O
1470	(	O
1470	onset	O
1470	)	O
1470	and	O
1470	until	O
1470	30	O
1470	%	O
1470	of	O
1470	peak	O
1470	ant	O
1470	##agon	O
1470	##ism	O
1470	remained	O
1470	(	O
1470	duration	O
1470	)	O
1470	were	O
1470	shorter	O
1470	for	O
1470	both	O
1470	ed	O
1470	##rop	O
1470	##hon	O
1470	##ium	O
1470	and	O
1470	p	O
1470	##t	O
1470	##ma	O
1470	than	O
1470	for	O
1470	neo	O
1470	##st	O
1470	##ig	O
1470	##mine	O
1470	and	O
1470	p	O
1470	##yr	O
1470	##ido	O
1470	##st	O
1470	##ig	O
1470	##mine	O
1470	.	O
1470	[SEP]	O
1471	[CLS]	O
1471	the	O
1471	disposition	O
1471	of	O
1471	but	O
1471	##or	O
1471	##pha	O
1471	##no	O
1471	##l	O
1471	following	O
1471	in	O
1471	##tra	O
1471	##ven	O
1471	##ous	O
1471	administration	O
1471	was	O
1471	characterized	O
1471	by	O
1471	rapid	O
1471	and	O
1471	extensive	O
1471	distribution	O
1471	followed	O
1471	by	O
1471	a	O
1471	slower	O
1471	elimination	O
1471	phase	O
1471	.	O
1471	[SEP]	O
1472	[CLS]	O
1472	both	O
1472	treatments	O
1472	showed	O
1472	efficacy	O
1472	more	O
1472	than	O
1472	95	O
1472	%	O
1472	at	O
1472	72	O
1472	h	O
1472	,	O
1472	lower	O
1472	95	O
1472	%	O
1472	confidence	O
1472	intervals	O
1472	were	O
1472	well	O
1472	above	O
1472	95	O
1472	%	O
1472	of	O
1472	success	O
1472	rate	O
1472	in	O
1472	both	O
1472	treatments	O
1472	(	O
1472	table	O
1472	2	O
1472	)	O
1472	.	O
1472	[SEP]	O
1473	[CLS]	O
1473	collectively	O
1473	,	O
1473	these	O
1473	studies	O
1473	support	O
1473	further	O
1473	development	O
1473	of	O
1473	r	O
1473	##t	O
1473	##d	O
1473	-	O
1473	1	O
1473	for	O
1473	treatment	O
1473	of	O
1473	c	O
1473	##f	O
1473	air	O
1473	##way	O
1473	disease	O
1473	.	O
1473	[SEP]	O
1474	[CLS]	O
1474	these	O
1474	were	O
1474	also	O
1474	assessed	O
1474	for	O
1474	clearance	B-PK
1474	using	O
1474	plate	O
1474	##d	O
1474	he	O
1474	##pa	O
1474	##to	O
1474	##cy	O
1474	##tes	O
1474	over	O
1474	a	O
1474	48	O
1474	-	O
1474	h	O
1474	time	O
1474	course	O
1474	(	O
1474	0	O
1474	,	O
1474	4	O
1474	,	O
1474	8	O
1474	,	O
1474	24	O
1474	,	O
1474	and	O
1474	48	O
1474	h	O
1474	)	O
1474	at	O
1474	the	O
1474	1	O
1474	µ	O
1474	##m	O
1474	chemical	O
1474	concentration	O
1474	(	O
1474	s	O
1474	##mith	O
1474	et	O
1474	al	O
1474	.	O
1474	,	O
1474	2012	O
1474	)	O
1474	.	O
1474	[SEP]	O
1475	[CLS]	O
1475	although	O
1475	6	O
1475	of	O
1475	9	O
1475	participants	O
1475	who	O
1475	had	O
1475	their	O
1475	patch	O
1475	removed	O
1475	had	O
1475	at	O
1475	least	O
1475	one	O
1475	variant	O
1475	all	O
1475	##ele	O
1475	,	O
1475	this	O
1475	difference	O
1475	in	O
1475	toxicity	O
1475	was	O
1475	not	O
1475	statistical	O
1475	##ly	O
1475	significant	O
1475	across	O
1475	g	O
1475	##eno	O
1475	##type	O
1475	groups	O
1475	.	O
1475	[SEP]	O
1476	[CLS]	O
1476	initial	O
1476	clinical	O
1476	trial	O
1476	of	O
1476	a	O
1476	selective	O
1476	re	O
1476	##tino	O
1476	##id	O
1476	x	O
1476	receptor	O
1476	l	O
1476	##igan	O
1476	##d	O
1476	,	O
1476	l	O
1476	##g	O
1476	##d	O
1476	##10	O
1476	##6	O
1476	##9	O
1476	.	O
1476	[SEP]	O
1477	[CLS]	O
1477	we	O
1477	also	O
1477	measured	O
1477	f	O
1477	##1	O
1477	+	O
1477	2	O
1477	pro	O
1477	##th	O
1477	##rom	O
1477	##bin	O
1477	fragment	O
1477	levels	O
1477	to	O
1477	assess	O
1477	the	O
1477	effect	O
1477	of	O
1477	s	O
1477	1832	O
1477	##6	O
1477	on	O
1477	th	O
1477	##rom	O
1477	##bin	O
1477	generation	O
1477	in	O
1477	v	O
1477	##ivo	O
1477	.	O
1477	[SEP]	O
1478	[CLS]	O
1478	e	O
1478	##q	O
1478	##s	O
1478	.	O
1478	(	O
1478	1	O
1478	)	O
1478	,	O
1478	(	O
1478	2	O
1478	)	O
1478	represent	O
1478	the	O
1478	linear	O
1478	re	O
1478	##gression	O
1478	models	O
1478	for	O
1478	particle	O
1478	size	O
1478	(	O
1478	p	O
1478	.	O
1478	s	O
1478	.	O
1478	)	O
1478	using	O
1478	t	O
1478	##80	O
1478	and	O
1478	s	O
1478	##80	O
1478	transfers	O
1478	##ome	O
1478	##s	O
1478	,	O
1478	respectively	O
1478	,	O
1478	as	O
1478	obtained	O
1478	from	O
1478	factor	O
1478	##ial	O
1478	design	O
1478	study	O
1478	.	O
1478	(	O
1478	1	O
1478	)	O
1478	particle	O
1478	size	O
1478	using	O
1478	##t	O
1478	##80	O
1478	=	O
1478	2	O
1478	.	O
1478	29	O
1478	-	O
1478	0	O
1478	.	O
1478	24	O
1478	##xa	O
1478	+	O
1478	0	O
1478	.	O
1478	02	O
1478	##4	O
1478	##x	O
1478	##b	O
1478	+	O
1478	0	O
1478	.	O
1478	29	O
1478	##x	O
1478	##c	O
1478	+	O
1478	0	O
1478	.	O
1478	47	O
1478	##xa	O
1478	##b	O
1478	+	O
1478	0	O
1478	.	O
1478	23	O
1478	##xa	O
1478	##c	O
1478	+	O
1478	0	O
1478	.	O
1478	43	O
1478	##x	O
1478	##b	O
1478	##c	O
1478	)	O
1478	[	O
1478	where	O
1478	f	O
1478	=	O
1478	21	O
1478	.	O
1478	9	O
1478	,	O
1478	p	O
1478	<	O
1478	0	O
1478	.	O
1478	000	O
1478	##1	O
1478	and	O
1478	r	O
1478	##2	O
1478	=	O
1478	0	O
1478	.	O
1478	93	O
1478	]	O
1478	(	O
1478	2	O
1478	)	O
1478	particle	O
1478	size	O
1478	using	O
1478	##s	O
1478	##80	O
1478	=	O
1478	2	O
1478	.	O
1478	9	O
1478	-	O
1478	0	O
1478	.	O
1478	4	O
1478	##xa	O
1478	+	O
1478	0	O
1478	.	O
1478	03	O
1478	##9	O
1478	##x	O
1478	##b	O
1478	+	O
1478	0	O
1478	.	O
1478	46	O
1478	##x	O
1478	##c	O
1478	-	O
1478	0	O
1478	.	O
1478	18	O
1478	##xa	O
1478	##b	O
1478	-	O
1478	3	O
1478	.	O
1478	12	O
1478	##xa	O
1478	##c	O
1478	-	O
1478	0	O
1478	.	O
1478	52	O
1478	##x	O
1478	##b	O
1478	##c	O
1478	[	O
1478	where	O
1478	f	O
1478	=	O
1478	15	O
1478	.	O
1478	28	O
1478	,	O
1478	p	O
1478	<	O
1478	0	O
1478	.	O
1478	000	O
1478	##1	O
1478	and	O
1478	r	O
1478	##2	O
1478	=	O
1478	0	O
1478	.	O
1478	91	O
1478	]	O
1478	[SEP]	O
1479	[CLS]	O
1479	to	O
1479	measure	O
1479	the	O
1479	effect	O
1479	of	O
1479	compounds	O
1479	on	O
1479	worm	O
1479	c	O
1479	##p	O
1479	activity	O
1479	in	O
1479	v	O
1479	##ivo	O
1479	[	O
1479	36	O
1479	]	O
1479	,	O
1479	one	O
1479	ha	O
1479	##ms	O
1479	##ter	O
1479	from	O
1479	each	O
1479	of	O
1479	the	O
1479	treatment	O
1479	and	O
1479	vehicle	O
1479	groups	O
1479	was	O
1479	sacrificed	O
1479	8	O
1479	h	O
1479	post	O
1479	-	O
1479	treatment	O
1479	.	O
1479	[SEP]	O
1480	[CLS]	O
1480	the	O
1480	aim	O
1480	of	O
1480	the	O
1480	study	O
1480	is	O
1480	to	O
1480	apply	O
1480	a	O
1480	multi	O
1480	##par	O
1480	##ame	O
1480	##tric	O
1480	method	O
1480	for	O
1480	the	O
1480	quantitative	O
1480	est	O
1480	##imation	O
1480	of	O
1480	mouse	O
1480	models	O
1480	with	O
1480	different	O
1480	degrees	O
1480	of	O
1480	hind	O
1480	##lim	O
1480	##b	O
1480	is	O
1480	##che	O
1480	##mia	O
1480	based	O
1480	on	O
1480	a	O
1480	dynamic	O
1480	flu	O
1480	##ores	O
1480	##cence	O
1480	imaging	O
1480	-	O
1480	based	O
1480	strategy	O
1480	.	O
1480	[SEP]	O
1481	[CLS]	O
1481	augmented	O
1481	re	B-PK
1481	##nal	I-PK
1481	clearance	I-PK
1481	in	O
1481	patients	O
1481	with	O
1481	f	O
1481	##eb	O
1481	##ril	O
1481	##e	O
1481	ne	O
1481	##ut	O
1481	##rop	O
1481	##enia	O
1481	is	O
1481	associated	O
1481	with	O
1481	increased	O
1481	risk	O
1481	for	O
1481	sub	O
1481	##ther	O
1481	##ap	O
1481	##eu	O
1481	##tic	O
1481	concentrations	O
1481	of	O
1481	van	O
1481	##com	O
1481	##y	O
1481	##cin	O
1481	.	O
1481	[SEP]	O
1482	[CLS]	O
1482	procedures	O
1482	were	O
1482	performed	O
1482	in	O
1482	40	O
1482	female	O
1482	w	O
1482	##ista	O
1482	##r	O
1482	rats	O
1482	weighing	O
1482	250	O
1482	–	O
1482	280	O
1482	g	O
1482	.	O
1482	s	O
1482	##tre	O
1482	##pt	O
1482	##oz	O
1482	##oto	O
1482	##cin	O
1482	-	O
1482	ni	O
1482	##cot	O
1482	##ina	O
1482	##mi	O
1482	##de	O
1482	-	O
1482	induced	O
1482	rat	O
1482	model	O
1482	of	O
1482	t	O
1482	##2	O
1482	##d	O
1482	was	O
1482	used	O
1482	(	O
1482	24	O
1482	,	O
1482	25	O
1482	)	O
1482	.	O
1482	[SEP]	O
1483	[CLS]	O
1483	however	O
1483	,	O
1483	the	O
1483	actions	O
1483	of	O
1483	this	O
1483	transport	O
1483	##er	O
1483	can	O
1483	contribute	O
1483	to	O
1483	resistance	O
1483	to	O
1483	a	O
1483	broad	O
1483	range	O
1483	of	O
1483	more	O
1483	than	O
1483	300	O
1483	compounds	O
1483	##45	O
1483	.	O
1483	[SEP]	O
1484	[CLS]	O
1484	the	O
1484	metabolic	O
1484	activity	O
1484	in	O
1484	rat	O
1484	micro	O
1484	##some	O
1484	##s	O
1484	was	O
1484	much	O
1484	higher	O
1484	than	O
1484	that	O
1484	in	O
1484	human	O
1484	micro	O
1484	##some	O
1484	##s	O
1484	within	O
1484	the	O
1484	clinical	O
1484	##ly	O
1484	observed	O
1484	plasma	O
1484	range	O
1484	.	O
1484	[SEP]	O
1485	[CLS]	O
1485	a	O
1485	total	O
1485	of	O
1485	97	O
1485	p	O
1485	##har	O
1485	##ma	O
1485	##co	O
1485	##kin	O
1485	##etic	O
1485	profiles	O
1485	were	O
1485	obtained	O
1485	following	O
1485	the	O
1485	first	O
1485	administration	O
1485	of	O
1485	bus	O
1485	##ulf	O
1485	##an	O
1485	or	O
1485	after	O
1485	the	O
1485	second	O
1485	dose	O
1485	for	O
1485	3	O
1485	patients	O
1485	(	O
1485	therapeutic	O
1485	monitoring	O
1485	could	O
1485	not	O
1485	be	O
1485	performed	O
1485	on	O
1485	the	O
1485	first	O
1485	dose	O
1485	and	O
1485	standard	O
1485	dose	O
1485	was	O
1485	administered	O
1485	on	O
1485	first	O
1485	and	O
1485	second	O
1485	dose	O
1485	)	O
1485	.	O
1485	[SEP]	O
1486	[CLS]	O
1486	cardiac	O
1486	toxicity	O
1486	of	O
1486	any	O
1486	grade	O
1486	was	O
1486	reported	O
1486	.	O
1486	[SEP]	O
1487	[CLS]	O
1487	mean	O
1487	cumulative	B-PK
1487	amounts	I-PK
1487	of	I-PK
1487	a	I-PK
1487	##g	I-PK
1487	##10	I-PK
1487	‐	I-PK
1487	a	I-PK
1487	##g	I-PK
1487	ex	I-PK
1487	##cre	I-PK
1487	##ted	I-PK
1487	in	I-PK
1487	urine	I-PK
1487	over	O
1487	72	O
1487	hours	O
1487	after	O
1487	dos	O
1487	##ing	O
1487	ranged	O
1487	from	O
1487	approximately	O
1487	21	O
1487	.	O
1487	27	O
1487	to	O
1487	270	O
1487	.	O
1487	9	O
1487	mg	O
1487	and	O
1487	increased	O
1487	with	O
1487	increasing	O
1487	dose	O
1487	of	O
1487	a	O
1487	##g	O
1487	##10	O
1487	administered	O
1487	and	O
1487	represented	O
1487	approximately	O
1487	19	O
1487	.	O
1487	5	O
1487	%	O
1487	to	O
1487	23	O
1487	.	O
1487	5	O
1487	%	O
1487	of	O
1487	the	O
1487	dose	O
1487	of	O
1487	a	O
1487	##g	O
1487	##10	O
1487	administered	O
1487	following	O
1487	a	O
1487	single	O
1487	dose	O
1487	of	O
1487	50	O
1487	to	O
1487	800	O
1487	mg	O
1487	a	O
1487	##g	O
1487	##10	O
1487	.	O
1487	[SEP]	O
1488	[CLS]	O
1488	the	O
1488	plasma	O
1488	concentrations	O
1488	of	O
1488	o	O
1488	##xy	O
1488	##co	O
1488	##don	O
1488	##e	O
1488	and	O
1488	its	O
1488	meta	O
1488	##bol	O
1488	##ites	O
1488	were	O
1488	affected	O
1488	significantly	O
1488	by	O
1488	presence	O
1488	or	O
1488	absence	O
1488	of	O
1488	a	O
1488	##p	O
1488	##re	O
1488	##pit	O
1488	##ant	O
1488	.	O
1488	[SEP]	O
1489	[CLS]	O
1489	blank	O
1489	plasma	O
1489	showed	O
1489	no	O
1489	significant	O
1489	interfering	O
1489	peaks	O
1489	at	O
1489	the	O
1489	retention	O
1489	times	O
1489	of	O
1489	each	O
1489	anal	O
1489	##yte	O
1489	(	O
1489	fi	O
1489	##g	O
1489	.	O
1489	3	O
1489	##a	O
1489	)	O
1489	.	O
1489	[SEP]	O
1490	[CLS]	O
1490	adverse	O
1490	events	O
1490	were	O
1490	recorded	O
1490	through	O
1490	the	O
1490	study	O
1490	.	O
1490	[SEP]	O
1491	[CLS]	O
1491	rats	O
1491	were	O
1491	allocated	O
1491	into	O
1491	four	O
1491	groups	O
1491	:	O
1491	normal	O
1491	group	O
1491	(	O
1491	n	O
1491	=	O
1491	5	O
1491	)	O
1491	,	O
1491	a	O
1491	##p	O
1491	model	O
1491	group	O
1491	(	O
1491	n	O
1491	=	O
1491	5	O
1491	)	O
1491	,	O
1491	a	O
1491	##p	O
1491	model	O
1491	with	O
1491	l	O
1491	##h	O
1491	##d	O
1491	group	O
1491	(	O
1491	n	O
1491	=	O
1491	5	O
1491	)	O
1491	,	O
1491	and	O
1491	a	O
1491	##p	O
1491	model	O
1491	with	O
1491	m	O
1491	##l	O
1491	##h	O
1491	##d	O
1491	group	O
1491	(	O
1491	n	O
1491	=	O
1491	5	O
1491	)	O
1491	.	O
1491	[SEP]	O
1492	[CLS]	O
1492	the	O
1492	study	O
1492	setup	O
1492	is	O
1492	illustrated	O
1492	in	O
1492	figure	O
1492	##1	O
1492	##b	O
1492	.	O
1492	[SEP]	O
1493	[CLS]	O
1493	formulation	O
1493	and	O
1493	in	O
1493	v	O
1493	##ivo	O
1493	evaluation	O
1493	of	O
1493	membrane	O
1493	-	O
1493	moderate	O
1493	##d	O
1493	trans	O
1493	##der	O
1493	##mal	O
1493	therapeutic	O
1493	systems	O
1493	of	O
1493	ni	O
1493	##card	O
1493	##ip	O
1493	##ine	O
1493	h	O
1493	##ydro	O
1493	##ch	O
1493	##lor	O
1493	##ide	O
1493	using	O
1493	car	O
1493	##von	O
1493	##e	O
1493	as	O
1493	a	O
1493	penetration	O
1493	enhance	O
1493	##r	O
1493	.	O
1493	[SEP]	O
1494	[CLS]	O
1494	the	O
1494	results	O
1494	were	O
1494	explained	O
1494	on	O
1494	the	O
1494	basis	O
1494	of	O
1494	previous	O
1494	results	O
1494	from	O
1494	our	O
1494	laboratory	O
1494	relating	O
1494	to	O
1494	the	O
1494	product	O
1494	en	O
1494	##anti	O
1494	##ose	O
1494	##lect	O
1494	##ivity	O
1494	of	O
1494	the	O
1494	formation	O
1494	of	O
1494	the	O
1494	su	O
1494	##lf	O
1494	##oxide	O
1494	and	O
1494	the	O
1494	substrate	O
1494	en	O
1494	##anti	O
1494	##ose	O
1494	##lect	O
1494	##ivity	O
1494	of	O
1494	the	O
1494	subsequent	O
1494	formation	O
1494	of	O
1494	the	O
1494	su	O
1494	##lf	O
1494	##one	O
1494	.	O
1494	[SEP]	O
1495	[CLS]	O
1495	as	O
1495	an	O
1495	alternative	O
1495	to	O
1495	current	O
1495	methods	O
1495	of	O
1495	local	O
1495	nerve	O
1495	block	O
1495	,	O
1495	we	O
1495	studied	O
1495	the	O
1495	f	O
1495	##eas	O
1495	##ibility	O
1495	of	O
1495	producing	O
1495	ankle	O
1495	block	O
1495	in	O
1495	the	O
1495	rat	O
1495	with	O
1495	i	O
1495	##v	O
1495	injection	O
1495	of	O
1495	magnetic	O
1495	na	O
1495	##no	O
1495	##par	O
1495	##tic	O
1495	##les	O
1495	(	O
1495	m	O
1495	##n	O
1495	##ps	O
1495	)	O
1495	associated	O
1495	with	O
1495	r	O
1495	##op	O
1495	##iva	O
1495	##ca	O
1495	##ine	O
1495	and	O
1495	application	O
1495	of	O
1495	a	O
1495	magnet	O
1495	at	O
1495	the	O
1495	ankle	O
1495	.	O
1495	[SEP]	O
1496	[CLS]	O
1496	information	O
1496	on	O
1496	the	O
1496	p	O
1496	##har	O
1496	##ma	O
1496	##co	O
1496	##kin	O
1496	##etic	O
1496	profile	O
1496	of	O
1496	l	O
1496	##d	O
1496	##x	O
1496	in	O
1496	children	O
1496	with	O
1496	ad	O
1496	##h	O
1496	##d	O
1496	is	O
1496	lacking	O
1496	.	O
1496	[SEP]	O
1497	[CLS]	O
1497	di	O
1497	##ssi	O
1497	##mi	O
1497	##lar	O
1497	##ity	O
1497	factor	O
1497	(	O
1497	f	O
1497	##1	O
1497	)	O
1497	given	O
1497	in	O
1497	su	O
1497	##pa	O
1497	##c	O
1497	guidelines	O
1497	for	O
1497	modified	O
1497	dos	O
1497	##age	O
1497	forms	O
1497	was	O
1497	used	O
1497	to	O
1497	further	O
1497	justify	O
1497	the	O
1497	selection	O
1497	of	O
1497	best	O
1497	formulation	O
1497	which	O
1497	showed	O
1497	least	O
1497	significance	O
1497	during	O
1497	multiple	O
1497	t	O
1497	-	O
1497	test	O
1497	at	O
1497	p	O
1497	>	O
1497	0	O
1497	.	O
1497	05	O
1497	.	O
1497	[SEP]	O
1498	[CLS]	O
1498	the	O
1498	kinetic	O
1498	##s	O
1498	of	O
1498	five	O
1498	c	O
1498	##is	O
1498	##p	O
1498	##lat	O
1498	##in	O
1498	analog	O
1498	##s	O
1498	binding	O
1498	to	O
1498	human	O
1498	plasma	O
1498	fraction	O
1498	##s	O
1498	possessing	O
1498	a	O
1498	molecular	O
1498	weight	O
1498	greater	O
1498	than	O
1498	50	O
1498	,	O
1498	000	O
1498	da	O
1498	##lton	O
1498	##s	O
1498	were	O
1498	studied	O
1498	.	O
1498	[SEP]	O
1499	[CLS]	O
1499	the	O
1499	ex	O
1499	##cre	O
1499	##ted	O
1499	radio	B-PK
1499	##act	I-PK
1499	##ivity	I-PK
1499	was	O
1499	profile	O
1499	##d	O
1499	using	O
1499	radio	O
1499	##ch	O
1499	##roma	O
1499	##tography	O
1499	,	O
1499	and	O
1499	approximately	O
1499	31	O
1499	%	O
1499	was	O
1499	structural	O
1499	##ly	O
1499	characterized	O
1499	as	O
1499	rub	O
1499	##ox	O
1499	##ista	O
1499	##uri	O
1499	##n	O
1499	or	O
1499	n	O
1499	-	O
1499	des	O
1499	##met	O
1499	##hyl	O
1499	rub	O
1499	##ox	O
1499	##ista	O
1499	##uri	O
1499	##n	O
1499	.	O
1499	[SEP]	O
